

Effects of chemotherapy and hormonal therapy for early 15-year survival: an overview of the randomised trials

Lancet, The

365, 1687-1717

DOI: [10.1016/s0140-6736\(05\)66544-0](https://doi.org/10.1016/s0140-6736(05)66544-0)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | ecancermedalscience. Ecancermedalscience, 2013, 7, 320. | 0.6 | 23 |
| 2 | ecancermedalscience. Ecancermedalscience, 2011, 5, 237. | 0.6 | 0 |
| 3 | Modification of gene expression induced by siRNA targeting of estrogen receptor β in MCF7 human breast cancer cells. International Journal of Oncology, 1992, 34, 231. | 1.4 | 17 |
| 4 | Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. Oncology Reports, 1994, 20, 987. | 1.2 | 6 |
| 5 | Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line. Oncology Reports, 1994, 20, 1545. | 1.2 | 9 |
| 6 | Ovarian ablation for early breast cancer. , 1998, , CD000485. | | 8 |
| 7 | Tamoxifen for early breast cancer. , 2001, , CD000486. | | 40 |
| 8 | Multi-agent chemotherapy for early breast cancer. , 2001, , CD000487. | | 17 |
| 9 | Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. The Cochrane Library, 2003, , CD002747. | 1.5 | 98 |
| 10 | Program for the Assessment of Clinical Cancer Tests (PACCT): assisting the development of tailored cancer therapy. Personalized Medicine, 2005, 2, 363-369. | 0.8 | 1 |
| 11 | Breast cancer risk: is postmenopausal hormone therapy ever safe?. Menopause, 2005, 12, 653-655. | 0.8 | 4 |
| 12 | Adjuvant chemotherapy in elderly patients with breast cancer: where are we?. Current Opinion in Oncology, 2005, 17, 566-572. | 1.1 | 13 |
| 13 | Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Current Opinion in Oncology, 2005, 17, 559-565. | 1.1 | 28 |
| 14 | Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 557-571. | 2.3 | 88 |
| 15 | Update in Medical Oncology for Older Patients. Cancer Journal (Sudbury, Mass), 2005, 11, 506-517. | 1.0 | 10 |
| 16 | Aromatase inhibitors as adjuvant therapy: how will results of the ATAC trial at San Antonio 2004 and BIG 1-98 at St Gallen 2005 impact on aromatase inhibitors as adjuvant endocrine therapy?. Breast Cancer Online: BCO, 2005, 8, 1-6. | 0.1 | 0 |
| 17 | Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?. British Journal of Cancer, 2005, 93, 1319-1323. | 2.9 | 43 |
| 18 | Breast cancer metastasis: markers and models. Nature Reviews Cancer, 2005, 5, 591-602. | 12.8 | 1,911 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | MRI Screening for Breast Cancer in Women with a Familial or Genetic Predisposition. <i>Imaging Decisions</i> (Berlin, Germany), 2005, 9, 11-18. | 0.2 | 5 |
| 20 | Of Snail, mice, and women. <i>Cancer Cell</i> , 2005, 8, 173-174. | 7.7 | 26 |
| 21 | Adjuvant endocrine therapy in postmenopausal breast cancer patients. <i>Breast</i> , 2005, 14, 446-451. | 0.9 | 4 |
| 22 | Adjuvant chemotherapy in 2005: Standards and beyond. <i>Breast</i> , 2005, 14, 439-445. | 0.9 | 20 |
| 23 | What extent of radiation therapy is standard?. <i>Breast</i> , 2005, 14, 532-540. | 0.9 | 3 |
| 24 | Special issues related to breast cancer adjuvant therapy in older women. <i>Breast</i> , 2005, 14, 600-611. | 0.9 | 18 |
| 25 | Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). <i>Cancer</i> , 2005, 104, 2334-2339. | 2.0 | 23 |
| 27 | Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 10-20. | 1.1 | 170 |
| 30 | The aromatase inhibitors in early breast cancer: who, when, and why?. <i>Medical Journal of Australia</i> , 2005, 183, 24-27. | 0.8 | 11 |
| 31 | Systemic adjuvant therapies for early breast cancer: 15-year results for recurrence and survival. <i>Medical Journal of Australia</i> , 2005, 183, 447-448. | 0.8 | 0 |
| 32 | Breast Cancer in the Elderly. , 0, , 1531-1540. | | 0 |
| 34 | Re: Medroxyprogesterone Acetate and Metastases: Of Mice and (Wo)Men. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1225-1225. | 3.0 | 1 |
| 35 | Squaring the Circle: Adjuvant Chemotherapy for Older Women With Breast Cancer. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 1135-1136. | 1.7 | 1 |
| 36 | RESPONSE: Re: Medroxyprogesterone Acetate and Metastases: Of Mice and (Wo)Men. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1225-1226. | 3.0 | 0 |
| 37 | Efficacy of Breast Cancer Screening in the Community According to Risk Level. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1035-1043. | 3.0 | 60 |
| 38 | Can We Approach Zero Relapse in Breast Cancer?. <i>Oncologist</i> , 2005, 10, 9-17. | 1.9 | 10 |
| 39 | Effectiveness: The Next Question for Breast Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1021-1023. | 3.0 | 19 |
| 40 | Tamoxifen Versus Control After Adjuvant, Risk-Adapted Chemotherapy in Postmenopausal, Receptor-Negative Patients With Breast Cancer: A Randomized Trial (GABC-IV D-93)â€”The German Adjuvant Breast Cancer Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 7842-7848. | 0.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 41 | Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis. <i>Journal of Clinical Oncology</i> , 2005, 23, 5178-5187. | 0.8 | 93 |
| 42 | Optimum Use of Aromatase Inhibitors in the Adjuvant Treatment of Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8544-8546. | 0.8 | 6 |
| 43 | Case 24-2005. <i>New England Journal of Medicine</i> , 2005, 353, 617-622. | 13.9 | 2 |
| 44 | Case 35-2005. <i>New England Journal of Medicine</i> , 2005, 353, 2177-2185. | 13.9 | 3 |
| 45 | Use of goserelin in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 591-604. | 1.1 | 13 |
| 46 | Aromatase Inhibitors – A Triumph of Translational Oncology. <i>New England Journal of Medicine</i> , 2005, 353, 2807-2809. | 13.9 | 28 |
| 47 | Role of chemotherapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 1095-1110. | 1.1 | 10 |
| 48 | A review of exemestane in the management of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2353-2363. | 0.9 | 2 |
| 49 | Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 598-599. | 4.3 | 12 |
| 50 | The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 596-597. | 4.3 | 3 |
| 51 | Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 498-499. | 4.3 | 0 |
| 52 | Deregulation of estrogen induced telomerase activity in tamoxifen-resistant breast cancer cells. <i>International Journal of Oncology</i> , 2005, 27, 1459. | 1.4 | 4 |
| 53 | Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. <i>BMJ: British Medical Journal</i> , 2005, 331, 1295. | 2.4 | 58 |
| 54 | Importance of rational pre-clinical development: Gemcitabine comes of age. <i>Cancer Biology and Therapy</i> , 2005, 4, 872-873. | 1.5 | 1 |
| 55 | Adjuvant aromatase inhibitors for breast cancer. <i>Lancet, The</i> , 2005, 366, 431-433. | 6.3 | 31 |
| 56 | Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. <i>Lancet, The</i> , 2005, 366, 455-462. | 6.3 | 828 |
| 57 | Adjuvant trastuzumab for HER2-positive breast cancer. <i>Lancet, The</i> , 2005, 366, 634. | 6.3 | 9 |
| 58 | Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. <i>Lancet, The</i> , 2005, 366, 1935-1944. | 6.3 | 108 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 59 | Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. <i>Lancet, The</i> , 2005, 366, 2087-2106. | 6.3 | 4,596 |
| 60 | Familial non-BRCA1/BRCA2-associated breast cancer. <i>Lancet Oncology, The</i> , 2005, 6, 705-711. | 5.1 | 36 |
| 61 | Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. <i>Lancet Oncology, The</i> , 2005, 6, 886-898. | 5.1 | 120 |
| 62 | Adjuvant treatment of early breast cancer. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 149-166. | 2.2 | 1 |
| 63 | Tailored endocrine therapy " ready for clinical practice. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 255-258. | 2.2 | 0 |
| 67 | Combination versus sequential single-agent therapy for the treatment of metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 3-8. | 2.2 | 4 |
| 68 | Gemcitabine plus docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: a review of the results of a European Phase III trial. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 17-21. | 2.2 | 3 |
| 69 | Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?. <i>Journal of Clinical Oncology</i> , 2005, 23, 7350-7360. | 0.8 | 798 |
| 70 | Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1262-1271. | 3.0 | 1,048 |
| 71 | Adjuvant Chemotherapy for Early Breast Cancer: Optimal Use of Epirubicin. <i>Oncologist</i> , 2005, 10, 780-791. | 1.9 | 55 |
| 73 | Vaginal oestrogen therapy after breast cancer: Is it safe?. <i>European Journal of Cancer</i> , 2005, 41, 2673-2681. | 1.3 | 79 |
| 74 | New developments in the treatment of postmenopausal breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 420-428. | 3.1 | 21 |
| 75 | Goserelin. <i>Drugs</i> , 2005, 65, 2639-2655. | 4.9 | 22 |
| 76 | 33 Adjuvant Chemotherapy in Older and Younger Women With Lymph Node Positive Breast Cancer. <i>Breast Diseases</i> , 2005, 16, 276. | 0.0 | 0 |
| 77 | Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes. <i>Journal of Clinical Oncology</i> , 2005, 23, 9312-9318. | 0.8 | 726 |
| 78 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1659-1672. | 13.9 | 4,601 |
| 79 | Clinical trial update: International Breast Cancer Study Group. <i>Breast Cancer Research</i> , 2005, 7, 252-4. | 2.2 | 21 |
| 80 | Menopausal hormone therapy after breast cancer. <i>Breast Cancer Research</i> , 2005, 7, 168-70. | 2.2 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 81 | p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy. <i>Breast Cancer Research</i> , 2006, 8, R73. | 2.2 | 20 |
| 82 | Sequencing of chemotherapy and radiation therapy for early breast cancer. , 2006, , CD005212. | | 15 |
| 83 | Exemestane. <i>American Journal of Cancer</i> , 2006, 5, 259-272. | 0.4 | 5 |
| 84 | The Extended Adjuvant Treatment Strategy in Early Breast Cancer. <i>American Journal of Cancer</i> , 2006, 5, 1-5. | 0.4 | 2 |
| 86 | Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. <i>Annals of Oncology</i> , 2006, 17, vii10-vii14. | 0.6 | 184 |
| 87 | Letrozole. <i>Pharmacoeconomics</i> , 2006, 24, 495-517. | 1.7 | 12 |
| 88 | Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 3337-3343. | 3.2 | 147 |
| 89 | CME information. <i>Gynecological Endocrinology</i> , 2006, 22, 1-13. | 0.7 | 16 |
| 90 | Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3726-3734. | 0.8 | 2,369 |
| 91 | Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. <i>Lancet Oncology, The</i> , 2006, 7, 141-148. | 5.1 | 446 |
| 92 | Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?. <i>Lancet Oncology, The</i> , 2006, 7, 191-193. | 5.1 | 6 |
| 93 | Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2006, 7, 633-643. | 5.1 | 356 |
| 94 | Emerging use of nanoparticles in diagnosis and treatment of breast cancer. <i>Lancet Oncology, The</i> , 2006, 7, 657-667. | 5.1 | 505 |
| 95 | Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. <i>Lancet Oncology, The</i> , 2006, 7, 991-996. | 5.1 | 231 |
| 97 | Trastuzumab for early breast cancer. <i>Lancet, The</i> , 2006, 367, 107. | 6.3 | 10 |
| 98 | Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. <i>Journal of Clinical Oncology</i> , 2006, 24, 2137-2150. | 0.8 | 3,155 |
| 99 | Estrogen Receptors: Role in Breast Cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2006, 43, 325-347. | 2.7 | 82 |
| 100 | Current and future directions for adjuvant chemotherapy in early-stage breast cancer. <i>European Journal of Cancer, Supplement</i> , 2006, 4, 14-20. | 2.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 102 | Maximising, outcomes in adjuvant breast cancer. European Journal of Cancer, Supplement, 2006, 4, 21-24. | 2.2 | 0 |
| 103 | Reducing the risk of recurrence in postmenopausal women with early breast cancer: a role for aromatase inhibitors. Community Oncology, 2006, 3, 275-281. | 0.2 | 0 |
| 104 | Estrogen Carcinogenesis in Breast Cancer. New England Journal of Medicine, 2006, 354, 270-282. | 13.9 | 1,531 |
| 105 | 4a€“34 Treatment of Axillary Lymph Nodea€“Negative, Estrogen Receptora€“Negative Breast Cancer: Updated Findings From National Surgical Adjuvant Breast and Bowel Project Clinical Trials. Breast Diseases, 2006, 16, 371-372. | 0.0 | 0 |
| 106 | Disease-specific and event-free survival in breast cancer patients: a hospital-based study between 1990 and 2001. Revue D'Epidemiologie Et De Sante Publique, 2006, 54, 313-325. | 0.3 | 9 |
| 107 | As the Median Size of Invasive Breast Cancers at Time of Diagnosis Continues to Fall, How Does the Oncologist Guard Against Over-Treatment?. Seminars in Breast Disease, 2006, 9, 25-29. | 0.0 | 2 |
| 108 | Hot Flash Therapies in Breast Cancer Survivors. Supportive Cancer Therapy, 2006, 4, 38-48. | 0.3 | 3 |
| 109 | Trastuzumab in the Treatment of Early-Stage Breast Cancer. Breast Diseases, 2006, 17, 19-22. | 0.0 | 0 |
| 110 | Adjuvant Therapy for Patients Who Have Node-Positive Breast Cancer. Advances in Surgery, 2006, 40, 77-98. | 0.6 | 3 |
| 111 | The Case for Adjuvant Therapy for Prostate Cancer. Journal of Urology, 2006, 176, S30-3. | 0.2 | 4 |
| 112 | Cardiovascular Health and Aromatase Inhibitors. Drugs, 2006, 66, 1727-1740. | 4.9 | 23 |
| 113 | Breast Cancer in Elderly Women: Outcome as Affected by Age, Tumor Features, Comorbidities, and Treatment Approach. Clinical Breast Cancer, 2006, 7, 59-66. | 1.1 | 56 |
| 114 | Controversies in Adjuvant Endocrine Treatment of Premenopausal Women. Clinical Breast Cancer, 2006, 6, S36-S40. | 1.1 | 3 |
| 115 | Coronary Heart Disease and Stroke with Aromatase Inhibitor, Tamoxifen, and Menopausal Hormone Therapy Use. Clinical Breast Cancer, 2006, 6, S58-S64. | 1.1 | 26 |
| 116 | What is the optimal strategy for postoperative treatment with aromatase inhibitors in the adjuvant setting?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, S31-S45. | 2.2 | 1 |
| 117 | Update on the MA.17 extended adjuvant trial. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, S5-S13. | 2.2 | 12 |
| 118 | Aromatase inhibitors: effective endocrine therapy in the early adjuvant setting for postmenopausal women with hormone-responsive breast cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, S15-S29. | 2.2 | 10 |
| 119 | Breaking the 5-year barrier: Results from the MA.17 extended adjuvant trial in women who have completed adjuvant tamoxifen treatment. European Journal of Cancer, Supplement, 2006, 4, 10-15. | 2.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 120 | Aromatase inhibitors in the early adjuvant setting – the latest evidence. <i>European Journal of Cancer, Supplement</i> , 2006, 4, 3-9. | 2.2 | 1 |
| 122 | Gene Expression Profiling and Clinical Outcome in Breast Cancer. <i>OMICS A Journal of Integrative Biology</i> , 2006, 10, 429-443. | 1.0 | 60 |
| 123 | Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. <i>Current Medical Research and Opinion</i> , 2006, 22, 1609-1621. | 0.9 | 62 |
| 125 | Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients. <i>Cancer Treatment Reviews</i> , 2006, 32, 325-332. | 3.4 | 17 |
| 126 | Adjuvant trials: Aromatase inhibitors in early breast cancer – Are they alike?. <i>Cancer Treatment Reviews</i> , 2006, 32, 532-540. | 3.4 | 2 |
| 127 | Safety of adjuvant aromatase inhibitor therapy. <i>Cancer Treatment Reviews</i> , 2006, 32, 548-556. | 3.4 | 17 |
| 129 | Targeted kinase inhibitors in lung cancer: From EGFR to patients. <i>European Journal of Cancer</i> , 2006, 42, 124-125. | 1.3 | 0 |
| 130 | Activated ERK1/2 and phosphorylated oestrogen receptor \pm are associated with improved breast cancer survival in women treated with tamoxifen. <i>European Journal of Cancer</i> , 2006, 42, 1104-1112. | 1.3 | 50 |
| 131 | CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABC trial IV-A-93). <i>European Journal of Cancer</i> , 2006, 42, 1780-1788. | 1.3 | 46 |
| 132 | What clinicians need to know about antioestrogen resistance in breast cancer therapy. <i>European Journal of Cancer</i> , 2006, 42, 2692-2705. | 1.3 | 48 |
| 133 | Generalisability of survival estimates for patients with breast cancer – A comparison across two population-based series. <i>European Journal of Cancer</i> , 2006, 42, 3228-3235. | 1.3 | 23 |
| 134 | Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. <i>European Journal of Cancer</i> , 2006, 42, 2729-2737. | 1.3 | 23 |
| 135 | Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: Why, who and how long?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 126, 146-154. | 0.5 | 9 |
| 136 | Cancer: A medical emergency. <i>Medical Hypotheses</i> , 2006, 67, 1054-1059. | 0.8 | 27 |
| 137 | Emerging principles for the development of resistance to antihormonal therapy: Implications for the clinical utility of fulvestrant. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2006, 102, 128-138. | 1.2 | 18 |
| 138 | Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor \pm negative fulvestrant-resistant MCF-7 cells. <i>International Journal of Oncology</i> , 2006, 29, 1237. | 1.4 | 9 |
| 139 | Aromatase Inhibitors: Changing the Face of Endocrine Therapy for Breast Cancer. <i>Breast Disease</i> , 2006, 24, 107-117. | 0.4 | 15 |
| 140 | Adjuvant Systemic Therapy in Young Women. <i>Breast Disease</i> , 2006, 23, 67-71. | 0.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 141 | Safety of Epirubicin Adjuvant Chemotherapy in a Breast Cancer Patient with Chronic Renal Failure Undergoing Hemodialytic Treatment. <i>Tumori</i> , 2006, 92, 364-365. | 0.6 | 11 |
| 142 | Adjuvant Chemotherapy in Primary Breast Cancer. <i>Breast Care</i> , 2006, 1, 238-241. | 0.8 | 1 |
| 143 | Trastuzumab as Intellectual, Medical and Economical Challenge. <i>Breast Care</i> , 2006, 1, 64-65. | 0.8 | 0 |
| 144 | Advances in Adjuvant and Primary Systemic Therapy of Early Breast Cancer. <i>Breast Care</i> , 2006, 1, 129-133. | 0.8 | 1 |
| 145 | Adjuvant Endocrine Therapy in Pre- and Postmenopausal Patients. <i>Breast Care</i> , 2006, 1, 242-247. | 0.8 | 3 |
| 146 | Gene Expression Profiling to Predict Chemotherapy Response in Primary Breast Cancer. <i>Breast Care</i> , 2006, 1, 362-367. | 0.8 | 2 |
| 147 | Adjuvant Treatment of Breast Cancer with Taxanes. <i>Breast Care</i> , 2006, 1, 171-175. | 0.8 | 3 |
| 148 | Trastuzumab for Early Breast Cancer: Hope or Hype?. <i>Breast Care</i> , 2006, 1, 66-67. | 0.8 | 0 |
| 149 | Significance and Usefulness of Guidelines. <i>Breast Care</i> , 2006, 1, 220-222. | 0.8 | 1 |
| 150 | The War on Cancer: A Report from the Front Lines. <i>Baylor University Medical Center Proceedings</i> , 2006, 19, 323-334. | 0.2 | 2 |
| 151 | ASCO 2006 Exemestane: Una Nuova Realt  per la Terapia Adiuvante Del Carcinoma Mammario. <i>Tumori</i> , 2006, 92, 1-9. | 0.6 | 0 |
| 152 | Age-Specific Incidence of Breast Cancer – Are Younger Women at a Higher Risk?. <i>Breast Care</i> , 2006, 1, 26-27. | 0.8 | 1 |
| 153 | The Early Breast Cancer Trialists Collaborative Group (EBCTCG) Process: Is it Still Relevant in 2006?. <i>Breast Care</i> , 2006, 1, 338-339. | 0.8 | 2 |
| 154 | Radiooncological Aspects Regarding Multimodal Primary Treatment of Breast Cancer – a Review. <i>Breast Care</i> , 2006, 1, 379-389. | 0.8 | 1 |
| 155 | Medical treatment of early breast cancer. I: adjuvant treatment. <i>BMJ: British Medical Journal</i> , 2006, 332, 34-37. | 2.4 | 15 |
| 156 | Relationship between the method of detection and prognostic factors for breast cancer in a community with a screening programme. <i>Journal of Medical Screening</i> , 2006, 13, 183-191. | 1.1 | 12 |
| 157 | Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 971-979. | 2.3 | 124 |
| 158 | The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 237-249. | 0.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 160 | Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective. <i>Anti-Cancer Drugs</i> , 2006, 17, 719-724. | 0.7 | 7 |
| 161 | Modest benefits of adjuvant chemotherapy in hormone receptor-positive breast cancer. <i>Breast Cancer Online: BCO</i> , 2006, 9, 1-4. | 0.1 | 1 |
| 162 | Can Anesthetic Technique for Primary Breast Cancer Surgery Affect Recurrence or Metastasis?. <i>Anesthesiology</i> , 2006, 105, 660-664. | 1.3 | 842 |
| 163 | Trastuzumab and Antiestrogen Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 90-95. | 0.6 | 31 |
| 165 | The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 207-215. | 0.4 | 9 |
| 166 | The regulatory effect of tamoxifen on fibronectin expression in estrogen-dependent MCF-7 breast carcinoma cells. <i>Oncology Reports</i> , 2006, 15, 1191. | 1.2 | 4 |
| 167 | Systemic Immune Activation, Anemia and Thrombocytosis in Breast Cancer Patients Treated by Doxorubicin and Paclitaxel. <i>Pteridines</i> , 2006, 17, 107-114. | 0.5 | 16 |
| 168 | Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). <i>Breast Disease</i> , 2006, 24, 93-105. | 0.4 | 55 |
| 169 | Sentinel Lymph Node Biopsy Alone Has No Adverse Impact on the Survival of Patients with Breast Cancer. <i>Breast Journal</i> , 2006, 12, S157-S164. | 0.4 | 16 |
| 171 | Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 538-542. | 1.2 | 15 |
| 172 | Can differences in breast cancer utilities explain disparities in breast cancer care?. <i>Journal of General Internal Medicine</i> , 2006, 21, 1253-1260. | 1.3 | 46 |
| 173 | Hormonal breast cancer agents: Implications for the primary care provider. <i>Journal of the American Academy of Nurse Practitioners</i> , 2006, 18, 518-523. | 1.4 | 3 |
| 174 | Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer?. <i>British Journal of Cancer</i> , 2006, 94, 938-939. | 2.9 | 5 |
| 175 | Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. <i>British Journal of Cancer</i> , 2006, 94, 1057-1065. | 2.9 | 136 |
| 176 | Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study. <i>British Journal of Cancer</i> , 2006, 95, 1291-1295. | 2.9 | 27 |
| 177 | Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. <i>British Journal of Pharmacology</i> , 2006, 147, S269-S276. | 2.7 | 254 |
| 178 | Clinical trials design and treatment tailoring: General principles applied to breast cancer research. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 98-105. | 2.0 | 12 |
| 179 | Retrospective study of the effect of comorbidity on use of adjuvant chemotherapy in older women with breast cancer in a tertiary care setting. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 250-255. | 2.0 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 180 | Radiotherapy for Ductal Carcinoma In Situ. <i>Clinical Oncology</i> , 2006, 18, 179-184. | 0.6 | 8 |
| 181 | Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1081-1091. | 0.4 | 178 |
| 182 | The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: How young is "young"? <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1345-1352. | 0.4 | 52 |
| 183 | Aromatase inhibitors in preventing breast cancer recurrence. <i>Future Prescriber</i> , 2006, 7, 21-24. | 0.1 | 0 |
| 184 | S-1 (TS-1) maintained complete response for approximately 10 years in a case of metastatic breast cancer. <i>Breast Cancer</i> , 2006, 13, 220-224. | 1.3 | 6 |
| 185 | Tolerability and safety of classic cyclophosphamide, methotrexate, and fluorouracil treatment in Japanese patients with early Breast Cancer. <i>Breast Cancer</i> , 2006, 13, 279-283. | 1.3 | 4 |
| 186 | Adjuvant therapy for Breast Cancer in Kyushu. <i>Breast Cancer</i> , 2006, 13, 308-312. | 1.3 | 1 |
| 187 | TGF-Beta Signaling in Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 119-126. | 1.8 | 128 |
| 188 | Antihormones in Prevention and Treatment of Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 143-158. | 1.8 | 24 |
| 189 | A genetic signature can predict prognosis and response to therapy in breast cancer: OncotypeDX. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 803-809. | 1.5 | 55 |
| 190 | Heterogeneity of Breast Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy. <i>Pharmaceutical Research</i> , 2006, 23, 1951-1958. | 1.7 | 11 |
| 191 | Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 343-348. | 1.1 | 85 |
| 192 | Adherence to tamoxifen over the five-year course. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 215-220. | 1.1 | 291 |
| 193 | Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 295-300. | 1.1 | 89 |
| 194 | Assessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943-2002). <i>Breast Cancer Research and Treatment</i> , 2006, 99, 333-340. | 1.1 | 72 |
| 195 | Effects of Estrogen Receptor Expression and Histopathology on Annual Hazard Rates of Death from Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 121-126. | 1.1 | 84 |
| 196 | E-cadherin Immunohistochemical Expression as a Prognostic Factor in Infiltrating Ductal Carcinoma of the Breast: a Systematic Review and Meta-Analysis. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 139-148. | 1.1 | 86 |
| 197 | Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 255-262. | 1.1 | 129 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 198 | Quality of Life of Postmenopausal Women in the ATAC (Arimidex, Tamoxifen, Alone or in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 Cancer Research and Treatment, 2006, 100, 273-284. | 1.1 | 218 |
| 199 | Is intravenous immunoglobulins (IVIg) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). Journal of Assisted Reproduction and Genetics, 2006, 23, 1-13. | 1.2 | 91 |
| 201 | Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Supportive Care in Cancer, 2006, 14, 917-927. | 1.0 | 33 |
| 202 | Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects. Journal of Cancer Research and Clinical Oncology, 2006, 132, 343-355. | 1.2 | 6 |
| 203 | Early breast cancer. International Journal of Clinical Oncology, 2006, 11, 108-119. | 1.0 | 19 |
| 205 | Meta-analyses in Cancer Clinical Trials: Principles and Pitfalls. World Journal of Surgery, 2006, 30, 1177-1183. | 0.8 | 2 |
| 206 | Angiotensin 1 ⁷ and risk for breast cancer recurrence. Cancer Chemotherapy and Pharmacology, 2006, 58, 283-283. | 1.1 | 1 |
| 207 | Once More Confirmed: Adjuvant Radiotherapy and Improved Local Control Provide a Significant Survival Benefit for Early Breast Cancer Patients. Strahlentherapie Und Onkologie, 2006, 182, 199-201. | 1.0 | 6 |
| 209 | Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clinical and Translational Oncology, 2006, 8, 339-348. | 1.2 | 16 |
| 211 | Gene expression in breast cancer. Current Treatment Options in Oncology, 2006, 7, 123-128. | 1.3 | 21 |
| 212 | Selection of optimal adjuvant endocrine therapy for early-stage breast cancer. Current Treatment Options in Oncology, 2006, 7, 153-165. | 1.3 | 6 |
| 213 | Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecologic Oncology, 2006, 101, 322-326. | 0.6 | 33 |
| 214 | Barriers to Diagnosis and Treatment of Breast Cancer in the Older Woman. Journal of the American College of Surgeons, 2006, 202, 495-508. | 0.2 | 2 |
| 215 | Breast cancer in 2020: What can we expect?. Cancer Detection and Prevention, 2006, 30, 109-110. | 2.1 | 5 |
| 216 | DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design. Biochimica Et Biophysica Acta: Reviews on Cancer, 2006, 1766, 197-204. | 3.3 | 16 |
| 217 | Toremifene: An evaluation of its safety profile. Breast, 2006, 15, 142-157. | 0.9 | 64 |
| 218 | What is the purpose of cancer staging?. Breast, 2006, 15, 1-2. | 0.9 | 5 |
| 219 | The extended adjuvant NCIC CTG MA.17 trials: Initial and rerandomization studies. Breast, 2006, 15, 14-20. | 0.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 220 | Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZO-FAST program. <i>Breast</i> , 2006, 15, 30-40. | 0.9 | 43 |
| 221 | Chemotherapy - overview and future perspectives. <i>Breast</i> , 2006, 15, S11-S14. | 0.9 | 3 |
| 222 | 2005 Highlights From: The 28th Annual San Antonio Breast Cancer Symposium; San Antonio, TX December 2005. <i>Clinical Breast Cancer</i> , 2006, 6, 481-489. | 1.1 | 0 |
| 223 | Axillary Dissection for Breast Cancer. <i>Operative Techniques in General Surgery</i> , 2006, 8, 66-80. | 0.0 | 4 |
| 224 | Future Directions in the Treatment of Hormone-Sensitive Advanced Breast Cancer: The RAD001 (Everolimus)-Letrozole Clinical Program. <i>Seminars in Oncology</i> , 2006, 33, 18-25. | 0.8 | 23 |
| 225 | Preventing Relapse Beyond 5 Years: The MA.17 Extended Adjuvant Trial. <i>Seminars in Oncology</i> , 2006, 33, 8-12. | 0.8 | 23 |
| 226 | Cardiotoxic Consequences of Anthracycline-Containing Therapy in Patients With Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 15-21. | 0.8 | 298 |
| 227 | Neoadjuvant Endocrine Therapy for Locally Advanced Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 650-656. | 0.8 | 20 |
| 228 | Adjuvant Hormonal Therapy for Premenopausal Women With Breast Cancer. <i>Seminars in Oncology</i> , 2006, 33, 657-663. | 0.8 | 21 |
| 229 | Adjuvant Therapy With Aromatase Inhibitors for Postmenopausal Women With Early Breast Cancer: Evidence and Ongoing Controversy. <i>Seminars in Oncology</i> , 2006, 33, 672-680. | 0.8 | 20 |
| 230 | Steroid Receptors and Their Role in the Biology and Control of Breast Cancer Growth. <i>Seminars in Oncology</i> , 2006, 33, 631-641. | 0.8 | 66 |
| 231 | Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. <i>BMC Cancer</i> , 2006, 6, 216. | 1.1 | 21 |
| 232 | Adjuvant Taxanes in the Treatment of Breast Cancer: No Longer at the Tip of the Iceberg. <i>Clinical Breast Cancer</i> , 2006, 7, 51-58. | 1.1 | 21 |
| 233 | NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared with Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 7, 416-421. | 1.1 | 35 |
| 234 | Emerging Data on Optimal Adjuvant Endocrine Therapy: Breast International Group Trial 1-98/MA.17. <i>Clinical Breast Cancer</i> , 2006, 6, S45-S50. | 1.1 | 13 |
| 235 | Adjuvant therapy for breast cancer. <i>British Journal of Surgery</i> , 2006, 93, 1443-1445. | 0.1 | 1 |
| 236 | Extracellular tumor DNA in plasma and overall survival in breast cancer patients. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 692-701. | 1.5 | 41 |
| 237 | Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 1033-1040. | 1.5 | 464 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 238 | Twenty-five years of follow-up in patients with operable breast carcinoma. <i>Cancer</i> , 2006, 106, 743-750. | 2.0 | 49 |
| 239 | Landmark trials in endocrine adjuvant therapy for breast carcinoma. <i>Cancer</i> , 2006, 106, 975-981. | 2.0 | 16 |
| 240 | Benefit of taxanes as adjuvant chemotherapy for early breast cancer. <i>Cancer</i> , 2006, 106, 2337-2344. | 2.0 | 131 |
| 241 | Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma. <i>Cancer</i> , 2006, 106, 2327-2336. | 2.0 | 26 |
| 242 | Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01). <i>Cancer</i> , 2006, 107, 215-215. | 2.0 | 0 |
| 244 | Impact of chemotherapy regimens prior to endocrine therapy. <i>Cancer</i> , 2006, 107, 472-480. | 2.0 | 23 |
| 245 | Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen. <i>Cancer</i> , 2006, 107, 2552-2558. | 2.0 | 7 |
| 246 | Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. <i>International Journal of Cancer</i> , 2006, 119, 783-791. | 2.3 | 80 |
| 247 | Time trends of breast cancer survival in Europe in relation to incidence and mortality. <i>International Journal of Cancer</i> , 2006, 119, 2417-2422. | 2.3 | 95 |
| 248 | Adherence to Endocrine Therapy for Breast Cancer. <i>Oncology</i> , 2006, 71, 1-9. | 0.9 | 276 |
| 249 | Overexpression of the Orotate Phosphoribosyl-Transferase Gene Enhances the Effect of 5-Fluorouracil on Gastric Cancer Cell Lines. <i>Oncology</i> , 2006, 70, 458-464. | 0.9 | 16 |
| 250 | G-CSF in the Prevention of Febrile Neutropenia in Chemotherapy in Breast Cancer Patients. <i>Oncology Research and Treatment</i> , 2006, 29, 171-178. | 0.8 | 5 |
| 251 | Medical treatment of early breast cancer. II: endocrine therapy. <i>BMJ: British Medical Journal</i> , 2006, 332, 101-103. | 2.4 | 4 |
| 252 | Harmful impact of EU clinical trials directive. <i>BMJ: British Medical Journal</i> , 2006, 332, 501-502. | 2.4 | 83 |
| 253 | Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data. <i>Clinical Cancer Research</i> , 2006, 12, 1037s-1048s. | 3.2 | 27 |
| 254 | The evolving role of exemestane in the management of breast cancer. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2006, 67, 427-430. | 0.2 | 1 |
| 255 | A Step in the Right Direction. <i>Journal of Clinical Oncology</i> , 2006, 24, 3717-3718. | 0.8 | 16 |
| 256 | Arzoxifene: the development and clinical outcome of an ideal SERM. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 317-326. | 1.9 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 257 | Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2465-2479. | 0.9 | 6 |
| 258 | Emerging drugs to replace current leaders in first-line therapy for breast cancer. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 489-501. | 1.0 | 12 |
| 259 | Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 5-10. | 1.1 | 3 |
| 260 | Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 427-436. | 1.1 | 12 |
| 261 | Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 178-179. | 4.3 | 2 |
| 262 | Should women with early hormone-responsive breast cancer be switched from tamoxifen to anastrozole?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 80-81. | 4.3 | 0 |
| 263 | American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. <i>Journal of Clinical Oncology</i> , 2006, 24, 5091-5097. | 0.8 | 478 |
| 264 | The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. <i>Human Reproduction</i> , 2006, 21, 2583-2592. | 0.4 | 323 |
| 265 | Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. <i>Current Medical Research and Opinion</i> , 2006, 22, 1575-1585. | 0.9 | 30 |
| 267 | Informed Choice and Breast Cancer Screening. <i>Women's Health</i> , 2006, 2, 835-838. | 0.7 | 1 |
| 268 | Targeting the insulin-like growth factor axis as a cancer therapy. <i>Future Oncology</i> , 2006, 2, 101-110. | 1.1 | 10 |
| 269 | Adjuvant Systemic Therapy for Elderly Women with Breast Cancer. <i>Women's Health</i> , 2006, 2, 75-87. | 0.7 | 0 |
| 270 | Taxanes in Adjuvant Chemotherapy for Early Breast Cancer. <i>Women's Health</i> , 2006, 2, 323-325. | 0.7 | 0 |
| 271 | Anthracyclines and the Tailoring of Treatment for Early Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 354, 2177-2179. | 13.9 | 28 |
| 272 | Molecular Signatures Predict Outcomes of Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 355, 615-617. | 13.9 | 44 |
| 273 | From adjuvant to preventive breast cancer treatment: bridging the gap over troubled waters. <i>Annals of Oncology</i> , 2006, 17, vii5-vii9. | 0.6 | 0 |
| 274 | Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 1013s-1018s. | 3.2 | 54 |
| 275 | Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. <i>Journal of Clinical Oncology</i> , 2006, 24, 337-344. | 0.8 | 328 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 276 | Adjuvant Therapy in Elderly Patients with Early Breast Cancer. <i>Current Cancer Therapy Reviews</i> , 2006, 2, 315-325. | 0.2 | 0 |
| 277 | Meta-analysis in the assessment of treatment outcome. <i>Journal of Psychopharmacology</i> , 2006, 20, 67-71. | 2.0 | 7 |
| 278 | Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. <i>Journal of Clinical Oncology</i> , 2006, 24, 5637-5644. | 0.8 | 177 |
| 279 | Axillary Surgery: Clinical Judgment Required. <i>Journal of Clinical Oncology</i> , 2006, 24, 325-326. | 0.8 | 5 |
| 280 | Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. <i>Annals of Oncology</i> , 2006, 17, 588-596. | 0.6 | 66 |
| 281 | Is HRT justified for symptom management in women at higher risk of developing breast cancer?. <i>Climacteric</i> , 2006, 9, 404-415. | 1.1 | 15 |
| 282 | Estrogen Receptors as Therapeutic Targets in Breast Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 195-213. | 1.0 | 29 |
| 283 | Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1183-1192. | 3.0 | 1,128 |
| 284 | Adjuvant trastuzumab in early breast cancer. <i>Annals of Oncology</i> , 2006, 17, x54-x58. | 0.6 | 3 |
| 285 | Screening in women's health, with emphasis on fetal Down's syndrome, breast cancer and osteoporosis. <i>Human Reproduction Update</i> , 2006, 12, 499-512. | 5.2 | 10 |
| 286 | Early breast cancer: Adjuvant chemotherapy or radiotherapy, or both?. <i>Acta Oncologica</i> , 2006, 45, 514-516. | 0.8 | 1 |
| 287 | Primary Systemic Therapy of Breast Cancer. <i>Oncologist</i> , 2006, 11, 574-589. | 1.9 | 125 |
| 288 | Diverging trends in breast cancer mortality within Switzerland. <i>Annals of Oncology</i> , 2006, 17, 57-59. | 0.6 | 22 |
| 289 | Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring. <i>Annals of Oncology</i> , 2006, 17, 807-812. | 0.6 | 20 |
| 290 | First to select the target: better choice of adjuvant treatments for breast cancer patients. <i>Annals of Oncology</i> , 2006, 17, 1772-1776. | 0.6 | 90 |
| 291 | Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. <i>Annals of Oncology</i> , 2006, 17, 818-826. | 0.6 | 240 |
| 292 | Gene Expression Preferentially Regulated by Tamoxifen in Breast Cancer Cells and Correlations with Clinical Outcome. <i>Cancer Research</i> , 2006, 66, 7334-7340. | 0.4 | 149 |
| 293 | Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth. <i>Future Oncology</i> , 2006, 2, 627-641. | 1.1 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 294 | The Science of Selective Estrogen Receptor Modulators: Concept to Clinical Practice. <i>Clinical Cancer Research</i> , 2006, 12, 5010-5013. | 3.2 | 51 |
| 295 | Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. <i>Annals of Oncology</i> , 2006, 17, 1631-1636. | 0.6 | 30 |
| 296 | Missed Opportunities: Racial Disparities in Adjuvant Breast Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2006, 24, 1357-1362. | 0.8 | 333 |
| 297 | Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4956-4962. | 0.8 | 52 |
| 298 | Time trends of breast cancer mortality in Spain during the period 1977-2001 and Bayesian approach for projections during 2002-2016. <i>Annals of Oncology</i> , 2006, 17, 1783-1791. | 0.6 | 37 |
| 299 | Adjuvant Chemotherapy Use and Outcomes in Older Women With Breast Cancer: What Have We Learned?. <i>Journal of Clinical Oncology</i> , 2006, 24, 2697-2699. | 0.8 | 12 |
| 300 | Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. <i>Annals of Oncology</i> , 2006, 17, 1228-1233. | 0.6 | 155 |
| 301 | End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Disease-Free Survival as a Surrogate End Point for Overall Survival?. <i>Oncologist</i> , 2006, 11, 624-629. | 1.9 | 66 |
| 302 | Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer. <i>Oncologist</i> , 2006, 11, 718-731. | 1.9 | 53 |
| 303 | Appraising Adjuvant Aromatase Inhibitor Therapy. <i>Oncologist</i> , 2006, 11, 1058-1069. | 1.9 | 21 |
| 304 | Topoisomerase II β Gene Amplification and Response to Anthracycline-Containing Adjuvant Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2409-2411. | 0.8 | 25 |
| 305 | The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4611-4619. | 0.8 | 232 |
| 307 | The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. <i>Journal of Clinical Pathology</i> , 2006, 60, 299-302. | 1.0 | 65 |
| 308 | Physical and Functional Interactions between Cas and c-Src Induce Tamoxifen Resistance of Breast Cancer Cells through Pathways Involving Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 5b. <i>Cancer Research</i> , 2006, 66, 7007-7015. | 0.4 | 90 |
| 309 | Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer. <i>Oncologist</i> , 2006, 11, 704-717. | 1.9 | 43 |
| 310 | Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms. <i>Journal of Clinical Oncology</i> , 2006, 24, 3991-3996. | 0.8 | 42 |
| 311 | Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bNOMO): A Review of the Literature. <i>Journal of Clinical Oncology</i> , 2006, 24, 2113-2122. | 0.8 | 102 |
| 312 | Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 354, 809-820. | 13.9 | 1,317 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 313 | Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA - Journal of the American Medical Association, 2006, 295, 2374. | 3.8 | 240 |
| 314 | Decreased Risk of Stroke Among 10-Year Survivors of Breast Cancer. Journal of Clinical Oncology, 2006, 24, 5388-5394. | 0.8 | 43 |
| 315 | A 62-Year-Old Woman With a New Diagnosis of Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 1434. | 3.8 | 4 |
| 316 | Dietary Modification and Risk of Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 691. | 3.8 | 7 |
| 317 | Low-Fat Dietary Pattern and Risk of Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 629. | 3.8 | 696 |
| 318 | Adjuvant treatment of breast cancer: sequence and duration of hormonal therapy. Annals of Oncology, 2006, 17, x50-x53. | 0.6 | 1 |
| 319 | The cost of life: should it matter to doctors?. Annals of Oncology, 2006, 17, 357-358. | 0.6 | 3 |
| 320 | Use and Outcomes of Adjuvant Chemotherapy in Older Women With Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2750-2756. | 0.8 | 285 |
| 321 | Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 1658. | 3.8 | 645 |
| 322 | Breast Cancer Heterogeneity: A Mixture of At Least Two Main Types?. Journal of the National Cancer Institute, 2006, 98, 948-951. | 3.0 | 104 |
| 323 | Pak up Your Breast Tumor and Grow!. Journal of the National Cancer Institute, 2006, 98, 657-659. | 3.0 | 8 |
| 324 | Estrogen Receptor: Methodology Matters. Journal of Clinical Oncology, 2006, 24, 5626-5628. | 0.8 | 33 |
| 325 | Adjuvant Chemotherapy in the Elderly: Whom to Treat, What Regimen?. Oncologist, 2006, 11, 234-242. | 1.9 | 33 |
| 326 | Aromatase Inhibitors in Breast Cancer: An Overview. Oncologist, 2006, 11, 553-562. | 1.9 | 110 |
| 327 | Community-Based Use of Chemotherapy and Hormonal Therapy for Early-Stage Breast Cancer: 1987-2000. Journal of Clinical Oncology, 2006, 24, 872-877. | 0.8 | 69 |
| 328 | Postmastectomy Radiation and Survival in Older Women With Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4901-4907. | 0.8 | 81 |
| 329 | Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer. Clinical Cancer Research, 2006, 12, 1031s-1036s. | 3.2 | 17 |
| 330 | Is There a Role for Adjuvant Tamoxifen in Progesterone Receptor-Positive Breast Cancer? An In silico Clinical Trial. Clinical Cancer Research, 2006, 12, 1049s-1055s. | 3.2 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 331 | Development and Therapeutic Options for the Treatment of Raloxifene-Stimulated Breast Cancer in Athymic Mice. <i>Clinical Cancer Research</i> , 2006, 12, 2255-2263. | 3.2 | 34 |
| 332 | Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches. <i>Clinical Cancer Research</i> , 2006, 12, 4790-4793. | 3.2 | 59 |
| 333 | Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialistsâ€™ Collaborative Group overview. <i>Annals of Oncology</i> , 2006, 17, x59-x62. | 0.6 | 87 |
| 334 | Taxane-containing chemotherapy in the treatment of early breast cancer patients. <i>Annals of Oncology</i> , 2006, 17, vii22-vii26. | 0.6 | 10 |
| 335 | Estrogen-Regulated Genes Predict Survival in Hormone Receptorâ€“Positive Breast Cancers. <i>Journal of Clinical Oncology</i> , 2006, 24, 1656-1664. | 0.8 | 300 |
| 336 | What Is the Impact of Shared Decision Making on Treatment and Outcomes for Older Women With Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2006, 24, 4908-4913. | 0.8 | 107 |
| 337 | Breast Cancer in Young Women: Climbing for Progress in Care and Knowledge. <i>Women's Health</i> , 2006, 2, 717-732. | 0.7 | 6 |
| 338 | Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. <i>Annals of Oncology</i> , 2006, 17, 1205-1212. | 0.6 | 171 |
| 339 | Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 5664-5671. | 0.8 | 512 |
| 340 | The adjuvant endocrine treatment revolution: focus on anastrozole. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 301-312. | 1.5 | 2 |
| 341 | Breast Cancer: Achievements in Adjuvant Systemic Therapies in the Preâ€“Genomic Era. <i>Oncologist</i> , 2006, 11, 111-125. | 1.9 | 52 |
| 342 | Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5769-5779. | 0.8 | 314 |
| 343 | Distribution of GPR30, a Seven Membraneâ€“Spanning Estrogen Receptor, in Primary Breast Cancer and its Association with Clinicopathologic Determinants of Tumor Progression. <i>Clinical Cancer Research</i> , 2006, 12, 6359-6366. | 3.2 | 314 |
| 344 | Adjuvant Chemotherapy and Survival in Older Women With Hormone Receptorâ€“Negative Breast Cancer: Assessing Outcome in a Population-Based, Observational Cohort. <i>Journal of Clinical Oncology</i> , 2006, 24, 2757-2764. | 0.8 | 197 |
| 345 | Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 3756-3762. | 0.8 | 268 |
| 346 | Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93. <i>Journal of Clinical Oncology</i> , 2006, 24, 1332-1341. | 0.8 | 215 |
| 347 | FGFR4 Arg388 Allele Is Associated With Resistance to Adjuvant Therapy in Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 3747-3755. | 0.8 | 127 |
| 348 | Docetaxel, Doxorubicin and Cyclophosphamide (the TAC regimen): An Effective Adjuvant Treatment for Operable Breast Cancer. <i>Women's Health</i> , 2006, 2, 527-537. | 0.7 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 349 | Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data. <i>Current Medical Research and Opinion</i> , 2006, 22, 2479-2487. | 0.9 | 9 |
| 350 | Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. <i>British Journal of Cancer</i> , 2006, 95, 347-354. | 2.9 | 104 |
| 351 | Do older women with breast cancer benefit from adjuvant chemotherapy?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 652-653. | 4.3 | 2 |
| 352 | Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. <i>British Journal of Cancer</i> , 2006, 94, 1233-1236. | 2.9 | 27 |
| 353 | Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 540-551. | 4.3 | 222 |
| 354 | Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer. <i>British Journal of Cancer</i> , 2006, 95, 1626-1631. | 2.9 | 44 |
| 355 | Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 621-632. | 4.3 | 116 |
| 356 | Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. <i>British Journal of Cancer</i> , 2006, 94, 460-464. | 2.9 | 65 |
| 357 | Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides. <i>British Journal of Cancer</i> , 2006, 94, 1697-1702. | 2.9 | 23 |
| 358 | Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1355-1359. | 1.1 | 19 |
| 359 | Treatment options for older woman with early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 941-950. | 1.1 | 2 |
| 360 | Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer. <i>Oncologist</i> , 2006, 11, 541-552. | 1.9 | 132 |
| 361 | Axillary Lymph Node Nanometastases Are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2006, 12, 6696-6701. | 3.2 | 71 |
| 363 | The enigma of young age. <i>Annals of Oncology</i> , 2006, 17, 1475-1477. | 0.6 | 19 |
| 364 | Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. <i>Carcinogenesis</i> , 2007, 28, 2139-2142. | 1.3 | 35 |
| 365 | Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. <i>Journal of Clinical Oncology</i> , 2007, 25, 2006-2011. | 0.8 | 126 |
| 366 | Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492. | 0.8 | 835 |
| 367 | Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1845-1853. | 3.0 | 288 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 368 | Aromatase inhibitors in post-menopausal metastatic breast carcinoma. Expert Opinion on Investigational Drugs, 2007, 16, 1023-1036. | 1.9 | 4 |
| 369 | Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?. Expert Review of Anticancer Therapy, 2007, 7, 1463-1472. | 1.1 | 20 |
| 370 | Breast Cancer in the Elderly. Journal of Clinical Oncology, 2007, 25, 1882-1890. | 0.8 | 151 |
| 371 | Adjuvant Chemotherapy for High-Risk Operable Breast Cancer. Journal of Clinical Oncology, 2007, 25, 1642-1644. | 0.8 | 7 |
| 372 | Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biology and Therapy, 2007, 6, 308-312. | 1.5 | 115 |
| 373 | Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer. Cancer Research, 2007, 67, 818-826. | 0.4 | 75 |
| 374 | HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study. Journal of Clinical Oncology, 2007, 25, 662-668. | 0.8 | 118 |
| 375 | Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 2007, 25, 625-633. | 0.8 | 128 |
| 376 | Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Annals of Oncology, 2007, 18, viii36-viii44. | 0.6 | 27 |
| 377 | Problems With the Progesterone Receptor in Practice?. Journal of Clinical Oncology, 2007, 25, 1957-1959. | 0.8 | 10 |
| 378 | Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer. Japanese Journal of Clinical Oncology, 2007, 37, 1-8. | 0.6 | 19 |
| 379 | Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. British Journal of Cancer, 2007, 96, 1633-1638. | 2.9 | 10 |
| 380 | Postoperative wound complications and systemic recurrence in breast cancer. British Journal of Cancer, 2007, 97, 1211-1217. | 2.9 | 217 |
| 381 | Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (Arimidex™). Tj ETQq1 12078431452BT /O | 2.9 | 7 |
| 382 | Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case-control study. British Journal of Cancer, 2007, 96, 850-855. | 2.9 | 7 |
| 383 | Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer. Expert Review of Anticancer Therapy, 2007, 7, 1243-1253. | 1.1 | 8 |
| 384 | Comparative economic analysis of aromatase inhibitors and tamoxifen in the treatment of hormone-dependent breast cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 1675-1691. | 0.9 | 1 |
| 385 | Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. Translational Medicine Series, 2007, , 103-120. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 386 | Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. <i>Acta Oncologica</i> , 2007, 46, 133-145. | 0.8 | 93 |
| 387 | Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer. <i>Translational Medicine Series</i> , 2007, , 147-158. | 0.0 | 0 |
| 388 | Breast cancer prognostication and prediction: are we making progress?. <i>Annals of Oncology</i> , 2007, 18, viii3-viii7. | 0.6 | 52 |
| 389 | SERMs: Meeting the Promise of Multifunctional Medicines. <i>Journal of the National Cancer Institute</i> , 2007, 99, 350-356. | 3.0 | 104 |
| 390 | Reply to "Conclusions regarding relative cost utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature" by Delea et al.. <i>Annals of Oncology</i> , 2007, 18, 198-199. | 0.6 | 0 |
| 391 | Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. <i>Annals of Oncology</i> , 2007, 18, 1477-1483. | 0.6 | 73 |
| 392 | Adjuvant Therapy in the Elderly: Making the Right Decision. <i>Journal of Clinical Oncology</i> , 2007, 25, 1870-1875. | 0.8 | 75 |
| 393 | Editorial: Gene Expression Profile Assays As an Aid in Treatment Decision Making in Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2007, 3, 187-188. | 2.5 | 1 |
| 394 | Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients. <i>Acta Oncologica</i> , 2007, 46, 1178-1183. | 0.8 | 40 |
| 395 | Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 506-515. | 3.0 | 35 |
| 396 | Drug Insight: breast cancer prevention and tissue-targeted hormone replacement therapy. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 584-593. | 2.9 | 49 |
| 397 | Reducing the risk of late recurrence in hormone-responsive breast cancer. <i>Annals of Oncology</i> , 2007, 18, viii18-viii25. | 0.6 | 9 |
| 398 | Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens. <i>Journal of Clinical Oncology</i> , 2007, 25, 2522-2527. | 0.8 | 133 |
| 399 | Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results From the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 516-525. | 3.0 | 80 |
| 400 | Estrogen Receptors in BRCA1-Mutant Breast Cancer: Now You See Them, Now You Don't. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1655-1657. | 3.0 | 2 |
| 401 | The Decrease in Breast-Cancer Incidence in 2003 in the United States. <i>New England Journal of Medicine</i> , 2007, 356, 1670-1674. | 13.9 | 879 |
| 402 | New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. <i>Annals of Oncology</i> , 2007, 18, xii8-xii14. | 0.6 | 20 |
| 403 | Endocrine resistance in breast cancer: what really matters?. <i>Annals of Oncology</i> , 2007, 18, 1289-1291. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 404 | Breast cancer prognostication and prediction in the postgenomic era. <i>Annals of Oncology</i> , 2007, 18, 1293-1306. | 0.6 | 55 |
| 405 | Cancer du sein. , 2007, , . | | 2 |
| 406 | Cancer du sein surexprimant l'antigène HER-2/Neu: Comment prescrire le trastuzumab en situation adjuvante ?. , 2007, , 445-452. | | 1 |
| 407 | Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade. <i>Journal of Clinical Oncology</i> , 2007, 25, 1239-1246. | 0.8 | 711 |
| 408 | Pharmacodiagnosics and Targeted Therapies: A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer. <i>Oncologist</i> , 2007, 12, 397-405. | 1.9 | 37 |
| 409 | Exercise and menstrual function. <i>BMJ: British Medical Journal</i> , 2007, 334, 164-165. | 2.4 | 5 |
| 410 | Mechanical circulatory support in the UK. <i>BMJ: British Medical Journal</i> , 2007, 334, 167-168. | 2.4 | 4 |
| 411 | Pregnancy in women with a history of breast cancer. <i>BMJ: British Medical Journal</i> , 2007, 334, 166-167. | 2.4 | 6 |
| 412 | Translating animal research into clinical benefit. <i>BMJ: British Medical Journal</i> , 2007, 334, 163-164. | 2.4 | 124 |
| 413 | Breast Cancer Mortality Trends in the United States According to Estrogen Receptor Status and Age at Diagnosis. <i>Journal of Clinical Oncology</i> , 2007, 25, 1683-1690. | 0.8 | 187 |
| 414 | Optimal Use of Aromatase Inhibitors: To Lead or to Follow?. <i>Journal of Clinical Oncology</i> , 2007, 25, 2639-2641. | 0.8 | 6 |
| 415 | Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience. <i>Journal of Clinical Oncology</i> , 2007, 25, 3699-3704. | 0.8 | 282 |
| 416 | Optimal Treatment Strategies in Hormone-Responsive Early Breast Cancer: The Role of Aromatase Inhibitors. <i>Oncology Research and Treatment</i> , 2007, 30, 55-64. | 0.8 | 3 |
| 417 | Clinical Management Recommendations for Surveillance and Risk-Reduction Strategies for Hereditary Breast and Ovarian Cancer Among Individuals Carrying a Deleterious BRCA1 or BRCA2 Mutation. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2007, 29, 45-60. | 0.3 | 38 |
| 418 | Breast-Cancer Therapy: Looking Back to the Future. <i>New England Journal of Medicine</i> , 2007, 357, 1547-1549. | 13.9 | 16 |
| 419 | Local Therapy and Survival in Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1051-1052. | 13.9 | 15 |
| 420 | Follow-up of Patients with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1052-1053. | 13.9 | 1 |
| 421 | Case 32-2007. <i>New England Journal of Medicine</i> , 2007, 357, 1640-1648. | 13.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 422 | HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 1496-1506. | 13.9 | 531 |
| 423 | Hormone receptors in defining breast cancer prognosis—time for a rethink?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 204-205. | 4.3 | 6 |
| 424 | Taxanes for adjuvant treatment of early breast cancer. <i>The Cochrane Library</i> , 2007, , CD004421. | 1.5 | 111 |
| 425 | Treatment of muscle-invasive bladder cancer: is cystectomy enough?. <i>Nature Reviews Urology</i> , 2007, 4, 126-127. | 1.4 | 1 |
| 426 | Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 143-153. | 0.7 | 4 |
| 428 | Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. <i>Pharmacogenomics</i> , 2007, 8, 1-3. | 0.6 | 8 |
| 429 | Advances in the Adjuvant and Neoadjuvant Treatment of Breast Cancer. <i>Women's Health</i> , 2007, 3, 325-339. | 0.7 | 1 |
| 432 | Aromatase inhibitors: a safety comparison. <i>Expert Opinion on Drug Safety</i> , 2007, 6, 165-174. | 1.0 | 18 |
| 433 | Strategies in treating male breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 193-202. | 0.9 | 88 |
| 434 | The FACE Trial: Letrozole or Anastrozole as Initial Adjuvant Therapy?. <i>Cancer Investigation</i> , 2007, 25, 14-18. | 0.6 | 12 |
| 435 | The Prevention and Management of Distant Metastases in Women with Breast Cancer. <i>Cancer Investigation</i> , 2007, 25, 6-13. | 0.6 | 18 |
| 436 | Modifiable Risk Factors for Breast Cancer Recurrence: What Can We Tell Survivors?. <i>Journal of Women's Health</i> , 2007, 16, 177-190. | 1.5 | 30 |
| 437 | The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 627-634. | 1.1 | 11 |
| 438 | Follow-up of Patients with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 2505-2513. | 13.9 | 83 |
| 439 | Women's Interest in Gene Expression Analysis for Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2007, 25, 4628-4634. | 0.8 | 42 |
| 440 | Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2207-2209. | 1.1 | 16 |
| 441 | Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 167-170. | 3.0 | 608 |
| 442 | Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. <i>Annals of Oncology</i> , 2007, 18, 1177-1184. | 0.6 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 443 | Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk. <i>Journal of Clinical Oncology</i> , 2007, 25, 3871-3876. | 0.8 | 134 |
| 444 | Continuing declines in cancer mortality in the European Union. <i>Annals of Oncology</i> , 2007, 18, 593-595. | 0.6 | 46 |
| 445 | Can Biology Trump Anatomy? Do All Node-Positive Patients With Breast Cancer Need Chemotherapy?. <i>Journal of Clinical Oncology</i> , 2007, 25, 2501-2503. | 0.8 | 17 |
| 446 | Some Aspects of the Endocrine Profile and Management of Hormone-Dependent Male Breast Cancer. <i>Oncologist</i> , 2007, 12, 798-807. | 1.9 | 20 |
| 447 | Recent Major Progress in Long-Term Cancer Patient Survival Disclosed by Modeled Period Analysis. <i>Journal of Clinical Oncology</i> , 2007, 25, 3274-3280. | 0.8 | 107 |
| 448 | Different Prognostic Value of Cytokeratin-19 mRNA-Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5194-5202. | 0.8 | 238 |
| 449 | Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2007, 99, 365-375. | 3.0 | 715 |
| 450 | The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm. <i>Clinical Cancer Research</i> , 2007, 13, 6921-6925. | 3.2 | 52 |
| 451 | First-Line Treatment Options for Patients with HER2-Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy. <i>Oncologist</i> , 2007, 12, 785-797. | 1.9 | 27 |
| 452 | Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 131-136. | 1.8 | 45 |
| 453 | Phase III Trial of Concurrent or Sequential Adjuvant Chemoradiotherapy After Conservative Surgery for Early-Stage Breast Cancer: Final Results of the ARCOSEIN Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 405-410. | 0.8 | 83 |
| 454 | Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2777-2785. | 1.9 | 32 |
| 455 | Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3808-3815. | 0.8 | 551 |
| 456 | Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment. <i>Journal of Clinical Oncology</i> , 2007, 25, 1858-1869. | 0.8 | 287 |
| 457 | Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. <i>Annals of Oncology</i> , 2007, 18, 45-51. | 0.6 | 90 |
| 458 | Clinical trials in emergency situations. <i>BMJ: British Medical Journal</i> , 2007, 334, 165-166. | 2.4 | 13 |
| 459 | An Interpretation of the EBCTCG Data. <i>Oncologist</i> , 2007, 12, 505-509. | 1.9 | 6 |
| 460 | Long-term follow-up of the SBC 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. <i>Annals of Oncology</i> , 2007, 18, 694-700. | 0.6 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 462 | Breast cancer in elderly women: a different reality? Results from the NORA study. <i>Annals of Oncology</i> , 2007, 18, 991-996. | 0.6 | 51 |
| 463 | Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2664-2670. | 0.8 | 246 |
| 466 | Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. <i>Annals of Oncology</i> , 2007, 18, 874-880. | 0.6 | 67 |
| 467 | Extended Adjuvant Therapy for Breast Cancer How Much Is Enough?. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1825-1827. | 3.0 | 1 |
| 468 | Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2007, 3, 182-186. | 2.5 | 96 |
| 469 | Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?. <i>Journal of Clinical Oncology</i> , 2007, 25, 611-613. | 0.8 | 43 |
| 470 | Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor-Positive Tumors of Tamoxifen-Treated Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2007, 13, 1405-1411. | 3.2 | 105 |
| 471 | Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2509-2515. | 0.8 | 72 |
| 472 | Lost Opportunities: Physicians' Reasons and Disparities in Breast Cancer Treatment. <i>Journal of Clinical Oncology</i> , 2007, 25, 2516-2521. | 0.8 | 104 |
| 473 | Preoperative Chemotherapy for Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2665. | 3.8 | 13 |
| 474 | Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose. <i>Cancer Research</i> , 2007, 67, 6995-7002. | 0.4 | 29 |
| 475 | Prognostic Implications of HER-2 Status in Steroid Receptor-Positive, Lymph Node-Negative Breast Carcinoma. <i>American Journal of Clinical Pathology</i> , 2007, 127, 780-786. | 0.4 | 13 |
| 476 | First-Line Chemotherapy for HER-2-Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment. <i>Oncologist</i> , 2007, 12, 1288-1298. | 1.9 | 11 |
| 477 | New Criteria for Selecting Elderly Patients for Breast Cancer Adjuvant Treatment Studies. <i>Oncologist</i> , 2007, 12, 952-959. | 1.9 | 16 |
| 478 | Effects of a phytoestrogen-containing soy extract on the growth-inhibitory activity of ICI 182 780 in an experimental model of estrogen-dependent breast cancer. <i>Endocrine-Related Cancer</i> , 2007, 14, 317-324. | 1.6 | 6 |
| 479 | Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623. <i>Journal of Clinical Oncology</i> , 2007, 25, 1677-1682. | 0.8 | 45 |
| 480 | Incidence and Prognosis of Synchronous and Metachronous Bilateral Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4210-4216. | 0.8 | 182 |
| 481 | Relationship Between Epidemiologic Risk Factors and Breast Cancer Recurrence. <i>Journal of Clinical Oncology</i> , 2007, 25, 4438-4444. | 0.8 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 482 | Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 196-205. | 3.0 | 260 |
| 483 | Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 272-282. | 3.0 | 510 |
| 484 | Tamoxifen: An Enduring Star. <i>Journal of the National Cancer Institute</i> , 2007, 99, 258-260. | 3.0 | 16 |
| 485 | Reducing the risk of early recurrence in hormone-responsive breast cancer. <i>Annals of Oncology</i> , 2007, 18, viii8-viii17. | 0.6 | 5 |
| 486 | Can a 70-gene signature provide useful prognostic information in patients with node-negative breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 216-217. | 4.3 | 4 |
| 487 | Gene Expression Signatures to Predict the Development of Metastasis in Breast Cancer. <i>Breast Disease</i> , 2007, 26, 149-156. | 0.4 | 15 |
| 489 | Publication Bias in Systematic Reviews. <i>Archives of General Psychiatry</i> , 2007, 64, 868. | 13.8 | 8 |
| 490 | The Phenotypic Spectrum of Basal-like Breast Cancers: A Critical Appraisal. <i>Advances in Anatomic Pathology</i> , 2007, 14, 358-373. | 2.4 | 70 |
| 491 | Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. <i>International Journal of Oncology</i> , 0, , . | 1.4 | 3 |
| 492 | The Rationale for Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 377-383. | 0.5 | 18 |
| 493 | Use of Adjuvant Systemic Therapy for Early Breast Cancer among Women 65 Years of Age and Older. <i>Cancer Control</i> , 2007, 14, 63-68. | 0.7 | 9 |
| 494 | Tolerance to Chemotherapy in Elderly Patients with Cancer. <i>Cancer Control</i> , 2007, 14, 44-56. | 0.7 | 93 |
| 495 | Dose-dense chemotherapy for primary breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007, 19, 75-81. | 0.9 | 11 |
| 496 | Granulocyte colony-stimulating factors: finding the right indication. <i>Current Opinion in Oncology</i> , 2007, 19, 299-307. | 1.1 | 24 |
| 497 | Breast Cancer Adjuvant Endocrine Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 148-155. | 1.0 | 14 |
| 498 | The Alphabet Soup of Chemotherapy. <i>Plastic Surgical Nursing</i> , 2007, 27, 173-175. | 0.3 | 0 |
| 499 | Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. <i>Anti-Cancer Drugs</i> , 2007, 18, 477-485. | 0.7 | 75 |
| 500 | The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review. <i>Current Opinion in Oncology</i> , 2007, 19, 564-572. | 1.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 501 | Breast Cancer Chemotherapy. Cancer Journal (Sudbury, Mass), 2007, 13, 141-147. | 1.0 | 15 |
| 502 | Roles for estrogen in bone loss and arthralgia during aromatase inhibitor treatment. Current Opinion in Oncology, 2007, 19, S1-S8. | 1.1 | 7 |
| 503 | Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications. Current Opinion in Oncology, 2007, 19, S9-S18. | 1.1 | 8 |
| 504 | Tamoxifen or Aromatase Inhibitors in Breast Cancer: Efficacy and Safety. Acta Chirurgica Belgica, 2007, 107, 240-256. | 0.2 | 2 |
| 505 | Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo. International Journal of Oncology, 2007, . . | 1.4 | 8 |
| 506 | Adjuvant Therapy of Colon Cancer: Current Status and Future Directions. Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT/Overl | 1.0 | 56 |
| 507 | Anastrozole therapy for postmenopausal women with early breast cancer. Expert Review of Obstetrics and Gynecology, 2007, 2, 279-291. | 0.4 | 0 |
| 508 | Tamoxifen: using pharmacogenetics to rediscover an old drug. Breast Cancer Online: BCO, 2007, 10, . | 0.1 | 0 |
| 509 | Efficacy of Selective Estrogen Receptor Modulators in Nude Mice Bearing Human Transitional Cell Carcinoma. Urology, 2007, 69, 1221-1226. | 0.5 | 56 |
| 510 | Managing High-Risk Breast Cancer. Seminars in Oncology Nursing, 2007, 23, 29-36. | 0.7 | 1 |
| 511 | Advances in Hormonal Therapy for Breast Cancer. Seminars in Oncology Nursing, 2007, 23, 46-54. | 0.7 | 27 |
| 512 | Choosing the Appropriate Breast Cancer Therapy for Today's Breast Cancer Patient. Seminars in Oncology Nursing, 2007, 23, S3-S9. | 0.7 | 1 |
| 513 | Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids, 2007, 72, 7-25. | 0.8 | 282 |
| 514 | New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids, 2007, 72, 829-842. | 0.8 | 147 |
| 515 | Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations. European Journal of Cancer, 2007, 43, 46-52. | 1.3 | 20 |
| 516 | The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. European Journal of Cancer, 2007, 43, 527-535. | 1.3 | 28 |
| 517 | Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: A randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. European Journal of Cancer, 2007, 43, 331-340. | 1.3 | 15 |
| 518 | Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. European Journal of Cancer, 2007, 43, 877-884. | 1.3 | 55 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 519 | DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. <i>European Journal of Cancer</i> , 2007, 43, 1679-1686. | 1.3 | 103 |
| 520 | Radiotherapy and tamoxifen after mastectomy in postmenopausal women – 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCC II:I. <i>European Journal of Cancer</i> , 2007, 43, 2100-2108. | 1.3 | 20 |
| 521 | Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of life. <i>European Journal of Cancer</i> , 2007, 43, 1644-1645. | 1.3 | 2 |
| 522 | Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?. <i>European Journal of Cancer</i> , 2007, 43, 2270-2278. | 1.3 | 26 |
| 523 | A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer – GABG-IV B-93. <i>European Journal of Cancer</i> , 2007, 43, 2351-2358. | 1.3 | 23 |
| 524 | The significance of the site of recurrence to subsequent breast cancer survival. <i>European Journal of Surgical Oncology</i> , 2007, 33, 420-423. | 0.5 | 36 |
| 525 | Local recurrence in breast carcinoma patients with T1–2 and 1–3 positive nodes: Indications for radiotherapy. <i>European Journal of Surgical Oncology</i> , 2007, 33, 28-32. | 0.5 | 26 |
| 526 | Justifying adjuvant chemotherapy in breast cancer: A survey of women and healthcare professionals. <i>European Journal of Surgical Oncology</i> , 2007, 33, 838-842. | 0.5 | 5 |
| 527 | Revised prognostic table to guide practitioners advising patients on adjuvant systematic therapy in early breast cancer. <i>European Journal of Surgical Oncology</i> , 2007, 33, 1211-1212. | 0.5 | 2 |
| 528 | Reducing the Risk for Breast Cancer Recurrence After Completion of Tamoxifen Treatment in Postmenopausal Women. <i>Clinical Therapeutics</i> , 2007, 29, 1535-1547. | 1.1 | 15 |
| 529 | Commentary: Evidence profiles for breast cancer: Benefit/Harms data based on the totality of randomized evidence. <i>Cancer Treatment Reviews</i> , 2007, 33, 85-86. | 3.4 | 0 |
| 530 | The 17q12-q21 amplicon: Her2 and topoisomerase-III± and their importance to the biology of solid tumours. <i>Cancer Treatment Reviews</i> , 2007, 33, 64-77. | 3.4 | 69 |
| 531 | Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. <i>Cancer Treatment Reviews</i> , 2007, 33, 474-483. | 3.4 | 16 |
| 532 | Reducing the risk of distant metastases in breast cancer patients: Role of aromatase inhibitors. <i>Cancer Treatment Reviews</i> , 2007, 33, 681-687. | 3.4 | 11 |
| 533 | Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. <i>Bone</i> , 2007, 40, 205-210. | 1.4 | 66 |
| 534 | Towards optimal endocrine therapy for hormone-sensitive breast cancer: Initial versus sequential adjuvant aromatase inhibition. <i>Cancer Letters</i> , 2007, 248, 165-174. | 3.2 | 7 |
| 535 | Adjuvant endocrine therapy for early breast cancer. <i>Cancer Letters</i> , 2007, 251, 17-27. | 3.2 | 8 |
| 536 | Effect of N,N-didesmethyltamoxifen upon DNA adduct formation by tamoxifen and 1±-hydroxytamoxifen. <i>Cancer Letters</i> , 2007, 257, 191-198. | 3.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 538 | Aromatase inhibitors – Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 55-61. | 1.2 | 2 |
| 540 | An alternative model of cancer cell growth and metastasis. International Journal of Surgery, 2007, 5, 73-75. | 1.1 | 9 |
| 541 | Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment. Radiotherapy and Oncology, 2007, 82, 287-293. | 0.3 | 32 |
| 542 | Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40) Tj ETQq1 1 0.784314 rgBT /Overlock 11 272-280. | 0.3 | 129 |
| 543 | Evidence based radiation oncology: Breast cancer. Radiotherapy and Oncology, 2007, 84, 84-101. | 0.3 | 99 |
| 544 | Questions about adjuvant trastuzumab still remain. Lancet, The, 2007, 369, 3-5. | 6.3 | 21 |
| 545 | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, The, 2007, 369, 29-36. | 6.3 | 1,361 |
| 546 | Survival and safety of exemestane versus tamoxifen after 2 – 3 years' tamoxifen treatment (Intergroup) Tj ETQq1 1 0.784314 rgBT /Ov 6.3 805 | 6.3 | 805 |
| 547 | Exemestane or tamoxifen? – Authors' reply. Lancet, The, 2007, 369, 1600-1601. | 6.3 | 0 |
| 548 | Ovarian suppression for early breast cancer. Lancet, The, 2007, 369, 1668-1670. | 6.3 | 1 |
| 549 | Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet, The, 2007, 369, 1711-1723. | 6.3 | 366 |
| 550 | Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 5815-5824. | 0.8 | 285 |
| 551 | Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncology, The, 2007, 8, 55-62. | 5.1 | 92 |
| 552 | Quantitative measures of oestrogen receptor and ERBB2 expression. Lancet Oncology, The, 2007, 8, 184-185. | 5.1 | 2 |
| 553 | How to kill two herpes viruses with one stone. Lancet Oncology, The, 2007, 8, 185-187. | 5.1 | 0 |
| 554 | Triple-negative breast cancer: therapeutic options. Lancet Oncology, The, 2007, 8, 235-244. | 5.1 | 769 |
| 555 | Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncology, The, 2007, 8, 940-949. | 5.1 | 40 |
| 557 | Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncology, The, 2007, 8, 1079-1087. | 5.1 | 268 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 558 | Breast cancer genomics: real-time use. <i>Lancet Oncology</i> , The, 2007, 8, 1045-1047. | 5.1 | 3 |
| 559 | Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2007, 8, 1101-1115. | 5.1 | 313 |
| 560 | Serial transplantation of NMU-induced rat mammary tumors: A model of human breast cancer progression. <i>International Journal of Cancer</i> , 2007, 121, 474-485. | 2.3 | 18 |
| 561 | To bury TNM classification in breast cancer or to praise it?. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 23-29. | 2.2 | 1 |
| 562 | Chemoprevention of breast cancer with selective oestrogen-receptor modulators. <i>Nature Reviews Cancer</i> , 2007, 7, 46-53. | 12.8 | 198 |
| 563 | Evaluating adjuvant hormonal therapy in early-stage breast cancer: a comparison of predictive decision models. <i>Community Oncology</i> , 2007, 4, 277-282. | 0.2 | 0 |
| 564 | Adjuvant Endocrine Treatment of Early Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 223-238. | 0.9 | 15 |
| 565 | Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. <i>The Cochrane Library</i> , 2007, , CD004921. | 1.5 | 68 |
| 566 | Adjuvant endocrine therapy for premenopausal women with early breast cancer. <i>Breast Cancer Research</i> , 2007, 9, 115. | 2.2 | 17 |
| 567 | Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. <i>Breast Cancer Research</i> , 2007, 9, R70. | 2.2 | 26 |
| 568 | Tumour dormancy in breast cancer: an update. <i>Breast Cancer Research</i> , 2007, 9, 208. | 2.2 | 93 |
| 569 | Is breast cancer prognosis inherited?. <i>Breast Cancer Research</i> , 2007, 9, R39. | 2.2 | 53 |
| 570 | Molecular response to aromatase inhibitor treatment in primary breast cancer. <i>Breast Cancer Research</i> , 2007, 9, R37. | 2.2 | 109 |
| 571 | An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells. <i>Breast Cancer Research</i> , 2007, 9, R38. | 2.2 | 45 |
| 572 | Oxford Overview. <i>Breast Cancer Research</i> , 2007, 9, . | 2.2 | 3 |
| 573 | Oestrogen is bad for patients with breast cancer?. <i>Breast Cancer Research</i> , 2007, 9, . | 2.2 | 1 |
| 575 | Preoperative chemotherapy for women with operable breast cancer. <i>The Cochrane Library</i> , 2007, , CD005002. | 1.5 | 205 |
| 576 | Overview of Adjuvant Systemic Therapy in Early Stage Breast Cancer. <i>Surgical Clinics of North America</i> , 2007, 87, 499-509. | 0.5 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 577 | Highlights from: The 24th Annual Miami Breast Cancer Conference; Miami, FL; March 14-17, 2007. Supportive Cancer Therapy, 2007, 4, 137-144. | 0.3 | 1 |
| 578 | Integrating Trastuzumab and Radiation into the Adjuvant Treatments of Breast Cancer. Breast Diseases, 2007, 18, 18-20. | 0.0 | 0 |
| 579 | The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer. Expert Review of Anticancer Therapy, 2007, 7, 1089-1094. | 1.1 | 11 |
| 580 | Tumor-Associated Proteolytic Factors uPA and PAI-1: Critical Appraisal of Their Clinical Relevance in Breast Cancer and Their Integration into Decision-Support Algorithms. Critical Reviews in Clinical Laboratory Sciences, 2007, 44, 179-201. | 2.7 | 34 |
| 581 | Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations. Expert Opinion on Pharmacotherapy, 2007, 8, 2347-2357. | 0.9 | 2 |
| 582 | Molecularly Targeted Therapeutics for Breast Cancer. BioDrugs, 2007, 21, 215-224. | 2.2 | 15 |
| 583 | Progression of endocrine therapies for breast cancer: where are we headed?. Expert Review of Anticancer Therapy, 2007, 7, 1651-1664. | 1.1 | 3 |
| 584 | Update on the use of letrozole in breast cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2329-2345. | 0.9 | 2 |
| 585 | A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/Neu-Positive Breast Cancer. Journal of Clinical Oncology, 2007, 25, 634-641. | 0.8 | 115 |
| 586 | Transcriptomic signatures in breast cancer. Molecular BioSystems, 2007, 3, 466. | 2.9 | 10 |
| 587 | Quality of life and adjuvant systemic therapy for early-stage breast cancer. Expert Review of Anticancer Therapy, 2007, 7, 1123-1134. | 1.1 | 28 |
| 588 | Renaming "Chemobrain". Cancer Investigation, 2007, 25, 373-377. | 0.6 | 129 |
| 589 | Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. Acta Oncologica, 2007, 46, 525-533. | 0.8 | 43 |
| 590 | Biomarqueurs moléculaires prédictifs du bénéfice des chimiothérapies dans le cancer du sein non métastatique: limites actuelles et apport potentiel des nouveaux outils statistiques et biotechnologiques. , 2007, , 307-313. | | 0 |
| 591 | American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology, 2007, 25, 5287-5312. | 0.8 | 1,998 |
| 592 | Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Annals of Oncology, 2007, 18, viii26-viii35. | 0.6 | 113 |
| 593 | Inference of Tamoxifen's Effects on Prevention of Breast Cancer From a Randomized Controlled Trial. Journal of the American Statistical Association, 2007, 102, 1235-1244. | 1.8 | 8 |
| 594 | Adjuvant Chemotherapy for Early-Stage Breast Cancer. Hematology/Oncology Clinics of North America, 2007, 21, 207-222. | 0.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 595 | 1â€“60 Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. <i>Breast Diseases</i> , 2007, 18, 99-100. | 0.0 | 0 |
| 596 | Oncologic Principles in Breast Reconstruction. <i>Clinics in Plastic Surgery</i> , 2007, 34, 1-13. | 0.7 | 5 |
| 597 | Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study. <i>Journal of Urology</i> , 2007, 177, 1777-1781. | 0.2 | 45 |
| 598 | A Multidisciplinary Approach to the Management of Breast Cancer, Part 2: Therapeutic Considerations. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1131-1140. | 1.4 | 20 |
| 599 | Local Therapy and Survival in Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 356, 2399-2405. | 13.9 | 287 |
| 600 | 2â€“59 High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients. <i>Breast Diseases</i> , 2007, 18, 200-201. | 0.0 | 0 |
| 601 | Anatomy Versus Biology: To What Extent Should Estrogen Receptor Status Influence the Decision to Recommend Adjuvant Chemotherapy?. <i>Breast Diseases</i> , 2007, 18, 232-234. | 0.0 | 0 |
| 602 | Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. <i>Breast Diseases</i> , 2007, 18, 314-316. | 0.0 | 0 |
| 603 | 4â€“58 HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. <i>Breast Diseases</i> , 2007, 17, 397-398. | 0.0 | 0 |
| 604 | The MINDACT trial: The first prospective clinical validation of a genomic tool. <i>Molecular Oncology</i> , 2007, 1, 246-251. | 2.1 | 117 |
| 605 | Tamoxifen-associated vasculitis in a breast cancer patient. <i>World Journal of Surgical Oncology</i> , 2007, 5, 9. | 0.8 | 9 |
| 606 | Treatment of Premenopausal Women with Early Breast Cancer. <i>Drugs</i> , 2007, 67, 1393-1401. | 4.9 | 11 |
| 607 | Luteinizing Hormone-Releasing Hormone Agonists in Premenopausal Hormone Receptorâ€“Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2007, 7, 455-464. | 1.1 | 21 |
| 608 | The Use of Taxanes in the Neoadjuvant Treatment of Breast Cancer: A Review of Randomized Phase II/III Trials. <i>Clinical Breast Cancer</i> , 2007, 7, 764-774. | 1.1 | 4 |
| 609 | Impact of Chemotherapy in Women with Metastatic Breast Cancer Diagnosed 1990-2003. <i>Clinical Breast Cancer</i> , 2007, 7, 801-803. | 1.1 | 1 |
| 610 | Adjuvant systemic therapy for operable breast cancer. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2007, 5, 101-106. | 0.8 | 0 |
| 611 | Early Breast Cancer Therapy and Cardiovascular Injury. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1435-1441. | 1.2 | 385 |
| 612 | Predicting risk of breast cancer recurrence using gene-expression profiling. <i>Pharmacogenomics</i> , 2007, 8, 101-111. | 0.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 613 | Use of the Oncotype DX [®] , [†] 21-Gene Assay to Guide Adjuvant Decision Making in Early-Stage Breast Cancer. <i>Molecular Diagnosis and Therapy</i> , 2007, 11, 355-360. | 1.6 | 20 |
| 614 | Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. <i>Pharmacogenomics</i> , 2007, 8, 1359-1368. | 0.6 | 4 |
| 615 | Raloxifene. , 2007, , 103-121. | | 5 |
| 617 | Breast Cancer in Older Patients. <i>Breast Care</i> , 2007, 2, 386-390. | 0.8 | 1 |
| 619 | Experience of Ovarian Function Suppression Therapy: Endocrine Response Preand Perimenopausal Korean Breast Cancer Patients in the Adjuvant Setting. <i>Journal of Breast Cancer</i> , 2007, 10, 134. | 0.8 | 0 |
| 620 | Arzoxifene: the evidence for its development in the management of breast cancer. <i>Core Evidence</i> , 0, . | 4.7 | 4 |
| 621 | Point: Combination Versus Single-Agent Chemotherapy: The Argument for Sequential Single Agents. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, 766-770. | 2.3 | 3 |
| 622 | Symptom-Oriented Follow-Up of Early Breast Cancer "as Good as Conventional Control and Sparing Resources. <i>Oncology Research and Treatment</i> , 2007, 30, 410-412. | 0.8 | 1 |
| 623 | AGO Recommendations for the Diagnosis and Therapy of Breast Cancer. <i>Breast Care</i> , 2007, 2, 244-250. | 0.8 | 2 |
| 624 | Words, words, words. <i>Medical Journal of Australia</i> , 2007, 187, 255-256. | 0.8 | 0 |
| 625 | Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. <i>International Journal of Oncology</i> , 2007, 31, 557-65. | 1.4 | 23 |
| 626 | Age-related patterns of care of breast cancer patients. <i>Women's Oncology Review</i> , 2007, 6, 93-95. | 0.0 | 0 |
| 627 | Prognostic effect of estrogen receptor status across age in primary breast cancer. <i>International Journal of Cancer</i> , 2008, 122, 1089-1094. | 2.3 | 139 |
| 628 | Recurrences and second primary breast cancers in older women with initial early-stage disease. <i>Cancer</i> , 2007, 109, 966-974. | 2.0 | 69 |
| 629 | Early discontinuation of tamoxifen. <i>Cancer</i> , 2007, 109, 832-839. | 2.0 | 254 |
| 630 | Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer. <i>Cancer</i> , 2007, 109, 1011-1018. | 2.0 | 178 |
| 631 | Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma. <i>Cancer</i> , 2007, 109, 1060-1067. | 2.0 | 30 |
| 632 | Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen. <i>Cancer</i> , 2007, 109, 1927-1928. | 2.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 634 | Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy. <i>Cancer</i> , 2007, 109, 2197-2204. | 2.0 | 12 |
| 635 | Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. <i>Cancer</i> , 2007, 110, 489-498. | 2.0 | 101 |
| 636 | Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. <i>Cancer</i> , 2007, 110, 499-508. | 2.0 | 21 |
| 637 | Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer. <i>Cancer</i> , 2007, 110, 1130-1138. | 2.0 | 289 |
| 638 | Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin. <i>Cancer</i> , 2007, 110, 1195-1200. | 2.0 | 62 |
| 639 | Accelerated partial breast irradiation. <i>Cancer</i> , 2007, 110, 1187-1194. | 2.0 | 47 |
| 640 | CYP2D6 polymorphisms and the impact on tamoxifen therapy. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 2224-2231. | 1.6 | 89 |
| 641 | Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 1-8. | 2.0 | 2 |
| 642 | Disparities in Breast Cancer. <i>Current Problems in Cancer</i> , 2007, 31, 134-156. | 1.0 | 38 |
| 643 | Improving Adjuvant Chemotherapy in Breast Cancer – Can We Get More for Less with TACT2?. <i>Clinical Oncology</i> , 2007, 19, 593-595. | 0.6 | 2 |
| 644 | Breast Cancer Patients With 10 or More Involved Axillary Lymph Nodes Treated by Multimodality Therapy: Influence of Clinical Presentation on Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 364-369. | 0.4 | 6 |
| 645 | Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 43, 1086-1093. | 1.4 | 15 |
| 646 | Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer. <i>Psycho-Oncology</i> , 2007, 16, 48-59. | 1.0 | 46 |
| 647 | Keeping faith with trial volunteers. <i>Nature</i> , 2007, 446, 137-138. | 13.7 | 22 |
| 648 | Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. <i>British Journal of Cancer</i> , 2007, 96, 639-645. | 2.9 | 94 |
| 649 | Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12%155 patients. <i>British Journal of Cancer</i> , 2007, 96, 1504-1513. | 2.9 | 763 |
| 650 | Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. <i>British Journal of Cancer</i> , 2007, 97, 1642-1647. | 2.9 | 8 |
| 651 | Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. <i>Modern Pathology</i> , 2007, 20, 1307-1315. | 2.9 | 97 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 652 | Critical review of the management of early-stage breast cancer in elderly women. <i>Internal Medicine Journal</i> , 2007, 37, 181-189. | 0.5 | 27 |
| 653 | Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?. <i>Histopathology</i> , 2007, 51, 491-498. | 1.6 | 61 |
| 654 | Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. <i>Cancer Science</i> , 2007, 99, 071027181834001-??? | 1.7 | 20 |
| 655 | Expression level of beta protein 1 mRNA in Chinese breast cancer patients: A potential molecular marker for poor prognosis. <i>Cancer Science</i> , 2007, 99, 071114225009001-??? | 1.7 | 14 |
| 656 | Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective. <i>Breast Journal</i> , 2007, 13, 28-35. | 0.4 | 54 |
| 657 | Phase I/II Trial of Adjuvant Dose-Dense Docetaxel/Epirubicin/Cyclophosphamide (TEC) in Stage II and III Breast Cancer. <i>Breast Journal</i> , 2007, 13, 274-280. | 0.4 | 11 |
| 658 | Cyclin D-1, Interleukin-6, HER-2/neu, Transforming Growth Factor Receptor-II and Prediction of Relapse in Women with Early Stage, Hormone Receptor-Positive Breast Cancer Treated with Tamoxifen. <i>Breast Journal</i> , 2007, 13, 337-345. | 0.4 | 14 |
| 659 | Effectiveness of Adjuvant Tamoxifen Therapy among Older Women with Early Stage Breast Cancer. <i>Breast Journal</i> , 2007, 13, 374-382. | 0.4 | 13 |
| 660 | Cost-Benefit Analysis of a Follow-up Program in Patients with Breast Cancer: A Randomized Prospective Study. <i>Breast Journal</i> , 2007, 13, 571-574. | 0.4 | 33 |
| 661 | Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 964-978. | 1.2 | 153 |
| 662 | Quality Indicators for the Care of Breast Cancer in Vulnerable Elders. <i>Journal of the American Geriatrics Society</i> , 2007, 55, S258-69. | 1.3 | 5 |
| 663 | Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer. <i>Value in Health</i> , 2007, 10, 367-376. | 0.1 | 29 |
| 664 | A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007, 114, 1510-1515. | 1.1 | 58 |
| 665 | The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. <i>International Journal of Clinical Practice</i> , 2007, 61, 2051-2063. | 0.8 | 154 |
| 666 | Prospective evaluation of cognitive function in patients with early breast cancer receiving adjuvant chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 125-133. | 0.7 | 14 |
| 667 | Evolving Nonendocrine Therapeutic Options for Metastatic Breast Cancer: How Adjuvant Chemotherapy Influences Treatment. <i>Clinical Breast Cancer</i> , 2007, 7, 841-849. | 1.1 | 13 |
| 668 | Clinical Course of 771 Patients with Bilateral Breast Cancer: Characteristics Associated with Overall and Recurrence-Free Survival. <i>Clinical Breast Cancer</i> , 2007, 7, 867-874. | 1.1 | 28 |
| 669 | Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model. <i>BMC Cancer</i> , 2007, 7, 26. | 1.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 670 | Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. <i>Breast</i> , 2007, 16, 307-315. | 0.9 | 25 |
| 671 | Patients'™ knowledge and experience of adjuvant endocrine therapy for early breast cancer: A European study. <i>Breast</i> , 2007, 16, 462-468. | 0.9 | 48 |
| 672 | Endocrine therapy for breast cancer: an overview. <i>Breast</i> , 2007, 16, 327-343. | 0.9 | 52 |
| 673 | Prescribing extended adjuvant letrozole. <i>Breast</i> , 2007, 16, 446-455. | 0.9 | 3 |
| 674 | The evolution of adjuvant endocrine therapy: Developments since St Gallen 2005. <i>Breast</i> , 2007, 16, 4-9. | 0.9 | 4 |
| 675 | Follow-up care of patients with breast cancer. <i>Breast</i> , 2007, 16, 45-50. | 0.9 | 17 |
| 676 | Disseminated tumor cells: Are they ready for clinical use?. <i>Breast</i> , 2007, 16, 51-54. | 0.9 | 4 |
| 677 | Using clinical trial data to tailor adjuvant treatments for individual patients. <i>Breast</i> , 2007, 16, 98-104. | 0.9 | 4 |
| 678 | Post-mastectomy radiation therapy: Translating local benefits into improved survival. <i>Breast</i> , 2007, 16, 78-83. | 0.9 | 20 |
| 679 | Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. <i>Breast</i> , 2007, 16, 105-113. | 0.9 | 20 |
| 680 | Current status of the taxanes as adjuvant therapy for breast cancer. <i>Breast</i> , 2007, 16, 132-135. | 0.9 | 1 |
| 681 | How to treat male breast cancer. <i>Breast</i> , 2007, 16, 147-154. | 0.9 | 41 |
| 682 | Adjuvant treatment of elderly breast cancer patients. <i>Breast</i> , 2007, 16, 159-165. | 0.9 | 21 |
| 683 | Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. <i>Breast</i> , 2007, 16, 127-131. | 0.9 | 18 |
| 684 | Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis. <i>Breast</i> , 2007, 16, 1-9. | 0.9 | 11 |
| 685 | Adjuvant therapy for breast cancer. <i>Surgery</i> , 2007, 25, 272-275. | 0.1 | 3 |
| 687 | 2007 Highlights from: The 2007 American Society of Clinical Oncology Breast Cancer Symposium; San Francisco, CA; September 7-8, 2007. <i>Clinical Breast Cancer</i> , 2007, 7, 734-738. | 1.1 | 3 |
| 688 | S22 State of the art of post mastectomy radiation therapy (PMRT). <i>Breast</i> , 2007, 16, S6-S7. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 689 | S23 Partial breast irradiation: Ready for Routine?. Breast, 2007, 16, S7. | 0.9 | 0 |
| 690 | S24 Systemic adjuvant therapies and radiotherapy to the conserved breast: Strategies revisited. Breast, 2007, 16, S7. | 0.9 | 0 |
| 691 | S25 The diversity of small tumors around the world: Are there implications for local and systemic therapies?. Breast, 2007, 16, S7-S8. | 0.9 | 0 |
| 692 | Estrogen Receptors: How Do They Signal and What Are Their Targets. Physiological Reviews, 2007, 87, 905-931. | 13.1 | 1,489 |
| 693 | Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. Breast Cancer, 2007, 14, 16-24. | 1.3 | 42 |
| 694 | Current clinical trials of endocrine therapy for breast cancer. Breast Cancer, 2007, 14, 200-214. | 1.3 | 13 |
| 695 | Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer, 2007, 14, 113-122. | 1.3 | 26 |
| 696 | UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the) Tj ETQq1 1 0.784314 rgBT /Over Direction. Surgery Today, 2007, 37, 923-943. | 0.7 | 26 |
| 697 | Controversies in Surgical Oncology: Routine Anthracycline-based Adjuvant Chemotherapy for Stage III Extremity Soft Tissue Sarcoma. Annals of Surgical Oncology, 2007, 14, 1254-1256. | 0.7 | 8 |
| 698 | Treatment Trends and Factors Associated with Survival in T1aNO and T1bNO Breast Cancer Patients. Annals of Surgical Oncology, 2007, 14, 2918-2927. | 0.7 | 37 |
| 699 | Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life, 2007, 59, 450-457. | 1.5 | 208 |
| 703 | Cardiac Risks in Multimodal Breast Cancer Treatment. Strahlentherapie Und Onkologie, 2007, 183, 9-10. | 1.0 | 5 |
| 704 | Breast Cancer Local Recurrence: Risk Factors and Prognostic Relevance of Early Time to Recurrence. World Journal of Surgery, 2007, 31, 36-45. | 0.8 | 38 |
| 705 | Lymph Node Ratio is More Valuable than Level III Involvement for Prediction of Outcome in Node-Positive Breast Carcinoma Patients. World Journal of Surgery, 2007, 31, 276-289. | 0.8 | 46 |
| 706 | Familial multiple myeloma: first case reported in a Mexican family. Annals of Hematology, 2007, 86, 527-528. | 0.8 | 1 |
| 707 | Factors affecting health-related quality of life in women with recurrent breast cancer in Korea. Quality of Life Research, 2007, 16, 559-569. | 1.5 | 16 |
| 708 | SERMs for the treatment and prevention of breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 229-239. | 2.6 | 72 |
| 709 | Aromatase inhibitors for breast cancer. Reviews in Endocrine and Metabolic Disorders, 2007, 8, 215-228. | 2.6 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 710 | Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Research and Treatment, 2007, 101, 215-223. | 1.1 | 57 |
| 711 | Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Research and Treatment, 2007, 102, 173-179. | 1.1 | 41 |
| 712 | Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer. Breast Cancer Research and Treatment, 2007, 102, 301-312. | 1.1 | 8 |
| 713 | Breast cancer patients on adjuvant chemotherapy report a wide range of problems not identified by health-care staff. Breast Cancer Research and Treatment, 2007, 103, 185-195. | 1.1 | 27 |
| 714 | Identifying menopause in breast cancer patients: considerations and implications. Breast Cancer Research and Treatment, 2007, 104, 115-120. | 1.1 | 31 |
| 715 | Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Research and Treatment, 2007, 105, 69-80. | 1.1 | 53 |
| 716 | Provider's volume and quality of breast cancer detection and treatment. Breast Cancer Research and Treatment, 2007, 105, 117-132. | 1.1 | 10 |
| 717 | Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Research and Treatment, 2007, 105, 169-175. | 1.1 | 20 |
| 718 | Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Research and Treatment, 2007, 105, 347-357. | 1.1 | 70 |
| 719 | Trends in breast cancer treatment in Korea and impact of compliance with consensus recommendations on survival. Breast Cancer Research and Treatment, 2007, 106, 245-253. | 1.1 | 14 |
| 720 | Study of time-course changes in annual recurrence rates for breast cancer: data analysis of 2,209 patients for 10 years post-surgery. Breast Cancer Research and Treatment, 2007, 106, 407-411. | 1.1 | 19 |
| 721 | TGF β 2 and T β RII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Research and Treatment, 2007, 107, 15-24. | 1.1 | 21 |
| 722 | Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Research and Treatment, 2007, 105, 45-53. | 1.1 | 64 |
| 723 | Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Research and Treatment, 2007, 105, 55-66. | 1.1 | 39 |
| 724 | A decade of letrozole: FACE. Breast Cancer Research and Treatment, 2007, 105, 67-74. | 1.1 | 17 |
| 725 | The patient experience. Breast Cancer Research and Treatment, 2007, 105, 91-103. | 1.1 | 11 |
| 726 | Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Research and Treatment, 2007, 105, 75-89. | 1.1 | 22 |
| 730 | Continuing with letrozole offers greater benefits. Journal of Cancer Research and Clinical Oncology, 2007, 133, 445-453. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 731 | Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: Als upfront vs. switching. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 905-916. | 1.2 | 3 |
| 732 | Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 134, 7-17. | 1.2 | 3 |
| 733 | The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations. <i>Current Treatment Options in Oncology</i> , 2007, 8, 47-60. | 1.3 | 29 |
| 734 | Integrating Circulating Tumor Cell Assays into the Management of Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2007, 8, 89-95. | 1.3 | 26 |
| 735 | Adjuvant endocrine therapies for premenopausal women. <i>Clinical and Translational Oncology</i> , 2007, 9, 369-374. | 1.2 | 0 |
| 736 | Current controversies in the management of early breast cancer. <i>Clinical and Translational Oncology</i> , 2007, 9, 375-84. | 1.2 | 3 |
| 737 | Pathological features of primary breast cancer in the elderly based on needle core biopsies—A large series from a single centre. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 263-267. | 2.0 | 49 |
| 738 | Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. <i>Patient Education and Counseling</i> , 2008, 72, 239-245. | 1.0 | 21 |
| 739 | Viability analysis and apoptosis induction of breast cancer cells in a microfluidic device: effect of cytostatic drugs. <i>Biomedical Microdevices</i> , 2008, 10, 727-737. | 1.4 | 45 |
| 740 | Exploring the two-gene ratio in breast cancer—Independent roles for HOXB13 and IL17BR in prediction of clinical outcome. <i>Breast Cancer Research and Treatment</i> , 2008, 107, 225-234. | 1.1 | 58 |
| 741 | An overview of prognostic factors for long-term survivors of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 107, 309-330. | 1.1 | 396 |
| 742 | Controversies in preservation of ovary function and fertility in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 1-7. | 1.1 | 42 |
| 743 | Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 259-264. | 1.1 | 10 |
| 744 | HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 183-190. | 1.1 | 85 |
| 745 | Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 255-262. | 1.1 | 59 |
| 746 | A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 343-350. | 1.1 | 40 |
| 747 | Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 231-239. | 1.1 | 137 |
| 748 | Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 463-470. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 749 | The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 559-566. | 1.1 | 44 |
| 750 | Breast cancer in elderly women. Optimizing the treatment. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 199-209. | 1.1 | 22 |
| 751 | The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 317-326. | 1.1 | 55 |
| 752 | Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). <i>Breast Cancer Research and Treatment</i> , 2008, 110, 411-416. | 1.1 | 66 |
| 753 | Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 261-267. | 1.1 | 25 |
| 754 | Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 89-98. | 1.1 | 77 |
| 755 | Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 99-108. | 1.1 | 36 |
| 756 | Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 175-187. | 1.1 | 49 |
| 757 | Extending the benefits of adjuvant therapy in early HR+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 45-52. | 1.1 | 6 |
| 758 | Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 53-66. | 1.1 | 44 |
| 759 | Improving decision-making in early breast cancer: who to treat and how?. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 15-24. | 1.1 | 14 |
| 760 | Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 25-34. | 1.1 | 33 |
| 761 | Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG). <i>Breast Cancer Research and Treatment</i> , 2008, 112, 557-563. | 1.1 | 5 |
| 762 | On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern Netherlands. <i>Cancer Causes and Control</i> , 2008, 19, 97-106. | 0.8 | 64 |
| 763 | BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 727-740. | 1.7 | 40 |
| 766 | Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivors. <i>Journal of Cancer Survivorship</i> , 2008, 2, 296-302. | 1.5 | 65 |
| 767 | The role of ovarian ablation in the adjuvant therapy of breast cancer. <i>Current Oncology Reports</i> , 2008, 10, 27-37. | 1.8 | 11 |
| 768 | Breast cancer follow-up in the adjuvant setting. <i>Current Oncology Reports</i> , 2008, 10, 38-46. | 1.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 769 | (Neo-)adjuvant chemotherapy in breast cancer – Trials, errors and new rationales from the SABCS 2007. Memo - Magazine of European Medical Oncology, 2008, 1, 23-26. | 0.3 | 0 |
| 770 | Adjuvant chemotherapy in breast cancer. Memo - Magazine of European Medical Oncology, 2008, 1, 91-98. | 0.3 | 2 |
| 771 | Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer, 2008, 15, 31-34. | 1.3 | 24 |
| 772 | Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature. Breast Cancer, 2008, 15, 262-269. | 1.3 | 8 |
| 773 | Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer, 2008, 15, 278-290. | 1.3 | 35 |
| 774 | Recent topics in endocrine therapy for hormone-dependent breast cancer: basic research and clinical applications. Breast Cancer, 2008, 15, 253-255. | 1.3 | 1 |
| 775 | Understanding the BIG results: Insights from the BIG –98 trial analyses. Advances in Therapy, 2008, 25, 1257-1275. | 1.3 | 4 |
| 776 | Under Utilization of Surveillance Mammography among Older Breast Cancer Survivors. Journal of General Internal Medicine, 2008, 23, 158-163. | 1.3 | 80 |
| 777 | Understanding and management of male breast cancer: a critical review. Medical Oncology, 2008, 25, 294-298. | 1.2 | 40 |
| 778 | Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clinical and Translational Oncology, 2008, 10, 646-653. | 1.2 | 52 |
| 779 | Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer. Clinical and Translational Oncology, 2008, 10, 739-744. | 1.2 | 2 |
| 780 | –New–molecular taxonomy in breast cancer. Clinical and Translational Oncology, 2008, 10, 777-785. | 1.2 | 16 |
| 784 | Update of evidence in chemotherapy for breast cancer. International Journal of Clinical Oncology, 2008, 13, 3-7. | 1.0 | 16 |
| 785 | Current research topics in endocrine therapy for breast cancer. International Journal of Clinical Oncology, 2008, 13, 380-383. | 1.0 | 30 |
| 786 | Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. International Journal of Clinical Oncology, 2008, 13, 384-394. | 1.0 | 16 |
| 787 | Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. European Journal of Health Economics, 2008, 9, 171-183. | 1.4 | 31 |
| 788 | Breast cancer: medical management of early stage breast cancer. Critical Reviews in Oncology/Hematology, 2008, 68, S15-S16. | 2.0 | 0 |
| 789 | Competing risk and heterogeneity of treatment effect in clinical trials. Trials, 2008, 9, 30. | 0.7 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 790 | Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer. <i>Trials</i> , 2008, 9, 47. | 0.7 | 15 |
| 791 | The UPS: a promising target for breast cancer treatment. <i>BMC Biochemistry</i> , 2008, 9, S2. | 4.4 | 20 |
| 792 | Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer. <i>Cancer</i> , 2008, 112, 260-267. | 2.0 | 119 |
| 794 | Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients. <i>Cancer</i> , 2008, 112, 731-736. | 2.0 | 56 |
| 795 | The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999-2004. <i>Cancer</i> , 2008, 112, 737-747. | 2.0 | 153 |
| 796 | Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. <i>Cancer</i> , 2008, 112, 1437-1444. | 2.0 | 36 |
| 797 | Prognostic significance of HER2 status in women with inflammatory breast cancer. <i>Cancer</i> , 2008, 112, 1905-1911. | 2.0 | 54 |
| 798 | Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy. <i>Cancer</i> , 2008, 113, 38-47. | 2.0 | 31 |
| 799 | The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. <i>Cancer</i> , 2008, 113, 1489-1495. | 2.0 | 14 |
| 800 | Guideline implementation for breast healthcare in low- and middle-income countries: Treatment resource allocation. <i>Cancer</i> , 2008, 113, 2269-2281. | 2.0 | 75 |
| 801 | Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. <i>International Journal of Cancer</i> , 2008, 123, 526-534. | 2.3 | 42 |
| 802 | Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 171-180. | 2.0 | 23 |
| 803 | Implications of applied research for prognosis and therapy of breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 223-234. | 2.0 | 6 |
| 804 | Overcoming challenges associated with chemotherapy treatment in the senior adult population. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, S1-S8. | 2.0 | 30 |
| 805 | National Cancer Institute Patient Navigation Research Program. <i>Cancer</i> , 2008, 113, 3391-3399. | 2.0 | 291 |
| 806 | The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations. <i>Annals of Surgical Oncology</i> , 2008, 15, 21-33. | 0.7 | 108 |
| 807 | The Importance of Surgical Margin Control in Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2008, 15, 659-660. | 0.7 | 1 |
| 808 | Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant Settings. <i>Annals of Surgical Oncology</i> , 2008, 15, 691-703. | 0.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 809 | Outcomes of Locoregional Recurrence after Surgical Chest Wall Resection and Reconstruction for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 1322-1329. | 0.7 | 28 |
| 810 | A Novel Assay to Assess the Effectiveness of Antiangiogenic Drugs in Human Breast Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 3407-14. | 0.7 | 5 |
| 811 | Screening for Recurrences in Patients Treated with Breast-Conserving Surgery: Is there a Role for MRI?. <i>Annals of Surgical Oncology</i> , 2008, 15, 1703-1709. | 0.7 | 33 |
| 812 | Clinical Application of the 70-Gene Profile: The MINDACT Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 729-735. | 0.8 | 449 |
| 813 | National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. <i>Clinical Chemistry</i> , 2008, 54, e11-e79. | 1.5 | 539 |
| 814 | Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?. <i>Clinical Cancer Research</i> , 2008, 14, 3646-3650. | 3.2 | 104 |
| 815 | Understanding reasons for underuse: An approach to improve quality and reduce disparities in breast cancer treatmentrr. <i>Mount Sinai Journal of Medicine</i> , 2008, 75, 23-30. | 1.9 | 11 |
| 817 | New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target?. <i>Apmis</i> , 2008, 116, 552-568. | 0.9 | 37 |
| 818 | The utility of MRI for the screening and staging of breast cancer. <i>International Journal of Clinical Practice</i> , 2008, 62, 450-453. | 0.8 | 10 |
| 819 | Pre-treatment with anastrozole may be the optimal treatment sequence with radiotherapy for breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 27-33. | 0.7 | 0 |
| 820 | Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. <i>British Journal of Cancer</i> , 2008, 99, 616-621. | 2.9 | 56 |
| 821 | tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. <i>British Journal of Cancer</i> , 2008, 99, 597-603. | 2.9 | 20 |
| 822 | Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease. <i>British Journal of Cancer</i> , 2008, 99, 774-780. | 2.9 | 47 |
| 823 | Cancer survival in England and Wales at the end of the 20th century. <i>British Journal of Cancer</i> , 2008, 99, S2-S10. | 2.9 | 105 |
| 824 | Survival from breast cancer in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2008, 99, S56-S58. | 2.9 | 2 |
| 825 | Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. <i>British Journal of Cancer</i> , 2008, 99, 1763-1768. | 2.9 | 292 |
| 826 | Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. <i>British Journal of Cancer</i> , 2008, 99, 1769-1774. | 2.9 | 36 |
| 827 | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>British Journal of Cancer</i> , 2008, 99, 1775-1785. | 2.9 | 56 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 828 | Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 160-166. | 2.3 | 158 |
| 829 | Advances in the Treatment of Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 26-36. | 2.3 | 105 |
| 830 | Role of Endocrine Responsiveness and HER2/neu Overexpression in Inflammatory Breast Cancer Treated with Multimodality Preoperative Therapy. <i>Breast Journal</i> , 2008, 14, 435-441. | 0.4 | 7 |
| 831 | Hormone Receptor and HER-2 Expression in Breast Cancers Among Sub-Saharan African Women. <i>Breast Journal</i> , 2008, 14, 510-511. | 0.4 | 26 |
| 832 | Women's experience of physical activity following breast cancer treatment. <i>Scandinavian Journal of Caring Sciences</i> , 2008, 22, 422-429. | 1.0 | 34 |
| 833 | LAPAROSCOPIC OOPHORECTOMY IN THE MANAGEMENT OF BREAST DISEASE. <i>ANZ Journal of Surgery</i> , 2008, 78, 670-672. | 0.3 | 15 |
| 834 | Comment on "Impact of CYP2D6 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy". <i>Cancer Science</i> , 2008, 99, 1706-1707. | 1.7 | 5 |
| 835 | Adaptation of the Herdecke Quality of Life questionnaire towards quality of life of cancer patients. <i>European Journal of Cancer Care</i> , 2008, 17, 593-600. | 0.7 | 2 |
| 836 | Recent Advances in the Hormonal Treatment of Breast Cancer. <i>Current Problems in Surgery</i> , 2008, 45, 13-55. | 0.6 | 5 |
| 837 | Do racial/ethnic disparities exist in the utilization of high-volume surgeons for women with ovarian cancer?. <i>Gynecologic Oncology</i> , 2008, 111, 166-172. | 0.6 | 43 |
| 838 | Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. <i>BMC Cancer</i> , 2008, 8, 309. | 1.1 | 63 |
| 839 | The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery. <i>BMC Cancer</i> , 2008, 8, 323. | 1.1 | 21 |
| 840 | Aromatase Inhibitors for Breast Cancer: Proven Efficacy Across the Spectrum of Disease. <i>Clinical Breast Cancer</i> , 2008, 8, 50-64. | 1.1 | 26 |
| 841 | Low-Dose Estrogen Therapy to Reverse Acquired Antihormonal Resistance in the Treatment of Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 124-133. | 1.1 | 21 |
| 842 | Insight into Barriers Against Optimal Adherence to Oral Hormonal Therapy in Women with Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 155-161. | 1.1 | 73 |
| 843 | Trastuzumab Administration Associated with Change in HER2 Status. <i>Clinical Breast Cancer</i> , 2008, 8, 366-369. | 1.1 | 6 |
| 844 | Extended Adjuvant Endocrine Therapy in Breast Cancer: Current Status and Future Directions. <i>Clinical Breast Cancer</i> , 2008, 8, 411-417. | 1.1 | 35 |
| 845 | Prolonged Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel in Breast Cancer Is Feasible. <i>Clinical Breast Cancer</i> , 2008, 8, 418-424. | 1.1 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 846 | Overcoming Recurrence Risk: Extended Adjuvant Endocrine Therapy. <i>Clinical Breast Cancer</i> , 2008, 8, 493-500. | 1.1 | 12 |
| 847 | Clinical Experience with Etoposides in Patients with Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, S71-S78. | 1.1 | 6 |
| 848 | Current Paradigms for the Use of HER2-Targeted Therapy in Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, S157-S165. | 1.1 | 30 |
| 849 | New Understanding of the Role of Anthracyclines in Early-Stage Breast Cancer: Patient Selection Considerations. <i>Clinical Breast Cancer</i> , 2008, 8, S179-S183. | 1.1 | 13 |
| 850 | Tamoxifen in breast cancer: Not so easy to write off. <i>Breast</i> , 2008, 17, 121-124. | 0.9 | 8 |
| 851 | Translating trial data into patients benefits: Making the right choice. <i>Breast</i> , 2008, 17, 9-15. | 0.9 | 10 |
| 852 | Postmastectomy locoregional recurrence and distant metastasis in breast carcinoma patients. <i>Breast</i> , 2008, 17, 367-371. | 0.9 | 5 |
| 853 | Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients. <i>Breast</i> , 2008, 17, 323-334. | 0.9 | 353 |
| 854 | Reducing early recurrence with adjuvant aromatase inhibitors: What is the evidence?. <i>Breast</i> , 2008, 17, 353-360. | 0.9 | 4 |
| 855 | Tolerance of adjuvant letrozole outside of clinical trials. <i>Breast</i> , 2008, 17, 376-381. | 0.9 | 49 |
| 856 | The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions. <i>Breast</i> , 2008, 17, 436-440. | 0.9 | 44 |
| 857 | Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage II and operable stage III Taiwanese breast cancer patients. <i>Breast</i> , 2008, 17, 646-653. | 0.9 | 14 |
| 858 | Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole. <i>Breast</i> , 2008, 17, 631-636. | 0.9 | 14 |
| 859 | Unraveling the Complexity of Endocrine Resistance in Breast Cancer by Functional Genomics. <i>Cancer Cell</i> , 2008, 13, 83-85. | 7.7 | 12 |
| 860 | Mortality Impact of Less-than-Standard Therapy in Older Breast Cancer Patients. <i>Journal of the American College of Surgeons</i> , 2008, 206, 66-75. | 0.2 | 143 |
| 861 | The Medical Treatment of Inflammatory Breast Cancer. <i>Seminars in Oncology</i> , 2008, 35, 64-71. | 0.8 | 38 |
| 862 | Adjuvant Chemotherapy and Hormonal Therapy for Older Adults With Breast Cancer. <i>Seminars in Oncology</i> , 2008, 35, 618-624. | 0.8 | 4 |
| 863 | The importance of distant metastases in hormone-sensitive breast cancer. <i>Breast</i> , 2008, 17, S3-S8. | 0.9 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 864 | A review of the BIG results: the Breast International Group 1â€“98 trial analyses. <i>Breast</i> , 2008, 17, S9-S14. | 0.9 | 17 |
| 865 | The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. <i>Breast</i> , 2008, 17, S15-S24. | 0.9 | 4 |
| 866 | 2007 Highlights from: The 2007 San Antonio Breast Cancer Symposium San Antonio, TX December 13-16, 2007. <i>Clinical Breast Cancer</i> , 2008, 8, 26-32. | 1.1 | 0 |
| 867 | Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. <i>Seminars in Cancer Biology</i> , 2008, 18, 311-321. | 4.3 | 236 |
| 868 | Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. <i>Oral Oncology</i> , 2008, 44, 162-173. | 0.8 | 80 |
| 869 | Breast Cancer and Fertility Preservation. <i>Placenta</i> , 2008, 29, 147-151. | 0.7 | 3 |
| 870 | Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor. <i>Surgical Oncology</i> , 2008, 17, 113-128. | 0.8 | 1 |
| 871 | Hormonal therapy for cancer. <i>Medicine</i> , 2008, 36, 29-32. | 0.2 | 0 |
| 872 | Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma. <i>Cancer Investigation</i> , 2008, 26, 1024-1031. | 0.6 | 91 |
| 873 | Differentiating Proteomic Biomarkers in Breast Cancer by Laser Capture Microdissection and MALDI MS. <i>Journal of Proteome Research</i> , 2008, 7, 1500-1507. | 1.8 | 57 |
| 874 | Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e34. | 1.6 | 33 |
| 875 | Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. <i>Cancer Investigation</i> , 2008, 26, 1-10. | 0.6 | 170 |
| 876 | Hormones and Mammary Cell Fateâ€”What Will I Become When I Grow Up?. <i>Endocrinology</i> , 2008, 149, 4317-4321. | 1.4 | 57 |
| 877 | Aromatase Inhibitors in Early Hormone Receptor-Positive Breast Cancer. <i>Drugs</i> , 2008, 68, 1-15. | 4.9 | 5 |
| 878 | A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. <i>Clinical Breast Cancer</i> , 2008, 8, 287-292. | 1.1 | 23 |
| 879 | Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, S100-S113. | 1.1 | 37 |
| 880 | Adjuvant therapy of melanoma with interferon: lessons of the past decade. <i>Journal of Translational Medicine</i> , 2008, 6, 62. | 1.8 | 64 |
| 881 | Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. <i>New England Journal of Medicine</i> , 2008, 358, 1663-1671. | 13.9 | 855 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 882 | Pregnancy after treatment of breast cancer – A population-based study on behalf of Danish Breast Cancer Cooperative Group. <i>Acta Oncologica</i> , 2008, 47, 545-549. | 0.8 | 117 |
| 883 | Epidermal Growth Factor Induces G Protein-Coupled Receptor 30 Expression in Estrogen Receptor-Negative Breast Cancer Cells. <i>Endocrinology</i> , 2008, 149, 3799-3808. | 1.4 | 131 |
| 884 | Estrogen Signaling through the Transmembrane G Protein-Coupled Receptor GPR30. <i>Annual Review of Physiology</i> , 2008, 70, 165-190. | 5.6 | 539 |
| 885 | Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 1-6. | 2.2 | 4 |
| 886 | Recent advances in breast cancer radiotherapy. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 13-14. | 2.2 | 0 |
| 887 | State of the art of adjuvant therapy. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 27-30. | 2.2 | 0 |
| 888 | The endocrine prevention of breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 615-623. | 2.2 | 38 |
| 889 | State of the art therapy for elderly patients with early-stage and locally advanced breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 22-27. | 2.2 | 2 |
| 890 | Treatment of HER-2 positive breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 21-25. | 2.2 | 0 |
| 891 | Making the right choice in the adjuvant chemotherapy of primary breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 10-12. | 2.2 | 1 |
| 892 | Controversies in adjuvant endocrine therapy for pre- and post-menopausal women with breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 4-9. | 2.2 | 9 |
| 894 | Methods of Cancer Diagnosis, Therapy and Prognosis. , 2008, , . | | 23 |
| 896 | Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. <i>Breast Cancer Research</i> , 2008, 10, R103. | 2.2 | 29 |
| 897 | A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R93. | 2.2 | 113 |
| 898 | On the way to specifically targeting minimal residual disease?. <i>Breast Cancer Research</i> , 2008, 10, 112. | 2.2 | 3 |
| 899 | Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R89. | 2.2 | 113 |
| 900 | A candidate molecular signature associated with tamoxifen failure in primary breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R88. | 2.2 | 54 |
| 901 | Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. <i>Breast Cancer Research</i> , 2008, 10, R34. | 2.2 | 53 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 902 | Application of Protein Microarrays for Multiplexed Detection of Antibodies to Tumor Antigens in Breast Cancer. <i>Journal of Proteome Research</i> , 2008, 7, 1490-1499. | 1.8 | 140 |
| 903 | Surgical oophorectomy for breast cancer: back to the future. <i>Future Oncology</i> , 2008, 4, 785-792. | 1.1 | 0 |
| 904 | Polychemotherapy for Early Breast Cancer: Results from the International Adjuvant Breast Cancer Chemotherapy Randomized Trial. <i>Breast Diseases</i> , 2008, 18, 400-401. | 0.0 | 6 |
| 905 | MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1. <i>Journal of Biological Chemistry</i> , 2008, 283, 29897-29903. | 1.6 | 676 |
| 906 | Breast Cancer 2nd edition. , 2008, , . | | 3 |
| 907 | Chemotherapy for Breast Cancer. , 2008, , 345-385. | | 5 |
| 908 | Early Breast Cancer in the Elderly. <i>Drugs and Aging</i> , 2008, 25, 35-45. | 1.3 | 66 |
| 909 | Estrogen Receptor Pathways and Breast Cancer. , 2008, , 189-206. | | 2 |
| 910 | Cancer Pharmacogenomics: DNA Genotyping and Gene Expression Profiling to Identify Molecular Determinants of Chemosensitivity. <i>Drug Metabolism Reviews</i> , 2008, 40, 303-315. | 1.5 | 16 |
| 911 | Prognostic differences of World Health Organizationâ€‘assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years. <i>Human Pathology</i> , 2008, 39, 584-590. | 1.1 | 21 |
| 912 | Effects of tibolone and conventional HRT on the expression of estrogen and progesterone receptors in the breast. <i>Maturitas</i> , 2008, 61, 345-349. | 1.0 | 4 |
| 913 | Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a Phase III Randomized Study of Prostatectomy Versus Prostatectomy with Adjuvant Docetaxel for Patients with High-Risk, Localized Prostate Cancer. <i>Urology</i> , 2008, 72, 474-480. | 0.5 | 18 |
| 914 | Effect of risedronate on hip structural geometry: A 1-year, double-blind trial in chemotherapy-induced postmenopausal women. <i>Bone</i> , 2008, 43, 274-278. | 1.4 | 10 |
| 917 | Tamoxifen: Catalyst for the change to targeted therapy. <i>European Journal of Cancer</i> , 2008, 44, 30-38. | 1.3 | 174 |
| 918 | Travel time to hospital and treatment for breast, colon, rectum, lung, ovary and prostate cancer. <i>European Journal of Cancer</i> , 2008, 44, 992-999. | 1.3 | 149 |
| 919 | Prognostic versus predictive value of biomarkers in oncology. <i>European Journal of Cancer</i> , 2008, 44, 946-953. | 1.3 | 286 |
| 920 | Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990â€‘2006 in the southeastern Netherlands. <i>European Journal of Cancer</i> , 2008, 44, 1846-1854. | 1.3 | 36 |
| 921 | Molecular analysis of hormone receptor positive (luminal) breast cancers â€‘ What have we learnt?. <i>European Journal of Cancer</i> , 2008, 44, 2813-2818. | 1.3 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 922 | The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer. <i>European Journal of Internal Medicine</i> , 2008, 19, 592-597. | 1.0 | 26 |
| 923 | Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses. <i>European Journal of Oncology Nursing</i> , 2008, 12, 14-25. | 0.9 | 6 |
| 924 | Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women. <i>European Journal of Oncology Nursing</i> , 2008, 12, 180-189. | 0.9 | 88 |
| 925 | The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer. <i>European Journal of Oncology Nursing</i> , 2008, 12, 233-243. | 0.9 | 7 |
| 926 | A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer. <i>European Journal of Surgical Oncology</i> , 2008, 34, 149-153. | 0.5 | 14 |
| 927 | Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: Aromatase inhibitors versus tamoxifen. <i>European Journal of Surgical Oncology</i> , 2008, 34, 746-755. | 0.5 | 12 |
| 928 | Aromatase inhibitors in the management of early breast cancer. <i>European Journal of Surgical Oncology</i> , 2008, 34, 1199-1207. | 0.5 | 12 |
| 929 | Is the biology of breast cancer changing? A study of hormone receptor status 1984-86 and 1996-1997. <i>European Journal of Surgical Oncology</i> , 2008, 34, 1172. | 0.5 | 0 |
| 933 | Beyond tamoxifen: Extended and late extended endocrine therapy in postmenopausal early breast cancer. <i>Cancer Treatment Reviews</i> , 2008, 34, 137-144. | 3.4 | 11 |
| 934 | Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. <i>Cancer Treatment Reviews</i> , 2008, 34, 275-282. | 3.4 | 114 |
| 935 | Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2008, 34, 157-174. | 3.4 | 80 |
| 936 | Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines. <i>Cancer Treatment Reviews</i> , 2008, 34, 391-406. | 3.4 | 65 |
| 937 | Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. <i>Cancer Treatment Reviews</i> , 2008, 34, S3-S18. | 3.4 | 209 |
| 938 | Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2008, 34, 539-557. | 3.4 | 73 |
| 939 | Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. <i>Cancer Treatment Reviews</i> , 2008, 34, 701-709. | 3.4 | 21 |
| 941 | Impact of <i>CYP2D6</i> on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. <i>Cancer Science</i> , 2008, 99, 995-999. | 1.7 | 173 |
| 942 | Targeted therapies in breast cancer. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 245-261. | 1.0 | 39 |
| 943 | Misconceptions, Challenges, Uncertainty, and Progress in Guideline Recommendations. <i>Seminars in Hematology</i> , 2008, 45, 167-175. | 1.8 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 944 | American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. <i>Journal of Clinical Oncology</i> , 2008, 26, 3631-3637. | 0.8 | 205 |
| 945 | Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. <i>Lancet, The</i> , 2008, 371, 29-40. | 6.3 | 243 |
| 946 | Primary endpoints for randomised trials of cancer therapy. <i>Lancet, The</i> , 2008, 371, 2156-2158. | 6.3 | 34 |
| 947 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2008, 9, 45-53. | 5.1 | 929 |
| 948 | Long-term outcomes of aromatase inhibition for breast cancer. <i>Lancet Oncology, The</i> , 2008, 9, 8-10. | 5.1 | 3 |
| 949 | Pharmacogenomics of Tamoxifen and Irinotecan Therapies. <i>Clinics in Laboratory Medicine</i> , 2008, 28, 553-567. | 0.7 | 6 |
| 950 | Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. <i>Breast Diseases</i> , 2008, 19, 85. | 0.0 | 1 |
| 951 | Second Primary Cancers: An Overview. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 271-289. | 0.9 | 60 |
| 952 | A Transcriptional Fingerprint of Estrogen in Human Breast Cancer Predicts Patient Survival. <i>Neoplasia</i> , 2008, 10, 79-IN34. | 2.3 | 32 |
| 953 | Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 1767-1774. | 3.2 | 81 |
| 954 | Breast Disease: Benign and Malignant. <i>Medical Clinics of North America</i> , 2008, 92, 1115-1141. | 1.1 | 21 |
| 955 | Chemotherapeutic Management of Soft Tissue Sarcoma. <i>Surgical Clinics of North America</i> , 2008, 88, 647-660. | 0.5 | 26 |
| 956 | Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. <i>Breast Diseases</i> , 2008, 19, 80-81. | 0.0 | 0 |
| 957 | Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. <i>Breast Diseases</i> , 2008, 19, 81-83. | 0.0 | 0 |
| 958 | Adjuvant Dose-Dense Sequential Chemotherapy with Epirubicin, CMF and Weekly Paclitaxel in Patients with Resected High-Risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>Cancer Investigation</i> , 2008, 26, 491-498. | 0.6 | 6 |
| 959 | Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer. <i>Pharmacoeconomics</i> , 2008, 26, 409-423. | 1.7 | 14 |
| 960 | Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 44-53. | 0.8 | 389 |
| 961 | Reducing the Risk of Distant Metastases: A Better End Point in Adjuvant Aromatase Inhibitor Breast Cancer Trials?. <i>Cancer Investigation</i> , 2008, 26, 481-490. | 0.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 962 | An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18490-18495. | 3.3 | 484 |
| 963 | Use of LHRH-agonists as adjuvant therapy for breast cancer. Expert Opinion on Therapeutic Targets, 2008, 12, 1065-1071. | 1.5 | 1 |
| 964 | Never too late: reducing late breast cancer relapse risk. Current Medical Research and Opinion, 2008, 24, 3295-3305. | 0.9 | 5 |
| 965 | By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy. Breast Cancer Research, 2008, 10, S16. | 2.2 | 3 |
| 966 | Markers of endocrine sensitivity. Breast Cancer Research, 2008, 10, S18. | 2.2 | 7 |
| 967 | Cell Cycle Dysregulation Influences Survival in High Risk Breast Cancer Patients. Cancer Investigation, 2008, 26, 734-740. | 0.6 | 16 |
| 968 | Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health. Expert Opinion on Drug Safety, 2008, 7, 241-258. | 1.0 | 14 |
| 969 | High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS. Expert Review of Proteomics, 2008, 5, 445-455. | 1.3 | 7 |
| 970 | Cardiovascular complications associated with biological therapies for breast cancer. Expert Opinion on Biological Therapy, 2008, 8, 1551-1559. | 1.4 | 5 |
| 971 | Is long-term adjuvant treatment of breast cancer with anastrozole indicated?. Expert Opinion on Pharmacotherapy, 2008, 9, 1619-1622. | 0.9 | 2 |
| 972 | Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 252-260. | 3.0 | 156 |
| 973 | Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. Journal of Clinical Oncology, 2008, 26, 798-805. | 0.8 | 112 |
| 974 | Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance. Endocrine Reviews, 2008, 29, 217-233. | 8.9 | 470 |
| 975 | The Rise of Raloxifene and the Fall of Invasive Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 831-833. | 3.0 | 11 |
| 976 | HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. Journal of the National Cancer Institute, 2008, 100, 14-20. | 3.0 | 344 |
| 978 | Recent advances in adjuvant systemic therapy for early-stage breast cancer. Annals of Oncology, 2008, 19, v122-v127. | 0.6 | 9 |
| 979 | Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Annals of Oncology, 2008, 19, 1402-1406. | 0.6 | 14 |
| 980 | Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux. Journal of Pharmacy Practice, 2008, 21, 46-56. | 0.5 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 981 | Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. <i>Annals of Oncology</i> , 2008, 19, 861-870. | 0.6 | 93 |
| 982 | Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial. <i>Annals of Oncology</i> , 2008, 19, 1837-1841. | 0.6 | 17 |
| 983 | Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. <i>Journal of Clinical Oncology</i> , 2008, 26, 4063-4071. | 0.8 | 312 |
| 984 | Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response. <i>Oncologist</i> , 2008, 13, 6-15. | 1.9 | 23 |
| 985 | Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Oncologist</i> , 2008, 13, 620-630. | 1.9 | 205 |
| 986 | Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer. <i>Oncologist</i> , 2008, 13, 1224-1234. | 1.9 | 43 |
| 987 | Sequential Therapy With Tamoxifen and Aromatase Inhibitors in Early-Stage Postmenopausal Breast Cancer: A Review of the Evidence. <i>Oncology Nursing Forum</i> , 2008, 35, 714-721. | 0.5 | 2 |
| 988 | Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 264-270. | 0.8 | 36 |
| 989 | Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1972-1979. | 0.8 | 133 |
| 990 | Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2008, 26, 5697-5704. | 0.8 | 260 |
| 991 | Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 549-555. | 0.8 | 268 |
| 992 | Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib. <i>Journal of Clinical Oncology</i> , 2008, 26, 1253-1259. | 0.8 | 44 |
| 993 | The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer—Survival or Death?. <i>Journal of Clinical Oncology</i> , 2008, 26, 3073-3082. | 0.8 | 98 |
| 994 | Monitoring the Response of Circulating Epithelial Tumor Cells to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse. <i>Journal of Clinical Oncology</i> , 2008, 26, 1208-1215. | 0.8 | 264 |
| 995 | Moving Research From Bench to Bedside to Community: There Is Still More to Do. <i>Journal of Clinical Oncology</i> , 2008, 26, 523-526. | 0.8 | 13 |
| 996 | Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. <i>Journal of the National Cancer Institute</i> , 2008, 100, 32-40. | 3.0 | 82 |
| 997 | Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 5849-5854. | 0.8 | 49 |
| 998 | Impact of Estrogen Deprivation on Gene Expression Profiles of Normal Postmenopausal Breast Tissue <i>in vivo</i> . <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 855-863. | 1.1 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 999 | Hormonal Therapy for the Treatment of Postmenopausal Breast Cancer Patients. <i>Journal of Pharmacy Practice</i> , 2008, 21, 36-45. | 0.5 | 1 |
| 1000 | Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 1404-1410. | 0.8 | 97 |
| 1001 | Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial. <i>Future Oncology</i> , 2008, 4, 603-610. | 1.1 | 107 |
| 1002 | Predictive tests for individualization of pharmacological cancer treatment. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 349-360. | 1.6 | 13 |
| 1003 | p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. <i>Annals of Oncology</i> , 2008, 19, 1261-1265. | 0.6 | 53 |
| 1005 | Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer. <i>Breast Care</i> , 2008, 3, 43-50. | 0.8 | 20 |
| 1006 | Mammography Screening and Treatment of Breast Cancer in the Elderly. <i>Breast Care</i> , 2008, 3, 5-5. | 0.8 | 2 |
| 1007 | Node-Positive Breast Cancer: Which Are the Best Chemotherapy Regimens?. <i>Breast Care</i> , 2008, 3, 244-250. | 0.8 | 0 |
| 1008 | Node-Negative Breast Cancer: Which Patients Should Be Treated?. <i>Breast Care</i> , 2008, 3, 237-243. | 0.8 | 5 |
| 1009 | Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer. <i>Breast Care</i> , 2008, 3, 317-324. | 0.8 | 2 |
| 1010 | Adjuvant Endocrine Therapy in Premenopausal Patients. <i>Breast Care</i> , 2008, 3, 311-316. | 0.8 | 1 |
| 1011 | The Future of Breast Cancer Management. <i>Breast Care</i> , 2008, 3, 381-382. | 0.8 | 1 |
| 1012 | Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 191-194. | 1.1 | 1 |
| 1013 | Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1871-1881. | 1.1 | 6 |
| 1014 | Indications and limitations of third-generation aromatase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 723-739. | 1.9 | 18 |
| 1015 | Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 8019-8026. | 3.2 | 220 |
| 1016 | Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. <i>Journal of Clinical Oncology</i> , 2008, 26, 1948-1955. | 0.8 | 176 |
| 1017 | Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. <i>Journal of Clinical Oncology</i> , 2008, 26, 778-785. | 0.8 | 1,524 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1018 | Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1059-1065. | 0.8 | 409 |
| 1019 | The value of <i>TOP2A</i> gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. <i>Acta Oncologica</i> , 2008, 47, 725-734. | 0.8 | 101 |
| 1020 | Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1859-1869. | 1.1 | 21 |
| 1022 | Paclitaxel and docetaxel in the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2603-2616. | 0.9 | 105 |
| 1023 | Facts and controversies in the use of trastuzumab in the adjuvant setting. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 645-654. | 4.3 | 18 |
| 1024 | Tamoxifen for early breast cancer. <i>The Cochrane Library</i> , 2010, 2010, CD000486. | 1.5 | 56 |
| 1025 | Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4679-4683. | 0.8 | 30 |
| 1026 | Biomarkers in breast cancer. <i>Cancer Biology and Therapy</i> , 2008, 7, 21-22. | 1.5 | 3 |
| 1027 | Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 2644-2652. | 0.8 | 82 |
| 1028 | The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. <i>Annals of Oncology</i> , 2008, 19, 16-27. | 0.6 | 60 |
| 1029 | Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4891-4898. | 0.8 | 171 |
| 1030 | Survival After Adjuvant Oophorectomy and Tamoxifen in Operable Breast Cancer in Premenopausal Women. <i>Journal of Clinical Oncology</i> , 2008, 26, 253-257. | 0.8 | 32 |
| 1031 | Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing PITX2 DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 5036-5042. | 0.8 | 105 |
| 1032 | Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time. <i>Journal of Clinical Oncology</i> , 2008, 26, 1919-1921. | 0.8 | 10 |
| 1033 | Danish Breast Cancer Cooperative Group - DBCG: History, organization, and status of scientific achievements at 30-year anniversary. <i>Acta Oncologica</i> , 2008, 47, 497-505. | 0.8 | 69 |
| 1034 | Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. <i>Annals of Oncology</i> , 2008, 19, 1110-1116. | 0.6 | 107 |
| 1035 | Treatment of breast cancer in older women. <i>Acta Oncologica</i> , 2008, 47, 187-198. | 0.8 | 38 |
| 1036 | <i>TP53</i> Status and Response to Chemotherapy in Breast Cancer. <i>Pathobiology</i> , 2008, 75, 132-139. | 1.9 | 92 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1037 | Menopausal symptoms and adjuvant therapy-associated adverse events. <i>Endocrine-Related Cancer</i> , 2008, 15, 73-90. | 1.6 | 49 |
| 1038 | The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients. <i>Annals of Oncology</i> , 2008, 19, 1213-1215. | 0.6 | 1 |
| 1039 | A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?. <i>Journal of the National Cancer Institute</i> , 2008, 100, 610-613. | 3.0 | 36 |
| 1040 | Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions. <i>Oncologist</i> , 2008, 13, 1137-1148. | 1.9 | 31 |
| 1041 | Efficacy and safety of aromatase inhibitors in early breast cancer. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 547-558. | 1.0 | 4 |
| 1042 | Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study. <i>Annals of Oncology</i> , 2008, 19, 1698-1705. | 0.6 | 11 |
| 1043 | Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. <i>Annals of Oncology</i> , 2008, 19, 1231-1241. | 0.6 | 50 |
| 1044 | Improving Outcomes for Patients With Hormone Receptor-Positive Breast Cancer: Back to the Drawing Board. <i>Journal of the National Cancer Institute</i> , 2008, 100, 159-161. | 3.0 | 5 |
| 1045 | Predicting distant dissemination in patients with early breast cancer. <i>Acta Oncologica</i> , 2008, 47, 1113-1121. | 0.8 | 21 |
| 1046 | Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. <i>Acta Oncologica</i> , 2008, 47, 755-764. | 0.8 | 58 |
| 1047 | Anthracycline Cardiotoxicity: One Size Does Not Fit All!. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1046-1047. | 3.0 | 5 |
| 1048 | Impact of a Reduced Dose Intensity of Adjuvant Anthracycline Based Chemotherapy in a Population-Based Cohort of Stage I-II Breast Cancers. <i>Ecancermedalscience</i> , 2008, 2, 63. | 0.6 | 1 |
| 1050 | Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis. <i>Journal of the National Cancer Institute</i> , 2008, 100, 642-648. | 3.0 | 93 |
| 1051 | Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. <i>Annals of Oncology</i> , 2008, 19, 481-486. | 0.6 | 36 |
| 1052 | Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 805-814. | 3.0 | 208 |
| 1053 | Reducing Disparities in Breast Cancer Care—A Daunting but Essential Responsibility. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1661-1663. | 3.0 | 7 |
| 1054 | Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort. <i>Clinical Cancer Research</i> , 2008, 14, 2988-2993. | 3.2 | 140 |
| 1055 | Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer. <i>Acta Oncologica</i> , 2008, 47, 120-123. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1056 | The impact of age on Health-Related Quality of Life (HRQoL) and symptoms among postmenopausal women with breast cancer receiving adjuvant chemotherapy. <i>Acta Oncologica</i> , 2008, 47, 207-215. | 0.8 | 29 |
| 1057 | Inflammatory breast cancer in Tunisia in the era of multimodality therapy. <i>Annals of Oncology</i> , 2008, 19, 473-480. | 0.6 | 36 |
| 1058 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premenopausal patients with node-positive breast cancer: Indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. <i>Acta Oncologica</i> , 2008, 47, 662-671. | 0.8 | 11 |
| 1059 | DBCG trial 89B comparing adjuvant CMF and ovarian ablation: Similar outcome for eligible but non-enrolled and randomized breast cancer patients. <i>Acta Oncologica</i> , 2008, 47, 709-717. | 0.8 | 4 |
| 1060 | TIMP-1 as a tumor marker in breast cancer – An update. <i>Acta Oncologica</i> , 2008, 47, 580-590. | 0.8 | 78 |
| 1061 | Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry. <i>Acta Oncologica</i> , 2008, 47, 525-536. | 0.8 | 40 |
| 1062 | Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii7-ii10. | 0.6 | 30 |
| 1063 | Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer?. <i>Annals of Oncology</i> , 2008, 19, vii177-vii183. | 0.6 | 5 |
| 1064 | Challenges in treating older cancer patients: breast cancer. <i>Annals of Oncology</i> , 2008, 19, vii99-vii103. | 0.6 | 10 |
| 1065 | Nonhormonal Systemic Therapy for Advanced Breast Cancer: Do the Math!. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1745-1747. | 3.0 | 2 |
| 1066 | Protective Effect of Leuprolide on Ovarian Function in Young Women Treated with Adjuvant Chemotherapy for Early Breast Cancer: A Multicenter Phase II Study. <i>Journal of Chemotherapy</i> , 2008, 20, 740-743. | 0.7 | 9 |
| 1068 | Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1179-1183. | 3.0 | 280 |
| 1069 | Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse. <i>Clinical Cancer Research</i> , 2008, 14, 3306-3311. | 3.2 | 128 |
| 1070 | Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance. <i>Clinical Cancer Research</i> , 2008, 14, 5864-5868. | 3.2 | 23 |
| 1071 | GATA-3 Expression in Breast Cancer Has a Strong Association with Estrogen Receptor but Lacks Independent Prognostic Value. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 365-373. | 1.1 | 125 |
| 1072 | The CYP19 TTTA Repeat Polymorphism Is Related to the Prognosis of Premenopausal Stage II and Operable Stage III Breast Cancers. <i>Oncologist</i> , 2008, 13, 751-760. | 1.9 | 19 |
| 1073 | Randomization Reveals Unexpected Acute Leukemias in Southwest Oncology Group Prostate Cancer Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1532-1536. | 0.8 | 47 |
| 1074 | Tamoxifen Treatment in Danish Breast Cancer Patients and 5-Year Risk of Arterial Atherosclerotic Events: A Null Association. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2509-2511. | 1.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1075 | Update: A 62-Year-Old Woman With a New Diagnosis of Breast Cancer. JAMA - Journal of the American Medical Association, 2008, 299, 1055. | 3.8 | 0 |
| 1076 | Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis. Journal of Clinical Oncology, 2008, 26, 925-933. | 0.8 | 36 |
| 1077 | Breast Cancer Onset in Twins and Women With Bilateral Disease. Journal of Clinical Oncology, 2008, 26, 4086-4091. | 0.8 | 11 |
| 1078 | Magnetic Resonance Imaging in the Breast Cancer Patient: Curb Your Enthusiasm. Journal of Clinical Oncology, 2008, 26, 352-353. | 0.8 | 79 |
| 1079 | Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. Journal of Clinical Oncology, 2008, 26, 2636-2643. | 0.8 | 54 |
| 1080 | Roles of Radiotherapy and Chemotherapy in the Development of Contralateral Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5561-5568. | 0.8 | 96 |
| 1081 | Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management. Oncologist, 2008, 13, 838-844. | 1.9 | 133 |
| 1082 | Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?. Oncologist, 2008, 13, 222-231. | 1.9 | 67 |
| 1083 | Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. Journal of Clinical Oncology, 2008, 26, 2473-2481. | 0.8 | 212 |
| 1085 | Breast Cancer Screening in BRCA1 Mutation Carriers: Effectiveness of MR Imaging—Markov Monte Carlo Decision Analysis. Radiology, 2008, 246, 763-771. | 3.6 | 44 |
| 1086 | Staging MR Lymphangiography of the Axilla for Early Breast Cancer: Cost-Effectiveness Analysis. American Journal of Roentgenology, 2008, 191, 1308-1319. | 1.0 | 17 |
| 1087 | Adjuvant aromatase inhibitors and emerging quality-of-life considerations. Expert Review of Anticancer Therapy, 2008, 8, 1-4. | 1.1 | 4 |
| 1088 | To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?. Expert Review of Anticancer Therapy, 2008, 8, 9-13. | 1.1 | 4 |
| 1089 | Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. Journal of Clinical Oncology, 2008, 26, 1965-1971. | 0.8 | 317 |
| 1090 | Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression. American Journal of Psychiatry, 2008, 165, 1251-1255. | 4.0 | 91 |
| 1092 | Gene Expression Profiles in Breast Cancer to Identify Estrogen Receptor Target Genes. Mini-Reviews in Medicinal Chemistry, 2008, 8, 448-454. | 1.1 | 15 |
| 1093 | The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nature Clinical Practice Oncology, 2008, 5, 531-542. | 4.3 | 153 |
| 1095 | Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest—Mammella Intergruppo (GONO-MIG) Group. Annals of Oncology, 2008, 19, 299-307. | 0.6 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1096 | Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. <i>Annals of Oncology</i> , 2008, 19, 649-654. | 0.6 | 27 |
| 1097 | Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 376-377. | 4.3 | 1 |
| 1098 | Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact. <i>Clinical Cancer Research</i> , 2008, 14, 25-31. | 3.2 | 20 |
| 1099 | Controversies in the Management of Patients With Breast Cancer: Adjuvant Endocrine Therapy in Premenopausal Women. <i>Journal of Clinical Oncology</i> , 2008, 26, 745-752. | 0.8 | 31 |
| 1100 | Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5553-5560. | 0.8 | 32 |
| 1101 | Type-1 receptor tyrosine kinases as predictive or prognostic markers in early breast cancer. <i>Biomarkers in Medicine</i> , 2008, 2, 397-407. | 0.6 | 7 |
| 1102 | Orthopedic surgery implications of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 949-956. | 1.1 | 4 |
| 1103 | Impact of Basal-Like Breast Carcinoma Determination for a More Specific Therapy. <i>Pathobiology</i> , 2008, 75, 95-103. | 1.9 | 31 |
| 1104 | Ixabepilone for the treatment of taxane-refractory breast cancer. <i>Future Oncology</i> , 2008, 4, 333-340. | 1.1 | 3 |
| 1105 | Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 453-463. | 1.1 | 10 |
| 1106 | Prognostic and predictive factors in breast cancer. , 2008, , 1-5. | | 4 |
| 1107 | Adjuvant chemotherapy for older women with breast cancer. <i>Breast Cancer Online: BCO</i> , 2008, 11, . | 0.1 | 1 |
| 1108 | Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Yearbook of Endocrinology</i> , 2008, 2008, 226-228. | 0.0 | 0 |
| 1109 | LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. , 2008, , CD004562. | | 20 |
| 1110 | Use of Levosimendan for Cardiogenic Shock in a Patient with the Apical Ballooning Syndrome. <i>Annals of Internal Medicine</i> , 2008, 149, 365. | 2.0 | 37 |
| 1111 | Ovarian ablation for early breast cancer. <i>The Cochrane Library</i> , 2010, 2010, CD000485. | 1.5 | 10 |
| 1112 | Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer: A Time for Excitement and Equipoise. <i>Journal of Thoracic Oncology</i> , 2008, 3, 84-93. | 0.5 | 26 |
| 1113 | Should We Shorten or Lengthen Postpolypectomy Surveillance Intervals?. <i>Annals of Internal Medicine</i> , 2008, 149, 360. | 2.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1114 | Lack of Nationwide Surveillance of Antimicrobial Resistance of <i>Neisseria gonorrhoeae</i> in Japan. <i>Annals of Internal Medicine</i> , 2008, 149, 363. | 2.0 | 22 |
| 1115 | Effect of Testosterone Therapy versus Other Factors on the Self-reported Sexual Satisfaction of Premenopausal Women. <i>Annals of Internal Medicine</i> , 2008, 149, 361. | 2.0 | 1 |
| 1116 | Adjuvant therapy for premenopausal patients with early breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2008, 20, 51-54. | 0.9 | 4 |
| 1117 | Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 564-574. | 1.1 | 15 |
| 1118 | Late-extended adjuvant treatment: does it work?. <i>Aging Health</i> , 2008, 4, 237-240. | 0.3 | 0 |
| 1120 | Adjuvant Chemotherapy Uptake in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1272-1278. | 0.5 | 38 |
| 1121 | Factors Predictive of Response to Hormone Therapy in Breast Cancer. <i>Tumori</i> , 2008, 94, 370-383. | 0.6 | 92 |
| 1122 | Competing Causes of Death for Women With Breast Cancer and Change Over Time From 1975 to 2003. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 105-116. | 0.6 | 64 |
| 1123 | Triple negative breast cancer: current understanding of biology and treatment options. <i>Current Opinion in Obstetrics and Gynecology</i> , 2008, 20, 40-46. | 0.9 | 59 |
| 1125 | Current controversies in extended adjuvant endocrine therapy for early breast cancer. <i>Current Opinion in Oncology</i> , 2008, 20, 627-633. | 1.1 | 5 |
| 1126 | Multi-agent chemotherapy for early breast cancer. <i>The Cochrane Library</i> , 2010, 2010, CD000487. | 1.5 | 13 |
| 1127 | Exemestane: an alternative treatment option in early breast cancer. <i>Anti-Cancer Drugs</i> , 2008, 19, S1. | 0.7 | 0 |
| 1128 | Neoadjuvant endocrine therapy for breast cancer: past, present and future. <i>Anti-Cancer Drugs</i> , 2008, 19, 339-347. | 0.7 | 14 |
| 1129 | Safety of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 595-605. | 0.6 | 14 |
| 1130 | Assessment of Surgical Treatment in Elderly Patients with Breast Cancer. <i>Tumori</i> , 2008, 94, 314-319. | 0.6 | 1 |
| 1132 | Hormones in cancer. , 0, , 23-38. | | 0 |
| 1134 | Breast cancer radiotherapy: controversies and prospectives. <i>Chinese Medical Journal</i> , 2008, 121, 1957-1959. | 0.9 | 2 |
| 1135 | Who Owns Vermont's Hospitals?. <i>Annals of Internal Medicine</i> , 2008, 149, 364. | 2.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1136 | Exogenous Lipoid Pneumonia: An Unexpected Complication of Substance Abuse. <i>Annals of Internal Medicine</i> , 2008, 149, 364. | 2.0 | 12 |
| 1137 | Exemestane in early breast cancer: a review. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 1295-1304. | 0.9 | 12 |
| 1138 | The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients. <i>Journal of Gynecologic Oncology</i> , 2008, 19, 256. | 1.0 | 22 |
| 1139 | A review of the use of exemestane in early breast cancer. <i>Therapeutics and Clinical Risk Management</i> , 0, 91. | 0.9 | 5 |
| 1140 | Integrating Medical Breast Specialists Into the Traditional Breast Center Practice Model: A Review of 11 Years of Experience. <i>Archives of Internal Medicine</i> , 2008, 168, 2042. | 4.3 | 1 |
| 1141 | Review: Mitochondrial Defects in Breast Cancer. <i>Clinical Medicine Oncology</i> , 2008, 2, CMO.S524. | 0.2 | 6 |
| 1142 | The Importance of Measuring Executive Function When Studying the Effects of Cognition-Enhancing Agents. <i>Annals of Internal Medicine</i> , 2008, 149, 358. | 2.0 | 1 |
| 1143 | Should We Shorten or Lengthen Postpolypectomy Surveillance Intervals?. <i>Annals of Internal Medicine</i> , 2008, 149, 360. | 2.0 | 2 |
| 1144 | Treatment Intensification Does Not Always Lead to Better Quality of Care in Patients with Hypertension. <i>Annals of Internal Medicine</i> , 2008, 149, 362. | 2.0 | 1 |
| 1145 | Effect of Testosterone Therapy versus Other Factors on the Self-reported Sexual Satisfaction of Premenopausal Women. <i>Annals of Internal Medicine</i> , 2008, 149, 361. | 2.0 | 0 |
| 1147 | Long-term safety of aromatase inhibitors in the treatment of breast cancer. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 189-204. | 0.9 | 46 |
| 1148 | Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer. <i>PLoS ONE</i> , 2008, 3, e2987. | 1.1 | 85 |
| 1149 | CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer. <i>PLoS ONE</i> , 2008, 3, e3062. | 1.1 | 74 |
| 1150 | The Controversial Clinicobiological Role of Breast Cancer Stem Cells. <i>Journal of Oncology</i> , 2008, 2008, 1-12. | 0.6 | 5 |
| 1151 | Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results. <i>Journal of Medical Investigation</i> , 2008, 55, 54-60. | 0.2 | 15 |
| 1152 | Peptides and Small Molecules Targeting the Plasminogen Activation System: Towards Prophylactic Anti-Metastasis Drugs for Breast Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2008, 3, 1-13. | 0.8 | 24 |
| 1153 | Are Stem-Like Cells Responsible for Resistance to Therapy in Breast Cancer?. <i>Breast Disease</i> , 2008, 29, 83-89. | 0.4 | 11 |
| 1154 | Are Short-Term or Long-Term Recurrence Rates More Important in Breast Cancer Screening?. <i>Annals of Internal Medicine</i> , 2008, 149, 357. | 2.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1155 | Circulating Vascular Endothelial Growth Factor, C-reactive Protein and Urinary Neopterin Concentrations During dose-dense Chemotherapy. <i>Pteridines</i> , 2008, 19, 65-71. | 0.5 | 0 |
| 1156 | What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?. <i>Medical Journal of Australia</i> , 2009, 190, 74-77. | 0.8 | 11 |
| 1157 | Molecular biomarkers to individualise treatment: assessing the evidence. <i>Medical Journal of Australia</i> , 2009, 190, 631-636. | 0.8 | 23 |
| 1158 | Relative Dose Intensity Delivered to Patients with Early Breast Cancer: Canadian Experience. <i>Current Oncology</i> , 2009, 16, 8-12. | 0.9 | 34 |
| 1159 | The Incidence and Severity of Adverse Effects Associated with Different Types of Aromatase Inhibitor Prescribed in Patients with Breast Cancer. <i>SSRN Electronic Journal</i> , 2009, , . | 0.4 | 0 |
| 1160 | New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin. <i>Breast Cancer: Targets and Therapy</i> , 2009, , 1. | 1.0 | 1 |
| 1161 | Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S9. | 0.1 | 27 |
| 1162 | Divide and Conquer: Progress in the Molecular Stratification of Cancer. <i>Yonsei Medical Journal</i> , 2009, 50, 464. | 0.9 | 4 |
| 1164 | Metastatic Bone Disease in Patients with Solid Tumors"-Burden of Bone Disease and the Role of Zoledronic Acid. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S1958. | 0.1 | 0 |
| 1165 | Geriatric Assessment in Older Patients with Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 226-236. | 2.3 | 33 |
| 1166 | Adjuvant Therapy of Breast Cancer: Can We Do Better?. <i>Breast Care</i> , 2009, 4, 8-8. | 0.8 | 0 |
| 1167 | Immunohistochemical study of androgen, estrogen and progesterone receptors in salivary gland tumors. <i>Brazilian Oral Research</i> , 2009, 23, 393-398. | 0.6 | 13 |
| 1168 | Principles of Adjuvant Chemotherapy for Breast Cancer. , 2009, , 247-266. | | 0 |
| 1169 | Cancer in the Elderly. , 0, , 392-411. | | 3 |
| 1170 | Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 291. | 0.9 | 7 |
| 1171 | An Updated Review on the Efficacy of Adjuvant Endocrine Therapies in Hormone Receptor"Positive Early Breast Cancer. <i>Current Oncology</i> , 2009, 16, 1-13. | 0.9 | 4 |
| 1172 | Pharmacogenomics of Tamoxifen Therapy. <i>Clinical Chemistry</i> , 2009, 55, 1770-1782. | 1.5 | 142 |
| 1173 | Role of Anthracyclines in the Treatment of Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4798-4808. | 0.8 | 82 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1174 | The Hedgehog signalling pathway as a therapeutic target in early breast cancer development. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 1095-1103. | 1.5 | 28 |
| 1175 | Luteinizing hormone-releasing hormone (LHRH) agonists in the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2633-2639. | 0.9 | 10 |
| 1176 | Treatment of pregnancy-associated breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2259-2267. | 0.9 | 6 |
| 1177 | Better treatment for breast cancer in older patients. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1081-1090. | 1.1 | 8 |
| 1178 | Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. <i>Annals of Oncology</i> , 2009, 20, 1203-1209. | 0.6 | 58 |
| 1179 | A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. <i>Carcinogenesis</i> , 2009, 30, 59-64. | 1.3 | 90 |
| 1180 | PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 5049-5059. | 3.2 | 338 |
| 1181 | Chapter 3 Tumor Dormancy and Metastasis. <i>Advances in Cancer Research</i> , 2009, 102, 67-101. | 1.9 | 91 |
| 1182 | Novel molecular prognostic markers in breast cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2009, 3, 523-532. | 1.6 | 1 |
| 1183 | Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction. <i>Journal of Clinical Oncology</i> , 2009, 27, 6117-6123. | 0.8 | 26 |
| 1184 | Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?. <i>Journal of Clinical Oncology</i> , 2009, 27, 996-997. | 0.8 | 18 |
| 1185 | Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2501-2506. | 1.1 | 23 |
| 1186 | What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?. <i>Annals of Oncology</i> , 2009, 20, 1157-1162. | 0.6 | 39 |
| 1187 | Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 5888-5894. | 3.2 | 26 |
| 1188 | Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2809-2815. | 0.8 | 214 |
| 1189 | International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1174-1181. | 3.0 | 202 |
| 1190 | CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. <i>British Journal of Cancer</i> , 2009, 101, 1817-1823. | 2.9 | 42 |
| 1191 | Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. <i>British Journal of Cancer</i> , 2009, 101, 589-597. | 2.9 | 94 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1192 | A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. <i>British Journal of Cancer</i> , 2009, 100, 305-310. | 2.9 | 36 |
| 1193 | Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients. <i>British Journal of Cancer</i> , 2009, 100, 494-500. | 2.9 | 11 |
| 1195 | Is tamoxifen a genotoxic carcinogen in women?. <i>Mutagenesis</i> , 2009, 24, 391-404. | 1.0 | 33 |
| 1196 | Current indications for post-mastectomy radiation. <i>International Seminars in Surgical Oncology</i> , 2009, 6, 5. | 1.1 | 16 |
| 1197 | Mathematical Modelling of Tumour Dormancy. <i>Mathematical Modelling of Natural Phenomena</i> , 2009, 4, 68-96. | 0.9 | 6 |
| 1198 | Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality. <i>Annals of Oncology</i> , 2009, 20, 857-861. | 0.6 | 11 |
| 1199 | Fertility Preservation for Breast Cancer Patients. <i>Seminars in Reproductive Medicine</i> , 2009, 27, 486-492. | 0.5 | 38 |
| 1200 | Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 478-483. | 0.6 | 39 |
| 1201 | Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 729-735. | 3.0 | 85 |
| 1202 | Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study. <i>Annals of Oncology</i> , 2009, 20, 41-48. | 0.6 | 52 |
| 1204 | Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines. <i>Journal of Clinical Oncology</i> , 2009, 27, 5906-5910. | 0.8 | 33 |
| 1205 | Review: Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 123-136. | 1.4 | 5 |
| 1206 | Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?. <i>Oncologist</i> , 2009, 14, 959-962. | 1.9 | 4 |
| 1207 | Adjuvant chemotherapy and prognosis in patients with breast cancer. <i>Annals of Oncology</i> , 2009, 20, 192-193. | 0.6 | 2 |
| 1208 | Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance. <i>Journal of Clinical Oncology</i> , 2009, 27, 542-549. | 0.8 | 93 |
| 1209 | Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. <i>Annals of Oncology</i> , 2009, 20, 628-635. | 0.6 | 200 |
| 1211 | Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. <i>Annals of Oncology</i> , 2009, 20, 655-659. | 0.6 | 18 |
| 1212 | Positive Cross-Talk between Estrogen Receptor and NF- κ B in Breast Cancer. <i>Cancer Research</i> , 2009, 69, 8918-8925. | 0.4 | 131 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1213 | Breast Cancer Recurrence in Older Women Five to Ten Years after Diagnosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2979-2983. | 1.1 | 39 |
| 1214 | Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3192-3197. | 0.8 | 71 |
| 1215 | Topoisomerase III \pm Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out. <i>Journal of Clinical Oncology</i> , 2009, 27, 3416-3417. | 0.8 | 16 |
| 1216 | Long-Term Health Outcomes of a Decision Aid: Data from a Randomized Trial of Adjuvant! in Women with Localized Breast Cancer. <i>Medical Decision Making</i> , 2009, 29, 461-467. | 1.2 | 9 |
| 1217 | The Dark Side of the Moon – the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management. <i>Breast Care</i> , 2009, 4, 144-147. | 0.8 | 2 |
| 1218 | Adjuvant Endocrine Treatment in Premenopausal Early Breast Cancer. <i>Oncology</i> , 2009, 77, 9-13. | 0.9 | 2 |
| 1219 | Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer. <i>Oncology</i> , 2009, 77, 14-17. | 0.9 | 2 |
| 1220 | Which Patients with Estrogen Receptor-Positive Early Breast Cancer Should Be Treated with Adjuvant Chemotherapy?. <i>Oncology</i> , 2009, 77, 18-22. | 0.9 | 2 |
| 1221 | Cost Analysis Comparing an Anthracycline/Docetaxel Regimen to CMF in Patients with Early Stage Breast Cancer. <i>Onkologie</i> , 2009, 32, 473-481. | 1.1 | 11 |
| 1222 | TRASTUZUMAB TREATMENT OF EARLY STAGE BREAST CANCER IS COST-EFFECTIVE FROM THE PERSPECTIVE OF THE BELGIAN HEALTH CARE AUTHORITIES. <i>Acta Clinica Belgica</i> , 2009, 64, 100-112. | 0.5 | 23 |
| 1223 | Adjuvant Chemotherapy for Older Adults with Breast Cancer: Making the Standard a Standard. <i>Women's Health</i> , 2009, 5, 481-484. | 0.7 | 2 |
| 1224 | Adjuvant Systemic Therapy for Older Adults with Early-Stage Breast Cancer. <i>Women's Health</i> , 2009, 5, 251-262. | 0.7 | 3 |
| 1225 | Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. <i>Breast Care</i> , 2009, 4, 389-396. | 0.8 | 6 |
| 1226 | Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. <i>Pharmacogenomics Journal</i> , 2009, 9, 258-264. | 0.9 | 69 |
| 1228 | Chemotherapy in Older Women with Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 1023-1024. | 13.9 | 5 |
| 1229 | Isolated Tumor Cells in Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 1994-1996. | 13.9 | 56 |
| 1230 | Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 766-776. | 13.9 | 448 |
| 1233 | Chemoprevention of Lung Cancer. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 187-193. | 3.5 | 33 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1234 | Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 1278-1294. | 2.5 | 94 |
| 1235 | Role of Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer. <i>Women's Health</i> , 2009, 5, 135-147. | 0.7 | 3 |
| 1236 | The silent estrogen receptor--can we make it speak?. <i>Cancer Biology and Therapy</i> , 2009, 8, 485-496. | 1.5 | 17 |
| 1237 | Should routine breast cancer staging include MRI?. <i>Nature Clinical Practice Oncology</i> , 2009, 6, 72-73. | 4.3 | 14 |
| 1238 | Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 341-349. | 3.0 | 54 |
| 1239 | Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial. <i>Clinical Cancer Research</i> , 2009, 15, 5258-5266. | 3.2 | 46 |
| 1240 | Temporal trends in the use of adjuvant systemic therapy in breast cancer -- a population based study in Sweden 1976-2005. <i>Acta Oncologica</i> , 2009, 48, 59-66. | 0.8 | 11 |
| 1241 | Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. <i>Annals of Oncology</i> , 2009, 20, 993-999. | 0.6 | 66 |
| 1242 | No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2562-2564. | 1.1 | 50 |
| 1243 | Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv10-iv14. | 0.6 | 86 |
| 1244 | Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation. <i>Annals of Oncology</i> , 2009, 20, 2000-2006. | 0.6 | 13 |
| 1245 | Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. <i>Endocrine-Related Cancer</i> , 2009, 16, 1091-1102. | 1.6 | 29 |
| 1246 | No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 651-656. | 0.6 | 34 |
| 1247 | Resource-sparing and cost-effective strategies in current management of breast cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2009, 5, 116. | 0.3 | 8 |
| 1248 | Trends in Area-Socioeconomic and Race-Ethnic Disparities in Breast Cancer Incidence, Stage at Diagnosis, Screening, Mortality, and Survival among Women Ages 50 Years and Over (1987-2005). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 121-131. | 1.1 | 185 |
| 1249 | G Protein-Coupled Receptor 30 Expression Is Up-Regulated by EGF and TGF β in Estrogen Receptor β -Positive Cancer Cells. <i>Molecular Endocrinology</i> , 2009, 23, 1815-1826. | 3.7 | 121 |
| 1251 | Estrogen Receptor- β Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1725-1729. | 3.0 | 55 |
| 1252 | Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?. <i>Annals of Oncology</i> , 2009, 20, 1751-1752. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1253 | Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers. <i>Journal of the National Cancer Institute</i> , 2009, 101, 615-618. | 3.0 | 64 |
| 1254 | Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2009, 20, 615-620. | 0.6 | 61 |
| 1255 | Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 1168-1176. | 0.8 | 461 |
| 1256 | Improved survival for women with stage I breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy. <i>Acta OncolÅ³gica</i> , 2009, 48, 504-513. | 0.8 | 6 |
| 1257 | Time-Varying Effects of Prognostic Factors Associated With Disease-Free Survival in Breast Cancer. <i>American Journal of Epidemiology</i> , 2009, 169, 1463-1470. | 1.6 | 43 |
| 1258 | The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 665-674. | 1.5 | 29 |
| 1259 | Breast cancer in women younger than 25: clinicopathological features and prognostic factors. <i>Annals of Oncology</i> , 2009, 20, 387-389. | 0.6 | 9 |
| 1260 | The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1207-1217. | 1.9 | 26 |
| 1261 | Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7693-7700. | 3.2 | 23 |
| 1262 | The Clinical Utility of Tumor Markers. <i>Laboratory Medicine</i> , 2009, 40, 99-103. | 0.8 | 21 |
| 1263 | Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer. <i>Cancer Investigation</i> , 2009, 27, 953-959. | 0.6 | 19 |
| 1265 | Clinical Implications of <i>CYP2D6</i> Genotyping in Tamoxifen Treatment for Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 15-21. | 3.2 | 74 |
| 1266 | Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function ofHER2andTOP2Astatus. <i>Journal of Clinical Oncology</i> , 2009, 27, 3881-3886. | 0.8 | 61 |
| 1267 | Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancerâ€”comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. <i>Annals of Oncology</i> , 2009, 20, 258-264. | 0.6 | 75 |
| 1268 | Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 720-725. | 0.8 | 23 |
| 1269 | Anthracyclines in Earlyâ€”Stage Breast Cancer: Is It the End of an Era?. <i>Oncologist</i> , 2009, 14, 950-958. | 1.9 | 16 |
| 1270 | Discussion about switch strategy in the adjuvant hormonal therapy of breast cancer: psychological aspects of physicianâ€”patient communication. <i>Annals of Oncology</i> , 2009, 20, 1647-1652. | 0.6 | 4 |
| 1271 | Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis. <i>Diagnostic Molecular Pathology</i> , 2009, 18, 125-132. | 2.1 | 109 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1272 | Anthracyclines and Early Breast Cancer: The End of an Era?. <i>Journal of Clinical Oncology</i> , 2009, 27, 1155-1157. | 0.8 | 15 |
| 1273 | Quo Vadis With Targeted Drugs in the 21st Century?. <i>Journal of Clinical Oncology</i> , 2009, 27, 2-5. | 0.8 | 45 |
| 1274 | <i>PIK3CA</i> and <i>PIK3CB</i> Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2009, 69, 3955-3962. | 0.4 | 198 |
| 1275 | Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2009, 27, 220-226. | 0.8 | 115 |
| 1276 | Adjuvant Hormonal Therapy Use Among Insured, Low-Income Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3445-3451. | 0.8 | 168 |
| 1277 | Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides. <i>Nucleic Acids Research</i> , 2009, 37, 4518-4531. | 6.5 | 91 |
| 1278 | Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 526-534. | 0.8 | 102 |
| 1279 | Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2466-2473. | 0.8 | 397 |
| 1280 | A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention. <i>Cancer Research</i> , 2009, 69, 1243-1254. | 0.4 | 91 |
| 1281 | Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2816-2822. | 0.8 | 15 |
| 1282 | p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 217-224. | 0.6 | 72 |
| 1283 | Gene expression profiling: Decoding breast cancer. <i>Surgical Oncology</i> , 2009, 18, 366-378. | 0.8 | 27 |
| 1284 | <i>In situ</i> estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology. <i>Pathology International</i> , 2009, 59, 777-789. | 0.6 | 80 |
| 1285 | Revisiting perioperative chemotherapy: the critical importance of targeting residual cancer prior to wound healing. <i>BMC Cancer</i> , 2009, 9, 118. | 1.1 | 13 |
| 1286 | Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis. <i>BMC Cancer</i> , 2009, 9, 127. | 1.1 | 17 |
| 1287 | In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer. <i>BMC Cancer</i> , 2009, 9, 185. | 1.1 | 14 |
| 1288 | Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study. <i>BMC Cancer</i> , 2009, 9, 322. | 1.1 | 16 |
| 1289 | Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. <i>BMC Health Services Research</i> , 2009, 9, 9. | 0.9 | 81 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-------|-----------|
| 1290 | Pharmacogenetics and pharmacogenomics of anticancer agents. <i>Ca-A Cancer Journal for Clinicians</i> , 2009, 59, 42-55. | 157.7 | 122 |
| 1291 | Highlights from: The 2008 San Antonio Breast Cancer Symposium December 10-14, 2008 San Antonio, TX. <i>Clinical Breast Cancer</i> , 2009, 9, 8-15. | 1.1 | 1 |
| 1292 | Sexual Dysfunction and Aromatase Inhibitor Use in Survivors of Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 219-224. | 1.1 | 24 |
| 1293 | A 2009 Update on the Treatment of Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, S6-S17. | 1.1 | 71 |
| 1294 | Maintaining Bone Density in Patients Undergoing Treatment for Breast Cancer: Is There an Adjuvant Benefit?. <i>Clinical Breast Cancer</i> , 2009, 9, S18-S27. | 1.1 | 11 |
| 1295 | A Question of Duration: Do Patients with Early-Stage Breast Cancer Need More Than Five Years of Adjuvant Endocrine Therapy?. <i>Clinical Breast Cancer</i> , 2009, 9, S37-S41. | 1.1 | 10 |
| 1296 | Evolving Approaches to Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes. <i>Clinical Breast Cancer</i> , 2009, 9, S58-S65. | 1.1 | 24 |
| 1297 | Breast Cancer in Premenopausal Women. <i>Current Problems in Surgery</i> , 2009, 46, 944-1004. | 0.6 | 11 |
| 1298 | Relationship between tamoxifen use and high risk endometrial cancer histologic types. <i>Gynecologic Oncology</i> , 2009, 112, 150-154. | 0.6 | 61 |
| 1299 | Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system. <i>Gynecologic Oncology</i> , 2009, 114, 452-456. | 0.6 | 79 |
| 1300 | Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1795, 62-81. | 3.3 | 30 |
| 1301 | Feasibility study on radiofrequency ablation followed by partial mastectomy for stage I breast cancer patients. <i>Breast</i> , 2009, 18, 130-134. | 0.9 | 54 |
| 1302 | The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. <i>Breast</i> , 2009, 18, 159-164. | 0.9 | 48 |
| 1303 | Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy. <i>Breast</i> , 2009, 18, 263-266. | 0.9 | 14 |
| 1304 | Stage I breast cancer in a regional oncology practice in Israel 2002-2006: Clinicopathologic features, risk estimation and planned therapy of 328 consecutive patients. <i>Breast</i> , 2009, 18, 316-321. | 0.9 | 9 |
| 1305 | The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors. <i>Breast</i> , 2009, 18, 351-355. | 0.9 | 22 |
| 1306 | Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II Trial. <i>Journal of the American College of Surgeons</i> , 2009, 208, 906-914. | 0.2 | 74 |
| 1307 | Attaining Negative Margins in Breast-Conservation Operations: Is There a Consensus among Breast Surgeons?. <i>Journal of the American College of Surgeons</i> , 2009, 209, 608-613. | 0.2 | 135 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1308 | Timing of Breast Cancer Treatments with Oocyte Retrieval and Embryo Cryopreservation. Journal of the American College of Surgeons, 2009, 209, 603-607. | 0.2 | 71 |
| 1309 | Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals. Cancer Cell, 2009, 16, 67-78. | 7.7 | 609 |
| 1310 | Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast, 2009, 18, S1-S11. | 0.9 | 35 |
| 1311 | Facilitating consensus by examining patterns of treatment effects. Breast, 2009, 18, S2-S8. | 0.9 | 17 |
| 1312 | New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast, 2009, 18, S10-S17. | 0.9 | 19 |
| 1313 | Innovations in radiation therapy (RT) for breast cancer. Breast, 2009, 18, S103-S111. | 0.9 | 27 |
| 1314 | Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast, 2009, 18, S122-S130. | 0.9 | 35 |
| 1315 | Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?. Breast, 2009, 18, S131-S134. | 0.9 | 4 |
| 1316 | Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast, 2009, 18, S141-S145. | 0.9 | 95 |
| 1317 | High expression of 90K (Macâ€² BP) is associated with poor survival in nodeâ€²negative breast cancer patients not receiving adjuvant systemic therapies. International Journal of Cancer, 2009, 124, 333-338. | 2.3 | 36 |
| 1318 | Large differences in patterns of breast cancer survival between Australia and England: A comparative study using cancer registry data. International Journal of Cancer, 2009, 124, 2391-2399. | 2.3 | 18 |
| 1319 | Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer, 2009, 115, 952-961. | 2.0 | 116 |
| 1320 | A woman's heart. Cancer, 2009, 115, 1813-1826. | 2.0 | 81 |
| 1321 | Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer, 2009, 115, 2041-2051. | 2.0 | 20 |
| 1322 | Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph nodeâ€²positive, operable breast cancer. Cancer, 2009, 115, 2999-3008. | 2.0 | 57 |
| 1323 | Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer, 2009, 115, 3848-3857. | 2.0 | 29 |
| 1324 | Secondary sarcomas after radiotherapy for breast cancer. Cancer, 2009, 115, 4055-4063. | 2.0 | 110 |
| 1325 | Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism. Cancer, 2009, 115, 4442-4449. | 2.0 | 145 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1326 | How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. <i>Cancer</i> , 2009, 115, 5095-5107. | 2.0 | 21 |
| 1327 | Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. <i>Cancer</i> , 2009, 115, 5296-5308. | 2.0 | 67 |
| 1328 | Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. <i>Cytometry Part B - Clinical Cytometry</i> , 2009, 76B, 107-117. | 0.7 | 22 |
| 1329 | Use of genome typing in breast cancer. <i>Journal of Surgical Oncology</i> , 2009, 99, 3-4. | 0.8 | 0 |
| 1330 | The evolution of lymph node assessment in breast cancer. <i>Journal of Surgical Oncology</i> , 2009, 99, 194-198. | 0.8 | 32 |
| 1331 | Implementation and limitations of meta-analysis of randomized trials from the clinical biostatistician's point of view. <i>International Journal of Clinical Oncology</i> , 2009, 14, 83-84. | 1.0 | 1 |
| 1333 | Gene expression profiling in breast cancer – design of a pooled database to address open questions. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2009, 41, 221-227. | 0.3 | 3 |
| 1334 | Breast conserving treatment (BCT) for stage II breast cancer in elderly women: Analysis of 927 cases. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 79-88. | 2.0 | 25 |
| 1335 | Nanotechnology for breast cancer therapy. <i>Biomedical Microdevices</i> , 2009, 11, 49-63. | 1.4 | 124 |
| 1336 | Effect of Coenzyme Q10, Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 377-384. | 1.1 | 17 |
| 1337 | Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 479-484. | 1.1 | 154 |
| 1338 | Time-varying pattern of recurrence risk for Chinese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 527-535. | 1.1 | 34 |
| 1339 | Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 503-511. | 1.1 | 45 |
| 1340 | Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 579-587. | 1.1 | 19 |
| 1341 | Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 335-342. | 1.1 | 79 |
| 1342 | Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 325-333. | 1.1 | 89 |
| 1343 | Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 205-210. | 1.1 | 48 |
| 1344 | Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 241-254. | 1.1 | 66 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1345 | The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1 ⁺ lymph nodes in an independent validation study. Breast Cancer Research and Treatment, 2009, 116, 295-302. | 1.1 | 260 |
| 1346 | The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 115, 373-380. | 1.1 | 9 |
| 1347 | Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma. Breast Cancer Research and Treatment, 2009, 117, 433-441. | 1.1 | 11 |
| 1348 | Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Research and Treatment, 2009, 116, 131-143. | 1.1 | 61 |
| 1349 | When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy. Breast Cancer Research and Treatment, 2009, 117, 25-29. | 1.1 | 20 |
| 1350 | Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Research and Treatment, 2009, 117, 483-495. | 1.1 | 154 |
| 1351 | Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Research and Treatment, 2009, 116, 595-602. | 1.1 | 116 |
| 1352 | Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. Breast Cancer Research and Treatment, 2009, 116, 351-358. | 1.1 | 10 |
| 1353 | Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12 ⁺ 93. Breast Cancer Research and Treatment, 2009, 116, 491-500. | 1.1 | 37 |
| 1354 | Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Research and Treatment, 2009, 117, 365-370. | 1.1 | 84 |
| 1355 | The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Research and Treatment, 2009, 118, 125-130. | 1.1 | 108 |
| 1356 | Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Research and Treatment, 2009, 117, 319-324. | 1.1 | 49 |
| 1357 | Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2009, 117, 91-98. | 1.1 | 70 |
| 1358 | Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Research and Treatment, 2009, 113, 137-144. | 1.1 | 53 |
| 1359 | Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Research and Treatment, 2009, 113, 231-237. | 1.1 | 18 |
| 1360 | Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Research and Treatment, 2009, 113, 315-320. | 1.1 | 93 |
| 1361 | Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment, 2009, 113, 275-283. | 1.1 | 56 |
| 1362 | Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Research and Treatment, 2009, 114, 23-30. | 1.1 | 43 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1363 | Delivery of adjuvant sequential dose-dense FECâ€œDoc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment, 2009, 114, 103-112. | 1.1 | 26 |
| 1364 | Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71Âyears of age. Breast Cancer Research and Treatment, 2009, 114, 39-45. | 1.1 | 42 |
| 1365 | Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Research and Treatment, 2009, 117, 561-567. | 1.1 | 146 |
| 1366 | Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Research and Treatment, 2009, 118, 547-552. | 1.1 | 56 |
| 1367 | Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Research and Treatment, 2009, 118, 425-432. | 1.1 | 25 |
| 1368 | Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer. Medical Oncology, 2009, 26, 452-459. | 1.2 | 27 |
| 1369 | Adjuvant Chemotherapy for Early Breast Cancer in the Elderly. Current Treatment Options in Oncology, 2009, 10, 144-158. | 1.3 | 3 |
| 1370 | What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. Current Oncology Reports, 2009, 11, 45-50. | 1.8 | 12 |
| 1371 | The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Targeted Oncology, 2009, 4, 235-252. | 1.7 | 52 |
| 1374 | St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy. Memo - Magazine of European Medical Oncology, 2009, 2, 229-231. | 0.3 | 4 |
| 1375 | Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group. Breast Cancer, 2009, 16, 37-41. | 1.3 | 1 |
| 1376 | Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer, 2009, 16, 301-306. | 1.3 | 23 |
| 1377 | Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer. Breast Cancer, 2009, 16, 207-218. | 1.3 | 6 |
| 1378 | Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. Current Breast Cancer Reports, 2009, 1, 1-2. | 0.5 | 3 |
| 1379 | The role of adjuvant anthracyclines for breast cancer treatment: Can we use molecular predictors?. Current Breast Cancer Reports, 2009, 1, 5-11. | 0.5 | 0 |
| 1380 | What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer?. Current Breast Cancer Reports, 2009, 1, 42-47. | 0.5 | 0 |
| 1381 | Advances in endocrine therapy and its implications for translational research. Current Breast Cancer Reports, 2009, 1, 207-215. | 0.5 | 0 |
| 1382 | Therapeutic strategies to eliminate breast cancer stem cells. Current Breast Cancer Reports, 2009, 1, 222-228. | 0.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1387 | Nanoparticles in sentinel lymph node mapping. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2009, 1, 610-623. | 3.3 | 51 |
| 1388 | Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer. <i>Journal of Pathology</i> , 2009, 218, 316-326. | 2.1 | 39 |
| 1389 | Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. <i>Psycho-Oncology</i> , 2009, 18, 811-821. | 1.0 | 125 |
| 1390 | Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: The TEAM Trial Experience. <i>Histopathology</i> , 2009, 55, 587-593. | 1.6 | 44 |
| 1391 | Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy. <i>Cancer Science</i> , 2009, 100, 1026-1033. | 1.7 | 15 |
| 1392 | Involvement of Gα patch domain containing 2 overexpression in breast carcinogenesis. <i>Cancer Science</i> , 2009, 100, 1443-1450. | 1.7 | 41 |
| 1393 | Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer. <i>Cancer Science</i> , 2009, 100, 2341-2345. | 1.7 | 32 |
| 1394 | CYP2D6 and tamoxifen: DNA matters in breast cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 576-586. | 12.8 | 287 |
| 1395 | Biological determinants of endocrine resistance in breast cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 631-643. | 12.8 | 1,113 |
| 1396 | Endocrine-therapy-related symptoms and breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 309-310. | 12.5 | 1 |
| 1397 | Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. <i>Oncogene</i> , 2009, 28, 4409-4420. | 2.6 | 73 |
| 1398 | BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. <i>British Journal of Cancer</i> , 2009, 100, 123-133. | 2.9 | 37 |
| 1399 | Rising incidence of breast cancer among female cancer survivors: implications for surveillance. <i>British Journal of Cancer</i> , 2009, 100, 77-81. | 2.9 | 3 |
| 1400 | Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. <i>British Journal of Cancer</i> , 2009, 100, 442-449. | 2.9 | 33 |
| 1401 | Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. <i>British Journal of Cancer</i> , 2009, 100, 563-570. | 2.9 | 40 |
| 1402 | Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. <i>British Journal of Cancer</i> , 2009, 100, 959-970. | 2.9 | 74 |
| 1403 | Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. <i>British Journal of Cancer</i> , 2009, 101, 598-604. | 2.9 | 25 |
| 1404 | Tamoxifen: the drug that came in from the cold. <i>British Journal of Cancer</i> , 2009, 101, 875-878. | 2.9 | 31 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1405 | An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. <i>British Journal of Cancer</i> , 2009, 101, 1074-1084. | 2.9 | 73 |
| 1406 | The size of the prize for earlier diagnosis of cancer in England. <i>British Journal of Cancer</i> , 2009, 101, S125-S129. | 2.9 | 195 |
| 1407 | Safety, Tolerability and Pharmacokinetics of TASâ€“108, a Novel Antiâ€“Oestrogen, in Healthy Postâ€“Menopausal Japanese Women: A Phase I Single Oral Dose Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 352-359. | 1.2 | 7 |
| 1408 | Phase 3 Trials of Aromatase Inhibitors for Breast Cancer Prevention. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 141-161. | 1.8 | 19 |
| 1409 | Biomarkers in Oncology. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 111-118. | 1.8 | 6 |
| 1410 | Responding to the challenge of cancer in Europe. <i>Australian and New Zealand Journal of Public Health</i> , 2009, 33, 298. | 0.8 | 12 |
| 1411 | Breast Cancer in the Elderly: Retrospective Study on Diagnosis and Treatment According to National Guidelines. <i>Breast Journal</i> , 2009, 15, 26-33. | 0.4 | 38 |
| 1412 | Breast-Conservation Treatment Outcomes: A Community Hospitalâ€™s Experience. <i>Breast Journal</i> , 2009, 15, 76-84. | 0.4 | 6 |
| 1413 | Enhancing the Adjuvant Treatment of Hormone Receptor Positive Breast Cancer. <i>Breast Journal</i> , 2009, 15, 194-198. | 0.4 | 7 |
| 1414 | Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004. <i>Breast Journal</i> , 2009, 15, 593-602. | 0.4 | 257 |
| 1415 | The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial. <i>Value in Health</i> , 2009, 12, 641-648. | 0.1 | 31 |
| 1416 | Patients With T1 to T2 Breast Cancer With One to Three Positive Nodes Have Higher Local and Regional Recurrence Risks Compared With Node-Negative Patients After Breast-Conserving Surgery and Whole-Breast Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 357-364. | 0.4 | 74 |
| 1417 | Coverage of Axillary Lymph Nodes in Supine vs. Prone Breast Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 745-751. | 0.4 | 49 |
| 1418 | Radiotherapy Timing in 4,820 Patients With Breast Cancer: University of Florence Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 365-369. | 0.4 | 32 |
| 1419 | Optimising Care of Elderly Breast Cancer Patients: a Challenging Priority. <i>Clinical Oncology</i> , 2009, 21, 118-130. | 0.6 | 9 |
| 1420 | Radiochemotherapy in the Treatment of Breast Cancer. <i>Clinical Oncology</i> , 2009, 21, 532-535. | 0.6 | 5 |
| 1421 | Microarray methods to identify factors determining breast cancer progression: Potentials, limitations, and challenges. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 1-11. | 2.0 | 18 |
| 1422 | Optimal timing for adjuvant radiation therapy in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 102-116. | 2.0 | 70 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1423 | Breast cancer in Chinese elderly women: Pathological and clinical characteristics and factors influencing treatment patterns. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 258-265. | 2.0 | 20 |
| 1424 | Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 265-269. | 2.0 | 10 |
| 1425 | Hypofractionated and Accelerated Radiotherapy With Subcutaneous Amifostine Cytoprotection as Short Adjuvant Regimen After Breast-Conserving Surgery: Interim Report. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1173-1180. | 0.4 | 14 |
| 1426 | Advantage of sentinel lymph node biopsy before neoadjuvant chemotherapy in breast cancer treatment. <i>Surgery Today</i> , 2009, 39, 374-380. | 0.7 | 23 |
| 1427 | Immune-Induced Epithelial to Mesenchymal Transition <i>In vivo</i> Generates Breast Cancer Stem Cells. <i>Cancer Research</i> , 2009, 69, 2887-2895. | 0.4 | 369 |
| 1428 | Predicting and Preventing Positive Surgical Margins and Local Failures in Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2009, 16, 544-545. | 0.7 | 0 |
| 1429 | Variations in Axillary Staging: Much Ado About Nothing?. <i>Annals of Surgical Oncology</i> , 2009, 16, 549-551. | 0.7 | 0 |
| 1430 | Ki-67 Expression Gives Additional Prognostic Information on St. Gallen 2007 and Adjuvant! Online Risk Categories in Early Breast Cancer. <i>Annals of Surgical Oncology</i> , 2009, 16, 1112-1121. | 0.7 | 76 |
| 1431 | Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2009, 16, 3388-3395. | 0.7 | 41 |
| 1432 | Breast Carcinoma: Stages I and II. , 2009, , 1523-1540. | | 0 |
| 1433 | Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1429. | 3.8 | 468 |
| 1434 | Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. <i>Clinical Trials</i> , 2009, 6, 272-287. | 0.7 | 37 |
| 1435 | Taxane-based adjuvant chemotherapy in node positive, early stage Turkish breast cancer patients. <i>Open Medicine (Poland)</i> , 2009, 4, 454-458. | 0.6 | 1 |
| 1436 | Breast cancer: beyond the cutting edge. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2479-2498. | 0.9 | 10 |
| 1437 | CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. <i>British Journal of Cancer</i> , 2009, 101, 1824-1832. | 2.9 | 37 |
| 1438 | Multidisciplinary Care for Patients with Breast Cancer. <i>Surgical Clinics of North America</i> , 2009, 89, 133-176. | 0.5 | 23 |
| 1439 | Treating elderly patients with hormone sensitive breast cancer: What do the data show?. <i>Cancer Treatment Reviews</i> , 2009, 35, 47-56. | 3.4 | 10 |
| 1440 | Combining systemic therapies with radiation in breast cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 409-416. | 3.4 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1441 | The role of topoisomerase II± and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. <i>Cancer Treatment Reviews</i> , 2009, 35, 662-667. | 3.4 | 30 |
| 1442 | Second non-breast primary cancer following adjuvant therapy for early breast cancer: A report from the International Breast Cancer Study Group. <i>European Journal of Cancer</i> , 2009, 45, 561-571. | 1.3 | 6 |
| 1443 | Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. <i>European Journal of Cancer</i> , 2009, 45, 2123-2131. | 1.3 | 47 |
| 1444 | Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. <i>European Journal of Cancer</i> , 2009, 45, 2496-2502. | 1.3 | 34 |
| 1445 | Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. <i>European Journal of Cancer</i> , 2009, 45, 2528-2536. | 1.3 | 29 |
| 1446 | Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The "personalised" approach?. <i>European Journal of Cancer</i> , 2009, 45, 2274-2283. | 1.3 | 61 |
| 1447 | Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2009, 45, 2940-2946. | 1.3 | 24 |
| 1448 | The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study. <i>European Journal of Cancer</i> , 2009, 45, 3198-3204. | 1.3 | 18 |
| 1449 | Breast cancer: From the earliest times through to the end of the 20th century. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009, 145, 3-8. | 0.5 | 21 |
| 1450 | Changes in health-related quality of life may predict recurrent breast cancer. <i>European Journal of Oncology Nursing</i> , 2009, 13, 323-329. | 0.9 | 18 |
| 1451 | Improvements in breast cancer survival over time, related to adjuvant treatment and node status. <i>European Journal of Surgical Oncology</i> , 2009, 35, 151-155. | 0.5 | 10 |
| 1452 | Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions. <i>European Journal of Surgical Oncology</i> , 2009, 35, 113-122. | 0.5 | 82 |
| 1453 | Locoregional recurrence in breast carcinoma patients. <i>European Journal of Surgical Oncology</i> , 2009, 35, 258-263. | 0.5 | 12 |
| 1454 | Decreasing arm morbidity by refining axillary surgery in breast cancer. <i>European Journal of Surgical Oncology</i> , 2009, 35, 335-338. | 0.5 | 3 |
| 1455 | The challenges of success. <i>European Journal of Surgical Oncology</i> , 2009, 35, 1-2. | 0.5 | 122 |
| 1456 | Surgical guidelines for the management of breast cancer. <i>European Journal of Surgical Oncology</i> , 2009, 35, S1-S22. | 0.5 | 151 |
| 1457 | Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea. <i>European Journal of Surgical Oncology</i> , 2009, 35, 936-941. | 0.5 | 6 |
| 1458 | Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2009, 63, 1-10. | 2.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1459 | Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. <i>Cancer Letters</i> , 2009, 280, 184-191. | 3.2 | 49 |
| 1460 | 18. Prediction of Thromboembolic Events in Women With Hormone Receptor-Positive Breast Cancer Receiving SERMs. <i>Journal of Surgical Research</i> , 2009, 151, 179. | 0.8 | 0 |
| 1463 | Are Stem-Like Cells Responsible for Resistance to Therapy in Breast Cancer?. , 2009, , 97-110. | | 1 |
| 1464 | Radiation Therapy for Early-Stage Breast Cancer after Breast-Conserving Surgery. <i>New England Journal of Medicine</i> , 2009, 360, 63-70. | 13.9 | 113 |
| 1465 | Systems pathologyâ€™taking molecular pathology into a new dimension. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 455-464. | 12.5 | 62 |
| 1466 | Tongue Cancer. , 2008, , 3003-3006. | | 0 |
| 1467 | Treatment of established breast cancer in post-menopausal women: Role of aromatase inhibitors. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2009, 7, 42-55. | 0.8 | 6 |
| 1468 | LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. <i>The Cochrane Library</i> , 2009, , CD004562. | 1.5 | 53 |
| 1469 | Application of Semiconductor Quantum Dots for Breast Cancer Cell Sensing. , 2009, , . | | 4 |
| 1470 | Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. <i>The Cochrane Library</i> , 2021, 2021, CD003370. | 1.5 | 129 |
| 1471 | Genomic Predictors of Outcome and Treatment Response in Breast Cancer. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 73-90. | 1.6 | 35 |
| 1472 | Unveiling Fuzzy Associations Between Breast Cancer Prognostic Factors and Gene Expression Data. , 2009, , . | | 3 |
| 1474 | Pharmacology and Pharmacogenetics of Chemotherapeutic Agents. <i>Cancer Investigation</i> , 2009, 27, 482-488. | 0.6 | 23 |
| 1475 | <i>Lycium Barbarum</i> Inhibits Growth of Estrogen Receptor Positive Human Breast Cancer Cells by Favorably Altering Estradiol Metabolism. <i>Nutrition and Cancer</i> , 2009, 61, 408-414. | 0.9 | 39 |
| 1477 | Update on the use of aromatase inhibitors in early-stage breast cancer. <i>Breast Cancer Research</i> , 2009, 11, 211. | 2.2 | 6 |
| 1478 | Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. <i>Breast Cancer Research</i> , 2009, 11, R44. | 2.2 | 69 |
| 1479 | Who would have thought a single Ki67 measurement would predict long-term outcome?. <i>Breast Cancer Research</i> , 2009, 11, S15. | 2.2 | 18 |
| 1480 | Tailored targeted therapy for all: a realistic and worthwhile objective against. <i>Breast Cancer Research</i> , 2009, 11, S8. | 2.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1481 | Tailored targeted therapy for all: a realistic and worthwhile objective?. Breast Cancer Research, 2009, 11, S7. | 2.2 | 2 |
| 1482 | Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Research, 2009, 11, R35. | 2.2 | 31 |
| 1483 | Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Research, 2009, 11, 204. | 2.2 | 27 |
| 1484 | The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Research, 2009, 11, R22. | 2.2 | 107 |
| 1485 | TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Research, 2009, 11, R17. | 2.2 | 23 |
| 1486 | Controversies in hormonal adjuvant therapy for premenopausal patients. Breast Cancer Research, 2009, 11, . | 2.2 | 0 |
| 1487 | The Breast. , 2009, , 235-248. | | 2 |
| 1489 | Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer. New England Journal of Medicine, 2009, 360, 2055-2065. | 13.9 | 504 |
| 1490 | Cancer Epidemiology. Methods in Molecular Biology, 2009, , . | 0.4 | 6 |
| 1491 | Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer. Journal of Molecular Diagnostics, 2009, 11, 381-389. | 1.2 | 9 |
| 1492 | Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. , 2009, , CD007245. | | 25 |
| 1493 | Triple-negative breast cancerâ€™ current status and future directions. Annals of Oncology, 2009, 20, 1913-1927. | 0.6 | 526 |
| 1494 | Breast cancer in young women and its impact on reproductive function. Human Reproduction Update, 2009, 15, 323-339. | 5.2 | 131 |
| 1495 | <i>Mea Culpa</i>with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Review of Molecular Diagnostics, 2009, 9, 217-221. | 1.5 | 94 |
| 1496 | MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. Expert Opinion on Medical Diagnostics, 2009, 3, 193-205. | 1.6 | 9 |
| 1497 | Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy. BioDrugs, 2009, 23, 175-186. | 2.2 | 49 |
| 1498 | Information Technology Facilitates Cost-Effectiveness Analysis in Developing Countries. Pharmacoeconomics, 2009, 27, 947-961. | 1.7 | 16 |
| 1499 | Pharmacology, Pharmacogenetics, and Pharmacoeconomics: Three Ps of Individualized Therapy. Cancer Investigation, 2009, 27, 809-815. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1500 | Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1435-1447. | 0.9 | 26 |
| 1501 | Radiotherapy to the chest wall following mastectomy for node-negative breast cancer: A systematic review. <i>Radiotherapy and Oncology</i> , 2009, 91, 23-32. | 0.3 | 63 |
| 1502 | Genotype-guided tamoxifen therapy: time to pause for reflection?. <i>Lancet Oncology</i> , The, 2009, 10, 825-833. | 5.1 | 111 |
| 1503 | Concurrent hormone and radiation therapy in patients with breast cancer: how does chemotherapy affect treatment?. <i>Lancet Oncology</i> , The, 2009, 10, 442-444. | 5.1 | 0 |
| 1504 | Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1077-1085. | 5.1 | 29 |
| 1505 | Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. <i>Lancet Oncology</i> , The, 2009, 10, 1070-1076. | 5.1 | 154 |
| 1506 | Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept. <i>European Journal of Cancer</i> , 2009, 45, 11-26. | 1.3 | 60 |
| 1507 | Early breast cancer. <i>Lancet</i> , The, 2009, 373, 1463-1479. | 6.3 | 214 |
| 1508 | Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1681-1692. | 6.3 | 168 |
| 1509 | Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. <i>Lancet</i> , The, 2009, 374, 2055-2063. | 6.3 | 237 |
| 1510 | Fighting overtreatment in adjuvant breast cancer therapy. <i>Lancet</i> , The, 2009, 374, 2029-2030. | 6.3 | 34 |
| 1511 | CĂncer de mama (I). <i>Medicine</i> , 2009, 10, 1575-1582. | 0.0 | 1 |
| 1513 | Prediction of Thromboembolic Events in Women with Hormone Receptor-Positive Breast Cancer Receiving SERMS. <i>Journal of Surgical Research</i> , 2009, , . | 0.8 | 0 |
| 1514 | Neoadjuvant Endocrine Therapy for Breast Cancer. <i>Breast Diseases</i> , 2009, 20, 355-357. | 0.0 | 0 |
| 1515 | Morphological and kinetic characteristics of dynamic contrast-enhanced MRI (DCE-MRI) correlated with histopathological factors of breast cancer: A potential prognostic role of breast MRI?. <i>European Journal of Radiography</i> , 2009, 1, 124-132. | 0.2 | 4 |
| 1516 | Triple Negative Breast Carcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 483-494. | 0.6 | 20 |
| 1517 | Adherence to Quality Indicators and Survival in Patients With Breast Cancer. <i>Medical Care</i> , 2009, 47, 217-225. | 1.1 | 67 |
| 1518 | Age-Specific Incidence of Breast Cancer in Breast Cancer Survivors and Their First-Degree Relatives. <i>Epidemiology</i> , 2009, 20, 175-180. | 1.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1519 | Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 99-108. | 2.3 | 265 |
| 1520 | NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, S-1-S-21. | 2.3 | 110 |
| 1521 | Pharmacogenetics of Tamoxifen: Who Should Undergo <i>CYP2D6</i> Genetic Testing?. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 203-213. | 2.3 | 47 |
| 1522 | Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?. Genetics in Medicine, 2009, 11, 66-73. | 1.1 | 130 |
| 1523 | Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 122-192. | 2.3 | 389 |
| 1524 | Adjuvant endocrine therapy in premenopausal women with breast cancer. Breast Cancer Online: BCO, 2009, 12, . | 0.1 | 0 |
| 1525 | Constructive Technology Assessment (CTA) as a tool in Coverage with Evidence Development: The case of the 70-gene prognosis signature for breast cancer diagnostics. International Journal of Technology Assessment in Health Care, 2009, 25, 73-83. | 0.2 | 24 |
| 1526 | Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of <i>Tabebuia avellandae</i> tree. International Journal of Molecular Medicine, 2009, 24, 253-60. | 1.8 | 27 |
| 1527 | Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Annals of Internal Medicine, 2009, 151, 738. | 2.0 | 509 |
| 1528 | Current and future approach to the pathologist's assessment for targeted therapy in breast cancer. Pathology, 2009, 41, 89-99. | 0.3 | 18 |
| 1529 | Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. Current Opinion in Oncology, 2009, 21, 491-498. | 1.1 | 4 |
| 1530 | Chemotherapy-related amenorrhea in premenopausal women with breast cancer. Menopause, 2009, 16, 98-103. | 0.8 | 34 |
| 1532 | Breast Cancer in the Personal Genomics Era. Current Genomics, 2010, 11, 146-161. | 0.7 | 70 |
| 1533 | Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further?. Personalized Medicine, 2010, 7, 597-606. | 0.8 | 7 |
| 1534 | Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review. Current Drug Metabolism, 2010, 11, 115-128. | 0.7 | 113 |
| 1536 | Doxorubicin translocation B7-H1 from the cell surface to the nucleus of breast cancer cells. Hematology/ Oncology and Stem Cell Therapy, 2010, 3, 163. | 0.6 | 2 |
| 1537 | Pattern of care and survival in older women with breast cancer in India. Journal of Radiotherapy in Practice, 2010, 9, 237-245. | 0.2 | 3 |
| 1538 | Lessons for pharmacogenomics studies: association study between <i>CYP2D6</i> genotype and tamoxifen response. Pharmacogenetics and Genomics, 2010, 20, 565-568. | 0.7 | 40 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1539 | Advances in therapy: eribulin improves survival for metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2010, 21, 885-889. | 0.7 | 17 |
| 1540 | Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. <i>Current Opinion in Oncology</i> , 2010, 22, 547-551. | 1.1 | 51 |
| 1541 | Identifying Subsets of Metastatic Breast Cancer Patients Likely to Benefit From Treatment With the Etoposide Analog Ixabepilone. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 561-567. | 0.6 | 2 |
| 1542 | Duration of adjuvant endocrine therapy of breast cancer: how much is enough?. <i>Current Opinion in Obstetrics and Gynecology</i> , 2010, 22, 51-55. | 0.9 | 14 |
| 1543 | What Is the Difference Between Triple-Negative and Basal Breast Cancers?. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 289-293. | 1.0 | 18 |
| 1544 | Relationship Between Chemotherapy Use and Cognitive Impairments in Older Women With Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 533-543. | 0.6 | 42 |
| 1545 | High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers. <i>Oncology Letters</i> , 2010, 1, 261-266. | 0.8 | 4 |
| 1546 | Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 59. | 1.0 | 1 |
| 1547 | Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk. <i>International Journal of Oncology</i> , 2010, 36, 889-98. | 1.4 | 4 |
| 1548 | Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study. <i>Oncology Letters</i> , 2010, 1, 749-753. | 0.8 | 4 |
| 1549 | Modification and Implementation of NCCN Guidelines on Breast Cancer in the Middle East and North Africa Region. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-8-S-15. | 2.3 | 31 |
| 1550 | Breast Cancer: Noninvasive and Special Situations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1182-1207. | 2.3 | 8 |
| 1551 | Clinicopathological features of breast cancer patients with nipple discharge. <i>Molecular Medicine Reports</i> , 2010, 3, 863-8. | 1.1 | 1 |
| 1552 | Combining and Sequencing Adjuvant Chemotherapy and Tamoxifen in Postmenopausal Women with Node-Positive Breast Cancer. <i>Women's Health</i> , 2010, 6, 357-360. | 0.7 | 0 |
| 1553 | Breast Cancer Risk Reduction. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1112-1146. | 2.3 | 34 |
| 1554 | Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer. <i>International Journal of Molecular Medicine</i> , 2010, 26, 837-43. | 1.8 | 21 |
| 1555 | High-risk early breast cancer in patients under 40 years of age: Improved clinical outcome with total estrogen blockade and tailored chemotherapy. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 867-872. | 0.8 | 0 |
| 1556 | | | |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1557 | Characterizing the HER2/neu Status and Metastatic Potential of Breast Cancer Stem/Progenitor Cells. <i>Annals of Surgical Oncology</i> , 2010, 17, 613-623. | 0.7 | 21 |
| 1558 | Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature. <i>Annals of Surgical Oncology</i> , 2010, 17, 1406-1413. | 0.7 | 66 |
| 1559 | Management of Operable Invasive Breast Cancer in Women Over the Age of 70: Long-Term Results of a Large-Scale Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2010, 17, 1530-1538. | 0.7 | 18 |
| 1560 | Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010. <i>Annals of Surgical Oncology</i> , 2010, 17, 1989-1994. | 0.7 | 17 |
| 1561 | The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up. <i>Annals of Surgical Oncology</i> , 2010, 17, 3259-3268. | 0.7 | 43 |
| 1562 | Triple-Negative Breast Cancers: Unique Clinical Presentations and Outcomes. <i>Annals of Surgical Oncology</i> , 2010, 17, 384-390. | 0.7 | 73 |
| 1563 | Controversies in Breast Surgery. <i>Annals of Surgical Oncology</i> , 2010, 17, 230-232. | 0.7 | 9 |
| 1564 | Hormone replacement therapy and breast disease. <i>The Obstetrician and Gynaecologist</i> , 2010, 12, 155-163. | 0.2 | 1 |
| 1565 | Selectively targeting estrogen receptors for cancer treatment. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 1265-1276. | 6.6 | 98 |
| 1566 | Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. <i>Journal of Zhejiang University: Science B</i> , 2010, 11, 1-9. | 1.3 | 12 |
| 1567 | Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R39. | 2.2 | 37 |
| 1568 | Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1 α in tumor and normal cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 277-287. | 1.1 | 108 |
| 1569 | Multiplexed immunoassays for the analysis of breast cancer biopsies. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 3329-3338. | 1.9 | 9 |
| 1572 | Prospective meta-analysis using individual patient data in intensive care medicine. <i>Intensive Care Medicine</i> , 2010, 36, 11-21. | 3.9 | 44 |
| 1573 | Chapter 2. Surge capacity and infrastructure considerations for mass critical care. <i>Intensive Care Medicine</i> , 2010, 36, 11-20. | 3.9 | 91 |
| 1574 | Hormone therapy in elderly breast cancer patients with comorbidities. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 92-98. | 2.0 | 20 |
| 1575 | Topoisomerase III α expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1029-1037. | 1.2 | 29 |
| 1576 | Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. <i>International Journal of Clinical Oncology</i> , 2010, 15, 588-593. | 1.0 | 65 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1577 | Les grands challenges de la prise en charge en phase mÃ©tastatique aujourdâ€™hui. <i>Oncologie</i> , 2010, 12, 278-284. | 0.2 | 1 |
| 1581 | Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview. <i>Wiener Medizinische Wochenschrift</i> , 2010, 160, 167-173. | 0.5 | 1 |
| 1582 | Disparities in the survival improvement of recurrent breast cancer. <i>Breast Cancer</i> , 2010, 17, 48-55. | 1.3 | 11 |
| 1583 | Pharmacogenomics of Tamoxifen: Ready for Prime Time?. <i>Current Breast Cancer Reports</i> , 2010, 2, 32-41. | 0.5 | 1 |
| 1584 | Adjuvant Chemotherapy for Early Stage Breast Cancer: Current Trends and Future Directions. <i>Current Breast Cancer Reports</i> , 2010, 2, 16-24. | 0.5 | 0 |
| 1585 | How Improved Local-Regional Therapy Impacts Survival. <i>Current Breast Cancer Reports</i> , 2010, 2, 83-89. | 0.5 | 1 |
| 1586 | Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients. <i>EPMA Journal</i> , 2010, 1, 421-437. | 3.3 | 11 |
| 1587 | Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer. <i>Indian Journal of Surgical Oncology</i> , 2010, 1, 19-26. | 0.3 | 1 |
| 1588 | Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. <i>Indian Journal of Surgical Oncology</i> , 2010, 1, 68-75. | 0.3 | 3 |
| 1589 | Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer. <i>Indian Journal of Surgical Oncology</i> , 2010, 1, 305-312. | 0.3 | 7 |
| 1590 | G protein-coupled receptor 30 in tumor development. <i>Endocrine</i> , 2010, 38, 29-37. | 1.1 | 73 |
| 1591 | Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. <i>Medical Oncology</i> , 2010, 27, 474-480. | 1.2 | 17 |
| 1592 | Neoadjuvant chemotherapy for â€œTriple Negativeâ€ breast cancer: a review of current practice and future outlook. <i>Medical Oncology</i> , 2010, 27, 531-539. | 1.2 | 22 |
| 1593 | Verification of a prolonged untreated natural history of breast cancer by the multigene assay. <i>Medical Oncology</i> , 2010, 27, 624-627. | 1.2 | 0 |
| 1594 | Mechanisms of resistance to hormonal treatment in breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 246-252. | 1.2 | 13 |
| 1595 | Current controversies in the management of breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 278-286. | 1.2 | 2 |
| 1596 | Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?. <i>Clinical and Translational Oncology</i> , 2010, 12, 614-620. | 1.2 | 6 |
| 1597 | SEOM clinical guidelines for the treatment of early breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 711-718. | 1.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1598 | Neoadjuvant combination chemotherapy with pegylated liposomal doxorubicin and vinorelbine for locally advanced breast cancer. <i>Clinical Oncology and Cancer Research</i> , 2010, 7, 7-11. | 0.1 | 0 |
| 1599 | CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance. <i>Current Oncology Reports</i> , 2010, 12, 7-15. | 1.8 | 56 |
| 1600 | Epigenetic Regulation in Estrogen Receptor Positive Breast Cancer—Role in Treatment Response. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2010, 15, 35-47. | 1.0 | 48 |
| 1601 | Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 33-38. | 1.1 | 76 |
| 1602 | The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 551-558. | 1.1 | 220 |
| 1603 | Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 575-591. | 1.1 | 23 |
| 1604 | The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 401-408. | 1.1 | 19 |
| 1605 | Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 511-527. | 1.1 | 3 |
| 1606 | FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). <i>Breast Cancer Research and Treatment</i> , 2010, 119, 95-104. | 1.1 | 36 |
| 1607 | Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). <i>Breast Cancer Research and Treatment</i> , 2010, 120, 715-723. | 1.1 | 29 |
| 1608 | Patterns of relapse in breast cancer: changes over time. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 753-759. | 1.1 | 33 |
| 1609 | Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor β and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 145-158. | 1.1 | 9 |
| 1610 | Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 771-776. | 1.1 | 2 |
| 1611 | Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 25-32. | 1.1 | 15 |
| 1612 | Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). <i>Breast Cancer Research and Treatment</i> , 2010, 119, 391-398. | 1.1 | 10 |
| 1613 | GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 51-58. | 1.1 | 69 |
| 1614 | Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 733-745. | 1.1 | 27 |
| 1615 | High levels of uPA and PAI-1 predict a good response to anthracyclines. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 615-624. | 1.1 | 24 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1616 | New troglitazone derivatives devoid of PPAR β agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Research and Treatment, 2010, 124, 101-110. | 1.1 | 25 |
| 1617 | Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Research and Treatment, 2010, 122, 843-851. | 1.1 | 112 |
| 1618 | Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Research and Treatment, 2010, 122, 585-590. | 1.1 | 32 |
| 1619 | Combinatorial biomarker expression in breast cancer. Breast Cancer Research and Treatment, 2010, 120, 293-308. | 1.1 | 176 |
| 1620 | Diagnostic work-up of contralateral breast cancers has not improved over calendar period. Breast Cancer Research and Treatment, 2010, 122, 889-895. | 1.1 | 1 |
| 1621 | Population-based survival-cure analysis of ER-negative breast cancer. Breast Cancer Research and Treatment, 2010, 123, 257-264. | 1.1 | 9 |
| 1622 | Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Research and Treatment, 2010, 121, 91-100. | 1.1 | 94 |
| 1623 | Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?. Breast Cancer Research and Treatment, 2010, 120, 525-538. | 1.1 | 70 |
| 1624 | Adjuvant Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Research and Treatment, 2010, 123, 303-310. | 1.1 | 24 |
| 1625 | The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment, 2010, 120, 655-661. | 1.1 | 242 |
| 1626 | The androgen receptor in breast cancer: learning from the past. Breast Cancer Research and Treatment, 2010, 124, 619-621. | 1.1 | 14 |
| 1627 | Is there a role for ovarian function suppression in operable breast cancer?. Breast Cancer Research and Treatment, 2010, 123, 311-313. | 1.1 | 1 |
| 1628 | Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Research and Treatment, 2010, 121, 379-387. | 1.1 | 44 |
| 1629 | A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer. Breast Cancer Research and Treatment, 2010, 124, 835-844. | 1.1 | 37 |
| 1630 | CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. Breast Cancer Research and Treatment, 2010, 123, 163-169. | 1.1 | 14 |
| 1631 | New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study. Breast Cancer Research and Treatment, 2010, 122, 439-451. | 1.1 | 69 |
| 1632 | Adjuvant chemotherapy is not for everyone. Breast Cancer Research and Treatment, 2010, 123, 159-162. | 1.1 | 3 |
| 1633 | Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Research and Treatment, 2010, 123, 9-24. | 1.1 | 70 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1634 | Adjuvant chemotherapy in young women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 39-41. | 1.1 | 121 |
| 1635 | Adjuvant endocrine therapy in premenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 43-47. | 1.1 | 5 |
| 1636 | Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 863-873. | 1.1 | 78 |
| 1637 | Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 387-391. | 1.1 | 28 |
| 1638 | Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 581-594. | 2.7 | 13 |
| 1639 | Therapeutic Potential of New 4-hydroxy-tamoxifen-Loaded pH-gradient Liposomes in a Multiple Myeloma Experimental Model. <i>Pharmaceutical Research</i> , 2010, 27, 327-339. | 1.7 | 15 |
| 1640 | Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer. <i>Seminars in Oncology</i> , 2010, 37, 1-10. | 0.8 | 21 |
| 1641 | Breast Cancer Prevention Trials: Large and Small Trials. <i>Seminars in Oncology</i> , 2010, 37, 367-383. | 0.8 | 18 |
| 1642 | Adjuvant treatment for breast cancer. <i>Surgery</i> , 2010, 28, 140-143. | 0.1 | 0 |
| 1643 | Breast Cancer Follow-Up: Strategies for Successful Collaboration between Cancer Care Specialists and Primary Care Providers. <i>Journal for Nurse Practitioners</i> , 2010, 6, 452-463. | 0.4 | 0 |
| 1644 | Secondary Malignancies Across the Age Spectrum. <i>Seminars in Radiation Oncology</i> , 2010, 20, 67-78. | 1.0 | 119 |
| 1645 | Herceptin and breast cancer: An overview for surgeons. <i>Surgical Oncology</i> , 2010, 19, e11-e21. | 0.8 | 12 |
| 1646 | Pregnancy after breast cancer: A need for global patient care, starting before adjuvant therapy. <i>Surgical Oncology</i> , 2010, 19, e47-e55. | 0.8 | 16 |
| 1647 | Comparison of immunohistochemistry assays and real-time reverse transcription-polymerase chain reaction for analyzing hormone receptor status in human breast carcinoma. <i>Pathology International</i> , 2010, 60, 305-315. | 0.6 | 9 |
| 1648 | The 2009 San Antonio Breast Cancer Symposium San Antonio, TX; December 9-13, 2009. <i>Clinical Breast Cancer</i> , 2010, 10, 19-26. | 1.1 | 2 |
| 1649 | Oncologists' Recommendations for Adjuvant Therapy in Hormone Receptor-Positive Breast Cancer Patients of Varying Age and Health Status. <i>Clinical Breast Cancer</i> , 2010, 10, 136-143. | 1.1 | 11 |
| 1650 | Changes to Adjuvant Systemic Therapy in Breast Cancer: A Decade in Review. <i>Clinical Breast Cancer</i> , 2010, 10, 196-208. | 1.1 | 23 |
| 1651 | Compliance Differences Between Patients With Breast Cancer in University and County Hospitals. <i>Clinical Breast Cancer</i> , 2010, 10, 385-391. | 1.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1652 | A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. <i>BMC Cancer</i> , 2010, 10, 2. | 1.1 | 32 |
| 1653 | Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study. <i>BMC Cancer</i> , 2010, 10, 205. | 1.1 | 8 |
| 1654 | Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients. <i>BMC Cancer</i> , 2010, 10, 281. | 1.1 | 32 |
| 1655 | A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. <i>BMC Cancer</i> , 2010, 10, 36. | 1.1 | 67 |
| 1656 | Adjuvant radiotherapy and chemotherapy in breast cancer: 30 year follow-up of survival. <i>BMC Cancer</i> , 2010, 10, 398. | 1.1 | 9 |
| 1657 | BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. <i>BMC Cancer</i> , 2010, 10, 654. | 1.1 | 53 |
| 1658 | A model building exercise of mortality risk for Taiwanese women with breast cancer. <i>BMC Medical Informatics and Decision Making</i> , 2010, 10, 43. | 1.5 | 3 |
| 1659 | Forecasting drug utilization and expenditure in a metropolitan health region. <i>BMC Health Services Research</i> , 2010, 10, 128. | 0.9 | 58 |
| 1660 | Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution. <i>BMC Research Notes</i> , 2010, 3, 247. | 0.6 | 10 |
| 1661 | Breast cancer in moroccan young women: a retrospective study. <i>BMC Research Notes</i> , 2010, 3, 286. | 0.6 | 14 |
| 1662 | Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 203, 595.e9-595.e16. | 0.7 | 33 |
| 1663 | Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. <i>Clinical Therapeutics</i> , 2010, 32, 311-326. | 1.1 | 12 |
| 1664 | Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for korean women with breast cancer: Retrospective cohort study of the korean breast cancer society database. <i>Clinical Therapeutics</i> , 2010, 32, 1122-1138. | 1.1 | 8 |
| 1665 | Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. <i>Breast</i> , 2010, 19, 69-75. | 0.9 | 12 |
| 1666 | Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy. <i>Breast</i> , 2010, 19, 76-83. | 0.9 | 38 |
| 1667 | Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: A pathological and immunohistochemical study. <i>Breast</i> , 2010, 19, 137-141. | 0.9 | 21 |
| 1668 | A vision to optimise the management of primary breast cancer in older women. <i>Breast</i> , 2010, 19, 153-155. | 0.9 | 6 |
| 1669 | Estimation of an evidence-based benchmark for the optimal endocrine therapy utilization rate in breast cancer. <i>Breast</i> , 2010, 19, 345-349. | 0.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1670 | Lipomodelling of the Breast: A review. <i>Breast</i> , 2010, 19, 202-209. | 0.9 | 54 |
| 1671 | Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 699-710. | 1.5 | 17 |
| 1672 | Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. <i>Cancer</i> , 2010, 116, 2307-2315. | 2.0 | 33 |
| 1673 | Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. <i>Cancer</i> , 2010, 116, 2081-2089. | 2.0 | 21 |
| 1674 | Primary systemic chemotherapy for inflammatory breast cancer. <i>Cancer</i> , 2010, 116, 2821-2828. | 2.0 | 22 |
| 1675 | Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. <i>Cancer</i> , 2010, 116, 4227-4237. | 2.0 | 100 |
| 1676 | Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. <i>International Journal of Cancer</i> , 2010, 127, 961-967. | 2.3 | 51 |
| 1677 | Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. <i>British Journal of Surgery</i> , 2010, 97, 671-679. | 0.1 | 28 |
| 1678 | An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: First evidence of 4-hydroxylated metabolites in breast cancer patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 3402-3414. | 1.2 | 35 |
| 1679 | Breast cancer in the elderly. <i>Archives of Gerontology and Geriatrics</i> , 2010, 50, 179-184. | 1.4 | 19 |
| 1680 | Breast Cancer Multidisciplinary Team Adjuvant Therapy Decision Making and Adjuvant! Online. <i>Clinical Oncology</i> , 2010, 22, 87-88. | 0.6 | 6 |
| 1681 | Review of Testing and Use of Adjuvant Trastuzumab across a Cancer Network - Are We Treating the Right Patients?. <i>Clinical Oncology</i> , 2010, 22, 289-293. | 0.6 | 15 |
| 1682 | Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 246-254. | 2.0 | 144 |
| 1683 | Male breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 141-155. | 2.0 | 138 |
| 1684 | The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 127-132. | 2.0 | 32 |
| 1685 | Outcome After Conservative Surgery and Breast Irradiation in 5,717 Patients With Breast Cancer: Implications for Supraclavicular Nodal Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 978-983. | 0.4 | 24 |
| 1686 | Dynamic Contrast-Enhanced MRI Kinetics of Invasive Breast Cancer: A Potential Prognostic Marker for Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1314-1319. | 0.4 | 14 |
| 1687 | Three-Year Outcomes of Breast Intensity-Modulated Radiation Therapy With Simultaneous Integrated Boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 523-530. | 0.4 | 76 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1688 | Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1296-1302. | 0.4 | 79 |
| 1689 | Risk of Parkinson's disease after tamoxifen treatment. <i>BMC Neurology</i> , 2010, 10, 23. | 0.8 | 33 |
| 1690 | Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. <i>Psycho-Oncology</i> , 2010, 19, 472-479. | 1.0 | 69 |
| 1691 | Antagonistic interaction between bicalutamide, (Casodex®) and radiation in androgen-positive prostate cancer LNCaP cells. <i>Prostate</i> , 2010, 70, 401-411. | 1.2 | 11 |
| 1692 | Routine Breast MRI as a Screening Modality for Occult Contralateral Breast Cancer: Where Do We Draw the Line?. <i>Breast Journal</i> , 2010, 16, 115-117. | 0.4 | 0 |
| 1693 | Alternation of Estrogen Receptor and Progesterone Receptor Expression in Primary Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Breast Journal</i> , 2010, 16, no-no. | 0.4 | 1 |
| 1694 | Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. <i>Breast Journal</i> , 2010, 16, 529-532. | 0.4 | 24 |
| 1695 | A Community Breast Center Report Card Determined by Participation in the National Quality Measures for Breast Centers Program. <i>Breast Journal</i> , 2010, 16, 472-480. | 0.4 | 15 |
| 1696 | Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands. <i>Value in Health</i> , 2010, 13, 375-380. | 0.1 | 29 |
| 1697 | Protein interacting with C ₁ kinase 1 (PICK1) is involved in promoting tumor growth and correlates with poor prognosis of human breast cancer. <i>Cancer Science</i> , 2010, 101, 1536-1542. | 1.7 | 22 |
| 1698 | Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer. <i>Cancer Science</i> , 2010, 101, 2171-2178. | 1.7 | 44 |
| 1699 | Decision modelling of economic evaluation of intervention programme of breast cancer. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 1282-1288. | 0.9 | 0 |
| 1700 | Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice. <i>Journal of Internal Medicine</i> , 2010, 268, 540-548. | 2.7 | 17 |
| 1701 | Effect of comorbidity on urinary neopterin in patients with breast carcinoma. <i>European Journal of Cancer Care</i> , 2010, 19, 340-345. | 0.7 | 2 |
| 1702 | Prognostic and predictive factors in breast cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 371-372. | 0.7 | 2 |
| 1703 | Relation of risk of contralateral breast cancer to the interval since the first primary tumour. <i>British Journal of Cancer</i> , 2010, 102, 213-219. | 2.9 | 33 |
| 1704 | Assessment of fracture risk in women with breast cancer using current vs emerging guidelines. <i>British Journal of Cancer</i> , 2010, 102, 645-650. | 2.9 | 31 |
| 1705 | Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction. <i>British Journal of Cancer</i> , 2010, 102, 1503-1510. | 2.9 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1706 | Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a caseâ€“control study. <i>British Journal of Cancer</i> , 2010, 103, 291-296. | 2.9 | 34 |
| 1707 | Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. <i>British Journal of Cancer</i> , 2010, 103, 759-764. | 2.9 | 72 |
| 1708 | Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. <i>British Journal of Cancer</i> , 2010, 103, 776-786. | 2.9 | 39 |
| 1709 | Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. <i>British Journal of Cancer</i> , 2010, 103, 1518-1523. | 2.9 | 32 |
| 1710 | Control of mammary stem cell function by steroid hormone signalling. <i>Nature</i> , 2010, 465, 798-802. | 13.7 | 617 |
| 1711 | Amplification of LPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. <i>Nature Medicine</i> , 2010, 16, 214-218. | 15.2 | 301 |
| 1712 | Breast and prostate cancer: more similar than different. <i>Nature Reviews Cancer</i> , 2010, 10, 205-212. | 12.8 | 212 |
| 1713 | Does tumour dormancy offer a therapeutic target?. <i>Nature Reviews Cancer</i> , 2010, 10, 871-877. | 12.8 | 270 |
| 1714 | Annular erythema as a sign of recurrent breast cancer. <i>Australasian Journal of Dermatology</i> , 2010, 51, 135-138. | 0.4 | 5 |
| 1715 | Advances in the adjuvant treatment of early breast cancer. , 2010, , 241-261. | | 0 |
| 1717 | Drug utilization, adherence, and unique side effects of targeted therapy in older adults. , 0, , 41-51. | | 0 |
| 1718 | Management of breast cancer in older adults. , 0, , 89-109. | | 0 |
| 1719 | Molecular Biology of Breast Cancer. , 2010, , 341-349. | | 3 |
| 1721 | The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. <i>Pharmaceuticals</i> , 2010, 3, 1122-1138. | 1.7 | 16 |
| 1722 | Use of Antidepressants in Patients with Breast Cancer Taking Tamoxifen. <i>Journal of Breast Cancer</i> , 2010, 13, 325. | 0.8 | 2 |
| 1723 | Seven Cases of Secondary Acute Leukemia Following Therapy of Breast Cancer. <i>Journal of Breast Cancer</i> , 2010, 13, 111. | 0.8 | 0 |
| 1724 | Breast cancer. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2010, 40, 335-339. | 0.2 | 28 |
| 1725 | Does Race Affect Outcomes in Triple Negative Breast Cancer?. <i>Breast Cancer: Basic and Clinical Research</i> , 2010, 4, 117822341000400. | 0.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1726 | Molecular Subtype Approximated by Quantitative Estrogen Receptor, Progesterone Receptor and Her2 Can Predict the Prognosis of Breast Cancer. <i>Tumori</i> , 2010, 96, 103-110. | 0.6 | 26 |
| 1727 | Análisis de costo-efectividad en Colombia de anastrozol Vs. tamoxifeno como terapia inicial en mujeres con cáncer temprano de mama y receptor hormonal positivo. <i>Biomedica</i> , 2010, 30, 46. | 0.3 | 5 |
| 1728 | Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women. <i>Journal of Bangladesh College of Physicians & Surgeons</i> , 2010, 28, 157-162. | 0.0 | 5 |
| 1729 | Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. <i>OncoTargets and Therapy</i> , 2010, 4, 1. | 1.0 | 29 |
| 1730 | Adjuvant Hormonal Therapy: Current Standard and Practical Issues. <i>Journal of Breast Cancer</i> , 2010, 13, 242. | 0.8 | 3 |
| 1731 | Human Mesenchymal Stem Cells as Mediators of Breast Carcinoma Tumorigenesis and Progression. <i>Scientific World Journal</i> , The, 2010, 10, 1084-1087. | 0.8 | 2 |
| 1732 | FACE: the barefaced facts of AI potency. <i>Cancer Management and Research</i> , 2010, , 267. | 0.9 | 2 |
| 1734 | Pharmacoeconomic considerations in the treatment of breast cancer. <i>ClinicoEconomics and Outcomes Research</i> , 0, , 47. | 0.7 | 6 |
| 1735 | Clinicopathological features and treatment sensitivity of elderly Chinese breast cancer patients. <i>Oncology Letters</i> , 2010, 1, 1037-1043. | 0.8 | 2 |
| 1736 | Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in brazil. <i>Revista Da Associação Médica Brasileira</i> , 2010, 56, 186-191. | 0.3 | 20 |
| 1737 | Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 286-293. | 0.6 | 27 |
| 1738 | Identification of Common Predictive Markers of <i>in vitro</i> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1985-1994. | 1.9 | 59 |
| 1739 | Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen. <i>Journal of Clinical Oncology</i> , 2010, 28, e584-e585. | 0.8 | 12 |
| 1740 | The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1272-1280. | 3.2 | 94 |
| 1741 | Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 367-380. | 12.5 | 94 |
| 1742 | Evidence and Practice Regarding the Role for CYP2D6 Inhibition in Decisions About Tamoxifen Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1273-1275. | 0.8 | 31 |
| 1743 | Reply to G. Ferretti et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e338-e339. | 0.8 | 1 |
| 1744 | Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1413-1421. | 3.0 | 100 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1745 | Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)â€”a randomised controlled trial of exemestane versus continued tamoxifen after 2â€”3 years tamoxifen. <i>Annals of Oncology</i> , 2010, 21, 498-505. | 0.6 | 34 |
| 1746 | Intratumoral Estrogen Disposition in Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1790-1801. | 3.2 | 92 |
| 1747 | Association Between <emph type="ital">CYP2D6</emph> Polymorphisms and Breast Cancer Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 516. | 3.8 | 2 |
| 1748 | Summary and Comparison of Myeloid Growth Factor Guidelines in Patients Receiving Cancer Chemotherapy. <i>Cancer Treatment and Research</i> , 2010, 157, 145-165. | 0.2 | 16 |
| 1749 | Decrease in Breast Density in the Contralateral Normal Breast of Patients Receiving Neoadjuvant Chemotherapy: MR Imaging Evaluation. <i>Radiology</i> , 2010, 255, 44-52. | 3.6 | 37 |
| 1750 | Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients. <i>Annals of Oncology</i> , 2010, 21, 2094-2101. | 0.6 | 49 |
| 1751 | A Derivate of the Antibiotic Doxorubicin Is a Selective Inhibitor of Dengue and Yellow Fever Virus Replication <i>In Vitro</i>. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5269-5280. | 1.4 | 72 |
| 1752 | Anastrozole. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 995-1003. | 1.0 | 20 |
| 1753 | Survival Analysis of Cancer Risk Reduction Strategies for <i>BRCA1/2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 222-231. | 0.8 | 217 |
| 1754 | Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptorâ€”Positive, Metastatic Carcinoma of the Breast in Premenopausal Women. <i>Journal of Clinical Oncology</i> , 2010, 28, 3917-3921. | 0.8 | 80 |
| 1755 | Accuracy of Perceived Risk of Recurrence Among Patients With Early-Stage Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 675-680. | 1.1 | 42 |
| 1756 | Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 731-737. | 0.8 | 163 |
| 1757 | Using Lifetime Risk Estimates to Recommend Magnetic Resonance Imaging Screening for Breast Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2010, 28, 4108-4110. | 0.8 | 29 |
| 1758 | RBCK1 Drives Breast Cancer Cell Proliferation by Promoting Transcription of Estrogen Receptor β and Cyclin B1. <i>Cancer Research</i> , 2010, 70, 1265-1274. | 0.4 | 47 |
| 1759 | Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue. <i>Clinical Cancer Research</i> , 2010, 16, 2176-2186. | 3.2 | 21 |
| 1760 | Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 628-633. | 0.8 | 43 |
| 1761 | Is It Time to ReSET the Standard for Estrogen Receptor Testing in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2010, 28, 4101-4103. | 0.8 | 3 |
| 1762 | Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 508-512. | 0.6 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1763 | Benefits and adverse effects of endocrine therapy. <i>Annals of Oncology</i> , 2010, 21, vii107-vii111. | 0.6 | 28 |
| 1764 | Chemotherapy with or without trastuzumab. <i>Annals of Oncology</i> , 2010, 21, vii112-vii119. | 0.6 | 8 |
| 1765 | Impact of interval from breast conserving surgery to radiotherapy on local recurrence in older women with breast cancer: retrospective cohort analysis. <i>BMJ: British Medical Journal</i> , 2010, 340, c845-c845. | 2.4 | 93 |
| 1766 | Optimal Sequence of Implied Modalities in the Adjuvant Setting of Breast Cancer Treatment: An Update on Issues To Consider. <i>Oncologist</i> , 2010, 15, 1169-1178. | 1.9 | 22 |
| 1767 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v9-v14. | 0.6 | 1,220 |
| 1768 | Breast Cancer Adjuvant Chemotherapy Decisions in Older Women: The Role of Patient Preference and Interactions With Physicians. <i>Journal of Clinical Oncology</i> , 2010, 28, 3146-3153. | 0.8 | 75 |
| 1769 | Long-term Prognostic Role of Functional Limitations Among Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1468-1477. | 3.0 | 112 |
| 1770 | A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canadaâ€”Clinical Trials Group Trial, Tj ETQq1 1 0.784314 rgB34Overlock | 0.7 | 114 |
| 1771 | Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 4120-4128. | 0.8 | 663 |
| 1772 | Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2â€”Negative Breast Cancer with Acquired Endocrine Resistance. <i>Clinical Cancer Research</i> , 2010, 16, 1486-1497. | 3.2 | 82 |
| 1773 | Cardiorespiratory Fitness and Quality-of-Life Analysis Posttreatment in Breast Cancer Survivors. <i>Journal of Psychosocial Oncology</i> , 2010, 28, 381-398. | 0.6 | 9 |
| 1774 | Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 2053-2065. | 13.9 | 292 |
| 1775 | Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1845-1854. | 3.0 | 190 |
| 1776 | Evolution of endocrine adjuvant therapy for early breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, S19-S30. | 1.9 | 5 |
| 1777 | American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€”Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3784-3796. | 0.8 | 655 |
| 1778 | Rechallenging with anthracyclines and taxanes in metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 561-574. | 12.5 | 55 |
| 1779 | Using Traditional Acupuncture for Breast Cancer-Related Hot Flashes and Night Sweats. <i>Journal of Alternative and Complementary Medicine</i> , 2010, 16, 1047-1057. | 2.1 | 40 |
| 1780 | Early recurrence risk: aromatase inhibitors versus tamoxifen. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1239-1253. | 1.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1781 | Intermeshing breast reconstruction and postmastectomy radiation. Expert Review of Anticancer Therapy, 2010, 10, 1273-1283. | 1.1 | 8 |
| 1782 | Prognostic factors for local recurrence following breast-conserving treatment in young women. Expert Review of Anticancer Therapy, 2010, 10, 1215-1227. | 1.1 | 4 |
| 1783 | Exemestane in postmenopausal women with early or advanced breast cancer: a review. Expert Opinion on Pharmacotherapy, 2010, 11, 1933-1942. | 0.9 | 7 |
| 1784 | Biology and management of inflammatory breast cancer. Expert Review of Anticancer Therapy, 2010, 10, 209-220. | 1.1 | 15 |
| 1785 | Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2974-2981. | 0.8 | 54 |
| 1786 | HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients. Journal of Clinical Oncology, 2010, 28, 984-990. | 0.8 | 72 |
| 1787 | Influence of Sex Hormones on Cancer Progression. Journal of Clinical Oncology, 2010, 28, 4038-4044. | 0.8 | 171 |
| 1788 | Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ: British Medical Journal, 2010, 340, c693-c693. | 2.4 | 358 |
| 1789 | FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Annals of Oncology, 2010, 21, 1636-1642. | 0.6 | 31 |
| 1790 | Genomic predictors of prostate cancer therapy outcomes. Expert Review of Molecular Diagnostics, 2010, 10, 619-636. | 1.5 | 4 |
| 1791 | Plasma Membrane Proteomics and Its Application in Clinical Cancer Biomarker Discovery. Molecular and Cellular Proteomics, 2010, 9, 1369-1382. | 2.5 | 142 |
| 1792 | Breast cancer associated with a concurrent or subsequent pregnancy. Expert Review of Obstetrics and Gynecology, 2010, 5, 357-369. | 0.4 | 2 |
| 1793 | Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls. Expert Review of Anticancer Therapy, 2010, 10, 185-198. | 1.1 | 9 |
| 1794 | Regulation of ER α Gene Expression by Estrogen Receptor Agonists and Antagonists in SKBR3 Breast Cancer Cells: Differential Molecular Mechanisms Mediated by G Protein-Coupled Receptor GPR30/GPER-1. Molecular Endocrinology, 2010, 24, 969-980. | 3.7 | 38 |
| 1795 | Delays in Adjuvant Chemotherapy Treatment Among Patients With Breast Cancer Are More Likely in African American and Hispanic Populations: A National Cohort Study 2004-2006. Journal of Clinical Oncology, 2010, 28, 4135-4141. | 0.8 | 150 |
| 1796 | BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy. Clinical Cancer Research, 2010, 16, 3988-3997. | 3.2 | 37 |
| 1797 | Coming of Age: Breast Cancer in Seniors. Oncologist, 2010, 15, 57-65. | 1.9 | 30 |
| 1798 | CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification. Clinical Cancer Research, 2010, 16, 4468-4477. | 3.2 | 81 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1799 | Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer – Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant Radiotherapy. <i>Breast Care</i> , 2010, 5, 259-265. | 0.8 | 2 |
| 1800 | Treatment of pT1N0 breast cancer: multigene predictors to assess risk of relapse. <i>Annals of Oncology</i> , 2010, 21, vii103-vii106. | 0.6 | 4 |
| 1801 | Activity of fulvestrant in HER2-overexpressing advanced breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1246-1253. | 0.6 | 20 |
| 1802 | Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. <i>Annals of Oncology</i> , 2010, 21, 949-954. | 0.6 | 19 |
| 1803 | Overview of the Randomized Trials of Radiotherapy in Ductal Carcinoma In Situ of the Breast. <i>Journal of the National Cancer Institute Monographs</i> , 2010, 2010, 162-177. | 0.9 | 511 |
| 1804 | Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. <i>Acta Oncologica</i> , 2010, 49, 305-312. | 0.8 | 82 |
| 1805 | Defining the Clinical Utility of Gene Expression Assays in Breast Cancer: The Intersection of Science and Art in Clinical Decision Making. <i>Journal of Clinical Oncology</i> , 2010, 28, 1625-1627. | 0.8 | 20 |
| 1806 | Nonadherence in Patients With Breast Cancer Receiving Oral Therapies. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 41-47. | 0.3 | 28 |
| 1807 | Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. <i>Acta Oncologica</i> , 2010, 49, 844-850. | 0.8 | 10 |
| 1808 | Adjuvant Endocrine Therapy for Early Breast Cancer: The Story So Far. <i>Cancer Investigation</i> , 2010, 28, 433-442. | 0.6 | 12 |
| 1809 | The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. <i>Annals of Oncology</i> , 2010, 21, 717-722. | 0.6 | 129 |
| 1810 | Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. <i>Annals of Oncology</i> , 2010, 21, 974-982. | 0.6 | 6 |
| 1811 | Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer. <i>Oncologist</i> , 2010, 15, 457-465. | 1.9 | 104 |
| 1812 | Using a Computer-Based Risk Assessment Tool to Identify Risk for Chemotherapy-Induced Febrile Neutropenia. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 87-91. | 0.3 | 3 |
| 1813 | Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 696-706. | 0.7 | 560 |
| 1814 | Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2010, 26, 2315-2328. | 0.9 | 6 |
| 1815 | Multi-Variant Pathway Association Analysis Reveals the Importance of Genetic Determinants of Estrogen Metabolism in Breast and Endometrial Cancer Susceptibility. <i>PLoS Genetics</i> , 2010, 6, e1001012. | 1.5 | 41 |
| 1816 | Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. <i>Endocrine-Related Cancer</i> , 2010, 17, 215-230. | 1.6 | 30 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1817 | Translating the Genomic Architecture of Breast Cancer into Clinical Applications. <i>Science Translational Medicine</i> , 2010, 2, 38ps32. | 5.8 | 0 |
| 1818 | Role of traditional and new biomarkers in breast carcinogenesis. <i>Ecancermedicalsecience</i> , 2010, 3, 157. | 0.6 | 1 |
| 1819 | Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer. <i>Acta OncolÃ³gica</i> , 2010, 49, 816-820. | 0.8 | 17 |
| 1820 | Biomarker Research in Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 771-783. | 0.3 | 4 |
| 1821 | Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2010, 31, 122. | 0.1 | 6 |
| 1822 | Dose-dense treatment for triple-negative breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 79-80. | 12.5 | 24 |
| 1823 | Contralateral Second Breast Cancers: Prediction and Prevention. <i>Journal of the National Cancer Institute</i> , 2010, 102, 444-445. | 3.0 | 14 |
| 1824 | A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. <i>Annals of Oncology</i> , 2010, 21, 1623-1629. | 0.6 | 6 |
| 1825 | Lasofixifene in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2010, 362, 686-696. | 13.9 | 342 |
| 1826 | The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. <i>Annals of Oncology</i> , 2010, 21, 40-47. | 0.6 | 56 |
| 1827 | Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 942-949. | 3.0 | 55 |
| 1828 | Pharmacogenomics: Bridging the gap between science and practice. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2010, 50, e1-e17. | 0.7 | 35 |
| 1829 | The Clinical Impact of a Cardiologic Follow-up in Breast Cancer Survivors: An Observational Study. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 1221-1227. | 1.0 | 8 |
| 1830 | Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy. <i>Case Reports in Oncology</i> , 2010, 3, 137-141. | 0.3 | 18 |
| 1831 | Targeted Therapy in Breast Cancer. <i>Breast Care</i> , 2010, 5, 132-133. | 0.8 | 0 |
| 1832 | Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer. <i>Oncology</i> , 2010, 78, 271-273. | 0.9 | 1 |
| 1833 | Phase II Trial in Japan of Sequential Administration of Weekly Paclitaxel Followed by FEC as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer [KBCSG0206 Trial: Kinki Breast Cancer Study Group (KBCSG)]. <i>Oncology</i> , 2010, 78, 302-308. | 0.9 | 10 |
| 1834 | Ductal Carcinoma in Situ: Clinical Perspective. <i>Breast Care</i> , 2010, 5, 227-232. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1835 | Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients. <i>Breast Care</i> , 2010, 5, 298-304. | 0.8 | 2 |
| 1836 | Chemotherapy for breast cancer (Review). <i>Oncology Reports</i> , 2010, 24, 1121-31. | 1.2 | 131 |
| 1837 | Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System. <i>Onkologie</i> , 2010, 33, 155-166. | 1.1 | 18 |
| 1838 | Women and Bone Health: Maximizing the Benefits of Aromatase Inhibitor Therapy. <i>Oncology</i> , 2010, 79, 13-26. | 0.9 | 7 |
| 1839 | Treatment and survival in breast cancer in the Eastern Region of England. <i>Annals of Oncology</i> , 2010, 21, 291-296. | 0.6 | 29 |
| 1840 | Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients. <i>Science Translational Medicine</i> , 2010, 2, 38ra47. | 5.8 | 138 |
| 1841 | Qualitative age interactions in breast cancer studies: a mini-review. <i>Future Oncology</i> , 2010, 6, 1781-1788. | 1.1 | 22 |
| 1842 | Intrinsic Resistance to Chemotherapy in Breast Cancer. <i>Women's Health</i> , 2010, 6, 821-830. | 0.7 | 25 |
| 1843 | Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 2200-2210. | 13.9 | 169 |
| 1844 | FOXA1 is an essential determinant of ER \pm expression and mammary ductal morphogenesis. <i>Development (Cambridge)</i> , 2010, 137, 2045-2054. | 1.2 | 184 |
| 1845 | Case 15-2010. <i>New England Journal of Medicine</i> , 2010, 362, 1921-1928. | 13.9 | 3 |
| 1846 | Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. <i>Modern Pathology</i> , 2010, 23, 270-275. | 2.9 | 43 |
| 1847 | Recent Advancement in Nonsteroidal Aromatase Inhibitors for Treatment of Estrogen-Dependent Breast Cancer. <i>Current Medicinal Chemistry</i> , 2010, 17, 3476-3487. | 1.2 | 19 |
| 1849 | Cost-effectiveness of Breast MR Imaging and Screen-Film Mammography for Screening<i>BRCA1</i> Gene Mutation Carriers. <i>Radiology</i> , 2010, 254, 793-800. | 3.6 | 65 |
| 1850 | The Association of Chemotherapy and Radiotherapy: Breast Cancer. <i>Current Drug Therapy</i> , 2010, 5, 192-201. | 0.2 | 2 |
| 1851 | Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer. <i>Biomarkers</i> , 2010, 15, 191-193. | 0.9 | 7 |
| 1852 | Issues and updates: evaluating estrogen receptor- \pm , progesterone receptor, and HER2 in breast cancer. <i>Modern Pathology</i> , 2010, 23, S52-S59. | 2.9 | 156 |
| 1853 | Breast Cancer Dormancy Can Be Maintained by Small Numbers of Micrometastases. <i>Cancer Research</i> , 2010, 70, 4310-4317. | 0.4 | 42 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1854 | Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. <i>Oncologist</i> , 2010, 15, 665-672. | 1.9 | 8 |
| 1855 | Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality. <i>Future Oncology</i> , 2010, 6, 877-880. | 1.1 | 14 |
| 1856 | Optimal Adjuvant Endocrine Therapy for Early Breast Cancer. <i>Women's Health</i> , 2010, 6, 383-398. | 0.7 | 8 |
| 1857 | Breast Cancer Recurrence in Older Women Five to Ten Years after Diagnosis. <i>Breast Diseases</i> , 2010, 21, 320-321. | 0.0 | 0 |
| 1858 | Attaining Negative Margins in Breast-Conservation Operations: Is There a Consensus among Breast Surgeons?. <i>Breast Diseases</i> , 2010, 21, 248-250. | 0.0 | 0 |
| 1859 | Adjuvant Hormonal Therapy for Early-Stage Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 639-647. | 0.6 | 22 |
| 1860 | Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. <i>Breast Diseases</i> , 2010, 21, 264-266. | 0.0 | 9 |
| 1861 | The Role of Taxanes in the Adjuvant Treatment of Breast Cancer. <i>Breast Diseases</i> , 2010, 21, 305-308. | 0.0 | 0 |
| 1862 | A Clinical Oncologic Perspective on Breast Magnetic Resonance Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2010, 18, 277-294. | 0.6 | 15 |
| 1863 | What's New in Neoadjuvant Therapy for Breast Cancer?. <i>Advances in Surgery</i> , 2010, 44, 199-228. | 0.6 | 8 |
| 1864 | Variations Among Experienced Surgeons in Cancer Control After Open Radical Prostatectomy. <i>Journal of Urology</i> , 2010, 183, 977-983. | 0.2 | 61 |
| 1865 | Managing Aromatase Inhibitors in Breast Cancer Survivors: Not Just for Oncologists. <i>Mayo Clinic Proceedings</i> , 2010, 85, 560-566. | 1.4 | 29 |
| 1866 | Breast Cancer Oligometastases: A Rationale for Aggressive Local Therapy. <i>Breast Diseases</i> , 2010, 21, 115-118. | 0.0 | 0 |
| 1867 | Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear (²³ Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer. <i>Academic Radiology</i> , 2010, 17, 1477-1485. | 1.3 | 49 |
| 1868 | Randomized Clinical Trials in Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 33-58. | 0.6 | 6 |
| 1869 | Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1187-1195. | 1.1 | 19 |
| 1870 | Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1159-1173. | 2.4 | 32 |
| 1871 | Acupuncture for Treating Common Side Effects Associated With Breast Cancer Treatment: A Systematic Review. <i>Medical Acupuncture</i> , 2010, 22, 81-97. | 0.3 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1872 | Molecular basis for therapy resistance. <i>Molecular Oncology</i> , 2010, 4, 284-300. | 2.1 | 37 |
| 1873 | Tissue proteomics of the human mammary gland: Towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. <i>Molecular Oncology</i> , 2010, 4, 539-561. | 2.1 | 24 |
| 1874 | Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 35-42. | 0.8 | 379 |
| 1875 | Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. <i>Molecular Cancer</i> , 2010, 9, 295. | 7.9 | 89 |
| 1876 | Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. <i>Molecular Cancer</i> , 2010, 9, 317. | 7.9 | 153 |
| 1877 | Breast cancer in young women. <i>Breast Cancer Research</i> , 2010, 12, 212. | 2.2 | 131 |
| 1878 | Lapatinib. <i>Drugs</i> , 2010, 70, 1411-1422. | 4.9 | 12 |
| 1879 | Triple-Negative Breast Cancer. <i>Drugs</i> , 2010, 70, 2247-2258. | 4.9 | 102 |
| 1880 | Optimizing Chemotherapy Regimens for Patients With Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, E8-E15. | 1.1 | 4 |
| 1881 | Prediction of Benefit From Adjuvant Treatment in Patients With Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, E32-E37. | 1.1 | 6 |
| 1882 | Challenging Clinical Scenarios: Treatment of Patients With Triple-Negative or Basal-Like Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, S20-S29. | 1.1 | 14 |
| 1883 | Adjuvant Taxanes: More to the Story. <i>Clinical Breast Cancer</i> , 2010, 10, S41-S49. | 1.1 | 13 |
| 1884 | 426 Resistance to anti-angiogenic therapy induced by hypoxia and notch signalling. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 183-184. | 2.2 | 1 |
| 1885 | 427 Late sequelae of breast cancer surgery. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 184. | 2.2 | 0 |
| 1887 | 430 Cross-sectional study of Quality of Life (QL) 6 years after start of treatment in the UK Taxotere as Adjuvant Chemotherapy Trial (TACT; CRUK01/001). <i>European Journal of Cancer, Supplement</i> , 2010, 8, 184. | 2.2 | 1 |
| 1888 | Management of Rare Adult Tumours. , 2010, , . | | 2 |
| 1889 | Neoadjuvant Endocrine Therapy for Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 627-638. | 0.6 | 2 |
| 1890 | Handbook of Evidence-Based Radiation Oncology. , 2010, , . | | 45 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1891 | Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer. <i>Pharmacoeconomics</i> , 2010, 28, 629-647. | 1.7 | 22 |
| 1892 | Proteomic Profiling of Mammary Carcinomas Identifies C7orf24, a \hat{I}^3 -Glutamyl Cyclotransferase, as a Potential Cancer Biomarker. <i>Journal of Proteome Research</i> , 2010, 9, 3941-3953. | 1.8 | 55 |
| 1893 | Personalized Tamoxifen: A Step Closer but Miles To Go. <i>Clinical Cancer Research</i> , 2010, 16, 4308-4310. | 3.2 | 4 |
| 1894 | Structure-Function Relationships of Estrogenic Triphenylethylenes Related to Endoxifen and 4-Hydroxytamoxifen. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 3273-3283. | 2.9 | 40 |
| 1895 | Body Mass Index, Hormone Replacement Therapy, and Endometrial Cancer Risk: A Meta-Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 3119-3130. | 1.1 | 231 |
| 1896 | Impact of <i>CYP2D6</i> genotype on progression free survival in tamoxifen breast cancer treatment. <i>Current Medical Research and Opinion</i> , 2010, 26, 2535-2542. | 0.9 | 35 |
| 1897 | Tamoxifen Metabolite Isomer Separation and Quantification by Liquid Chromatography-Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2010, 82, 10186-10193. | 3.2 | 28 |
| 1898 | Aromatase inhibitors: prediction of response and nature of resistance. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1873-1887. | 0.9 | 16 |
| 1899 | Coprescription of Tamoxifen and Medications That Inhibit CYP2D6. <i>Journal of Clinical Oncology</i> , 2010, 28, 2768-2776. | 0.8 | 122 |
| 1901 | What have we really learned from <i>LIBERATE</i> ™ trial?. <i>Maturitas</i> , 2010, 66, 99-100. | 1.0 | 0 |
| 1904 | A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 64-74. | 2.4 | 300 |
| 1905 | Expectations, validity, and reality in pharmacogenetics. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 960-969. | 2.4 | 44 |
| 1906 | Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, 54-62. | 3.4 | 16 |
| 1907 | Adjuvant aromatase inhibitor therapy: Outcomes and safety. <i>Cancer Treatment Reviews</i> , 2010, 36, 249-261. | 3.4 | 55 |
| 1908 | Gene-expression profiles, tumor microenvironment, and cancer stem cells in breast cancer: Latest advances towards an integrated approach. <i>Cancer Treatment Reviews</i> , 2010, 36, 477-484. | 3.4 | 23 |
| 1909 | Current perspectives of treatment of ductal carcinoma in situ. <i>Cancer Treatment Reviews</i> , 2010, 36, 507-517. | 3.4 | 18 |
| 1910 | Personalized treatment of early-stage breast cancer: Present concepts and future directions. <i>Cancer Treatment Reviews</i> , 2010, 36, 584-594. | 3.4 | 51 |
| 1911 | Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 37, 422-30. | 3.4 | 160 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1912 | 17 β -Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer. <i>European Journal of Cancer</i> , 2010, 46, 892-900. | 1.3 | 8 |
| 1913 | Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. <i>European Journal of Cancer</i> , 2010, 46, 1382-1391. | 1.3 | 94 |
| 1914 | The impact of young age on breast cancer outcome. <i>European Journal of Surgical Oncology</i> , 2010, 36, 639-645. | 0.5 | 29 |
| 1915 | Variation in management of early breast cancer in the Netherlands, 2003–2006. <i>European Journal of Surgical Oncology</i> , 2010, 36, S36-S43. | 0.5 | 25 |
| 1916 | New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. <i>Food and Chemical Toxicology</i> , 2010, 48, 1425-1438. | 1.8 | 134 |
| 1917 | Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review. <i>Fertility and Sterility</i> , 2010, 94, 138-143. | 0.5 | 30 |
| 1918 | Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. <i>Fertility and Sterility</i> , 2010, 94, 645-654. | 0.5 | 50 |
| 1919 | Clinical Practice Decisions in Endocrine Therapy. <i>Cancer Investigation</i> , 2010, 28, 4-13. | 0.6 | 6 |
| 1920 | Care of the Cancer Survivor: Metabolic Syndrome after Hormone-Modifying Therapy. <i>American Journal of Medicine</i> , 2010, 123, 87.e1-87.e6. | 0.6 | 55 |
| 1921 | Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro. <i>American Journal of Surgery</i> , 2010, 200, 577-580. | 0.9 | 27 |
| 1922 | Significant Effect of Polymorphisms in <i>CYP2D6</i> and <i>ABCC2</i> on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 1287-1293. | 0.8 | 214 |
| 1923 | Should bisphosphonates be utilized in the adjuvant setting for breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 627-636. | 1.1 | 19 |
| 1924 | Low rate of neutropenia and related events in patients with breast cancer receiving pegfilgrastim from the first cycle of chemotherapy in community practices. <i>Community Oncology</i> , 2010, 7, 273-280. | 0.2 | 3 |
| 1925 | Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. <i>Breast Cancer Research</i> , 2010, 12, R48. | 2.2 | 191 |
| 1926 | Determinants of variability in waiting times for radiotherapy in the treatment of breast cancer. <i>Radiotherapy and Oncology</i> , 2010, 97, 541-547. | 0.3 | 14 |
| 1927 | Molecularly targeted endocrine therapies for breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, S67-S71. | 3.4 | 61 |
| 1928 | Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. <i>Annals of Oncology</i> , 2010, 21, 1254-1261. | 0.6 | 148 |
| 1929 | Breast Cancer in Younger Women. , 2010, , 509-540. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1930 | Breast cancer assessment tools and optimizing adjuvant therapy. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 725-732. | 12.5 | 83 |
| 1931 | Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen. <i>Journal of Clinical Oncology</i> , 2010, 28, 509-518. | 0.8 | 716 |
| 1932 | Dose-dense chemotherapy for breast cancer: what does the future hold?. <i>Future Oncology</i> , 2010, 6, 951-965. | 1.1 | 8 |
| 1933 | Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 22-36. | 12.5 | 97 |
| 1934 | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <i>Lancet Oncology</i> , The, 2010, 11, 55-65. | 5.1 | 1,252 |
| 1935 | Molecular epidemiology and its current clinical use in cancer management. <i>Lancet Oncology</i> , The, 2010, 11, 383-390. | 5.1 | 39 |
| 1936 | Doubling back on centromere 17 in early breast cancer. <i>Lancet Oncology</i> , The, 2010, 11, 216-217. | 5.1 | 0 |
| 1937 | Lung cancer after treatment for breast cancer. <i>Lancet Oncology</i> , The, 2010, 11, 1184-1192. | 5.1 | 30 |
| 1938 | Management of small HER2-positive breast cancers. <i>Lancet Oncology</i> , The, 2010, 11, 1193-1199. | 5.1 | 50 |
| 1939 | Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology</i> , The, 2010, 11, 1135-1141. | 5.1 | 1,017 |
| 1940 | The future of diagnostic gene-expression microarrays: bridging the gap between bench and bedside. <i>Bioanalysis</i> , 2010, 2, 249-262. | 0.6 | 8 |
| 1941 | Gene Polymorphisms in Cyclophosphamide Metabolism Pathway, Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 6169-6176. | 3.2 | 50 |
| 1942 | Adjuvant Chemotherapy in Early-Stage Breast Cancer: What, When, and for Whom?. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 649-668. | 0.6 | 11 |
| 1943 | Optimizing dose-dense regimens for early-stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 678-679. | 12.5 | 5 |
| 1944 | A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 481-487. | 0.6 | 43 |
| 1945 | <i>CYP2C19*2</i> polymorphism is associated with increased survival in breast cancer patients using tamoxifen. <i>Pharmacogenomics</i> , 2010, 11, 1367-1375. | 0.6 | 41 |
| 1946 | Magnetic Resonance Imaging for Screening, Diagnosis, and Eligibility for Breast-conserving Surgery: Promises and Pitfalls. <i>Surgical Oncology Clinics of North America</i> , 2010, 19, 475-492. | 0.6 | 25 |
| 1947 | Breast Cancer Epidemiology. , 2010, , . | | 34 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1948 | Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis. <i>Future Oncology</i> , 2010, 6, 209-219. | 1.1 | 14 |
| 1949 | Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?. <i>Breast Cancer Research</i> , 2010, 12, S18. | 2.2 | 7 |
| 1950 | Are current development programs realising the full potential of new agents?. <i>Breast Cancer Research</i> , 2010, 12, S23. | 2.2 | 0 |
| 1951 | Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. <i>Breast Cancer Research</i> , 2010, 12, R52. | 2.2 | 72 |
| 1952 | CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. <i>Breast Cancer Research</i> , 2010, 12, R64. | 2.2 | 76 |
| 1953 | Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. <i>Breast Cancer Research</i> , 2010, 12, R47. | 2.2 | 104 |
| 1954 | Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. <i>Breast Cancer Research</i> , 2010, 12, R17. | 2.2 | 79 |
| 1955 | The ATAC adjuvant breast-cancer trial: Six-year results of the endometrial subprotocol. <i>Journal of Obstetrics and Gynaecology</i> , 2010, 30, 596-604. | 0.4 | 10 |
| 1956 | Screening Mammography – A Long Run for a Short Slide?. <i>New England Journal of Medicine</i> , 2010, 363, 1276-1278. | 13.9 | 102 |
| 1957 | Adjuvant Endocrine Therapy for Early Breast Cancer: The Story So Far. <i>Cancer Investigation</i> , 2010, 28, 433-442. | 0.6 | 12 |
| 1958 | Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. <i>Drug Metabolism Reviews</i> , 2010, 42, 182-194. | 1.5 | 35 |
| 1959 | Current and emerging biomarkers in breast cancer: prognosis and prediction. <i>Endocrine-Related Cancer</i> , 2010, 17, R245-R262. | 1.6 | 380 |
| 1960 | Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. <i>Annals of Oncology</i> , 2010, 21, 2153-2160. | 0.6 | 71 |
| 1961 | Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2010, 32, 836-846. | 0.8 | 32 |
| 1962 | Anthracyclines in the Treatment of Early-Stage Breast Cancer: Ally or Adversary?. <i>Cancer Investigation</i> , 2010, 28, 217-219. | 0.6 | 2 |
| 1963 | Metastatic Behavior of Breast Cancer Subtypes. <i>Journal of Clinical Oncology</i> , 2010, 28, 3271-3277. | 0.8 | 1,718 |
| 1964 | From tumor size and <i>HER2</i> status to systems oncology for very early breast cancer treatment. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 123-128. | 1.1 | 67 |
| 1965 | Breast MRI Screening of Women With a Personal History of Breast Cancer. <i>American Journal of Roentgenology</i> , 2010, 195, 510-516. | 1.0 | 143 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1966 | Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials. <i>Acta Oncologica</i> , 2011, 50, 1068-1074. | 0.8 | 4 |
| 1968 | Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. <i>Acta Oncologica</i> , 2011, 50, 329-337. | 0.8 | 10 |
| 1969 | Therapeutic management of breast cancer in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 945-960. | 0.9 | 15 |
| 1970 | Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. <i>Acta Oncologica</i> , 2011, 50, 344-352. | 0.8 | 41 |
| 1971 | Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab. <i>Cancer Investigation</i> , 2011, 29, 573-584. | 0.6 | 19 |
| 1972 | Calibrating Models in Economic Evaluation. <i>Pharmacoeconomics</i> , 2011, 29, 51-62. | 1.7 | 52 |
| 1973 | Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2040-2045. | 0.8 | 94 |
| 1974 | Effect of Luteinizing Hormone-Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2334-2341. | 0.8 | 263 |
| 1975 | Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. <i>British Journal of Cancer</i> , 2011, 105, 272-280. | 2.9 | 50 |
| 1976 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2011, 22, vi12-vi24. | 0.6 | 197 |
| 1977 | Value of Mismatch Repair, <i>KRAS</i> , and <i>BRAF</i> Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1261-1270. | 0.8 | 593 |
| 1978 | Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma. <i>Modern Pathology</i> , 2011, 24, 201-208. | 2.9 | 37 |
| 1979 | A CUE hints at tumor resistance. <i>Nature Medicine</i> , 2011, 17, 658-660. | 15.2 | 6 |
| 1980 | Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15Years of Follow-Up. <i>Breast Diseases</i> , 2011, 22, 385-387. | 0.0 | 0 |
| 1981 | Postmenopausal Hormone Therapy and Breast Cancer Risk: Current Status and Unanswered Questions. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 509-518. | 1.2 | 14 |
| 1982 | Hormonal Modulation in the Treatment of Breast Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 519-532. | 1.2 | 6 |
| 1983 | The impact of young age on breast cancer outcome. <i>Breast Diseases</i> , 2011, 22, 128-129. | 0.0 | 0 |
| 1985 | CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark. <i>Breast Diseases</i> , 2011, 22, 298-299. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1986 | Preoperative Breast Magnetic Resonance Imaging: Controversies Arising in the Quest to Evaluate Clinical Benefit. <i>Canadian Association of Radiologists Journal</i> , 2011, 62, 8-14. | 1.1 | 2 |
| 1988 | Anthracyclines in the adjuvant treatment of breast cancer: state of the art. <i>European Journal of Cancer, Supplement</i> , 2011, 9, 5-10. | 2.2 | 0 |
| 1989 | Case histories: breast cancer. <i>European Journal of Cancer, Supplement</i> , 2011, 9, 36-42. | 2.2 | 0 |
| 1990 | Tissue Inhibitors of Metalloproteinases. , 2011, , 3703-3705. | | 0 |
| 1991 | Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 924-938. | 1.5 | 154 |
| 1992 | Tubulin Interacting Proteins. , 2011, , 3792-3792. | | 0 |
| 1994 | Comparison of EQ-5D Scores among Anthracycline-Containing Regimens followed by Taxane and Taxane-Only Regimens for Node-Positive Breast Cancer Patients after Surgery: The N-SAS BC 02 Trial. <i>Value in Health</i> , 2011, 14, 746-751. | 0.1 | 11 |
| 1995 | NFIB is a potential target for estrogen receptor-negative breast cancers. <i>Molecular Oncology</i> , 2011, 5, 538-544. | 2.1 | 54 |
| 1996 | Putting the Cardiovascular Safety of Aromatase Inhibitors in Patients with Early Breast Cancer into Perspective. <i>Drug Safety</i> , 2011, 34, 1125-1149. | 1.4 | 20 |
| 1998 | Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. <i>Pharmacogenomics Journal</i> , 2011, 11, 81-92. | 0.9 | 78 |
| 1999 | Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 72. | 3.5 | 4 |
| 2000 | Optimal Management of Cancer Treatment-Induced Bone Loss. <i>Drugs and Aging</i> , 2011, 28, 867-883. | 1.3 | 13 |
| 2001 | Biological Markers. , 2011, , 404-404. | | 0 |
| 2002 | Tunicamycin. , 2011, , 3816-3819. | | 1 |
| 2003 | Endocrine Therapy of Breast Cancer. <i>Current Medicinal Chemistry</i> , 2011, 18, 513-522. | 1.2 | 140 |
| 2004 | Late effects of breast cancer treatment and potentials for rehabilitation. <i>Acta Oncologica</i> , 2011, 50, 187-193. | 0.8 | 229 |
| 2005 | Pharmacogenomic Testing in Current Clinical Practice. , 2011, , . | | 2 |
| 2006 | Hematopoietic Growth Factors in Oncology. <i>Cancer Treatment and Research</i> , 2011, , . | 0.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2007 | Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R98. | 2.2 | 49 |
| 2008 | Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. <i>Genome Medicine</i> , 2011, 3, 64. | 3.6 | 11 |
| 2010 | Antiestrogens and Their Therapeutic Applications in Breast Cancer and Other Diseases. <i>Annual Review of Medicine</i> , 2011, 62, 217-232. | 5.0 | 74 |
| 2011 | Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 605-611. | 2.3 | 73 |
| 2012 | Pharmacogenetics of Endocrine Therapy for Breast Cancer. <i>Annual Review of Medicine</i> , 2011, 62, 281-293. | 5.0 | 51 |
| 2013 | Five-Year Analysis of Treatment Efficacy and Cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in Patients Treated with Accelerated Partial Breast Irradiation. <i>Breast Diseases</i> , 2011, 22, 299-300. | 0.0 | 0 |
| 2014 | Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer Model. <i>American Journal of Pathology</i> , 2011, 178, 838-852. | 1.9 | 127 |
| 2015 | Do the CMS proposed breast cancer quality measures actually predict improved outcomes?. <i>American Journal of Surgery</i> , 2011, 202, 787-795. | 0.9 | 2 |
| 2016 | Reporting and management of breast lesions detected using MRI. <i>Clinical Radiology</i> , 2011, 66, 1120-1128. | 0.5 | 10 |
| 2017 | Use of molecular markers for predicting therapy response in cancer patients. <i>Cancer Treatment Reviews</i> , 2011, 37, 151-159. | 3.4 | 94 |
| 2018 | Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives. <i>Cancer Treatment Reviews</i> , 2011, 37, 208-211. | 3.4 | 15 |
| 2019 | Uncovering the metabolomic fingerprint of breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1010-1020. | 1.2 | 77 |
| 2020 | Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. <i>Cancer Letters</i> , 2011, 302, 63-68. | 3.2 | 37 |
| 2022 | Antral follicle count provides additive information to hormone measures for determining ovarian function in breast cancer survivors. <i>Fertility and Sterility</i> , 2011, 95, 1857-1859. | 0.5 | 10 |
| 2023 | Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. <i>Fertility and Sterility</i> , 2011, 95, 2158-2161. | 0.5 | 100 |
| 2024 | Breast cancer and fertility preservation. <i>Fertility and Sterility</i> , 2011, 95, 1535-1543. | 0.5 | 74 |
| 2025 | The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. <i>European Journal of Cancer</i> , 2011, 47, 2742-2749. | 1.3 | 99 |
| 2026 | Professionals' opinion on follow-up in breast cancer patients; perceived purpose and influence of patients' risk factors. <i>European Journal of Surgical Oncology</i> , 2011, 37, 217-224. | 0.5 | 30 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2027 | Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection. <i>European Journal of Surgical Oncology</i> , 2011, 37, 404-410. | 0.5 | 16 |
| 2028 | Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: A retrospective clinical study. <i>European Journal of Surgical Oncology</i> , 2011, 37, 876-882. | 0.5 | 50 |
| 2029 | Innovative biomarker development for personalized medicine in breast cancer care. <i>Biomarkers in Medicine</i> , 2011, 5, 73-78. | 0.6 | 5 |
| 2030 | Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen. <i>Medical Hypotheses</i> , 2011, 77, 1028-1030. | 0.8 | 1 |
| 2031 | Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: Effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. <i>International Journal of Cardiology</i> , 2011, 148, 194-198. | 0.8 | 138 |
| 2032 | Transcriptional Analysis of Novel Hormone Receptors PGRMC1 and PGRMC2 as Potential Biomarkers of Breast Adenocarcinoma Staging. <i>Journal of Surgical Research</i> , 2011, 171, 615-622. | 0.8 | 27 |
| 2033 | New therapeutic approaches in breast cancer. <i>Maturitas</i> , 2011, 68, 121-128. | 1.0 | 37 |
| 2034 | Overview of long term care of breast cancer survivors. <i>Maturitas</i> , 2011, 69, 106-112. | 1.0 | 25 |
| 2035 | The role of capecitabine in the management of breast cancer in elderly patients. <i>Journal of Geriatric Oncology</i> , 2011, 2, 72-81. | 0.5 | 5 |
| 2036 | Neoadjuvant Therapy. , 2011, , 261-279. | | 1 |
| 2037 | Adjuvant Systemic Therapy. , 2011, , 291-305. | | 0 |
| 2038 | Surveillance and Detection of Recurrence of Breast Cancer. , 2011, , 307-318. | | 0 |
| 2039 | Overview of adjuvant trials of aromatase inhibitors in early breast cancer. <i>Steroids</i> , 2011, 76, 765-767. | 0.8 | 24 |
| 2040 | The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. <i>Steroids</i> , 2011, 76, 807-811. | 0.8 | 2 |
| 2041 | Recent data on intratumor estrogens in breast cancer. <i>Steroids</i> , 2011, 76, 786-791. | 0.8 | 28 |
| 2042 | Tratamiento conservador en pacientes con cáncer de mama multicéntrico. <i>Progresos En Obstetricia Y Ginecología</i> , 2011, 54, 85-90. | 0.0 | 0 |
| 2043 | Pronóstico de pacientes con cáncer de mama tratadas con cirugía en un sistema privado extra de salud. <i>Progresos En Obstetricia Y Ginecología</i> , 2011, 54, 235-241. | 0.0 | 0 |
| 2044 | Role of hormonal manipulations in patients with hormone-sensitive metastatic breast cancer. <i>European Journal of Cancer</i> , 2011, 47, S28-S37. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2045 | Preventive therapy for breast cancer: a consensus statement. <i>Lancet Oncology</i> , The, 2011, 12, 496-503. | 5.1 | 196 |
| 2046 | Optimum chemotherapy regimen for early breast cancer. <i>Lancet Oncology</i> , The, 2011, 12, 514-515. | 5.1 | 1 |
| 2047 | Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 1531-1538. | 0.8 | 160 |
| 2048 | Tubulin. , 2011, , 3792-3792. | | 0 |
| 2049 | Association between Genetic Polymorphisms of <i>CYP2D6</i> and Outcomes in Breast Cancer Patients with Tamoxifen Treatment. <i>Journal of Korean Medical Science</i> , 2011, 26, 1007. | 1.1 | 28 |
| 2050 | Wnt pathway is affected by endocrine therapy in breast carcinomas. <i>Basic and Applied Pathology</i> , 2011, 4, 38-45. | 0.2 | 1 |
| 2051 | Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R11. | 2.2 | 53 |
| 2052 | Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. <i>Breast Cancer Research</i> , 2011, 13, R12. | 2.2 | 22 |
| 2053 | Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R21. | 2.2 | 162 |
| 2054 | The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines. <i>Breast Cancer Research</i> , 2011, 13, R33. | 2.2 | 36 |
| 2055 | Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. <i>Breast Cancer Research</i> , 2011, 13, R34. | 2.2 | 91 |
| 2056 | Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. <i>Breast Cancer Research</i> , 2011, 13, R60. | 2.2 | 74 |
| 2057 | Estrogen receptor degradation: a CUE for endocrine resistance?. <i>Breast Cancer Research</i> , 2011, 13, 312. | 2.2 | 8 |
| 2058 | Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. <i>Breast Cancer Research</i> , 2011, 13, 224. | 2.2 | 365 |
| 2059 | Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial. <i>Breast Cancer Research</i> , 2011, 13, R109. | 2.2 | 24 |
| 2060 | Challenges of ensuring adherence to oral therapy in patients with solid malignancies. <i>Community Oncology</i> , 2011, 8, 254-262. | 0.2 | 4 |
| 2061 | Targeted therapies for breast cancer. <i>Journal of Clinical Investigation</i> , 2011, 121, 3797-3803. | 3.9 | 313 |
| 2062 | BrdU. , 2011, , 485-485. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2063 | <i>In vitro</i> metabolic interactions between black cohosh (<i>Cimicifuga racemosa</i>) and tamoxifen via inhibition of cytochromes P450 2D6 and 3A4. <i>Xenobiotica</i> , 2011, 41, 1021-1030. | 0.5 | 31 |
| 2064 | Cancer and fertility: strategies to preserve fertility. <i>Reproductive BioMedicine Online</i> , 2011, 22, 232-248. | 1.1 | 33 |
| 2065 | Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: Results on local control and survival. <i>Radiotherapy and Oncology</i> , 2011, 100, 215-220. | 0.3 | 38 |
| 2066 | Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. <i>Radiotherapy and Oncology</i> , 2011, 100, 167-175. | 0.3 | 389 |
| 2067 | Oocyte cryopreservation as a fertility preservation measure for cancer patients. <i>Reproductive BioMedicine Online</i> , 2011, 23, 323-333. | 1.1 | 69 |
| 2068 | Early-Stage Young Breast Cancer Patients: Impact of Local Treatment on Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e553-e559. | 0.4 | 47 |
| 2069 | The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. <i>European Journal of Cancer</i> , 2011, 47, 2517-2530. | 1.3 | 35 |
| 2070 | Time to TEAM: exemestane, or tamoxifen then exemestane?. <i>Lancet, The</i> , 2011, 377, 280-281. | 6.3 | 2 |
| 2071 | Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. <i>Lancet, The</i> , 2011, 378, 771-784. | 6.3 | 2,495 |
| 2072 | Radiotherapy and survival in breast cancer. <i>Lancet, The</i> , 2011, 378, 1680-1682. | 6.3 | 15 |
| 2073 | MRI for breast cancer screening, diagnosis, and treatment. <i>Lancet, The</i> , 2011, 378, 1804-1811. | 6.3 | 320 |
| 2074 | Gene expression profiling in breast cancer: classification, prognostication, and prediction. <i>Lancet, The</i> , 2011, 378, 1812-1823. | 6.3 | 629 |
| 2075 | Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. <i>Lancet, The</i> , 2011, 378, 1707-1716. | 6.3 | 3,080 |
| 2076 | Correlation of Peripheral Blood CD14+CD16+ Monocytes, Urinary Neopterin and the Risk Factors of Atherosclerosis in Patients with Breast Carcinoma. <i>Pteridines</i> , 2011, 22, 66-72. | 0.5 | 4 |
| 2077 | Mammary stem cells and their regulation by steroid hormones. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 371-381. | 1.2 | 3 |
| 2078 | Clinical Significance of Age at the Time of Diagnosis among Young Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2011, 14, 314. | 0.8 | 10 |
| 2079 | Melding breast and prostate cancers alter egos. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 301-307. | 1.2 | 1 |
| 2080 | Markers of sensitivity, dependence and resistance to endocrine therapy for breast cancer. <i>Expert Review of Endocrinology and Metabolism</i> , 2011, 6, 345-357. | 1.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2081 | G-protein Coupled Estrogen Receptor 1 Expression in Primary Breast Cancers and Its Correlation with Clinicopathological Variables. <i>Journal of Breast Cancer</i> , 2011, 14, 185. | 0.8 | 27 |
| 2082 | Real-World Experience with Adjuvant FEC-D Chemotherapy in Four Ontario Regional Cancer Centres. <i>Current Oncology</i> , 2011, 18, 119-125. | 0.9 | 34 |
| 2083 | Interaction of human adipose tissue-derived mesenchymal stromal cells with breast cancer cells. <i>Neoplasma</i> , 2011, 58, 361-370. | 0.7 | 40 |
| 2084 | AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. <i>Breast Care</i> , 2011, 6, 299-313. | 0.8 | 7 |
| 2085 | A systematic review of the effectiveness of secondary prevention lifestyle interventions designed to change lifestyle behaviour following stroke. <i>JBI Library of Systematic Reviews</i> , 2011, 9, 1782-1827. | 0.1 | 7 |
| 2086 | Triple-Negative Breast Cancers: An Updated Review on Treatment Options. <i>Current Oncology</i> , 2011, 18, 173-179. | 0.9 | 66 |
| 2087 | Prevalence of breast cancer in the city of Goi nia, Goi s, Brazil, between 1988 and 2002. <i>Sao Paulo Medical Journal</i> , 2011, 129, 309-314. | 0.4 | 1 |
| 2088 | Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay. <i>Pathology</i> , 2011, 43, 248-253. | 0.3 | 9 |
| 2091 | Breast cancer and fertility preservation. , 0, , 49-61. | | 0 |
| 2092 | Breast cancer therapy and reproduction. , 0, , 62-72. | | 0 |
| 2093 | Metastatic Inefficiency and Tumor Dormancy. , 0, , 148-154. | | 0 |
| 2094 | Breast Metastasis. , 0, , 425-439. | | 0 |
| 2095 | Prospects for Clinical Trials of Metastasis Inhibitors. , 0, , 622-626. | | 0 |
| 2096 | High-risk screening using breast MRI. , 0, , 112-134. | | 0 |
| 2097 | Estrogen and progesterone receptor testing in breast carcinoma: concordance of results between local and reference laboratories in Brazil. <i>Sao Paulo Medical Journal</i> , 2011, 129, 236-242. | 0.4 | 4 |
| 2098 | Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer. <i>Journal of Breast Cancer</i> , 2011, 14, 223. | 0.8 | 0 |
| 2099 | MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. <i>Cancer Biomarkers</i> , 2011, 8, 53-60. | 0.8 | 23 |
| 2100 | Correlation of Early Systemic Recurrence with In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Stage II and III Breast Cancer Patients Treated with Doxorubicin-Based Chemotherapy. <i>Journal of Breast Cancer</i> , 2011, 14, S50. | 0.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2101 | Tamoxifeno y antidepresivos: ¿Antagonistas en la prevención del cáncer de mama?. Revista Medica De Chile, 2011, 139, 89-99. | 0.1 | 6 |
| 2102 | A Canadian Economic Analysis of U.S. Oncology Adjuvant Trial 9735. Current Oncology, 2011, 18, 67-75. | 0.9 | 6 |
| 2103 | The Value of Serum Biomarkers (Bc1, Bc2, Bc3) in the Diagnosis of Early Breast Cancer. International Journal of Medical Sciences, 2011, 8, 148-155. | 1.1 | 14 |
| 2104 | The influence of aerobic training on body composition in premenopausal women undergoing endocrine therapy for breast cancer. Wspolczesna Onkologia, 2011, 5, 261-266. | 0.7 | 0 |
| 2105 | Survival of women with breast cancer in central and northern Denmark, 1998–2009. Clinical Epidemiology, 2011, 3 Suppl 1, 35. | 1.5 | 10 |
| 2106 | Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer: Targets and Therapy, 2011, 3, 113. | 1.0 | 19 |
| 2107 | Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole. Menopause, 2011, 18, 224-229. | 0.8 | 2 |
| 2108 | Incidence of Brain Metastasis and Related Subtypes in Patients with Breast Cancer Receiving Adjuvant Radiation Therapy after Surgery. Journal of Breast Cancer, 2011, 14, S57. | 0.8 | 1 |
| 2109 | Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk. Clinics, 2011, 66, 607-612. | 0.6 | 13 |
| 2110 | Management of cardiac and pulmonary treatmentâ€“related side effects. , 2011, , 67-94. | | 2 |
| 2111 | Adjuvant Therapy for Early Breast Cancer. , 2011, , . | | 0 |
| 2112 | An immunohistochemical study of androgen receptor in carcinoma arising in pleomorphic salivary adenoma. Medicina Oral, Patologia Oral Y Cirurgia Bucal, 2011, 16, e330-e334. | 0.7 | 8 |
| 2113 | Proteomics-Based Disease Biomarkers. International Journal of Proteomics, 2011, 2011, 1-2. | 2.0 | 3 |
| 2114 | Protein Biomarkers for the Early Detection of Breast Cancer. International Journal of Proteomics, 2011, 2011, 1-9. | 2.0 | 62 |
| 2115 | The Costâ€“Utility of Adjuvant Chemotherapy Using Docetaxel and Cyclophosphamide Compared with Doxorubicin and Cyclophosphamide in Breast Cancer. Current Oncology, 2011, 18, 288-296. | 0.9 | 26 |
| 2116 | The 70-Gene Prognostic Signature for Korean Breast Cancer Patients. Journal of Breast Cancer, 2011, 14, 33. | 0.8 | 22 |
| 2117 | Breast Cancer, Sickness Absence, Income and Marital Status. A Study on Life Situation 1 Year Prior Diagnosis Compared to 3 and 5 Years after Diagnosis. PLoS ONE, 2011, 6, e18040. | 1.1 | 68 |
| 2118 | Response of Estrogen Receptor-Positive Breast Cancer Tumorspheres to Antiestrogen Treatments. PLoS ONE, 2011, 6, e18810. | 1.1 | 32 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2119 | The influence of the genetic variant within miRNA-binding site in estrogen receptor alpha gene on the risk of breast cancer in postmenopausal women on hormone replacement therapy. <i>Cancer Biomarkers</i> , 2011, 8, 123-128. | 0.8 | 3 |
| 2120 | Trastuzumab in the adjuvant setting: a practical review. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 161-177. | 0.2 | 0 |
| 2121 | The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore. <i>Current Opinion in Obstetrics and Gynecology</i> , 2011, 23, 31-36. | 0.9 | 11 |
| 2122 | Breast Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 150-156. | 0.6 | 5 |
| 2123 | Pharmacogenomic Contribution to Drug Response. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 80-88. | 1.0 | 16 |
| 2124 | Gene Expression Profiling: Changing Face of Breast Cancer Classification and Management. <i>Gene Expression</i> , 2011, 15, 105-115. | 0.5 | 39 |
| 2125 | Potential adverse impact of ovariectomy on physical and psychological function of younger women with breast cancer. <i>Menopause</i> , 2011, 18, 786-793. | 0.8 | 25 |
| 2126 | Emerging Role of MicroRNAs in Drug-Resistant Breast Cancer. <i>Gene Expression</i> , 2011, 15, 141-151. | 0.5 | 36 |
| 2127 | Breast Cancer Posttreatment Surveillance. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 157-163. | 0.6 | 16 |
| 2128 | Effect of Primary Prophylactic Granulocyte-Colony Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving Chemotherapy. <i>Medical Care</i> , 2011, 49, 649-657. | 1.1 | 16 |
| 2129 | Editorial [Hot topic: Breast Cancer: Novel Therapeutic Targets (Guest Editor: George W. Yip)]. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 164-165. | 0.8 | 1 |
| 2130 | Molecular classification of breast cancer. <i>Pathology</i> , 2011, 43, S7-S8. | 0.3 | 0 |
| 2131 | Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer. <i>Cancer Biology and Therapy</i> , 2011, 11, 1059-1064. | 1.5 | 6 |
| 2132 | Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts. <i>Oncology Reports</i> , 2012, 27, 303-10. | 1.2 | 10 |
| 2134 | Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011). <i>Breast Care</i> , 2011, 6, 144-152. | 0.8 | 5 |
| 2135 | Measuring the Performance of Markers for Guiding Treatment Decisions. <i>Annals of Internal Medicine</i> , 2011, 154, 253. | 2.0 | 120 |
| 2136 | Invasive Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 136-222. | 2.3 | 124 |
| 2137 | NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-1-S-32. | 2.3 | 227 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2138 | Molecular assays in breast cancer pathology. <i>Pathology</i> , 2011, 43, 116-127. | 0.3 | 15 |
| 2139 | Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia. <i>Internal Medicine Journal</i> , 2011, 41, 162-166. | 0.5 | 10 |
| 2140 | Aromatase inhibitors: what is the true cost?. <i>Internal Medicine Journal</i> , 2011, 41, 139-140. | 0.5 | 2 |
| 2141 | Impact of <i>CYP2D6</i> , <i>CYP3A5</i> , <i>CYP2C9</i> and <i>CYP2C19</i> polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 737-750. | 1.1 | 107 |
| 2142 | Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer. <i>Cancer Science</i> , 2011, 102, 130-136. | 1.7 | 2 |
| 2143 | Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 cancer. <i>Cancer Science</i> , 2011, 102, 2038-2042. | 1.7 | 36 |
| 2144 | Cost-Benefit of Laparoscopic Versus Medical Ovarian Suppression in Premenopausal Breast Cancer. <i>Breast Journal</i> , 2011, 17, 103-105. | 0.4 | 7 |
| 2145 | Age <40 Years is an Independent Prognostic Factor Predicting Inferior Overall Survival in Patients Treated with Breast Conservative Therapy. <i>Breast Journal</i> , 2011, 17, 75-78. | 0.4 | 9 |
| 2146 | The Predictive Value of Epidermal Growth Factor Receptor Expression for Sensitivity to Vinorelbine in Breast Cancer. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 499-505. | 1.2 | 0 |
| 2147 | Use of non- ϵ anthracycline regimens in early stage breast cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 4-10. | 0.7 | 9 |
| 2148 | Changes in medical oncology admissions for the management of breast cancer complications: An Australian institution's experience. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 146-153. | 0.7 | 5 |
| 2149 | Taming the dragon: genomic biomarkers to individualize the treatment of cancer. <i>Nature Medicine</i> , 2011, 17, 304-312. | 15.2 | 94 |
| 2150 | The different roles of ER subtypes in cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2011, 11, 597-608. | 12.8 | 555 |
| 2151 | Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 708-717. | 2.3 | 241 |
| 2152 | Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. <i>British Journal of Cancer</i> , 2011, 104, 1558-1563. | 2.9 | 61 |
| 2153 | A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. <i>British Journal of Cancer</i> , 2011, 104, 1828-1835. | 2.9 | 338 |
| 2154 | Increasingly strong reduction in breast cancer mortality due to screening. <i>British Journal of Cancer</i> , 2011, 104, 910-914. | 2.9 | 114 |
| 2155 | Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial. <i>British Journal of Cancer</i> , 2011, 104, 899-902. | 2.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2156 | Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?. <i>British Journal of Cancer</i> , 2011, 104, 1059-1066. | 2.9 | 72 |
| 2157 | Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care. <i>British Journal of Cancer</i> , 2011, 104, 1057-1058. | 2.9 | 61 |
| 2158 | Hormonal therapy for cancer. <i>Medicine</i> , 2011, 39, 723-727. | 0.2 | 6 |
| 2159 | Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 1016-1023. | 1.4 | 39 |
| 2160 | Molecular Predictors of Local Tumor Control in Early-Stage Breast Cancer. <i>Seminars in Radiation Oncology</i> , 2011, 21, 35-42. | 1.0 | 15 |
| 2161 | Elective versus therapeutic neck dissection in the clinically node negative neck in early oral cavity cancers: Do we have the answer yet?. <i>Oral Oncology</i> , 2011, 47, 780-782. | 0.8 | 27 |
| 2162 | The St. Gallen Prize Lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. <i>Breast</i> , 2011, 20, S1-S11. | 0.9 | 23 |
| 2163 | Modeling the impact of population screening on breast cancer mortality in the United States. <i>Breast</i> , 2011, 20, S75-S81. | 0.9 | 20 |
| 2164 | Prophylactic mastectomy of the contralateral breast. <i>Breast</i> , 2011, 20, S108-S110. | 0.9 | 27 |
| 2165 | Adjuvant chemotherapy in luminal breast cancers. <i>Breast</i> , 2011, 20, S128-S131. | 0.9 | 15 |
| 2166 | Adjuvant systemic treatment for individual patients with triple negative breast cancer. <i>Breast</i> , 2011, 20, S135-S141. | 0.9 | 14 |
| 2167 | Adjuvant therapies for very young women with early stage breast cancer. <i>Breast</i> , 2011, 20, S146-S149. | 0.9 | 10 |
| 2168 | Commentary on adjuvant chemotherapy for the older woman with early stage breast cancer. <i>Breast</i> , 2011, 20, S150-S152. | 0.9 | 0 |
| 2169 | Disease related indicators for a proper choice of adjuvant treatments. <i>Breast</i> , 2011, 20, S162-S164. | 0.9 | 1 |
| 2170 | CYP2D6 Genotyping and Tamoxifen: An Unfinished Story in the Quest for Personalized Medicine. <i>Seminars in Oncology</i> , 2011, 38, 263-273. | 0.8 | 33 |
| 2171 | The impact of advances in treatment on the efficacy of mammography screening. <i>Preventive Medicine</i> , 2011, 53, 103-104. | 1.6 | 31 |
| 2172 | Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. <i>BMC Cancer</i> , 2011, 11, 118. | 1.1 | 22 |
| 2173 | Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBC, EORTC-PBG) comparing 6 – FEC versus 3 – FEC/3 – Docetaxel. <i>BMC Cancer</i> , 2011, 11, 140. | 1.1 | 40 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2174 | Current Opinion of Aromatase Inhibitor-induced Arthralgia in Breast Cancer in the UK. <i>Clinical Oncology</i> , 2011, 23, 674-680. | 0.6 | 11 |
| 2175 | Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trial. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 160-170. | 2.0 | 47 |
| 2176 | Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: Results of an observational study. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 466-473. | 2.0 | 31 |
| 2178 | Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 26.e1-26.e7. | 0.7 | 66 |
| 2179 | The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer. <i>Breast</i> , 2011, 20, 151-154. | 0.9 | 8 |
| 2180 | Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. <i>Breast</i> , 2011, 20, 111-118. | 0.9 | 71 |
| 2181 | Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. <i>Breast</i> , 2011, 20, 215-219. | 0.9 | 32 |
| 2182 | Breast cancer management in low resource countries (LRCs): Consensus statement from the Breast Health Global Initiative. <i>Breast</i> , 2011, 20, S3-S11. | 0.9 | 154 |
| 2183 | How not to neglect the care of elderly breast cancer patients?. <i>Breast</i> , 2011, 20, 293-296. | 0.9 | 20 |
| 2184 | Optimal adjuvant therapy for very young breast cancer patients. <i>Breast</i> , 2011, 20, 297-302. | 0.9 | 13 |
| 2185 | Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer. <i>Breast</i> , 2011, 20, 505-509. | 0.9 | 8 |
| 2186 | Optimising the management of primary breast cancer in older women – A report of a multi-disciplinary study day. <i>Breast</i> , 2011, 20, 581-584. | 0.9 | 3 |
| 2187 | Management of Early Invasive Breast Cancer in Very Young Women (<35 years). <i>Clinical Breast Cancer</i> , 2011, 11, 196-203. | 1.1 | 17 |
| 2188 | Feasibility and Safety of Weekly Sequential Epirubicin-Paclitaxel as Adjuvant Treatment for Operable Breast Cancer Patients Older than 70 Years. <i>Clinical Breast Cancer</i> , 2011, 11, 235-240. | 1.1 | 4 |
| 2189 | Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. <i>British Journal of Cancer</i> , 2011, 105, 1676-1683. | 2.9 | 29 |
| 2190 | Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer. <i>Surgery Today</i> , 2011, 41, 48-53. | 0.7 | 5 |
| 2191 | Prognostic Value of Lymph Node Micrometastases in Breast Cancer: A Multicenter Cohort Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 1657-1664. | 0.7 | 45 |
| 2192 | PKA-induced phosphorylation of ER α at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 1-12. | 1.1 | 49 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2193 | COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Research and Treatment, 2011, 125, 671-685. | 1.1 | 45 |
| 2194 | DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer. Breast Cancer Research and Treatment, 2011, 127, 53-63. | 1.1 | 57 |
| 2195 | Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Research and Treatment, 2011, 127, 345-355. | 1.1 | 51 |
| 2196 | Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment, 2011, 127, 363-373. | 1.1 | 11 |
| 2197 | Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Research and Treatment, 2011, 126, 185-192. | 1.1 | 113 |
| 2198 | Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Research and Treatment, 2011, 126, 529-537. | 1.1 | 687 |
| 2199 | Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts. Breast Cancer Research and Treatment, 2011, 128, 381-390. | 1.1 | 10 |
| 2200 | Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Research and Treatment, 2011, 126, 695-703. | 1.1 | 24 |
| 2201 | Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast Cancer Research and Treatment, 2011, 126, 421-430. | 1.1 | 52 |
| 2202 | One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy. Breast Cancer Research and Treatment, 2011, 125, 751-753. | 1.1 | 2 |
| 2203 | Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer. Breast Cancer Research and Treatment, 2011, 127, 511-520. | 1.1 | 9 |
| 2204 | Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment, 2011, 125, 145-156. | 1.1 | 228 |
| 2205 | Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. Breast Cancer Research and Treatment, 2011, 129, 401-409. | 1.1 | 5 |
| 2206 | Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TRO3). Breast Cancer Research and Treatment, 2011, 127, 739-749. | 1.1 | 71 |
| 2207 | Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Research and Treatment, 2011, 129, 725-736. | 1.1 | 53 |
| 2208 | Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Research and Treatment, 2011, 126, 93-99. | 1.1 | 40 |
| 2209 | Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Research and Treatment, 2011, 129, 117-124. | 1.1 | 26 |
| 2210 | The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Research and Treatment, 2011, 126, 797-802. | 1.1 | 99 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2211 | Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 133-142. | 1.1 | 176 |
| 2212 | Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 295-310. | 1.1 | 83 |
| 2213 | Improved web-based calculators for predicting breast carcinoma outcomes. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 827-835. | 1.1 | 59 |
| 2214 | Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 795-805. | 1.1 | 47 |
| 2215 | Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the "gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)" 01-Trial in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 653-661. | 1.1 | 6 |
| 2216 | Prognostic utility of β -tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 179-193. | 1.1 | 36 |
| 2217 | Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 127-136. | 1.1 | 66 |
| 2218 | Trends in improving survival in breast cancer: two steps forward but one step back?. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 807-809. | 1.1 | 0 |
| 2219 | The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 897-904. | 1.1 | 14 |
| 2220 | Value of post-operative reassessment of estrogen receptor β expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 165-170. | 1.1 | 3 |
| 2221 | Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 165-173. | 1.1 | 85 |
| 2222 | Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 255-266. | 1.1 | 15 |
| 2223 | Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 625-631. | 1.1 | 40 |
| 2224 | Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography-CT in follow-up of postoperative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 267-272. | 1.1 | 12 |
| 2225 | Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 421-427. | 1.1 | 11 |
| 2226 | Biologic markers determine both the risk and the timing of recurrence in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 607-616. | 1.1 | 89 |
| 2227 | Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 755-763. | 1.1 | 26 |
| 2228 | Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 553-560. | 1.1 | 68 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2229 | Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 599-608. | 1.1 | 9 |
| 2230 | Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 619-626. | 1.1 | 11 |
| 2231 | Pregnancy after breast cancer: if you wish, maâ€™am. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 309-317. | 1.1 | 81 |
| 2232 | A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 819-827. | 1.1 | 30 |
| 2233 | The After Breast Cancer Pooling Project: rationale, methodology, and breast cancer survivor characteristics. <i>Cancer Causes and Control</i> , 2011, 22, 1319-1331. | 0.8 | 34 |
| 2234 | The melanoma-associated antigen-A3, -A4 genes: relation to the risk and clinicopathological parameters in breast cancer patients. <i>Molecular and Cellular Biochemistry</i> , 2011, 351, 261-268. | 1.4 | 12 |
| 2235 | Recovery of menstruation after long-term chemotherapy and endocrine therapy in pre-menopausal patients with breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 615-620. | 1.2 | 6 |
| 2236 | Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 897-905. | 1.2 | 4 |
| 2237 | Characteristics of triple-negative breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 183-192. | 1.2 | 225 |
| 2238 | Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1123-1130. | 1.2 | 29 |
| 2239 | Somatic variation and cancer: therapies lost in the mix. <i>Human Genetics</i> , 2011, 130, 79-91. | 1.8 | 40 |
| 2240 | Use of a genomic test (MammaPrintâ„¢) in daily clinical practice to assist in risk stratification of young breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2011, 283, 597-602. | 0.8 | 23 |
| 2243 | Bilateral oophorectomy combined with exemestane treating advanced refractory breast cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 43-46. | 0.1 | 0 |
| 2244 | Survey on physiciansâ€™ opinions of post-mastectomy radiotherapy for breast cancer in Guangdong province. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 202-207. | 0.1 | 0 |
| 2245 | The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1007-1015. | 1.1 | 11 |
| 2246 | Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 661-668. | 1.1 | 3 |
| 2247 | Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. <i>Medical Oncology</i> , 2011, 28, 57-63. | 1.2 | 68 |
| 2248 | Acute promyelocytic leukemia in a young patient with breast cancer. <i>Medical Oncology</i> , 2011, 28, 249-250. | 1.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2249 | Should adjuvant trastuzumab be offered in very early-stage (pT1a/bNOMO) HER2-neu-positive breast cancer? A current debate. <i>Medical Oncology</i> , 2011, 28, 401-408. | 1.2 | 3 |
| 2250 | Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?. <i>Medical Oncology</i> , 2011, 28, 726-732. | 1.2 | 20 |
| 2251 | Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. <i>Medical Oncology</i> , 2011, 28, 80-90. | 1.2 | 45 |
| 2252 | CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. <i>Medical Oncology</i> , 2011, 28, 129-134. | 1.2 | 29 |
| 2253 | HER2 status in breast cancer: experience of a Spanish National Reference Centre. <i>Clinical and Translational Oncology</i> , 2011, 13, 335-340. | 1.2 | 7 |
| 2254 | Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. <i>Clinical and Translational Oncology</i> , 2011, 13, 485-498. | 1.2 | 23 |
| 2255 | SEOM clinical guidelines for using molecular markers in clinical practice. <i>Clinical and Translational Oncology</i> , 2011, 13, 587-591. | 1.2 | 0 |
| 2256 | Neoadjuvant endocrine treatment of women with breast cancer. <i>Oncology Reviews</i> , 2011, 5, 157-166. | 0.8 | 0 |
| 2257 | Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. <i>Breast Cancer</i> , 2011, 18, 182-188. | 1.3 | 34 |
| 2258 | Update on adjuvant hormonal treatment of early breast cancer. <i>Advances in Therapy</i> , 2011, 28, 1-18. | 1.3 | 8 |
| 2259 | Adjuvant hormonal therapy in perimenopausal patients. <i>Advances in Therapy</i> , 2011, 28, 39-49. | 1.3 | 1 |
| 2260 | Individualization of treatment strategies. <i>Advances in Therapy</i> , 2011, 28, 19-38. | 1.3 | 5 |
| 2261 | Initialization of adjuvant hormonal treatment for breast cancer. <i>Advances in Therapy</i> , 2011, 28, 66-84. | 1.3 | 9 |
| 2262 | An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer. <i>Advances in Therapy</i> , 2011, 28, 1045-1058. | 1.3 | 21 |
| 2263 | The International Core Literature Consensus (ICLC): an Alternative Curriculum for Oncologists. <i>Journal of Cancer Education</i> , 2011, 26, 420-426. | 0.6 | 4 |
| 2264 | Concomitant adjuvant chemo-radiation therapy with anthracyclinebased regimens in breast cancer: a single centre experience. <i>Radiologia Medica</i> , 2011, 116, 1050-1058. | 4.7 | 6 |
| 2265 | Mammakarzinom. <i>Wiener Klinische Wochenschrift Education</i> , 2011, 6, 95-110. | 0.0 | 0 |
| 2266 | Adjuvant Chemotherapy for Breast Cancer in Older Women: Emerging Evidence to Aid in Decision Making. <i>Current Treatment Options in Oncology</i> , 2011, 12, 286-301. | 1.3 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2267 | How do I Treat "Triple-Negative" Disease. <i>Current Treatment Options in Oncology</i> , 2011, 12, 369-388. | 1.3 | 9 |
| 2268 | The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury?. <i>Current Oncology Reports</i> , 2011, 13, 17-25. | 1.8 | 32 |
| 2269 | Growth of breast cancer recurrences assessed by consecutive MRI. <i>BMC Cancer</i> , 2011, 11, 155. | 1.1 | 17 |
| 2270 | Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. <i>BMC Cancer</i> , 2011, 11, 213. | 1.1 | 31 |
| 2271 | Younger age as a prognostic indicator in breast cancer: A cohort study. <i>BMC Cancer</i> , 2011, 11, 383. | 1.1 | 67 |
| 2272 | ICOS gene polymorphisms are associated with sporadic breast cancer: a case-control study. <i>BMC Cancer</i> , 2011, 11, 392. | 1.1 | 15 |
| 2273 | Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: Is there a role for radiation therapy?. <i>Radiation Oncology</i> , 2011, 6, 28. | 1.2 | 31 |
| 2274 | Poor physical health predicts time to additional breast cancer events and mortality in breast cancer survivors. <i>Psycho-Oncology</i> , 2011, 20, 252-259. | 1.0 | 59 |
| 2275 | Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer. <i>Psycho-Oncology</i> , 2011, 20, 1044-1052. | 1.0 | 64 |
| 2276 | Optimizing conservative breast surgery. <i>Journal of Surgical Oncology</i> , 2011, 103, 306-312. | 0.8 | 19 |
| 2277 | When to start an aromatase inhibitor: Now or later?. <i>Journal of Surgical Oncology</i> , 2011, 103, 730-738. | 0.8 | 5 |
| 2278 | Accumulation of p53 determined by immunohistochemistry as a prognostic marker in node negative breast cancer; analysis according to st gallen consensus and intrinsic subtypes. <i>Journal of Surgical Oncology</i> , 2011, 103, 207-211. | 0.8 | 11 |
| 2279 | Systemic treatment of early breast cancer—a biological perspective. <i>Journal of Surgical Oncology</i> , 2011, 103, 619-626. | 0.8 | 9 |
| 2280 | Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ. <i>Cancer</i> , 2011, 117, 54-62. | 2.0 | 45 |
| 2281 | Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. <i>Cancer</i> , 2011, 117, 398-405. | 2.0 | 20 |
| 2282 | Socioeconomic status and survival after an invasive breast cancer diagnosis. <i>Cancer</i> , 2011, 117, 1542-1551. | 2.0 | 124 |
| 2283 | Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early. <i>Cancer</i> , 2011, 117, 1819-1826. | 2.0 | 121 |
| 2284 | Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. <i>Cancer</i> , 2011, 117, 1595-1601. | 2.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2285 | GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. <i>International Journal of Cancer</i> , 2011, 128, 726-731. | 2.3 | 67 |
| 2286 | Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients. <i>International Journal of Cancer</i> , 2011, 129, 9-22. | 2.3 | 46 |
| 2287 | Interference with ER α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER α -positive breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 1103-1117. | 1.2 | 9 |
| 2288 | Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine. <i>Cell Biochemistry and Function</i> , 2011, 29, 651-659. | 1.4 | 12 |
| 2289 | Outcomes of Node-Negative Breast Cancer 5 Centimeters and Larger Treated With and Without Postmastectomy Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 758-764. | 0.4 | 23 |
| 2290 | Patterns of Utilization of Adjuvant Radiotherapy and Outcomes in Black Women After Breast Conservation at a Large Multidisciplinary Cancer Center. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1102-1108. | 0.4 | 5 |
| 2291 | Adjuvant! Online as a Decision-making Tool in Early Breast Cancer – a UK National Survey. <i>Clinical Oncology</i> , 2011, 23, 159-160. | 0.6 | 16 |
| 2292 | Radiotherapy for Malignant Spinal Cord Compression. <i>Clinical Oncology</i> , 2011, 23, 160. | 0.6 | 1 |
| 2293 | Adjuvant endocrine therapy in postmenopausal breast cancer patients: Does hormone receptor status influence decision-making?. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 87-99. | 2.0 | 1 |
| 2294 | Optimizing the use of anthracyclines in older patients with breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 131-141. | 2.0 | 1 |
| 2295 | Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 196-204. | 2.0 | 64 |
| 2296 | Dosing of zoledronic acid throughout the treatment continuum in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 175-188. | 2.0 | 9 |
| 2297 | Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Aromatase Inhibitor-associated Joint Symptoms in Women with Early-stage Breast Cancer.. <i>Deutsche Zeitschrift für Akupunktur</i> , 2011, 54, 40-41. | 0.1 | 0 |
| 2298 | Prognostic importance of PAI-1 in node negative breast cancer patients – Results after 10 years of follow up. <i>Pathology Research and Practice</i> , 2011, 207, 290-294. | 1.0 | 9 |
| 2299 | Estrogen Receptor (<i>ESR1</i>) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4160-4167. | 0.8 | 120 |
| 2301 | <i>SULT1A1</i> , <i>CYP2C19</i> and disease-free survival in early breast cancer patients receiving tamoxifen. <i>Pharmacogenomics</i> , 2011, 12, 1535-1543. | 0.6 | 39 |
| 2302 | The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment. <i>Pathobiology</i> , 2011, 78, 99-114. | 1.9 | 101 |
| 2303 | Research Highlights. <i>Pharmacogenomics</i> , 2011, 12, 9-13. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2304 | Can Ovarian Reserve Assessment Predict Fertility following Breast Cancer Treatment?. <i>Women's Health</i> , 2011, 7, 623-625. | 0.7 | 1 |
| 2307 | Do All Patients with Breast Cancer Require Systemic Adjuvant Therapy?. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1350-1351. | 3.0 | 2 |
| 2308 | Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. <i>Annals of Oncology</i> , 2011, 22, 2021-2030. | 0.6 | 19 |
| 2310 | D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients. <i>Modern Pathology</i> , 2011, 24, 502-511. | 2.9 | 18 |
| 2311 | Is Mammographic Screening Justifiable Considering Its Substantial Overdiagnosis Rate and Minor Effect on Mortality?. <i>Radiology</i> , 2011, 260, 621-627. | 3.6 | 114 |
| 2312 | Therapeutic targeting of B7-H1 in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 1211-1225. | 1.5 | 36 |
| 2313 | Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4452-4461. | 0.8 | 346 |
| 2314 | Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 363-377. | 1.3 | 22 |
| 2315 | High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti-IGF-IR Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 2314-2327. | 3.2 | 112 |
| 2316 | BRCA Mutation Testing in Determining Breast Cancer Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 492-499. | 1.0 | 50 |
| 2317 | Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. <i>Annals of Oncology</i> , 2011, 22, 1770-1776. | 0.6 | 32 |
| 2318 | Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1657-1663. | 0.8 | 95 |
| 2319 | Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18879-18886. | 3.3 | 151 |
| 2320 | How Long Is Long Enough?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2129-2130. | 0.8 | 3 |
| 2321 | Older Women With Breast Cancer: Slow Progress, Great Opportunity, Now Is the Time. <i>Journal of Clinical Oncology</i> , 2011, 29, 4608-4610. | 0.8 | 19 |
| 2322 | Reply to S.A. Narod et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3107-3107. | 0.8 | 1 |
| 2323 | Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. <i>Annals of Oncology</i> , 2011, 22, 2216-2226. | 0.6 | 40 |
| 2324 | Declining Incidence of Contralateral Breast Cancer in the United States From 1975 to 2006. <i>Journal of Clinical Oncology</i> , 2011, 29, 1564-1569. | 0.8 | 210 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2325 | Association Between Prescription Co-Payment Amount and Compliance With Adjuvant Hormonal Therapy in Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2534-2542. | 0.8 | 297 |
| 2326 | Tamoxifen Chemoprevention and Cardiac Disease. <i>Journal of Clinical Oncology</i> , 2011, 29, 3106-3107. | 0.8 | 3 |
| 2327 | Approval Summary: Letrozole (Femara® Tablets) for Adjuvant and Extended Adjuvant Postmenopausal Breast Cancer Treatment: Conversion of Accelerated to Full Approval. <i>Oncologist</i> , 2011, 16, 1762-1770. | 1.9 | 6 |
| 2328 | Expanding Our Therapeutic Options: Beta Blockers for Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2612-2616. | 0.8 | 26 |
| 2329 | Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2653-2659. | 0.8 | 196 |
| 2330 | Bevacizumab Treatment for Solid Tumors. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 506. | 3.8 | 51 |
| 2331 | Lack of Survival Gain for Elderly Women with Breast Cancer. <i>Oncologist</i> , 2011, 16, 415-423. | 1.9 | 67 |
| 2332 | Coming of Age: Breast Cancer in Seniors. <i>Oncologist</i> , 2011, 16, 79-87. | 1.9 | 19 |
| 2333 | Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study. <i>Clinical Cancer Research</i> , 2011, 17, 1147-1159. | 3.2 | 158 |
| 2334 | Reply to R. Glynne-Jones. <i>Journal of Clinical Oncology</i> , 2011, 29, 4059-4060. | 0.8 | 0 |
| 2335 | Personalized Tamoxifen: What Is the Best Way Forward?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3206-3208. | 0.8 | 11 |
| 2336 | Targeting the Insulin-Like Growth Factor Pathway in Estrogen Receptor-Positive Breast Cancer: A Bumpy Start With an Uncertain Future. <i>Journal of Clinical Oncology</i> , 2011, 29, 3846-3848. | 0.8 | 5 |
| 2337 | Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?. <i>Future Oncology</i> , 2011, 7, 37-55. | 1.1 | 5 |
| 2338 | Prognosis of Patients With Breast Cancer: Causes of Death and Effects of Time Since Diagnosis, Age, and Tumor Characteristics. <i>Journal of Clinical Oncology</i> , 2011, 29, 4014-4021. | 0.8 | 163 |
| 2339 | Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1363-1372. | 3.0 | 52 |
| 2340 | Gene Expression Profiles of Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancers Are Detectable in Histologically Normal Breast Epithelium. <i>Clinical Cancer Research</i> , 2011, 17, 236-246. | 3.2 | 66 |
| 2341 | A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3398-3407. | 3.2 | 28 |
| 2342 | The Breast Screening Programme and misinforming the public. <i>Journal of the Royal Society of Medicine</i> , 2011, 104, 361-369. | 1.1 | 36 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2343 | The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor-Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists. <i>Oncologist</i> , 2011, 16, 1520-1526. | 1.9 | 77 |
| 2344 | Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without Capecitabine in Locally Advanced Breast Cancer: Long-Term Results. <i>Oncologist</i> , 2011, 16, 1527-1534. | 1.9 | 29 |
| 2345 | ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1046-1058. | 1.9 | 140 |
| 2346 | Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer. <i>Cancer Research</i> , 2011, 71, 603-613. | 0.4 | 140 |
| 2347 | Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 3270-3277. | 0.8 | 60 |
| 2348 | Improvement in Breast Cancer Outcomes Over Time: Are Older Women Missing Out?. <i>Journal of Clinical Oncology</i> , 2011, 29, 4647-4653. | 0.8 | 131 |
| 2349 | Early Breast Cancer in the Older Woman. <i>Oncologist</i> , 2011, 16, 479-485. | 1.9 | 19 |
| 2350 | Immunohistochemical Assessment of Expression of Centromere Protein A (CENPA) in Human Invasive Breast Cancer. <i>Cancers</i> , 2011, 3, 4212-4227. | 1.7 | 36 |
| 2351 | CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark. <i>Journal of the National Cancer Institute</i> , 2011, 103, 489-500. | 3.0 | 84 |
| 2352 | Management Options in Triple-Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2011, 5, BCBCR.S6562. | 0.6 | 34 |
| 2353 | Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer. <i>ISRN Oncology</i> , 2011, 2011, 1-5. | 2.1 | 11 |
| 2354 | Effect of Very Small Tumor Size on Cancer-Specific Mortality in Node-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2619-2627. | 0.8 | 100 |
| 2355 | Edmonton Symptom Assessment System Screening and Depression at the End of Life. <i>Journal of Clinical Oncology</i> , 2011, 29, 3107-3108. | 0.8 | 2 |
| 2356 | Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. <i>Clinical Cancer Research</i> , 2011, 17, 4948-4958. | 3.2 | 58 |
| 2357 | The Effect of Toremifene on Lipid Metabolism Compared with That of Tamoxifen in vitro. <i>Gynecologic and Obstetric Investigation</i> , 2011, 71, 213-216. | 0.7 | 5 |
| 2358 | Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 1699-1706. | 0.5 | 10 |
| 2359 | Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS BC07)]. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 709-712. | 0.6 | 38 |
| 2360 | Alteration of Topoisomerase II α Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 859-867. | 0.8 | 192 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2361 | Likelihood That a Woman With Screen-Detected Breast Cancer Has Had Her "Life Saved" by That Screening. <i>Archives of Internal Medicine</i> , 2011, 171, 2043. | 4.3 | 60 |
| 2362 | Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies. <i>Molecular Endocrinology</i> , 2011, 25, 199-211. | 3.7 | 138 |
| 2364 | Contralateral Prophylactic Mastectomy: What Do We Know and What Do Our Patients Know?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2132-2135. | 0.8 | 21 |
| 2365 | All Nodes Lead to Chemo. <i>Oncologist</i> , 2011, 16, 722-725. | 1.9 | 1 |
| 2366 | Cracking the Estrogen Receptor's Posttranslational Code in Breast Tumors. <i>Endocrine Reviews</i> , 2011, 32, 597-622. | 8.9 | 244 |
| 2367 | The conformation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: a hypothesis. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2011, 5, 27-34. | 0.3 | 17 |
| 2368 | Screening: Simple Messages. Sometimes. <i>Archives of Internal Medicine</i> , 2011, 171, 2046. | 4.3 | 3 |
| 2369 | Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1529-1539. | 3.0 | 27 |
| 2371 | Adjuvant Systemic Therapy of Breast Cancer. <i>Breast Care</i> , 2011, 6, 179-183. | 0.8 | 4 |
| 2372 | Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer. <i>Breast Care</i> , 2011, 6, 193-198. | 0.8 | 10 |
| 2373 | Late Toxicity of Radiotherapy: A Problem or a Challenge for the Radiation Oncologist?. <i>Breast Care</i> , 2011, 6, 369-374. | 0.8 | 34 |
| 2374 | Prognostic Impact of Ki-67 Overexpression in Subgroups Categorized according to St. Gallen with Early Stage Breast Cancer. <i>Oncology</i> , 2011, 81, 345-352. | 0.9 | 11 |
| 2375 | Overcoming resistance: Targeting the PI3K/mTOR pathway in endocrine refractory breast cancer. <i>Cancer Biology and Therapy</i> , 2011, 11, 947-949. | 1.5 | 5 |
| 2377 | Anti-proliferative effects of Chinese herb <i>Cornus officinalis</i> in a cell culture model for estrogen receptor-positive clinical breast cancer. <i>Molecular Medicine Reports</i> , 2011, 5, 22-8. | 1.1 | 34 |
| 2379 | Genomics and Drug Response. <i>New England Journal of Medicine</i> , 2011, 364, 1144-1153. | 13.9 | 552 |
| 2380 | Clinical Management Factors Contribute to the Decision for Contralateral Prophylactic Mastectomy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2158-2164. | 0.8 | 298 |
| 2381 | A Lipid-Modified Estrogen Derivative that Treats Breast Cancer Independent of Estrogen Receptor Expression through Simultaneous Induction of Autophagy and Apoptosis. <i>Molecular Cancer Research</i> , 2011, 9, 364-374. | 1.5 | 40 |
| 2382 | Long-Term Follow-Up of Women in Trials of Adjuvant Therapy for Breast Cancer: Is It Still Important?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1651-1652. | 0.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2383 | Hereditary breast cancer: clinical features and risk reduction strategies. <i>Annals of Oncology</i> , 2011, 22, i31-i36. | 0.6 | 26 |
| 2384 | Can Quantifying Hormone Receptor Levels Guide the Choice of Adjuvant Endocrine Therapy for Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1504-1506. | 0.8 | 10 |
| 2385 | US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2011, 7, e38s-e45s. | 2.5 | 40 |
| 2386 | An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1561-1570. | 0.6 | 150 |
| 2387 | Influence of Sex Hormones on Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e94-e95. | 0.8 | 32 |
| 2388 | Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects. <i>Journal of Clinical Oncology</i> , 2011, 29, 2301-2304. | 0.8 | 151 |
| 2389 | Profile of V. Craig Jordan. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18876-18878. | 3.3 | 0 |
| 2390 | Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14252-14257. | 3.3 | 68 |
| 2391 | Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. <i>Annals of Oncology</i> , 2011, 22, 257-267. | 0.6 | 148 |
| 2392 | Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. <i>British Journal of Cancer</i> , 2011, 105, 1825-1829. | 2.9 | 26 |
| 2393 | Adjuvant chemotherapy in older women (ACTION) study – what did we learn from the pilot phase?. <i>British Journal of Cancer</i> , 2011, 105, 1260-1266. | 2.9 | 51 |
| 2394 | The treatment of early breast cancer in women over the age of 70. <i>British Journal of Cancer</i> , 2011, 105, 189-193. | 2.9 | 50 |
| 2395 | ERasing breast cancer resistance through the kinome. <i>Nature Medicine</i> , 2011, 17, 660-661. | 15.2 | 15 |
| 2396 | The silent minority – unpublished data on cancer care. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 631-632. | 12.5 | 3 |
| 2397 | Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1277-1282. | 1.1 | 12 |
| 2398 | Knockdown of Osteopontin Chemosensitizes MDA-MB-231 Cells to Cyclophosphamide by Enhancing Apoptosis Through Activating p38 MAPK Pathway. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 165-173. | 0.7 | 46 |
| 2399 | Comparing guidelines for adjuvant endocrine therapy in postmenopausal women with breast cancer: a coming of age. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 277-286. | 1.1 | 3 |
| 2400 | Sleep Aid Prescribing Practices during Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer. <i>Journal of Palliative Medicine</i> , 2011, 14, 563-566. | 0.6 | 16 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2401 | Zoledronic acid for adjuvant use in patients with breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 333-349. | 1.1 | 9 |
| 2402 | Target Therapy in HER2-Overexpressing Breast Cancer Patients. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 363-367. | 1.0 | 14 |
| 2403 | Motherhood after breast cancer: searching for la dolce vita. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 287-298. | 1.1 | 41 |
| 2404 | Cancer du sein. , 2011, , 626-632. | | 0 |
| 2405 | Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 272-279. | 12.5 | 28 |
| 2406 | Incidence and Outcome of Male Breast Cancer: An International Population-Based Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4381-4386. | 0.8 | 175 |
| 2407 | Cancer stem cells in the human mammary gland and regulation of their differentiation by estrogen. <i>Future Oncology</i> , 2011, 7, 995-1006. | 1.1 | 26 |
| 2408 | Independent Prognostic Value of Screen Detection in Invasive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 585-597. | 3.0 | 100 |
| 2409 | Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1336-1343. | 1.8 | 200 |
| 2410 | Preoperative Chemotherapy for Operable Breast Cancer Improves Surgical Outcomes in the Community Hospital Setting. <i>Oncologist</i> , 2011, 16, 752-759. | 1.9 | 16 |
| 2411 | Prognostic Assessment and Adjuvant Treatment Strategies Within Early-Stage, Sporadic Triple Negative Breast Cancer Patients. <i>Cancer Investigation</i> , 2011, 29, 180-186. | 0.6 | 6 |
| 2412 | Race-Specific Impact of Natural History, Mammography Screening, and Adjuvant Treatment on Breast Cancer Mortality Rates in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 112-122. | 1.1 | 65 |
| 2413 | HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. <i>Annals of Oncology</i> , 2011, 22, 1326-1331. | 0.6 | 27 |
| 2415 | Second Malignancies Among Elderly Survivors of Cancer. <i>Oncologist</i> , 2011, 16, 1572-1581. | 1.9 | 27 |
| 2416 | Molecular Class as a Predictor of Locoregional and Distant Recurrence in the Neoadjuvant Setting for Breast Cancer. <i>Oncology</i> , 2011, 80, 341-349. | 0.9 | 14 |
| 2417 | The End of an Era: Shall We Move Forward?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3849-3851. | 0.8 | 3 |
| 2418 | Estrogen Receptor: A Never Ending Story?. <i>Journal of Clinical Oncology</i> , 2011, 29, 2955-2958. | 0.8 | 19 |
| 2419 | Pregnancy associated breast cancer and pregnancy after breast cancer treatment. <i>Journal of the Turkish German Gynecology Association</i> , 2011, 12, 247-255. | 0.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2420 | Factors Influencing Treatment Recommendations in Node-Negative Breast Cancer. <i>Journal of Oncology Practice</i> , 2011, 7, 26-30. | 2.5 | 6 |
| 2421 | Breast Cancer-Initiating Cells: Insights into Novel Treatment Strategies. <i>Cancers</i> , 2011, 3, 1405-1425. | 1.7 | 9 |
| 2422 | Current role and safety profile of aromatase inhibitors in early breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1253-1263. | 1.1 | 29 |
| 2423 | Reply to R. Simon. <i>Journal of Clinical Oncology</i> , 2011, 29, 2941-2944. | 0.8 | 0 |
| 2424 | TP53 Status and Response to Treatment in Breast Cancers. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9. | 3.0 | 51 |
| 2425 | Tumor Characteristics Associated With Mammographic Detection of Breast Cancer in the Ontario Breast Screening Program. <i>Journal of the National Cancer Institute</i> , 2011, 103, 942-950. | 3.0 | 101 |
| 2426 | Functional Polymorphisms in UDP-Glucuronosyl Transferases and Recurrence in Tamoxifen-Treated Breast Cancer Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1937-1943. | 1.1 | 21 |
| 2427 | Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2011, 22, 1748-1754. | 0.6 | 23 |
| 2428 | Novel Drug Delivery System Based on Docetaxel-Loaded Nanocapsules as a Therapeutic Strategy Against Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2012, 13, 4906-4919. | 1.8 | 39 |
| 2429 | Cost-effectiveness of adjuvant systemic therapy in low-risk breast cancer patients with nodal isolated tumor cells or micrometastases. <i>Annals of Oncology</i> , 2012, 23, 2585-2591. | 0.6 | 1 |
| 2430 | Using Functional Signatures to Identify Repositioned Drugs for Breast, Myelogenous Leukemia and Prostate Cancer. <i>PLoS Computational Biology</i> , 2012, 8, e1002347. | 1.5 | 56 |
| 2432 | Locally advanced breast cancer: Prevention is better than cure!. <i>Indian Journal of Cancer</i> , 2012, 49, 57. | 0.2 | 4 |
| 2433 | General Commentary to the "Management of Biochemical Recurrence after Primary Localized Therapy for Prostate Cancer" by Darwish O. M. and Raj G. V.. <i>Frontiers in Oncology</i> , 2012, 2, 126. | 1.3 | 2 |
| 2434 | The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis. <i>International Journal of Molecular Sciences</i> , 2012, 13, 13414-13437. | 1.8 | 161 |
| 2436 | Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer. <i>Indian Journal of Cancer</i> , 2012, 49, 266. | 0.2 | 4 |
| 2437 | Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. <i>Annals of Oncology</i> , 2012, 23, 2059-2064. | 0.6 | 12 |
| 2438 | Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices. <i>International Journal of Breast Cancer</i> , 2012, 2012, 1-5. | 0.6 | 6 |
| 2439 | Evaluating the Efficacy of Current Clinical Practice of Adjuvant Chemotherapy in Postmenopausal Women with Early-Stage, Estrogen or Progesterone Receptor-Positive, One-To-Three Positive Axillary Lymph Node, Breast Cancer. <i>Current Oncology</i> , 2012, 19, 319-328. | 0.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2440 | Initiation of Adjuvant Hormone Therapy by Medicaid Insured Women With Nonmetastatic Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1102-1105. | 3.0 | 25 |
| 2441 | Refining the Use of Endocrine Therapy for Ductal Carcinoma in Situ. <i>Journal of Clinical Oncology</i> , 2012, 30, 1249-1251. | 0.8 | 10 |
| 2442 | Breast cancer management: Past, present and evolving. <i>Indian Journal of Cancer</i> , 2012, 49, 277. | 0.2 | 38 |
| 2443 | Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?. <i>Annals of Oncology</i> , 2012, 23, 866-869. | 0.6 | 9 |
| 2444 | Is there a future for selective estrogen-receptor modulators in osteoporosis?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012, 4, 55-59. | 1.2 | 3 |
| 2445 | Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers. <i>Annals of Oncology</i> , 2012, 23, 891-897. | 0.6 | 24 |
| 2446 | Anthracycline Regimen Adherence in Older Patients with Early Breast Cancer. <i>Oncologist</i> , 2012, 17, 303-311. | 1.9 | 23 |
| 2447 | Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. <i>Annals of Oncology</i> , 2012, 23, 625-631. | 0.6 | 106 |
| 2448 | Stage-to-stage Comparison of Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Pathological Lymph Node Positive Breast Cancer Patients. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 995-1001. | 0.6 | 4 |
| 2449 | CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2012, 104, 452-460. | 3.0 | 247 |
| 2450 | Mammography screening. <i>European Journal of Cancer Prevention</i> , 2012, 21, 222-226. | 0.6 | 8 |
| 2451 | Assessment of Progesterone Receptors in Breast Carcinoma by PET with ^{18}F -Fluoro-16 α ,17 β -[1 α - ^{18}F -furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione. <i>Journal of Nuclear Medicine</i> , 2012, 53, 363-370. | 2.8 | 71 |
| 2452 | Patient and Physician Decision Styles and Breast Cancer Chemotherapy Use in Older Women: Cancer and Leukemia Group B Protocol 369901. <i>Journal of Clinical Oncology</i> , 2012, 30, 2609-2614. | 0.8 | 39 |
| 2453 | Personalized management of patients with solid cancers. <i>Current Opinion in Oncology</i> , 2012, 24, 297-304. | 1.1 | 16 |
| 2454 | ACR Appropriateness Criteria [®] Local-regional Recurrence (LR) and Salvage Surgery. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 178-182. | 0.6 | 12 |
| 2455 | Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition. <i>Current Opinion in Oncology</i> , 2012, 24, 623-634. | 1.1 | 44 |
| 2456 | Surveillance of Patients With Breast Cancer After Curative-Intent Primary Treatment: Current Practice Patterns. <i>Journal of Oncology Practice</i> , 2012, 8, 79-83. | 2.5 | 31 |
| 2457 | Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 4477-4484. | 0.8 | 58 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2458 | Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!. <i>Journal of Clinical Oncology</i> , 2012, 30, 1264-1267. | 0.8 | 59 |
| 2459 | Oncostatin M suppresses oestrogen receptor- β expression and is associated with poor outcome in human breast cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, 181-195. | 1.6 | 64 |
| 2460 | A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. <i>Clinical Cancer Research</i> , 2012, 18, 4465-4472. | 3.2 | 258 |
| 2461 | Statistical Issues and Recommendations for Noninferiority Trials in Oncology: A Systematic Review. <i>Clinical Cancer Research</i> , 2012, 18, 1837-1847. | 3.2 | 45 |
| 2462 | Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. <i>Carcinogenesis</i> , 2012, 33, 895-901. | 1.3 | 52 |
| 2463 | Age-Specific Nonpersistence of Endocrine Therapy in Postmenopausal Patients Diagnosed with Hormone Receptor-Positive Breast Cancer: A TEAM Study Analysis. <i>Oncologist</i> , 2012, 17, 55-63. | 1.9 | 41 |
| 2464 | Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. <i>Annals of Oncology</i> , 2012, 23, 2859-2865. | 0.6 | 46 |
| 2465 | Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. <i>Oncologist</i> , 2012, 17, 900-909. | 1.9 | 28 |
| 2466 | A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. <i>Annals of Oncology</i> , 2012, 23, 1164-1169. | 0.6 | 42 |
| 2467 | Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort. <i>Cancer Prevention Research</i> , 2012, 5, 735-745. | 0.7 | 28 |
| 2468 | Influence of Race, Insurance, Socioeconomic Status, and Hospital Type on Receipt of Guideline-Concordant Adjuvant Systemic Therapy for Locoregional Breast Cancers. <i>Journal of Clinical Oncology</i> , 2012, 30, 142-150. | 0.8 | 147 |
| 2469 | Noninitiation of Adjuvant Chemotherapy in Women With Localized Breast Cancer: The Breast Cancer Quality of Care Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3800-3809. | 0.8 | 32 |
| 2470 | Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. <i>Annals of Oncology</i> , 2012, 23, 1138-1144. | 0.6 | 19 |
| 2471 | COST-UTILITY ANALYSIS OF ADJUVANT THERAPIES FOR BREAST CANCER IN IRAN. <i>International Journal of Technology Assessment in Health Care</i> , 2012, 28, 110-114. | 0.2 | 11 |
| 2472 | Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2402-2412. | 3.2 | 132 |
| 2473 | Uptake and Economic Impact of First-Cycle Colony-Stimulating Factor Use During Adjuvant Treatment of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 806-812. | 0.8 | 27 |
| 2474 | The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 259-272. | 1.5 | 27 |
| 2475 | Pregnancy after Successful Cancer Treatment: What Needs to Be Considered?. <i>Onkologie</i> , 2012, 35, 128-132. | 1.1 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2476 | Biomarkers in Breast Cancer – An Update. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 819-832. | 0.8 | 38 |
| 2477 | Hazard of Breast Cancer-Specific Mortality among Women with Estrogen Receptor-Positive Breast Cancer after Five Years from Diagnosis: Implication for Extended Endocrine Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2201-E2209. | 1.8 | 65 |
| 2479 | Adjuvant chemotherapy for breast cancer patients: Patients'™ expectations and physicians'™ attitudes. <i>Palliative and Supportive Care</i> , 2012, 10, 107-114. | 0.6 | 2 |
| 2480 | Adjuvant Hormonal Therapy Use Among Women with Ductal Carcinoma <i>In Situ</i> . <i>Journal of Women's Health</i> , 2012, 21, 35-42. | 1.5 | 23 |
| 2481 | Wiser Use of Dose-Dense Adjuvant Therapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 772-774. | 0.8 | 3 |
| 2483 | Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) Trial: results of a German substudy. <i>Climacteric</i> , 2012, 15, 460-466. | 1.1 | 17 |
| 2484 | NADA Ear Acupuncture for Breast Cancer Treatment-Related Hot Flashes and Night Sweats: An Observational Study. <i>Medical Acupuncture</i> , 2012, 24, 256-268. | 0.3 | 7 |
| 2485 | Racial and Ethnic Differences in Adjuvant Hormonal Therapy Use. <i>Journal of Women's Health</i> , 2012, 21, 950-958. | 1.5 | 7 |
| 2486 | Breast cancer sentinel lymph node and axillary lymphadenectomy: new tools for new challenges. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 147-158. | 1.5 | 3 |
| 2487 | Weight-Based Chemotherapy Dosing in Obese Patients With Cancer: Back to the Future. <i>Journal of Oncology Practice</i> , 2012, 8, e62-e64. | 2.5 | 20 |
| 2488 | Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. <i>British Journal of Cancer</i> , 2012, 107, 1249-1256. | 2.9 | 62 |
| 2489 | Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. <i>British Journal of Cancer</i> , 2012, 107, 1901-1907. | 2.9 | 57 |
| 2490 | Loss of GPER identifies new targets for therapy among a subgroup of ER±-positive endometrial cancer patients with poor outcome. <i>British Journal of Cancer</i> , 2012, 106, 1682-1688. | 2.9 | 54 |
| 2491 | Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells. <i>Oncogene</i> , 2012, 31, 4353-4361. | 2.6 | 26 |
| 2492 | Minireview: Inflammation: An Instigator of More Aggressive Estrogen Receptor (ER) Positive Breast Cancers. <i>Molecular Endocrinology</i> , 2012, 26, 360-371. | 3.7 | 149 |
| 2493 | Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells. <i>Oncogene</i> , 2012, 31, 3845-3856. | 2.6 | 38 |
| 2494 | Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. <i>British Journal of Cancer</i> , 2012, 107, 1257-1267. | 2.9 | 14 |
| 2495 | Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. <i>British Journal of Cancer</i> , 2012, 106, 1760-1765. | 2.9 | 64 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2496 | Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 1080-1086. | 0.8 | 408 |
| 2497 | Administrative Data Algorithms to Identify Second Breast Cancer Events Following Early-Stage Invasive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 931-940. | 3.0 | 88 |
| 2498 | Can We Really Use Retrospective Subset Analyses and Surveillance, Epidemiology, and End Results Data to Drive Clinical Practice?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3148-3149. | 0.8 | 5 |
| 2499 | A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. <i>GOIM (Gruppo) Tj ETQq1 106784314rgBT /O</i> | | |
| 2500 | Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1421-1431. | 1.9 | 79 |
| 2501 | FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1919-1925. | 0.8 | 248 |
| 2502 | Nomogram to Predict the Benefit of Radiation for Older Patients With Breast Cancer Treated With Conservative Surgery. <i>Journal of Clinical Oncology</i> , 2012, 30, 2837-2843. | 0.8 | 86 |
| 2503 | Surgical considerations in patients receiving neoadjuvant systemic therapy. <i>Future Oncology</i> , 2012, 8, 239-250. | 1.1 | 11 |
| 2504 | mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. <i>Annals of Oncology</i> , 2012, 23, 2526-2535. | 0.6 | 45 |
| 2505 | Preoperative Delays in the US Medicare Population With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4485-4492. | 0.8 | 115 |
| 2506 | Risk of treatment-related esophageal cancer among breast cancer survivors. <i>Annals of Oncology</i> , 2012, 23, 3081-3091. | 0.6 | 71 |
| 2508 | Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 127-137. | 1.4 | 26 |
| 2509 | Decline in the Use of Anthracyclines for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2232-2239. | 0.8 | 160 |
| 2510 | Sex Differences in Fertility-Related Information Received by Young Adult Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2012, 30, 2147-2153. | 0.8 | 163 |
| 2511 | Change in Working Time in a Population-Based Cohort of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2853-2860. | 0.8 | 30 |
| 2512 | Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator. <i>Journal of Oncology Practice</i> , 2012, 8, 144-148. | 2.5 | 100 |
| 2513 | Use of a Urine Anastrozole Assay to Determine Treatment Discontinuation Among Women With Hormone-Sensitive Breast Cancer: A Pilot Study. <i>Journal of Oncology Practice</i> , 2012, 8, e100-e104. | 2.5 | 8 |
| 2514 | The Effect of 96-Hour Formalin Fixation on the Immunohistochemical Evaluation of Estrogen Receptor, Progesterone Receptor, and HER2 Expression in Invasive Breast Carcinoma. <i>American Journal of Clinical Pathology</i> , 2012, 137, 691-698. | 0.4 | 28 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2515 | Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 800-809. | 1.1 | 99 |
| 2516 | Regulation of Estrogen Receptor α N-Terminus Conformation and Function by Peptidyl Prolyl Isomerase Pin1. <i>Molecular and Cellular Biology</i> , 2012, 32, 445-457. | 1.1 | 64 |
| 2517 | Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, R21-R33. | 1.6 | 35 |
| 2518 | Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 709-717. | 0.8 | 110 |
| 2519 | Facteurs de décision des traitements médicaux, conférences de consensus et recommandations. , 2012, , 87-97. | | 0 |
| 2520 | Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. <i>British Journal of Psychiatry</i> , 2012, 200, 97-106. | 1.7 | 332 |
| 2521 | Toward Individualized Breast Cancer Therapy: Translating Biological Concepts to the Bedside. <i>Oncologist</i> , 2012, 17, 577-584. | 1.9 | 17 |
| 2522 | Optimal Duration of Adjuvant Therapy for Patients With Resected Gastrointestinal Stromal Tumors. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1312. | 3.8 | 4 |
| 2523 | Influence of aerobic training on mechanical bone strength in premenopausal women undergoing breast cancer endocrine therapy. <i>Przeegląd Menopauzalny</i> , 2012, 6, 449-455. | 0.6 | 0 |
| 2524 | Quality of Breast Cancer Care: Perception Versus Practice. <i>Journal of Clinical Oncology</i> , 2012, 30, 1791-1795. | 0.8 | 42 |
| 2525 | Is Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1260-1263. | 0.8 | 60 |
| 2526 | Validity of Eight Integrated Healthcare Delivery Organizations' Administrative Clinical Data to Capture Breast Cancer Chemotherapy Exposure. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 673-680. | 1.1 | 19 |
| 2527 | Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2012, 9, 143-163. | 0.3 | 62 |
| 2528 | Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 173. | 1.0 | 9 |
| 2529 | CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 149. | 0.4 | 20 |
| 2530 | Using Simulation Modeling to Inform Strategies to Reduce Breast Cancer Mortality in Black Women in the District of Columbia. <i>Epidemiology Research International</i> , 2012, 2012, 1-10. | 0.2 | 3 |
| 2531 | Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24. <i>Journal of Clinical Oncology</i> , 2012, 30, 1268-1273. | 0.8 | 310 |
| 2532 | Previous Chemotherapy Influences the Symptom Experience and Quality of Life of Women With Breast Cancer Prior to Radiation Therapy. <i>Cancer Nursing</i> , 2012, 35, 167-177. | 0.7 | 40 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2533 | Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 722-728. | 0.8 | 91 |
| 2534 | Radiosensitization effects of berberine on human breast cancer cells. <i>International Journal of Molecular Medicine</i> , 2012, 30, 1166-1172. | 1.8 | 35 |
| 2535 | Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. <i>International Journal of Oncology</i> , 2012, 41, 1845-1854. | 1.4 | 29 |
| 2536 | Hematologic Safety of Breast Cancer Chemotherapies in Patients with Hepatitis B or C Virus Infection. <i>Oncology</i> , 2012, 82, 228-233. | 0.9 | 4 |
| 2537 | Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer. <i>Breast Care</i> , 2012, 7, 289-295. | 0.8 | 11 |
| 2538 | HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics. <i>Breast Care</i> , 2012, 7, 465-470. | 0.8 | 16 |
| 2539 | Radiotherapy Issues in Elderly Breast Cancer Patients. <i>Breast Care</i> , 2012, 7, 453-459. | 0.8 | 13 |
| 2540 | Obesity, Energy Balance, and Cancer: New Opportunities for Prevention. <i>Cancer Prevention Research</i> , 2012, 5, 1260-1272. | 0.7 | 156 |
| 2541 | Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 930-935. | 0.8 | 31 |
| 2542 | Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy. <i>Obstetrics and Gynecology</i> , 2012, 120, 1267-1272. | 1.2 | 70 |
| 2544 | Senior Adult Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 162-209. | 2.3 | 105 |
| 2545 | Axillary Staging Prior to Neoadjuvant Chemotherapy: The Roles of Sentinel Lymph Node Biopsy and Axillary Ultrasonography. <i>Cancer Control</i> , 2012, 19, 277-285. | 0.7 | 19 |
| 2546 | Evaluating the Feasibility of Extended Partial Mastectomy and Immediate Reduction Mammoplasty Reconstruction as an Alternative to Mastectomy. <i>Annals of Surgery</i> , 2012, 255, 1151-1157. | 2.1 | 38 |
| 2547 | Tamoxifen Increases the Risk of Microvascular Flap Complications in Patients Undergoing Microvascular Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2012, 129, 305-314. | 0.7 | 53 |
| 2548 | Safe chemotherapy and hormone therapy for treating early breast cancer in a glucose 6-phosphate dehydrogenase-deficient patient. <i>Anti-Cancer Drugs</i> , 2012, 23, 758-760. | 0.7 | 5 |
| 2549 | Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy. <i>Anti-Cancer Drugs</i> , 2012, 23, 326-334. | 0.7 | 14 |
| 2550 | Regional Recurrence in Breast Cancer Patients With Sentinel Node Micrometastases and Isolated Tumor Cells. <i>Annals of Surgery</i> , 2012, 255, 116-121. | 2.1 | 93 |
| 2551 | Pharmacogenetic screening for drug therapy: From single gene markers to decision making in the next generation sequencing era. <i>Pathology</i> , 2012, 44, 166-180. | 0.3 | 23 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2552 | Breast radiotherapy in the prone position primarily reduces the maximum out-of-field measured dose to the ipsilateral lung. <i>Medical Physics</i> , 2012, 39, 2417-2423. | 1.6 | 13 |
| 2553 | miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. <i>Oncology Letters</i> , 2012, 4, 1027-1032. | 0.8 | 42 |
| 2554 | Sonographic Features of Triple-Negative and Non-Triple-Negative Breast Cancer. <i>Journal of Ultrasound in Medicine</i> , 2012, 31, 1531-1541. | 0.8 | 63 |
| 2555 | Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 122-131. | 1.1 | 80 |
| 2556 | Comparison of adherence to antiestrogen therapy in patients with early breast cancer followed at tertiary centers versus through family physicians and primary surgeons: a practice review. <i>Breast Cancer Management</i> , 2012, 1, 209-215. | 0.2 | 2 |
| 2557 | Epithelial cell culture models for the prevention and therapy of clinical breast cancer (Review). <i>Oncology Letters</i> , 2012, 3, 744-750. | 0.8 | 5 |
| 2558 | Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. <i>International Journal of Oncology</i> , 2012, 40, 1858-64. | 1.4 | 23 |
| 2559 | Combining radiation and therapeutic cancer vaccines: a synergistic approach. <i>Breast Cancer Management</i> , 2012, 1, 325-335. | 0.2 | 0 |
| 2560 | Treatment of breast cancer in young women. <i>Clinical Practice (London, England)</i> , 2012, 9, 171-180. | 0.1 | 1 |
| 2561 | Structural and Molecular Imaging in Cancer Therapy Clinical Trials. , 2012, , 387-412. | | 0 |
| 2562 | Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. <i>Lancet, The</i> , 2012, 379, 432-444. | 6.3 | 1,753 |
| 2563 | The 2011 EBCTCG polychemotherapy overview. <i>Lancet, The</i> , 2012, 379, 390-392. | 6.3 | 39 |
| 2564 | Molecular hydrogelators consist of Taxol and short peptides/amino acids. <i>Journal of Materials Chemistry</i> , 2012, 22, 16933. | 6.7 | 30 |
| 2565 | Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. <i>New England Journal of Medicine</i> , 2012, 367, 1998-2005. | 13.9 | 1,119 |
| 2566 | Molecular Alterations Between the Primary Breast Cancer and the Subsequent Locoregional/Metastatic Tumor. <i>Oncologist</i> , 2012, 17, 172-178. | 1.9 | 39 |
| 2567 | Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. <i>Journal of Clinical Oncology</i> , 2012, 30, 2601-2608. | 0.8 | 411 |
| 2568 | CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 441-451. | 3.0 | 316 |
| 2569 | Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 426, 26-32. | 1.0 | 30 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2570 | Adenocarcinoma of the Uterine Corpus. , 2012, , 141-174.e6. | | 11 |
| 2571 | Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. <i>Histopathology</i> , 2012, 61, 1134-1144. | 1.6 | 105 |
| 2572 | Immunophenotyping of male breast cancer. <i>Histopathology</i> , 2012, 61, 1145-1155. | 1.6 | 31 |
| 2573 | Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2012, 30, 497-506. | 0.8 | 81 |
| 2574 | A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. <i>Investigational New Drugs</i> , 2012, 30, 1887-1898. | 1.2 | 32 |
| 2575 | Estrogen receptor- α , RBCK1, and protein kinase C δ 1 cooperate to regulate estrogen receptor- α gene expression. <i>Journal of Molecular Endocrinology</i> , 2012, 49, 277-287. | 1.1 | 14 |
| 2576 | High-content quantum dot-based subtype diagnosis and classification of breast cancer patients using hypermulticolor quantitative single cell imaging cytometry. <i>Nano Today</i> , 2012, 7, 231-244. | 6.2 | 25 |
| 2577 | Molecular hydrogels of hydrophobic compounds: a novel self-delivery system for anti-cancer drugs. <i>Soft Matter</i> , 2012, 8, 2344-2347. | 1.2 | 77 |
| 2578 | Predictive Biomarkers in Breast Cancer: Their Value in Neoadjuvant Chemotherapy. <i>Cancer Investigation</i> , 2012, 30, 663-678. | 0.6 | 18 |
| 2579 | Risk of Colorectal Adenomas in Women with Prior Breast Cancer. <i>Digestive Diseases and Sciences</i> , 2012, 57, 3240-3245. | 1.1 | 6 |
| 2580 | Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf Oncology, The</i> , 2012, 13, 734-742. | 5.1 | 168 |
| 2581 | Current approaches to the management of Her2-negative metastatic breast cancer. <i>Breast Cancer Research</i> , 2012, 14, 205. | 2.2 | 16 |
| 2582 | STAT1-deficient mice spontaneously develop estrogen receptor α -positive luminal mammary carcinomas. <i>Breast Cancer Research</i> , 2012, 14, R16. | 2.2 | 155 |
| 2583 | Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. <i>Breast Cancer Research</i> , 2012, 14, R57. | 2.2 | 75 |
| 2584 | Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. <i>Breast Cancer Research</i> , 2012, 14, R95. | 2.2 | 87 |
| 2585 | Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. <i>Breast Cancer Research</i> , 2012, 14, R117. | 2.2 | 59 |
| 2586 | The efficacy and its related issues of combination of bevacizumab and taxanes-based regimens in Chinese patients with metastatic breast cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2012, 11, 585-591. | 0.1 | 1 |
| 2587 | Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 903-913. | 1.1 | 41 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2588 | Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1103-1114. | 1.1 | 72 |
| 2589 | Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 29-37. | 1.1 | 39 |
| 2590 | Letter in response: the value of mammography screening. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1345-1346. | 1.1 | 0 |
| 2591 | Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1125-1132. | 1.1 | 17 |
| 2592 | Lipid profiles within the SABRE trial of anastrozole with and without risnedronate. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1141-1147. | 1.1 | 8 |
| 2593 | The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 381-390. | 1.1 | 17 |
| 2594 | Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 153-160. | 1.1 | 107 |
| 2595 | Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 547-557. | 1.1 | 14 |
| 2596 | Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 823-835. | 1.1 | 25 |
| 2597 | Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 495-502. | 1.1 | 52 |
| 2598 | The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status. <i>Cancer Causes and Control</i> , 2012, 23, 1721-1728. | 0.8 | 37 |
| 2599 | An 81-Year-Old Patient With Distant Metastasis of Invasive Lobular Carcinoma Occurring 41 Years After Mastectomy. <i>Clinical Breast Cancer</i> , 2012, 12, 293-295. | 1.1 | 2 |
| 2600 | Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. <i>Fertility and Sterility</i> , 2012, 98, 1363-1369. | 0.5 | 88 |
| 2601 | Response to "Timing of Radiotherapy and Outcome in Patients Receiving Adjuvant Endocrine Therapy." (<i>Int J Radiat Oncol Biol Phys</i> 2011;80:398-402). <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 519. | 0.4 | 1 |
| 2602 | Sequence of Radiotherapy and Chemotherapy in Breast Cancer After Breast-Conserving Surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e811-e817. | 0.4 | 9 |
| 2603 | Preoperative radio-chemotherapy in early breast cancer patients: Long-term results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2012, 102, 82-88. | 0.3 | 37 |
| 2604 | A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer. <i>Cancer Investigation</i> , 2012, 30, 309-316. | 0.6 | 11 |
| 2605 | The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy. <i>Pharmacogenomics</i> , 2012, 13, 659-675. | 0.6 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2606 | Breast cancer screening in women over 75: Is modesty a barrier in the elderly?. <i>Journal of Geriatric Oncology</i> , 2012, 3, S42-S43. | 0.5 | 0 |
| 2607 | Measuring postoperative cognitive dysfunction in elderly cancer patients with user-friendly tools. <i>Journal of Geriatric Oncology</i> , 2012, 3, S43-S44. | 0.5 | 0 |
| 2608 | Breast Cancer Primary Prevention: "SERM-Mounting"™ Existing Obstacles and Future Directions. <i>Breast Diseases</i> , 2012, 23, 19-23. | 0.0 | 0 |
| 2609 | Rates of febrile neutropaenia in women aged 70 or over receiving adjuvant chemotherapy for early breast cancer. <i>Journal of Geriatric Oncology</i> , 2012, 3, S43. | 0.5 | 0 |
| 2610 | Structure-function relationship of estrogen receptors in cardiovascular pathophysiological models. <i>Thrombosis Research</i> , 2012, 130, S7-S11. | 0.8 | 13 |
| 2611 | Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, e58-e69. | 2.0 | 10 |
| 2612 | Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. <i>Value in Health Regional Issues</i> , 2012, 1, 46-53. | 0.5 | 9 |
| 2613 | The Roles of the Learned Societies in Improving Quality of Life in the context of Globalisation. <i>Annals of Medicine and Surgery</i> , 2012, 1, 16-18. | 0.5 | 0 |
| 2614 | Making Sense of Clinical Trial Data: Is Inverse Probability of Censoring Weighted Analysis the Answer to Crossover Bias?. <i>Journal of Clinical Oncology</i> , 2012, 30, 453-458. | 0.8 | 26 |
| 2615 | Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 533-538. | 0.8 | 214 |
| 2616 | Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients. <i>Climacteric</i> , 2012, 15, 473-480. | 1.1 | 17 |
| 2617 | Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL™ CALGB 150007/150012, ACRIN 6657. <i>Journal of Clinical Oncology</i> , 2012, 30, 3242-3249. | 0.8 | 379 |
| 2618 | Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. <i>Journal of Medical Economics</i> , 2012, 15, 1167-1175. | 1.0 | 13 |
| 2619 | FOXA1: a transcription factor with parallel functions in development and cancer. <i>Bioscience Reports</i> , 2012, 32, 113-130. | 1.1 | 163 |
| 2620 | Plasma surface modification of electrospun fibers for adhesion-based cancer cell sorting. <i>Integrative Biology (United Kingdom)</i> , 2012, 4, 1112. | 0.6 | 15 |
| 2621 | Post mastectomy radiotherapy in one to three lymph node positive breast cancer. <i>Acta Oncologica</i> , 2012, 51, 547-550. | 0.8 | 2 |
| 2622 | Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer. <i>Pharmacoeconomics</i> , 2012, 30, 103-118. | 1.7 | 9 |
| 2623 | Outcomes after Total Skin-sparing Mastectomy and Immediate Reconstruction in 657 Breasts. <i>Annals of Surgical Oncology</i> , 2012, 19, 3402-3409. | 0.7 | 167 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2624 | Axillary Node Staging for Microinvasive Breast Cancer: Is It Justified?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3416-3421. | 0.7 | 42 |
| 2625 | Efficacy of Adjuvant Chemotherapy after Surgery when Considered over all Cancer Types: A Synthesis of Meta-Analyses. <i>Annals of Surgical Oncology</i> , 2012, 19, 3343-3350. | 0.7 | 10 |
| 2626 | The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ER α , and is an independent prognostic factor in node-negative breast cancer. <i>Oncogene</i> , 2012, 31, 3483-3494. | 2.6 | 10 |
| 2627 | Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S17-S22. | 1.5 | 9 |
| 2628 | Chemoprevention of Breast Cancer. <i>Women's Health</i> , 2012, 8, 635-646. | 0.7 | 6 |
| 2629 | Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. <i>Genome Research</i> , 2012, 22, 220-231. | 2.4 | 165 |
| 2630 | Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 603-609. | 1.1 | 132 |
| 2631 | Does the Rapid Acceptance of ACOSOG Z0011 Compromise Selection of Systemic Therapy?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3643-3645. | 0.7 | 6 |
| 2633 | Surgical Margins in Lumpectomy for Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 1269-1270. | 13.9 | 4 |
| 2634 | Tamoxifen downregulation of miR-451 increases 14-3-3 σ and promotes breast cancer cell survival and endocrine resistance. <i>Oncogene</i> , 2012, 31, 39-47. | 2.6 | 167 |
| 2636 | Estrogen-independent effects of ER α 36 in ER-negative breast cancer. <i>Steroids</i> , 2012, 77, 666-673. | 0.8 | 36 |
| 2637 | Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: A population-based experience. <i>Thrombosis Research</i> , 2012, 130, 27-31. | 0.8 | 44 |
| 2638 | Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2218-2226. | 0.8 | 114 |
| 2639 | Dose-Dense Chemotherapy for Breast Cancer. <i>Breast Journal</i> , 2012, 18, 261-266. | 0.4 | 12 |
| 2640 | The Breast Cancer Quality of Care Study (BQUAL): A Multi-Center Study to Determine Causes for Noncompliance with Breast Cancer Adjuvant Therapy. <i>Breast Journal</i> , 2012, 18, 203-213. | 0.4 | 22 |
| 2641 | Challenges translating breast cancer gene signatures into the clinic. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 58-64. | 12.5 | 108 |
| 2642 | The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 259-263. | 1.4 | 26 |
| 2643 | Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1068-1079. | 3.0 | 76 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2644 | Genetics for the General Internist. American Journal of Medicine, 2012, 125, 7-13. | 0.6 | 6 |
| 2645 | Differentially Expressed Genes in Wound Trials are Influenced by the Wound-Healing Process: Lessons Learned from a Pilot Study with Anastrozole. Journal of Surgical Research, 2012, 176, 121-132. | 0.8 | 13 |
| 2646 | Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer. Human Pathology, 2012, 43, 865-873. | 1.1 | 11 |
| 2647 | Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology, 2012, 128, 69-75. | 1.2 | 15 |
| 2648 | FOXM1: From cancer initiation to progression and treatment. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2012, 1819, 28-37. | 0.9 | 350 |
| 2649 | Preserved learning and memory in mice following chemotherapy: 5-Fluorouracil and doxorubicin single agent treatment, doxorubicin+cyclophosphamide combination treatment. Behavioural Brain Research, 2012, 226, 154-162. | 1.2 | 32 |
| 2650 | The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiology, 2012, 36, 237-248. | 0.8 | 557 |
| 2651 | Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. Cancer Treatment Reviews, 2012, 38, 318-328. | 3.4 | 77 |
| 2652 | Chemoprevention for breast cancer. Cancer Treatment Reviews, 2012, 38, 329-339. | 3.4 | 26 |
| 2653 | Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treatment Reviews, 2012, 38, 442-450. | 3.4 | 28 |
| 2654 | Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed?. European Journal of Cancer, 2012, 48, 1939-1946. | 1.3 | 87 |
| 2655 | Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11years using propensity score matching. European Journal of Cancer, 2012, 48, 2300-2310. | 1.3 | 4 |
| 2656 | Tumor characteristics and recurrence patterns in triple negative breast cancer: A comparison between younger (<65) and elderly (≥65) patients. European Journal of Cancer, 2012, 48, 2962-2968. | 1.3 | 25 |
| 2657 | Timing of fertility preservation procedures in a cohort of female patients with cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 160, 170-173. | 0.5 | 8 |
| 2658 | Sentinel lymph node biopsy after previous axillary surgery: A review. European Journal of Surgical Oncology, 2012, 38, 8-15. | 0.5 | 40 |
| 2659 | High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. European Journal of Surgical Oncology, 2012, 38, 110-117. | 0.5 | 47 |
| 2660 | The prognostic value of tumour-stroma ratio in triple-negative breast cancer. European Journal of Surgical Oncology, 2012, 38, 307-313. | 0.5 | 109 |
| 2661 | Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction. Journal of Clinical Oncology, 2012, 30, 3734-3745. | 0.8 | 263 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2662 | Effectiveness of radiation for prevention of mastectomy in older breast cancer patients treated with conservative surgery. <i>Cancer</i> , 2012, 118, 4642-4651. | 2.0 | 34 |
| 2663 | Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. <i>Cancer</i> , 2012, 118, 5937-5946. | 2.0 | 174 |
| 2664 | A Woman with Breast Cancer and Severe Impaired Lactose Tolerance: An Intriguing Therapeutic Dilemma. <i>Breast Journal</i> , 2012, 18, 628-629. | 0.4 | 2 |
| 2665 | Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue – a GC-TOFMS based metabolomics study. <i>BMC Genomics</i> , 2012, 13, 334. | 1.2 | 123 |
| 2666 | Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis. <i>BMC Cancer</i> , 2012, 12, 106. | 1.1 | 25 |
| 2667 | Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. <i>BMC Cancer</i> , 2012, 12, 110. | 1.1 | 41 |
| 2668 | Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. <i>BMC Cancer</i> , 2012, 12, 247. | 1.1 | 12 |
| 2669 | Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer. <i>BMC Cancer</i> , 2012, 12, 447. | 1.1 | 30 |
| 2670 | Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. <i>BMC Cancer</i> , 2012, 12, 458. | 1.1 | 62 |
| 2671 | Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment. <i>BMC Cancer</i> , 2012, 12, 472. | 1.1 | 17 |
| 2672 | The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors. <i>BMC Cancer</i> , 2012, 12, 525. | 1.1 | 32 |
| 2673 | Accuracy validation of adjuvant! online in Taiwanese breast cancer patients - a 10-year analysis. <i>BMC Medical Informatics and Decision Making</i> , 2012, 12, 108. | 1.5 | 19 |
| 2674 | Temporal trends in the surgical outcomes of patients with breast cancer. <i>World Journal of Surgical Oncology</i> , 2012, 10, 108. | 0.8 | 2 |
| 2675 | How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study. <i>Implementation Science</i> , 2012, 7, 102. | 2.5 | 2 |
| 2676 | An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. <i>BMC Medical Genomics</i> , 2012, 5, 54. | 0.7 | 14 |
| 2677 | Therapeutic Drug Monitoring of Selected Anticancer Drugs. , 2012, , 291-321. | | 1 |
| 2678 | Granulosa cell tumor of the ovary after long-term use of tamoxifen and toremifene. <i>Journal of Obstetrics and Gynaecology Research</i> , 2012, 38, 1379-1384. | 0.6 | 3 |
| 2679 | STAT3 mediates resistance of CD44+CD24-low breast cancer stem cells to tamoxifen in vitro. <i>Journal of Biomedical Research</i> , 2012, 26, 325-335. | 0.7 | 51 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2680 | A Mechanistic Study of the Effect of Doxorubicin/Adriamycin on the Estrogen Response in a Breast Cancer Model. <i>Oncology</i> , 2012, 83, 305-320. | 0.9 | 19 |
| 2681 | Fresh Surgical Specimens Yield Breast Stem/Progenitor Cells and Reveal Their Oncogenic Abnormalities. <i>Annals of Surgical Oncology</i> , 2012, 19, 527-535. | 0.7 | 12 |
| 2682 | Effects of CYP Induction by Rifampicin on Tamoxifen Exposure. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 62-67. | 2.3 | 34 |
| 2683 | Cutaneous Radiation-Associated Angiosarcoma of the Breast: Poor Prognosis in a Rare Secondary Malignancy. <i>Annals of Surgical Oncology</i> , 2012, 19, 3801-3808. | 0.7 | 76 |
| 2684 | Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation. <i>Molecular Medicine Reports</i> , 2012, 5, 1453-6. | 1.1 | 121 |
| 2685 | An Overview of the Current Development of Phytotherapies for Breast Cancer. <i>Evidence-based Anticancer Complementary and Alternative Medicine</i> , 2012, , 47-67. | 0.1 | 3 |
| 2686 | Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. <i>Breast</i> , 2012, 21, 769-778. | 0.9 | 19 |
| 2687 | A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. <i>Breast</i> , 2012, 21, 621-628. | 0.9 | 5 |
| 2688 | Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 252-260. | 2.0 | 36 |
| 2689 | Nonsurgical Adjunctive Treatment and Its Effects on the Axilla. <i>Current Problems in Cancer</i> , 2012, 36, 305-324. | 1.0 | 0 |
| 2690 | Long-term Adherence to Hormone Therapy in Medicaid-enrolled Women with Breast Cancer. <i>Health Outcomes Research in Medicine</i> , 2012, 3, e195-e203. | 0.6 | 3 |
| 2692 | Oncology Scan " February 1, 2012. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 505-507. | 0.4 | 4 |
| 2693 | Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. <i>Toxicology and Applied Pharmacology</i> , 2012, 264, 42-50. | 1.3 | 18 |
| 2694 | Issues in the Curative Therapy of Breast Cancer in Elderly Women. <i>Seminars in Radiation Oncology</i> , 2012, 22, 295-303. | 1.0 | 5 |
| 2695 | Fertility after breast cancer. <i>Maturitas</i> , 2012, 73, 191-196. | 1.0 | 38 |
| 2696 | Limites de la scintigraphie osseuse dans le suivi des métastases osseuses du carcinome mammaire: Étude du centre tunisien. <i>Medecine Nucleaire</i> , 2012, 36, 574-581. | 0.2 | 1 |
| 2697 | Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. <i>Molecular Oncology</i> , 2012, 6, 222-236. | 2.1 | 63 |
| 2701 | Toremifene versus tamoxifen for advanced breast cancer. <i>The Cochrane Library</i> , 2012, , CD008926. | 1.5 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2702 | Early Patient Stratification and Predictive Biomarkers in Drug Discovery and Development. <i>Advances in Experimental Medicine and Biology</i> , 2012, 736, 645-653. | 0.8 | 20 |
| 2703 | Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 529-541. | 12.5 | 63 |
| 2704 | Microvessel Density and Status of p53 Protein as Potential Prognostic Factors for Adjuvant Anthracycline Chemotherapy in Retrospective Analysis of Early Breast Cancer Patients Group. <i>Pathology and Oncology Research</i> , 2012, 18, 949-960. | 0.9 | 18 |
| 2705 | Early Breast Cancer in the Older Woman. <i>Clinics in Geriatric Medicine</i> , 2012, 28, 73-91. | 1.0 | 23 |
| 2706 | Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. <i>Nature</i> , 2012, 481, 389-393. | 13.7 | 1,655 |
| 2707 | Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. <i>Journal of Clinical Oncology</i> , 2012, 30, 4017-4025. | 0.8 | 172 |
| 2708 | “Axillary recurrences after sentinel lymph node biopsy: A multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients” <i>European Journal of Surgical Oncology</i> , 2012, 38, 925-931. | 0.5 | 25 |
| 2711 | Amphetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. <i>European Child and Adolescent Psychiatry</i> , 2012, 21, 477-492. | 2.8 | 114 |
| 2712 | Breast Cancer in South East Asia: Comparison of Presentation and Outcome Between a Middle Income and a High Income Country. <i>World Journal of Surgery</i> , 2012, 36, 2838-2846. | 0.8 | 30 |
| 2713 | Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 331-338. | 1.1 | 50 |
| 2714 | High-Risk Estrogen-Receptor-Positive Breast Cancer. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 235-240. | 1.6 | 4 |
| 2715 | Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2504-2512. | 1.2 | 292 |
| 2716 | The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. <i>Modern Pathology</i> , 2012, 25, 1098-1105. | 2.9 | 132 |
| 2717 | Research Highlights: Highlights from the latest articles in methotrexate- and tamoxifen-related pharmacogenomics. <i>Pharmacogenomics</i> , 2012, 13, 993-995. | 0.6 | 3 |
| 2718 | Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries. <i>Breast Cancer Research</i> , 2012, 14, R91. | 2.2 | 69 |
| 2719 | CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R48. | 2.2 | 376 |
| 2720 | Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer. <i>Tumor Biology</i> , 2012, 33, 2371-2377. | 0.8 | 25 |
| 2721 | Dormancy Signatures and Metastasis in Estrogen Receptor Positive and Negative Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e35569. | 1.1 | 168 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2722 | Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast Cancers. PLoS ONE, 2012, 7, e38575. | 1.1 | 33 |
| 2723 | Progranulin as a Prognostic Biomarker for Breast Cancer Recurrence in Patients Who Had Hormone Receptor-Positive Tumors: A Cohort Study. PLoS ONE, 2012, 7, e39880. | 1.1 | 44 |
| 2724 | Differential Gene Expression in Tamoxifen-Resistant Breast Cancer Cells Revealed by a New Analytical Model of RNA-Seq Data. PLoS ONE, 2012, 7, e41333. | 1.1 | 53 |
| 2725 | Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer—A Population-Based Cohort Study. PLoS ONE, 2012, 7, e46535. | 1.1 | 16 |
| 2726 | Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer. Bulletin Du Cancer, 2012, 99, E75-E80. | 0.6 | 5 |
| 2727 | Do the benefits of screening mammography outweigh the harms of overdiagnosis and unnecessary treatment?. Medical Journal of Australia, 2012, 196, 17-17. | 0.8 | 10 |
| 2728 | Personalized Medicine in Breast Cancer: A Systematic Review. Journal of Breast Cancer, 2012, 15, 265. | 0.8 | 75 |
| 2729 | Circulating Tumor Cells Detected by RT-PCR for CK-20 before Surgery Indicate Worse Prognostic Impact in Triple-Negative and HER2 Subtype Breast Cancer. Journal of Breast Cancer, 2012, 15, 34. | 0.8 | 20 |
| 2730 | Promise and failure of targeted therapy in breast cancer. Frontiers in Bioscience - Scholar, 2012, S4, 356. | 0.8 | 2 |
| 2732 | Extended Adjuvant Temozolomide with cis-Retinoic Acid for Adult Glioblastoma. Current Oncology, 2012, 19, 308-314. | 0.9 | 9 |
| 2733 | Breast Cancer Guide - Encouraging Self-Study Among Patients of Non-Medical Scientific Professionals, Do it Yourself. SSRN Electronic Journal, 2012, , . | 0.4 | 0 |
| 2734 | Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid. International Journal of Women's Health, 2012, 4, 569. | 1.1 | 7 |
| 2735 | Promise and failure of targeted therapy in breast cancer. Frontiers in Bioscience - Scholar, 2012, S4, 356-374. | 0.8 | 6 |
| 2736 | Response to Neoadjuvant Chemotherapy in the Breast Predicts Axillary Nodal Status. American Surgeon, 2012, 78, 693-697. | 0.4 | 4 |
| 2737 | Sequential Docetaxel as Adjuvant Chemotherapy for Node-Positive or/and T3 Or T4 Breast Cancer: Clinical Outcome (Mansoura University). Annals of Oncology, 2012, 23, ix129. | 0.6 | 0 |
| 2738 | Magnetic resonance imaging of the breast: A clinical perspective. South African Journal of Radiology, 2012, 16, 61-64. | 0.1 | 0 |
| 2739 | Adjuvant Therapy for Older Women with Early-Stage Breast Cancer: Treatment Selection in a Complex Population. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 3-9. | 1.8 | 6 |
| 2740 | Breast Cancer and Benign Breast Disorders. , 2012, , 1309-1317. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2741 | Novel and Targeted Therapies. , 2012, , 95-101. | | 0 |
| 2743 | Tamoxifen Resistance in Breast Cancer. <i>Biomolecules and Therapeutics</i> , 2012, 20, 256-267. | 1.1 | 213 |
| 2744 | Adjuvant Chemotherapy and Survival of Elderly Korean Patients with Breast Carcinoma. <i>Journal of Breast Cancer</i> , 2012, 15, 296. | 0.8 | 1 |
| 2745 | Adjuvant Therapy for Elderly Patients with Breast, Colon, and Lung Cancer. , 2012, , 79-88. | | 1 |
| 2748 | Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2012, 15, 288. | 0.8 | 44 |
| 2749 | Breast cancer and depression: issues in clinical care. <i>Medical Journal of Indonesia</i> , 0, , 240. | 0.2 | 0 |
| 2750 | HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. <i>Journal of Translational Medicine</i> , 2012, 10, 10. | 1.8 | 46 |
| 2751 | A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. <i>Human Molecular Genetics</i> , 2012, 21, 1665-1672. | 1.4 | 54 |
| 2752 | The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1. <i>AAPS Journal</i> , 2012, 14, 52-59. | 2.2 | 58 |
| 2753 | Strategies for the discovery and development of therapies for metastatic breast cancer. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 479-497. | 21.5 | 310 |
| 2754 | Artichoke polyphenols induce apoptosis and decrease the invasive potential of the human breast cancer cell line MDA-MB231. <i>Journal of Cellular Physiology</i> , 2012, 227, 3301-3309. | 2.0 | 72 |
| 2755 | The positive non-sentinel status is not the main decisional factor for chemotherapy assignment in breast cancer with micrometastatic disease in the sentinel lymph node. <i>Journal of Surgical Oncology</i> , 2012, 106, 703-707. | 0.8 | 12 |
| 2756 | Progress against cancer in the Netherlands since the late 1980s: An epidemiological evaluation. <i>International Journal of Cancer</i> , 2012, 130, 2981-2989. | 2.3 | 37 |
| 2757 | Validation of an immunohistochemical signature predictive of 8-year outcome for patients with breast carcinoma. <i>International Journal of Cancer</i> , 2012, 131, E236-43. | 2.3 | 20 |
| 2758 | Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. <i>Annals of Oncology</i> , 2012, 23, 3069-3074. | 0.6 | 158 |
| 2759 | Annual screening strategies in <i>BRCA1</i> and <i>BRCA2</i> gene mutation carriers. <i>Cancer</i> , 2012, 118, 2021-2030. | 2.0 | 104 |
| 2760 | Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection. <i>Cancer</i> , 2012, 118, 1994-2003. | 2.0 | 25 |
| 2761 | Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline and nonanthracycline-based regimens for HER2-positive breast cancer. <i>Cancer</i> , 2012, 118, 2385-2393. | 2.0 | 54 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2762 | Clinical trial results of the HER2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients. <i>Cancer</i> , 2012, 118, 2594-2602. | 2.0 | 157 |
| 2763 | An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer. <i>Cancer</i> , 2012, 118, 4098-4104. | 2.0 | 33 |
| 2764 | HER2 pulsed dendritic cell vaccine can eliminate HER2 expression and impact ductal carcinoma in situ. <i>Cancer</i> , 2012, 118, 4354-4362. | 2.0 | 133 |
| 2765 | Cost effectiveness of gene expression profiling for early stage breast cancer. <i>Cancer</i> , 2012, 118, 5163-5170. | 2.0 | 64 |
| 2766 | Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women. <i>Cancer</i> , 2012, 118, 4394-4403. | 2.0 | 13 |
| 2767 | Immunohistochemical Detection of Breast Cancer Stem Cells in Hormone Receptor-Positive Breast Cancer and Their Role in Response to Endocrine Therapy and Clinical Outcome. <i>Oncology</i> , 2012, 82, 168-174. | 0.9 | 16 |
| 2768 | CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells. <i>Cancer Research</i> , 2012, 72, 3839-3850. | 0.4 | 240 |
| 2769 | Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). <i>Breast Cancer Research and Treatment</i> , 2012, 134, 419-428. | 1.1 | 54 |
| 2770 | Long-term survival of older breast cancer patients: population-based estimates over three decades. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 853-857. | 1.1 | 15 |
| 2771 | Association of CTLA-4 gene polymorphisms with sporadic breast cancer risk and clinical features in Han women of Northeast China. <i>Molecular and Cellular Biochemistry</i> , 2012, 364, 283-290. | 1.4 | 35 |
| 2772 | Patients With Metastatic Breast Cancer Using Bevacizumab as a Treatment: Is There Still a Role for it?. <i>Current Treatment Options in Oncology</i> , 2012, 13, 249-262. | 1.3 | 13 |
| 2773 | Breast Cancer and Fertility. <i>Current Treatment Options in Oncology</i> , 2012, 13, 137-145. | 1.3 | 24 |
| 2774 | Patients With Positive Axillary Lymph Nodes: How to Use Genomic Assays. <i>Current Treatment Options in Oncology</i> , 2012, 13, 240-248. | 1.3 | 0 |
| 2775 | Prediction of Anthracycline Cardiotoxicity after Chemotherapy by Biomarkers Kinetic Analysis. <i>Cardiovascular Toxicology</i> , 2012, 12, 135-142. | 1.1 | 31 |
| 2776 | ER ⁺ /ER ⁺ breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection. <i>Medical Oncology</i> , 2012, 29, 495-502. | 1.2 | 9 |
| 2777 | Killer cell immunoglobulin-like receptor genes in patients with breast cancer. <i>Medical Oncology</i> , 2012, 29, 511-515. | 1.2 | 25 |
| 2778 | Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 109-115. | 1.2 | 12 |
| 2779 | Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?. <i>Clinical and Translational Oncology</i> , 2012, 14, 163-168. | 1.2 | 22 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2780 | Evolving strategies to overcome endocrine resistance in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 105-109. | 0.3 | 0 |
| 2781 | Oophorectomy in Breast Cancer—Controversies and Current Status. <i>Indian Journal of Surgery</i> , 2012, 74, 210-212. | 0.2 | 4 |
| 2782 | Future treatment strategies for metastatic breast cancer: curable or incurable?. <i>Breast Cancer</i> , 2012, 19, 200-205. | 1.3 | 26 |
| 2783 | Breast Cancer Local Therapy: What Is Its Effect on Mortality?. <i>World Journal of Surgery</i> , 2012, 36, 1460-1474. | 0.8 | 8 |
| 2784 | Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 923-930. | 1.1 | 14 |
| 2785 | Psychotropic medication during endocrine treatment for breast cancer. <i>Supportive Care in Cancer</i> , 2012, 20, 1533-1540. | 1.0 | 23 |
| 2786 | Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?. <i>Wiener Medizinische Wochenschrift</i> , 2012, 162, 252-261. | 0.5 | 6 |
| 2787 | Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor–positive early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 49-59. | 1.1 | 80 |
| 2788 | The role of antiestrogenic therapies in improving patient care in early and metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 355-363. | 1.1 | 7 |
| 2789 | Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 895-915. | 1.1 | 246 |
| 2790 | Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 831-841. | 1.1 | 333 |
| 2791 | Clinical and biomarker predictors of side effects from tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1107-1118. | 1.1 | 109 |
| 2792 | Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1049-1062. | 1.1 | 286 |
| 2793 | GPER mediates the Egr-1 expression induced by 17 β -estradiol and 4-hydroxytamoxifen in breast and endometrial cancer cells. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1025-1035. | 1.1 | 84 |
| 2794 | Black–white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 285-296. | 1.1 | 32 |
| 2795 | Primary and secondary angiosarcomas of the breast: a single institution experience. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1081-1088. | 1.1 | 47 |
| 2796 | Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 311-320. | 1.1 | 33 |
| 2797 | Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 367-373. | 1.1 | 102 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2798 | Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 759-768. | 1.1 | 23 |
| 2799 | Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1115-1123. | 1.1 | 56 |
| 2800 | Achieving Optimal Dose Intensity with Adjuvant Chemotherapy in Elderly Breast Cancer Patients: A 10-Year Retrospective Study in a UK Institution. <i>Breast Journal</i> , 2012, 18, 16-22. | 0.4 | 10 |
| 2801 | Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. <i>European Journal of Cancer Care</i> , 2012, 21, 10-19. | 0.7 | 69 |
| 2802 | A Case of Late Breast Cancer Metastases to Both Suprarenal Glands 28 Years After Mastectomy. <i>Clinical Breast Cancer</i> , 2012, 12, 68-70. | 1.1 | 0 |
| 2803 | A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 102-109. | 1.1 | 6 |
| 2804 | Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 151-156. | 1.1 | 7 |
| 2805 | Comorbidity and survival after early breast cancer. A review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 196-205. | 2.0 | 91 |
| 2806 | Genomic analysis: Toward a new approach in breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 207-223. | 2.0 | 21 |
| 2807 | Adjuvant early breast cancer systemic therapies according to daily used technologies. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 361-369. | 2.0 | 11 |
| 2808 | Synthesis of new troglitazone derivatives: Anti-proliferative activity in breast cancer cell lines and preliminary toxicological study. <i>European Journal of Medicinal Chemistry</i> , 2012, 51, 206-215. | 2.6 | 55 |
| 2809 | Taxane resistance in breast cancer: A closed HER2 circuit?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 197-206. | 3.3 | 22 |
| 2810 | Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. <i>Breast</i> , 2012, 21, 272-275. | 0.9 | 21 |
| 2811 | The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: The relationship between the outcome and the clinicopathological characteristics. <i>Breast</i> , 2012, 21, 289-295. | 0.9 | 94 |
| 2812 | Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. <i>Breast</i> , 2012, 21, 142-149. | 0.9 | 151 |
| 2813 | A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy. <i>Breast</i> , 2012, 21, 562-569. | 0.9 | 8 |
| 2814 | Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. <i>Breast</i> , 2012, 21, 507-513. | 0.9 | 36 |
| 2815 | Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: A systematic review with meta-analysis. <i>Breast</i> , 2012, 21, 343-349. | 0.9 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2816 | A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50 747 Breast, 2012, 21, 570-577. | 0.9 | 14 |
| 2817 | Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. Breast, 2012, 21, 366-373. | 0.9 | 42 |
| 2818 | Axillary and systemic treatment of patients with breast cancer and micrometastatic disease or isolated tumor cells in the sentinel lymph node. Breast, 2012, 21, 524-528. | 0.9 | 7 |
| 2819 | Metastatic breast cancer: We do need primary cost data. Breast, 2012, 21, 384-388. | 0.9 | 22 |
| 2820 | Life-threatening Disparities: The Treatment of Black and White Cancer Patients. Journal of Social Issues, 2012, 68, 328-357. | 1.9 | 45 |
| 2821 | Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 62-70. | 0.7 | 2 |
| 2823 | Predictive Factors for Local Recurrence in Breast Cancer. Seminars in Radiation Oncology, 2012, 22, 100-107. | 1.0 | 57 |
| 2825 | Adjuvant therapy. Medicine, 2012, 40, 1-4. | 0.2 | 0 |
| 2826 | Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecologic Oncology, 2012, 125, 661-666. | 0.6 | 166 |
| 2827 | Correlation of type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Science, 2012, 103, 382-389. | 1.7 | 152 |
| 2828 | Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Science, 2012, 103, 1679-1687. | 1.7 | 48 |
| 2829 | Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretations and positive attitudes. European Journal of Cancer Care, 2012, 21, 242-250. | 0.7 | 29 |
| 2830 | Using a bubble chart to enhance adherence to quality-of-care guidelines for colorectal cancer patients. European Journal of Cancer Care, 2012, 21, 712-721. | 0.7 | 7 |
| 2831 | NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer, 2012, 12, 24. | 1.1 | 100 |
| 2832 | The co-presence of deletion 7q, 20q and inversion 16 in therapy-related acute myeloid leukemia developed secondary to treatment of breast cancer with cyclophosphamide, doxorubicin, and radiotherapy: a case report. Journal of Medical Case Reports, 2012, 6, 67. | 0.4 | 5 |
| 2833 | Reconstruction of nuclear receptor network reveals that <i>NR2E3</i> is a novel upstream regulator of <i>ESR1</i> in breast cancer. EMBO Molecular Medicine, 2012, 4, 52-67. | 3.3 | 42 |
| 2834 | The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer, 2012, 118, 899-907. | 2.0 | 83 |
| 2835 | Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer, 2012, 118, 1221-1227. | 2.0 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2836 | Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. <i>Cancer</i> , 2012, 118, 1498-1506. | 2.0 | 69 |
| 2837 | Tumour Topoisomerase II Alpha Protein Expression and Outcome After Adjuvant Dose-Dense Anthracycline-Based Chemotherapy. <i>Pathology and Oncology Research</i> , 2012, 18, 61-68. | 0.9 | 9 |
| 2838 | Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study. <i>Breast Cancer</i> , 2012, 19, 16-22. | 1.3 | 4 |
| 2839 | Non-haematopoietic toxicity of anthracyclines is more favourable than that of taxanes: experience from Nairobi. <i>Journal African Du Cancer</i> , 2012, 4, 3-8. | 0.1 | 1 |
| 2840 | Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 223-245. | 2.4 | 59 |
| 2841 | A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 35-42. | 1.1 | 29 |
| 2842 | Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 533-546. | 1.1 | 22 |
| 2843 | Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 809-818. | 1.1 | 25 |
| 2844 | Neoadjuvant chemotherapy in ER+ HER2 ⁺ breast cancer: response prediction based on immunohistochemical and molecular characteristics. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 827-836. | 1.1 | 71 |
| 2845 | Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 607-617. | 1.1 | 69 |
| 2846 | Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 137-145. | 1.1 | 86 |
| 2847 | Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 949-955. | 1.1 | 52 |
| 2848 | Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 483-490. | 1.1 | 63 |
| 2849 | Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 1021-1027. | 1.1 | 14 |
| 2850 | TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 225-234. | 1.1 | 11 |
| 2851 | Factors associated with mortality after breast cancer metastasis. <i>Cancer Causes and Control</i> , 2012, 23, 103-112. | 0.8 | 104 |
| 2852 | Why mammography screening has not lived up to expectations from the randomised trials. <i>Cancer Causes and Control</i> , 2012, 23, 15-21. | 0.8 | 60 |
| 2853 | Pure mucinous carcinoma of the breast: clinicopathologic characteristics and long-term outcome among Taiwanese women. <i>World Journal of Surgical Oncology</i> , 2013, 11, 139. | 0.8 | 21 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 2854 | Impact of chemotherapy-induced amenorrhea in breast cancer patients: the evaluation of ovarian function by menstrual history and hormonal levels. <i>World Journal of Surgical Oncology</i> , 2013, 11, 101. | 0.8 | 19 |
| 2855 | Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?. <i>EPMA Journal</i> , 2013, 4, 6. | 3.3 | 36 |
| 2856 | Exposures to Synthetic Estrogens at Different Times During the Life, and Their Effect on Breast Cancer Risk. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2013, 18, 25-42. | 1.0 | 60 |
| 2857 | The shifting landscape of metastatic breast cancer to the CNS. <i>Neurosurgical Review</i> , 2013, 36, 377-382. | 1.2 | 42 |
| 2858 | Chemotherapy dosing in overweight and obese patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 451-459. | 12.5 | 79 |
| 2859 | Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study. <i>Cancer Causes and Control</i> , 2013, 24, 1605-1614. | 0.8 | 6 |
| 2860 | Sequencing of chemotherapy and radiotherapy for early breast cancer. <i>The Cochrane Library</i> , 2013, , CD005212. | 1.5 | 34 |
| 2861 | Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation Treatment. <i>Clinical Breast Cancer</i> , 2013, 13, 88-94. | 1.1 | 137 |
| 2862 | The Emerging Role of the Molecular Diagnostics Laboratory in Breast Cancer Personalized Medicine. <i>American Journal of Pathology</i> , 2013, 183, 1075-1083. | 1.9 | 37 |
| 2863 | Physical activity during and after adjuvant chemotherapy in patients with breast cancer. <i>Physiotherapy</i> , 2013, 99, 221-227. | 0.2 | 20 |
| 2864 | The Future of Chemotherapy in the Era of Personalized Medicine. <i>Current Breast Cancer Reports</i> , 2013, 5, 57-68. | 0.5 | 2 |
| 2865 | The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. <i>BMC Cancer</i> , 2013, 13, 174. | 1.1 | 100 |
| 2866 | Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. <i>BMC Cancer</i> , 2013, 13, 163. | 1.1 | 27 |
| 2867 | Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. <i>FEBS Journal</i> , 2013, 280, 5237-5257. | 2.2 | 36 |
| 2868 | Clearing the Air: A Review of Our Current Understanding of "Chemo Fog". <i>Current Oncology Reports</i> , 2013, 15, 260-269. | 1.8 | 70 |
| 2869 | Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 915-923. | 1.2 | 4 |
| 2870 | Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 837-843. | 1.2 | 8 |
| 2872 | Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Controversies and Current Indications for Use. <i>Current Treatment Options in Oncology</i> , 2013, 14, 51-65. | 1.3 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2873 | Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis. <i>Breast Cancer</i> , 2013, 20, 111-122. | 1.3 | 14 |
| 2874 | CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 649-655. | 1.1 | 21 |
| 2875 | A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 863-872. | 1.1 | 39 |
| 2876 | Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 923-929. | 1.1 | 56 |
| 2877 | Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 63-71. | 1.1 | 85 |
| 2878 | Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool. <i>Annals of Surgical Oncology</i> , 2013, 20, 2615-2624. | 0.7 | 18 |
| 2879 | Hormone Receptor-Negative Breast Cancer: Undertreatment of Patients Over 80. <i>Annals of Surgical Oncology</i> , 2013, 20, 3274-3278. | 0.7 | 29 |
| 2880 | A miniaturized flow-through cell to evaluate skin permeation of endoxifen. <i>International Journal of Pharmaceutics</i> , 2013, 441, 433-440. | 2.6 | 17 |
| 2881 | Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. <i>European Journal of Cancer</i> , 2013, 49, 3431-3441. | 1.3 | 123 |
| 2882 | The role of antioxidants in the era of cardio-oncology. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1157-1168. | 1.1 | 57 |
| 2883 | How can we improve survival from breast cancer in developing countries?. <i>Breast Cancer Management</i> , 2013, 2, 179-183. | 0.2 | 10 |
| 2884 | Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 565-575. | 1.1 | 32 |
| 2885 | CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 287-303. | 1.1 | 25 |
| 2886 | Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 103-113. | 1.1 | 9 |
| 2887 | Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 245-255. | 1.1 | 48 |
| 2888 | Breast Cancer Heterogeneity in Primary and Metastatic Disease. , 2013, , 65-95. | | 1 |
| 2889 | The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 783-794. | 1.1 | 78 |
| 2891 | Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy. <i>Cancer</i> , 2013, 119, 1140-1148. | 2.0 | 173 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2892 | Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in <i>BRCA1</i> and <i>BRCA2</i> gene mutation carriers. <i>Cancer</i> , 2013, 119, 1266-1276. | 2.0 | 73 |
| 2893 | Which strategies reduce breast cancer mortality most?. <i>Cancer</i> , 2013, 119, 2541-2548. | 2.0 | 35 |
| 2894 | A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. <i>International Journal of Cancer</i> , 2013, 133, 929-936. | 2.3 | 192 |
| 2896 | Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 101-111. | 2.0 | 46 |
| 2897 | Radiation Field Design and Patterns of Locoregional Recurrence Following Definitive Radiotherapy for Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 309-314. | 0.4 | 9 |
| 2898 | The role of the pathologist in the decision-making process. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 23-26. | 2.2 | 3 |
| 2899 | Second primary cancers after adjuvant radiotherapy in early breast cancer patients: A national population based study under the Danish Breast Cancer Cooperative Group (DBCG). <i>Radiotherapy and Oncology</i> , 2013, 106, 42-49. | 0.3 | 148 |
| 2900 | Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway. <i>Breast Care</i> , 2013, 8, 248-255. | 0.8 | 40 |
| 2901 | The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 13-22. | 1.1 | 198 |
| 2902 | Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. <i>Annals of Oncology</i> , 2013, 24, 2515-2521. | 0.6 | 36 |
| 2904 | Management of breast cancer in very young women. <i>Breast</i> , 2013, 22, S176-S179. | 0.9 | 56 |
| 2905 | AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. <i>Breast Care</i> , 2013, 8, 181-185. | 0.8 | 68 |
| 2906 | Is regional nodes radiotherapy an alternative to surgery?. <i>Breast</i> , 2013, 22, S118-S128. | 0.9 | 4 |
| 2907 | The first two lines of chemotherapy for anthracycline-naïve metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines. <i>Breast</i> , 2013, 22, 1148-1154. | 0.9 | 3 |
| 2909 | Everolimus in hormone receptor-positive advanced breast cancer: Targeting receptor-based mechanisms of resistance. <i>Breast</i> , 2013, 22, 405-410. | 0.9 | 17 |
| 2910 | Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. <i>International Journal of Cancer</i> , 2013, 133, 1470-1478. | 2.3 | 15 |
| 2911 | ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. <i>Nature Genetics</i> , 2013, 45, 1439-1445. | 9.4 | 960 |
| 2912 | SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 1011-1017. | 1.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 2913 | Prospective cost-effectiveness analysis of genomic profiling in breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 3773-3779. | 1.3 | 29 |
| 2914 | miRNA Dysregulation in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6554-6562. | 0.4 | 217 |
| 2915 | Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. <i>Lancet Oncology</i> , The, 2013, 14, 1067-1076. | 5.1 | 332 |
| 2916 | Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. <i>Breast</i> , 2013, 22, S165-S170. | 0.9 | 23 |
| 2917 | Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. <i>Annals of Oncology</i> , 2013, 24, 2324-2329. | 0.6 | 34 |
| 2918 | Adjuvant Aromatase Inhibitor Therapy in Patients with Stage I Breast Cancer at a Regional Oncology Center in Israel: Implementation of a 'Switching' Policy in Postmenopausal Patients after Initial Tamoxifen. <i>Oncology</i> , 2013, 85, 145-152. | 0.9 | 2 |
| 2919 | Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines. <i>Science Signaling</i> , 2013, 6, ra84. | 1.6 | 90 |
| 2920 | Extended adjuvant chemotherapy in endocrine non-responsive disease. <i>Breast</i> , 2013, 22, S161-S164. | 0.9 | 4 |
| 2921 | Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis. <i>Breast</i> , 2013, 22, 879-886. | 0.9 | 34 |
| 2922 | Prognostische und prädiaktive Faktoren. , 2013, , 183-201. | | 0 |
| 2923 | Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node-â€“Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX. <i>Journal of Clinical Oncology</i> , 2013, 31, 3083-3090. | 0.8 | 259 |
| 2924 | Three molecular classifications surrogate to four immunohistochemical markers in 374 invasive breast carcinomas with long follow-up: Which is better?. <i>Pathology Research and Practice</i> , 2013, 209, 337-344. | 1.0 | 1 |
| 2925 | A robust prognostic signature for hormone-positive node-negative breast cancer. <i>Genome Medicine</i> , 2013, 5, 92. | 3.6 | 18 |
| 2926 | Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2013, 431, 146-151. | 1.0 | 16 |
| 2927 | In vitro survival of MCF-7 breast cancer cells following combined treatment with ionizing radiation and mitoxantrone-mediated photodynamic therapy. <i>Photodiagnosis and Photodynamic Therapy</i> , 2013, 10, 72-78. | 1.3 | 30 |
| 2928 | Challenges in the Treatment of Older Breast Cancer Patients. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 785-804. | 0.9 | 13 |
| 2929 | â€“Suspect molecular signatureâ€™ in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention. <i>EPMA Journal</i> , 2013, 4, 22. | 3.3 | 9 |
| 2930 | Change of mammographic density predicts the risk of contralateral breast cancer - a case-control study. <i>Breast Cancer Research</i> , 2013, 15, R57. | 2.2 | 44 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2931 | Rates and predictors of consideration for adjuvant radiotherapy among high-risk breast cancer patients: a cohort study. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 397-405. | 1.1 | 6 |
| 2932 | Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 233-240. | 1.1 | 44 |
| 2933 | Prognosis in Women with Breast Cancer and Private Extra Insurance Coverage. <i>Annals of Surgical Oncology</i> , 2013, 20, 2822-2827. | 0.7 | 7 |
| 2934 | Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 553-560. | 1.1 | 23 |
| 2935 | Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 931-939. | 1.1 | 74 |
| 2936 | Optimal Management of Brain Metastases from Breast Cancer. <i>CNS Drugs</i> , 2013, 27, 121-134. | 2.7 | 27 |
| 2937 | Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. <i>BMC Cancer</i> , 2013, 13, 612. | 1.1 | 16 |
| 2938 | Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 559-567. | 1.1 | 42 |
| 2939 | Projections of cancer prevalence by phase of care: a potential tool for planning future health service needs. <i>Journal of Cancer Survivorship</i> , 2013, 7, 641-651. | 1.5 | 10 |
| 2940 | Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients. <i>Familial Cancer</i> , 2013, 12, 683-689. | 0.9 | 11 |
| 2941 | Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 1203-1212. | 0.8 | 9 |
| 2942 | Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 703-714. | 0.9 | 5 |
| 2943 | Endocrine Therapy for Advanced/Metastatic Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 715-736. | 0.9 | 37 |
| 2944 | Review of risk factors for the development of contralateral breast cancer. <i>American Journal of Surgery</i> , 2013, 206, 704-708. | 0.9 | 57 |
| 2945 | Biomarkers in Oncology. , 2013, , . | | 1 |
| 2946 | TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells. <i>Journal of Proteome Research</i> , 2013, 12, 4136-4151. | 1.8 | 36 |
| 2947 | Exercise Therapy as Treatment for Cardiovascular and Oncologic Disease After a Diagnosis of Early-Stage Cancer. <i>Seminars in Oncology</i> , 2013, 40, 218-228. | 0.8 | 38 |
| 2948 | Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial. <i>Breast</i> , 2013, 22, 130-137. | 0.9 | 48 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 2949 | CYP2D6 Genotype Should Not Be Used to Determine Endocrine Therapy in Postmenopausal Breast Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 183-185. | 2.3 | 13 |
| 2950 | CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients. <i>Pharmacogenomics</i> , 2013, 14, 613-622. | 0.6 | 21 |
| 2951 | Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. <i>Nature Communications</i> , 2013, 4, 2175. | 5.8 | 53 |
| 2952 | Lack of Either Estrogen or Progesterone Receptor Expression Is Associated with Poor Survival Outcome among Luminal A Breast Cancer Subtype. <i>Annals of Surgical Oncology</i> , 2013, 20, 1505-1513. | 0.7 | 31 |
| 2953 | Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR. <i>NMR in Biomedicine</i> , 2013, 26, 1705-1713. | 1.6 | 9 |
| 2954 | Too much surgery and too little benefit? Sentinel node biopsy for melanoma as it currently stands. <i>British Journal of Dermatology</i> , 2013, 169, 233-235. | 1.4 | 6 |
| 2955 | Current modalities of accelerated partial breast irradiation. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 344-356. | 12.5 | 23 |
| 2957 | The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. <i>Breast Cancer Research</i> , 2013, 15, 203. | 2.2 | 94 |
| 2958 | Effects of 17 β -ethynylestradiol-induced cholestasis on the pharmacokinetics of doxorubicin in rats: reduced biliary excretion and hepatic metabolism of doxorubicin. <i>Xenobiotica</i> , 2013, 43, 901-907. | 0.5 | 10 |
| 2959 | MiR-221/222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. <i>British Journal of Cancer</i> , 2013, 109, 2714-2723. | 2.9 | 54 |
| 2960 | Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?. <i>Annals of Oncology</i> , 2013, 24, 283-291. | 0.6 | 57 |
| 2961 | Ovarian cysts during tamoxifen use may affect the prognostic markers of premenopausal breast cancer. <i>Gynecological Endocrinology</i> , 2013, 29, 16-19. | 0.7 | 5 |
| 2962 | Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1085-1095. | 1.5 | 5 |
| 2963 | Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. <i>Tumor Biology</i> , 2013, 34, 81-90. | 0.8 | 74 |
| 2964 | Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. <i>Contemporary Clinical Trials</i> , 2013, 34, 1-9. | 0.8 | 84 |
| 2965 | Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. <i>Lancet Oncology</i> , The, 2013, 14, 72-80. | 5.1 | 192 |
| 2966 | Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet</i> , The, 2013, 381, 805-816. | 6.3 | 1,664 |
| 2967 | Derailed Estrogen Signaling and Breast Cancer: An Authentic Couple. <i>Endocrine Reviews</i> , 2013, 34, 1-32. | 8.9 | 104 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2968 | Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 247-260. | 1.1 | 37 |
| 2969 | Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 285-296. | 1.1 | 26 |
| 2970 | Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 523-531. | 1.1 | 25 |
| 2971 | Interpersonal influences and attitudes about adjuvant therapy treatment decisions among non-metastatic breast cancer patients: an examination of differences by age and race/ethnicity in the BQUAL study. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 817-828. | 1.1 | 32 |
| 2972 | Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 829-836. | 1.1 | 110 |
| 2973 | Estrogen receptor signaling as a target for novel breast cancer therapeutics. <i>Biochemical Pharmacology</i> , 2013, 85, 449-465. | 2.0 | 148 |
| 2974 | What Is the Optimal Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1391-1397. | 0.8 | 13 |
| 2975 | How relevant is hormone receptor status in the context of outcome to HER2-positive breast cancer?. <i>Breast Cancer Research</i> , 2013, 15, 101. | 2.2 | 3 |
| 2976 | Prescripción conjunta de antidepressivos y tamoxifeno: una cuestión a tener en cuenta. <i>Revista De Senología Y Patología Mamaria</i> , 2013, 26, 134-137. | 0.0 | 0 |
| 2978 | Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. <i>European Journal of Cancer</i> , 2013, 49, 3598-3608. | 1.3 | 72 |
| 2979 | Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 3404-3411. | 1.3 | 108 |
| 2980 | Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?. <i>Breast</i> , 2013, 22, 488-494. | 0.9 | 3 |
| 2981 | Biodistribution and radiation dosimetry of [18F]-5-fluorouracil. <i>Applied Radiation and Isotopes</i> , 2013, 75, 11-17. | 0.7 | 6 |
| 2982 | The continued evidence from overviews: What is the clinical utility?. <i>Breast</i> , 2013, 22, S8-S11. | 0.9 | 1 |
| 2983 | The role of adjuvant radiation treatment in older women with early breast cancer. <i>Journal of Geriatric Oncology</i> , 2013, 4, 402-412. | 0.5 | 5 |
| 2984 | Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2013, 17, 208-214. | 0.6 | 13 |
| 2985 | The evolution in management of patients with subcentimeter, node-negative, triple-negative breast cancer. <i>American Journal of Surgery</i> , 2013, 206, 888-893. | 0.9 | 3 |
| 2986 | In vivo dissection of the estrogen receptor alpha: Uncoupling of its physiological effects and medical perspectives. <i>Annales D'Endocrinologie</i> , 2013, 74, 82-89. | 0.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 2987 | Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer. <i>Breast</i> , 2013, 22, S171-S175. | 0.9 | 24 |
| 2988 | Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial. <i>European Journal of Cancer</i> , 2013, 49, 1546-1554. | 1.3 | 33 |
| 2989 | 17 β -Estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXCR1. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 314-324. | 1.2 | 36 |
| 2990 | Lessons from the dissection of the activation functions (AF-1 and AF-2) of the estrogen receptor alpha in vivo. <i>Steroids</i> , 2013, 78, 576-582. | 0.8 | 41 |
| 2991 | Role of Ki67 in predicting resistance to adjuvant tamoxifen in postmenopausal breast cancer patients. <i>Journal of the Egyptian National Cancer Institute</i> , 2013, 25, 181-191. | 0.6 | 12 |
| 2992 | Breast cancer in the elderly—Should it be treated differently?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2013, 18, 26-33. | 0.3 | 62 |
| 2993 | Disentangling breast cancer patients' perceptions and experiences with regard to endocrine therapy: Nature and relevance for non-adherence. <i>Breast</i> , 2013, 22, 661-666. | 0.9 | 27 |
| 2994 | From genome to bedside: Are we lost in translation?. <i>Breast</i> , 2013, 22, S22-S26. | 0.9 | 13 |
| 2995 | Predictors of recovery of ovarian function during aromatase inhibitor therapy. <i>Annals of Oncology</i> , 2013, 24, 2011-2016. | 0.6 | 29 |
| 2996 | S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin. <i>Cell Biology and Toxicology</i> , 2013, 29, 273-282. | 2.4 | 23 |
| 2997 | The DietCompLyf study: A prospective cohort study of breast cancer survival and phytoestrogen consumption. <i>Maturitas</i> , 2013, 75, 232-240. | 1.0 | 25 |
| 2998 | Adjuvant treatment for breast cancer. <i>Surgery</i> , 2013, 31, 37-40. | 0.1 | 1 |
| 2999 | Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study. <i>Breast Diseases</i> , 2013, 24, 82-83. | 0.0 | 0 |
| 3000 | Radiation dose and contralateral breast cancer risk associated with megavoltage cone-beam computed tomographic image verification in breast radiation therapy. <i>Practical Radiation Oncology</i> , 2013, 3, 93-100. | 1.1 | 11 |
| 3001 | Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: A meta-analysis of randomized controlled trials. <i>Breast</i> , 2013, 22, 150-157. | 0.9 | 73 |
| 3002 | Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 181-190. | 1.9 | 12 |
| 3003 | Tamoxifen Elicits Atheroprotection through Estrogen Receptor β AF-1 But Does Not Accelerate Reendothelialization. <i>American Journal of Pathology</i> , 2013, 183, 304-312. | 1.9 | 26 |
| 3004 | Long-term Follow-up of a Phase II Trial of Chemotherapy Plus Hormone Therapy for Biochemical Relapse After Definitive Local Therapy for Prostate Cancer. <i>Urology</i> , 2013, 81, 611-616. | 0.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 3005 | Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. <i>Radiotherapy and Oncology</i> , 2013, 108, 190-196. | 0.3 | 25 |
| 3006 | Breast cancer prevention: SERMs come of age. <i>Lancet, The</i> , 2013, 381, 1795-1797. | 6.3 | 6 |
| 3007 | Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 3-22. | 2.2 | 6 |
| 3008 | The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis. <i>Pathology Research and Practice</i> , 2013, 209, 555-561. | 1.0 | 22 |
| 3009 | Who should not undergo breast conservation?. <i>Breast</i> , 2013, 22, S110-S114. | 0.9 | 25 |
| 3010 | Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNase, cytokeratin-18 fragments and survivin. <i>Cancer Letters</i> , 2013, 336, 140-148. | 3.2 | 46 |
| 3011 | The course of Health Related Quality of Life in postmenopausal women with breast cancer from breast surgery and up to five years post-treatment. <i>Breast</i> , 2013, 22, 952-957. | 0.9 | 12 |
| 3012 | Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 23-32. | 2.0 | 32 |
| 3013 | Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis. <i>Breast</i> , 2013, 22, 643-649. | 0.9 | 3 |
| 3014 | Speakers' Abstracts. <i>Breast</i> , 2013, 22, S1-S19. | 0.9 | 1 |
| 3015 | Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. <i>Breast Diseases</i> , 2013, 24, 60-62. | 0.0 | 0 |
| 3016 | The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy. <i>Clinical Biochemistry</i> , 2013, 46, 1585-1589. | 0.8 | 16 |
| 3017 | Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients. <i>Medical Oncology</i> , 2013, 30, 354. | 1.2 | 6 |
| 3018 | Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). <i>Medical Oncology</i> , 2013, 30, 457. | 1.2 | 8 |
| 3019 | Worry About Cancer Progression and Low Perceived Social Support: Implications for Quality of Life Among Early-Stage Breast Cancer Patients. <i>Annals of Behavioral Medicine</i> , 2013, 45, 57-68. | 1.7 | 34 |
| 3020 | Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment. <i>Breast Cancer</i> , 2013, 20, 67-74. | 1.3 | 2 |
| 3021 | Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer. <i>Pathology International</i> , 2013, 63, 20-28. | 0.6 | 5 |
| 3022 | Translating metastasis-related biomarkers to the clinic—progress and pitfalls. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 169-179. | 12.5 | 40 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 3023 | Adjuvant Systemic Therapies in Breast Cancer. <i>Surgical Clinics of North America</i> , 2013, 93, 473-491. | 0.5 | 55 |
| 3024 | Biomarkers for the clinical management of breast cancer: International perspective. <i>International Journal of Cancer</i> , 2013, 133, 1-13. | 2.3 | 144 |
| 3025 | Chemotherapy regimens in early breast cancer: major controversies and future outlook. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 165-178. | 1.1 | 20 |
| 3026 | Using Multiple Targeted Therapies in Oncology: Considerations for Use, and Progress to Date in Breast Cancer. <i>Drugs</i> , 2013, 73, 505-515. | 4.9 | 14 |
| 3027 | Instrumentation and Its Applications in Nuclear Medicine. , 2013, , 451-494. | | 2 |
| 3028 | FOXA1 represses the molecular phenotype of basal breast cancer cells. <i>Oncogene</i> , 2013, 32, 554-563. | 2.6 | 129 |
| 3029 | Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 349-365. | 1.5 | 22 |
| 3030 | Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 289-301. | 12.5 | 207 |
| 3032 | Gene expression profiling in breast cancer: A clinical perspective. <i>Breast</i> , 2013, 22, 109-120. | 0.9 | 73 |
| 3033 | Screening for breast cancer with mammography. <i>The Cochrane Library</i> , 2013, 2013, CD001877. | 1.5 | 814 |
| 3034 | Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. <i>Nature Reviews Cancer</i> , 2013, 13, 385-396. | 12.8 | 204 |
| 3035 | Research Highlights: Highlights from the latest pharmacogenomic genome-wide association studies. <i>Pharmacogenomics</i> , 2013, 14, 357-360. | 0.6 | 0 |
| 3036 | Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. <i>Journal of Human Genetics</i> , 2013, 58, 327-333. | 1.1 | 29 |
| 3037 | The benefits and harms of breast cancer screening: an independent review. <i>British Journal of Cancer</i> , 2013, 108, 2205-2240. | 2.9 | 767 |
| 3038 | Contralateral risk-reducing mastectomy in sporadic breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, e262-e269. | 5.1 | 38 |
| 3039 | Estrogen-Mediated Mechanisms to Control the Growth and Apoptosis of Breast Cancer Cells. <i>Vitamins and Hormones</i> , 2013, 93, 1-49. | 0.7 | 13 |
| 3040 | Sex Hormone Receptors in Breast Cancer. <i>Vitamins and Hormones</i> , 2013, 93, 99-133. | 0.7 | 10 |
| 3041 | Modulation of Estrogen Receptor Alpha Activity and Expression During Breast Cancer Progression. <i>Vitamins and Hormones</i> , 2013, 93, 135-160. | 0.7 | 24 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3042 | Treatment Decisions and Medical Treatment of Cancer in Elderly Patients. , 2013, , 229-247. | | 1 |
| 3043 | Narrowing racial gaps in breast cancer chemotherapy initiation: the role of the patientâ€“provider relationship. Breast Cancer Research and Treatment, 2013, 139, 207-216. | 1.1 | 51 |
| 3044 | A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer. PLoS ONE, 2013, 8, e62614. | 1.1 | 19 |
| 3045 | Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treatment Reviews, 2013, 39, 27-43. | 3.4 | 14 |
| 3046 | Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials. Cancer Treatment Reviews, 2013, 39, 44-50. | 3.4 | 71 |
| 3047 | Modern concepts of the natural history of breast cancer: A guide to the design and publication of trials of the treatment of breast cancer. European Journal of Cancer, 2013, 49, 60-64. | 1.3 | 14 |
| 3048 | Arm morbidity and sick leave among working women shortly after breast cancer surgery. European Journal of Oncology Nursing, 2013, 17, 101-106. | 0.9 | 7 |
| 3049 | The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. British Journal of Cancer, 2013, 109, 589-596. | 2.9 | 57 |
| 3050 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi7-vi23. | 0.6 | 400 |
| 3051 | St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer, 2013, 13, 558. | 1.1 | 45 |
| 3053 | Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)??. Breast Cancer Research and Treatment, 2013, 138, 359-368. | 1.1 | 3 |
| 3054 | Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Research and Treatment, 2013, 138, 185-191. | 1.1 | 85 |
| 3055 | Time-trends in survival in young women with breast cancer in a SEER population-based study. Breast Cancer Research and Treatment, 2013, 138, 241-248. | 1.1 | 29 |
| 3056 | Impact of local surgical treatment on survival in young women with T1 breast cancer: long-term results of a population-based cohort. Breast Cancer Research and Treatment, 2013, 138, 475-484. | 1.1 | 13 |
| 3057 | Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up. Breast Cancer Research and Treatment, 2013, 138, 467-473. | 1.1 | 20 |
| 3058 | SHON Is a Novel Estrogen-Regulated Oncogene in Mammary Carcinoma That Predicts Patient Response to Endocrine Therapy. Cancer Research, 2013, 73, 6951-6962. | 0.4 | 5 |
| 3059 | Axillary Surgery Among Estrogen Receptor Positive Women 70Â“Years of Age or Older with Clinical Stage I Breast Cancer, 2004â€“2010: A Report from the National Cancer Data Base. Annals of Surgical Oncology, 2013, 20, 3259-3265. | 0.7 | 14 |
| 3060 | Adjuvant Endocrine Therapy for the Surgeon: Options, Side Effects, and their Management. Annals of Surgical Oncology, 2013, 20, 3188-3193. | 0.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3061 | Bupropion for Control of Hot Flashes in Breast Cancer Survivors: A Prospective, Double-Blind, Randomized, Crossover, Pilot Phase II Trial. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 969-979. | 0.6 | 16 |
| 3062 | A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. <i>Annals of Oncology</i> , 2013, 24, 47-53. | 0.6 | 40 |
| 3063 | Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: A comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months. <i>European Journal of Cancer</i> , 2013, 49, 3396-3403. | 1.3 | 54 |
| 3064 | Antitumor efficacy of piperine in the treatment of human HER2-overexpressing breast cancer cells. <i>Food Chemistry</i> , 2013, 141, 2591-2599. | 4.2 | 125 |
| 3065 | Progress in Breast Cancer: Overview. <i>Clinical Cancer Research</i> , 2013, 19, 6353-6359. | 3.2 | 8 |
| 3066 | Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer. <i>Cancer</i> , 2013, 119, 3746-3752. | 2.0 | 19 |
| 3067 | Association between survival in patients with primary invasive breast cancer and computer aided MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 146-155. | 1.9 | 25 |
| 3068 | The development of endocrine therapy for women with breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 507-517. | 3.4 | 63 |
| 3069 | Overexpression of activated phospholipase C β 1 is a risk factor for distant metastases in T1 \leq T2, N0 breast cancer patients undergoing adjuvant chemotherapy. <i>International Journal of Cancer</i> , 2013, 132, 1022-1031. | 2.3 | 41 |
| 3070 | Risk factors of atherosclerosis in patients with history of breast cancer. <i>Pteridines</i> , 2013, 24, 201-210. | 0.5 | 7 |
| 3071 | Prophylactic Use of Levonorgestrel-Releasing Intrauterine System in Women With Breast Cancer Treated With Tamoxifen. <i>Obstetrics and Gynecology</i> , 2013, 121, 943-950. | 1.2 | 33 |
| 3072 | Side Effects of Standard Adjuvant and Neoadjuvant Chemotherapy Regimens According to Age Groups in Primary Breast Cancer. <i>Breast Care</i> , 2013, 8, 60-66. | 0.8 | 27 |
| 3073 | Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: a population-based cohort study. <i>CMAJ Open</i> , 2013, 1, E134-E141. | 1.1 | 21 |
| 3074 | Comparison of Different Adjuvant Therapies for 9 Resectable Cancer Types. <i>Postgraduate Medicine</i> , 2013, 125, 83-91. | 0.9 | 1 |
| 3075 | Metastasis Dormancy in Estrogen Receptor α -Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6389-6397. | 3.2 | 199 |
| 3076 | Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer. <i>Epigenomics</i> , 2013, 5, 595-598. | 1.0 | 8 |
| 3079 | Unilateral Breast Cancer: Screening of Contralateral Breast by Using Preoperative MR Imaging Reduces Incidence of Metachronous Cancer. <i>Radiology</i> , 2013, 267, 57-66. | 3.6 | 56 |
| 3080 | Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2013, 73, 556-583. | 0.8 | 45 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3081 | Research Highlights: Highlights from the latest research in cytochromes pharmacogenomics. <i>Pharmacogenomics</i> , 2013, 14, 459-463. | 0.6 | 1 |
| 3082 | Privatization of medical training: the shape of things to come. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 595-595. | 0.2 | 0 |
| 3083 | Prophylactic mastectomy and breast cancer. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 595-595. | 0.2 | 0 |
| 3084 | Pathways to Breast Cancer Recurrence. <i>ISRN Oncology</i> , 2013, 2013, 1-16. | 2.1 | 80 |
| 3085 | Gene Expression Profile Analysis of T1 and T2 Breast Cancer Reveals Different Activation Pathways. <i>ISRN Oncology</i> , 2013, 2013, 1-12. | 2.1 | 3 |
| 3086 | Tualang Honey Promotes Apoptotic Cell Death Induced by Tamoxifen in Breast Cancer Cell Lines. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-9. | 0.5 | 51 |
| 3087 | Herbal Medicine and Acupuncture for Breast Cancer Palliative Care and Adjuvant Therapy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-17. | 0.5 | 38 |
| 3088 | EP1: a novel rabbit monoclonal antibody for detection of oestrogen receptor β . <i>Journal of Clinical Pathology</i> , 2013, 66, 1051-1057. | 1.0 | 13 |
| 3089 | Efficacy and Tolerability of Toremifene and Tamoxifen Therapy in Premenopausal Patients with Operable Breast Cancer: A Retrospective Analysis. <i>Current Oncology</i> , 2013, 20, 196-204. | 0.9 | 14 |
| 3090 | Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. <i>Annals of Oncology</i> , 2013, 24, 355-361. | 0.6 | 78 |
| 3091 | <i>Pneumocystis pneumonia</i> during Postoperative Adjuvant Chemotherapy for Breast Cancer. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-4. | 0.2 | 3 |
| 3092 | Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. <i>Journal of Medical Economics</i> , 2013, 16, 30-40. | 1.0 | 53 |
| 3093 | Changes in Gene Methylation Following Chemotherapy in Breast Cancer Cell Lines. <i>Turkish Journal of Biochemistry</i> , 2013, 38, 154-162. | 0.3 | 0 |
| 3094 | Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?. <i>Annals of Oncology</i> , 2013, 24, 1834-1840. | 0.6 | 12 |
| 3095 | Retrospective Evaluation of the Female Patients with Breast Cancer: Western Black Sea Region, Uncentered, Clinical Data of Oncology. <i>UHD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2013, , 117-123. | 0.1 | 0 |
| 3096 | False Positive 18F-FDG Uptake in Mediastinal Lymph Nodes Detected with Positron Emission Tomography in Breast Cancer: A Case Report. <i>Case Reports in Medicine</i> , 2013, 2013, 1-5. | 0.3 | 11 |
| 3097 | Irradiation after Surgery for Breast Cancer Patients with Primary Tumours and One to Three Positive Axillary Lymph Nodes: Yes or No?. <i>Current Oncology</i> , 2013, 20, 585-592. | 0.9 | 14 |
| 3098 | Heterogeneity of Mesenchymal Markers Expression – Molecular Profiles of Cancer Cells Disseminated by Lymphatic and Hematogenous Routes in Breast Cancer. <i>Cancers</i> , 2013, 5, 1485-1503. | 1.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3099 | Endothelin-1 Enriched Tumor Phenotype Predicts Breast Cancer Recurrence. <i>ISRN Oncology</i> , 2013, 2013, 1-7. | 2.1 | 12 |
| 3100 | SpliceArray Profiling of Breast Cancer Reveals a Novel Variant of <i>NCOR2/SMRT</i> That Is Associated with Tamoxifen Resistance and Control of <i>ERβ</i> Transcriptional Activity. <i>Cancer Research</i> , 2013, 73, 246-255. | 0.4 | 29 |
| 3101 | The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. <i>Annals of Oncology</i> , 2013, 24, 1505-1512. | 0.6 | 106 |
| 3102 | Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER. <i>Frontiers in Endocrinology</i> , 2013, 4, 50. | 1.5 | 15 |
| 3103 | Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score. <i>International Journal of Molecular Sciences</i> , 2013, 14, 23685-23699. | 1.8 | 14 |
| 3104 | Management of the axilla in early breast cancer patients in the genomic era. <i>Annals of Oncology</i> , 2013, 24, 1163-1170. | 0.6 | 9 |
| 3105 | The Global Challenge of Reducing Breast Cancer Mortality. <i>Oncologist</i> , 2013, 18, 1200-1202. | 1.9 | 16 |
| 3107 | Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. <i>Annals of Oncology</i> , 2013, 24, 2029-2035. | 0.6 | 96 |
| 3108 | Adherence to Adjuvant Hormonal Therapy and Its Relationship to Breast Cancer Recurrence and Survival Among Low-income Women. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 181-187. | 0.6 | 61 |
| 3109 | Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. <i>Cell Cycle</i> , 2013, 12, 2384-2394. | 1.3 | 67 |
| 3110 | Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making. <i>Annals of Oncology</i> , 2013, 24, 1211-1219. | 0.6 | 38 |
| 3111 | Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. <i>Nuclear Medicine Communications</i> , 2013, 34, 1055-1067. | 0.5 | 37 |
| 3112 | Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence. <i>Clinical Cancer Research</i> , 2013, 19, 4196-4205. | 3.2 | 184 |
| 3113 | Racial/Ethnic Differences in Use and Duration of Adjuvant Hormonal Therapy for Breast Cancer in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 365-373. | 1.1 | 23 |
| 3114 | Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2593-2599. | 0.8 | 52 |
| 3115 | Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX [®] , clinicopathological markers and tumor cell dissemination in the blood and bone marrow. <i>Molecular and Clinical Oncology</i> , 2013, 1, 1049-1054. | 0.4 | 18 |
| 3116 | Expression of both Estrogen Receptor-beta 1 (ER β 1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER α)-Negative Early Breast Cancer (EBC). <i>Annals of Oncology</i> , 2013, 24, 1986-1993. | 0.6 | 46 |
| 3117 | Breast cancer: diagnosis and overview of treatment. <i>InnovAiT</i> , 2013, 6, 214-221. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3118 | GENETICS/GENOMICS AND DRUG EFFECTS. Acta Clinica Belgica, 2013, 68, 77-80. | 0.5 | 11 |
| 3119 | Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics, 2013, 14, 205-213. | 0.6 | 35 |
| 3120 | Prolactin Activates ER α in the Absence of Ligand in Female Mammary Development and Carcinogenesis in Vivo. Endocrinology, 2013, 154, 4483-4492. | 1.4 | 23 |
| 3121 | Tumors of the Mammary Gland. , 2013, , 538-556. | | 65 |
| 3122 | Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. Journal of the National Cancer Institute, 2013, 105, 1036-1042. | 3.0 | 166 |
| 3123 | Treatment-Emergent Effects May Predict Benefit From Endocrine Therapy. Journal of Clinical Oncology, 2013, 31, 2233-2235. | 0.8 | 4 |
| 3124 | Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study. Chemotherapy, 2013, 59, 207-213. | 0.8 | 7 |
| 3125 | Elderly Postmenopausal Patients With Breast Cancer Are at Increased Risk for Distant Recurrence: A Tamoxifen Exemestane Adjuvant Multinational Study Analysis. Oncologist, 2013, 18, 8-13. | 1.9 | 21 |
| 3126 | Identification of Tools to Measure Changes in Musculoskeletal Symptoms and Physical Functioning in Women With Breast Cancer Receiving Aromatase Inhibitors. Oncology Nursing Forum, 2013, 40, 549-557. | 0.5 | 20 |
| 3127 | Radiation Treatments After Breast-Conserving Therapy for Elderly Patients. Journal of Clinical Oncology, 2013, 31, 2367-2368. | 0.8 | 20 |
| 3128 | Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer. Molecular Cancer Research, 2013, 11, 1269-1278. | 1.5 | 40 |
| 3129 | Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation. Journal of Clinical Pathology, 2013, 66, 140-145. | 1.0 | 15 |
| 3130 | EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Annals of Oncology, 2013, 24, 640-647. | 0.6 | 170 |
| 3131 | Adjuvant chemotherapy in resectable cholangiocarcinoma patients. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1885-1891. | 1.4 | 35 |
| 3132 | Circulating tumour cells: insights into tumour heterogeneity. Journal of Internal Medicine, 2013, 274, 137-143. | 2.7 | 42 |
| 3133 | <i>CYP19</i> Genetic Polymorphism Haplotype <i>AASA</i> Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer. BioMed Research International, 2013, 2013, 1-9. | 0.9 | 10 |
| 3134 | Meme Kanserli Hastalarda Hastalarda PARP1 Gen Ekspresyonu. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2013, 23, 213-218. | 0.1 | 0 |
| 3135 | The Global Challenge of Reducing Breast Cancer Mortality. Oncologist, 2013, 18, 3-5. | 1.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3136 | Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy. <i>Acta Oncologica</i> , 2013, 52, 91-101. | 0.8 | 20 |
| 3137 | Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer. <i>International Journal of Breast Cancer</i> , 2013, 2013, 1-6. | 0.6 | 7 |
| 3138 | Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer. <i>Annals of Oncology</i> , 2013, 24, 2534-2542. | 0.6 | 17 |
| 3139 | Treatment of Estrogen Receptor-Positive Breast Cancer. <i>Current Medicinal Chemistry</i> , 2013, 20, 596-604. | 1.2 | 213 |
| 3140 | The Relationship Between Eight GWAS-Identified Single-Nucleotide Polymorphisms and Primary Breast Cancer Outcomes. <i>Oncologist</i> , 2013, 18, 493-500. | 1.9 | 28 |
| 3141 | Major Changes in Chemotherapy Regimens Administered to Breast Cancer Patients During 2000-2008 in the Netherlands. <i>Breast Journal</i> , 2013, 19, 394-401. | 0.4 | 8 |
| 3142 | Relative dose intensity in early stage breast cancer chemotherapy: A retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 365-372. | 0.7 | 9 |
| 3143 | Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 1411-1414. | 0.6 | 2 |
| 3144 | The Relative Benefits of Tamoxifen in Older Women with T1 Early-Stage Breast Cancer Treated with Breast-Conserving Surgery and Radiation Therapy. <i>Breast Journal</i> , 2013, 19, n/a-n/a. | 0.4 | 5 |
| 3145 | The challenges of individualized care for older patients with localized breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 963-973. | 1.1 | 0 |
| 3146 | Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 243-250. | 0.7 | 13 |
| 3147 | A hidden Markov model to identify combinatorial epigenetic regulation patterns for estrogen receptor target genes. <i>Bioinformatics</i> , 2013, 29, 22-28. | 1.8 | 14 |
| 3148 | Adherence to adjuvant endocrine therapy in women with breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 105-110. | 0.5 | 14 |
| 3150 | Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial. <i>British Journal of Cancer</i> , 2013, 109, 582-588. | 2.9 | 13 |
| 3151 | Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. <i>British Journal of Cancer</i> , 2013, 109, 2453-2461. | 2.9 | 6 |
| 3152 | A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage III breast cancer. <i>British Journal of Cancer</i> , 2013, 109, 1513-1521. | 2.9 | 56 |
| 3153 | Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 549-556. | 2.9 | 32 |
| 3154 | The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 2959-2964. | 2.9 | 288 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3155 | Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis. <i>Annals of Oncology</i> , 2013, 24, 101-108. | 0.6 | 145 |
| 3156 | Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. <i>Journal of the National Cancer Institute</i> , 2013, 105, 104-112. | 3.0 | 100 |
| 3157 | Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581. <i>Journal of Clinical Oncology</i> , 2013, 31, 1775-1781. | 0.8 | 163 |
| 3158 | HOXB13 Mediates Tamoxifen Resistance and Invasiveness in Human Breast Cancer by Suppressing ER α and Inducing IL-6 Expression. <i>Cancer Research</i> , 2013, 73, 5449-5458. | 0.4 | 80 |
| 3159 | Potential Role of <i>UGT1A4</i> Promoter SNPs in Anastrozole Pharmacogenomics. <i>Drug Metabolism and Disposition</i> , 2013, 41, 870-877. | 1.7 | 25 |
| 3161 | STAT3-RANTES Autocrine Signaling Is Essential for Tamoxifen Resistance in Human Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2013, 11, 31-42. | 1.5 | 67 |
| 3162 | Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required. <i>Breast Cancer Management</i> , 2013, 2, 367-374. | 0.2 | 10 |
| 3163 | Prophylactic mastectomy and breast cancer. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq1 1 0.784314 rgBT /Overlaid | 0.2 | 0 |
| 3164 | The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines. <i>Oncology Reports</i> , 2013, 29, 1268-1274. | 1.2 | 7 |
| 3165 | Rationale for the design of an oncology trial using a generic targeted therapy multi-drug regimen for NSCLC patients without treatment options (Review). <i>Oncology Reports</i> , 2013, 30, 1535-1541. | 1.2 | 7 |
| 3166 | Hormone Receptors and Endocrine Therapy in Breast Cancer. , 2013, , 121-153. | | 0 |
| 3167 | Role of the Renin-Angiotensin-Aldosterone System and the Glutathione S-Transferase μ and θ Gene Polymorphisms in Cardiotoxicity after Anthracycline Chemotherapy for Breast Carcinoma. <i>International Journal of Biological Markers</i> , 2013, 28, 336-347. | 0.7 | 29 |
| 3168 | Molecular Profiling for Breast Cancer: A Comprehensive Review. <i>Biomarkers in Cancer</i> , 2013, 5, BIC.S9455. | 3.6 | 152 |
| 3169 | Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer. <i>Breast Care</i> , 2013, 8, 429-437. | 0.8 | 9 |
| 3170 | ENDOCRINE PREVENTION OF BREAST CANCER. , 2013, , 361-390. | | 0 |
| 3171 | Survival probability and prognostic factors for breast cancer patients in Vietnam. <i>Global Health Action</i> , 2013, 6, 18860. | 0.7 | 50 |
| 3172 | Differences in the Receptor Status between Primary and Recurrent Breast Cancer - The Frequency of and the Reasons for Discordance. <i>Oncology</i> , 2013, 84, 319-325. | 0.9 | 23 |
| 3173 | Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 325-334. | 0.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3174 | Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsivenessâ€”a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. <i>BMC Cancer</i> , 2013, 13, 425. | 1.1 | 64 |
| 3175 | Using decision aids to improve treatment choices for women with breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 23-31. | 0.2 | 1 |
| 3176 | Endocrine therapy for breast cancer. <i>Menopause</i> , 2013, 20, 714-716. | 0.8 | 4 |
| 3177 | Overexpression of ER β inhibits proliferation and invasion of MKN28 gastric cancer cells by suppressing β -catenin. <i>Oncology Reports</i> , 2013, 30, 1622-1630. | 1.2 | 20 |
| 3178 | A CENTURY OF DECIPHERING THE CONTROL MECHANISMS OF ESTROGEN ACTION IN BREAST CANCER: THE ORIGINS OF TARGETED THERAPY AND CHEMOPREVENTION. , 2013, , 1-29. | | 0 |
| 3179 | ROLE OF ESTROGEN IN FAMILIAL BREAST CANCER. , 2013, , 175-200. | | 0 |
| 3181 | Locoregional recurrence of breast cancer. , 2013, , 389-408. | | 0 |
| 3182 | How useful are molecular assays in breast cancer in the elderly?. <i>Aging Health</i> , 2013, 9, 291-305. | 0.3 | 1 |
| 3183 | In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab. <i>Menopause</i> , 2013, 20, 646-654. | 0.8 | 25 |
| 3184 | A population perspective to mitigating risk for second primary breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 123-134. | 0.2 | 0 |
| 3185 | An Assessment of the Risks and Benefits of Immediate Autologous Breast Reconstruction in Patients Undergoing Postmastectomy Radiation Therapy. <i>Annals of Plastic Surgery</i> , 2013, 71, 149-155. | 0.5 | 53 |
| 3186 | Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. <i>Menopause</i> , 2013, 20, 721-726. | 0.8 | 8 |
| 3187 | Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptorâ€”positive invasive breast cancer nearly 4 years from diagnosis. <i>Menopause</i> , 2013, 20, 15-21. | 0.8 | 20 |
| 3188 | Long-term efficacy and safety of exemestane in the treatment of breast cancer. <i>Patient Preference and Adherence</i> , 2013, 7, 245. | 0.8 | 14 |
| 3189 | Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 93. | 0.4 | 21 |
| 3190 | Functional Polymorphisms in Xenobiotic Metabolizing Enzymes and Their Impact on the Therapy of Breast Cancer. <i>Frontiers in Genetics</i> , 2013, 3, 329. | 1.1 | 8 |
| 3191 | Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review). <i>Oncology Letters</i> , 2013, 6, 295-305. | 0.8 | 15 |
| 3192 | Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. <i>Molecular and Clinical Oncology</i> , 2013, 1, 225-230. | 0.4 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3193 | Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. <i>Menopause</i> , 2013, 20, 372-382. | 0.8 | 34 |
| 3194 | Prognostic comparison of the proliferation markers mitotic activity index, phosphohistone H3, Ki67, steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T 1-2 N 0 M 0 breast cancer. <i>Polish Journal of Pathology</i> , 2013, 1, 1-8. | 0.1 | 27 |
| 3195 | Cancer Screening Guidelines and Mortality. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 3196 | Evaluation of host quality of life and immune function in breast cancer patients treated with combination of adjuvant chemotherapy and oral administration of <i>Lentinula edodes mycelia</i> extract. <i>OncoTargets and Therapy</i> , 2013, 6, 853. | 1.0 | 18 |
| 3197 | Efficacy of intraarterial chemoinfusion therapy for locally advanced breast cancer patients: a retrospective analysis of 28 cases. <i>OncoTargets and Therapy</i> , 2013, 6, 761. | 1.0 | 7 |
| 3198 | Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2013, 84, 273. | 1.1 | 1 |
| 3199 | Effect Modification of Hormonal Therapy by p53 Status in Invasive Breast Cancer. <i>Journal of Breast Cancer</i> , 2013, 16, 386. | 0.8 | 8 |
| 3200 | Real-World Impact of Granulocyte-Colony Stimulating Factor on Febrile Neutropenia. <i>Current Oncology</i> , 2013, 20, 171-179. | 0.9 | 20 |
| 3201 | Vascular endothelial growth factor expression and T-regulatory cells in premenopausal breast cancer. <i>Oncology Letters</i> , 2013, 5, 1117-1122. | 0.8 | 4 |
| 3202 | Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens. <i>OncoTargets and Therapy</i> , 2013, 6, 1073. | 1.0 | 4 |
| 3203 | Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer. <i>Molecular and Clinical Oncology</i> , 2013, 1, 93-99. | 0.4 | 7 |
| 3204 | Germline DNA Copy Number Aberrations Identified as Potential Prognostic Factors for Breast Cancer Recurrence. <i>PLoS ONE</i> , 2013, 8, e53850. | 1.1 | 20 |
| 3205 | Endoxifen's Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens. <i>PLoS ONE</i> , 2013, 8, e54613. | 1.1 | 38 |
| 3206 | Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma. <i>PLoS ONE</i> , 2013, 8, e55901. | 1.1 | 26 |
| 3207 | Candidate Markers That Associate with Chemotherapy Resistance in Breast Cancer through the Study on Taxotere-Induced Damage to Tumor Microenvironment and Gene Expression Profiling of Carcinoma-Associated Fibroblasts (CAFs). <i>PLoS ONE</i> , 2013, 8, e70960. | 1.1 | 33 |
| 3208 | Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e72219. | 1.1 | 20 |
| 3209 | Molecular Detection of Peripheral Blood Breast Cancer mRNA Transcripts as a Surrogate Biomarker for Circulating Tumor Cells. <i>PLoS ONE</i> , 2013, 8, e74079. | 1.1 | 14 |
| 3210 | Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. <i>Cancer Management and Research</i> , 2013, 5, 357. | 0.9 | 24 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3211 | Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 317. | 1.3 | 4 |
| 3212 | Prevention and Treatment of Bone Metastases in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2013, 2, 151-175. | 1.0 | 12 |
| 3213 | Tissue Banking, Bioinformatics, and Electronic Medical Records: The Front-End Requirements for Personalized Medicine. <i>Journal of Oncology</i> , 2013, 2013, 1-12. | 0.6 | 34 |
| 3214 | Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in postmenopausal Early Breast Cancer. <i>Clinical Medicine Insights Women's Health</i> , 2013, 6, CMWH.S8692. | 0.6 | 3 |
| 3215 | Improvement of the Protective Effect for Phlebitis by Reduced Infusion Time of Epirubicin and Flushing after the Infusion. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2013, 39, 644-649. | 0.0 | 1 |
| 3216 | Intensity-modulated versus conventional radiotherapy for breast cancer. <i>The Cochrane Library</i> , 2013, , . | 1.5 | 1 |
| 3217 | How to Improve Breast Cancer Care Measurement and Reporting: Suggestions from a Complex Urban Hospital. <i>Journal of Healthcare Management</i> , 2013, 58, 205-223. | 0.4 | 5 |
| 3218 | Adherence to adjuvant hormonal treatment for breast cancer in patients opting for local hospital direct drug distribution in Italy. <i>European Journal of Hospital Pharmacy</i> , 2013, 20, 232-235. | 0.5 | 0 |
| 3219 | Endocrine Resistance: What Do We Know?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e37-e42. | 1.8 | 13 |
| 3220 | Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. <i>Menopause</i> , 2013, 20, 162-168. | 0.8 | 132 |
| 3222 | Pathogenesis, prevention, diagnosis and treatment of breast cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 283. | 0.9 | 184 |
| 3223 | Unique Features of Young Age Breast Cancer and Its Management. <i>Journal of Breast Cancer</i> , 2014, 17, 301. | 0.8 | 92 |
| 3224 | Selective estrogen receptor modulators: tissue specificity and clinical utility. <i>Clinical Interventions in Aging</i> , 2014, 9, 1437. | 1.3 | 157 |
| 3225 | Prevention of Bone Metastases in Breast Cancer Patients. <i>Therapeutic Perspectives. Journal of Clinical Medicine</i> , 2014, 3, 521-536. | 1.0 | 9 |
| 3226 | Resveratrol and Arsenic Trioxide Act Synergistically to Kill Tumor Cells In Vitro and In Vivo. <i>PLoS ONE</i> , 2014, 9, e98925. | 1.1 | 31 |
| 3227 | Crowdsourcing Awareness: Exploration of the Ovarian Cancer Knowledge Gap through Amazon Mechanical Turk. <i>PLoS ONE</i> , 2014, 9, e85508. | 1.1 | 42 |
| 3228 | Interruption and Non-Adherence to Long-Term Adjuvant Hormone Therapy Is Associated with Adverse Survival Outcome of Breast Cancer Women - An Asian Population-Based Study. <i>PLoS ONE</i> , 2014, 9, e87027. | 1.1 | 55 |
| 3229 | Prognostic Value of Ki-67 in Breast Cancer Patients with Positive Axillary Lymph Nodes: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e87264. | 1.1 | 33 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3230 | Biological Characteristics and Clinical Outcome of Triple Negative Primary Breast Cancer in Older Women – Comparison with Their Younger Counterparts. PLoS ONE, 2014, 9, e100573. | 1.1 | 30 |
| 3231 | Estrogen Receptor- α 36 Is Involved in Pterostilbene-Induced Apoptosis and Anti-Proliferation in In Vitro and In Vivo Breast Cancer. PLoS ONE, 2014, 9, e104459. | 1.1 | 31 |
| 3232 | [18F]-Fluorodeoxyglucose Positron Emission Tomography Can Contribute to Discriminate Patients with Poor Prognosis in Hormone Receptor-Positive Breast Cancer. PLoS ONE, 2014, 9, e105905. | 1.1 | 18 |
| 3233 | Age-Related Mortality Trends in Italy from 1901 to 2008. PLoS ONE, 2014, 9, e114027. | 1.1 | 6 |
| 3234 | A Systematic Analysis of miRNA-mRNA Paired Variations Reveals Widespread miRNA Misregulation in Breast Cancer. BioMed Research International, 2014, 2014, 1-8. | 0.9 | 9 |
| 3235 | Endocrine Resistance in Breast Cancer. New Journal of Science, 2014, 2014, 1-27. | 1.0 | 55 |
| 3236 | Screening to Identify Commonly Used Chinese Herbs That Affect ERBB2 and ESR1 Gene Expression Using the Human Breast Cancer MCF-7 Cell Line. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-11. | 0.5 | 10 |
| 3237 | Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer. Global Journal of Health Science, 2014, 7, 98-106. | 0.1 | 20 |
| 3239 | Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims. Patient Preference and Adherence, 2014, 8, 671. | 0.8 | 20 |
| 3240 | Tamoxifen for women at high risk of breast cancer. Breast Cancer: Targets and Therapy, 2014, 6, 29. | 1.0 | 43 |
| 3241 | A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors. Journal of Cancer, 2014, 5, 156-165. | 1.2 | 81 |
| 3242 | BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase. Breast Cancer: Targets and Therapy, 2014, 6, 179. | 1.0 | 10 |
| 3243 | Long-Term Survival Analysis of Korean Breast Cancer Patients at a Single Center: Improving Outcome Over Time. Yonsei Medical Journal, 2014, 55, 1187. | 0.9 | 10 |
| 3244 | Endocrine Therapy for Breast Cancer. The Ewha Medical Journal, 2014, 37, 83. | 0.1 | 2 |
| 3245 | The Optimal Duration and Selection of Adjuvant Endocrine Therapy for Breast Cancer: How Long Is Enough?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e16-e24. | 1.8 | 9 |
| 3246 | Regional Disparities in Breast Cancer Outcomes and the Process of Care. American Surgeon, 2014, 80, 669-674. | 0.4 | 3 |
| 3247 | Endocrine Therapy Toxicity: Management Options. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e25-e30. | 1.8 | 26 |
| 3248 | Effect of neoadjuvant chemotherapy on expressions of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in breast cancer. Chinese Medical Journal, 2014, 127, 3272-3277. | 0.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3249 | An Approach to Evaluating and Comparing Biomarkers for Patient Treatment Selection. International Journal of Biostatistics, 2014, 10, 99-121. | 0.4 | 47 |
| 3250 | Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy – A single-arm phase II study. Journal of the Egyptian National Cancer Institute, 2014, 26, 195-202. | 0.6 | 12 |
| 3251 | Pharmacogenomics and Stratified Medicine. , 2014, , 3-25. | | 21 |
| 3252 | Optimal adjuvant chemotherapy in breast cancer: selection of agents. Expert Review of Clinical Pharmacology, 2014, 7, 605-611. | 1.3 | 4 |
| 3253 | Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer. Cancer Biology and Therapy, 2014, 15, 1586-1587. | 1.5 | 15 |
| 3254 | Effects of zoledronic acid and the association between its efficacy and β 2-microglobulin cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. Journal of Translational Medicine, 2014, 12, 310. | 1.8 | 5 |
| 3255 | Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Research, 2014, 16, 485. | 2.2 | 51 |
| 3256 | Factors responsible for long-term survival in metastatic breast cancer. World Journal of Surgical Oncology, 2014, 12, 344. | 0.8 | 22 |
| 3257 | The challenges of long-term follow-up data collection in non-commercial, academically-led breast cancer clinical trials: the UK perspective. Trials, 2014, 15, 379. | 0.7 | 8 |
| 3258 | Up-regulation of S100A16 expression promotes epithelial-mesenchymal transition via Notch1 pathway in breast cancer. Journal of Biomedical Science, 2014, 21, 97. | 2.6 | 42 |
| 3259 | Effect of tamoxifen on ovarian reserve: A randomized controlled assessor-blind trial in a mouse model. Journal of the Turkish German Gynecology Association, 2014, 15, 228-232. | 0.2 | 10 |
| 3260 | High-density array analysis of DNA methylation in Tamoxifen-resistant breast cancer cell lines. Epigenetics, 2014, 9, 297-307. | 1.3 | 25 |
| 3262 | #Rethinkpink. Gender and Society, 2014, 28, 655-678. | 3.0 | 11 |
| 3263 | Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer. BMC Cancer, 2014, 14, 820. | 1.1 | 183 |
| 3264 | Risk of contralateral second primary breast cancer according to hormone receptor status in Germany. Breast Cancer Research, 2014, 16, 452. | 2.2 | 19 |
| 3265 | Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Research, 2014, 16, 429. | 2.2 | 49 |
| 3266 | Challenges in the Delivery of Quality Breast Cancer Care: Initiation of Adjuvant Hormone Therapy at an Urban Safety Net Hospital. Journal of Oncology Practice, 2014, 10, e107-e112. | 2.5 | 10 |
| 3267 | The Role of Antihypertensive Drug Classes and Statins in Preventing Aortic Elasticity. Angiology, 2014, 65, 650-650. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3268 | ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody⁸⁹Zr-RG7116. <i>MABs</i> , 2014, 6, 1051-1058. | 2.6 | 46 |
| 3269 | Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance. <i>Cancer Research</i> , 2014, 74, 2946-2961. | 0.4 | 20 |
| 3270 | Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. <i>British Journal of Cancer</i> , 2014, 110, 1950-1957. | 2.9 | 15 |
| 3271 | Breast cancer: the menacing face of Janus kinase. <i>Cell Death and Differentiation</i> , 2014, 21, 185-186. | 5.0 | 6 |
| 3272 | Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer. <i>Oncogene</i> , 2014, 33, 4579-4588. | 2.6 | 35 |
| 3273 | Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, NO luminal-A early breast cancer. <i>Oncogenesis</i> , 2014, 3, e118-e118. | 2.1 | 35 |
| 3274 | Current status of autologous breast tumor cell-based vaccines. <i>Expert Review of Vaccines</i> , 2014, 13, 1439-1445. | 2.0 | 19 |
| 3276 | IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. <i>Oncogene</i> , 2014, , . | 2.6 | 49 |
| 3277 | Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. <i>Molecular and Cellular Oncology</i> , 2014, 1, e963447. | 0.3 | 9 |
| 3278 | Pharmacological Relevance of Endoxifen in a Laboratory Simulation of Breast Cancer in Postmenopausal Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 3.0 | 17 |
| 3279 | The Clinical Significance of PR, ER, NF- κ B, and TNF- α in Breast Cancer. <i>Disease Markers</i> , 2014, 2014, 1-7. | 0.6 | 32 |
| 3280 | Hormonal Therapy and Radiation Therapy: Randomized and Prospective Trials. <i>Medical Radiology</i> , 2014, , 137-148. | 0.0 | 0 |
| 3281 | A highly-sensitive anti-M μ llerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. <i>European Journal of Cancer</i> , 2014, 50, 2367-2374. | 1.3 | 37 |
| 3282 | Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer. <i>Neoplasia</i> , 2014, 16, 861-867. | 2.3 | 12 |
| 3283 | Aromatase Inhibitors: A New Reality for the Adjuvant Endocrine Treatment of Early-Stage Breast Cancer in Postmenopausal Women. , 2014, , 99-130. | | 0 |
| 3284 | Gene Expression Profiles in Breast Cancer to Identify Estrogen Receptor Target Genes. , 2014, , 381-403. | | 0 |
| 3285 | Do Community-Based Patient Assistance Programs Affect the Treatment and Well-Being of Patients With Breast Cancer?. <i>Journal of Oncology Practice</i> , 2014, 10, 48-54. | 2.5 | 11 |
| 3286 | No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients. <i>Acta Oncologica</i> , 2014, 53, 195-200. | 0.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3287 | Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer. <i>Acta Oncologica</i> , 2014, 53, 201-208. | 0.8 | 3 |
| 3288 | Incidence of metachronous contralateral breast cancer in Denmark 1978–2009. <i>International Journal of Epidemiology</i> , 2014, 43, 1855-1864. | 0.9 | 31 |
| 3289 | Survival Analysis of Breast Cancer Subtypes in Patients With Spinal Metastases. <i>Spine</i> , 2014, 39, 1620-1627. | 1.0 | 23 |
| 3290 | Current Clinical Role of Genetic Profiling in Breast Cancer. <i>Medical Radiology</i> , 2014, , 15-34. | 0.0 | 0 |
| 3291 | Personalized medicine and the clinical laboratory. <i>Einstein (Sao Paulo, Brazil)</i> , 2014, 12, 366-373. | 0.3 | 8 |
| 3292 | Value of F-18 FDG PET/CT in detection and prognostication of isolated extra-axillary lymph node recurrences in postoperative breast cancer. <i>Bio-Medical Materials and Engineering</i> , 2014, 24, 1173-1184. | 0.4 | 5 |
| 3293 | The Role and Clinical Relevance of Disseminated Tumor Cells in Breast Cancer. <i>Cancers</i> , 2014, 6, 143-152. | 1.7 | 21 |
| 3294 | Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients. <i>Climacteric</i> , 2014, 17, 48-54. | 1.1 | 28 |
| 3295 | Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2014, 4, 277. | 1.3 | 79 |
| 3296 | A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells. <i>Oncology Reports</i> , 2014, 32, 627-634. | 1.2 | 6 |
| 3298 | Body image struggles and breast cancer care: an under-recognized and undertreated issue with important implications for all patients. <i>Breast Cancer Management</i> , 2014, 3, 251-260. | 0.2 | 5 |
| 3299 | Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases. <i>Oncology Letters</i> , 2014, 8, 1279-1282. | 0.8 | 12 |
| 3300 | Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2014, 30, 1017-1024. | 0.9 | 3 |
| 3302 | Role of endocrine therapy in ER ⁺ /HER2 ⁺ breast cancers. <i>Breast Cancer Management</i> , 2014, 3, 103-111. | 0.2 | 2 |
| 3305 | Estrogen and progesterone receptors in breast cancer. <i>Future Oncology</i> , 2014, 10, 2293-2301. | 1.1 | 127 |
| 3306 | MTDH Mediates Estrogen-Independent Growth and Tamoxifen Resistance by Down-Regulating PTEN in MCF-7 Breast Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2014, 33, 1557-1567. | 1.1 | 36 |
| 3308 | High Expression of LMTK3 is an Independent Factor Indicating a Poor Prognosis in Estrogen Receptor \pm -Positive Breast Cancer Patients. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 889-897. | 0.6 | 4 |
| 3309 | Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use. <i>Tumor Biology</i> , 2014, 35, 8461-8470. | 0.8 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3310 | Clinicopathologic Characteristics and Prognosis of Glycogen-Rich Clear Cell Carcinoma of the Breast. <i>Breast Journal</i> , 2014, 20, 166-173. | 0.4 | 23 |
| 3311 | Measuring persistence to hormonal therapy in patients with breast cancer: accounting for temporary treatment discontinuation. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 882-889. | 0.9 | 8 |
| 3312 | Clinical Outcome With Correlation to Disseminated Tumor Cell (DTC) Status After DTC-Guided Secondary Adjuvant Treatment With Docetaxel in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3848-3857. | 0.8 | 71 |
| 3313 | Loss of B cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance. <i>Cancer Science</i> , 2014, 105, 675-682. | 1.7 | 8 |
| 3314 | Young childless women with breast cancer in the UK: a qualitative study of their fertility-related experiences, options, and the information given by health professionals. <i>Psycho-Oncology</i> , 2014, 23, 20-26. | 1.0 | 67 |
| 3315 | Breast cancer treatment across health care systems: Linking electronic medical records and state registry data to enable outcomes research. <i>Cancer</i> , 2014, 120, 103-111. | 2.0 | 48 |
| 3316 | Linking Estrogen-Induced Apoptosis With Decreases in Mortality Following Long-term Adjuvant Tamoxifen Therapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju296-dju296. | 3.0 | 34 |
| 3317 | The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 3.0 | 85 |
| 3318 | Management of breast cancer in elderly patients. <i>Clinical Practice (London, England)</i> , 2014, 11, 59-69. | 0.1 | 2 |
| 3319 | TheHOXB13:IL17BRbiomarker: prognostic for late recurrence and predictive for benefit from endocrine therapy. <i>Breast Cancer Management</i> , 2014, 3, 155-163. | 0.2 | 0 |
| 3321 | A Novel Function of the Fe65 Neuronal Adaptor in Estrogen Receptor Action in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 12217-12231. | 1.6 | 11 |
| 3322 | Outcomes of Breast Cancer in Brazil Related to Health Care Coverage: A Retrospective Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 126-133. | 1.1 | 69 |
| 3323 | Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 337-343. | 1.1 | 9 |
| 3324 | Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 571-580. | 1.1 | 6 |
| 3325 | Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). <i>Breast Cancer Research and Treatment</i> , 2014, 148, 591-597. | 1.1 | 10 |
| 3326 | Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials. <i>Medical Oncology</i> , 2014, 31, 340. | 1.2 | 10 |
| 3327 | Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer. <i>BMC Cancer</i> , 2014, 14, 190. | 1.1 | 13 |
| 3328 | Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. <i>BMC Cancer</i> , 2014, 14, 762. | 1.1 | 16 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3329 | Preferential, enhanced breast cancer cell migration on biomimetic electrospun nanofiber "cell highways". BMC Cancer, 2014, 14, 825. | 1.1 | 61 |
| 3330 | Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. BMC Cancer, 2014, 14, 908. | 1.1 | 42 |
| 3331 | Contemplative self healing in women breast cancer survivors: a pilot study in underserved minority women shows improvement in quality of life and reduced stress. BMC Complementary and Alternative Medicine, 2014, 14, 349. | 3.7 | 35 |
| 3332 | Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells. Breast Cancer Research, 2014, 16, 431. | 2.2 | 80 |
| 3333 | Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Research, 2014, 16, 494. | 2.2 | 83 |
| 3334 | Quantifying the Benefits and Harms of Screening Mammography. JAMA Internal Medicine, 2014, 174, 448. | 2.6 | 175 |
| 3335 | Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1-3 positive lymph nodes: a retrospective study. Journal of Radiation Research, 2014, 55, 121-128. | 0.8 | 5 |
| 3336 | Axillary Skin Malignancy. Annals of Plastic Surgery, 2014, 72, 513-514. | 0.5 | 1 |
| 3337 | The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anti-Cancer Drugs, 2014, 25, 950-957. | 0.7 | 32 |
| 3338 | Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptor-positive, Node-positive Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 404-410. | 0.6 | 22 |
| 3339 | Primary endocrine therapy as an approach for patients with localized breast cancer deemed not to be surgical candidates. Current Opinion in Supportive and Palliative Care, 2014, 8, 53-58. | 0.5 | 9 |
| 3340 | Biomarkers in Early-Stage Non-Small-Cell Lung Cancer: Current Concepts and Future Directions. Journal of Thoracic Oncology, 2014, 9, 1609-1617. | 0.5 | 54 |
| 3341 | Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer. Future Oncology, 2014, 10, 195-209. | 1.1 | 15 |
| 3342 | In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen. Integrative Cancer Therapies, 2014, 13, 226-239. | 0.8 | 10 |
| 3343 | Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocrine-Related Cancer, 2014, 21, R235-R246. | 1.6 | 128 |
| 3344 | Effect of Radiotherapy on Impaired Aortic Elasticity and Stiffness in Patients With Breast Cancer. Angiology, 2014, 65, 643-648. | 0.8 | 9 |
| 3345 | Cognitive Factors Associated with Adherence to Oral Antiestrogen Therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Study. Cancer Prevention Research, 2014, 7, 161-168. | 0.7 | 21 |
| 3346 | Screening mammography "early detection or over-diagnosis? Contribution from Australian data. Climacteric, 2014, 17, 66-72. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3347 | Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 609-616. | 1.1 | 75 |
| 3348 | No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 135-142. | 1.1 | 11 |
| 3349 | Omics Approaches in Breast Cancer. , 2014, , . | | 10 |
| 3350 | Breast Cancer Genomics. , 2014, , 53-103. | | 0 |
| 3351 | Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis. <i>Oncolimmunology</i> , 2014, 3, e968001. | 2.1 | 32 |
| 3352 | Prognostic information of a previously diagnosed sister is an independent prognosticator for a newly diagnosed sister with breast cancer. <i>Annals of Oncology</i> , 2014, 25, 1966-1972. | 0.6 | 5 |
| 3353 | Screening Mammography in Older Women. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1336. | 3.8 | 194 |
| 3354 | Impact of Cell Arrangement of Pleural Effusion in Survival of Patients with Breast Cancer. <i>Acta Cytologica</i> , 2014, 58, 446-452. | 0.7 | 6 |
| 3355 | Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2010-2017. | 0.8 | 99 |
| 3356 | Prognostic Factors in Operated Stage IIIc, Pathological N3a Breast Cancer Patients. <i>Breast Care</i> , 2014, 9, 1-1. | 0.8 | 5 |
| 3357 | Second malignancies after breast cancer: The impact of adjuvant therapy. <i>Molecular and Clinical Oncology</i> , 2014, 2, 331-336. | 0.4 | 26 |
| 3358 | Anthracycline-based induction chemotherapy followed by concurrent cyclophosphamide, methotrexate and 5-fluorouracil and radiation therapy in surgically resected axillary node-positive breast cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 473-478. | 0.4 | 2 |
| 3359 | Managing the changing burden of cancer in Asia. <i>BMC Medicine</i> , 2014, 12, 3. | 2.3 | 117 |
| 3360 | Status of adjuvant endocrine therapy for breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 206. | 2.2 | 61 |
| 3361 | Tumor Response Ratio Predicts Overall Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3317-3323. | 0.7 | 13 |
| 3362 | A review of clinical aspects of breast cancer. <i>International Review of Psychiatry</i> , 2014, 26, 4-15. | 1.4 | 129 |
| 3363 | External Validity of a Trial Comprised of Elderly Patients With Hormone Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju051-dju051. | 3.0 | 64 |
| 3364 | Breast Magnetic Resonance Imaging Incidental Findings. <i>Topics in Magnetic Resonance Imaging</i> , 2014, 23, 361-371. | 0.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3365 | Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. <i>Breast Cancer</i> , 2014, 21, 52-57. | 1.3 | 9 |
| 3366 | Prediction of tamoxifen outcome by genetic variation of <sc>CYP2D6</sc> in postmenopausal women with early breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 695-703. | 1.1 | 42 |
| 3367 | Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ER \pm tumorigenesis. <i>Cell Death and Differentiation</i> , 2014, 21, 234-246. | 5.0 | 41 |
| 3368 | Everolimus: a new hope for patients with breast cancer. <i>Current Medical Research and Opinion</i> , 2014, 30, 75-87. | 0.9 | 21 |
| 3369 | Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 27-42. | 2.0 | 68 |
| 3370 | The experience of providing support about menopausal symptoms to women with breast cancer. <i>European Journal of Oncology Nursing</i> , 2014, 18, 110-117. | 0.9 | 4 |
| 3371 | Tamoxifen induces resistance to activated protein C. <i>Thrombosis Research</i> , 2014, 133, 886-891. | 0.8 | 20 |
| 3372 | Treatment and prognosis of breast cancer in elderly: Different from young patients?. <i>European Geriatric Medicine</i> , 2014, 5, 261-264. | 1.2 | 2 |
| 3373 | Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery. <i>Irish Journal of Medical Science</i> , 2014, 183, 71-75. | 0.8 | 2 |
| 3374 | Diffusion-weighted imaging reflects pathological therapeutic response and relapse in breast cancer. <i>Breast Cancer</i> , 2014, 21, 724-731. | 1.3 | 25 |
| 3375 | Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution. <i>Breast Cancer</i> , 2014, 21, 86-95. | 1.3 | 25 |
| 3376 | Personalized Health Care (PHC) in Cancer. , 2014, , 23-49. | | 0 |
| 3377 | Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 45-54. | 1.0 | 56 |
| 3378 | Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401). <i>International Journal of Clinical Oncology</i> , 2014, 19, 982-988. | 1.0 | 10 |
| 3379 | Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis. <i>Tumor Biology</i> , 2014, 35, 3113-3117. | 0.8 | 6 |
| 3380 | Competing risks analysis in mortality estimation for breast cancer patients from independent risk groups. <i>Health Care Management Science</i> , 2014, 17, 259-269. | 1.5 | 2 |
| 3381 | Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju034-dju034. | 3.0 | 47 |
| 3382 | Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population. <i>Supportive Care in Cancer</i> , 2014, 22, 1949-58. | 1.0 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3383 | Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification. <i>Cellular Oncology (Dordrecht)</i> , 2014, 37, 107-118. | 2.1 | 14 |
| 3384 | Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 569-576. | 1.1 | 50 |
| 3385 | Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. <i>Breast Cancer Research</i> , 2014, 16, R8. | 2.2 | 31 |
| 3386 | Expression profiling of breast cancer patients treated with tamoxifen: prognostic or predictive significance. <i>Medical Oncology</i> , 2014, 31, 896. | 1.2 | 8 |
| 3387 | How Do I Recommend Extended Adjuvant Hormonal Therapy?. <i>Current Treatment Options in Oncology</i> , 2014, 15, 55-62. | 1.3 | 3 |
| 3388 | Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. <i>Breast Cancer Research</i> , 2014, 16, R6. | 2.2 | 46 |
| 3389 | AQP5 Expression Predicts Survival in Patients with Early Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 375-383. | 0.7 | 60 |
| 3390 | Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 814-822. | 1.2 | 7 |
| 3391 | Association between variants of 5-hydroxytryptamine receptor 3C (HTR3C) and chemotherapy-induced symptoms in women receiving adjuvant treatment for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 123-131. | 1.1 | 11 |
| 3392 | Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy. <i>Current Breast Cancer Reports</i> , 2014, 6, 71-78. | 0.5 | 13 |
| 3393 | Global collaborative networks on meta-analyses of randomized trials published in high impact factor medical journals: a social network analysis. <i>BMC Medicine</i> , 2014, 12, 15. | 2.3 | 30 |
| 3394 | Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. <i>Investigational New Drugs</i> , 2014, 32, 14-24. | 1.2 | 49 |
| 3395 | The Application of Oncotype DX in Early-Stage Lymph-Node-Positive Disease. <i>Current Oncology Reports</i> , 2014, 16, 360. | 1.8 | 6 |
| 3396 | The impact of the pathological lymph node status on adjuvant systemic treatment recommendations in clinically node negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 469-476. | 1.1 | 21 |
| 3397 | Long-term impact of the 70-gene signature on breast cancer outcome. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 587-592. | 1.1 | 54 |
| 3398 | Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials. <i>Molecular Biology Reports</i> , 2014, 41, 751-756. | 1.0 | 13 |
| 3399 | The Effect of Local Therapy on Breast Cancer Mortality: Is There an Age-Interaction?. <i>Indian Journal of Surgical Oncology</i> , 2014, 5, 5-9. | 0.3 | 0 |
| 3400 | The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. <i>Surgery Today</i> , 2014, 44, 1841-1846. | 0.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 3401 | Pin1 modulates ER \pm levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation. <i>Oncogene</i> , 2014, 33, 1438-1447. | 2.6 | 61 |
| 3402 | The development of low-molecular weight hydrogels for applications in cancer therapy. <i>Nanoscale</i> , 2014, 6, 3474. | 2.8 | 94 |
| 3403 | Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 683-694. | 1.6 | 45 |
| 3404 | Survival of women with inflammatory breast cancer: a large population-based study. <i>Annals of Oncology</i> , 2014, 25, 1143-1151. | 0.6 | 52 |
| 3405 | Using K-Means Clustering Technique to Study of Breast Cancer. , 2014, , . | | 16 |
| 3406 | What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 113-128. | 1.1 | 71 |
| 3407 | Low concordance of biomarkers in histopathological and cytological material from breast cancer. <i>Histopathology</i> , 2014, 64, 971-980. | 1.6 | 18 |
| 3408 | Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 419-428. | 1.1 | 26 |
| 3409 | Bilateral breast cancers. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 157-166. | 12.5 | 54 |
| 3410 | The management of breast cancer. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 753-757. | 1.8 | 10 |
| 3411 | In Vitro Chemoresponse Assay Based on the Intrinsic Subtypes in Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 624-631. | 0.6 | 8 |
| 3412 | Minimal Residual Disease in Breast Cancer: In Blood Veritas. <i>Clinical Cancer Research</i> , 2014, 20, 2505-2507. | 3.2 | 14 |
| 3413 | Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2643-2650. | 3.2 | 341 |
| 3414 | Oligometastatic Breast Cancer: A Shift from Palliative to Potentially Curative Treatment?. <i>Breast Care</i> , 2014, 9, 7-14. | 0.8 | 65 |
| 3415 | Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study. <i>Lancet Oncology</i> , The, 2014, 15, 722-729. | 5.1 | 81 |
| 3416 | Trastuzumab in small tumours and in elderly women. <i>Cancer Treatment Reviews</i> , 2014, 40, 41-47. | 3.4 | 15 |
| 3417 | Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2A–2 factorial randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 201-212. | 5.1 | 106 |
| 3418 | Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression. <i>Clinical Breast Cancer</i> , 2014, 14, 258-264. | 1.1 | 51 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3419 | Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. <i>Modern Pathology</i> , 2014, 27, 554-561. | 2.9 | 66 |
| 3420 | Internal Mammary Sentinel Node Biopsy in Breast Cancer. Is it Indicated?. <i>Pathology and Oncology Research</i> , 2014, 20, 169-177. | 0.9 | 13 |
| 3421 | Targeting cancer stem cells to suppress acquired chemotherapy resistance. <i>Oncogene</i> , 2014, 33, 4451-4463. | 2.6 | 213 |
| 3422 | COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 358-367. | 1.6 | 20 |
| 3424 | The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2014, 7, 1-17. | 0.6 | 83 |
| 3425 | Comparative Efficacy of Extracts from Lycium Barbarum Bark and Fruit on Estrogen Receptor Positive Human Mammary Carcinoma MCF-7 Cells. <i>Nutrition and Cancer</i> , 2014, 66, 278-284. | 0.9 | 22 |
| 3426 | A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil+epirubicin+cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial Tj ETQq0 0 0 tgb /Overlock 10 Tf | | |
| 3427 | Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 11-28. | 0.5 | 54 |
| 3428 | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2014, 383, 1041-1048. | 6.3 | 504 |
| 3429 | Effect of prior chemotherapy regimens on the efficacy of endocrine therapy within a German cohort of the TEAM trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 117-126. | 1.2 | 0 |
| 3430 | Contemporary Systemic Therapy for Male Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 31-39. | 1.1 | 37 |
| 3431 | The Optimal Duration of Adjuvant Endocrine Therapy for Early Stage Breast Cancer—With What Drugs and for How Long?. <i>Current Oncology Reports</i> , 2014, 16, 358. | 1.8 | 9 |
| 3432 | Adherence to Anti-estrogen Therapy in Seniors with Breast Cancer: How Well are we Doing?. <i>Breast Journal</i> , 2014, 20, 632-638. | 0.4 | 12 |
| 3433 | Comparative analysis of breast cancer mortality following mammography screening in Denmark and Norway. <i>Annals of Oncology</i> , 2014, 25, 1137-1143. | 0.6 | 6 |
| 3434 | Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers. <i>Cancer Treatment Reviews</i> , 2014, 40, 1137-1152. | 3.4 | 26 |
| 3435 | An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case. <i>European Journal of Cancer</i> , 2014, 50, 3089-3097. | 1.3 | 13 |
| 3436 | Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. <i>International Journal of Hyperthermia</i> , 2014, 30, 285-294. | 1.1 | 93 |
| 3437 | Safety and efficacy of progressive resistance training in breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 249-268. | 1.1 | 111 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3438 | Association between <i>CYP2D6</i> genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis. <i>Pharmacogenomics</i> , 2014, 15, 49-60. | 0.6 | 36 |
| 3439 | Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. <i>Breast</i> , 2014, 23, 710-720. | 0.9 | 37 |
| 3440 | Screening for Distress in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 226-234. | 0.5 | 2 |
| 3441 | Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 3.0 | 120 |
| 3442 | Treatment strategies in elderly breast cancer patients: Is there a need for surgery?. <i>Breast</i> , 2014, 23, 793-798. | 0.9 | 16 |
| 3443 | Breast cancer during follow-up and progression – A population based cohort on new cancers and changed biology. <i>European Journal of Cancer</i> , 2014, 50, 2916-2924. | 1.3 | 35 |
| 3444 | Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193). <i>J Clin Oncol</i> 2014;32:3948-3958. | 0.8 | 118 |
| 3445 | G Protein-Coupled Estrogen Receptor Regulates Mammary Tumorigenesis and Metastasis. <i>Molecular Cancer Research</i> , 2014, 12, 1644-1654. | 1.5 | 79 |
| 3447 | Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3513-3519. | 0.8 | 28 |
| 3448 | Lack of diversity in cancer drug clinical trials may exacerbate racial disparities in mortality rates. <i>Cancer Epidemiology</i> , 2014, 38, 645-646. | 0.8 | 12 |
| 3449 | Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. <i>Fertility and Sterility</i> , 2014, 102, 488-495.e3. | 0.5 | 95 |
| 3450 | Simulation with cells <i>in vitro</i> of tamoxifen treatment in premenopausal breast cancer patients with different <i>CYP2D6</i> genotypes. <i>British Journal of Pharmacology</i> , 2014, 171, 5624-5635. | 2.7 | 29 |
| 3451 | A Patient-Level Calibration Framework for Evaluating Surveillance Strategies: A Case Study of Mammographic Follow-Up After Early Breast Cancer. <i>Value in Health</i> , 2014, 17, 669-678. | 0.1 | 8 |
| 3452 | CCNB1 is a prognostic biomarker for ER+ breast cancer. <i>Medical Hypotheses</i> , 2014, 83, 359-364. | 0.8 | 117 |
| 3454 | Radionuclide imaging of drug delivery for patient selection in targeted therapy. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 175-185. | 2.4 | 7 |
| 3455 | Preoperative MRI in Patients with Locoregional Recurrent Breast Cancer. <i>Academic Radiology</i> , 2014, 21, 1276-1285. | 1.3 | 5 |
| 3456 | Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. <i>British Journal of Cancer</i> , 2014, 110, 1378-1384. | 2.9 | 64 |
| 3457 | Factors influencing Oncotype DX use in the management of early breast cancer: A single centre experience. <i>European Journal of Cancer</i> , 2014, 50, 2544-2549. | 1.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3458 | Breast health in developing countries. <i>Climacteric</i> , 2014, 17, 54-59. | 1.1 | 13 |
| 3459 | The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators. <i>Steroids</i> , 2014, 90, 3-12. | 0.8 | 22 |
| 3460 | An update on the medical management of breast cancer. <i>BMJ, The</i> , 2014, 348, g3608-g3608. | 3.0 | 54 |
| 3461 | Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. <i>Annals of Oncology</i> , 2014, 25, 339-345. | 0.6 | 326 |
| 3462 | Patients' preferences for surgical and adjuvant systemic treatment in early breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 1005-1018. | 3.4 | 66 |
| 3463 | Prise en charge du cancer du sein. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 740-744. | 0.0 | 1 |
| 3464 | Ado-trastuzumab Emtansine. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1484-1493. | 0.9 | 37 |
| 3465 | Adjuvant Chemotherapy in Older Women With Breast Cancer: Who and What?. <i>Journal of Clinical Oncology</i> , 2014, 32, 1996-2000. | 0.8 | 24 |
| 3466 | Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. <i>Future Oncology</i> , 2014, 10, 107-122. | 1.1 | 75 |
| 3467 | B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells. <i>BMC Cancer</i> , 2014, 14, 418. | 1.1 | 33 |
| 3468 | Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. <i>BMC Cancer</i> , 2014, 14, 515. | 1.1 | 26 |
| 3469 | Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. <i>BMC Cancer</i> , 2014, 14, 525. | 1.1 | 23 |
| 3470 | Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study. <i>BMC Health Services Research</i> , 2014, 14, 326. | 0.9 | 1 |
| 3471 | Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying <i>Clostridium perfringens</i> iota toxin cytotoxicity in breast cancer. <i>Molecular Cancer</i> , 2014, 13, 163. | 7.9 | 16 |
| 3472 | Clinically cNO breast cancer in elderly: What surgery?. <i>International Journal of Surgery</i> , 2014, 12, S130-S134. | 1.1 | 5 |
| 3473 | Biomarker Testing for Breast, Lung, and Gastroesophageal Cancers at NCI Designated Cancer Centers. <i>Journal of the National Cancer Institute</i> , 2014, 106, . | 3.0 | 18 |
| 3474 | Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 617-629. | 1.1 | 69 |
| 3476 | Haste makes waste, but lack of urgency is opportunity lost. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 223-224. | 1.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3477 | ERÎ ² splice variant expression in four large cohorts of human breast cancer patient tumors. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 657-667. | 1.1 | 39 |
| 3478 | Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 637-646. | 1.1 | 1 |
| 3479 | FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2014, 1839, 1316-1322. | 0.9 | 158 |
| 3480 | Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy. <i>Supportive Care in Cancer</i> , 2014, 22, 2851-2859. | 1.0 | 55 |
| 3482 | Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 317-330. | 1.1 | 10 |
| 3483 | Letter in response: breast cancer screening of women aged 70â€“74Âˆyears. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 563-564. | 1.1 | 1 |
| 3484 | Rebuttal to: Letter to the Editor by Robert Burton, in response to doi:10.1007/s10549-013-2794-5. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 565-566. | 1.1 | 0 |
| 3485 | Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 743-751. | 1.1 | 49 |
| 3486 | Prognostic factors for survival in metastatic breast cancer by hormone receptor status. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 503-511. | 1.1 | 26 |
| 3487 | Breast cancer and aging: results of the U13 conference breast cancer panel. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 1-6. | 1.1 | 23 |
| 3488 | Emerging strategies to overcome resistance to endocrine therapy for breast cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 791-807. | 2.7 | 23 |
| 3489 | USP9X Downregulation Renders Breast Cancer Cells Resistant to Tamoxifen. <i>Cancer Research</i> , 2014, 74, 3810-3820. | 0.4 | 38 |
| 3490 | PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. <i>Breast Cancer Research</i> , 2014, 16, R13. | 2.2 | 54 |
| 3491 | Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. <i>Breast Cancer Research</i> , 2014, 16, R47. | 2.2 | 86 |
| 3492 | Effect of Axillary Lymph Node Dissection after Sentinel Lymph Node Biopsy on Overall Survival in Patients with T1 or T2 Node-positive Breast Cancer: Report from the Korean Breast Cancer Society. <i>Annals of Surgical Oncology</i> , 2014, 21, 1231-1236. | 0.7 | 21 |
| 3493 | Rate of Contralateral Prophylactic Mastectomy is Influenced by Preoperative MRI Recommendations. <i>Annals of Surgical Oncology</i> , 2014, 21, 4133-4138. | 0.7 | 13 |
| 3494 | Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 735-744. | 0.8 | 237 |
| 3495 | ALERT - Adverse Late Effects of Cancer Treatment. <i>Medical Radiology</i> , 2014, , . | 0.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3496 | Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2142-2150. | 0.8 | 207 |
| 3497 | Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. <i>Journal of Cancer Survivorship</i> , 2014, 8, 603-610. | 1.5 | 29 |
| 3498 | Luminal breast cancer classification according to proliferative indices: clinicopathological characteristics and short-term survival analysis. <i>Medical Oncology</i> , 2014, 31, 55. | 1.2 | 4 |
| 3499 | Breast cancer management in the elderly. <i>Clinical and Translational Oncology</i> , 2014, 16, 351-361. | 1.2 | 5 |
| 3500 | Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. <i>Breast Cancer</i> , 2014, 21, 780-785. | 1.3 | 9 |
| 3501 | Can Molecular Subtyping Replace Axillary Nodal Status as Prognostic Marker in Breast Cancer?. <i>Indian Journal of Surgical Oncology</i> , 2014, 5, 282-289. | 0.3 | 5 |
| 3502 | Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer. <i>Tumor Biology</i> , 2014, 35, 8581-8589. | 0.8 | 3 |
| 3503 | Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand. <i>Pharmacoeconomics</i> , 2014, 32, 707-724. | 1.7 | 7 |
| 3504 | Cost-Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer. <i>Pharmacoeconomics</i> , 2014, 32, 1005-1013. | 1.7 | 11 |
| 3505 | Testing the treatment effect on competing causes of death in oncology clinical trials. <i>BMC Medical Research Methodology</i> , 2014, 14, 72. | 1.4 | 7 |
| 3506 | Estrogen receptor β -coupled Bmi1 regulation pathway in breast cancer and its clinical implications. <i>BMC Cancer</i> , 2014, 14, 122. | 1.1 | 13 |
| 3507 | Adherence to hormone therapy among women with breast cancer. <i>BMC Cancer</i> , 2014, 14, 397. | 1.1 | 53 |
| 3508 | The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer. <i>World Journal of Surgical Oncology</i> , 2014, 12, 93. | 0.8 | 16 |
| 3509 | Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial. <i>Trials</i> , 2014, 15, 171. | 0.7 | 4 |
| 3510 | Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. <i>Steroids</i> , 2014, 90, 44-52. | 0.8 | 30 |
| 3511 | Synthesis and cytotoxicity of thieno[2,3-b]pyridine and furo[2,3-b]pyridine derivatives. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 420-437. | 2.6 | 56 |
| 3512 | The potential to target CCL5/CCR5 in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1265-1275. | 1.5 | 86 |
| 3513 | BETs abet Tam-R in ER-positive breast cancer. <i>Cell Research</i> , 2014, 24, 899-900. | 5.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3514 | Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: An analysis of 1655 patients. <i>Breast</i> , 2014, 23, 676-682. | 0.9 | 9 |
| 3515 | Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients. <i>Molecular Oncology</i> , 2014, 8, 1014-1025. | 2.1 | 49 |
| 3516 | Local Recurrence in Women With Stage I Breast Cancer: Declining Rates Over Time in a Large, Population-Based Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 80-86. | 0.4 | 27 |
| 3517 | Major depressive disorder in breast cancer: A critical systematic review of pharmacological and psychotherapeutic clinical trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 349-355. | 3.4 | 40 |
| 3518 | Variation in Use of Estrogen Receptor- β Gene Promoters in Breast Cancer Compared by Quantification of Promoter-Specific Messenger RNA. <i>Clinical Breast Cancer</i> , 2014, 14, 249-257.e2. | 1.1 | 9 |
| 3519 | Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. <i>Patient Education and Counseling</i> , 2014, 95, 98-103. | 1.0 | 51 |
| 3521 | Cost-Utility Analysis of Platinum-Based Chemotherapy versus Taxane and Other Regimens for Ovarian Cancer. <i>Value in Health</i> , 2014, 17, 34-42. | 0.1 | 10 |
| 3522 | New cancer drugs in Sweden: Assessment, implementation and access. <i>Journal of Cancer Policy</i> , 2014, 2, 45-62. | 0.6 | 11 |
| 3523 | Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. <i>Breast</i> , 2014, 23, 346-351. | 0.9 | 26 |
| 3524 | Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells. <i>Journal of Surgical Research</i> , 2014, 190, 203-209. | 0.8 | 12 |
| 3525 | Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 85-93. | 1.1 | 13 |
| 3526 | Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis. <i>Reports of Practical Oncology and Radiotherapy</i> , 2014, 19, 173-181. | 0.3 | 11 |
| 3527 | Preoperative Breast MRI for Early-Stage Breast Cancer: Effect on Surgical and Long-Term Outcomes. <i>American Journal of Roentgenology</i> , 2014, 202, 1376-1382. | 1.0 | 94 |
| 3528 | Smaller Reduction in 3D Breast Density Associated With Subsequent Cancer Recurrence in Patients With Breast Cancer Receiving Adjuvant Tamoxifen Therapy. <i>American Journal of Roentgenology</i> , 2014, 202, 912-921. | 1.0 | 9 |
| 3529 | Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies. <i>European Journal of Cancer</i> , 2014, 50, 2020-2036. | 1.3 | 248 |
| 3530 | Endocrine Therapy for Breast Cancer: Assessing an Array of Women's Treatment Experiences and Perceptions, Their Perceived Self-Efficacy and Nonadherence. <i>Clinical Breast Cancer</i> , 2014, 14, 460-467.e2. | 1.1 | 37 |
| 3531 | Luminal (Her2 negative) prognostic index and survival of breast cancer patients. <i>Cancer Epidemiology</i> , 2014, 38, 286-290. | 0.8 | 12 |
| 3532 | Drug resistance to targeted therapies: D'Almeida all over again. <i>Molecular Oncology</i> , 2014, 8, 1067-1083. | 2.1 | 187 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3533 | Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. <i>Cancer Epidemiology</i> , 2014, 38, 427-434. | 0.8 | 67 |
| 3534 | High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level. <i>Breast Cancer</i> , 2014, 21, 482-490. | 1.3 | 37 |
| 3535 | Tetrandrine enhances the anticancer effects of arsenic trioxide in vitro. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 416-424. | 0.3 | 15 |
| 3536 | Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. <i>F1000Research</i> , 2014, 3, 198. | 0.8 | 40 |
| 3537 | Far Beyond the Usual Biomarkers in Breast Cancer: A Review. <i>Journal of Cancer</i> , 2014, 5, 559-571. | 1.2 | 44 |
| 3538 | Abstract 2876: Genetic polymorphism in the mir-196a as a prognostic biomarker for early breast cancer. , 2014, , . | | 0 |
| 3539 | Women with breast cancer taking chemotherapy: depression symptoms and treatment adherence. <i>Revista Latino-Americana De Enfermagem</i> , 2014, 22, 866-873. | 0.4 | 30 |
| 3540 | Forkhead-box A1 suppresses the progression of endometrial cancer via crosstalk with estrogen receptor β . <i>Oncology Reports</i> , 2014, 31, 1225-1234. | 1.2 | 24 |
| 3541 | MYC and MXI1 Protein Expression: Potential Prognostic Significance in Women with Breast Cancer in China. <i>Oncology Research and Treatment</i> , 2014, 37, 118-123. | 0.8 | 5 |
| 3542 | Breast Cancer Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 542-590. | 2.3 | 159 |
| 3543 | Involvement of B3GALNT2 overexpression in the cell growth of breast cancer. <i>International Journal of Oncology</i> , 2014, 44, 427-434. | 1.4 | 11 |
| 3544 | Quantification of Tamoxifen in Pharmaceutical Formulations Using Micellar Liquid Chromatography. <i>Analytical Sciences</i> , 2014, 30, 925-930. | 0.8 | 12 |
| 3546 | Important Factors Affecting Adjuvant Treatment Decision in Stage IA Breast Cancer Patients in Turkey. <i>Breast Care</i> , 2014, 9, 4-4. | 0.8 | 1 |
| 3547 | The integration of locoregional with systemic adjuvant therapy for early-stage breast cancer: the shifting sands of decision-making. <i>Breast Cancer Management</i> , 2014, 3, 205-212. | 0.2 | 0 |
| 3549 | Prognostic impact of chemotherapy-induced amenorrhea on premenopausal breast cancer. <i>Menopause</i> , 2015, 22, 1091-1097. | 0.8 | 20 |
| 3550 | Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. <i>Journal of Bone Oncology</i> , 2015, 4, 54-58. | 1.0 | 17 |
| 3551 | Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer. <i>Medicine (United States)</i> , 2015, 94, e1006. | 0.4 | 10 |
| 3552 | Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. <i>JAMA Oncology</i> , 2015, 1, 158. | 3.4 | 55 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3553 | Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Population-Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992-2009. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1570-1582. | 1.3 | 11 |
| 3554 | Application status of tamoxifen in endocrine therapy for early breast cancer. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 2207-2212. | 0.8 | 5 |
| 3555 | Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites. <i>Npj Breast Cancer</i> , 2015, 1, 15018. | 2.3 | 37 |
| 3556 | Nuclear factor- κ B plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. <i>Scientific Reports</i> , 2014, 4, 4057. | 1.6 | 54 |
| 3557 | Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 737-743. | 2.3 | 21 |
| 3558 | Synthetic lethality and chemoresistance in cancer. , 0, , 65-82. | | 0 |
| 3559 | A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients. <i>Scientific Reports</i> , 2015, 5, 16553. | 1.6 | 99 |
| 3560 | Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1109-1112. | 0.4 | 22 |
| 3561 | Follow-up design of unexpected enhancing lesions on preoperative MRI of breast cancer patients. <i>Diagnostic and Interventional Radiology</i> , 2015, 21, 16-21. | 0.7 | 3 |
| 3562 | Discharge to Primary Care for Survivorship Follow-Up: How Are Patients With Early-Stage Breast Cancer Faring?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 762-771. | 2.3 | 10 |
| 3563 | Breast Cancer Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 448-475. | 2.3 | 158 |
| 3564 | The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer. <i>Breast Care</i> , 2015, 10, 312-315. | 0.8 | 10 |
| 3565 | PG 1.04 Big data: are large prospective randomized trials obsolete in the future?. <i>Breast</i> , 2015, 24, S3-S4. | 0.9 | 1 |
| 3566 | Programming cancer through phase-functionalized silicon based biomaterials. <i>Scientific Reports</i> , 2015, 5, 10826. | 1.6 | 4 |
| 3567 | The effect of HCV serological status on Doxorubicin based chemotherapy induced toxicity and disease-free survival in breast cancer patients. <i>Alexandria Journal of Medicine</i> , 2015, 51, 287-293. | 0.4 | 1 |
| 3569 | Geographic variation in the intended choice of adjuvant treatments for women diagnosed with screen-detected breast cancer in Queensland. <i>BMC Public Health</i> , 2015, 15, 1204. | 1.2 | 10 |
| 3570 | Allelic imbalance at the HER2/TOP2A locus in breast cancer. <i>Diagnostic Pathology</i> , 2015, 10, 56. | 0.9 | 6 |
| 3571 | Tamoxifen retinopathy: a case report. <i>SpringerPlus</i> , 2015, 4, 501. | 1.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3572 | Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells. SpringerPlus, 2015, 4, 689. | 1.2 | 26 |
| 3573 | Variations in Guidelineâ€Concordant Breast Cancer Adjuvant Therapy in Rural Georgia. Health Services Research, 2015, 50, 1088-1108. | 1.0 | 21 |
| 3574 | Population-Based Assessment of Emergency Room Visits and Hospitalizations Among Women Receiving Adjuvant Chemotherapy for Early Breast Cancer. Journal of Oncology Practice, 2015, 11, 126-132. | 2.5 | 56 |
| 3575 | PG 1.03 Picking the optimal endocrine adjuvant treatment for pre-menopausal women. Breast, 2015, 24, S3. | 0.9 | 0 |
| 3576 | Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. BMC Cancer, 2015, 15, 697. | 1.1 | 3 |
| 3577 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. BMC Cancer, 2015, 15, 978. | 1.1 | 6 |
| 3578 | Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells. Molecular Cancer, 2015, 14, 72. | 7.9 | 38 |
| 3579 | Systematic review of high-intensity focused ultrasound ablation in the treatment of breast cancer. British Journal of Surgery, 2015, 102, 873-882. | 0.1 | 70 |
| 3580 | Racial/Ethnic and Socioeconomic Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review. American Journal of Public Health, 2015, 105, e4-e15. | 1.5 | 102 |
| 3581 | Advances in the Molecular Analysis of Breast Cancer: Pathway toward Personalized Medicine. Cancer Control, 2015, 22, 211-219. | 0.7 | 25 |
| 3582 | Predicting Late-stage Breast Cancer Diagnosis and Receipt of Adjuvant Therapy. Medical Care, 2015, 53, 980-988. | 1.1 | 22 |
| 3583 | Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma. Archives of Pathology and Laboratory Medicine, 2015, 139, 1546-1549. | 1.2 | 36 |
| 3584 | Costâ€effectiveness of digital mammography screening before the age of 50 in <sc>T</sc>he <sc>N</sc>etherlands. International Journal of Cancer, 2015, 137, 1990-1999. | 2.3 | 35 |
| 3585 | Survival benefit in women with <i>BRCA1</i> mutation or familial risk in the <sc>MRI</sc> screening study (<sc>MRISC</sc>). International Journal of Cancer, 2015, 137, 1729-1738. | 2.3 | 78 |
| 3586 | Risk of Gastric and Colorectal Cancer After Tamoxifen Use for Breast Cancer. Journal of Clinical Gastroenterology, 2015, 49, 666-674. | 1.1 | 11 |
| 3587 | Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?. Medicine (United States), 2015, 94, e1259. | 0.4 | 16 |
| 3588 | Populationâ€based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. Cancer, 2015, 121, 4062-4070. | 2.0 | 21 |
| 3589 | Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer, 2015, 121, 2544-2552. | 2.0 | 162 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3590 | Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2015, 7, 797-816. | 3.3 | 55 |
| 3591 | Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. <i>The Cochrane Library</i> , 2015, , CD007245. | 1.5 | 39 |
| 3592 | Tumour bed boost radiotherapy for women after breast conserving surgery. <i>The Cochrane Library</i> , 2015, , . | 1.5 | 1 |
| 3593 | The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy. <i>International Journal of Cancer</i> , 2015, 137, 165-172. | 2.3 | 37 |
| 3594 | Designing a study to evaluate the benefit of a biomarker for selecting patient treatment. <i>Statistics in Medicine</i> , 2015, 34, 3503-3515. | 0.8 | 11 |
| 3595 | Hormones in cancer. , 0, , 24-41. | | 0 |
| 3596 | Precision Medicine for Metastatic Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e2-e7. | 1.8 | 14 |
| 3597 | Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2015, 18, 271. | 0.8 | 15 |
| 3598 | Effect of radiotherapy on survival of women with locally excised ductal carcinoma in situ of the breast: a Surveillance, Epidemiology, and End Results population-based analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 1407. | 1.0 | 3 |
| 3599 | Advances of Non-Surgical Therapy for Different Molecular Subtypes of Breast Cancer. <i>Advancements in Genetic Engineering</i> , 2015, 04, . | 0.1 | 0 |
| 3600 | Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction. <i>Clinical Epidemiology</i> , 2015, 7, 441. | 1.5 | 29 |
| 3601 | New and emerging factors in tumorigenesis: an overview. <i>Cancer Management and Research</i> , 2015, 7, 225. | 0.9 | 27 |
| 3602 | Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem. <i>Journal of Breast Cancer</i> , 2015, 18, 207. | 0.8 | 30 |
| 3603 | Pilot study investigating the prognostic significance of thymidine phosphorylase expression in patients with metastatic breast cancer: a single institution retrospective analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 911. | 1.0 | 2 |
| 3604 | Tumor Markers: Precision, Accuracy, Validity and Statistical Matters of Concern. <i>Chattagram Maa-O-Shishu Hospital Medical College Journal</i> , 2015, 13, 89-92. | 0.1 | 0 |
| 3605 | Clinical utility of exemestane in the treatment of breast cancer. <i>International Journal of Women's Health</i> , 2015, 7, 551. | 1.1 | 13 |
| 3606 | The Effect of Freezing on the Immunoprofile of Breast Carcinoma Cells. <i>Balkan Medical Journal</i> , 2015, 31, 335-339. | 0.3 | 1 |
| 3607 | Adjuvant chemotherapy may improve survival of patients with luminal A breast cancer and positive lymph nodes. <i>Genetics and Molecular Research</i> , 2015, 14, 8563-8573. | 0.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3608 | Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment. <i>Oncotarget</i> , 2015, 6, 14687-14699. | 0.8 | 35 |
| 3609 | Carcinogenesis and Sex Hormones: A Review. <i>Endocrinology & Metabolic Syndrome: Current Research</i> , 2015, 04, . | 0.3 | 4 |
| 3610 | Bone Health in Adults Treated with Endocrine Therapy for Early Breast or Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e567-e574. | 1.8 | 13 |
| 3611 | Endometrial Cancer Prevention with Levonorgestrel-Releasing Intrauterine System. , 2015, , . | | 0 |
| 3612 | Effects of Age on the Detection and Management of Breast Cancer. <i>Cancers</i> , 2015, 7, 908-929. | 1.7 | 263 |
| 3613 | The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2015, 16, 24243-24275. | 1.8 | 51 |
| 3614 | Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins. <i>Frontiers in Microbiology</i> , 2015, 6, 628. | 1.5 | 18 |
| 3615 | Management of cancer of the breast. , 0, , 262-292. | | 1 |
| 3616 | Overexpression of C35 in breast carcinomas is associated with tumor progression and lymphnode metastasis. <i>BioScience Trends</i> , 2015, 9, 386-392. | 1.1 | 4 |
| 3617 | New Findings on Breast Cancer Stem Cells: A Review. <i>Journal of Breast Cancer</i> , 2015, 18, 303. | 0.8 | 92 |
| 3618 | Impact of the 21-Gene Recurrence Score Assay in adjuvant chemotherapy selection for node-negative, hormone receptor-positive breast cancer in the Chinese population. <i>Neoplasma</i> , 2015, 62, 658-665. | 0.7 | 11 |
| 3619 | Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 2721. | 1.0 | 6 |
| 3620 | Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. <i>PLoS ONE</i> , 2015, 10, e0124658. | 1.1 | 27 |
| 3621 | Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment. <i>PLoS ONE</i> , 2015, 10, e0126128. | 1.1 | 39 |
| 3622 | Costâ€“Utility of Adjuvant Zoledronic Acid in Patients with Breast Cancer and Low Estrogen Levels. <i>Current Oncology</i> , 2015, 22, 246-253. | 0.9 | 0 |
| 3623 | Optimal management of breast cancer in the elderly patient: current perspectives. <i>Clinical Interventions in Aging</i> , 2015, 10, 157. | 1.3 | 21 |
| 3624 | Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials. <i>OncoTargets and Therapy</i> , 2015, 8, 1433. | 1.0 | 19 |
| 3625 | Statistical Methods for Establishing Personalized Treatment Rules in Oncology. <i>BioMed Research International</i> , 2015, 2015, 1-13. | 0.9 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 3626 | Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies. <i>International Journal of Surgical Oncology</i> , 2015, 2015, 1-7. | 0.3 | 15 |
| 3627 | Managing breast cancer in younger women: challenges and solutions. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 1. | 1.0 | 20 |
| 3628 | Aromatase inhibitors for prevention of breast cancer in postmenopausal women. <i>Menopause</i> , 2015, 22, 342-350. | 0.8 | 8 |
| 3629 | Adherence to Intravenous Chemotherapy in African American and White Women With Early-Stage Breast Cancer. <i>Cancer Nursing</i> , 2015, 38, 89-98. | 0.7 | 25 |
| 3630 | Oncotype DX RT-qPCR Assay for ER and PR Correlation With IHC. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 178-187. | 0.6 | 6 |
| 3631 | Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen. <i>Cancer Biology and Therapy</i> , 2015, 16, 317-324. | 1.5 | 72 |
| 3632 | Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. <i>Drug Metabolism Reviews</i> , 2015, 47, 281-290. | 1.5 | 32 |
| 3633 | Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. <i>EMBO Molecular Medicine</i> , 2015, 7, 1034-1047. | 3.3 | 380 |
| 3635 | Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists. <i>Future Oncology</i> , 2015, 11, 1181-1189. | 1.1 | 0 |
| 3636 | The Emerging Role of Intraoperative Radiation Therapy [IORT] in Breast Cancer. , 2015, , 413-461. | | 2 |
| 3637 | Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors. <i>Molecular Oncology</i> , 2015, 9, 1744-1759. | 2.1 | 26 |
| 3638 | Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219. | 13.9 | 1,239 |
| 3640 | Is "Me, Me, Me" the New "We, We, We"? Can We Afford (Not) to Take the Plunge into the Personalised, Stratified Medicine Era?. , 2015, , 217-226. | | 0 |
| 3641 | Prediction of Response to Aromatase Inhibitors in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 191-228. | 0.1 | 1 |
| 3642 | DEGRO practical guidelines for radiotherapy of breast cancer. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 623-633. | 1.0 | 22 |
| 3643 | Trends and Present Treatment Patterns of Early Breast Cancer in Southwest China. <i>Pathology and Oncology Research</i> , 2015, 21, 367-378. | 0.9 | 6 |
| 3644 | Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases. <i>Clinical Proteomics</i> , 2015, 12, 13. | 1.1 | 15 |
| 3645 | Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2015, 61, 974-982. | 1.5 | 155 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3646 | Risks of nonadherence to hormone therapy in Asian women with breast cancer. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 328-334. | 0.8 | 12 |
| 3647 | Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. <i>Clinical Cancer Research</i> , 2015, 21, 4305-4311. | 3.2 | 51 |
| 3648 | Cardiac risk in the treatment of breast cancer: assessment and management. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 21. | 1.0 | 32 |
| 3649 | Factors associated with contralateral preventive mastectomy. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 1. | 1.0 | 8 |
| 3650 | Prognostic Significance of Single Progesterone Receptor Positivity. <i>Medicine (United States)</i> , 2015, 94, e2066. | 0.4 | 21 |
| 3651 | Utilisation of ¹ H-MRS spectroscopy and diffusion weighted imaging in predicting and monitoring of breast cancer response to chemotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 268-277. | 0.9 | 26 |
| 3652 | Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival. <i>Translational Oncology</i> , 2015, 8, 424-433. | 1.7 | 27 |
| 3653 | The Introduction of Generic Aromatase Inhibitors and Treatment Adherence Among Medicare D Enrollees. <i>Journal of the National Cancer Institute</i> , 2015, 107, . | 3.0 | 40 |
| 3654 | New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv245. | 3.0 | 21 |
| 3655 | Cáncer de mama con receptores hormonales positivos: tratamiento adyuvante, primera línea en cáncer metastásico y nuevas estrategias (inhibición de mTOR). <i>Gaceta Mexicana De Oncología</i> , 2015, 14, 277-292. | 0.0 | 1 |
| 3657 | Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. <i>Value in Health</i> , 2015, 18, 1070-1078. | 0.1 | 10 |
| 3658 | What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study. <i>Cancer Epidemiology</i> , 2015, 39, 848-853. | 0.8 | 8 |
| 3659 | Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 239-246. | 1.1 | 111 |
| 3660 | Treatment of Breast Cancer in the Elderly. <i>Current Oncology Reports</i> , 2015, 17, 51. | 1.8 | 19 |
| 3661 | Expression and function of miR-155 in breast cancer. <i>Biotechnology and Biotechnological Equipment</i> , 2015, 29, 840-843. | 0.5 | 13 |
| 3662 | Longitudinal Noninvasive Imaging of Progesterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy. <i>Breast Diseases</i> , 2015, 26, 307-309. | 0.0 | 0 |
| 3663 | Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 533-541. | 1.1 | 31 |
| 3664 | Management of breast cancer in very young women. <i>Breast</i> , 2015, 24, S154-S158. | 0.9 | 79 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 3665 | Molecular-Based Diagnostic, Prognostic and Predictive Tests in Breast Cancer. <i>Molecular Pathology Library</i> , 2015, , 177-195. | 0.1 | 1 |
| 3666 | Carcinoma Breast with Endometrial Metastasis. <i>Indian Journal of Gynecologic Oncology</i> , 2015, 13, 1. | 0.1 | 0 |
| 3667 | Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer. <i>Pathobiology</i> , 2015, 82, 113-123. | 1.9 | 59 |
| 3668 | Is adjuvant chemotherapy omissible in women with T1â€²2 stage, node-positive, luminal A type breast cancer?. <i>Journal of Chemotherapy</i> , 2015, 27, 290-296. | 0.7 | 5 |
| 3670 | Enhanced cytotoxicity in triple-negative and estrogen receptor-positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel. <i>Oncology Reports</i> , 2015, 34, 1589-1598. | 1.2 | 33 |
| 3671 | Molecular segmentation of luminal breast: Reality in 2015?. <i>Breast</i> , 2015, 24, S41-S43. | 0.9 | 0 |
| 3672 | LH-RH analogues in the treatment of young women with early breast cancer: Long-term follow-up of a phase II study. <i>International Journal of Oncology</i> , 2015, 46, 1354-1360. | 1.4 | 9 |
| 3673 | Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells. <i>International Journal of Oncology</i> , 2015, 46, 841-848. | 1.4 | 27 |
| 3674 | With better adjuvant therapy, does breast cancer stage still matter?. <i>BMJ, The</i> , 2015, 351, h5273. | 3.0 | 0 |
| 3675 | Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 821-827. | 1.9 | 49 |
| 3676 | Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward â€œprecisionâ€•cancer therapy. <i>Biotechnic and Histochemistry</i> , 2015, 90, 81-92. | 0.7 | 12 |
| 3677 | Case 1-2015. <i>New England Journal of Medicine</i> , 2015, 372, 162-170. | 13.9 | 2 |
| 3678 | MiR-873 regulates ERÎ± transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. <i>Oncogene</i> , 2015, 34, 3895-3907. | 2.6 | 88 |
| 3679 | Prognostic implications of receptor discordance between primary and recurrent breast cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 701-708. | 1.0 | 25 |
| 3680 | Circulating tumor cell enumeration by the CellSearch system: The clinicianâ€™s guide to breast cancer treatment?. <i>Cancer Treatment Reviews</i> , 2015, 41, 144-150. | 3.4 | 62 |
| 3681 | Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76. | 3.4 | 83 |
| 3682 | Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju437-dju437. | 3.0 | 12 |
| 3684 | Surgical management of lobular carcinoma from a national screening program: A retrospective analysis. <i>European Journal of Surgical Oncology</i> , 2015, 41, 79-85. | 0.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 3685 | Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping. <i>Cancer Treatment Reviews</i> , 2015, 41, 289-299. | 3.4 | 95 |
| 3686 | The potential role of estrogen receptor β 2 in breast cancer. <i>International Journal of Surgery</i> , 2015, 14, 17-22. | 1.1 | 24 |
| 3687 | Perfecting Breast-Cancer Treatment â€” Incremental Gains and Musculoskeletal Pains. <i>New England Journal of Medicine</i> , 2015, 372, 477-478. | 13.9 | 14 |
| 3688 | Systemic Treatment for Breast Cancer: Chemotherapy and Biotherapy Agents. <i>Seminars in Oncology Nursing</i> , 2015, 31, 156-162. | 0.7 | 4 |
| 3689 | Tamoxifen resistance: From cell culture experiments towards novel biomarkers. <i>Pathology Research and Practice</i> , 2015, 211, 189-197. | 1.0 | 59 |
| 3690 | Current management of lesions associated with an increased risk of breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 227-238. | 12.5 | 110 |
| 3691 | Overall survival in patients with a re-excision following breast conserving surgery compared to those without in a large population-based cohort. <i>European Journal of Cancer</i> , 2015, 51, 282-291. | 1.3 | 31 |
| 3692 | Markers for the identification of late breast cancer recurrence. <i>Breast Cancer Research</i> , 2015, 17, 10. | 2.2 | 60 |
| 3693 | The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R1-R31. | 1.6 | 111 |
| 3694 | The Development of Dose-Dense Adjuvant Chemotherapy. <i>Breast Journal</i> , 2015, 21, 42-51. | 0.4 | 12 |
| 3695 | A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. <i>Molecular Oncology</i> , 2015, 9, 115-127. | 2.1 | 38 |
| 3696 | Predictive markers in breast cancer: An update on ER and HER2 testing and reporting. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 362-369. | 1.0 | 47 |
| 3697 | Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 145-155. | 2.7 | 264 |
| 3698 | Adjuvant systemic therapy in breast cancer: quo vadis?. <i>Annals of Oncology</i> , 2015, 26, 1629-1634. | 0.6 | 18 |
| 3699 | Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase. <i>British Journal of Cancer</i> , 2015, 112, 809-818. | 2.9 | 67 |
| 3700 | Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family Historyâ€”Based Testing. <i>Journal of the National Cancer Institute</i> , 2015, 107, 380. | 3.0 | 135 |
| 3701 | Treatment With Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: Is It Forever?. <i>Journal of Clinical Oncology</i> , 2015, 33, 823-828. | 0.8 | 12 |
| 3702 | The Effect of an Evidence-Based Medicine Curriculum on Breast Cancer Knowledge and Satisfaction of Surgical Residents. <i>Journal of Surgical Education</i> , 2015, 72, 717-725. | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3703 | Evolving paradigms in multifocal breast cancer. <i>Seminars in Cancer Biology</i> , 2015, 31, 111-118. | 4.3 | 34 |
| 3704 | Identification and validation of gene module associated with lung cancer through coexpression network analysis. <i>Gene</i> , 2015, 563, 56-62. | 1.0 | 37 |
| 3705 | Adjuvant Chemotherapy for Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. <i>Current Oncology</i> , 2015, 22, 82-94. | 0.9 | 29 |
| 3706 | The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. <i>Molecular and Cellular Endocrinology</i> , 2015, 418, 245-263. | 1.6 | 27 |
| 3707 | Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study. <i>British Journal of Cancer</i> , 2015, 113, 390-395. | 2.9 | 41 |
| 3708 | Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 173-181. | 1.1 | 17 |
| 3709 | Gene-Expression-Based Predictors for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3418-3432. | 0.7 | 24 |
| 3710 | Transition From Film to Digital Mammography. <i>American Journal of Preventive Medicine</i> , 2015, 48, 535-542. | 1.6 | 17 |
| 3711 | Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. <i>Lancet, The</i> , 2015, 386, 1341-1352. | 6.3 | 1,072 |
| 3712 | Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. <i>Lancet, The</i> , 2015, 386, 1353-1361. | 6.3 | 581 |
| 3713 | Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. <i>Hormones and Cancer</i> , 2015, 6, 206-213. | 4.9 | 88 |
| 3714 | FOXF2 suppresses the FOXC2-mediated epithelialâ€“mesenchymal transition and multidrug resistance of basal-like breast cancer. <i>Cancer Letters</i> , 2015, 367, 129-137. | 3.2 | 69 |
| 3715 | New Insights into Endocrine Therapy for Young Women with Breast Cancer. <i>Women's Health</i> , 2015, 11, 343-354. | 0.7 | 3 |
| 3716 | An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy. <i>Journal of Materials Chemistry B</i> , 2015, 3, 7153-7172. | 2.9 | 108 |
| 3717 | Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. <i>Annals of Oncology</i> , 2015, 26, 1685-1691. | 0.6 | 108 |
| 3718 | Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. <i>Oncologist</i> , 2015, 20, 873-879. | 1.9 | 43 |
| 3719 | A multidisciplinary team approach minimises prophylactic mastectomy rates. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1005-1012. | 0.5 | 19 |
| 3720 | Final 10-year results of the Breast International Group 2â€“98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489. | 1.3 | 32 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3721 | How individual participant data meta-analyses have influenced trial design, conduct, and analysis. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1325-1335. | 2.4 | 60 |
| 3722 | Development and validation of an UPLC-MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 416-425. | 1.4 | 16 |
| 3724 | Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages III breast cancer: A systematic review and meta-analysis. <i>Patient Education and Counseling</i> , 2015, 98, 1524-1539. | 1.0 | 60 |
| 3725 | Ovarian stimulation in patients with breast cancer. <i>Ecancermedalscience</i> , 2015, 9, 504. | 0.6 | 20 |
| 3726 | Adjuvant Endocrine Therapy for Early Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. <i>Current Oncology</i> , 2015, 22, 95-113. | 0.9 | 37 |
| 3727 | Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. <i>Molecular and Clinical Oncology</i> , 2015, 3, 232-236. | 0.4 | 42 |
| 3728 | Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2262-2269. | 0.8 | 78 |
| 3729 | Special Issues in Older Women with Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 862, 23-37. | 0.8 | 7 |
| 3730 | Optimizing Adjuvant Taxanes in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2334-2336. | 0.8 | 1 |
| 3731 | DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer. <i>Nature Communications</i> , 2015, 6, 7758. | 5.8 | 105 |
| 3732 | Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1867-1869. | 0.8 | 13 |
| 3733 | IVF for fertility preservation in breast cancer patients' efficacy and safety issues. <i>Journal of Assisted Reproduction and Genetics</i> , 2015, 32, 1171-1178. | 1.2 | 45 |
| 3734 | Living with Metastatic Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 862, 243-254. | 0.8 | 11 |
| 3735 | Household Net Worth, Racial Disparities, and Hormonal Therapy Adherence Among Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1053-1059. | 0.8 | 102 |
| 3736 | Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes. <i>Acta Radiologica</i> , 2015, 56, 269-275. | 0.5 | 46 |
| 3737 | Adjuvant Chemotherapy in Breast Cancer. , 2015, , 335-351. | | 0 |
| 3738 | Quality of Care, Including Survivorship Care Plans. <i>Advances in Experimental Medicine and Biology</i> , 2015, 862, 255-269. | 0.8 | 6 |
| 3739 | Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. <i>Progress in Lipid Research</i> , 2015, 59, 106-125. | 5.3 | 130 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 3740 | A Canadian National Expert Consensus on Neoadjuvant Therapy for Breast Cancer: Linking Practice to Evidence and Beyond. <i>Current Oncology</i> , 2015, 22, 43-53. | 0.9 | 14 |
| 3741 | A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. <i>Hormones and Cancer</i> , 2015, 6, 214-224. | 4.9 | 30 |
| 3742 | Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis. <i>Oncologist</i> , 2015, 20, 466-473. | 1.9 | 70 |
| 3743 | Fertility preservation and breast cancer: a review. <i>Ecancermedicalscience</i> , 2015, 9, 503. | 0.6 | 34 |
| 3744 | ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 573-583. | 12.5 | 458 |
| 3745 | Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin. <i>Cancer Treatment Communications</i> , 2015, 3, 28-32. | 0.4 | 11 |
| 3746 | Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. <i>Breast Diseases</i> , 2015, 26, 84-86. | 0.0 | 0 |
| 3747 | Traditional herbal medicine as adjunctive therapy for breast cancer: A systematic review. <i>Complementary Therapies in Medicine</i> , 2015, 23, 626-632. | 1.3 | 30 |
| 3748 | Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 309-318. | 1.1 | 37 |
| 3749 | Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. <i>Cancer Research</i> , 2015, 75, 405-414. | 0.4 | 53 |
| 3750 | A systematic review and quality appraisal of international guidelines for early breast cancer systemic therapy: Are recommendations sensitive to different global resources?. <i>Breast</i> , 2015, 24, 309-317. | 0.9 | 7 |
| 3751 | Radiotherapy for elderly patients with low-risk breast cancer. <i>Lancet Oncology</i> , The, 2015, 16, e196-e197. | 5.1 | 3 |
| 3752 | Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. <i>Molecular Oncology</i> , 2015, 9, 1218-1233. | 2.1 | 64 |
| 3753 | Do national cancer screening guidelines reduce mortality?. <i>Journal of Population Economics</i> , 2015, 28, 1075-1095. | 3.5 | 4 |
| 3754 | Breast cancer: a new imaging approach as an addition to existing guidelines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 813-817. | 3.3 | 5 |
| 3755 | Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. <i>Supportive Care in Cancer</i> , 2015, 23, 3115-3130. | 1.0 | 47 |
| 3756 | Cost-Effectiveness of the 21-Gene Breast Cancer Assay in Mexico. <i>Advances in Therapy</i> , 2015, 32, 239-253. | 1.3 | 20 |
| 3757 | Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. <i>BMC Cancer</i> , 2015, 15, 239. | 1.1 | 24 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3758 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, 18. | 2.2 | 20 |
| 3759 | In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor I±. <i>Breast Cancer Research</i> , 2015, 17, 27. | 2.2 | 20 |
| 3760 | Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2015, 22, 3861-3865. | 0.7 | 6 |
| 3761 | Using a Sequence of Estrogen Response Elements as a DNA Aptamer for Estrogen Receptors<i>In Vitro</i>. <i>Nucleic Acid Therapeutics</i> , 2015, 25, 152-161. | 2.0 | 6 |
| 3762 | Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. <i>Clinical Proteomics</i> , 2015, 12, 8. | 1.1 | 31 |
| 3763 | Breast cancer in young women in southern Tunisia: Anatomical study and clinical prognostic factors: About a series of 83 patients. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 155-160. | 0.3 | 8 |
| 3764 | Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen. <i>Clinical Pharmacokinetics</i> , 2015, 54, 797-810. | 1.6 | 51 |
| 3765 | Expression of integrin-binding protein Nischarin in metastatic breast cancer. <i>Molecular Medicine Reports</i> , 2015, 12, 77-82. | 1.1 | 7 |
| 3766 | How much is the axillary nodal status in breast cancer affected by neoadjuvant chemotherapy? An Alexandria medical research institute hospital experience. <i>The Egyptian Journal of Surgery</i> , 2015, 34, 94. | 0.3 | 0 |
| 3767 | Estrogen regulates Hippo signaling via GPER in breast cancer. <i>Journal of Clinical Investigation</i> , 2015, 125, 2123-2135. | 3.9 | 179 |
| 3768 | Risk Factors for Trauma-Induced Coagulopathy- and Transfusion-Associated Multiple Organ Failure in Severely Injured Trauma Patients. <i>Frontiers in Medicine</i> , 2015, 2, 24. | 1.2 | 21 |
| 3769 | Resistance to Aromatase Inhibitors in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , . | 0.1 | 4 |
| 3770 | Patient pathway for breast cancer: turning points and future aspirations. <i>Future Oncology</i> , 2015, 11, 1059-1070. | 1.1 | 2 |
| 3771 | Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTEMIS): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 656-666. | 5.1 | 114 |
| 3772 | Breast Cancer Subtypes Predispose the Site of Distant Metastases. <i>American Journal of Clinical Pathology</i> , 2015, 143, 471-478. | 0.4 | 191 |
| 3773 | Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 639-652. | 1.1 | 11 |
| 3774 | Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 597-606. | 1.1 | 38 |
| 3775 | Reply to the letter to the editor "Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients" by Fouad et al.. <i>Annals of Oncology</i> , 2015, 26, 1799-1800. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3776 | Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 169-180. | 1.1 | 10 |
| 3777 | Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 231-242. | 1.1 | 35 |
| 3778 | Adjuvant therapeutic decisions in elderly breast cancer patients: the role of chemotherapy in a retrospective analysis. <i>Archives of Gynecology and Obstetrics</i> , 2015, 292, 1101-1107. | 0.8 | 10 |
| 3779 | Indications for Prognostic Gene Expression Profiling in Early Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 23. | 1.3 | 26 |
| 3780 | Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 357-364. | 1.1 | 22 |
| 3781 | Tamoxifen Prevents Apoptosis and Follicle Loss from Cyclophosphamide in Cultured Rat Ovaries ¹ . <i>Biology of Reproduction</i> , 2015, 92, 132. | 1.2 | 30 |
| 3782 | Update on breast cancer risk prediction and prevention. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 92-97. | 0.9 | 27 |
| 3783 | Long Follow-up of Patients With Locally Advanced Cervical Cancer Treated With Concomitant Chemobrachyradiotherapy With Cisplatin and Ifosfamide Followed by Consolidation Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 315-319. | 1.2 | 16 |
| 3784 | The novel role of miRNAs for tamoxifen resistance in human breast cancer. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 2575-2584. | 2.4 | 20 |
| 3785 | CMF-regimen Preferred as First-course Chemotherapy for Older and Sicker Women With Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 165-173. | 0.6 | 7 |
| 3786 | Nab-paclitaxel for the management of triple-negative metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 117-122. | 0.7 | 8 |
| 3787 | An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy. <i>Medical Oncology</i> , 2015, 32, 147. | 1.2 | 17 |
| 3788 | The role of anthracyclines in the treatment of early breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 201-212. | 0.5 | 21 |
| 3789 | Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial. <i>Annals of Oncology</i> , 2015, 26, 1254-1262. | 0.6 | 25 |
| 3790 | Landscape of Neoadjuvant Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1408-1415. | 0.7 | 47 |
| 3791 | Patients' satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 270-278. | 2.0 | 5 |
| 3792 | Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. <i>Health Affairs</i> , 2015, 34, 592-600. | 2.5 | 15 |
| 3793 | Comparison of Cancer Yields and Diagnostic Performance of Screening Mammography vs. Supplemental Screening Ultrasound in 4394 Women with Average Risk for Breast Cancer. <i>Ultraschall in Der Medizin</i> , 2015, 36, 255-263. | 0.8 | 34 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 3794 | Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 659-667. | 1.1 | 13 |
| 3795 | 4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 647-658. | 1.1 | 51 |
| 3796 | Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1311. | 3.4 | 65 |
| 3797 | Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 291-296. | 1.4 | 24 |
| 3798 | Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2005-2014. | 13.9 | 1,146 |
| 3799 | Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v8-v30. | 0.6 | 1,168 |
| 3800 | Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3788-3795. | 0.8 | 56 |
| 3801 | A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. <i>BMC Clinical Pathology</i> , 2015, 15, 14. | 1.8 | 31 |
| 3802 | Mammography screening is harmful and should be abandoned. <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 341-345. | 1.1 | 33 |
| 3803 | In the Modern Treatment Era, Is Breast Conservation Equivalent to Mastectomy in Women Younger Than 40 Years of Age? A Multi-Institution Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1096-1103. | 0.4 | 18 |
| 3804 | Five-Year Risk for Interval-Invasive Second Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, . | 3.0 | 31 |
| 3806 | Chemotherapy options for patients suffering from heavily pretreated metastatic breast cancer. <i>Future Oncology</i> , 2015, 11, 1775-1789. | 1.1 | 16 |
| 3807 | Clinical and molecular complexity of breast cancer metastases. <i>Seminars in Cancer Biology</i> , 2015, 35, 85-95. | 4.3 | 118 |
| 3808 | Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer. <i>Annals of Oncology</i> , 2015, 26, 2363-2366. | 0.6 | 18 |
| 3809 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , 2015, 13, 156. | 2.3 | 51 |
| 3810 | Interferons and the Immunogenic Effects of Cancer Therapy. <i>Trends in Immunology</i> , 2015, 36, 725-737. | 2.9 | 107 |
| 3811 | Optimal management of hormone receptor positive metastatic breast cancer in 2016. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 304-320. | 1.4 | 104 |
| 3812 | Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. <i>BMC Health Services Research</i> , 2015, 15, 307. | 0.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3813 | Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ER \pm -positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 225-237. | 1.1 | 45 |
| 3814 | Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2229-2240. | 1.2 | 11 |
| 3815 | Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 247-252. | 1.1 | 18 |
| 3816 | Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 627-636. | 1.1 | 48 |
| 3817 | Adjuvant vs. salvage radiotherapy for patients at high risk for recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 451-455. | 0.8 | 4 |
| 3818 | Adherence to Adjuvant Endocrine Therapy for Breast Cancer: Importance in Women with Low Income. <i>Journal of Women's Health</i> , 2015, 24, 403-408. | 1.5 | 13 |
| 3819 | Progesterone and Overlooked Endocrine Pathways in Breast Cancer Pathogenesis. <i>Endocrinology</i> , 2015, 156, 3442-3450. | 1.4 | 63 |
| 3821 | Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2015, 31, 1129-1137. | 0.9 | 37 |
| 3822 | Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2015, 13, 139. | 2.3 | 36 |
| 3823 | Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer. <i>Drugs</i> , 2015, 75, 1311-1321. | 4.9 | 5 |
| 3824 | <sc>YM155</sc> downâ€regulates survivin and <sc>XIAP</sc>, modulates autophagy and induces autophagyâ€dependent <sc>DNA</sc> damage in breast cancer cells. <i>British Journal of Pharmacology</i> , 2015, 172, 214-234. | 2.7 | 79 |
| 3825 | Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. <i>Oncolmmunology</i> , 2015, 4, e991228. | 2.1 | 15 |
| 3826 | Progress in adjuvant chemotherapy for breast cancer: an overview. <i>BMC Medicine</i> , 2015, 13, 195. | 2.3 | 241 |
| 3827 | Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 697-707. | 1.1 | 32 |
| 3828 | Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 133-143. | 1.1 | 27 |
| 3829 | Picking the optimal endocrine adjuvant treatment for pre-menopausal women. <i>Breast</i> , 2015, 24, S11-S14. | 0.9 | 6 |
| 3830 | Genetics, Genomics, and Pharmacogenomics. <i>Annals of Surgical Oncology</i> , 2015, 22, 3414-3417. | 0.7 | 0 |
| 3831 | Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 119-128. | 1.1 | 30 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3832 | St. Gallen endocrine response classes predict recurrence rates over time. <i>Breast</i> , 2015, 24, 705-712. | 0.9 | 5 |
| 3834 | Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells. <i>Nanoscale</i> , 2015, 7, 18010-18014. | 2.8 | 80 |
| 3835 | Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. <i>Future Medicinal Chemistry</i> , 2015, 7, 1511-1519. | 1.1 | 115 |
| 3836 | Molecular Classification of Breast Cancer. <i>Molecular Pathology Library</i> , 2015, , 137-155. | 0.1 | 0 |
| 3837 | Identifying and targeting tumor-initiating cells in the treatment of breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R135-R155. | 1.6 | 42 |
| 3838 | Cancer Genetics and Implications for Clinical Management. <i>Surgical Clinics of North America</i> , 2015, 95, 919-934. | 0.5 | 6 |
| 3839 | Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 137-145. | 1.1 | 6 |
| 3840 | Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv212. | 3.0 | 79 |
| 3841 | Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 611-625. | 1.1 | 38 |
| 3843 | Breast Cancer Recurrence in Patients with Newly Diagnosed Breast Cancer without and with Preoperative MR Imaging: A Matched Cohort Study. <i>Radiology</i> , 2015, 276, 695-705. | 3.6 | 36 |
| 3844 | Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR+/HER2-metastatic breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 315-326. | 0.6 | 2 |
| 3845 | Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. <i>Breast</i> , 2015, 24, 630-636. | 0.9 | 52 |
| 3846 | Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. <i>Breast</i> , 2015, 24, S6-S10. | 0.9 | 13 |
| 3847 | Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. <i>British Journal of Cancer</i> , 2015, 113, 30-36. | 2.9 | 25 |
| 3848 | Therapeutic drug monitoring of targeted anticancer therapy. <i>Biomarkers in Medicine</i> , 2015, 9, 887-893. | 0.6 | 24 |
| 3849 | Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. <i>JAMA Oncology</i> , 2015, 1, 1098. | 3.4 | 49 |
| 3850 | Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. <i>European Journal of Cancer</i> , 2015, 51, 2517-2524. | 1.3 | 40 |
| 3851 | Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 217-226. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3852 | Reexcision for positive margins in breast cancer: A predictive score of residual disease. <i>Surgical Oncology</i> , 2015, 24, 129-135. | 0.8 | 9 |
| 3853 | Management of breast cancer in older and frail patients. <i>Breast</i> , 2015, 24, S159-S162. | 0.9 | 13 |
| 3854 | Transformation of tamoxifen and its major metabolites during water chlorination: Identification and in silico toxicity assessment of their disinfection byproducts. <i>Water Research</i> , 2015, 85, 199-207. | 5.3 | 53 |
| 3855 | Rethinking the Local Therapy of Breast Cancer: Integration of Biology and Anatomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 3168-3173. | 0.7 | 13 |
| 3859 | Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. <i>Cell Cycle</i> , 2015, 14, 2091-2099. | 1.3 | 11 |
| 3860 | The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 31. | 1.3 | 0 |
| 3861 | 3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience. <i>Future Oncology</i> , 2015, 11, 3109-3112. | 1.1 | 0 |
| 3862 | Selective estrogen receptor modulators (SERMs): A review of clinical data. <i>Maturitas</i> , 2015, 80, 52-57. | 1.0 | 75 |
| 3863 | The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines. <i>Gene</i> , 2015, 555, 377-381. | 1.0 | 22 |
| 3864 | Breast Diseases. , 2015, , . | | 7 |
| 3865 | Determination of tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatography. <i>Talanta</i> , 2015, 131, 535-540. | 2.9 | 18 |
| 3866 | Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. <i>Oncogene</i> , 2015, 34, 506-515. | 2.6 | 112 |
| 3867 | Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor \pm -positive breast cancer. <i>Oncogene</i> , 2015, 34, 3760-3769. | 2.6 | 101 |
| 3868 | Breast cancer incidence and mortality in a transitioning Chinese population: current and future trends. <i>British Journal of Cancer</i> , 2015, 112, 167-170. | 2.9 | 50 |
| 3870 | Breast Cancer Screening and Diagnosis. , 2015, , . | | 8 |
| 3871 | Different Patterns in the Prognostic Value of Age for Breast Cancer-Specific Mortality Depending on Hormone Receptor Status: A SEER Population-Based Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 1102-1110. | 0.7 | 27 |
| 3872 | Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns. <i>Journal of Molecular Medicine</i> , 2015, 93, 13-29. | 1.7 | 15 |
| 3873 | Intratumoural inflammation and endocrine resistance in breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R51-R67. | 1.6 | 21 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 3874 | Is axillary lymph node clearance required in node-positive breast cancer?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 55-61. | 12.5 | 15 |
| 3875 | Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. <i>Pharmacogenomics Journal</i> , 2015, 15, 84-94. | 0.9 | 148 |
| 3876 | Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. <i>Psycho-Oncology</i> , 2015, 24, 130-137. | 1.0 | 57 |
| 3877 | Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. <i>Oncogene</i> , 2015, 34, 3617-3626. | 2.6 | 211 |
| 3878 | A rare complication resulting in a rare disease: radiation-induced male breast cancer. <i>BMJ Case Reports</i> , 2016, 2016, bcr2015211874. | 0.2 | 1 |
| 3879 | A Case of Bilateral Branch Retinal Vein Occlusion after Taking Tamoxifen. <i>Journal of Korean Ophthalmological Society</i> , 2016, 57, 1806. | 0.0 | 1 |
| 3880 | Imaging Surveillance of Women With a Personal History of Breast Cancer. , 2016, , 299-322. | | 1 |
| 3881 | Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. <i>Medical Science Monitor</i> , 2016, 22, 3860-3867. | 0.5 | 80 |
| 3883 | Integrating Personalization of Treatment with Tamoxifen into Pharmacy Practice Via Clinical Pharmacist Role in Therapy Management. <i>Journal of Pharmaceutical Care & Health Systems</i> , 2016, 3, . | 0.1 | 0 |
| 3884 | Treatment of Breast Cancer in Women Aged 80 and Older. <i>Breast Cancer Current Research</i> , 2016, 01, . | 0.0 | 2 |
| 3885 | The Impact of Pretreatment 18F-FDG (PET/CT) Maximum Standardized Uptake Value and Neutrophil/Lymphocyte Ratio (NLR) in Predicting Prognosis in Surgically Treated Oligometastatic Breast Cancer Patients. <i>Journal of Nuclear Medicine & Radiation Therapy</i> , 2016, 07, . | 0.2 | 0 |
| 3886 | Adjuvant systemic therapy in older women with breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2016, Volume 8, 141-147. | 1.0 | 9 |
| 3887 | Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. <i>Journal of Breast Cancer</i> , 2016, 19, 169. | 0.8 | 11 |
| 3888 | Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer. <i>Oncotarget</i> , 2016, 7, 20496-20506. | 0.8 | 39 |
| 3889 | Disease-free survival in patients with non-metastatic breast cancer. <i>Revista Da Associação Médica Brasileira</i> , 2016, 62, 407-413. | 0.3 | 12 |
| 3890 | ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. <i>OncoTargets and Therapy</i> , 2016, 9, 2121. | 1.0 | 17 |
| 3891 | Increased risk of breast cancer in individuals carrying the TNRC9 rs3803662 C>T polymorphism: a meta-analysis of case-control studies. <i>Genetics and Molecular Research</i> , 2016, 15, . | 0.3 | 4 |
| 3892 | Association of PTP1B with Outcomes of Breast Cancer Patients who Underwent Neoadjuvant Chemotherapy. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S40934. | 0.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3893 | Application of Canonical Correlation Analysis for Detecting Risk Factors Leading to Recurrence of Breast Cancer. Iranian Red Crescent Medical Journal, 2016, 18, e23131. | 0.5 | 10 |
| 3894 | Accelerated partial breast irradiation: Past, present, and future. World Journal of Clinical Oncology, 2016, 7, 370. | 0.9 | 19 |
| 3895 | Hormonothérapie adjuvante dans le cancer du sein. , 2016, , 95-107. | | 0 |
| 3896 | Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer. Journal of Breast Cancer, 2016, 19, 341. | 0.8 | 11 |
| 3897 | Paeoniflorin prevents hypoxia-induced epithelial–mesenchymal transition in human breast cancer cells. OncoTargets and Therapy, 2016, 9, 2511. | 1.0 | 37 |
| 3898 | Danish Breast Cancer Cooperative Group. Clinical Epidemiology, 2016, Volume 8, 445-449. | 1.5 | 76 |
| 3899 | Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. Ecancermedicalscience, 2016, 10, 609. | 0.6 | 30 |
| 3900 | Less Is More: The Evolving Surgical Approach to Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e5-e10. | 1.8 | 4 |
| 3901 | Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e31-e38. | 1.8 | 9 |
| 3902 | Precision medicine in early breast cancer” can this apply to radiotherapy?. Journal of Thoracic Disease, 2016, 8, 2982-2985. | 0.6 | 3 |
| 3903 | Real-World Adjuvant TAC or FEC-D for HER2-Negative Node-Positive Breast Cancer in Women Less Than 50 Years of Age. Current Oncology, 2016, 23, 164-170. | 0.9 | 4 |
| 3904 | Is breast conservative surgery a reasonable option in multifocal or multicentric tumors?. World Journal of Clinical Oncology, 2016, 7, 234. | 0.9 | 22 |
| 3905 | Ethical and Societal Considerations in Breast Cancer Screening. , 2016, , 347-374. | | 2 |
| 3906 | Proteomic Analysis of Stage-II Breast Cancer from Formalin-Fixed Paraffin-Embedded Tissues. BioMed Research International, 2016, 2016, 1-6. | 0.9 | 5 |
| 3907 | A structured review of health utility measures and elicitation in advanced/metastatic breast cancer. ClinicoEconomics and Outcomes Research, 2016, 8, 293. | 0.7 | 15 |
| 3908 | Molecular-level effects of eribulin and paclitaxel on breast cancer based on differential co-expression network analysis. Genetics and Molecular Research, 2016, 15, . | 0.3 | 5 |
| 3910 | Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents. Frontiers in Oncology, 2016, 6, 152. | 1.3 | 24 |
| 3911 | Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women. Frontiers in Oncology, 2016, 6, 241. | 1.3 | 23 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3912 | Comparative metabolic and lipidomic profiling of human breast cancer cells with different metastatic potentials. <i>Oncotarget</i> , 2016, 7, 67111-67128. | 0.8 | 95 |
| 3913 | Beliefs and Behaviors about Breast Cancer Recurrence Risk Reduction among African American Breast Cancer Survivors. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 46. | 1.2 | 20 |
| 3914 | Optimized Method for Untargeted Metabolomics Analysis of MDA-MB-231 Breast Cancer Cells. <i>Metabolites</i> , 2016, 6, 30. | 1.3 | 17 |
| 3915 | Soy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future Perspectives. <i>Molecules</i> , 2016, 21, 13. | 1.7 | 77 |
| 3916 | Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer. <i>BMC Cancer</i> , 2016, 16, 307. | 1.1 | 43 |
| 3917 | Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia. <i>BMC Cancer</i> , 2016, 16, 820. | 1.1 | 16 |
| 3918 | Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells. <i>PLoS ONE</i> , 2016, 11, e0148049. | 1.1 | 57 |
| 3919 | Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0148849. | 1.1 | 2 |
| 3920 | Therapeutic options for management of endometrial hyperplasia. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e8. | 1.0 | 140 |
| 3921 | Molecular Classification of Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2016, 19, 223. | 0.8 | 111 |
| 3922 | Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. <i>Journal of Cancer</i> , 2016, 7, 1281-1294. | 1.2 | 300 |
| 3923 | Velocity time integral for right upper pulmonary vein in VLBW infants with patent ductus arteriosus. <i>Clinics</i> , 2016, 71, 586-592. | 0.6 | 11 |
| 3924 | Influences on quality of prescribing in breast cancer patients. <i>NursePrescribing</i> , 2016, 14, 502-506. | 0.1 | 0 |
| 3925 | Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes. <i>Oncology Letters</i> , 2016, 12, 663-669. | 0.8 | 4 |
| 3926 | Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 479-487. | 1.1 | 10 |
| 3927 | Cardiotoxic heart failure in breast cancer survivors: a concept analysis. <i>Journal of Advanced Nursing</i> , 2016, 72, 1518-1528. | 1.5 | 3 |
| 3928 | Embryo Cryopreservation in Breast Cancer Patients. , 2016, , 39-52. | | 0 |
| 3929 | The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 953-959. | 0.9 | 39 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3930 | Association of <i>CYP2C19</i> * <i>2</i> and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1142-1152. | 1.1 | 18 |
| 3931 | Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2454-2463. | 1.2 | 8 |
| 3932 | Pharmacogenomics. <i>Journal of Infusion Nursing</i> , 2016, 39, 139-148. | 1.2 | 1 |
| 3933 | The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. <i>BMC Cancer</i> , 2016, 16, 319. | 1.1 | 19 |
| 3934 | Early-Stage Breast Cancer in the Octogenarian: Tumor Characteristics, Treatment Choices, and Clinical Outcomes. <i>Annals of Surgical Oncology</i> , 2016, 23, 3371-3378. | 0.7 | 25 |
| 3935 | MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3. <i>Biochemical and Biophysical Research Communications</i> , 2016, 477, 768-773. | 1.0 | 54 |
| 3936 | Prognostic Effects of Adjuvant Chemotherapy-Induced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients. <i>Medicine (United States)</i> , 2016, 95, e3301. | 0.4 | 11 |
| 3937 | Liver X receptor as a drug target for the treatment of breast cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 373-382. | 0.7 | 25 |
| 3938 | Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 516-524. | 0.8 | 5 |
| 3939 | Long-range regulators of the lncRNA <i>HOTAIR</i> enhance its prognostic potential in breast cancer. <i>Human Molecular Genetics</i> , 2016, 25, 3269-3283. | 1.4 | 58 |
| 3940 | LSD1 engages a corepressor complex for the activation of the estrogen receptor β by estrogen and cAMP. <i>Nucleic Acids Research</i> , 2016, 44, 8655-8670. | 6.5 | 62 |
| 3941 | Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study. <i>CMAJ Open</i> , 2016, 4, E7-E12. | 1.1 | 5 |
| 3942 | Changes over time in the impact of gene expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study. <i>International Journal of Cancer</i> , 2016, 139, 769-775. | 2.3 | 7 |
| 3943 | NCCN Guidelines Update: Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 641-644. | 2.3 | 81 |
| 3945 | Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. <i>BMC Cancer</i> , 2016, 16, 430. | 1.1 | 15 |
| 3946 | Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. <i>Breast Cancer Research</i> , 2016, 18, 118. | 2.2 | 65 |
| 3947 | Hormone Receptors in Breast Cancer. , 2016, , 45-58. | | 0 |
| 3948 | Beliefs in Chemotherapy and Knowledge of Cancer and Treatment Among African American Women With Newly Diagnosed Breast Cancer. <i>Oncology Nursing Forum</i> , 2016, 43, 180-189. | 0.5 | 16 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3949 | Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells. <i>Oncology Reports</i> , 2016, 36, 1377-1384. | 1.2 | 27 |
| 3950 | Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases. <i>Annals of Surgery</i> , 2016, 264, 413-420. | 2.1 | 392 |
| 3951 | Evaluating EHR Data Availability for Cohort Selection in Retrospective Studies. , 2016, , . | | 3 |
| 3952 | Recent developments and translational aspects in targeted therapy for metastatic breast cancer. <i>ESMO Open</i> , 2016, 1, e000036. | 2.0 | 1 |
| 3953 | Circulating Tumor Cells. , 2016, , 219-234. | | 0 |
| 3954 | Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> . 2016. 12. 485-488. | 2.5 | 2 |
| 3955 | Biomarkers in the Clinic. , 2016, , 415-426. | | 0 |
| 3956 | Novel Immunohistochemical Based Biomarkers in Breast Cancer. , 2016, , 99-119. | | 0 |
| 3957 | Access to Care in Vermont: Factors Linked With Time to Chemotherapy for Women With Breast Cancer—A Retrospective Cohort Study. <i>Journal of Oncology Practice</i> , 2016, 12, e848-e857. | 2.5 | 11 |
| 3958 | Predicting Risk of Disease Recurrence. , 2016, , 15-30. | | 0 |
| 3959 | Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. <i>Npj Breast Cancer</i> , 2016, 2, 16017. | 2.3 | 125 |
| 3960 | Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer. <i>Medicine (United States)</i> , 2016, 95, e3240. | 0.4 | 16 |
| 3962 | Cancer Care Coordinators to Improve Tamoxifen Persistence in Breast Cancer: How Heterogeneity in Baseline Prognosis Impacts on Cost-Effectiveness. <i>Value in Health</i> , 2016, 19, 936-944. | 0.1 | 0 |
| 3963 | Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 455-460. | 1.1 | 9 |
| 3964 | BET Bromodomain Proteins as Cancer Therapeutic Targets. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 123-129. | 2.0 | 56 |
| 3965 | Winging It: How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment. <i>Journal of Oncology Practice</i> , 2016, 12, e991-e1000. | 2.5 | 16 |
| 3966 | Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. <i>British Journal of Cancer</i> , 2016, 114, 863-871. | 2.9 | 9 |
| 3967 | Importance of patient reported outcome measures versus clinical outcomes for breast cancer patients evaluation on quality of care. <i>Breast</i> , 2016, 27, 62-68. | 0.9 | 26 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 3968 | The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2016, 32, 1217-1224. | 0.9 | 25 |
| 3969 | Adjuvant Treatment for Older Women with Invasive Breast Cancer. <i>Women's Health</i> , 2016, 12, 129-146. | 0.7 | 13 |
| 3970 | Validation of the Web-Based IBTR! 2.0 Nomogram to Predict for Ipsilateral Breast Tumor Recurrence After Breast-Conserving Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1477-1484. | 0.4 | 9 |
| 3971 | AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment. <i>Cancer Research</i> , 2016, 76, 3295-3306. | 0.4 | 69 |
| 3972 | Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. <i>Drug Discovery Today</i> , 2016, 21, 1181-1188. | 3.2 | 53 |
| 3973 | Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 394-402. | 1.0 | 6 |
| 3974 | A Review of Local and Systemic Therapy in Breast Cancer. , 2016, , 731-764. | | 0 |
| 3975 | A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 379-388. | 1.1 | 33 |
| 3976 | Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 335-343. | 1.1 | 193 |
| 3977 | Adjuvant Chemotherapy for Breast Cancer in Older Women. <i>Clinical Oncology</i> , 2016, 28, 542. | 0.6 | 0 |
| 3978 | Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 51. | 1.0 | 8 |
| 3979 | Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. <i>Journal of Clinical Oncology</i> , 2016, 34, 2452-2459. | 0.8 | 178 |
| 3980 | A potential peptide vector that allows targeted delivery of a desired fusion protein into the human breast cancer cell line MDA-MB-231. <i>Oncology Letters</i> , 2016, 11, 3943-3952. | 0.8 | 2 |
| 3981 | Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial. <i>Breast</i> , 2016, 27, 69-77. | 0.9 | 8 |
| 3982 | Goniothalamine induces apoptosis associated with autophagy activation through MAPK signaling in SK-BR-3 cells. <i>Oncology Reports</i> , 2016, 35, 2851-2858. | 1.2 | 16 |
| 3983 | FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer. <i>American Journal of Roentgenology</i> , 2016, 206, 846-855. | 1.0 | 15 |
| 3984 | The oncolytic herpes simplex virus vector, G47 Δ , effectively targets tamoxifen-resistant breast cancer cells. <i>Oncology Reports</i> , 2016, 35, 1741-1749. | 1.2 | 11 |
| 3985 | A novel gene expression signature for bone metastasis in breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 249-259. | 1.1 | 77 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 3986 | Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). <i>Breast Cancer Research and Treatment</i> , 2016, 157, 133-143. | 1.1 | 51 |
| 3987 | Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2416-2427. | 0.8 | 112 |
| 3988 | CTCs in early breast cancer: A path worth taking. <i>Cancer Letters</i> , 2016, 376, 205-210. | 3.2 | 28 |
| 3989 | The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 751-755. | 1.5 | 21 |
| 3990 | Pattern of relapse after breast conserving therapy, a study of 1519 early breast cancer patients treated in the Central Region of Denmark 2000–2009. <i>Acta Oncologica</i> , 2016, 55, 964-969. | 0.8 | 13 |
| 3991 | Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 193-200. | 1.1 | 5 |
| 3992 | The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong. <i>Clinical Breast Cancer</i> , 2016, 16, 372-378. | 1.1 | 19 |
| 3993 | BACH1, the master regulator gene: A novel candidate target for cancer therapy. <i>Gene</i> , 2016, 588, 30-37. | 1.0 | 89 |
| 3994 | Cancer drug related cardiotoxicity during breast cancer treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1063-1074. | 1.0 | 12 |
| 3995 | Failure pattern and survival after breast conserving therapy. Long-term results of the Danish Breast Cancer Group (DBCC) 89 cohort. <i>Acta Oncologica</i> , 2016, 55, 983-992. | 0.8 | 14 |
| 3996 | Adjuvant Surgical Oophorectomy Plus Tamoxifen in Premenopausal Women With Operable Hormone Receptor-Positive Breast Cancer: A Global Treatment Option. <i>Clinical Breast Cancer</i> , 2016, 16, 233-237. | 1.1 | 9 |
| 3997 | Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 390-393. | 2.5 | 30 |
| 3998 | Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 339-350. | 1.1 | 14 |
| 3999 | Adjuvant ovarian function suppression and cognitive function in women with breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 956-964. | 2.9 | 38 |
| 4000 | Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 77-90. | 1.1 | 52 |
| 4001 | A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort. <i>Modern Pathology</i> , 2016, 29, 799-809. | 2.9 | 19 |
| 4002 | Late Axillary Recurrence After Negative Sentinel Lymph Node Biopsy is Uncommon. <i>Annals of Surgical Oncology</i> , 2016, 23, 2456-2461. | 0.7 | 14 |
| 4003 | Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 1721-1733. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4004 | Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients. <i>Medicine (United States)</i> , 2016, 95, e2909. | 0.4 | 15 |
| 4005 | Trends in breast cancer in the elderly in Denmark, 1980-2012. <i>Acta Oncologica</i> , 2016, 55, 59-64. | 0.8 | 20 |
| 4006 | Doxorubicin-loaded mesoporous silica nanoparticle composite nanofibers for long-term adjustments of tumor apoptosis. <i>Nanotechnology</i> , 2016, 27, 245101. | 1.3 | 70 |
| 4007 | Persistence to 5-year hormonal breast cancer therapy: a French national population-based study. <i>British Journal of Cancer</i> , 2016, 115, 912-919. | 2.9 | 20 |
| 4008 | IL-1 β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. <i>BMC Cancer</i> , 2016, 16, 724. | 1.1 | 69 |
| 4009 | The Benefit of Adjuvant Radiation Therapy After Breast-Conserving Surgery in Older Patients With Low-Risk Breast Cancer: A Meta-Analysis of Randomized Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E6. | 0.4 | 0 |
| 4011 | Moduladores selectivos de los receptores estrogénicos (MSRE). <i>EMC - Ginecología-Obstetricia</i> , 2016, 52, 1-10. | 0.0 | 0 |
| 4012 | Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 542-550. | 0.8 | 7 |
| 4013 | Use of Baicalin-Conjugated Gold Nanoparticles for Apoptotic Induction of Breast Cancer Cells. <i>Nanoscale Research Letters</i> , 2016, 11, 381. | 3.1 | 38 |
| 4014 | Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population. <i>Breast</i> , 2016, 30, 13-18. | 0.9 | 9 |
| 4016 | Aromatase inhibitors: A comprehensive review in mechanisms of action, side effects and treatment in postmenopausal early breast cancer patients. <i>Hellenike Cheirurgike Acta Chirurgica Hellenica</i> , 2016, 88, 245-251. | 0.1 | 7 |
| 4017 | Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute. <i>Breast</i> , 2016, 30, 19-25. | 0.9 | 7 |
| 4018 | Cancro della mammella: ruolo del medico generico nella gestione. <i>EMC - AKOS - Trattato Di Medicina</i> , 2016, 18, 1-5. | 0.0 | 0 |
| 4019 | De-escalation of axillary surgery in early breast cancer. <i>Lancet Oncology, The</i> , 2016, 17, e430-e441. | 5.1 | 54 |
| 4020 | Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer. <i>Cancer Medicine</i> , 2016, 5, 3282-3291. | 1.3 | 22 |
| 4021 | Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study. <i>Public Health Genomics</i> , 2016, 19, 276-281. | 0.6 | 3 |
| 4023 | The Future of Precision Medicine in Oncology. <i>Clinics in Laboratory Medicine</i> , 2016, 36, 557-573. | 0.7 | 39 |
| 4024 | Comparison of adjuvant ED and EC-D regimens in operable breast invasive ductal carcinoma. <i>Oncology Letters</i> , 2016, 12, 1448-1454. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4025 | Biomarker assessment and molecular testing for prognostication in breast cancer. <i>Histopathology</i> , 2016, 68, 70-85. | 1.6 | 53 |
| 4026 | Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks. <i>Annals of Surgical Oncology</i> , 2016, 23, 3100-3105. | 0.7 | 125 |
| 4027 | The association of mood disorders with breast cancer survival: an investigation of linked cancer registration and hospital admission data for South East England. <i>Psycho-Oncology</i> , 2016, 25, 19-27. | 1.0 | 38 |
| 4028 | Molecular Testing in Breast Cancer: A Guide to Current Practices. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 815-824. | 1.2 | 43 |
| 4029 | Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort. <i>Modern Pathology</i> , 2016, 29, 1492-1500. | 2.9 | 10 |
| 4030 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Heart Journal</i> , 2016, 37, 2768-2801. | 1.0 | 1,996 |
| 4031 | Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. <i>World Journal of Surgical Oncology</i> , 2016, 14, 223. | 0.8 | 53 |
| 4032 | Estrogen receptor expression and gene promoter methylation in non-small cell lung cancer - a short report. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 583-589. | 2.1 | 8 |
| 4033 | Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 357-365. | 1.1 | 7 |
| 4034 | Radiation therapy for breast cancer: Literature review. <i>Medical Dosimetry</i> , 2016, 41, 253-257. | 0.4 | 57 |
| 4035 | 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 315-326. | 1.1 | 18 |
| 4036 | Prevalence of <i>ESR1</i> Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1310. | 3.4 | 395 |
| 4037 | Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. <i>BMC Cancer</i> , 2016, 16, 515. | 1.1 | 11 |
| 4038 | Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1148-1156. | 2.5 | 7 |
| 4039 | Deficiency of X-Linked Protein Kinase Nrk during Pregnancy Triggers Breast Tumor in Mice. <i>American Journal of Pathology</i> , 2016, 186, 2751-2760. | 1.9 | 10 |
| 4040 | Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: A systematic review and meta-analysis of population-based studies including 522,739 patients. <i>Radiotherapy and Oncology</i> , 2016, 121, 402-413. | 0.3 | 90 |
| 4041 | Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1 α feedback regulatory loop. <i>Tumor Biology</i> , 2016, 37, 14733-14743. | 0.8 | 97 |
| 4042 | New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2179-2189. | 0.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4043 | Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. <i>BMC Cancer</i> , 2016, 16, 734. | 1.1 | 126 |
| 4044 | Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea. <i>Oncology</i> , 2016, 91, 274-282. | 0.9 | 16 |
| 4045 | Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers. <i>FASEB Journal</i> , 2016, 30, 3702-3713. | 0.2 | 11 |
| 4046 | Goserelin toxicities and preferences for ovarian suppression method in premenopausal women with breast cancer. <i>Internal Medicine Journal</i> , 2016, 46, 1153-1159. | 0.5 | 7 |
| 4047 | Application prospective of nanoprobe with MRI and FI dual-modality imaging on breast cancer stem cells in tumor. <i>Journal of Nanobiotechnology</i> , 2016, 14, 52. | 4.2 | 18 |
| 4048 | FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4968-4972. | 3.2 | 109 |
| 4049 | Factors Associated With Disease Recurrence in Breast Cancer Patients With Negative Sentinel Lymph Node Biopsy. <i>Clinical Breast Cancer</i> , 2016, 16, e181-e186. | 1.1 | 2 |
| 4050 | Non-canonical NF- κ B pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma. <i>British Journal of Cancer</i> , 2016, 115, 322-331. | 2.9 | 21 |
| 4051 | Minireview: Lymphangioliomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer. <i>Endocrinology</i> , 2016, 157, 3374-3383. | 1.4 | 32 |
| 4052 | Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 333-340. | 1.1 | 8 |
| 4053 | Is Breast Cancer a Curable Disease?. <i>Journal of Oncology Practice</i> , 2016, 12, 13-16. | 2.5 | 6 |
| 4054 | Targeted adjuvant therapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1263-1275. | 1.1 | 11 |
| 4055 | A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes. <i>Scientific Reports</i> , 2016, 6, 37003. | 1.6 | 9 |
| 4056 | Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands. <i>BMC Cancer</i> , 2016, 16, 712. | 1.1 | 2 |
| 4057 | Determination of the optimal time for tamoxifen treatment in combination with radiotherapy. <i>International Journal of Oncology</i> , 2016, 49, 2147-2154. | 1.4 | 4 |
| 4058 | Cardiac Mortality Among 200,000 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age. <i>Circulation</i> , 2016, 134, 1519-1531. | 1.6 | 87 |
| 4059 | Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. <i>Npj Breast Cancer</i> , 2016, 2, 16024. | 2.3 | 6 |
| 4060 | Clinicopathological Characteristics and Survival Outcomes in Invasive Papillary Carcinoma of the Breast: A SEER Population-Based Study. <i>Scientific Reports</i> , 2016, 6, 24037. | 1.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4061 | Î²2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions. <i>Cell Cycle</i> , 2016, 15, 3402-3412. | 1.3 | 4 |
| 4062 | Circulating tumor cells in breast cancer: applications in personalized medicine. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 411-424. | 1.1 | 44 |
| 4063 | Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. <i>BMJ, The</i> , 2016, 354, i5014. | 3.0 | 32 |
| 4064 | Berberine enhances the anti-tumor activity of tamoxifen in drug-sensitive MCF-7 and drug-resistant MCF-7/TAM cells. <i>Molecular Medicine Reports</i> , 2016, 14, 2250-2256. | 1.1 | 33 |
| 4065 | Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients. <i>Medicine (United States)</i> , 2016, 95, e5151. | 0.4 | 19 |
| 4066 | The Experience of Initiating Oral Adjuvant Treatment for Estrogen Receptor-Positive Breast Cancer. <i>Oncology Nursing Forum</i> , 2016, 43, E143-E152. | 0.5 | 2 |
| 4067 | A cost-effective handheld breast scanner for use in low-resource environments: a validation study. <i>World Journal of Surgical Oncology</i> , 2016, 14, 277. | 0.8 | 18 |
| 4068 | SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study. <i>BMC Cancer</i> , 2016, 16, 337. | 1.1 | 17 |
| 4069 | Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. <i>Breast Cancer Research</i> , 2016, 18, 65. | 2.2 | 33 |
| 4070 | Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 82. | 2.2 | 20 |
| 4071 | Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033). <i>Breast Cancer Research</i> , 2016, 18, 93. | 2.2 | 7 |
| 4072 | Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1519-1526. | 2.3 | 17 |
| 4073 | Breast Cancer Posttreatment Surveillance: Diagnosis and Management of Recurrent Disease. <i>Clinical Obstetrics and Gynecology</i> , 2016, 59, 772-778. | 0.6 | 7 |
| 4074 | Mutated Pathways as a Guide to Adjuvant Therapy Treatments for Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 184-189. | 1.9 | 2 |
| 4075 | Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 475-488. | 1.1 | 37 |
| 4076 | Subacute pulmonary embolism in a hemodialysis patient, successfully treated with surgical thrombectomy. <i>CEN Case Reports</i> , 2016, 5, 74-77. | 0.5 | 2 |
| 4077 | Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids. <i>Journal of Translational Medicine</i> , 2016, 14, 112. | 1.8 | 38 |
| 4078 | Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 109-115. | 1.1 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4079 | Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 485-494. | 1.1 | 18 |
| 4080 | Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer â€” a Single Centre Study. (PPLB â€” 01). <i>Indian Journal of Surgical Oncology</i> , 2016, 7, 397-406. | 0.3 | 9 |
| 4081 | Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer. <i>Cancer Biology and Therapy</i> , 2016, 17, 674-683. | 1.5 | 10 |
| 4082 | Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptorâ€”Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2961-2968. | 0.8 | 573 |
| 4083 | Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptorâ€”Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408. | 0.8 | 65 |
| 4084 | Role of the Intravoxel Incoherent Motion Diffusion Weighted Imaging in the Pre-treatment Prediction and Early Response Monitoring to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. <i>Medicine (United States)</i> , 2016, 95, e2420. | 0.4 | 42 |
| 4085 | Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 597-603. | 1.1 | 11 |
| 4086 | On the road to precision, there is more practical medicine to be implemented. <i>Breast</i> , 2016, 29, 188-191. | 0.9 | 2 |
| 4087 | 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. <i>Lancet Oncology</i> , The, 2016, 17, 1158-1170. | 5.1 | 301 |
| 4088 | European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer. <i>European Journal of Cancer</i> , 2016, 63, 168-179. | 1.3 | 8 |
| 4089 | Protein interaction network (PIN)-based breast cancer subsystem identification and activation measurement for prognostic modeling. <i>Methods</i> , 2016, 110, 81-89. | 1.9 | 21 |
| 4090 | Effects of locoregional radiotherapy in patients with metastatic breast cancer. <i>Breast</i> , 2016, 28, 73-78. | 0.9 | 21 |
| 4091 | Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008â€”2011. <i>Journal of Geriatric Oncology</i> , 2016, 7, 15-23. | 0.5 | 10 |
| 4092 | Regional Nodal Radiotherapy in Early-Stage Breast Cancer: Where Are We in 2016?. <i>Current Breast Cancer Reports</i> , 2016, 8, 95-104. | 0.5 | 0 |
| 4093 | Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview. <i>SpringerPlus</i> , 2016, 5, 585. | 1.2 | 8 |
| 4094 | Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany. <i>Journal of Geriatric Oncology</i> , 2016, 7, 169-175. | 0.5 | 13 |
| 4095 | Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models. <i>Breast Diseases</i> , 2016, 27, 45-46. | 0.0 | 0 |
| 4096 | ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors. <i>Cancer Cell International</i> , 2016, 16, 8. | 1.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4097 | Toward precision medicine of breast cancer. <i>Theoretical Biology and Medical Modelling</i> , 2016, 13, 7. | 2.1 | 48 |
| 4098 | Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. <i>Breast Cancer Research</i> , 2016, 18, 1. | 2.2 | 110 |
| 4099 | Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 10. | 2.2 | 186 |
| 4100 | Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors. SpringerPlus, 2016, 5, 486. | 1.2 | 68 |
| 4101 | Die gegenwärtige Landschaft der endokrinen Therapie für prämenopausale Frauen mit Brustkrebs. <i>Karger Kompass Onkologie</i> , 2016, 3, 14-18. | 0.0 | 0 |
| 4102 | Management of the Clinically Node-Negative Axilla in Primary Breast Cancer. , 2016, , 103-117. | | 0 |
| 4103 | A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL). <i>Breast Cancer Research and Treatment</i> , 2016, 158, 127-138. | 1.1 | 16 |
| 4104 | Les traitements adjuvants des cancers du sein : dernières avancées et perspectives pour des cancers très différents. <i>Oncologie</i> , 2016, 18, 120-127. | 0.2 | 1 |
| 4105 | Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. <i>International Journal of Oncology</i> , 2016, 49, 471-478. | 1.4 | 32 |
| 4106 | Clinical Significance of Internal Mammary Lymph Node Biopsy during Microsurgical Breast Reconstruction: Review of 264 Cases. <i>Plastic and Reconstructive Surgery</i> , 2016, 137, 917e-922e. | 0.7 | 12 |
| 4107 | Clinicopathological features and prognosis of triple-negative breast cancer: a comparison between younger (<60) and elderly (≥60) patients. <i>European Journal of Cancer Care</i> , 2016, 25, 1065-1075. | 0.7 | 14 |
| 4108 | Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors. <i>Cutaneous and Ocular Toxicology</i> , 2016, 35, 13-20. | 0.5 | 11 |
| 4109 | Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 46-53. | 0.5 | 18 |
| 4110 | Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting. <i>Breast Cancer</i> , 2016, 23, 261-265. | 1.3 | 2 |
| 4111 | Hormonal therapy for cancer. <i>Medicine</i> , 2016, 44, 30-33. | 0.2 | 21 |
| 4113 | Computer-based risk prediction models: Ethical issues of Adjuvant! Online use in early-stage breast cancer. <i>Gynécologie, Obstétrique & Fertilité</i> , 2016, 44, 79-81. | 0.7 | 0 |
| 4114 | Breast Cancer Subtypes: Morphologic and Biologic Characterization. <i>Women's Health</i> , 2016, 12, 103-119. | 0.7 | 38 |
| 4115 | Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. <i>Journal of Clinical Oncology</i> , 2016, 34, 927-935. | 0.8 | 390 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4116 | Validity of the online PREDICT tool in older patients with breast cancer: a population-based study. <i>British Journal of Cancer</i> , 2016, 114, 395-400. | 2.9 | 74 |
| 4118 | Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 866-873. | 6.3 | 149 |
| 4120 | Approach and Management of Breast Cancer in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 133-153. | 1.0 | 25 |
| 4121 | Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits. <i>Lancet, The</i> , 2016, 387, 819-821. | 6.3 | 4 |
| 4122 | Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 322. | 3.4 | 267 |
| 4123 | Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 239-245. | 1.0 | 13 |
| 4124 | A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 139-144.e3. | 1.1 | 19 |
| 4125 | Adjuvant chemotherapy in elderly patients with breast cancer: key challenges. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 661-671. | 1.1 | 6 |
| 4127 | CTCs for Biomarker and Companion Diagnostic Development. <i>Current Cancer Research</i> , 2016, , 293-313. | 0.2 | 0 |
| 4128 | The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. <i>Annals of Oncology</i> , 2016, 27, 818-827. | 0.6 | 79 |
| 4129 | Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. <i>Journal of Clinical Oncology</i> , 2016, 34, 1689-1701. | 0.8 | 243 |
| 4130 | EJE PRIZE 2016: Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. <i>European Journal of Endocrinology</i> , 2016, 175, R41-R49. | 1.9 | 68 |
| 4131 | The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?. <i>Tumor Biology</i> , 2016, 37, 9555-9563. | 0.8 | 7 |
| 4132 | Pharmacogenetics and pharmacogenomics as tools in cancer therapy. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 25-34. | 0.3 | 23 |
| 4133 | Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. <i>Annals of Oncology</i> , 2016, 27, 806-812. | 0.6 | 21 |
| 4134 | Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 16. | 2.2 | 22 |
| 4135 | Patterns in target-directed breast cancer research. <i>SpringerPlus</i> , 2016, 5, 109. | 1.2 | 1 |
| 4136 | Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 1134-1150. | 0.8 | 683 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 4137 | Molecular Imaging of Biomarkers in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 53S-59S. | 2.8 | 56 |
| 4138 | The far-upstream element-binding protein 2 is correlated with proliferation and doxorubicin resistance in human breast cancer cell lines. <i>Tumor Biology</i> , 2016, 37, 9755-9769. | 0.8 | 12 |
| 4139 | The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 454-468. | 13.9 | 227 |
| 4140 | Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study. <i>Current Medical Research and Opinion</i> , 2016, 32, 835-839. | 0.9 | 6 |
| 4141 | Circulating Tumor Cells. <i>Current Cancer Research</i> , 2016, , . | 0.2 | 6 |
| 4142 | Adjuvant therapy. <i>Medicine</i> , 2016, 44, 39-41. | 0.2 | 1 |
| 4143 | Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 415-420. | 0.6 | 5 |
| 4144 | Paeoniflorin inhibits proliferation and invasion of breast cancer cells through suppressing Notch-1 signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2016, 78, 197-203. | 2.5 | 49 |
| 4145 | Evaluation of a breast cancer nomogram to predict ipsilateral breast relapse after breast-conserving therapy. <i>Radiotherapy and Oncology</i> , 2016, 119, 45-51. | 0.3 | 7 |
| 4146 | Deciding about (neo-)adjuvant rectal and breast cancer treatment: Missed opportunities for shared decision making. <i>Acta Oncologica</i> , 2016, 55, 134-139. | 0.8 | 68 |
| 4147 | Phenotype anchoring in zebrafish reveals a potential role for matrix metalloproteinases (MMPs) in tamoxifen's effects on skin epithelium. <i>Toxicology and Applied Pharmacology</i> , 2016, 296, 31-41. | 1.3 | 6 |
| 4148 | Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 284-290. | 1.1 | 2 |
| 4149 | Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. <i>Annals of Oncology</i> , 2016, 27, 1041-1047. | 0.6 | 45 |
| 4150 | Impact of Neoadjuvant and Adjuvant Chemotherapy on Immediate Tissue Expander Breast Reconstruction. <i>Annals of Surgical Oncology</i> , 2016, 23, 2357-2366. | 0.7 | 41 |
| 4151 | Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1573-1579. | 0.8 | 15 |
| 4152 | Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 16-23. | 0.7 | 26 |
| 4153 | Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. <i>Journal of Proteome Research</i> , 2016, 15, 1230-1242. | 1.8 | 21 |
| 4154 | The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study. <i>British Journal of Cancer</i> , 2016, 114, 731-736. | 2.9 | 24 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4155 | Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K. <i>Experimental Cell Research</i> , 2016, 340, 125-131. | 1.2 | 12 |
| 4156 | Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1580-1583. | 0.8 | 26 |
| 4157 | Rhodiola crenulata induces an early estrogenic response and reduces proliferation and tumorsphere formation over time in MCF7 breast cancer cells. <i>Phytomedicine</i> , 2016, 23, 87-94. | 2.3 | 31 |
| 4158 | Cancer of the Breast: An Overview. , 2016, , 147-209. | | 0 |
| 4159 | The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients. <i>Tumor Biology</i> , 2016, 37, 7675-7684. | 0.8 | 11 |
| 4160 | Palbociclib for the treatment of postmenopausal breast cancer – an update. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 255-263. | 0.9 | 15 |
| 4161 | Factors Affecting the Completion of Adjuvant Chemotherapy in Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1537-1542. | 0.7 | 16 |
| 4162 | Design, synthesis and antitumor properties of glycosylated antitumor ether lipid (GAEL)-chlorambucil-hybrids. <i>Chemistry and Physics of Lipids</i> , 2016, 194, 139-148. | 1.5 | 16 |
| 4163 | Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 321-328. | 0.8 | 36 |
| 4164 | Synthesis of novel trifluoromethyl substituted furo[2,3- b]pyridine and pyrido[3- ϵ :2- δ]furo[3,2- d]pyrimidine derivatives as potential anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 68-78. | 2.6 | 29 |
| 4165 | Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study. <i>Genetics in Medicine</i> , 2016, 18, 720-726. | 1.1 | 13 |
| 4166 | Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 337-345. | 3.2 | 58 |
| 4167 | Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer. <i>Cancer Epidemiology</i> , 2016, 40, 7-14. | 0.8 | 22 |
| 4168 | <i>ESR1</i> Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 993-999. | 3.2 | 152 |
| 4169 | Modeling Spontaneous Metastasis following Surgery: An <i>In Vivo-In Silico</i> Approach. <i>Cancer Research</i> , 2016, 76, 535-547. | 0.4 | 73 |
| 4171 | Circulating tumor cells in breast cancer – current status and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 22-29. | 2.0 | 36 |
| 4172 | S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 546-551. | 0.7 | 30 |
| 4173 | Prognostic impact of a single-nucleotide polymorphism near the CTSO gene in hormone receptor-positive breast cancer patients. <i>International Journal of Clinical Oncology</i> , 2016, 21, 539-547. | 1.0 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4174 | Anticancer treatment and fertility: Effect of therapeutic modalities on reproductive system and functions. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 328-334. | 2.0 | 56 |
| 4175 | Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. <i>Surgery Today</i> , 2016, 46, 821-826. | 0.7 | 35 |
| 4176 | Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 65. | 3.4 | 134 |
| 4177 | Minimally invasive, maximal outcomes in breast surgery. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2016, 14, 174-178. | 0.8 | 2 |
| 4178 | Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 411-417. | 0.8 | 39 |
| 4179 | Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?. <i>Supportive Care in Cancer</i> , 2016, 24, 387-394. | 1.0 | 8 |
| 4180 | A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. <i>Breast Cancer</i> , 2016, 23, 499-509. | 1.3 | 11 |
| 4181 | Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 261-264. | 0.5 | 5 |
| 4182 | Tolerability and pharmacokinetic profile of a novel benzene-poly-carboxylic acids complex with cisplatin diammineplatinum dichloride in dogs with malignant mammary tumours. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 118-132. | 0.8 | 6 |
| 4183 | Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer. <i>American Journal of Therapeutics</i> , 2017, 24, e3-e11. | 0.5 | 18 |
| 4184 | Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study. <i>Breast Cancer</i> , 2017, 24, 161-170. | 1.3 | 11 |
| 4185 | Older Patients With Early-stage Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 300-305. | 0.6 | 10 |
| 4186 | A Multidisciplinary Patient Navigation Program Improves Compliance With Adjuvant Breast Cancer Therapy in a Public Hospital. <i>American Journal of Medical Quality</i> , 2017, 32, 406-413. | 0.2 | 26 |
| 4187 | Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. <i>Cancer Letters</i> , 2017, 400, 259-266. | 3.2 | 14 |
| 4188 | MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 840-846. | 1.0 | 50 |
| 4189 | How could breast cancer molecular features contribute to locoregional treatment decision making?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 43-48. | 2.0 | 37 |
| 4190 | Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX [®] Breast Recurrence Score Assay. <i>European Journal of Surgical Oncology</i> , 2017, 43, 921-930. | 0.5 | 20 |
| 4191 | Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs. <i>Journal of Medical Economics</i> , 2017, 20, 405-408. | 1.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4192 | Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats. <i>Clinical Cancer Research</i> , 2017, 23, 814-824. | 3.2 | 45 |
| 4193 | Prevalence of preterm, low birthweight, and small for gestational age delivery after breast cancer diagnosis: a population-based study. <i>Breast Cancer Research</i> , 2017, 19, 11. | 2.2 | 27 |
| 4194 | Imaging Surveillance After Primary Breast Cancer Treatment. <i>American Journal of Roentgenology</i> , 2017, 208, 676-686. | 1.0 | 59 |
| 4195 | Emerging functional roles of nuclear receptors in breast cancer. <i>Journal of Molecular Endocrinology</i> , 2017, 58, R169-R190. | 1.1 | 34 |
| 4196 | Breast Cancer Metastasis. , 2017, , 13-31. | | 9 |
| 4197 | An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer. <i>Breast Journal</i> , 2017, 23, 677-686. | 0.4 | 33 |
| 4198 | Trade-offs Between Efficacy and Cardiac Toxicity of Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients: Do Competing Risks Matter?. <i>Breast Journal</i> , 2017, 23, 401-409. | 0.4 | 9 |
| 4199 | Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK. <i>European Journal of Surgical Oncology</i> , 2017, 43, 931-937. | 0.5 | 49 |
| 4200 | Is Sentinel Node Biopsy of the Internal Mammary Lymph Nodes Relevant in the Management of Breast Cancer?. <i>Breast Journal</i> , 2017, 23, 410-414. | 0.4 | 8 |
| 4201 | Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 119-130. | 1.1 | 29 |
| 4202 | Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. <i>Cancer Treatment Reviews</i> , 2017, 55, 26-35. | 3.4 | 19 |
| 4203 | Impact of prior breast cancer on mode of delivery and pregnancy-associated disorders: a retrospective analysis of subsequent pregnancy outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1069-1074. | 1.2 | 22 |
| 4204 | Integrated precision medicine: the role of electronic health records in delivering personalized treatment. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2017, 9, e1378. | 6.6 | 45 |
| 4205 | Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?. <i>Cancer Causes and Control</i> , 2017, 28, 215-225. | 0.8 | 16 |
| 4206 | New Insights in Estrogen Receptor (ER) Biology and Implications for Treatment. <i>Current Breast Cancer Reports</i> , 2017, 9, 13-25. | 0.5 | 4 |
| 4207 | Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2017, 1865, 488-498. | 1.1 | 19 |
| 4208 | Postmastectomy Radiation Therapy Is Associated With Improved Survival in Node-Positive Male Breast Cancer: A Population Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 384-391. | 0.4 | 27 |
| 4209 | Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. <i>Breast Cancer Research</i> , 2017, 19, 9. | 2.2 | 104 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4210 | Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. <i>Journal of Surgical Oncology</i> , 2017, 115, 647-662. | 0.8 | 13 |
| 4211 | Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 297-310. | 1.1 | 3 |
| 4212 | Women, thrombosis, and cancer: A gender-specific analysis. <i>Thrombosis Research</i> , 2017, 151, S21-S29. | 0.8 | 11 |
| 4213 | Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. <i>Bioorganic Chemistry</i> , 2017, 71, 257-274. | 2.0 | 116 |
| 4214 | Hydrolysis of Hyaluronic Acid in Lymphedematous Tissue Alleviates Fibrogenesis via TH1 Cell-Mediated Cytokine Expression. <i>Scientific Reports</i> , 2017, 7, 35. | 1.6 | 19 |
| 4215 | Management Strategies for Sexual Health After Breast Cancer Diagnosis. , 2017, , 303-322. | | 0 |
| 4216 | Oncoplastic breast surgery does not delay the onset of adjuvant chemotherapy: a population-based study. <i>Acta Oncol</i> , 2017, 56, 719-723. | 0.8 | 16 |
| 4217 | Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era. <i>Clinical Breast Cancer</i> , 2017, 17, e185-e189. | 1.1 | 16 |
| 4218 | Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011. <i>British Journal of Cancer</i> , 2017, 116, 828-839. | 2.9 | 37 |
| 4219 | Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review. <i>Breast Journal</i> , 2017, 23, 694-705. | 0.4 | 12 |
| 4220 | Extended Endocrine Therapy: Is 5 Years Enough?. <i>Current Oncology Reports</i> , 2017, 19, 16. | 1.8 | 5 |
| 4221 | Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 311-319. | 1.1 | 20 |
| 4222 | miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. <i>Oncology Reports</i> , 2017, 37, 1093-1099. | 1.2 | 57 |
| 4223 | Synthesis and <i>in vitro</i> anti-proliferative activity of some novel isatins conjugated with quinazoline/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 600-613. | 2.5 | 70 |
| 4224 | Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast. <i>BMC Cancer</i> , 2017, 17, 115. | 1.1 | 19 |
| 4225 | MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 559-569. | 1.1 | 32 |
| 4226 | Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 1-10. | 1.1 | 25 |
| 4227 | WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1003-1011. | 1.1 | 29 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4228 | Distant recurrence risk following early ipsilateral breast tumor recurrence. <i>Oncology Letters</i> , 2017, 13, 2886-2890. | 0.8 | 1 |
| 4230 | Does the Risk of Metabolic Syndrome Increase in Thyroid Cancer Survivors?. <i>Thyroid</i> , 2017, 27, 936-943. | 2.4 | 6 |
| 4231 | Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. <i>Journal of Surgical Oncology</i> , 2017, 115, 917-923. | 0.8 | 72 |
| 4232 | A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2 ⁻ early breast cancer. <i>Scientific Reports</i> , 2017, 7, 45554. | 1.6 | 26 |
| 4233 | Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 4735-4743. | 3.2 | 14 |
| 4234 | Single CpG site methylation controls estrogen receptor gene transcription and correlates with hormone therapy resistance. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 171, 209-217. | 1.2 | 44 |
| 4235 | Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4482-E4491. | 3.3 | 83 |
| 4236 | GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. <i>Annals of Oncology</i> , 2017, 28, 1811-1816. | 0.6 | 119 |
| 4238 | Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. <i>Npj Breast Cancer</i> , 2017, 3, 3. | 2.3 | 17 |
| 4239 | Current status of the prognostic molecular biomarkers in breast cancer: A systematic review. <i>Oncology Letters</i> , 2017, 13, 1491-1498. | 0.8 | 21 |
| 4240 | The influence of socioeconomic status and ethnicity on adjuvant systemic treatment guideline adherence for early-stage breast cancer in the Netherlands. <i>Annals of Oncology</i> , 2017, 28, 1970-1978. | 0.6 | 12 |
| 4241 | Unusual Horner's Syndrome in Recurrent Breast Cancer: Evaluation Using 18F-FDG PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 93-96. | 0.6 | 4 |
| 4242 | Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial. <i>Annals of Oncology</i> , 2017, 28, 1817-1824. | 0.6 | 36 |
| 4243 | The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 285-294. | 1.1 | 11 |
| 4244 | Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay). <i>American Journal of Clinical Pathology</i> , 2017, 147, 541-548. | 0.4 | 23 |
| 4245 | Adjuvant Endocrine Therapy in Breast Cancer: Evolving Paradigms in Premenopausal Women. <i>Current Treatment Options in Oncology</i> , 2017, 18, 28. | 1.3 | 11 |
| 4246 | The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2 ⁻) breast cancer: When might multigene assays be of value?. <i>Breast</i> , 2017, 33, 191-199. | 0.9 | 4 |
| 4247 | The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up. <i>International Journal of Cancer</i> , 2017, 141, 671-677. | 2.3 | 52 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 4248 | Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients. <i>Breast</i> , 2017, 31, 186-191. | 0.9 | 11 |
| 4249 | Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336. | 4.9 | 39 |
| 4250 | Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2017, 109, . | 3.0 | 11 |
| 4251 | Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials. <i>Medical Oncology</i> , 2017, 34, 131. | 1.2 | 14 |
| 4252 | Optimal duration of adjuvant chemotherapy for high-risk node-negative (Nâ€“) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). <i>European Journal of Cancer</i> , 2017, 79, 166-175. | 1.3 | 5 |
| 4253 | Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers. <i>Oncology Letters</i> , 2017, 13, 4708-4712. | 0.8 | 40 |
| 4254 | Short tangential arcs in VMAT based breast and chest wall radiotherapy lead to conformity of the breast dose with lesser cardiac and lung doses: a prospective study of breast conservation and mastectomy patients. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2017, 40, 729-736. | 1.4 | 14 |
| 4255 | Influence of comorbidity on chemotherapy use for early breast cancer: systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 17-39. | 1.1 | 29 |
| 4256 | High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 667-678. | 1.1 | 79 |
| 4257 | Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation. <i>Hormones and Cancer</i> , 2017, 8, 219-229. | 4.9 | 14 |
| 4258 | Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 929-945. | 5.1 | 58 |
| 4259 | The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival. <i>British Journal of Cancer</i> , 2017, 117, 179-188. | 2.9 | 38 |
| 4261 | Clinical utility of gene-expression signatures in early stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 595-610. | 12.5 | 197 |
| 4262 | The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 391-402. | 1.1 | 32 |
| 4263 | Nestin and cluster of differentiation 146 expression in breast cancer: Predicting early recurrence by targeting metastasis?. <i>Tumor Biology</i> , 2017, 39, 101042831769118. | 0.8 | 9 |
| 4264 | A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1088-1096. | 1.0 | 3 |
| 4265 | Which women decide to take tamoxifen?. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 149-155. | 1.1 | 5 |
| 4266 | Nuclear Membrane-Targeted Gold Nanoparticles Inhibit Cancer Cell Migration and Invasion. <i>ACS Nano</i> , 2017, 11, 3716-3726. | 7.3 | 135 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4267 | Chemotherapy-induced irreversible alopecia in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 527-533. | 1.1 | 16 |
| 4268 | Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 148-156. | 3.3 | 16 |
| 4269 | Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?. <i>Oncology</i> , 2017, 92, 317-324. | 0.9 | 7 |
| 4270 | Formulation of a Sustained Release Docetaxel Loaded Cockle Shell-Derived Calcium Carbonate Nanoparticles against Breast Cancer. <i>Pharmaceutical Research</i> , 2017, 34, 1193-1203. | 1.7 | 50 |
| 4271 | The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials. <i>Radiation Oncology</i> , 2017, 12, 60. | 1.2 | 75 |
| 4272 | Acceptance of adjuvant chemotherapy recommendations in early-stage hormone-positive breast cancer. <i>Journal of Surgical Research</i> , 2017, 214, 79-85. | 0.8 | 5 |
| 4273 | The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ER±-negative breast cancer. <i>Oncogene</i> , 2017, 36, 4124-4134. | 2.6 | 60 |
| 4274 | AQP5 Variants Affect Tumoral Expression of AQP5 and Survival in Patients with Early Breast Cancer. <i>Oncology</i> , 2017, 92, 153-160. | 0.9 | 8 |
| 4275 | Protecting Effects of Gonadotropin-Releasing Hormone Agonist on Chemotherapy-Induced Ovarian Damage in Premenopausal Breast Cancer Patients: A Systematic Review and Meta-Analysis. <i>Breast Care</i> , 2017, 12, 46-50. | 0.8 | 13 |
| 4276 | Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy. <i>Biotechnic and Histochemistry</i> , 2017, 92, 175-200. | 0.7 | 10 |
| 4277 | UPLC-MS/MS method for the determination of tobacco-specific biomarker NNAL, tamoxifen and its main metabolites in rat plasma. <i>Biomedical Chromatography</i> , 2017, 31, e3890. | 0.8 | 4 |
| 4278 | Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 549-556. | 1.1 | 147 |
| 4279 | An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 567-574. | 1.1 | 18 |
| 4280 | Efficacy of Sentinel Lymph Node Biopsy in Detecting Axillary Metastasis in Breast Cancer Using Methylene Blue. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 109-112. | 0.3 | 15 |
| 4281 | A Hybrid Computer-aided-diagnosis System for Prediction of Breast Cancer Recurrence (HPBCR) Using Optimized Ensemble Learning. <i>Computational and Structural Biotechnology Journal</i> , 2017, 15, 75-85. | 1.9 | 105 |
| 4282 | Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 515-524. | 1.1 | 8 |
| 4283 | Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management. <i>Supportive Care in Cancer</i> , 2017, 25, 1055-1061. | 1.0 | 13 |
| 4284 | POWERPIINC (PreOperative Window of Endocrine Therapy Provides Information to Increase) Tj ETQq1 1 0.784314 rgBT /Overlock 10 tamoxifen. <i>Breast</i> , 2017, 31, 219-223. | 0.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4285 | Synergistic disruption of ER \pm /HER2 crosstalk by endoxifen and lapatinib in breast cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 117-130. | 1.1 | 2 |
| 4286 | Cytochrome P-450 2D6 (<i>CYP2D6</i>) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. <i>American Journal of Epidemiology</i> , 2017, 185, 75-85. | 1.6 | 30 |
| 4287 | Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER Antagonists. <i>Cancer Discovery</i> , 2017, 7, 277-287. | 7.7 | 286 |
| 4288 | Significant Effect of Polymorphisms in <i>CYP2D6</i> on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. <i>Clinical Cancer Research</i> , 2017, 23, 2019-2026. | 3.2 | 33 |
| 4289 | Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. <i>Annals of Surgical Oncology</i> , 2017, 24, 375-397. | 0.7 | 61 |
| 4290 | Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1161-1172. | 0.5 | 13 |
| 4291 | Current Trends in Postmastectomy Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2017, 140, 7S-13S. | 0.7 | 283 |
| 4292 | Breast cancer in the 21st century: From early detection to new therapies. <i>Radiologia</i> , 2017, 59, 368-379. | 0.3 | 67 |
| 4293 | Quality indicators in breast cancer care: An update from the EUSOMA working group. <i>European Journal of Cancer</i> , 2017, 86, 59-81. | 1.3 | 163 |
| 4294 | Ribociclib: a valuable addition to treatment options in breast cancer?. <i>ESMO Open</i> , 2017, 2, e000246. | 2.0 | 3 |
| 4295 | Circular RNA hsa_circ_0001982 Promotes Breast Cancer Cell Carcinogenesis Through Decreasing miR-143. <i>DNA and Cell Biology</i> , 2017, 36, 901-908. | 0.9 | 155 |
| 4296 | NEAT1 negatively regulates miR-218 expression and promotes breast cancer progression. <i>Cancer Biomarkers</i> , 2017, 20, 247-254. | 0.8 | 56 |
| 4297 | <i>CYP2C19*2</i> and <i>CYP2C19*17</i> variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. <i>Scientific Reports</i> , 2017, 7, 7727. | 1.6 | 19 |
| 4298 | Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence. <i>Cell Metabolism</i> , 2017, 26, 842-855.e5. | 7.2 | 180 |
| 4299 | Bim may be a poor prognostic biomarker in breast cancer patients especially in those with luminal A tumors. <i>Cancer Biomarkers</i> , 2017, 19, 411-418. | 0.8 | 5 |
| 4300 | Grip Strength in Women Being Treated for Breast Cancer and Receiving Adjuvant Endocrine Therapy: Systematic Review. <i>Physical Therapy</i> , 2017, 97, 904-914. | 1.1 | 6 |
| 4301 | Effective treatment of drug resistant recurrent breast tumors harboring cancer stem-like cells by staurosporine/epirubicin co-loaded polymeric micelles. <i>Journal of Controlled Release</i> , 2017, 264, 127-135. | 4.8 | 29 |
| 4302 | Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 406-413. | 0.8 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4303 | Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study. <i>Oncology Nursing Forum</i> , 2017, 44, E101-E110. | 0.5 | 38 |
| 4304 | Effects of tamoxifen on urinary incontinence. <i>Medicine (United States)</i> , 2017, 96, e6785. | 0.4 | 6 |
| 4305 | Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area. <i>European Journal of Cancer</i> , 2017, 84, 270-277. | 1.3 | 4 |
| 4306 | Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study. <i>Molecular and Clinical Oncology</i> , 2017, 7, 661-666. | 0.4 | 3 |
| 4307 | The WISDOM Study: breaking the deadlock in the breast cancer screening debate. <i>Npj Breast Cancer</i> , 2017, 3, 34. | 2.3 | 179 |
| 4308 | Chemotherapy-Induced Macrophage Infiltration into Tumors Enhances Nanographene-Based Photodynamic Therapy. <i>Cancer Research</i> , 2017, 77, 6021-6032. | 0.4 | 16 |
| 4309 | A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2017, 95, 1209-1218. | 2.5 | 222 |
| 4310 | Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment. <i>Clinical Drug Investigation</i> , 2017, 37, 1093-1102. | 1.1 | 8 |
| 4311 | Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. <i>Current Opinion in Oncology</i> , 2017, 29, 428-433. | 1.1 | 2 |
| 4312 | T-cadherin is associated with prognosis in triple-negative breast cancer. <i>Oncology Letters</i> , 2017, 14, 2975-2981. | 0.8 | 3 |
| 4313 | Catalpol promotes cellular apoptosis in human HCT116 colorectal cancer cells via microRNA-200 and the downregulation of PI3K-Akt signaling pathway. <i>Oncology Letters</i> , 2017, 14, 3741-3747. | 0.8 | 30 |
| 4314 | A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes. <i>Clinical Cancer Research</i> , 2017, 23, 7217-7224. | 3.2 | 27 |
| 4315 | Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy. <i>Acta Biomaterialia</i> , 2017, 62, 257-272. | 4.1 | 56 |
| 4316 | Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035). <i>Cancer Treatment Reviews</i> , 2017, 60, 12-17. | 3.4 | 15 |
| 4317 | The anticancer estrogen receptor antagonist tamoxifen impairs consolidation of inhibitory avoidance memory through estrogen receptor alpha. <i>Journal of Neural Transmission</i> , 2017, 124, 1331-1339. | 1.4 | 20 |
| 4318 | Survival of node-negative breast cancer patients treated at the university medical centre Maribor in the period 2000-2009. <i>Zdravstveno Varstvo</i> , 2017, 56, 185-192. | 0.6 | 0 |
| 4319 | Aromatase Inhibitors for the adjuvant treatment of breast cancer in postmenopausal women. <i>The Cochrane Library</i> , 0, , . | 1.5 | 0 |
| 4320 | Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study. <i>Breast</i> , 2017, 35, 130-135. | 0.9 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4321 | Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer. <i>Medicine (United States)</i> , 2017, 96, e6777. | 0.4 | 8 |
| 4322 | Breast Cancer Molecular Stratification. <i>American Journal of Pathology</i> , 2017, 187, 2152-2162. | 1.9 | 198 |
| 4323 | El c ncer de mama en el siglo XXI: de la detecci3n precoz a los nuevos tratamientos. <i>Radiologia</i> , 2017, 59, 368-379. | 0.3 | 86 |
| 4324 | Deciphering metabolic rewiring in breast cancer subtypes. <i>Translational Research</i> , 2017, 189, 105-122. | 2.2 | 45 |
| 4325 | Increase in contralateral prophylactic mastectomy conversation online unrelated to decision-making. <i>Journal of Surgical Research</i> , 2017, 218, 253-260. | 0.8 | 4 |
| 4326 | Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318. | 0.1 | 31 |
| 4327 | Preventive therapy for cancer. <i>Lancet Oncology</i> , The, 2017, 18, e472-e482. | 5.1 | 81 |
| 4328 | Short-term and long-term clinical outcomes of uncommon types of invasive breast cancer. <i>Histopathology</i> , 2017, 71, 874-886. | 1.6 | 13 |
| 4329 | CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data. <i>Npj Breast Cancer</i> , 2017, 3, 27. | 2.3 | 30 |
| 4330 | Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 28. | 2.3 | 13 |
| 4331 | A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. <i>Scientific Reports</i> , 2017, 7, 6584. | 1.6 | 30 |
| 4332 | Integrated diagnostic network construction reveals a 4-gene panel and 5 cancer hallmarks driving breast cancer heterogeneity. <i>Scientific Reports</i> , 2017, 7, 6827. | 1.6 | 25 |
| 4333 | Body mass index, waist-to-hip ratio and late outcomes: a report from the Shanghai Breast Cancer Survival Study. <i>Scientific Reports</i> , 2017, 7, 6996. | 1.6 | 16 |
| 4334 | Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. <i>Annals of Surgical Oncology</i> , 2017, 24, 2889-2897. | 0.7 | 28 |
| 4335 | Cognitive impairment and chemotherapy: a brief overview. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 7-14. | 2.0 | 55 |
| 4336 | <i>Lentinula edodes mycelia</i> extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement. <i>Molecular and Clinical Oncology</i> , 2017, 7, 359-366. | 0.4 | 13 |
| 4337 | Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2017, 63, 1585-1593. | 1.5 | 45 |
| 4338 | Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study. <i>Breast Care</i> , 2017, 12, 160-164. | 0.8 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 4339 | Hypofractionated Nodal Radiation Therapy for Breast Cancer Was Not Associated With Increased Patient-Reported Arm or Brachial Plexopathy Symptoms. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1166-1172. | 0.4 | 27 |
| 4340 | An oral cavity squamous cell carcinoma quantitative histomorphometric-based image classifier of nuclear morphology can risk stratify patients for disease-specific survival. <i>Modern Pathology</i> , 2017, 30, 1655-1665. | 2.9 | 60 |
| 4341 | Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 593-601. | 1.1 | 17 |
| 4342 | Geographic Variation of Adjuvant Breast Cancer Therapy Initiation in the United States: Lessons From Medicare Part D. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1509-1517. | 2.3 | 2 |
| 4345 | The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 210-216. | 0.5 | 0 |
| 4346 | Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma. <i>Oncology Reports</i> , 2018, 39, 151-159. | 1.2 | 39 |
| 4347 | Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population. <i>European Journal of Cancer</i> , 2017, 86, 364-372. | 1.3 | 32 |
| 4348 | Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?. <i>Tumor Biology</i> , 2017, 39, 101042831773151. | 0.8 | 20 |
| 4349 | Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1079-1087. | 0.8 | 4 |
| 4350 | Tumour bed boost radiotherapy for women after breast-conserving surgery. <i>The Cochrane Library</i> , 2017, 2017, CD011987. | 1.5 | 42 |
| 4351 | 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017, 377, 1836-1846. | 13.9 | 1,052 |
| 4352 | Prognostic and Predictive Role of Genetic Signatures. , 2017, , 121-131. | | 0 |
| 4353 | The Pathology Report. , 2017, , 157-168. | | 1 |
| 4354 | Endocrine Therapies in the Adjuvant and Advanced Disease Settings. , 2017, , 557-568. | | 0 |
| 4355 | Adjuvant Systemic Therapies by Subtypes: Guidelines. , 2017, , 535-539. | | 0 |
| 4356 | Breast Cancer Microenvironment and the Metastatic Process. , 2017, , 39-48. | | 1 |
| 4357 | Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses. <i>Journal of Cancer Survivorship</i> , 2017, 11, 525-541. | 1.5 | 31 |
| 4358 | Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. <i>British Journal of Cancer</i> , 2017, 117, 164-170. | 2.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4359 | Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?. <i>British Journal of Cancer</i> , 2017, 117, 157-158. | 2.9 | 1 |
| 4360 | Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial. <i>Contemporary Clinical Trials</i> , 2017, 61, 96-100. | 0.8 | 13 |
| 4361 | Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 851-856. | 1.1 | 30 |
| 4362 | Breast cancer treatment-induced cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1021-1038. | 1.0 | 58 |
| 4363 | Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 1-13. | 1.1 | 7 |
| 4364 | Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1167-1178. | 0.9 | 21 |
| 4365 | Margin Proximity Correlates with Local Recurrence After Mastectomy for Patients Not Receiving Adjuvant Radiotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3148-3156. | 0.7 | 14 |
| 4366 | 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 69-76. | 1.1 | 31 |
| 4367 | Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. <i>Oncologist</i> , 2017, 22, 1189-1196. | 1.9 | 3 |
| 4368 | Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis. <i>Bioscience Reports</i> , 2017, 37, . | 1.1 | 14 |
| 4369 | Precision medicine in breast cancer: reality or utopia?. <i>Journal of Translational Medicine</i> , 2017, 15, 139. | 1.8 | 56 |
| 4370 | An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. <i>Breast Cancer Research</i> , 2017, 19, 58. | 2.2 | 161 |
| 4371 | Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 573-583. | 1.1 | 149 |
| 4372 | Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer. <i>Gynecologic Oncology</i> , 2017, 147, 153-157. | 0.6 | 9 |
| 4373 | The impact of nodal micrometastasis on mortality among women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 103-115. | 1.1 | 18 |
| 4374 | A model for individualized risk prediction of contralateral breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 153-160. | 1.1 | 38 |
| 4375 | Effect of hospital volume on processes of breast cancer care: A National Cancer Data Base study. <i>Cancer</i> , 2017, 123, 957-966. | 2.0 | 33 |
| 4376 | Antiestrogens: structure-activity relationships and use in breast cancer treatment. <i>Journal of Molecular Endocrinology</i> , 2017, 58, R15-R31. | 1.1 | 66 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4377 | Survival of de novo stage IV breast cancer patients over three decades. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 509-519. | 1.2 | 30 |
| 4378 | Tumor cell dormancy. <i>Molecular Oncology</i> , 2017, 11, 62-78. | 2.1 | 129 |
| 4379 | Deep inspiration breath-hold produces a clinically meaningful reduction in ipsilateral lung dose during locoregional radiation therapy for some women with right-sided breast cancer. <i>Practical Radiation Oncology</i> , 2017, 7, 147-153. | 1.1 | 25 |
| 4380 | Post-surgical depressive symptoms and long-term survival in non-metastatic breast cancer patients at 11-year follow-up. <i>General Hospital Psychiatry</i> , 2017, 44, 16-21. | 1.2 | 33 |
| 4381 | The impact of the Biomolecular Era on breast cancer surgery. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2017, 15, 169-181. | 0.8 | 7 |
| 4382 | Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2017, 17, 11-17. | 1.1 | 60 |
| 4383 | The Growth Inhibitory Potential and Antimetastatic Effect of Camel Urine on Breast Cancer Cells In Vitro and In Vivo. <i>Integrative Cancer Therapies</i> , 2017, 16, 540-555. | 0.8 | 15 |
| 4384 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42. | 2.9 | 920 |
| 4385 | Why Are There So Many Mastectomies in the United States?. <i>Annual Review of Medicine</i> , 2017, 68, 229-241. | 5.0 | 37 |
| 4386 | How cancer cells dictate their microenvironment: present roles of extracellular vesicles. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 697-713. | 2.4 | 126 |
| 4387 | Methylparaben stimulates tumor initiating cells in ER+ breast cancer models. <i>Journal of Applied Toxicology</i> , 2017, 37, 417-425. | 1.4 | 38 |
| 4388 | Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw188. | 3.0 | 28 |
| 4389 | Outcomes After Mastectomy and Lumpectomy in Elderly Patients with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 100-107. | 0.7 | 22 |
| 4390 | The influence of breast cancer subtype on bone metastases development and survival in women with metastatic breast cancer. <i>Irish Journal of Medical Science</i> , 2017, 186, 97-102. | 0.8 | 4 |
| 4391 | Functional and prognostic significance of the genomic amplification of frizzled 6 (<i>FZD6</i>) in breast cancer. <i>Journal of Pathology</i> , 2017, 241, 350-361. | 2.1 | 66 |
| 4392 | Can polyacrylic acid treat sexual dysfunction in women with breast cancer receiving tamoxifen?. <i>Climacteric</i> , 2017, 20, 62-66. | 1.1 | 17 |
| 4393 | Over-using chemotherapy in the adjuvant setting. <i>Breast</i> , 2017, 31, 303-308. | 0.9 | 9 |
| 4394 | Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly. <i>British Journal of Cancer</i> , 2017, 116, 4-9. | 2.9 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4395 | Further evidence to support bimodality of oestrogen receptor expression in breast cancer. <i>Histopathology</i> , 2017, 70, 456-465. | 1.6 | 12 |
| 4397 | Downregulation of regulator of G protein signaling 2 expression in breast invasive carcinoma of no special type: Clinicopathological associations and prognostic relevance. <i>Oncology Letters</i> , 2017, 15, 213-220. | 0.8 | 6 |
| 4398 | MicroRNA-10b expression in node-negative breast cancer—correlation with metastasis and angiogenesis. <i>Oncology Letters</i> , 2017, 14, 5845-5852. | 0.8 | 13 |
| 4399 | Non-Menstrual Vaginal Bleeding Management in Primary Care. , 0, , 134-141. | | 0 |
| 4400 | Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming. <i>Genes and Development</i> , 2017, 31, 2235-2249. | 2.7 | 41 |
| 4402 | Toward precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis. , 2017, , . | | 4 |
| 4403 | Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin. <i>Case Reports in Oncology</i> , 2017, 9, 840-846. | 0.3 | 4 |
| 4404 | A REVIEW ON SCREENING METHODS OF BREAST CANCER, CANCER BIOMARKERS AND PHYTOCONSTITUENTS AGAINST BREAST CANCER. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2017, 10, 17. | 0.3 | 1 |
| 4405 | Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. <i>Frontiers in Pharmacology</i> , 2017, 8, 67. | 1.6 | 3 |
| 4406 | In vivo validation of metastasis-regulating microRNA-766 in human triple-negative breast cancer cells. <i>Laboratory Animal Research</i> , 2017, 33, 256. | 1.1 | 14 |
| 4407 | Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Oncology Research</i> , 2017, 25, 1567-1578. | 0.6 | 9 |
| 4408 | Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. <i>Genes</i> , 2017, 8, 217. | 1.0 | 24 |
| 4409 | Tumor Heterogeneity in Breast Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 227. | 1.2 | 379 |
| 4410 | Radiation therapy and early breast cancer: current controversies. <i>Medical Journal of Australia</i> , 2017, 207, 216-222. | 0.8 | 26 |
| 4412 | Self-Assembling RADA16-I Peptide Hydrogel Scaffold Loaded with Tamoxifen for Breast Reconstruction. <i>BioMed Research International</i> , 2017, 2017, 1-10. | 0.9 | 13 |
| 4413 | Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 1641-1649. | 0.8 | 555 |
| 4414 | Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial. <i>Wspolczesna Onkologia</i> , 2017, 1, 83-89. | 0.7 | 5 |
| 4415 | The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study. <i>Oncotarget</i> , 2017, 8, 26368-26379. | 0.8 | 64 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4416 | The past and future of breast cancer treatment“from the papyrus to individualised treatment approaches. <i>Ecancermedalscience</i> , 2017, 11, 746. | 0.6 | 35 |
| 4417 | Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients. <i>PLoS ONE</i> , 2017, 12, e0173862. | 1.1 | 12 |
| 4418 | Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. <i>PLoS ONE</i> , 2017, 12, e0185566. | 1.1 | 7 |
| 4419 | Tamoxifen use and acute pancreatitis: A population-based cohort study. <i>PLoS ONE</i> , 2017, 12, e0173089. | 1.1 | 0 |
| 4420 | Tamoxifen reverses epithelial“mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells. <i>BMC Cancer</i> , 2017, 17, 492. | 1.1 | 32 |
| 4421 | Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers. <i>BMC Cancer</i> , 2017, 17, 662. | 1.1 | 3 |
| 4422 | PSAT1 is regulated by“ATF4 and enhances cell proliferation via the GSK3“/“-catenin/cyclin D1 signaling pathway in ER-negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 179. | 3.5 | 98 |
| 4423 | Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. <i>Breast Cancer Research</i> , 2017, 19, 120. | 2.2 | 93 |
| 4424 | Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. <i>Breast Cancer Research</i> , 2017, 19, 125. | 2.2 | 58 |
| 4425 | Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 386. | 0.7 | 13 |
| 4426 | Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial. <i>BMC Cancer</i> , 2017, 17, 632. | 1.1 | 23 |
| 4428 | Changing patterns of breast cancer incidence and mortality by education level over four decades in Norway, 1971“2009. <i>European Journal of Public Health</i> , 2017, 27, 160-166. | 0.1 | 19 |
| 4429 | Postablation Endometrial Carcinoma. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2017, 21, e2017.00011. | 0.5 | 13 |
| 4430 | Investigating Associations Between Health-Related Quality of Life and Endocrine Therapy Underuse in Women With Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e463-e473. | 2.5 | 12 |
| 4431 | Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer. <i>Perinatology</i> , 2017, 28, 184. | 0.0 | 1 |
| 4432 | Febrile Neutropenia Risk with Adjuvant Docetaxel and Cyclophosphamide (TC) Chemotherapy Regimen in Two Brazilians Cancer Centers. <i>Journal of Integrative Oncology</i> , 2017, 06, . | 0.3 | 1 |
| 4433 | Risk Reduction Strategies in Breast Cancer Prevention. <i>The Journal of Breast Health</i> , 2017, 13, 103-112. | 0.4 | 20 |
| 4434 | Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. <i>Journal of Breast Cancer</i> , 2017, 20, 347. | 0.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4435 | Synergistic cytotoxic effects of arsenite and tetrandrine in human breast cancer cell line MCF-7. <i>International Journal of Oncology</i> , 2017, 51, 587-598. | 1.4 | 33 |
| 4436 | Nuclear expression of XBP1s is correlated with breast cancer survival: a retrospective analysis based on tissue microarray. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5927-5934. | 1.0 | 7 |
| 4437 | A Population-Based Assessment of Primary Care Visits during Adjuvant Chemotherapy for Breast Cancer. <i>Current Oncology</i> , 2017, 24, 90-94. | 0.9 | 7 |
| 4438 | Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. <i>Oncotarget</i> , 2017, 8, 52156-52177. | 0.8 | 40 |
| 4439 | Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 31347-31354. | 0.8 | 147 |
| 4440 | Chemotherapy-Induced Ovarian Failure in Pre-Menopausal Patients with Breast Cancer. <i>Journal of the Nihon University Medical Association</i> , 2017, 76, 241-243. | 0.0 | 0 |
| 4441 | Cell-free DNA detected by liquid biopsy as a potential prognostic biomarker in early breast cancer. <i>Oncotarget</i> , 2017, 8, 16642-16649. | 0.8 | 29 |
| 4442 | Possible benefits from post-mastectomy radiotherapy in node-negative breast cancer patients: a multicenter analysis in Korea (KROG 14-22). <i>Oncotarget</i> , 2017, 8, 59800-59809. | 0.8 | 5 |
| 4443 | Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2639-2646. | 0.8 | 43 |
| 4444 | Cell-specific regulation of proliferation by Ano1/TMEM16A in breast cancer with different ER, PR, and HER2 status. <i>Oncotarget</i> , 2017, 8, 84996-85013. | 0.8 | 29 |
| 4445 | Long-Term Follow-Up of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2507-2514. | 0.8 | 22 |
| 4446 | Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-10. | 1.0 | 30 |
| 4447 | Ovarian Suppression for Women Younger Than 35 Years: New Data to Support Informed Decision Making. <i>Journal of Clinical Oncology</i> , 2017, 35, 3092-3094. | 0.8 | 0 |
| 4448 | Reply to A.Y. Lin. <i>Journal of Clinical Oncology</i> , 2017, 35, 121-122. | 0.8 | 0 |
| 4449 | Correlations between Tumor to Background Ratio on Breast-Specific Gamma Imaging and Prognostic Factors in Breast Cancer. <i>Journal of Korean Medical Science</i> , 2017, 32, 1031. | 1.1 | 6 |
| 4450 | A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. <i>Oncotarget</i> , 2017, 8, 48362-48374. | 0.8 | 10 |
| 4451 | Role of MR Imaging for the Locoregional Staging of Breast Cancer. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 191-205. | 0.6 | 10 |
| 4452 | Reducing Overtreatment of Cancer With Precision Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1091. | 3.8 | 24 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4453 | Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. <i>Breast Cancer</i> , 2018, 25, 479-488. | 1.3 | 40 |
| 4454 | First-line paclitaxel and cisplatin used sequentially or in combination in metastatic breast cancer: A phase II randomized study. <i>Journal of the Egyptian National Cancer Institute</i> , 2018, 30, 13-20. | 0.6 | 9 |
| 4455 | ESR1 and endocrine therapy resistance: more than just mutations. <i>Annals of Oncology</i> , 2018, 29, 787-789. | 0.6 | 10 |
| 4456 | Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485. | 5.1 | 59 |
| 4457 | Synthesis and in vitro study of modified chitosan-polycaprolactam nanocomplex as delivery system. <i>International Journal of Biological Macromolecules</i> , 2018, 113, 1287-1293. | 3.6 | 41 |
| 4458 | Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review. <i>PharmacoEconomics - Open</i> , 2018, 2, 359-369. | 0.9 | 6 |
| 4459 | Cancer survivors: An expanding population with an increased cardiometabolic risk. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 432-442. | 1.1 | 27 |
| 4460 | Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 45-53. | 1.1 | 3 |
| 4461 | Preoperative breast MRI and mortality in older women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 149-157. | 1.1 | 10 |
| 4462 | Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 143-148. | 1.1 | 5 |
| 4463 | Thioredoxin-1 and MMP-9 as biomarkers in breast cancer metastasis in Egyptian female patients. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2018, 5, 63-68. | 0.2 | 0 |
| 4464 | Good adherence to adjuvant endocrine therapy in early breast cancer – a population-based study based on the Swedish Prescribed Drug Register. <i>Acta Oncologica</i> , 2018, 57, 935-940. | 0.8 | 20 |
| 4465 | Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 755-762. | 1.1 | 8 |
| 4466 | Breast cancer-specific survival by age: Worse outcomes for the oldest patients. <i>Cancer</i> , 2018, 124, 2184-2191. | 2.0 | 46 |
| 4467 | Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1447-1453. | 2.9 | 46 |
| 4468 | The risk of cardiovascular disease following breast cancer by Framingham risk score. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 119-127. | 1.1 | 49 |
| 4469 | Cerberus Nanoparticles: Cotargeting of Mitochondrial DNA and Mitochondrial Topoisomerase I in Breast Cancer Cells. <i>ACS Applied Nano Materials</i> , 2018, 1, 2195-2205. | 2.4 | 16 |
| 4470 | Comparison of epidemiological features, clinicopathological features, and treatments between premenopausal and postmenopausal female breast cancer patients in western China: a retrospective multicenter study of 15,389 female patients. <i>Cancer Medicine</i> , 2018, 7, 2753-2763. | 1.3 | 19 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4471 | Patterns of breast cancer relapse in accordance to biological subtype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1347-1355. | 1.2 | 60 |
| 4472 | Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 623-631. | 1.1 | 26 |
| 4473 | Fear of recurrence among older breast, ovarian, endometrial, and colorectal cancer survivors: Findings from the WHI LILAC study. <i>Psycho-Oncology</i> , 2018, 27, 1810-1815. | 1.0 | 19 |
| 4474 | A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. <i>Cell Reports</i> , 2018, 23, 918-929. | 2.9 | 39 |
| 4475 | Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer. <i>Histopathology</i> , 2018, 73, 545-558. | 1.6 | 15 |
| 4476 | Metastatic Spine Tumor Epidemiology: Comparison of Trends in Surgery Across Two Decades and Three Continents. <i>World Neurosurgery</i> , 2018, 114, e809-e817. | 0.7 | 50 |
| 4477 | Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?. <i>Annals of Oncology</i> , 2018, 29, 1096-1098. | 0.6 | 9 |
| 4479 | Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 525-533. | 1.1 | 12 |
| 4480 | Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. <i>European Journal of Cancer</i> , 2018, 95, 59-67. | 1.3 | 7 |
| 4481 | Development and External Validation of Prediction Models for 10-Year Survival of Invasive Breast Cancer. Comparison with PREDICT and CancerMath. <i>Clinical Cancer Research</i> , 2018, 24, 2110-2115. | 3.2 | 15 |
| 4483 | Tamoxifen enhances stemness and promotes metastasis of ER ⁺ 36+ breast cancer by upregulating ALDH1A1 in cancer cells. <i>Cell Research</i> , 2018, 28, 336-358. | 5.7 | 98 |
| 4484 | The tale of two stories: Challenges and innovations in breast cancer management. <i>American Journal of Surgery</i> , 2018, 215, 1062-1065. | 0.9 | 1 |
| 4485 | The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. <i>International Journal of Cancer</i> , 2018, 143, 184-189. | 2.3 | 25 |
| 4486 | A new class of agents for estrogen-receptor-positive breast cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 325-328. | 1.3 | 2 |
| 4487 | Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage III breast cancer: ER+/PR+, HER2- vs. triple-negative. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 175-187. | 1.1 | 37 |
| 4488 | Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. <i>Oncologist</i> , 2018, 23, 768-775. | 1.9 | 19 |
| 4489 | Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. <i>Clinical Cancer Research</i> , 2018, 24, 2452-2463. | 3.2 | 32 |
| 4490 | Characterization of bone only metastasis patients with respect to tumor subtypes. <i>Npj Breast Cancer</i> , 2018, 4, 2. | 2.3 | 40 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4491 | Improved overall survival over recent decades in patients with hormone-receptor-positive, HER2-negative breast cancer: a single-center retrospective analysis of prognostic factors. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 248-254. | 0.6 | 1 |
| 4492 | Oral health-related concerns, behavior, and communication with health care providers of patients with breast cancer: impact of different treatments. <i>Special Care in Dentistry</i> , 2018, 38, 36-45. | 0.4 | 7 |
| 4493 | FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node. <i>Oncogene</i> , 2018, 37, 1857-1868. | 2.6 | 49 |
| 4494 | Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 413-425. | 1.1 | 14 |
| 4495 | Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. <i>Annals of Oncology</i> , 2018, 29, 872-880. | 0.6 | 73 |
| 4496 | Adjuvant Endocrine Therapy. <i>Cancer Treatment and Research</i> , 2018, 173, 15-29. | 0.2 | 12 |
| 4497 | Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study. <i>Breast Cancer</i> , 2018, 25, 343-349. | 1.3 | 1 |
| 4498 | Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 153-162. | 1.1 | 13 |
| 4499 | CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. <i>Cancer Research</i> , 2018, 78, 1657-1671. | 0.4 | 97 |
| 4500 | Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2018, 20, 815-826. | 1.2 | 57 |
| 4501 | Preferred and Perceived Participation of Younger and Older Patients in Decision Making About Treatment for Early Breast Cancer: A Prospective Study. <i>Clinical Breast Cancer</i> , 2018, 18, e245-e253. | 1.1 | 38 |
| 4502 | Outcomes by molecular subtype after accelerated partial breast irradiation using single-entry catheters. <i>Brachytherapy</i> , 2018, 17, 415-424. | 0.2 | 5 |
| 4503 | Breast Cancer in Low- and Middle-Income Countries. <i>Clinics in Laboratory Medicine</i> , 2018, 38, 161-173. | 0.7 | 58 |
| 4504 | Ancillary Techniques. <i>Monographs in Clinical Cytology</i> , 2018, 24, 106-112. | 0.1 | 0 |
| 4505 | Therapeutic Strategies for Breast Cancer. , 2018, , 315-330.e7. | | 5 |
| 4506 | Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. , 2018, , 604-630.e6. | | 8 |
| 4507 | Radiation Therapy for Locally Advanced Breast Cancer. , 2018, , 726-735.e2. | | 0 |
| 4508 | Adjuvant Endocrine Therapy. , 2018, , 736-751.e4. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4509 | Adjuvant and Neoadjuvant Systemic Therapies for Early-Stage Breast Cancer. , 2018, , 752-762.e4. | | 0 |
| 4510 | Locally Advanced Breast Cancer. , 2018, , 819-831.e6. | | 3 |
| 4511 | Neoadjuvant Chemotherapy and Radiotherapy. , 2018, , 839-857.e7. | | 0 |
| 4512 | Detection and Clinical Implications of Occult Systemic Micrometastatic Breast Cancer. , 2018, , 858-866.e3. | | 2 |
| 4513 | Endocrine Therapy for Breast Cancer. , 2018, , 907-923.e6. | | 2 |
| 4514 | Bilateral Breast Cancer. , 2018, , 967-973.e2. | | 1 |
| 4515 | General Considerations for Follow-Up. , 2018, , 1011-1023.e6. | | 0 |
| 4516 | Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. , 2018, 186, 1-24. | | 297 |
| 4517 | Adjuvant Endocrine Therapy. , 2018, , 427-438. | | 0 |
| 4518 | Adjuvant Chemotherapy. , 2018, , 439-445. | | 0 |
| 4519 | Primary Systemic Therapy for Breast Cancer. , 2018, , 453-462. | | 0 |
| 4520 | A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 735-745. | 1.8 | 8 |
| 4521 | Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. <i>Seminars in Cancer Biology</i> , 2018, 51, 22-35. | 4.3 | 115 |
| 4522 | PTGS2 polymorphism rs689466 favors breast cancer recurrence in obese patients. <i>Endocrine-Related Cancer</i> , 2018, 25, 351-365. | 1.6 | 4 |
| 4523 | Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 727-737. | 1.1 | 11 |
| 4524 | PAQR4 has a tumorigenic effect in human breast cancers in association with reduced CDK4 degradation. <i>Carcinogenesis</i> , 2018, 39, 439-446. | 1.3 | 24 |
| 4525 | Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes. <i>Oncology</i> , 2018, 94, 176-189. | 0.9 | 20 |
| 4526 | Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options. <i>BMC Cancer</i> , 2018, 18, 203. | 1.1 | 38 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4527 | Euterpe oleracea extract inhibits tumorigenesis effect of the chemical carcinogen DMBA in breast experimental cancer. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 116. | 3.7 | 26 |
| 4528 | Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. <i>World Journal of Surgical Oncology</i> , 2018, 16, 51. | 0.8 | 22 |
| 4529 | Patterns of Care of Breast Cancer Patients in a Rural Cancer Center in Western India. <i>Indian Journal of Surgical Oncology</i> , 2018, 9, 374-380. | 0.3 | 5 |
| 4530 | Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 26. | 1.3 | 44 |
| 4532 | <i>Clostridium difficile</i> toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression, triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model. <i>Biomedicine and Pharmacotherapy</i> , 2018, 101, 391-398. | 2.5 | 23 |
| 4533 | The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). <i>Journal of Geriatric Oncology</i> , 2018, 9, 221-227. | 0.5 | 14 |
| 4534 | Incidence of isolated local breast cancer recurrence and contralateral breast cancer: A systematic review. <i>Breast</i> , 2018, 39, 70-79. | 0.9 | 60 |
| 4535 | Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 515-531. | 2.6 | 175 |
| 4536 | Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer. <i>Breast Journal</i> , 2018, 24, 610-614. | 0.4 | 1 |
| 4537 | Breast cancer lung metastasis: Molecular biology and therapeutic implications. <i>Cancer Biology and Therapy</i> , 2018, 19, 858-868. | 1.5 | 178 |
| 4538 | Ovarian function, fertility and reproductive lifespan in cancer patients. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 125-136. | 1.2 | 52 |
| 4539 | Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. <i>Future Oncology</i> , 2018, 14, 849-859. | 1.1 | 14 |
| 4540 | A Molecular Subtypeâ€“Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010. <i>Medical Decision Making</i> , 2018, 38, 89S-98S. | 1.2 | 8 |
| 4541 | Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment. <i>Medical Decision Making</i> , 2018, 38, 32S-43S. | 1.2 | 26 |
| 4542 | Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320. | 2.3 | 476 |
| 4543 | Survival of breast cancer patients in rural Ethiopia. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 111-118. | 1.1 | 31 |
| 4544 | Breast Cancer in Nepal: Current status and future directions (Review). <i>Biomedical Reports</i> , 2018, 8, 325-329. | 0.9 | 9 |
| 4545 | Factores de riesgo para carcinoma de endometrio de alto grado. <i>Clinica E Investigacion En Ginecologia Y Obstetricia</i> , 2018, 45, 64-68. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4546 | Retrospective evaluation of premenopausal hormone-sensitive breast cancer patients treated with adjuvant gonadotropin-releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e145-e151. | 0.7 | 1 |
| 4547 | Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?. <i>Familial Cancer</i> , 2018, 17, 5-14. | 0.9 | 3 |
| 4548 | The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 264-271. | 0.5 | 2 |
| 4549 | Adenocarcinoma of the Uterine Corpus. , 2018, , 121-154.e8. | | 1 |
| 4550 | A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality. <i>Medical Decision Making</i> , 2018, 38, 78S-88S. | 1.2 | 16 |
| 4551 | Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature. <i>American Journal of Surgery</i> , 2018, 215, 171-178. | 0.9 | 13 |
| 4552 | Indications for Contralateral Prophylactic Mastectomy. <i>Annals of Surgery</i> , 2018, 267, 271-279. | 2.1 | 42 |
| 4553 | A role for G-protein coupled estrogen receptor (GPER) in estrogen-induced carcinogenesis: Dysregulated glandular homeostasis, survival and metastasis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 176, 38-48. | 1.2 | 41 |
| 4554 | The Breast Cancer Screening "Arcade" and the "Whack-A-Mole" Efforts to Reduce Access to Screening. <i>Seminars in Ultrasound, CT and MRI</i> , 2018, 39, 2-15. | 0.7 | 8 |
| 4555 | Evaluation of Prognostic Factors and Proposed Changes to the Modified Tokuhashi Score in Patients With Spinal Metastases From Breast Cancer. <i>Spine</i> , 2018, 43, 512-519. | 1.0 | 14 |
| 4556 | Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer. <i>Radiology</i> , 2018, 286, 49-57. | 3.6 | 43 |
| 4557 | 17 β -hydroxyundecanoic acid induces apoptosis by ROS mediated JNK and p38 phosphorylation in breast cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 998-1007. | 1.2 | 14 |
| 4558 | Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 2752-2758. | 2.0 | 16 |
| 4559 | Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 198-203. | 0.7 | 6 |
| 4560 | Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes. <i>Clinical Breast Cancer</i> , 2018, 18, e501-e506. | 1.1 | 19 |
| 4561 | Comparison of quality of life between 2-year and 3-or-more-year administration of leuprolerin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial. <i>Supportive Care in Cancer</i> . 2018. 26. 933-945. | 1.0 | 0 |
| 4562 | Meta-analysis of associations between maternal breast cancer and the risk of adverse delivery outcomes. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 140, 146-152. | 1.0 | 4 |
| 4563 | The Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer. <i>Journal of Women's Health</i> , 2018, 27, 466-475. | 1.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4564 | Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 99-107. | 0.8 | 18 |
| 4565 | Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?. <i>Gastric Cancer</i> , 2018, 21, 446-452. | 2.7 | 33 |
| 4566 | Introduction to Cancer Stem Cells: Past, Present, and Future. <i>Methods in Molecular Biology</i> , 2018, 1692, 1-16. | 0.4 | 16 |
| 4567 | Estrogen and progesterone signalling in the normal breast and its implications for cancer development. <i>Molecular and Cellular Endocrinology</i> , 2018, 466, 2-14. | 1.6 | 99 |
| 4568 | Obesity and breast cancer – Role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue. <i>Molecular and Cellular Endocrinology</i> , 2018, 466, 15-30. | 1.6 | 95 |
| 4569 | Neurological Complications of Chemotherapy. , 2018, , 275-310. | | 1 |
| 4570 | Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials. <i>Acta Oncologica</i> , 2018, 57, 135-140. | 0.8 | 5 |
| 4571 | The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study. <i>Acta Oncologica</i> , 2018, 57, 141-145. | 0.8 | 3 |
| 4572 | First site of recurrence after breast cancer adjuvant treatment in the era of multimodality therapy: which imaging for which patient during follow-up?. <i>Breast Disease</i> , 2018, 37, 123-132. | 0.4 | 0 |
| 4573 | Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study. <i>Clinical and Translational Oncology</i> , 2018, 20, 785-793. | 1.2 | 3 |
| 4574 | ER± Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 410-421. | 0.4 | 55 |
| 4575 | Effect of the FE2+ chelation by 2,2-dipyridyl in the doxorubicin-induced lethality in breast tumor cell lines. <i>Life Sciences</i> , 2018, 192, 128-135. | 2.0 | 4 |
| 4576 | PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 531-542. | 1.1 | 39 |
| 4577 | Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology</i> , The, 2018, 19, 27-39. | 5.1 | 717 |
| 4578 | Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2018, 18, e677-e685. | 1.1 | 20 |
| 4579 | Oncotype DX® in breast cancer patients: clinical experience, outcome and follow-up – a case-control study. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 443-447. | 0.8 | 8 |
| 4580 | Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± Trastuzumab. <i>Breast</i> , 2018, 37, 64-71. | 0.9 | 40 |
| 4581 | First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 297-305. | 1.9 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4582 | Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 315-321. | 0.8 | 5 |
| 4583 | Low Lifetime Risk of Contralateral Breast Cancer in a Middle-Income Asian Country: Evidence to Guide Post-treatment Surveillance. <i>World Journal of Surgery</i> , 2018, 42, 1270-1277. | 0.8 | 0 |
| 4584 | Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. <i>Cancer Treatment Reviews</i> , 2018, 62, 74-90. | 3.4 | 61 |
| 4585 | Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 107-115. | 1.1 | 12 |
| 4586 | Patients' experiences with decisions on timing of chemotherapy for breast cancer. <i>Breast</i> , 2018, 37, 99-106. | 0.9 | 10 |
| 4587 | Molecular Subtypes and Local-Regional Control of Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 95-120. | 0.6 | 297 |
| 4588 | Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 53-62.e3. | 1.1 | 8 |
| 4589 | Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 32-39. | 0.7 | 92 |
| 4590 | A situational analysis of breast cancer early detection services in Trinidad and Tobago. <i>Cancer Causes and Control</i> , 2018, 29, 33-42. | 0.8 | 4 |
| 4591 | Can Chemotherapy-Related Acute Care Visits Be Accurately Identified in Administrative Data?. <i>Journal of Oncology Practice</i> , 2018, 14, e51-e58. | 2.5 | 20 |
| 4592 | Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , 2018, 36, 1941-1948. | 0.8 | 116 |
| 4593 | Prognosis vs Treatment Interaction. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky006. | 1.4 | 7 |
| 4594 | Reply to J.L. Blum et al and S. Lange et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 430-431. | 0.8 | 1 |
| 4596 | Comparative efficacy of non-pharmacological adjuvant therapies for quality of life in the patients with breast cancer receiving chemo- or radio-therapy. <i>Medicine (United States)</i> , 2018, 97, e12096. | 0.4 | 5 |
| 4597 | Risk-Imaging Mismatch: Why Is There a Disconnect?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2975-2977. | 0.8 | 2 |
| 4599 | Sexuality, fertility and pregnancy following breast cancer treatment. <i>Gland Surgery</i> , 2018, 7, 404-410. | 0.5 | 12 |
| 4600 | Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials. <i>Gland Surgery</i> , 2018, 7, 449-457. | 0.5 | 10 |
| 4601 | Biotinylation enhances the anticancer effects of 15d-PGJ2 against breast cancer cells. <i>International Journal of Oncology</i> , 2018, 52, 1991-2000. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4602 | Respuesta cl nica en pacientes con tumores de mama tratadas con radioterapia conformacional postmastectom a en el Instituto Nacional de Cancerolog a, Colombia. Revista Colombiana De Cancerolog a, 2018, 22, 132-137. | 0.0 | 0 |
| 4603 | BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score. BMC Clinical Pathology, 2018, 18, 14. | 1.8 | 3 |
| 4604 | Multi-Component Herbal Products in the Prevention and Treatment of Chemotherapy-Associated Toxicity and Side Effects: A Review on Experimental and Clinical Evidences. Frontiers in Pharmacology, 2018, 9, 1394. | 1.6 | 85 |
| 4605 | Predictive value of circulating cell-free DNA in the survival of breast cancer patients. Medicine (United States), 2018, 97, e11417. | 0.4 | 12 |
| 4606 | The Warwick Experience of the Oncotype DX  Breast Recurrence Score  Assay as a Predictor of Chemotherapy Administration. Breast Care, 2018, 13, 369-372. | 0.8 | 6 |
| 4607 | The expression and biological function of the PHF2 gene in breast cancer. RSC Advances, 2018, 8, 39520-39528. | 1.7 | 3 |
| 4608 | Natural history of luminal A breast invasive ductal carcinoma in an elderly. BMJ Case Reports, 2018, 2018, bcr-2018-224218. | 0.2 | 0 |
| 4609 | Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER- )-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro. Medical Science Monitor, 2018, 24, 7883-7890. | 0.5 | 2 |
| 4610 | An Overview of Cancer Treatment Modalities. , 0, , . | | 72 |
| 4611 | MicroRNA 663b mediates TAM resistance in breast cancer by modulating TP73 expression. Molecular Medicine Reports, 2018, 18, 1120-1126. | 1.1 | 11 |
| 4613 | Combination of Trastuzumab and Radiotherapy in the Adjuvant Treatment of Breast Cancer: A Single Center Experience and Focus on the Cardiac Safety. Journal of Nuclear Medicine & Radiation Therapy, 2018, 09, . | 0.2 | 0 |
| 4615 | Development of a nomogram to predict overall survival among non-metastatic breast cancer patients in China: a retrospective multicenter study. Journal of Bio-X Research, 2018, 1, 18-24. | 0.3 | 9 |
| 4616 | Characteristics and prognostic values of traditional pathological parameters and advanced molecular subtypes in women in Beijing with operable breast cancer: a retrospective analysis. BMJ Open, 2018, 8, e021819. | 0.8 | 0 |
| 4617 | Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer   the SONIA study: study protocol for a randomized controlled trial. BMC Cancer, 2018, 18, 1146. | 1.1 | 36 |
| 4618 | Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition. PLoS ONE, 2018, 13, e0207417. | 1.1 | 32 |
| 4619 | Toward the precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis. BMC Medical Genomics, 2018, 11, 104. | 0.7 | 10 |
| 4621 | Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment. British Journal of Cancer, 2018, 119, 1144-1154. | 2.9 | 13 |
| 4622 | New Cancer Treatment Evaluation through Big Data Analytics. , 2018, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4623 | Use and Impact of the 21-Gene Recurrence Score in Relation to the Clinical Risk of Developing Metastases in Early Breast Cancer Patients in the Netherlands. <i>Public Health Genomics</i> , 2018, 21, 85-92. | 0.6 | 4 |
| 4624 | Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer. <i>PLoS ONE</i> , 2018, 13, e0209040. | 1.1 | 6 |
| 4625 | CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. <i>Breast Cancer Research</i> , 2018, 20, 149. | 2.2 | 11 |
| 4626 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1056-1088. | 0.8 | 69 |
| 4627 | Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes. <i>The Journal of Breast Health</i> , 2018, 14, 173-179. | 0.4 | 2 |
| 4628 | Intestinal metastasis from breast invasive ductal carcinoma after a long latency: case report and literature review. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8599-8603. | 1.0 | 5 |
| 4630 | Androgen receptor expression in normal breast tissue and subsequent breast cancer risk. <i>Npj Breast Cancer</i> , 2018, 4, 33. | 2.3 | 24 |
| 4631 | Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2-; advanced breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1319-1327. | 0.9 | 17 |
| 4632 | Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 566-574. | 0.4 | 6 |
| 4634 | Emerging ways to treat breast cancer: will promises be met?. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 605-621. | 2.1 | 43 |
| 4635 | Biomarkers in Breast Cancer. , 0, , . | | 2 |
| 4636 | Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 131-141. | 1.0 | 47 |
| 4637 | Estimating Contralateral Breast Cancer Risk. <i>Current Breast Cancer Reports</i> , 2018, 10, 91-97. | 0.5 | 5 |
| 4638 | Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen. <i>Journal of Breast Cancer</i> , 2018, 21, 277. | 0.8 | 7 |
| 4639 | Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences. <i>British Journal of Cancer</i> , 2018, 119, 832-839. | 2.9 | 15 |
| 4640 | Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. <i>Breast Cancer Research</i> , 2018, 20, 115. | 2.2 | 63 |
| 4641 | LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ER- pathway. <i>Nature Communications</i> , 2018, 9, 4180. | 5.8 | 47 |
| 4642 | Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 1038. | 1.1 | 20 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4643 | Prognostic significance of heparanase expression in primary and metastatic breast carcinoma. <i>Oncotarget</i> , 2018, 9, 6238-6244. | 0.8 | 17 |
| 4644 | Dormant tumour cells, their niches and the influence of immunity. <i>Nature Cell Biology</i> , 2018, 20, 1240-1249. | 4.6 | 134 |
| 4645 | Breast Cancer Tissue Markers, Genomic Profiling, and Other Prognostic Factors: A Primer for Radiologists. <i>Radiographics</i> , 2018, 38, 1902-1920. | 1.4 | 30 |
| 4646 | Clinical outcomes comparison of 10Âyears versus 5Âyears of adjuvant endocrine therapy in patients with early breast cancer. <i>BMC Cancer</i> , 2018, 18, 977. | 1.1 | 19 |
| 4647 | Return to work after breast cancer diagnosis: An observational prospective study in Brazil. <i>Cancer</i> , 2018, 124, 4700-4710. | 2.0 | 30 |
| 4650 | Prediction of potential disease-associated microRNAs by composite network based inference. <i>Scientific Reports</i> , 2018, 8, 15813. | 1.6 | 9 |
| 4651 | Chemotherapy-Exacerbated Breast Cancer Metastasis: A Paradox Explainable by Dysregulated Adaptive-Response. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3333. | 1.8 | 51 |
| 4652 | Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen. <i>Cancer Biology and Medicine</i> , 2018, 15, 29. | 1.4 | 3 |
| 4653 | The Network of Non-coding RNAs in Cancer Drug Resistance. <i>Frontiers in Oncology</i> , 2018, 8, 327. | 1.3 | 96 |
| 4654 | Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34Âyears longitudinal data from the Stockholmâ€“Gotland cancer registry. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 703-712. | 1.1 | 3 |
| 4655 | Adjuvant dose-dense doxorubicin-cyclophosphamideÂversus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). <i>European Journal of Cancer</i> , 2018, 102, 40-48. | 1.3 | 9 |
| 4656 | Preoperative platelet distribution width predicts breast cancer survival. <i>Cancer Biomarkers</i> , 2018, 23, 205-211. | 0.8 | 27 |
| 4657 | Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkinâ€™s lymphoma: influence on long-term adverse effects (SOPHIA). <i>BMJ Open</i> , 2018, 8, e018120. | 0.8 | 3 |
| 4658 | Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. <i>Breast Cancer Research</i> , 2018, 20, 112. | 2.2 | 8 |
| 4659 | Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 111, 205-212. | 0.3 | 7 |
| 4660 | Managing side effects in adjuvant endocrine therapy for breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1101-1112. | 1.1 | 70 |
| 4661 | SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment. <i>Journal of Clinical Medicine</i> , 2018, 7, 245. | 1.0 | 15 |
| 4662 | Optimizing Vascular Access for Patients Receiving Intravenous Systemic Therapy for Early-Stage Breast Cancerâ€“A Survey of Oncology Nurses and Physicians. <i>Current Oncology</i> , 2018, 25, 298-304. | 0.9 | 24 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4663 | A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study. <i>PLoS ONE</i> , 2018, 13, e0201606. | 1.1 | 1 |
| 4664 | Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 39-49. | 1.0 | 3 |
| 4665 | Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 138-143. | 3.4 | 9 |
| 4666 | Clinical value of circulating $ESR1$ mutations for patients with metastatic breast cancer: a meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 2573-2580. | 0.9 | 32 |
| 4667 | Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 887-897. | 0.8 | 16 |
| 4668 | Time to death in breast cancer patients as an indicator of treatment response. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 659-669. | 1.1 | 24 |
| 4669 | Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness. <i>Biochemical Pharmacology</i> , 2018, 156, 322-339. | 2.0 | 18 |
| 4670 | Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting. <i>BioMed Research International</i> , 2018, 2018, 1-8. | 0.9 | 8 |
| 4671 | Recent Improvement in the Long-term Survival of Breast Cancer Patients by Age and Stage in Japan. <i>Journal of Epidemiology</i> , 2018, 28, 420-427. | 1.1 | 36 |
| 4672 | Tumor Site and Breast Cancer Prognosis. <i>Clinical Breast Cancer</i> , 2018, 18, e1045-e1052. | 1.1 | 27 |
| 4673 | Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction?. <i>Plastic and Reconstructive Surgery</i> , 2018, 141, 805e-813e. | 0.7 | 11 |
| 4674 | MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ER \pm Positive Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2018, 46, 2601-2615. | 1.1 | 46 |
| 4675 | The CDK4/6 inhibitor in HR-positive advanced breast cancer. <i>Medicine (United States)</i> , 2018, 97, e10746. | 0.4 | 14 |
| 4676 | Targeting invadopodia for blocking breast cancer metastasis. <i>Drug Resistance Updates</i> , 2018, 39, 1-17. | 6.5 | 63 |
| 4677 | Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study. <i>Breast Cancer</i> , 2018, 25, 639-649. | 1.3 | 3 |
| 4678 | A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery. <i>International Journal of Clinical Oncology</i> , 2018, 23, 860-866. | 1.0 | 8 |
| 4679 | Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. <i>Advances in Pharmacology</i> , 2018, 83, 65-91. | 1.2 | 34 |
| 4680 | Development and pilot testing of a Decision Aid (DA) for women with early-stage breast cancer considering contralateral prophylactic mastectomy. <i>Breast</i> , 2018, 40, 156-164. | 0.9 | 16 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4681 | Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology. <i>Annals of Surgical Oncology</i> , 2018, 25, 2884-2889. | 0.7 | 23 |
| 4682 | The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer. <i>Deutsches A&#x0308;rzteblatt International</i> , 2018, 115, 316-323. | 0.6 | 37 |
| 4683 | Overview of Breast Cancer Therapy. <i>PET Clinics</i> , 2018, 13, 339-354. | 1.5 | 279 |
| 4684 | PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 190-192. | 0.5 | 7 |
| 4685 | Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 408-418. | 2.9 | 50 |
| 4686 | The effect of mammography screening regimen on incidence-based breast cancer mortality. <i>Journal of Medical Screening</i> , 2018, 25, 197-204. | 1.1 | 7 |
| 4687 | Improving Cancer Detection and Treatment with Liquid Biopsies and ptDNA. <i>Trends in Cancer</i> , 2018, 4, 643-654. | 3.8 | 6 |
| 4688 | Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark. <i>BMJ Open</i> , 2018, 8, e021805. | 0.8 | 11 |
| 4689 | Development of a Novel Proteomic Risk-Classifer for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer. <i>Biomarker Insights</i> , 2018, 13, 117727191878910. | 1.0 | 18 |
| 4690 | Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 273-282. | 1.1 | 3 |
| 4691 | Sexual health in long-term breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 159-166. | 1.1 | 29 |
| 4692 | Barriers to care for breast cancer: A qualitative study in Ireland. <i>European Journal of Cancer Care</i> , 2018, 27, e12876. | 0.7 | 6 |
| 4693 | The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 79. | 2.2 | 41 |
| 4694 | Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years. <i>Clinical Breast Cancer</i> , 2018, 18, e1353-e1360. | 1.1 | 7 |
| 4695 | Spotlight on the utility of the Oncotype DX [®] breast cancer assay. <i>International Journal of Women's Health</i> , 2018, Volume 10, 89-100. | 1.1 | 57 |
| 4696 | <i>Streptomyces nigra</i> sp. nov. Is a Novel Actinobacterium Isolated From Mangrove Soil and Exerts a Potent Antitumor Activity in Vitro. <i>Frontiers in Microbiology</i> , 2018, 9, 1587. | 1.5 | 29 |
| 4697 | Lymph Node Radiotherapy Instead of Extended Axillary Surgery - the New Standard. <i>Breast Care</i> , 2018, 13, 173-175. | 0.8 | 6 |
| 4698 | Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study. <i>BMC Cancer</i> , 2018, 18, 781. | 1.1 | 38 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4699 | Quantitative nuclear histomorphometry predicts onco-type DX risk categories for early stage ER+ breast cancer. <i>BMC Cancer</i> , 2018, 18, 610. | 1.1 | 67 |
| 4700 | Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. <i>BMC Cancer</i> , 2018, 18, 761. | 1.1 | 7 |
| 4701 | Integration of in vitro and in silico perspectives to explain chemical characterization, biological potential and anticancer effects of <i>Hypericum salsugineum</i> : A pharmacologically active source for functional drug formulations. <i>PLoS ONE</i> , 2018, 13, e0197815. | 1.1 | 27 |
| 4703 | Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis. <i>Frontiers in Oncology</i> , 2018, 8, 31. | 1.3 | 115 |
| 4704 | Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2018, 8, 89. | 1.3 | 64 |
| 4705 | Precision Medicine in Hormone Receptor-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 144. | 1.3 | 32 |
| 4706 | Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 759-765. | 1.1 | 4 |
| 4707 | Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. <i>BMC Cancer</i> , 2018, 18, 732. | 1.1 | 45 |
| 4708 | The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?. <i>Cancers</i> , 2018, 10, 189. | 1.7 | 52 |
| 4709 | Curcumin-Loaded Solid Lipid Nanoparticles Enhanced Anticancer Efficiency in Breast Cancer. <i>Molecules</i> , 2018, 23, 1578. | 1.7 | 117 |
| 4710 | Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer—Challenges and Opportunities. <i>Nanomaterials</i> , 2018, 8, 361. | 1.9 | 32 |
| 4711 | Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 143-150. | 1.1 | 12 |
| 4712 | Recurrence prediction using microRNA expression in hormone receptor positive breast cancer during tamoxifen treatment. <i>Biomarkers</i> , 2018, 23, 804-811. | 0.9 | 19 |
| 4713 | Synthesis and structure–activity relationships of cyclopropane-containing analogs of pharmacologically active compounds. <i>Russian Chemical Bulletin</i> , 2018, 67, 395-418. | 0.4 | 24 |
| 4714 | An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. <i>BioScience Trends</i> , 2018, 12, 220-239. | 1.1 | 174 |
| 4715 | Omission of chemotherapy for low-grade, luminal A N1 breast cancer: Patterns of care and clinical outcomes. <i>Breast</i> , 2018, 41, 67-73. | 0.9 | 10 |
| 4717 | miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer. <i>Future Oncology</i> , 2018, 14, 1847-1867. | 1.1 | 28 |
| 4718 | Aromatase Inhibitors in Premenopausal Women with Breast Cancer: The State of the Art and Future Prospects. <i>Current Oncology</i> , 2018, 25, 168-175. | 0.9 | 36 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 4719 | Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study. <i>Journal of Breast Cancer</i> , 2018, 21, 70. | 0.8 | 12 |
| 4720 | Cardiovascular sequelae of breast cancer treatments: A review. <i>Current Problems in Cancer</i> , 2018, 42, 409-421. | 1.0 | 4 |
| 4721 | Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents. <i>Molecular Oncology</i> , 2018, 12, 953-971. | 2.1 | 12 |
| 4722 | Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 181-188. | 1.1 | 4 |
| 4723 | Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review. <i>Current Treatment Options in Oncology</i> , 2018, 19, 30. | 1.3 | 54 |
| 4724 | Diagnostic serum vitamin D level is not a reliable prognostic factor for resectable breast cancer. <i>Future Oncology</i> , 2018, 14, 1461-1467. | 1.1 | 4 |
| 4725 | Recent Trends in Local-Regional Recurrence Rates: Implications for Therapeutic Intervention. <i>Current Breast Cancer Reports</i> , 2018, 10, 83-90. | 0.5 | 0 |
| 4726 | Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. <i>Annual Review of Biomedical Data Science</i> , 2018, 1, 1-27. | 2.8 | 27 |
| 4727 | Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?. <i>Cancer Management and Research</i> , 2018, Volume 10, 1015-1025. | 0.9 | 5 |
| 4728 | Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics. <i>Experimental Cell Research</i> , 2018, 371, 1-19. | 1.2 | 59 |
| 4729 | Endocrine Therapy for Breast Cancer in the Primary Care Setting. <i>Current Oncology</i> , 2018, 25, 285-291. | 0.9 | 40 |
| 4730 | Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 265-272. | 1.1 | 6 |
| 4731 | Streamlining Decision Making in Contralateral Risk-Reducing Mastectomy: Impact of PREDICT and BOADICEA Computations. <i>Annals of Surgical Oncology</i> , 2018, 25, 3057-3063. | 0.7 | 3 |
| 4732 | Upregulating MMP-1 in carcinoma-associated fibroblasts reduces the efficacy of Taxotere on breast cancer synergized by Collagen IV. <i>Oncology Letters</i> , 2018, 16, 3537-3544. | 0.8 | 25 |
| 4733 | The Evolving Role of Postmastectomy Radiation Therapy. <i>Surgical Clinics of North America</i> , 2018, 98, 801-817. | 0.5 | 4 |
| 4734 | Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121. | 13.9 | 1,558 |
| 4735 | Influence of a history of cancer on long-term cardiovascular outcomes after coronary stent implantation (an Observation from Coronary Revascularization Demonstrating Outcome Study-Kyoto) <i>Tj ETQq0 0 0.8 BT /Overlock 10 T</i> | 0.8 | 25 |
| 4736 | Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy. <i>Medical Oncology</i> , 2018, 35, 107. | 1.2 | 8 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4737 | Overexpression of MAPT-AS1 is associated with better patient survival in breast cancer. <i>Biochemistry and Cell Biology</i> , 2019, 97, 158-164. | 0.9 | 25 |
| 4738 | Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations. , 2015, 19, 48-79. | | 232 |
| 4739 | Where youth mattersâ€”clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer. <i>Irish Journal of Medical Science</i> , 2019, 188, 59-67. | 0.8 | 5 |
| 4740 | Axillary reverse mapping (ARM): where to go. <i>Breast Cancer</i> , 2019, 26, 1-10. | 1.3 | 19 |
| 4741 | Change of paradigm in treating elderly with breast cancer: are we undertreating elderly patients?. <i>Irish Journal of Medical Science</i> , 2019, 188, 379-388. | 0.8 | 15 |
| 4742 | Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2019, 27, 1099-1108. | 1.0 | 5 |
| 4743 | All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study. <i>Cancer Medicine</i> , 2019, 8, 6127-6138. | 1.3 | 27 |
| 4744 | Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 688-700. | 2.3 | 15 |
| 4745 | High-intensity interval training can modulate the systemic inflammation and HSP70 in the breast cancer: a randomized control trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2583-2593. | 1.2 | 33 |
| 4746 | The role of regional anesthesia in the propagation of cancer: A comprehensive review. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2019, 33, 507-522. | 1.7 | 8 |
| 4747 | Factors Associated with Multidisciplinary Consultations in Patients with Early Stage Breast Cancer. <i>Cancer Investigation</i> , 2019, 37, 233-241. | 0.6 | 8 |
| 4748 | The effect of Oncotype DX [®] on adjuvant chemotherapy treatment decisions in early breast cancer. <i>Annals of the Royal College of Surgeons of England</i> , 2019, 101, 596-601. | 0.3 | 3 |
| 4749 | A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation. <i>Nucleic Acids Research</i> , 2019, 47, 9557-9572. | 6.5 | 21 |
| 4750 | Pure Mucinous Breast Carcinoma with Micropapillary Pattern (MUMPC): A Case Report. <i>Case Reports in Oncology</i> , 2019, 12, 554-559. | 0.3 | 5 |
| 4751 | A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690. | | 0 |
| 4752 | Application of St Gallen Categories in Predicting Survival for Patients With Breast Cancer in Vietnam. <i>Cancer Control</i> , 2019, 26, 107327481986279. | 0.7 | 7 |
| 4753 | Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2 ⁺ breast cancer. <i>Breast Journal</i> , 2019, 25, 880-888. | 0.4 | 4 |
| 4754 | Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score [®] test. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 611-618. | 1.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4755 | Non-classical estrogen signaling in ovarian cancer improves chemo-sensitivity and patients outcome. <i>Theranostics</i> , 2019, 9, 3952-3965. | 4.6 | 16 |
| 4757 | Optoacoustic Imaging and Gray-Scale US Features of Breast Cancers: Correlation with Molecular Subtypes. <i>Radiology</i> , 2019, 292, 564-572. | 3.6 | 39 |
| 4758 | Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy. , 2019, , 449-462. | | 0 |
| 4759 | Autoantibodies Specific to ER \pm are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer. <i>Cells</i> , 2019, 8, 750. | 1.8 | 8 |
| 4760 | Synchronous and metachronous bilateral breast cancer: clinicopathologic characteristics and prognostic outcomes. <i>Human Pathology</i> , 2019, 92, 1-9. | 1.1 | 20 |
| 4761 | The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer. <i>Cancers</i> , 2019, 11, 1028. | 1.7 | 54 |
| 4762 | The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 81. | 6.9 | 174 |
| 4763 | In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 1039. | 1.7 | 3 |
| 4764 | Novel insights into breast cancer progression and metastasis: A multidisciplinary opportunity to transition from biology to clinical oncology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 138-148. | 3.3 | 31 |
| 4765 | Investigation into breast cancer and partial breast reconstruction: A review. <i>European Journal of Translational Myology</i> , 2019, 29, 8157. | 0.8 | 2 |
| 4766 | <p>Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4849-4857. | 1.0 | 12 |
| 4767 | <p>Estradiol promotes the progression of ER+ breast cancer through methylation-mediated RSK4 inactivation</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5907-5916. | 1.0 | 10 |
| 4768 | A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. <i>Breast Cancer Management</i> , 2019, 8, BMT22. | 0.2 | 8 |
| 4769 | PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes. <i>BMC Cancer</i> , 2019, 19, 747. | 1.1 | 22 |
| 4770 | Development of breast cancer mortality considering the implementation of mammography screening programs â€“ a comparison of western European countries. <i>BMC Public Health</i> , 2019, 19, 823. | 1.2 | 18 |
| 4771 | Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2019, 15, 211-217. | 0.2 | 0 |
| 4772 | Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. <i>Journal of Global Oncology</i> , 2019, 5, 1-9. | 0.5 | 13 |
| 4773 | The potential influence of breast cancer estrogen receptorsâ€™ distribution on active DNA demethylation. <i>Wspolczesna Onkologia</i> , 2019, 23, 74-80. | 0.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4774 | A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 691-703. | 1.1 | 10 |
| 4775 | Combined Fascin-1 and MAP17 Expression in Breast Cancer Identifies Patients with High Risk for Disease Recurrence. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 635-644. | 1.6 | 10 |
| 4776 | Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. <i>Journal of Clinical Oncology</i> , 2019, 37, 3425-3435. | 0.8 | 51 |
| 4777 | Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days. <i>International Journal of Pharmaceutics</i> , 2019, 570, 118691. | 2.6 | 3 |
| 4778 | Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30. <i>Breast Cancer Research</i> , 2019, 21, 110. | 2.2 | 25 |
| 4779 | A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. <i>Value in Health</i> , 2019, 22, 1102-1110. | 0.1 | 12 |
| 4780 | Multifunctional MoS ₂ nanosheets with Au NPs grown in situ for synergistic chemo-photothermal therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 184, 110551. | 2.5 | 25 |
| 4781 | Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value. <i>Journal of Breast Cancer</i> , 2019, 22, 439. | 0.8 | 19 |
| 4782 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz050. | 1.4 | 15 |
| 4783 | Racial Disparities in Breast Cancer Outcomes in the Metropolitan Atlanta Area: New Insights and Approaches for Health Equity. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz053. | 1.4 | 14 |
| 4784 | Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2-Advanced/Metastatic Breast Cancer. <i>In Vivo</i> , 2019, 33, 2037-2044. | 0.6 | 2 |
| 4785 | Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy. <i>BMC Musculoskeletal Disorders</i> , 2019, 20, 515. | 0.8 | 4 |
| 4786 | Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer. <i>Clinical Epigenetics</i> , 2019, 11, 155. | 1.8 | 9 |
| 4787 | Preoperative morphological diagnosis of axillary lymph nodes in a breast center consultation service: evaluation of fine-needle aspiration and core biopsy techniques. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1659-1670. | 0.8 | 3 |
| 4788 | Microenvironmental IL1 β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. <i>Nature Communications</i> , 2019, 10, 5016. | 5.8 | 105 |
| 4789 | FA2H Exhibits Tumor Suppressive Roles on Breast Cancers via Cancer Stemness Control. <i>Frontiers in Oncology</i> , 2019, 9, 1089. | 1.3 | 19 |
| 4790 | Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients. <i>BMC Cancer</i> , 2019, 19, 1101. | 1.1 | 6 |
| 4791 | G Protein-Coupled Estrogen Receptor: A Potential Therapeutic Target in Cancer. <i>Frontiers in Endocrinology</i> , 2019, 10, 725. | 1.5 | 69 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4792 | Elevated Hexokinase II Expression Confers Acquired Resistance to 4-Hydroxytamoxifen in Breast Cancer Cells. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 2273-2284. | 2.5 | 35 |
| 4793 | Taxanes for adjuvant treatment of early breast cancer. <i>The Cochrane Library</i> , 2019, 9, CD004421. | 1.5 | 32 |
| 4794 | The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study. <i>Diagnostic and Prognostic Research</i> , 2019, 3, 20. | 0.8 | 1 |
| 4795 | The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer. <i>Frontiers in Endocrinology</i> , 2019, 10, 547. | 1.5 | 26 |
| 4796 | Breast Cancer Metastasis and Drug Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2019, , . | 0.8 | 38 |
| 4797 | Physicians' perspectives on medication adherence and health promotion among cancer survivors. <i>Cancer</i> , 2019, 125, 4319-4328. | 2.0 | 16 |
| 4798 | Metastatic Latency, a Veiled Threat. <i>Frontiers in Immunology</i> , 2019, 10, 1836. | 2.2 | 19 |
| 4799 | Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells. <i>Cell Communication and Signaling</i> , 2019, 17, 107. | 2.7 | 21 |
| 4800 | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1239. | 1.7 | 9 |
| 4801 | Breast Cancer Heterogeneity in Primary and Metastatic Disease. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 75-104. | 0.8 | 27 |
| 4802 | Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies. <i>Acta Oncol3gica</i> , 2019, 58, 1581-1593. | 0.8 | 2 |
| 4803 | Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. <i>Scientific Reports</i> , 2019, 9, 12184. | 1.6 | 39 |
| 4804 | Women, thrombosis, and cancer. <i>Thrombosis Research</i> , 2019, 181, S47-S53. | 0.8 | 7 |
| 4805 | Long Non-Coding RNA in the Pathogenesis of Cancers. <i>Cells</i> , 2019, 8, 1015. | 1.8 | 562 |
| 4806 | Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 505-512. | 1.1 | 6 |
| 4807 | Comparison of clinicopathological features and treatments between pre- and postmenopausal female breast cancer patients – a retrospective study. <i>Przegląd Menopauzalny</i> , 2019, 18, 68-73. | 0.6 | 8 |
| 4808 | Mitochondrial fragmentation, elevated mitochondrial superoxide and respiratory supercomplexes disassembly is connected with the tamoxifen-resistant phenotype of breast cancer cells. <i>Free Radical Biology and Medicine</i> , 2019, 143, 510-521. | 1.3 | 40 |
| 4809 | Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay. <i>JCO Precision Oncology</i> , 2019, 3, 1-10. | 1.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 4810 | Validation of the online prediction model CancerMath in the Dutch breast cancer population. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 665-681. | 1.1 | 4 |
| 4811 | CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 535-544. | 1.1 | 36 |
| 4812 | Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. <i>Nature Communications</i> , 2019, 10, 3840. | 5.8 | 93 |
| 4813 | Optimal treatment of breast cancer in women older than 75 years: a Korea Breast Cancer Registry analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 693-701. | 1.1 | 13 |
| 4814 | Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol. <i>BMC Cancer</i> , 2019, 19, 884. | 1.1 | 8 |
| 4815 | De-escalation yes, but not at the expense of efficacy: in defense of better treatment. <i>Npj Breast Cancer</i> , 2019, 5, 25. | 2.3 | 3 |
| 4816 | <p>Oncologistsâ€™ perspectives on adherence/non-adherence to adjuvant endocrine therapy and management strategies in women with breast cancer</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1311-1323. | 0.8 | 5 |
| 4817 | Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptorâ€“Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 795-802. | 0.4 | 39 |
| 4818 | ERÎ±-targeted endocrine therapy, resistance and the role of GPER. <i>Steroids</i> , 2019, 152, 108493. | 0.8 | 18 |
| 4819 | Decentralization of Next-Generation RNA Sequencing-Based MammaPrintÂ® and BlueprintÂ® Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565. | 1.7 | 6 |
| 4820 | Bone Marrow Stromal Cells Transcriptionally Repress ESR1 but Cannot Overcome Constitutive ESR1 Mutant Activity. <i>Endocrinology</i> , 2019, 160, 2427-2440. | 1.4 | 4 |
| 4821 | Epidemiologic Signatures in Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1378-1386. | 13.9 | 134 |
| 4822 | CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients. <i>Cancers</i> , 2019, 11, 1353. | 1.7 | 14 |
| 4823 | Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2019, 26, 4317-4325. | 0.7 | 6 |
| 4824 | 21â€“gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes. <i>Oncology Letters</i> , 2019, 18, 4346-4356. | 0.8 | 2 |
| 4825 | Elevated Risk of Radiation Therapyâ€“Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-IIIa Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 275-284. | 0.4 | 2 |
| 4826 | Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 785-794. | 1.1 | 50 |
| 4827 | Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 188-196. | 1.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4828 | Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. <i>BMC Cancer</i> , 2019, 19, 84. | 1.1 | 8 |
| 4829 | Stimuli-responsive polyvinylpyrrolidone-NIPPA ^m -lysine graphene oxide nano-hybrid as an anticancer drug delivery on MCF7 cell line. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 443-454. | 1.9 | 17 |
| 4830 | Hybrid volumetric modulated arc therapy for whole breast irradiation: a dosimetric comparison of different arc designs. <i>Radiologia Medica</i> , 2019, 124, 546-554. | 4.7 | 8 |
| 4831 | Prognostic significance of fatty acid binding protein-4 in the invasive ductal carcinoma of the breast. <i>Pathology International</i> , 2019, 69, 68-75. | 0.6 | 8 |
| 4832 | Off-label use of tamoxifen in a Chinese tertiary care hospital. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 555-562. | 1.0 | 3 |
| 4833 | Symptom Map of Endocrine Therapy for Breast Cancer: A Scoping Review. <i>Cancer Nursing</i> , 2019, 42, E19-E30. | 0.7 | 21 |
| 4834 | Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. <i>Seminars in Oncology</i> , 2019, 46, 83-99. | 0.8 | 23 |
| 4835 | Plasma levels of dichlorodiphenyldichloroethene (DDE) and dichlorodiphenyltrichloroethane (DDT) and survival following breast cancer in the Carolina Breast Cancer Study. <i>Environment International</i> , 2019, 125, 161-171. | 4.8 | 22 |
| 4836 | PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer. <i>Cancer Letters</i> , 2019, 458, 66-75. | 3.2 | 18 |
| 4837 | Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. , 2019, 7, 133. | | 32 |
| 4838 | Update on Precision Medicine in Breast Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 45-80. | 0.2 | 27 |
| 4839 | The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 1117-1122. | 0.4 | 7 |
| 4840 | Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1980-1981. | 0.8 | 18 |
| 4841 | Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia. <i>European Journal of Cancer Care</i> , 2019, 28, e13125. | 0.7 | 1 |
| 4842 | Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 193, 105415. | 1.2 | 44 |
| 4843 | Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 118, 178-186. | 1.3 | 39 |
| 4844 | Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 589-605. | 2.6 | 12 |
| 4845 | TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. <i>Journal of Clinical Oncology</i> , 2019, 37, 1841-1842. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 4846 | Early Diagnosis of Cardiotoxicity in Patients Undergoing Chemotherapy for Acute Lymphoblastic Leukemia. <i>Anticancer Research</i> , 2019, 39, 3255-3264. | 0.5 | 5 |
| 4847 | circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. <i>Molecular Therapy</i> , 2019, 27, 1638-1652. | 3.7 | 298 |
| 4848 | Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. <i>BMC Cancer</i> , 2019, 19, 549. | 1.1 | 7 |
| 4849 | Advanced drug delivery system with nanomaterials for personalised medicine to treat breast cancer. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 52, 1051-1060. | 1.4 | 37 |
| 4850 | A Novel Predictor of Chemotherapeutic Cardiotoxicity in Patients with Non-Hodgkin Lymphoma. <i>Oncology Research and Treatment</i> , 2019, 42, 375-381. | 0.8 | 6 |
| 4851 | Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 220. | 3.5 | 58 |
| 4852 | The use of contralateral prophylactic mastectomy among elderly patients in the United States. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 175-183. | 1.1 | 9 |
| 4853 | Breast Cancer Survivorsâ€™ Perceptions of Prevention versus Control of Future Cancer Recurrence. <i>International Journal of Breast Cancer</i> , 2019, 2019, 1-12. | 0.6 | 4 |
| 4854 | Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405. | 13.9 | 349 |
| 4855 | Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1194-1220. | 0.6 | 1,241 |
| 4856 | Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. <i>Cancer Letters</i> , 2019, 459, 122-134. | 3.2 | 80 |
| 4857 | Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites. <i>Frontiers in Pharmacology</i> , 2019, 10, 530. | 1.6 | 21 |
| 4858 | Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. <i>Journal of Molecular Medicine</i> , 2019, 97, 1155-1167. | 1.7 | 9 |
| 4859 | Immediate versus delayed autologous breast reconstruction: A retrospective matched cohort study of irradiated patients. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2019, 72, 1769-1775. | 0.5 | 17 |
| 4860 | Adjuvant Systemic Therapy in Breast Cancer. , 2019, , 179-194. | | 0 |
| 4861 | The assessment of 8th edition AJCC prognostic staging system and a simplified staging system for breast cancer: The analytic results from the SEER database. <i>Breast Journal</i> , 2019, 25, 838-847. | 0.4 | 16 |
| 4862 | Management of Breast Cancer in Older Women. , 2019, , . | | 0 |
| 4863 | PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?. <i>American Journal of Roentgenology</i> , 2019, 213, 254-265. | 1.0 | 78 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4864 | Acute aerobic exercise effects on cognitive function in breast cancer survivors: a randomized crossover trial. <i>BMC Cancer</i> , 2019, 19, 371. | 1.1 | 27 |
| 4865 | Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study. <i>Cancers</i> , 2019, 11, 680. | 1.7 | 7 |
| 4867 | Adjuvant Chemotherapy for Breast Cancer in Older Women: An Analysis of Retrospective English Cancer Registration Data. <i>Clinical Oncology</i> , 2019, 31, 444-452. | 0.6 | 16 |
| 4868 | Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 523-536. | 1.3 | 60 |
| 4869 | NEMP1 Promotes Tamoxifen Resistance in Breast Cancer Cells. <i>Biochemical Genetics</i> , 2019, 57, 813-826. | 0.8 | 12 |
| 4870 | Predicting breast cancer metastasis by using serum biomarkers and clinicopathological data with machine learning technologies. <i>International Journal of Medical Informatics</i> , 2019, 128, 79-86. | 1.6 | 81 |
| 4871 | Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer. <i>BMC Cancer</i> , 2019, 19, 436. | 1.1 | 68 |
| 4872 | Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 578-586. | 0.5 | 16 |
| 4873 | Local/regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310. | 1.1 | 30 |
| 4874 | Early breast cancer in England: Evidence into practice. <i>Journal of Cancer Policy</i> , 2019, 20, 100186. | 0.6 | 0 |
| 4875 | Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 377-386. | 1.1 | 61 |
| 4876 | Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. <i>Clinical Cancer Research</i> , 2019, 25, 4255-4263. | 3.2 | 281 |
| 4877 | Imaging features of triple-negative breast cancers according to androgen receptor status. <i>European Journal of Radiology</i> , 2019, 114, 167-174. | 1.2 | 14 |
| 4878 | Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials. <i>Clinical Breast Cancer</i> , 2019, 19, e578-e588. | 1.1 | 4 |
| 4879 | Communicating prognosis to women with early breast cancer – overview of prediction tools and the development and pilot testing of a decision aid. <i>BMC Health Services Research</i> , 2019, 19, 171. | 0.9 | 11 |
| 4880 | Early breast cancer patients benefit more from longer course chemotherapy: a matched-pair analysis. <i>Future Oncology</i> , 2019, 15, 1781-1789. | 1.1 | 1 |
| 4881 | Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients. <i>BMC Cancer</i> , 2019, 19, 249. | 1.1 | 19 |
| 4882 | Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 233-236. | 1.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4883 | Tripartite motif-containing 11 regulates the proliferation and apoptosis of breast cancer cells. <i>Oncology Reports</i> , 2019, 41, 2567-2574. | 1.2 | 12 |
| 4884 | Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials. <i>Cancer Medicine</i> , 2019, 8, 1389-1400. | 1.3 | 12 |
| 4885 | The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME). <i>BMJ Open</i> , 2019, 9, e023568. | 0.8 | 42 |
| 4886 | What does risk of future cancer mean to breast cancer patients?. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 579-584. | 1.1 | 9 |
| 4887 | Resveratrol and other dietary polyphenols are inhibitors of estrogen metabolism in human breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 190, 11-18. | 1.2 | 41 |
| 4888 | Survival outcome of adjuvant endocrine therapy alone for patients with lymph node-positive, hormone-responsive, HER2-negative breast cancer. <i>Asian Journal of Surgery</i> , 2019, 42, 914-921. | 0.2 | 3 |
| 4889 | Real-world evidence was feasible for estimating effectiveness of chemotherapy in breast cancer: a cohort study. <i>Journal of Clinical Epidemiology</i> , 2019, 109, 125-132. | 2.4 | 7 |
| 4890 | Clinical validation of an immunohistochemistry-based CanAssist Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. <i>Cancer Medicine</i> , 2019, 8, 1755-1764. | 1.3 | 29 |
| 4891 | The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. <i>Health Policy and Technology</i> , 2019, 8, 75-83. | 1.3 | 4 |
| 4892 | The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers. <i>Molecular and Cellular Endocrinology</i> , 2019, 488, 79-88. | 1.6 | 14 |
| 4893 | Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. <i>Cancers</i> , 2019, 11, 403. | 1.7 | 31 |
| 4894 | Association between tamoxifen use and acute myocardial infarction in women with breast cancer. <i>Medicine (United States)</i> , 2019, 98, e13925. | 0.4 | 6 |
| 4895 | Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data. <i>BMC Cancer</i> , 2019, 19, 210. | 1.1 | 29 |
| 4896 | Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. <i>Oncologist</i> , 2019, 24, 762-771. | 1.9 | 56 |
| 4897 | Prognostic impact of TP53INP1 gene expression in estrogen receptor \pm -positive breast cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 567-575. | 0.6 | 5 |
| 4898 | Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 812-820. | 0.9 | 7 |
| 4899 | Prognostic nomogram for patients with non-metastatic HER2 positive breast cancer in a prospective cohort. <i>International Journal of Biological Markers</i> , 2019, 34, 41-46. | 0.7 | 10 |
| 4900 | Drug Combinations in Breast Cancer Therapy. <i>Pharmaceutical Nanotechnology</i> , 2019, 7, 3-23. | 0.6 | 213 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4902 | Validation study of MARCKSL1 as a prognostic factor in lymph node-negative breast cancer patients. <i>PLoS ONE</i> , 2019, 14, e0212527. | 1.1 | 5 |
| 4903 | Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening. <i>BMC Medicine</i> , 2019, 17, 24. | 2.3 | 7 |
| 4904 | Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study. <i>Clinical Epigenetics</i> , 2019, 11, 45. | 1.8 | 36 |
| 4906 | Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. <i>Journal of Clinical Oncology</i> , 2019, 37, 689-692. | 0.8 | 26 |
| 4907 | The Role of ZNF143 in Breast Cancer Cell Survival Through the NAD(P)H Quinone Dehydrogenase 1â€“p53â€“Beclin1 Axis Under Metabolic Stress. <i>Cells</i> , 2019, 8, 296. | 1.8 | 15 |
| 4908 | Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients. <i>Journal of Breast Cancer</i> , 2019, 22, 86. | 0.8 | 9 |
| 4909 | Synergistic effects of hormone therapy drugs and usnic acid on hormone receptorâ€“positive breast and prostate cancer cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22338. | 1.4 | 5 |
| 4910 | The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells. <i>Oncogene</i> , 2019, 38, 5551-5565. | 2.6 | 73 |
| 4911 | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. <i>Journal of Clinical Medicine</i> , 2019, 8, 435. | 1.0 | 106 |
| 4912 | Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways. <i>Inflammopharmacology</i> , 2019, 27, 1021-1036. | 1.9 | 92 |
| 4913 | <p>Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression<p>. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 137-142. | 1.0 | 22 |
| 4914 | Shoulder girdle impairment in breast cancer survivors: the role of range of motion as predictive factor for dose distribution and clinical outcome. <i>Tumori</i> , 2019, 105, 319-330. | 0.6 | 12 |
| 4915 | West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 799-808. | 0.8 | 85 |
| 4916 | Adjuvant Endocrine Therapy for Women With Hormone Receptorâ€“Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2019, 37, 423-438. | 0.8 | 384 |
| 4917 | Adjuvant Chemotherapy Guidance in Young Breast Cancer Patients With Luminal Subtypes and Stage pT1N0. <i>Journal of Surgical Research</i> , 2019, 240, 165-174. | 0.8 | 0 |
| 4918 | Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 100. | 3.5 | 18 |
| 4919 | Stapled Peptides Inhibitors: A New Window for Target Drug Discovery. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 263-281. | 1.9 | 118 |
| 4920 | Surgical resection of breast cancers: Molecular analysis of cancer stem cells in residual disease. <i>Surgery</i> , 2019, 165, 1008-1013. | 1.0 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4921 | Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381982870. | 0.8 | 26 |
| 4922 | Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1â€“98. <i>Breast Cancer Research</i> , 2019, 21, 30. | 2.2 | 76 |
| 4923 | Transcriptome analysis of Luminal Breast Cancer Reveals a Role for LOL in Tumor Progression and Tamoxifen Resistance. <i>International Journal of Cancer</i> , 2019, 145, 842-856. | 2.3 | 20 |
| 4924 | Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€“298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452. | 6.3 | 260 |
| 4925 | Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions. <i>PLoS ONE</i> , 2019, 14, e0211737. | 1.1 | 7 |
| 4926 | Therapeutics strategies against cancer stem cell in breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 109, 76-81. | 1.2 | 40 |
| 4927 | Tamoxifen related Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A case report and literature review of this possible association. <i>Pathology Research and Practice</i> , 2019, 215, 1089-1092. | 1.0 | 13 |
| 4929 | Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015. <i>Breast</i> , 2019, 44, 153-159. | 0.9 | 28 |
| 4930 | Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells. <i>Cancers</i> , 2019, 11, 189. | 1.7 | 45 |
| 4931 | Factors influencing oncologistsâ€™ prescribing hormonal therapy in women with breast cancer: a qualitative study in CÃ“rdoba, Argentina. <i>International Journal for Equity in Health</i> , 2019, 18, 35. | 1.5 | 9 |
| 4932 | Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 487-497. | 1.1 | 15 |
| 4933 | Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients. <i>Breast Care</i> , 2019, 14, 159-164. | 0.8 | 2 |
| 4934 | Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S104-S104. | 0.7 | 0 |
| 4935 | Evaluation of the Patient Profile and Current Pattern of Care with Docetaxel Based Adjuvant Regimen in Operable Breast Cancer. <i>Delta Medical College Journal</i> , 2019, 7, 4-10. | 0.0 | 0 |
| 4936 | Breast Cancer: Management and Survivorship. , 0, , . | | 3 |
| 4937 | The risk factors and preventive measures for the recurrence of endometrial polyps. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , 2019, 8, 787. | 0.0 | 1 |
| 4939 | Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer. <i>British Journal of Surgery</i> , 2019, 107, 33-43. | 0.1 | 22 |
| 4940 | Cross-Canada Differences in Early-Stage Breast Cancer Treatment and Acute-Care Use. <i>Current Oncology</i> , 2019, 26, 624-639. | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 4942 | Chemotherapy effectiveness in trial-underrepresented groups with early breast cancer: A retrospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1003006. | 3.9 | 14 |
| 4943 | <p>Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10353-10373. | 0.9 | 8 |
| 4944 | Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study. <i>BMC Cancer</i> , 2019, 19, 1158. | 1.1 | 31 |
| 4945 | Tumors of the Mammary Gland. , 2019, , 604-625. | | 15 |
| 4946 | Counseling young women with early breast cancer on fertility preservation. <i>Journal of Assisted Reproduction and Genetics</i> , 2019, 36, 2593-2604. | 1.2 | 27 |
| 4947 | Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988900. | 1.4 | 25 |
| 4948 | The Evolving Landscape of Cancer Therapeutics. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 43-79. | 0.9 | 10 |
| 4949 | ASCO 2019â€™Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 305-307. | 0.3 | 1 |
| 4950 | In Reply to Braunstein. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1162-1163. | 0.4 | 0 |
| 4952 | Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052). <i>Scientific Reports</i> , 2019, 9, 18135. | 1.6 | 12 |
| 4953 | Breast Magnetic Resonance Spectroscopy at 3 T in Biopsy-Proven Breast Cancers. <i>Investigative Radiology</i> , 2019, 54, 767-773. | 3.5 | 17 |
| 4954 | <p>A Nomogram To Predict The Overall Survival Of Breast Cancer Patients And Guide The Postoperative Adjuvant Chemotherapy In China</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10029-10039. | 0.9 | 8 |
| 4956 | <p>Cystatin SN Affects Cell Proliferation by Regulating the ERÎ±/PI3K/AKT/ERÎ± Loopback Pathway in Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 11359-11369. | 1.0 | 13 |
| 4957 | Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapyâ€™Resistant Early Breast Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-13. | 1.5 | 0 |
| 4959 | Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1â€™T3, N0â€™N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , 2019, 24, 1424-1431. | 1.9 | 22 |
| 4960 | Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. <i>Modern Pathology</i> , 2019, 32, 81-87. | 2.9 | 10 |
| 4961 | A novel tissue-engineered 3D tumor model for anti-cancer drug discovery. <i>Biofabrication</i> , 2019, 11, 015004. | 3.7 | 24 |
| 4962 | Progress in adjuvant systemic therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 27-44. | 12.5 | 175 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4963 | LncRNA DSCAM acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 2880-2894. | 2.0 | 52 |
| 4964 | CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. <i>Cancer Causes and Control</i> , 2019, 30, 103-112. | 0.8 | 9 |
| 4965 | Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 505-514. | 1.1 | 20 |
| 4966 | Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 262-273. | 1.0 | 39 |
| 4967 | Effects of serum estradiol and progesterone on estrogen-regulated gene expression in breast cancers of premenopausal patients. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 12-21. | 0.6 | 3 |
| 4968 | Changes of breast and axillary surgery patterns in patients with primary breast cancer during the past decade. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1043-1053. | 0.8 | 15 |
| 4969 | Adjuvant Chemotherapy for HER2-Negative Early-Stage Breast Cancer. , 2019, , 357-381. | | 0 |
| 4970 | Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy?. <i>Acta Oncologica</i> , 2019, 58, 162-167. | 0.8 | 8 |
| 4971 | Cancer and AIDS. , 2019, , . | | 0 |
| 4972 | Novel Biomarkers Predicting the Development of Bone Metastasis in Early Breast Cancer. , 2019, , 363-370. | | 0 |
| 4973 | The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale. <i>Cancer Drug Discovery and Development</i> , 2019, , 151-188. | 0.2 | 1 |
| 4974 | Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses' Health Studies. <i>Journal of the National Cancer Institute</i> , 2019, 111, 700-708. | 3.0 | 44 |
| 4975 | ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF- κ B activation. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1386-1397. | 1.2 | 20 |
| 4976 | SEOM clinical guidelines in early stage breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 18-30. | 1.2 | 48 |
| 4977 | Providers' perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?. <i>Health and Technology</i> , 2019, 9, 175-184. | 2.1 | 11 |
| 4978 | Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study. <i>Acta Oncologica</i> , 2019, 58, 168-174. | 0.8 | 4 |
| 4979 | A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. <i>Human Pathology</i> , 2019, 85, 221-227. | 1.1 | 59 |
| 4980 | <sc>DLC</sc>5 suppresses breast cancer stem cell-like characteristics to restore tamoxifen sensitivity by inhibiting <sc>TAZ</sc> expression. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 512-521. | 1.6 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 4981 | Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacy. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 98-107. | 2.4 | 12 |
| 4982 | Dormancy in cancer. <i>Cancer Science</i> , 2019, 110, 474-480. | 1.7 | 121 |
| 4983 | A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol. <i>BMC Cancer</i> , 2019, 19, 7. | 1.1 | 13 |
| 4984 | Clinical target sequencing for precision medicine of breast cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 131-140. | 1.0 | 14 |
| 4985 | Pre-diagnostic sex hormone levels and survival among breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 749-758. | 1.1 | 15 |
| 4986 | The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 357-363. | 1.1 | 13 |
| 4987 | Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). <i>Contemporary Clinical Trials</i> , 2019, 76, 120-131. | 0.8 | 12 |
| 4988 | Cause-specific mortality after a breast cancer diagnosis: a cohort study of 10,195 women in Girona and Tarragona. <i>Clinical and Translational Oncology</i> , 2019, 21, 1014-1025. | 1.2 | 9 |
| 4989 | Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 595-604. | 0.4 | 80 |
| 4990 | Role of Aldehyde Dehydrogenases in Physiopathological Processes. <i>Chemical Research in Toxicology</i> , 2019, 32, 405-420. | 1.7 | 35 |
| 4991 | Long-term survival outcomes in invasive lobular carcinoma patients with and without preoperative MR imaging: a matched cohort study. <i>European Radiology</i> , 2019, 29, 2526-2534. | 2.3 | 9 |
| 4992 | An exploration of the experiences of women treated with radiotherapy for breast cancer: Learning from recent and historical cohorts to identify enduring needs. <i>European Journal of Oncology Nursing</i> , 2019, 39, 47-54. | 0.9 | 17 |
| 4993 | Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery. <i>Journal of Surgical Research</i> , 2019, 236, 288-299. | 0.8 | 7 |
| 4994 | Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study. <i>Breast</i> , 2019, 43, 22-27. | 0.9 | 57 |
| 4995 | Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 375-383. | 1.1 | 1 |
| 4996 | Molecular Mechanisms of Endocrine Resistance. <i>Cancer Drug Discovery and Development</i> , 2019, , 265-307. | 0.2 | 5 |
| 4997 | OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database. <i>Breast Cancer</i> , 2019, 26, 339-348. | 1.3 | 2 |
| 4998 | Impact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer – Preliminary Results From the MENOCOR Study. <i>Clinical Breast Cancer</i> , 2019, 19, e74-e84. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 4999 | Flightless-I mediates the repression of estrogen receptor $\hat{\pm}$ target gene expression by the glucocorticoid receptor in MCF-7 cells. <i>Endocrine Journal</i> , 2019, 66, 65-74. | 0.7 | 6 |
| 5000 | Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. <i>Cancer</i> , 2019, 125, 269-277. | 2.0 | 18 |
| 5001 | Optimizing multi-modal cancer treatment under 3D spatio-temporal tumor growth. <i>Mathematical Biosciences</i> , 2019, 307, 53-69. | 0.9 | 11 |
| 5002 | Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?. <i>Cancer</i> , 2019, 125, 213-222. | 2.0 | 28 |
| 5003 | A systematic review of interventions to improve adherence to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 499-510. | 1.1 | 38 |
| 5004 | Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?. <i>Cancer</i> , 2019, 125, 177-180. | 2.0 | 3 |
| 5005 | Strategies to degrade estrogen receptor $\hat{\pm}$ in primary and ESR1 mutant-expressing metastatic breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2019, 480, 107-121. | 1.6 | 30 |
| 5006 | Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer. <i>Breast Cancer</i> , 2019, 26, 272-281. | 1.3 | 22 |
| 5007 | Systemic Treatment of HER2-Negative Metastatic Breast Cancer. , 2019, , 483-508. | | 0 |
| 5008 | Optimization studies for encapsulation and controlled release of curcumin drug using Zn ²⁺ cross-linked alginate and carboxy methylcellulose blend. <i>Journal of Polymer Research</i> , 2019, 26, 1. | 1.2 | 13 |
| 5009 | Tamoxifen therapy benefit predictive signature combining with prognostic signature in surgical-only ER $\hat{\pm}$ positive breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 11140-11148. | 2.0 | 3 |
| 5010 | Cancer survivorship: an integral part of Europe's research agenda. <i>Molecular Oncology</i> , 2019, 13, 624-635. | 2.1 | 103 |
| 5011 | Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer. <i>Translational Oncology</i> , 2019, 12, 381-388. | 1.7 | 14 |
| 5012 | From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand. <i>Value in Health Regional Issues</i> , 2019, 18, 47-53. | 0.5 | 6 |
| 5013 | Potential protein markers for breast cancer recurrence: a retrospective cohort study. <i>Cancer Causes and Control</i> , 2019, 30, 41-51. | 0.8 | 3 |
| 5014 | Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study. <i>Advances in Therapy</i> , 2019, 36, 131-146. | 1.3 | 4 |
| 5015 | Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER $\hat{\pm}$ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 93-102. | 1.1 | 17 |
| 5016 | T-Type voltage gated calcium channels: a target in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 11-21. | 1.1 | 25 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5017 | Clinicopathologic features of hormone receptor-positive breast cancer patients with late recurrence. <i>Breast Journal</i> , 2019, 25, 9-15. | 0.4 | 4 |
| 5018 | Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors. <i>Reumatologia Clínica</i> , 2019, 15, 211-217. | 0.2 | 3 |
| 5019 | Discussions about contralateral prophylactic mastectomy among surgical oncology providers and women with sporadic breast cancer: a content analysis. <i>Translational Behavioral Medicine</i> , 2020, 10, 347-354. | 1.2 | 0 |
| 5020 | My best case: homeopathic management of adverse effects of tamoxifen. <i>Wiener Medizinische Wochenschrift</i> , 2020, 170, 224-229. | 0.5 | 6 |
| 5021 | Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases. <i>Surgery Today</i> , 2020, 50, 657-663. | 0.7 | 11 |
| 5022 | Weighted gene correlation network analysis identifies RSAD2, HERC5, and CCL8 as prognostic candidates for breast cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 394-407. | 2.0 | 37 |
| 5023 | Factors associated with longer endocrine therapy use by South Carolina Medicaid-insured breast cancer survivors. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 36-42. | 0.5 | 2 |
| 5024 | Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 434-443. | 0.8 | 52 |
| 5025 | Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 125-130. | 1.1 | 16 |
| 5026 | Rationally Designed Antibody Drug Conjugates Targeting the Breast Cancer-Associated Endothelium. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 2563-2569. | 2.6 | 11 |
| 5028 | Multigene assays in early breast cancer: Insights from recent phase 3 studies. <i>European Journal of Surgical Oncology</i> , 2020, 46, 656-666. | 0.5 | 20 |
| 5029 | Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 275-285. | 1.1 | 26 |
| 5030 | Examining factors associated with adherence to hormonal therapy in breast cancer patients. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 574-582. | 1.5 | 5 |
| 5032 | Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival. <i>Supportive Care in Cancer</i> , 2020, 28, 2139-2143. | 1.0 | 1 |
| 5033 | Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 181-191. | 2.3 | 51 |
| 5034 | Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence. <i>Breast Cancer</i> , 2020, 27, 54-61. | 1.3 | 28 |
| 5035 | Timeliness of Treatment Initiation in Newly Diagnosed Patients With Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e27-e35. | 1.1 | 7 |
| 5036 | A 17-marker panel for global genomic instability in breast cancer. <i>Genomics</i> , 2020, 112, 1151-1161. | 1.3 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5037 | Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 147-155. | 1.8 | 2 |
| 5038 | <i>Cancer of the Lung.</i> , 2020, , 1108-1158.e16. | | 11 |
| 5039 | Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. <i>Biotechnic and Histochemistry</i> , 2020, 95, 71-91. | 0.7 | 57 |
| 5040 | Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. <i>Journal of Cellular Physiology</i> , 2020, 235, 1962-1972. | 2.0 | 244 |
| 5041 | Mechanisms of resistance to estrogen receptor modulators in ER+/HER2 ⁻ advanced breast cancer. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 559-572. | 2.4 | 19 |
| 5042 | Membranous overexpression of S100A10 is associated with a high-grade cellular status of breast carcinoma. <i>Medical Molecular Morphology</i> , 2020, 53, 104-114. | 0.4 | 7 |
| 5043 | Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials. <i>Current Problems in Cancer</i> , 2020, 44, 100507. | 1.0 | 6 |
| 5044 | The Effects of Adjuvant Tamoxifen Use on Macula Pigment Epithelium Optical Density, Visual Acuity and Retinal Thickness in Patients with Breast Cancer. <i>Current Eye Research</i> , 2020, 45, 623-628. | 0.7 | 5 |
| 5045 | FSIP1 is correlated with estrogen receptor status and poor prognosis. <i>Molecular Carcinogenesis</i> , 2020, 59, 126-135. | 1.3 | 4 |
| 5046 | Oestrogen receptors and breast cancer: are we prepared to move forward? A critical review. <i>BioSocieties</i> , 2020, 15, 627-649. | 0.8 | 1 |
| 5047 | Time to initiation of neo-adjuvant chemotherapy for breast cancer treatment does not influence patient survival: A study of US breast cancer patients. <i>Breast Journal</i> , 2020, 26, 625-629. | 0.4 | 8 |
| 5048 | IGF1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER ⁺ breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 2348-2359. | 2.3 | 18 |
| 5049 | Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 4147-4154. | 1.0 | 8 |
| 5050 | Hormonal therapy for cancer. <i>Medicine</i> , 2020, 48, 103-107. | 0.2 | 4 |
| 5051 | Carryover effects of aromatase inhibitors in prevention. <i>Lancet, The</i> , 2020, 395, 91-92. | 6.3 | 2 |
| 5053 | Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study. <i>Translational Oncology</i> , 2020, 13, 321-328. | 1.7 | 16 |
| 5054 | Melatonin protects against Epirubicin-induced ovarian damage. <i>Journal of Reproduction and Development</i> , 2020, 66, 19-27. | 0.5 | 17 |
| 5055 | Adherence and Persistence to Adjuvant Hormonal Therapy in Early-Stage Breast Cancer Patients: A Population-Based Retrospective Cohort Study in Israel. <i>Breast Care</i> , 2020, 15, 45-54. | 0.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5056 | Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 220-227. | 1.1 | 10 |
| 5057 | Wage losses among spouses of women with nonmetastatic breast cancer. <i>Cancer</i> , 2020, 126, 1124-1134. | 2.0 | 3 |
| 5058 | Optimizing cancer cure dialog: an analysis of pancreatic cancer patients'™ views regarding survival and cure. <i>Supportive Care in Cancer</i> , 2020, 28, 3731-3737. | 1.0 | 1 |
| 5059 | CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 548-557. | 0.8 | 31 |
| 5060 | Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 725-733. | 0.8 | 46 |
| 5061 | The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-™positive, human epidermal growth factor receptor 2™negative metastatic breast cancer: A population-™based study in British Columbia from 2003 to 2013. <i>Cancer</i> , 2020, 126, 971-977. | 2.0 | 3 |
| 5062 | Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 573-583. | 0.8 | 9 |
| 5063 | Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results. <i>Breast</i> , 2020, 49, 101-107. | 0.9 | 13 |
| 5064 | Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients. <i>Cancer Treatment Reviews</i> , 2020, 83, 101944. | 3.4 | 3 |
| 5065 | Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP™1 and HER2 expression and converted MCF7 breast cancer subtype. <i>British Journal of Pharmacology</i> , 2020, 177, 2024-2041. | 2.7 | 4 |
| 5066 | The changing role of pathologists from morphologists to molecular pathologists in the era of precision medicine. <i>Breast Journal</i> , 2020, 26, 27-34. | 0.4 | 4 |
| 5067 | The effect of perceived social support on chemotherapy-related symptoms in patients with breast cancer: A prospective observational study. <i>Journal of Psychosomatic Research</i> , 2020, 130, 109911. | 1.2 | 24 |
| 5068 | Breast cancer pathology services in sub-Saharan Africa: a survey within population-based cancer registries. <i>BMC Health Services Research</i> , 2020, 20, 912. | 0.9 | 15 |
| 5069 | Clinical practice to address tamoxifen nonadherence. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 675-682. | 1.1 | 1 |
| 5070 | Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations. <i>Journal of Oncology</i> , 2020, 2020, 1-13. | 0.6 | 6 |
| 5071 | Development and Validation of a Next-Generation Sequencing-™Based Multigene Assay to Predict the Prognosis of Estrogen Receptor-™Positive, HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6513-6522. | 3.2 | 6 |
| 5072 | The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs). <i>ChemMedChem</i> , 2020, 15, 2072-2097. | 1.6 | 15 |
| 5073 | MYBL2 amplification in breast cancer: Molecular mechanisms and therapeutic potential. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188407. | 3.3 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 5074 | Adenylate Kinase 4 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an m6A-Based Epitranscriptomic Mechanism. <i>Molecular Therapy</i> , 2020, 28, 2593-2604. | 3.7 | 52 |
| 5075 | Landmark trials in the medical oncology management of early stage breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 278-292. | 0.8 | 6 |
| 5076 | Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 6568-6580. | 3.2 | 30 |
| 5077 | Circulating Levels of Epirubicin Cause Endothelial Senescence While Compromising Metabolic Activity and Vascular Function. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 799. | 1.8 | 5 |
| 5078 | Breast cancer in the young patient: review of therapy and treatment considerations. <i>Breast Cancer Management</i> , 2020, 9, BMT39. | 0.2 | 0 |
| 5079 | Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 504-509. | 0.6 | 21 |
| 5080 | Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H ⁺ -Centered Anticancer Paradigm of the Late Post-Warburg Era. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7475. | 1.8 | 4 |
| 5081 | Adherence to breast cancer guidelines is associated with better survival outcomes: a systematic review and meta-analysis of observational studies in EU countries. <i>BMC Health Services Research</i> , 2020, 20, 920. | 0.9 | 36 |
| 5082 | Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016. <i>BMC Cancer</i> , 2020, 20, 847. | 1.1 | 5 |
| 5083 | Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX. <i>Cancer Medicine</i> , 2020, 9, 7810-7818. | 1.3 | 9 |
| 5084 | Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?. <i>Current Oncology Reports</i> , 2020, 22, 123. | 1.8 | 6 |
| 5085 | Cancer progression and the invisible phase of metastatic colonization. <i>Nature Reviews Cancer</i> , 2020, 20, 681-694. | 12.8 | 194 |
| 5086 | Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer. <i>BMC Cancer</i> , 2020, 20, 676. | 1.1 | 8 |
| 5087 | Bayesian Pathway Analysis for Complex Interactions. <i>American Journal of Epidemiology</i> , 2020, 189, 1610-1622. | 1.6 | 3 |
| 5088 | Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems. <i>Cancers</i> , 2020, 12, 1929. | 1.7 | 49 |
| 5089 | Metabolomic profiling of mouse mammary tumor-derived cell lines reveals targeted therapy options for cancer subtypes. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 1117-1127. | 2.1 | 3 |
| 5090 | Management of hormone receptor-positive, HER2-negative early breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 187-200. | 0.8 | 24 |
| 5091 | The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2 ⁺ Breast Cancer. <i>Cells</i> , 2020, 9, 1643. | 1.8 | 76 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5092 | Cellular Mechanisms Triggered by the Cotreatment of Resveratrol and Doxorubicin in Breast Cancer: A Translational In Vitro–In Silico Model. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-23. | 1.9 | 23 |
| 5093 | Histological Aspects and Quantitative Assessment of Ki67 as Prognostic Factors in Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study. <i>Medicina (Lithuania)</i> , 2020, 56, 600. | 0.8 | 15 |
| 5094 | Metastatic Colonization: Escaping Immune Surveillance. <i>Cancers</i> , 2020, 12, 3385. | 1.7 | 28 |
| 5095 | Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis. <i>Lancet Oncology, The</i> , 2020, 21, 1611-1619. | 5.1 | 45 |
| 5096 | <p>Resistance and Overcoming Resistance in Breast Cancer</p>. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 211-229. | 1.0 | 50 |
| 5097 | Emerging roles of N6-methyladenosine (m6A) modification in breast cancer. <i>Cell and Bioscience</i> , 2020, 10, 136. | 2.1 | 20 |
| 5098 | <p>Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy</p>. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 123-130. | 1.0 | 0 |
| 5099 | Viroimmunotherapy for breast cancer: promises, problems and future directions. <i>Cancer Gene Therapy</i> , 2021, 28, 757-768. | 2.2 | 13 |
| 5100 | Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 3557. | 1.7 | 41 |
| 5101 | Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 316. | 0.8 | 16 |
| 5102 | Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. <i>Frontiers in Immunology</i> , 2020, 11, 2166. | 2.2 | 60 |
| 5103 | <p>A Comparison Between the Online Prediction Models CancerMath and PREDICT as Prognostic Tools in Thai Breast Cancer Patients</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5549-5559. | 0.9 | 7 |
| 5104 | Molecular mechanisms and clinical management of cancer bone metastasis. <i>Bone Research</i> , 2020, 8, 30. | 5.4 | 78 |
| 5105 | Age-related disparities in older women with breast cancer. <i>Advances in Cancer Research</i> , 2020, 146, 23-56. | 1.9 | 15 |
| 5106 | The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 13241. | 1.6 | 10 |
| 5107 | Tailored optimal posttreatment surveillance for cancer recurrence. <i>Biometrics</i> , 2021, 77, 942-955. | 0.8 | 0 |
| 5108 | Delayed initiation of adjuvant chemotherapy in older women with breast cancer. <i>Cancer Medicine</i> , 2020, 9, 6961-6971. | 1.3 | 20 |
| 5109 | Changes in hot flash experiences and related factors in women with breast cancer. <i>Menopause</i> , 2020, 27, 535-542. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5110 | Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3273-3281. | 0.8 | 20 |
| 5111 | A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing HER2 expression in breast cancer. <i>Journal of Biological Chemistry</i> , 2020, 295, 14140-14152. | 1.6 | 16 |
| 5112 | The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population-based observational study. <i>Cancer</i> , 2020, 126, 3830-3836. | 2.0 | 7 |
| 5113 | A Role for Estrogen Receptor alpha36 in Cancer Progression. <i>Frontiers in Endocrinology</i> , 2020, 11, 506. | 1.5 | 29 |
| 5114 | Effective <i>in vitro</i> delivery of paclitaxel by nanocargo of mesoporous polycaprolactone against triple negative breast cancer cells by minimalizing drug dose. <i>RSC Advances</i> , 2020, 10, 24095-24107. | 1.7 | 6 |
| 5115 | <i>Platycodon grandiflorum</i> Protects Against Anthracycline-Induced Cardiotoxicity in Early Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542094501. | 0.8 | 8 |
| 5116 | Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1315. | 1.3 | 3 |
| 5117 | Identification and targeting of selective vulnerability rendered by tamoxifen resistance. <i>Breast Cancer Research</i> , 2020, 22, 80. | 2.2 | 11 |
| 5118 | Bone marrow mammaglobin-1 (SCGB2A2) immunohistochemistry expression as a breast cancer specific marker for early detection of bone marrow micrometastases. <i>Scientific Reports</i> , 2020, 10, 13061. | 1.6 | 14 |
| 5119 | Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases. <i>Human Pathology</i> , 2020, 104, 54-65. | 1.1 | 2 |
| 5120 | PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. <i>Nature Communications</i> , 2020, 11, 4053. | 5.8 | 77 |
| 5121 | Neoadjuvant chemotherapy and its affects to the axilla—Can we safely downgrade axillary surgery to mirror the approach in the breast. <i>Breast Journal</i> , 2020, 26, 1667-1672. | 0.4 | 0 |
| 5122 | Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 107-113. | 1.1 | 14 |
| 5123 | Triggering a switch from basal- to luminal-like breast cancer subtype by the small-molecule diptoindonesin G via induction of GABARAPL1. <i>Cell Death and Disease</i> , 2020, 11, 635. | 2.7 | 28 |
| 5124 | <p></p>ANLN Directly Interacts with RhoA to Promote Doxorubicin Resistance in Breast Cancer Cells</p>.</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9725-9734. | 0.9 | 9 |
| 5125 | Frequency of CD4+ regulatory T cells, CD8+ T cells, and human papilloma virus infection in Egyptian Women with breast cancer. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842096682. | 1.0 | 9 |
| 5126 | Role of microRNA in forming breast carcinoma. <i>Life Sciences</i> , 2020, 259, 118256. | 2.0 | 13 |
| 5127 | Beliefs and attitudes toward endocrine therapy in patients with hormone receptor-positive breast cancer. <i>Health Care for Women International</i> , 2021, 42, 1086-1097. | 0.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5128 | Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model. <i>Anticancer Research</i> , 2020, 40, 4869-4874. | 0.5 | 7 |
| 5129 | Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 212. | 1.2 | 4 |
| 5130 | Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 783-795. | 1.1 | 3 |
| 5131 | Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?. <i>The Surgery Journal</i> , 2020, 06, e135-e138. | 0.3 | 0 |
| 5132 | Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. <i>Cancers</i> , 2020, 12, 2634. | 1.7 | 7 |
| 5133 | Assessment of Breast Cancer Mortality Trends Associated With Mammographic Screening and Adjuvant Therapy From 1986 to 2013 in the State of Victoria, Australia. <i>JAMA Network Open</i> , 2020, 3, e208249. | 2.8 | 9 |
| 5134 | <p>>Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer</p><p>>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3535-3545. | 2.0 | 11 |
| 5135 | Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data. <i>Breast</i> , 2020, 54, 25-30. | 0.9 | 11 |
| 5136 | Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3743-3752. | 0.8 | 50 |
| 5137 | Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 665-674. | 1.1 | 8 |
| 5138 | Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer. <i>Cancers</i> , 2020, 12, 2490. | 1.7 | 25 |
| 5139 | Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 323-325. | 7.7 | 1 |
| 5140 | Tamoxifen and Endometrial Cancer: A Janus-Headed Drug. <i>Cancers</i> , 2020, 12, 2535. | 1.7 | 42 |
| 5141 | First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1461-1467. | 0.8 | 6 |
| 5142 | Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study. <i>Breast</i> , 2020, 54, 1-7. | 0.9 | 3 |
| 5143 | Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 965-975. | 1.1 | 6 |
| 5144 | Quality of Life Indicators in Patients Operated on for Breast Cancer in Relation to the Type of Surgery – A Retrospective Cohort Study of Women in Serbia. <i>Medicina (Lithuania)</i> , 2020, 56, 402. | 0.8 | 8 |
| 5145 | Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. <i>Cells</i> , 2020, 9, 2644. | 1.8 | 30 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5146 | Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2020, 42, 726-730. | 0.3 | 4 |
| 5147 | Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function. <i>Frontiers in Endocrinology</i> , 2020, 11, 591217. | 1.5 | 30 |
| 5148 | Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 3725. | 1.7 | 3 |
| 5149 | Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio. <i>Breast</i> , 2020, 54, 229-234. | 0.9 | 3 |
| 5150 | M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome. <i>Frontiers in Immunology</i> , 2020, 11, 560074. | 2.2 | 18 |
| 5151 | The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer. <i>Breast Cancer Management</i> , 2020, 9, . | 0.2 | 9 |
| 5152 | A Pilot Study of Cardiac MRI in Breast Cancer Survivors After Cardiotoxic Chemotherapy and Three-Dimensional Conformal Radiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 506739. | 1.3 | 10 |
| 5153 | The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance. <i>Genes and Development</i> , 2020, 34, 1422-1438. | 2.7 | 28 |
| 5154 | First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study. <i>ESMO Open</i> , 2020, 5, e000859. | 2.0 | 6 |
| 5155 | Radiation Therapy in the Management of Oligometastatic Breast Cancer: Current Evidence and Future Directions. <i>Current Breast Cancer Reports</i> , 2020, 12, 266-274. | 0.5 | 0 |
| 5156 | Design, synthesis and anticancer/antiestrogenic activities of novel indole-benzimidazoles. <i>Bioorganic Chemistry</i> , 2020, 100, 103929. | 2.0 | 28 |
| 5157 | Identification and Analysis of Estrogen Receptor Promoting Tamoxifen Resistance-Related lncRNAs. <i>BioMed Research International</i> , 2020, 2020, 1-10. | 0.9 | 13 |
| 5158 | Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers. <i>Scientific Reports</i> , 2020, 10, 8188. | 1.6 | 5 |
| 5159 | Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers. <i>Molecular Oncology</i> , 2020, 14, 2271-2287. | 2.1 | 17 |
| 5160 | The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. <i>Cancer Medicine</i> , 2020, 9, 4603-4612. | 1.3 | 3 |
| 5161 | Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (IBCRG-M06/EMERALD). <i>Trials</i> , 2020, 21, 391. | 0.7 | 8 |
| 5162 | Breast Cancer Health Disparities in Hispanics/Latinas. <i>Current Breast Cancer Reports</i> , 2020, 12, 175-184. | 0.5 | 10 |
| 5163 | Estrogen-induced epigenetic silencing of FTH1 and TFRC genes reduces liver cancer cell growth and survival. <i>Epigenetics</i> , 2020, 15, 1302-1318. | 1.3 | 35 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 5164 | Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia. <i>World Journal of Surgical Oncology</i> , 2020, 18, 117. | 0.8 | 17 |
| 5165 | Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?. <i>Frontiers in Oncology</i> , 2020, 10, 708. | 1.3 | 2 |
| 5166 | The dormant cancer cell life cycle. <i>Nature Reviews Cancer</i> , 2020, 20, 398-411. | 12.8 | 286 |
| 5167 | The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. <i>PLoS ONE</i> , 2020, 15, e0231999. | 1.1 | 36 |
| 5168 | In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors. <i>Journal of Controlled Release</i> , 2020, 324, 146-155. | 4.8 | 9 |
| 5169 | Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?. <i>Breast Journal</i> , 2020, 26, 1199-1207. | 0.4 | 8 |
| 5170 | Treatment and patient related quality of life issues in elderly and very elderly breast cancer patients. <i>Translational Cancer Research</i> , 2020, 9, S146-S153. | 0.4 | 7 |
| 5171 | The Network of Angiotensin Receptors in Breast Cancer. <i>Cells</i> , 2020, 9, 1336. | 1.8 | 17 |
| 5172 | Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer. <i>Breast</i> , 2020, 52, 64-70. | 0.9 | 8 |
| 5173 | <p>Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3547-3560. | 0.9 | 13 |
| 5174 | Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients. <i>PLoS ONE</i> , 2020, 15, e0234058. | 1.1 | 18 |
| 5175 | Triple-negative breast cancer molecular subtyping and treatment progress. <i>Breast Cancer Research</i> , 2020, 22, 61. | 2.2 | 1,022 |
| 5176 | Computer-Aided Ligand Discovery for Estrogen Receptor Alpha. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4193. | 1.8 | 33 |
| 5177 | Association between Waiting Time for Radiotherapy after Surgery for Early-Stage Breast Cancer and Survival Outcomes in Ontario: A Population-Based Outcomes Study. <i>Current Oncology</i> , 2020, 27, 216-221. | 0.9 | 9 |
| 5178 | Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 33-33. | 0.4 | 7 |
| 5179 | The impact of menstruation persistence or recovery after chemotherapy on survival in young patients with hormone receptor negative breast cancer. <i>Breast</i> , 2020, 52, 102-109. | 0.9 | 2 |
| 5180 | Development of a Novel Tool for the Retrieval and Analysis of Hormone Receptor Expression Characteristics in Metastatic Breast Cancer via Data Mining on Pathology Reports. <i>BioMed Research International</i> , 2020, 2020, 1-7. | 0.9 | 1 |
| 5181 | Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype. <i>Oncology Research and Treatment</i> , 2020, 43, 362-371. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5182 | Evaluating the Age-Based Recommendations for Long-Term Follow-Up in Breast Cancer. <i>Oncologist</i> , 2020, 25, e1330-e1338. | 1.9 | 6 |
| 5183 | Analysis of Breast Cancer Patients with T1-2 Tumors and 1-3 Positive Lymph Nodes Treated with or without Postmastectomy Radiation Therapy. <i>Scientific Reports</i> , 2020, 10, 9887. | 1.6 | 4 |
| 5184 | The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 7. | 2.3 | 17 |
| 5185 | Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer. <i>Oncology Research and Treatment</i> , 2020, 43, 153-159. | 0.8 | 6 |
| 5186 | Impact of chemotherapy schedule modification on breast cancer patients: a single-centre retrospective study. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 642-651. | 1.0 | 8 |
| 5187 | Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles. <i>Journal of Assisted Reproduction and Genetics</i> , 2020, 37, 913-921. | 1.2 | 10 |
| 5188 | Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria. <i>Breast Care</i> , 2020, 15, 642-647. | 0.8 | 1 |
| 5189 | The impact of 21-gene Recurrence Score test and classic clinical-pathologic factors in guiding adjuvant therapy for HER2-negative, ER-positive, early-stage breast cancer: A retrospective study. <i>Breast Journal</i> , 2020, 26, 1064-1066. | 0.4 | 0 |
| 5190 | Methylome Variation Predicts Exemestane Resistance in Advanced ER ⁺ Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303381989633. | 0.8 | 5 |
| 5191 | Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. <i>The Cochrane Library</i> , 2020, 3, CD013538. | 1.5 | 23 |
| 5192 | Annotation and cluster analysis of long noncoding RNA linked to male sex and estrogen in cancers. <i>Npj Precision Oncology</i> , 2020, 4, 5. | 2.3 | 14 |
| 5193 | Cytokine Production by Blood Immune Cells, Tumor and its Microenvironment, Characteristics of Extracellular Matrix in Patients with Invasive Ductal Carcinoma of No Special Type. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2020, 14, 44-51. | 0.2 | 1 |
| 5194 | Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 3402-3411. | 0.7 | 5 |
| 5195 | Dual in vitro invasion/migration suppressing and tamoxifen response modulating effects of a recombinant anti-ALCAM scFv on breast cancer cells. <i>Cell Biochemistry and Function</i> , 2020, 38, 651-659. | 1.4 | 7 |
| 5196 | LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1464-1472. | 0.9 | 39 |
| 5197 | Early Detection and Prediction of Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional Echocardiography. <i>JACC: CardioOncology</i> , 2020, 2, 13-22. | 1.7 | 36 |
| 5198 | Breast Cancer Presentation, Surgical Management and Mortality Across the Rural-Urban Continuum in the National Cancer Database. <i>Annals of Surgical Oncology</i> , 2020, 27, 1805-1815. | 0.7 | 29 |
| 5199 | ER ⁺ , A Key Target for Cancer Therapy: A Review. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2183-2191. | 1.0 | 52 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5200 | Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020, 122, 1611-1617. | 2.9 | 12 |
| 5201 | Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. <i>Cancers</i> , 2020, 12, 781. | 1.7 | 8 |
| 5202 | A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 715-724. | 1.1 | 2 |
| 5203 | A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation. <i>Scientific Reports</i> , 2020, 10, 4553. | 1.6 | 35 |
| 5204 | Transvaginal laparoscopic salpingo-oophorectomy: an oncological risk-reducing procedure. <i>Future Science OA</i> , 2020, 6, FSO429. | 0.9 | 0 |
| 5205 | Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary review. <i>Future Oncology</i> , 2020, 16, 395-412. | 1.1 | 11 |
| 5206 | Influence of Competing Risks on Estimates of Recurrence Risk and Breast Cancer-specific Mortality in Analyses of the Early Breast Cancer Trialists Collaborative Group. <i>Scientific Reports</i> , 2020, 10, 4091. | 1.6 | 7 |
| 5207 | Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1. <i>Hormones and Cancer</i> , 2020, 11, 129-147. | 4.9 | 22 |
| 5208 | Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients. <i>Journal of Surgical Oncology</i> , 2020, 122, 861-868. | 0.8 | 2 |
| 5209 | Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 621-632. | 1.6 | 33 |
| 5210 | Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer. <i>Cancer</i> , 2020, 126, 4059-4066. | 2.0 | 7 |
| 5211 | Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone Therapy. <i>Hormones and Cancer</i> , 2020, 11, 148-154. | 4.9 | 9 |
| 5212 | Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. <i>Clinical Chemistry</i> , 2020, 66, 934-945. | 1.5 | 5 |
| 5213 | Nomogram for Predicting the Overall Survival of Patients With Breast Cancer With Pathologic Nodal Status N3. <i>Clinical Breast Cancer</i> , 2020, 20, e778-e785. | 1.1 | 7 |
| 5214 | Functional nanostructures for drug resistance breast cancer theranostics. , 2020, , 131-152. | | 1 |
| 5215 | <p>Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 615-621. | 1.0 | 7 |
| 5216 | Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries. <i>International Journal of Cancer</i> , 2020, 147, 1437-1449. | 2.3 | 26 |
| 5217 | A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1110. | 1.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5218 | Invasive breast cancer: Current perspectives and emerging views. <i>Pathology International</i> , 2020, 70, 242-252. | 0.6 | 11 |
| 5219 | UBE2C Overexpression Aggravates Patient Outcome by Promoting Estrogen-Dependent/Independent Cell Proliferation in Early Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 9, 1574. | 1.3 | 27 |
| 5220 | Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50)</i> , 2020, 99, 10400. | 0.4 | 0 |
| 5221 | Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors. <i>Psycho-Oncology</i> , 2020, 29, 647-654. | 1.0 | 24 |
| 5222 | In the Era After the European Organisation for Research and Treatment of Cancer â€œBoostâ€™ Study, is the Additional Radiotherapy to the Breast Tumour Bed Still Beneficial for Young Women?. <i>Clinical Oncology</i> , 2020, 32, 373-381. | 0.6 | 4 |
| 5223 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2020, 31, 451-469. | 0.6 | 34 |
| 5224 | Extended endocrine therapy in early breast cancer: how long and who for?. <i>Future Oncology</i> , 2020, 16, 4327-4336. | 1.1 | 5 |
| 5225 | A review on anti-cancer properties of Quercetin in breast cancer. <i>Life Sciences</i> , 2020, 248, 117463. | 2.0 | 189 |
| 5226 | The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1231-1241. | 3.0 | 61 |
| 5227 | Health-related Quality of Life of Breast Cancer Survivors Attending an Exercise Intervention Study: A Five-year Follow-up. <i>In Vivo</i> , 2020, 34, 667-674. | 0.6 | 15 |
| 5228 | A Novel Prognostic Signature of mRNA-lncRNA in Breast Cancer. <i>DNA and Cell Biology</i> , 2020, 39, 671-682. | 0.9 | 4 |
| 5229 | Development of an Immune-Related Prognostic Signature in Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 1390. | 1.1 | 29 |
| 5230 | Impact of delayed treatment in women diagnosed with breast cancer: A population-based study. <i>Cancer Medicine</i> , 2020, 9, 2435-2444. | 1.3 | 46 |
| 5231 | AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 321-333. | 2.1 | 12 |
| 5232 | Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort. <i>Breast Cancer Research</i> , 2020, 22, 10. | 2.2 | 29 |
| 5233 | Rationally Designed Ruthenium Complexes for Breast Cancer Therapy. <i>Molecules</i> , 2020, 25, 265. | 1.7 | 54 |
| 5234 | Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup â€“ the â€œATRESSâ€™-phenomenon. <i>Breast</i> , 2020, 50, 39-48. | 0.9 | 14 |
| 5235 | miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. <i>Cells</i> , 2020, 9, 276. | 1.8 | 693 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5236 | Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer. <i>Journal of Clinical Pathology</i> , 2020, 73, 147-153. | 1.0 | 7 |
| 5237 | Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). <i>Clinical Breast Cancer</i> , 2020, 20, 183-193. | 1.1 | 13 |
| 5238 | Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 157-165. | 1.1 | 7 |
| 5239 | Breast cancer patients's experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis. <i>European Journal of Oncology Nursing</i> , 2020, 44, 101706. | 0.9 | 36 |
| 5240 | Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients. <i>Scientific Reports</i> , 2020, 10, 7029. | 1.6 | 14 |
| 5241 | The Effects of Pharmacological and Non-Pharmacological Interventions on Symptom Management and Quality of Life among Breast Cancer Survivors Undergoing Adjuvant Endocrine Therapy: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2950. | 1.2 | 17 |
| 5242 | The prognostic and predictive role of 21-gene recurrence scores in hormone receptor-positive early-stage breast cancer. <i>Journal of Surgical Oncology</i> , 2020, 122, 144-154. | 0.8 | 7 |
| 5243 | Tumour characteristics and survivorship in a cohort of breast cancer: the MCC-Spain study. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 667-678. | 1.1 | 14 |
| 5244 | Heightened Tamoxifen Activation Masquerading as a Venlafaxine-Associated Adverse Event After Rotation From Duloxetine. <i>Journal of Pain and Symptom Management</i> , 2020, 60, e104-e106. | 0.6 | 0 |
| 5245 | Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 155-165. | 1.1 | 14 |
| 5246 | What are the appropriate thresholds for High Quality Performance Indicators for breast surgery in Australia and New Zealand?. <i>Breast</i> , 2020, 51, 94-101. | 0.9 | 4 |
| 5247 | Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. <i>Npj Breast Cancer</i> , 2020, 6, 11. | 2.3 | 2 |
| 5248 | Genetic 3'UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 5736. | 1.6 | 14 |
| 5249 | A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data. <i>Journal of the National Cancer Institute</i> , 2020, 112, 979-988. | 3.0 | 17 |
| 5250 | Clinical analgesic efficacy of pectoral nerve block in patients undergoing breast cancer surgery. <i>Medicine (United States)</i> , 2020, 99, e19614. | 0.4 | 22 |
| 5251 | Improving the transparency of meta-analyses with interactive web applications. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, 327-332. | 1.7 | 3 |
| 5252 | Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer. <i>Journal of Chemotherapy</i> , 2020, 32, 202-207. | 0.7 | 10 |
| 5253 | Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer. <i>PLoS ONE</i> , 2020, 15, e0231786. | 1.1 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5254 | Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study. <i>Scientific Reports</i> , 2020, 10, 6714. | 1.6 | 7 |
| 5255 | The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancer Management and Research</i> , 2020, Volume 12, 2491-2499. | 0.9 | 3 |
| 5256 | Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 369-381. | 1.1 | 25 |
| 5257 | Breast cancer nanomedicine market update and other industrial perspectives of nanomedicine. , 2020, , 371-404. | | 6 |
| 5258 | Targeted MIP-3 β plasmid nanoparticles induce dendritic cell maturation and inhibit M2 macrophage polarisation to suppress cancer growth. <i>Biomaterials</i> , 2020, 249, 120046. | 5.7 | 20 |
| 5259 | Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDx study. <i>Breast</i> , 2020, 52, 1-7. | 0.9 | 8 |
| 5260 | Two novel chiral tetranucleate copper-based complexes: crystal structures, nanoparticles, and inhibiting angiogenesis and the growth of human breast cancer by regulating the VEGF/VEGFR2 signal pathway <i>in vitro</i> . <i>Dalton Transactions</i> , 2020, 49, 6043-6055. | 1.6 | 16 |
| 5261 | The NF- κ B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. <i>Molecular Cancer Research</i> , 2020, 18, 1018-1027. | 1.5 | 31 |
| 5262 | Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands. <i>PLoS ONE</i> , 2020, 15, e0230909. | 1.1 | 7 |
| 5263 | Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine. <i>Cancers</i> , 2020, 12, 821. | 1.7 | 10 |
| 5265 | New Advances in Molecular Breast Cancer Pathology. <i>Seminars in Cancer Biology</i> , 2021, 72, 102-113. | 4.3 | 37 |
| 5266 | Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma. <i>Seminars in Cancer Biology</i> , 2021, 72, 114-122. | 4.3 | 27 |
| 5267 | Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy. <i>Supportive Care in Cancer</i> , 2021, 29, 437-443. | 1.0 | 6 |
| 5268 | Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 547-554. | 0.5 | 6 |
| 5269 | Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors. <i>Journal of Obstetrics and Gynaecology</i> , 2021, 41, 447-452. | 0.4 | 3 |
| 5270 | A new treatment of alopecia induced by palbociclib: Topical cetirizine. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 460-463. | 0.5 | 8 |
| 5271 | The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. <i>Breast Cancer</i> , 2021, 28, 67-74. | 1.3 | 5 |
| 5272 | Impact of sex hormones dysregulation and adiposity on the outcome of postmenopausal breast cancer patients. <i>Clinical Obesity</i> , 2021, 11, e12423. | 1.1 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 5273 | ESR1 genetic alterations and their association with clinicopathologic characteristics in advanced breast cancer: a single academic institution experience. <i>Human Pathology</i> , 2021, 107, 80-86. | 1.1 | 7 |
| 5274 | Commentary on "Continuation of Annual Screening Mammography and Breast Cancer Mortality in Women Older Than 70 Years": <i>American Journal of Roentgenology</i> , 2021, 216, 583-583. | 1.0 | 0 |
| 5275 | Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1243-1252. | 1.1 | 18 |
| 5276 | Adjuvant Chemotherapy for Low-Clinical-Risk Breast Cancer Defined by Modified Version of Adjuvant! Online: A Propensity Score Matched SEER Analysis. <i>Breast Care</i> , 2021, 16, 156-162. | 0.8 | 1 |
| 5277 | Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. <i>International Journal of Cancer</i> , 2021, 148, 375-384. | 2.3 | 10 |
| 5278 | EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen. <i>Breast Cancer</i> , 2021, 28, 355-367. | 1.3 | 5 |
| 5279 | Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 93-98. | 0.7 | 5 |
| 5281 | A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 507-515. | 1.1 | 6 |
| 5282 | Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 237-245. | 1.1 | 6 |
| 5283 | Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand. <i>Breast Cancer</i> , 2021, 28, 387-397. | 1.3 | 12 |
| 5284 | Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects. <i>Cancer Research</i> , 2021, 81, 539-551. | 0.4 | 35 |
| 5285 | Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 61, 102073. | 1.4 | 16 |
| 5286 | Low Z ⁴ O ^H am concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen. <i>Molecular Oncology</i> , 2021, 15, 957-967. | 2.1 | 10 |
| 5287 | Repurposed Antiviral Drugs for Covid-19 " Interim WHO Solidarity Trial Results. <i>New England Journal of Medicine</i> , 2021, 384, 497-511. | 13.9 | 2,014 |
| 5288 | RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 191-206. | 2.9 | 16 |
| 5289 | Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 50. | 3.8 | 113 |
| 5290 | Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan. <i>Breast Cancer</i> , 2021, 28, 1-8. | 1.3 | 11 |
| 5291 | Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians. <i>Experimental and Molecular Pathology</i> , 2021, 118, 104574. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5292 | The lingering mysteries of metastatic recurrence in breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 13-26. | 2.9 | 263 |
| 5293 | The effect of environmental Bisphenol A exposure on breast cancer associated with obesity. <i>Environmental Toxicology and Pharmacology</i> , 2021, 81, 103544. | 2.0 | 24 |
| 5294 | Adjuvant Chemotherapy in Two-Stage Tissue Expander/Implant Breast Reconstruction: Does it Affect Final Outcomes?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2191-2198. | 0.7 | 5 |
| 5295 | Insulin-Induced Gene 2 Expression Is Associated with Breast Cancer Metastasis. <i>American Journal of Pathology</i> , 2021, 191, 385-395. | 1.9 | 2 |
| 5296 | Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 557-564. | 0.8 | 69 |
| 5297 | Microvascular breast reconstruction and thromboembolic events in patients on hormone therapy: Audit of practice from a tertiary referral centre. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, 74, 957-965. | 0.5 | 4 |
| 5298 | Targeting Subtype-Specific Metabolic Preferences in Nucleotide Biosynthesis Inhibits Tumor Growth in a Breast Cancer Model. <i>Cancer Research</i> , 2021, 81, 303-314. | 0.4 | 8 |
| 5299 | Breast cancer in the oldest old (≥ 89 years): Tumor characteristics, treatment choices, clinical outcomes and literature review. <i>European Journal of Surgical Oncology</i> , 2021, 47, 796-803. | 0.5 | 4 |
| 5300 | The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ER α to inhibit the growth of breast cancer induced by oestrogen. <i>Cancer Letters</i> , 2021, 498, 54-69. | 3.2 | 15 |
| 5301 | Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 984-994. | 3.3 | 16 |
| 5302 | Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 517-525. | 1.1 | 16 |
| 5303 | Cardiac serum marker alterations after intraoperative radiotherapy with low-energy x-rays in early breast cancer as an indicator of possible cardiac toxicity. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 39-47. | 1.0 | 2 |
| 5304 | Obesity as potential breast cancer risk factor for postmenopausal women. <i>Genes and Diseases</i> , 2021, 8, 117-123. | 1.5 | 33 |
| 5305 | Nanotoxicology profiling of cancer nanomedicines. , 2021, , 291-301. | | 1 |
| 5306 | Assessment of Human Papillomavirus Infection and Risk Factors in Egyptian Women With Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342199627. | 0.6 | 8 |
| 5307 | Validity of the prognostication tool PREDICT version 2.2 in Japanese breast cancer patients. <i>Cancer Medicine</i> , 2021, 10, 1605-1613. | 1.3 | 7 |
| 5308 | Clinical importance of serum secreted clusterin in predicting invasive breast cancer and treatment responses. <i>Bioengineered</i> , 2021, 12, 278-285. | 1.4 | 12 |
| 5309 | Androgen Misuse and Abuse. <i>Endocrine Reviews</i> , 2021, 42, 457-501. | 8.9 | 41 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5310 | Targeting breast cancer. , 2021, , 341-350. | | 0 |
| 5311 | Body Composition Analysis of 10 Years versus 5 Years of Adjuvant Endocrine Therapy in Patients with Nonmetastatic Breast Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-8. | 0.6 | 1 |
| 5312 | Real world data on adjuvant treatment of older HER2-positive breast cancer patients – A single institution experience through 8 years. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100430. | 0.7 | 1 |
| 5313 | Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110284. | 1.4 | 12 |
| 5314 | Analysis of early stage breast cancer treatment techniques. , 2021, , 71-80. | | 4 |
| 5316 | Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 699-709. | 1.1 | 16 |
| 5317 | Update on systemic treatment in early triple negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098674. | 1.4 | 19 |
| 5318 | Associated factors and outcomes of delaying adjuvant chemotherapy in breast cancer by biologic subtypes: a National Cancer Database study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2447-2458. | 1.2 | 8 |
| 5319 | Breast Cancer Recurrence and Survival. , 2021, , 33-52. | | 0 |
| 5320 | Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1484-1494. | 3.0 | 92 |
| 5321 | Overexpression of miR-1225 promotes the progression of breast cancer, resulting in poor prognosis. <i>Clinical and Experimental Medicine</i> , 2021, 21, 287-296. | 1.9 | 8 |
| 5322 | Perceived New Normal and Inner Strength on Quality of Life in Breast Cancer Patients Receiving Adjuvant Endocrine Therapy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 377. | 0.7 | 2 |
| 5323 | The Multidisciplinary Approach to Breast Cancer Management. , 2021, , 137-156. | | 0 |
| 5324 | Guideline-concordant treatment predicts survival: a National Cancer Database validation study of novel composite locoregional and systemic treatment scores among women with early stage breast cancer. <i>Breast Cancer</i> , 2021, 28, 698-709. | 1.3 | 2 |
| 5325 | Expert consensus on diagnosis, treatment and fertility management of young breast cancer patients. <i>Journal of the National Cancer Center</i> , 2021, 1, 23-23. | 3.0 | 2 |
| 5326 | Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. <i>British Journal of Cancer</i> , 2021, 124, 1503-1512. | 2.9 | 24 |
| 5328 | Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer. <i>World Journal of Surgical Oncology</i> , 2021, 19, 52. | 0.8 | 3 |
| 5329 | Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor ± positive breast cancer. <i>Oncology Letters</i> , 2021, 21, 294. | 0.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5330 | Clinical Perspectives in Addressing Unsolved Issues in (Neo)Adjuvant Therapy for Primary Breast Cancer. <i>Cancers</i> , 2021, 13, 926. | 1.7 | 5 |
| 5331 | Amongst Women Stratified to Receive Endocrine Therapy on the Basis of Their Tumor Estrogen and Progesterone Receptor Levels, Those with Higher Tumor Progesterone Receptor Levels Had a Better Outcome Than Those with Lower Levels of Tumor Progesterone Receptor. <i>Cancers</i> , 2021, 13, 905. | 1.7 | 4 |
| 5332 | A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. <i>Breast Cancer</i> , 2021, 28, 684-697. | 1.3 | 1 |
| 5333 | Dissection of Level III Axillary Lymph Nodes in Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 2041-2046. | 0.9 | 5 |
| 5334 | Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2 ⁻ Breast Cancer Patient With High Tumor Mutational Burden. <i>Frontiers in Oncology</i> , 2020, 10, 588080. | 1.3 | 7 |
| 5335 | Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 843-852. | 1.1 | 7 |
| 5336 | A novel signature predicts recurrence risk and therapeutic response in breast cancer patients. <i>International Journal of Cancer</i> , 2021, 148, 2848-2856. | 2.3 | 1 |
| 5337 | Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2 ⁻ Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 588728. | 1.3 | 2 |
| 5338 | Analgesic efficacy and safety of erector spinae plane block in breast cancer surgery: a systematic review and meta-analysis. <i>BMC Anesthesiology</i> , 2021, 21, 59. | 0.7 | 26 |
| 5339 | A 58-Year-Old Woman with Acute Gastric Perforation Due to Metastatic Ductal Carcinoma 18 Years Following Bilateral Mastectomy for Invasive Ductal Carcinoma of the Breast. <i>American Journal of Case Reports</i> , 2021, 22, e927094. | 0.3 | 3 |
| 5340 | Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors. <i>Cancer</i> , 2021, 127, 1847-1856. | 2.0 | 9 |
| 5341 | Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 135-144. | 1.1 | 5 |
| 5342 | The IHC4+C score: an affordable and reproducible non-molecular decision aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 368-376. | 0.7 | 2 |
| 5343 | Genomic Assays in Node Positive Breast Cancer Patients: A Review. <i>Frontiers in Oncology</i> , 2020, 10, 609100. | 1.3 | 13 |
| 5344 | Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis. <i>JCO Global Oncology</i> , 2021, 7, 289-301. | 0.8 | 6 |
| 5345 | Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222. | 5.1 | 169 |
| 5346 | MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. <i>Oncogenesis</i> , 2021, 10, 19. | 2.1 | 79 |
| 5347 | Prediction models for breast cancer prognosis among Asian women. <i>Cancer</i> , 2021, 127, 1758-1769. | 2.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5348 | Multifocality, Multicentricity, and Bilaterality of Breast Cancer. , 0, , . | | 0 |
| 5349 | Treatment patterns and outcomes in older women with early breast cancer: a population-based cohort study in China. <i>BMC Cancer</i> , 2021, 21, 226. | 1.1 | 1 |
| 5350 | Reconsidering the Meaning of Curing Primary Breast Cancer as a Systemic Disease. <i>Frontiers in Oncology</i> , 2021, 11, 639420. | 1.3 | 0 |
| 5351 | Involvement of actin cytoskeletal modifications in the inhibition of triple-negative breast cancer growth and metastasis by nimbolide. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 596-606. | 2.0 | 10 |
| 5352 | Uridine Glucuronosyltransferase 2B7 Polymorphism-Based Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy for Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e584-e593. | 1.1 | 3 |
| 5353 | Distinct Somatic Alteration Features Identified by Gene Panel Sequencing in Korean Triple-Negative Breast Cancer with High Ki67 Expression. <i>Diagnostics</i> , 2021, 11, 416. | 1.3 | 0 |
| 5354 | Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer. <i>Medicine (United States)</i> , 2021, 100, e25000. | 0.4 | 2 |
| 5355 | Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 201. | 1.1 | 13 |
| 5356 | Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. <i>Npj Breast Cancer</i> , 2021, 7, 26. | 2.3 | 7 |
| 5357 | Chemotherapy Treatment Considerations in Metastatic Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 6-12. | 0.2 | 5 |
| 5358 | G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives. <i>Cells</i> , 2021, 10, 672. | 1.8 | 32 |
| 5359 | Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment. <i>BMC Cancer</i> , 2021, 21, 215. | 1.1 | 3 |
| 5360 | Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase III clinical trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 117-131. | 1.1 | 10 |
| 5361 | Liposome nanoformulation with cationic polar lipid DOTAP and cholesterol as a suitable pH-responsive carrier for molecular therapeutic drug (all-trans retinoic acid) delivery to lung cancer cells. <i>IET Nanobiotechnology</i> , 2021, 15, 380-390. | 1.9 | 13 |
| 5362 | Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study. <i>Scientific Reports</i> , 2021, 11, 5375. | 1.6 | 1 |
| 5363 | Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN Survey. <i>Cancers</i> , 2021, 13, 1161. | 1.7 | 4 |
| 5364 | Epigenetic mechanisms in breast cancer therapy and resistance. <i>Nature Communications</i> , 2021, 12, 1786. | 5.8 | 187 |
| 5365 | Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer. <i>Oncologist</i> , 2021, 26, e943-e953. | 1.9 | 36 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5366 | Emerging strategies for treating metastasis. <i>Nature Cancer</i> , 2021, 2, 258-270. | 5.7 | 71 |
| 5367 | Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer. <i>Frontiers in Endocrinology</i> , 2021, 12, 599586. | 1.5 | 44 |
| 5368 | Factors associated with late risks of breast cancer-specific mortality in the SEER registry. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 203-212. | 1.1 | 11 |
| 5369 | PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC. <i>Breast Disease</i> , 2021, 40, 43-50. | 0.4 | 11 |
| 5370 | Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609. | 3.4 | 15 |
| 5371 | Crosstalk between progesterone receptor membrane component 1 and estrogen receptor α promotes breast cancer cell proliferation. <i>Laboratory Investigation</i> , 2021, 101, 733-744. | 1.7 | 17 |
| 5372 | Metastatic relapse of stage Iâ€“III breast cancer in New Zealand. <i>Cancer Causes and Control</i> , 2021, 32, 753-761. | 0.8 | 5 |
| 5373 | Theranostic Advances in Breast Cancer in Nuclear Medicine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4597. | 1.8 | 38 |
| 5374 | MicroRNA Regulation of Breast Cancer Stemness. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3756. | 1.8 | 14 |
| 5375 | Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4687. | 1.8 | 23 |
| 5376 | A Role for TGF β 2 Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4463. | 1.8 | 6 |
| 5377 | Prospective study of hair recovery after (neo)adjuvant chemotherapy with scalp cooling in Japanese breast cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 6119-6125. | 1.0 | 4 |
| 5378 | miR-1224-3p Promotes Breast Cancer Cell Proliferation and Migration through PGM5-Mediated Aerobic Glycolysis. <i>Journal of Oncology</i> , 2021, 2021, 1-15. | 0.6 | 12 |
| 5379 | 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , 2021, 22, 476-488. | 5.1 | 179 |
| 5380 | Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 3099-3109. | 1.4 | 15 |
| 5382 | Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOGâ€“ACRIN TAILORx trial. <i>Cancer</i> , 2021, 127, 2545-2552. | 2.0 | 20 |
| 5383 | Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5766-5786. | 2.9 | 4 |
| 5384 | Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review. <i>Current Oncology Reports</i> , 2021, 23, 63. | 1.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5385 | Genetic Testing and De-escalation of Contralateral Prophylactic Mastectomy. <i>Annals of Surgical Oncology</i> , 2021, 28, 4764-4766. | 0.7 | 2 |
| 5386 | Breast-conserving Surgery Without Radiation Therapy for Invasive Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 112-119. | 1.1 | 5 |
| 5387 | Performance of functionality measures and phase angle in women exposed to chemotherapy for early breast cancer. <i>Clinical Nutrition ESPEN</i> , 2021, 42, 105-116. | 0.5 | 15 |
| 5388 | Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study. <i>BMC Cancer</i> , 2021, 21, 647. | 1.1 | 7 |
| 5389 | Shared decision making with breast cancer patients: impact on patient engagement and fear of recurrence. Protocol for a Danish randomized trial in radiotherapy (DBCG RT SDM). <i>Acta OncolÃ³gica</i> , 2021, 60, 1032-1037. | 0.8 | 6 |
| 5390 | Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study. <i>Cancers</i> , 2021, 13, 2254. | 1.7 | 9 |
| 5391 | Impact of timing of adjuvant chemotherapy for early breast cancer: the Royal Marsden Hospital experience. <i>British Journal of Cancer</i> , 2021, 125, 299-304. | 2.9 | 2 |
| 5392 | What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?. <i>Current Opinion in Oncology</i> , 2021, 33, 329-335. | 1.1 | 3 |
| 5393 | Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. The Cochrane Library, 2021, 2021, CD011220. | 1.5 | 8 |
| 5394 | Cancer Progress and Priorities: Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 822-844. | 1.1 | 47 |
| 5395 | MicroRNAs as therapeutic targets in breast cancer metastasis. <i>Drug Delivery and Translational Research</i> , 2022, 12, 1029-1046. | 3.0 | 6 |
| 5396 | Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?. <i>Cancers</i> , 2021, 13, 2506. | 1.7 | 17 |
| 5397 | Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1803-1822. | 0.9 | 24 |
| 5399 | Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands. <i>Value in Health</i> , 2021, 24, 668-675. | 0.1 | 4 |
| 5400 | Cell lineage tracing links ER \pm loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 3.3 | 6 |
| 5401 | NR4A1 Ligands as Potent Inhibitors of Breast Cancer Cell and Tumor Growth. <i>Cancers</i> , 2021, 13, 2682. | 1.7 | 15 |
| 5402 | Analysis of Increased EGFR and IGF-1R Signaling and Its Correlation with Socio-Epidemiological Features and Biological Profile in Breast Cancer Patients: A Study in Northern Brazil. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 325-339. | 1.0 | 1 |
| 5403 | Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 904-909. | 1.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5404 | A comparison of breast cancer survival across different age groups: a multicentric database study in Penang, Malaysia. <i>Epidemiology and Health</i> , 2021, 43, e2021038. | 0.8 | 11 |
| 5405 | Breast surgery for young women with early-stage breast cancer. <i>Medicine (United States)</i> , 2021, 100, e25880. | 0.4 | 11 |
| 5406 | Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform. <i>BMC Cancer</i> , 2021, 21, 487. | 1.1 | 2 |
| 5407 | Deep Learning for the Detection of Breast Cancers on Chest Computed Tomography. <i>Clinical Breast Cancer</i> , 2022, 22, 26-31. | 1.1 | 13 |
| 5408 | Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1039-1049. | 0.8 | 11 |
| 5409 | Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 159-170. | 1.3 | 41 |
| 5410 | Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e47-e61. | 1.8 | 12 |
| 5411 | Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3611-3624. | 1.0 | 1 |
| 5412 | Are NCCN Resource-Stratified Guidelines for Breast Cancer Systemic Therapy Achievable? A Population-Based Study of Global Need and Economic Impact. <i>JCO Global Oncology</i> , 2021, 7, 1074-1083. | 0.8 | 3 |
| 5413 | Deep inspiration breath-hold for patients with left-sided breast cancer – A one-fits-all approach? A prospective analysis of patient selection using dosimetrical and practical aspects. <i>British Journal of Radiology</i> , 2022, 95, 20210295. | 1.0 | 4 |
| 5414 | Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. <i>JCO Oncology Practice</i> , 2021, 17, 305-313. | 1.4 | 62 |
| 5415 | Perceptions of Endocrine Therapy in African-American Breast Cancer Survivors: Mixed Methods Study. <i>JMIR Formative Research</i> , 2021, 5, e23884. | 0.7 | 5 |
| 5416 | Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 383-392. | 1.0 | 5 |
| 5417 | Using data mining technology to predict medication-taking behaviour in women with breast cancer: A retrospective study. <i>Nursing Open</i> , 2021, , . | 1.1 | 2 |
| 5418 | Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience. <i>Cancer Investigation</i> , 2021, 39, 473-481. | 0.6 | 9 |
| 5419 | Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2021, 7, 77. | 2.3 | 16 |
| 5420 | Successful Stabilization of Symptomatic Bone Marrow Metastasis Two Times in a Breast Cancer Patient. <i>Anticancer Research</i> , 2021, 41, 3139-3144. | 0.5 | 5 |
| 5421 | Maintenance of Muscle Mass and Cardiorespiratory Fitness to Cancer Patients During COVID-19 Era and After SARS-CoV-2 Vaccine. <i>Frontiers in Physiology</i> , 2021, 12, 655955. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5422 | Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e000082. | 1.6 | 55 |
| 5423 | Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites. <i>Journal of Personalized Medicine</i> , 2021, 11, 507. | 1.1 | 4 |
| 5424 | Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e794-e808. | 1.4 | 5 |
| 5425 | YAP, CTGF and Cyr61 are overexpressed in tamoxifen-resistant breast cancer and induce transcriptional repression of ER α . <i>Journal of Cell Science</i> , 2021, 134, . | 1.2 | 18 |
| 5426 | Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 399-410. | 1.1 | 5 |
| 5427 | Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e147-e156. | 1.1 | 1 |
| 5428 | Bilateral Breast Carcinoma In Visceral Crisis. <i>Revista De La Facultad De Medicina Humana</i> , 2021, 21, 646-653. | 0.1 | 1 |
| 5429 | NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer. <i>Cells</i> , 2021, 10, 1633. | 1.8 | 7 |
| 5430 | The prognostic value of cyclin D1 in breast cancer patients treated with hormonal therapy: A pilot study. <i>Pathology Research and Practice</i> , 2021, 222, 153430. | 1.0 | 1 |
| 5431 | Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 11, 100158. | 1.3 | 9 |
| 5432 | Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. <i>Breast</i> , 2021, 57, 43-48. | 0.9 | 2 |
| 5433 | Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study. <i>Npj Breast Cancer</i> , 2021, 7, 71. | 2.3 | 10 |
| 5434 | Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1506-1514. | 3.0 | 6 |
| 5435 | Extending Adjuvant Endocrine Therapy for 10 Years: A Mixed-Methods Analysis of Women's Decision Making in an Online Breast Cancer Forum. <i>Healthcare (Switzerland)</i> , 2021, 9, 688. | 1.0 | 4 |
| 5436 | Adoption and effectiveness of de-escalated radiation and endocrine therapy strategies for older women with low-risk breast cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 731-740. | 0.5 | 2 |
| 5437 | Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea. <i>Frontiers in Oncology</i> , 2021, 11, 691277. | 1.3 | 4 |
| 5438 | In Vitro and In Silico Determination of Some N-ferrocenylmethylamine Derivatives as Anti-Proliferative Agents Against MCF-7 Human Breast Cancer Cell Lines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1426-1437. | 0.9 | 2 |
| 5439 | The rate of estrogen receptor α -conversion associated with tumor progression in estrogen receptor α -positive breast cancer patients following adjuvant Tamoxifen administration. <i>Cancer Reports</i> , 2021, , e1431. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5440 | A case of tamoxifen-induced hypertriglyceridemia monitoring the changes in lipoprotein fractions over time. <i>BMC Endocrine Disorders</i> , 2021, 21, 115. | 0.9 | 5 |
| 5441 | Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer. <i>BMC Cancer</i> , 2021, 21, 707. | 1.1 | 1 |
| 5442 | The effect of IL-1 β on MRP2 expression and tamoxifen toxicity in MCF-7 breast cancer cells. <i>Breast Disease</i> , 2021, 40, 1-6. | 0.4 | 2 |
| 5443 | Patients With Invasive Breast Cancer Who Refuse Treatment: An Analysis of Associated Factors and Impact on Survival. <i>American Surgeon</i> , 2021, 87, 1627-1632. | 0.4 | 6 |
| 5444 | Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. <i>Nature Cancer</i> , 2021, 2, 658-671. | 5.7 | 34 |
| 5445 | Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30. <i>Future Oncology</i> , 2021, 17, 2183-2192. | 1.1 | 1 |
| 5446 | Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer. <i>Cancer Cell International</i> , 2021, 21, 306. | 1.8 | 4 |
| 5447 | Evaluation of whether adjuvant chemotherapy can be safely omitted for older female patients with ER-positive, HER2-negative N1 breast cancer: a study based on the SEER database. <i>Annals of Translational Medicine</i> , 2021, 9, 1082-1082. | 0.7 | 2 |
| 5448 | Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy. <i>Life Sciences</i> , 2021, 276, 119392. | 2.0 | 7 |
| 5449 | Racial/ethnic differences in health-related quality of life among female breast cancer survivors: cross-sectional findings from the Medical Expenditure Panel Survey. <i>Public Health</i> , 2021, 196, 74-81. | 1.4 | 3 |
| 5450 | From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells. <i>Cancers</i> , 2021, 13, 3688. | 1.7 | 8 |
| 5451 | Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates. <i>Npj Breast Cancer</i> , 2021, 7, 85. | 2.3 | 8 |
| 5452 | Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 98, 102222. | 3.4 | 21 |
| 5453 | Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7840. | 1.8 | 15 |
| 5454 | Cancer-related vulnerable lesions in patients with stable coronary artery disease. <i>International Journal of Cardiology</i> , 2021, 335, 1-6. | 0.8 | 3 |
| 5455 | Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 638619. | 1.3 | 9 |
| 5456 | Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258. | 0.8 | 4 |
| 5457 | Protective Effect of Polysaccharides Extracted from <i>Cudrania tricuspidata</i> Fruit against Cisplatin-Induced Cytotoxicity in Macrophages and a Mouse Model. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7512. | 1.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5458 | Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. <i>Frontiers in Oncology</i> , 2021, 11, 645026. | 1.3 | 4 |
| 5459 | European trends in breast cancer mortality, 1980–2017 and predictions to 2025. <i>European Journal of Cancer</i> , 2021, 152, 4-17. | 1.3 | 43 |
| 5460 | Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 807-815. | 1.1 | 0 |
| 5461 | Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 3612. | 1.7 | 4 |
| 5462 | Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture. <i>Molecular Oncology</i> , 2022, 16, 921-939. | 2.1 | 10 |
| 5463 | ATF3 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an <i>N</i> ⁶ -Methyladenosine-Based Epitranscriptomic Mechanism. <i>Chemical Research in Toxicology</i> , 2021, 34, 1814-1821. | 1.7 | 17 |
| 5464 | Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 704. | 1.1 | 9 |
| 5465 | Breast Cancer Mortality in the Americas and Australasia over the Period 1980–2017 with Predictions for 2025. <i>Biology</i> , 2021, 10, 814. | 1.3 | 4 |
| 5466 | Machine Learning to Predict Tamoxifen Nonadherence Among US Commercially Insured Patients With Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 814-825. | 1.0 | 8 |
| 5467 | Case Report: Young Adults With Breast Cancer: A Case Series of Fertility Preservation Management and Literature Review. <i>Frontiers in Medicine</i> , 2021, 8, 670872. | 1.2 | 5 |
| 5468 | Integrated printed BDNF/collagen/chitosan scaffolds with low temperature extrusion 3D printer accelerated neural regeneration after spinal cord injury. <i>International Journal of Energy Production and Management</i> , 2021, 8, rbab047. | 1.9 | 24 |
| 5469 | Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies. <i>Aging</i> , 2021, 13, 19835-19866. | 1.4 | 4 |
| 5470 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, 86. | 2.2 | 7 |
| 5471 | Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. <i>Cancers</i> , 2021, 13, 4287. | 1.7 | 441 |
| 5472 | Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk. <i>Cancers</i> , 2021, 13, 4003. | 1.7 | 2 |
| 5473 | Self-preparation system using glucose oxidase-inspired nitroreductase amplification for cascade-responsive drug release and multidrug resistance reversion. <i>Biomaterials</i> , 2021, 275, 120927. | 5.7 | 23 |
| 5474 | Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 58, 113-120. | 0.9 | 28 |
| 5475 | Effect of estrogen in malignant melanoma. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 1905-1912. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5477 | Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2452-2462. | 0.8 | 16 |
| 5478 | Transcriptomic Profiling Reveals Novel Candidate Genes and Signalling Programs in Breast Cancer Quiescence and Dormancy. <i>Cancers</i> , 2021, 13, 3922. | 1.7 | 5 |
| 5479 | Breast Cancer Heterogeneity. <i>Diagnostics</i> , 2021, 11, 1555. | 1.3 | 19 |
| 5480 | Competing nomogram for late-period breast cancer-specific death in patients with early-stage hormone receptor-positive breast cancer. <i>Clinical Breast Cancer</i> , 2021, , . | 1.1 | 2 |
| 5481 | Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer. <i>Medicine (United States)</i> , 2021, 100, e26949. | 0.4 | 2 |
| 5482 | Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis. <i>Cancer Management and Research</i> , 2021, Volume 13, 6279-6289. | 0.9 | 3 |
| 5483 | Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research. <i>American Journal of Human Biology</i> , 2022, 34, e23665. | 0.8 | 4 |
| 5484 | Predicting Nonsentinel Lymph Node Metastasis in Breast Cancer: A Multicenter Retrospective Study. <i>Journal of Surgical Research</i> , 2021, 264, 45-50. | 0.8 | 4 |
| 5485 | Aromatase Inhibitor-induced Musculoskeletal Syndrome: a Review of Rehabilitation Interventions. <i>Current Physical Medicine and Rehabilitation Reports</i> , 2021, 9, 119-126. | 0.3 | 2 |
| 5486 | Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy. <i>Current Opinion in Oncology</i> , 2021, 33, 553-573. | 1.1 | 11 |
| 5487 | Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13~864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150. | 5.1 | 147 |
| 5488 | Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. <i>Annals of Oncology</i> , 2021, 32, 1410-1424. | 0.6 | 34 |
| 5489 | Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation. <i>Npj Breast Cancer</i> , 2021, 7, 104. | 2.3 | 26 |
| 5490 | Radiomics of MRI for the Prediction of the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Single Referral Centre Analysis. <i>Cancers</i> , 2021, 13, 4271. | 1.7 | 18 |
| 5491 | New enzyme-targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer. <i>Molecular and Clinical Oncology</i> , 2021, 15, 241. | 0.4 | 5 |
| 5492 | Network-based approach to identify prognosis-related genes in tamoxifen-treated patients with estrogen receptor-positive breast cancer. <i>Bioscience Reports</i> , 2021, 41, . | 1.1 | 4 |
| 5493 | Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance. <i>Clinical Epigenetics</i> , 2021, 13, 175. | 1.8 | 10 |
| 5494 | Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2051-2061. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5495 | Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 451-462. | 1.1 | 1 |
| 5496 | Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. <i>Cancers</i> , 2021, 13, 4455. | 1.7 | 73 |
| 5497 | Human estrogen receptor β antagonists, part 2: Synthesis driven by rational design, in vitro antiproliferative, and in vivo anticancer evaluation of innovative coumarin-related antiestrogens as breast cancer suppressants. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113869. | 2.6 | 6 |
| 5498 | Case series, Chemotherapy-induced cardiomyopathy: mind the family history!. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab333. | 0.3 | 4 |
| 5499 | Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust. <i>Annals of Oncology</i> , 2021, 32, 1077-1082. | 0.6 | 13 |
| 5500 | Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis. <i>International Journal of Breast Cancer</i> , 2021, 2021, 1-5. | 0.6 | 0 |
| 5501 | Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study. <i>Breast Cancer Research</i> , 2021, 23, 94. | 2.2 | 4 |
| 5502 | MLL3 is a de novo cause of endocrine therapy resistance. <i>Cancer Medicine</i> , 2021, 10, 7692-7711. | 1.3 | 6 |
| 5503 | Molecular Pathology of Breast Tumors. <i>Surgical Pathology Clinics</i> , 2021, 14, 455-471. | 0.7 | 2 |
| 5504 | Perturbations of Adjuvant Chemotherapy on Cardiovascular Responses and Exercise Tolerance in Patients with Early-Stage Breast Cancer. <i>Biology</i> , 2021, 10, 910. | 1.3 | 0 |
| 5505 | Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. <i>Frontiers in Oncology</i> , 2021, 11, 700722. | 1.3 | 12 |
| 5506 | Influential factors in Black and White breast cancer survivors' beliefs about breast cancer. <i>Psycho-Oncology</i> , 2021, , . | 1.0 | 0 |
| 5507 | <i>In Silico</i> Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study. <i>Molecular Informatics</i> , 2022, 41, e2060039. | 1.4 | 21 |
| 5508 | High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 127. | 2.3 | 9 |
| 5510 | Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 653-663. | 1.1 | 10 |
| 5511 | BreastSurgANZ members recommendations for adjuvant systemic treatment and patient compliance in Australian breast cancer patients. <i>ANZ Journal of Surgery</i> , 2021, 91, 2418-2424. | 0.3 | 0 |
| 5512 | Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells. <i>Cells</i> , 2021, 10, 2398. | 1.8 | 8 |
| 5513 | Metabolic reprogramming confers tamoxifen resistance in breast cancer. <i>Chemico-Biological Interactions</i> , 2021, 347, 109602. | 1.7 | 27 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5514 | Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries. <i>Frontiers in Oncology</i> , 2021, 11, 693689. | 1.3 | 6 |
| 5515 | Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives. <i>Obesity Reviews</i> , 2022, 23, e13358. | 3.1 | 20 |
| 5516 | CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial. <i>Annals of Oncology</i> , 2021, 32, 1286-1293. | 0.6 | 10 |
| 5517 | Systemic therapy for older patients with early breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 100, 102292. | 3.4 | 5 |
| 5518 | Breast Cancer in Women Over 65 years- a Review of Screening and Treatment Options. <i>Clinics in Geriatric Medicine</i> , 2021, 37, 611-623. | 1.0 | 8 |
| 5519 | The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. <i>Clinica Chimica Acta</i> , 2021, 523, 19-25. | 0.5 | 19 |
| 5520 | Bispecific antibodies: A promising entrant in cancer immunotherapy. , 2021, , 233-266. | | 2 |
| 5521 | Hormone Receptors and Endocrine Therapy in Breast Cancer. , 2021, , 149-186. | | 1 |
| 5522 | Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy. <i>Annals of Surgical Treatment and Research</i> , 2021, 100, 59. | 0.4 | 2 |
| 5523 | Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. <i>Breast Cancer Research</i> , 2021, 23, 16. | 2.2 | 2 |
| 5524 | Serine synthesis influences tamoxifen response in ER+ human breast carcinoma. <i>Endocrine-Related Cancer</i> , 2021, 28, 27-37. | 1.6 | 9 |
| 5525 | Osteolytic effects of tumoral estrogen signaling in an estrogen receptor-positive breast cancer bone metastasis model. , 2021, 7, . | | 3 |
| 5526 | Current Stimuli-Responsive Mesoporous Silica Nanoparticles for Cancer Therapy. <i>Pharmaceutics</i> , 2021, 13, 71. | 2.0 | 37 |
| 5527 | Ppm1b Negatively Regulates 3-Bromopyruvate Induced Necroptosis in Breast Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 555546. | 1.3 | 1 |
| 5529 | Integration of Radiation Therapy and Systemic Therapy for Breast Cancer. , 2006, , 251-265. | | 2 |
| 5530 | Hormone Resistance. <i>Cancer Treatment and Research</i> , 2009, 147, 1-33. | 0.2 | 2 |
| 5531 | Response and Resistance to the Endocrine Prevention of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 617, 201-211. | 0.8 | 10 |
| 5532 | Advances in Adjuvant Chemotherapy of Early Stage Breast Cancer. <i>Cancer Treatment and Research</i> , 2008, 141, 37-53. | 0.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5533 | Overview of Randomized Trials of Systemic Adjuvant Therapy. <i>Cancer Treatment and Research</i> , 2008, 141, 55-62. | 0.2 | 4 |
| 5534 | Adjuvant Hormonal Therapy for Early-Stage Breast Cancer. <i>Cancer Treatment and Research</i> , 2008, 141, 63-78. | 0.2 | 1 |
| 5535 | Postoperative Endocrine Therapy for Invasive Breast Cancer. <i>Cancer Treatment and Research</i> , 2009, 151, 139-161. | 0.2 | 4 |
| 5536 | Special Populations: Elderly Patients. <i>Cancer Treatment and Research</i> , 2009, 151, 299-315. | 0.2 | 2 |
| 5537 | Adjuvant Chemotherapy. <i>Cancer Treatment and Research</i> , 2009, 151, 121-137. | 0.2 | 2 |
| 5538 | Principles of Breast Cancer Therapy. , 2010, , 371-388. | | 4 |
| 5539 | Epidemiology of Cancer Recurrence, Second Primary Cancer, and Comorbidity Among Cancer Survivors. , 2011, , 277-297. | | 4 |
| 5540 | Hematopoietic Growth Factors in Older Cancer Patients. <i>Cancer Treatment and Research</i> , 2010, 157, 383-402. | 0.2 | 4 |
| 5541 | Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective. , 2012, , 197-250. | | 2 |
| 5542 | Epidemiology of Multiple Primary Cancers. <i>Methods in Molecular Biology</i> , 2009, 471, 85-105. | 0.4 | 73 |
| 5543 | Clinical Importance of Prognostic Factors. , 2008, , 27-41. | | 2 |
| 5545 | Traitement mÃ©dical du cancer du sein mÃ©tastatique. , 2007, , 205-237. | | 3 |
| 5546 | Modeling Prolactin Actions in Breast Cancer In Vivo: Insights from the NRL-PRL Mouse. <i>Advances in Experimental Medicine and Biology</i> , 2015, 846, 201-220. | 0.8 | 21 |
| 5547 | Prognostic and Predictive Factors of Invasive Breast Cancer. , 2016, , 187-206. | | 1 |
| 5548 | Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing. , 2016, , 161-185. | | 1 |
| 5549 | Molecular Profiling in Breast Cancer. , 2006, , 977-1006. | | 1 |
| 5550 | Mammakarzinom. , 0, , 1119-1183. | | 1 |
| 5551 | The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition. , 2007, 172, 99-124. | | 33 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5552 | Inflammatory and Locally Advanced Breast Cancer. , 2010, , 391-415. | | 1 |
| 5554 | Onkologika. , 2014, , 821-860. | | 1 |
| 5555 | Onkologika. , 2016, , 583-619. | | 1 |
| 5556 | Onkologika. , 2017, , 597-639. | | 1 |
| 5557 | Maligne Tumoren der Mamma. , 2019, , 1-31. | | 1 |
| 5559 | Circulating Nucleosomes and DNase in Breast Cancer Patients During Neoadjuvant Chemotherapy. , 2010, , 85-89. | | 1 |
| 5560 | Mortality Affected by Health Care and Public Health Policy Interventions. International Handbooks of Population, 2011, , 583-607. | 0.2 | 7 |
| 5562 | Immunohistochemistry and Molecular Biology of Breast Cancers: Old and New Prognostic Factors. , 2011, , 119-148. | | 5 |
| 5563 | Patientsâ€™ perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict. Breast Cancer Research and Treatment, 2020, 182, 107-115. | 1.1 | 2 |
| 5564 | Real-world evaluation of effectiveness and tolerance of chemotherapy for early-stage breast cancer in older women. Breast Cancer Research and Treatment, 2020, 182, 247-258. | 1.1 | 11 |
| 5565 | Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. , 2008, , 1307-1366. | | 7 |
| 5567 | Infiltrating Carcinomas of the Breast. , 2009, , 231-247. | | 3 |
| 5569 | Predictive and Prognostic Marker Testing in Breast Pathology: Immunophenotypic Subclasses of Disease. , 2012, , 151-172. | | 1 |
| 5570 | Diseases of the Breast. , 2012, , 824-869. | | 5 |
| 5571 | Breast Cancer Biomarkers. , 2011, , 306-316. | | 1 |
| 5572 | Cancer of the Lung. , 2014, , 1143-1192.e13. | | 5 |
| 5574 | Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England. Journal of Geriatric Oncology, 2020, 11, 836-842. | 0.5 | 7 |
| 5576 | Functional Nanocarriers for Drug Delivery by Surface Engineering of Polymeric Nanoparticle Post-Polymerization-Induced Self-Assembly. ACS Applied Bio Materials, 2021, 4, 1045-1056. | 2.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5580 | Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 307-321. | 1.5 | 7 |
| 5581 | Combining results from several studies: systematic review and meta-analysis. , 2007, , 281-322. | | 1 |
| 5582 | Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 760-769. | 3.0 | 45 |
| 5583 | Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819. | 3.0 | 319 |
| 5584 | High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance. <i>Anti-Cancer Drugs</i> , 2020, 31, 558-566. | 0.7 | 13 |
| 5585 | Effect of Radiation Therapy on Microsurgical Deep Inferior Epigastric Perforator Flap Breast Reconstructions. <i>Annals of Plastic Surgery</i> , 2021, 86, 627-631. | 0.5 | 9 |
| 5589 | Extracellular vesicle long non-coding RNA-mediated crosstalk in the tumor microenvironment: Tiny molecules, huge roles. <i>Cancer Science</i> , 2020, 111, 2726-2735. | 1.7 | 31 |
| 5590 | New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target?. <i>Apmis</i> , 2008, 116, 552-568. | 0.9 | 21 |
| 5591 | A systematic review of the effectiveness of secondary prevention lifestyle interventions designed to change lifestyle behaviour following stroke. <i>JB Database of Systematic Reviews and Implementation Reports</i> , 2011, 9, 1782-1827. | 1.7 | 6 |
| 5592 | Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors. <i>Journal of Biomedical Optics</i> , 2017, 22, 1. | 1.4 | 16 |
| 5593 | Management of breast cancer--Part I. <i>BMJ: British Medical Journal</i> , 2008, 337, a421-a421. | 2.4 | 12 |
| 5594 | Management of breast cancer--Part II. <i>BMJ: British Medical Journal</i> , 2008, 337, a540-a540. | 2.4 | 10 |
| 5595 | TOP2A, TIMP-1 and responsiveness to adjuvant anthracycline containing chemotherapy in high risk breast cancer patients.. , 2009, , . | | 5 |
| 5596 | Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women. <i>Clinical Cancer Research</i> , 2021, 27, 1421-1428. | 3.2 | 19 |
| 5597 | Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer. <i>Singapore Medical Journal</i> , 2017, 58, 145-149. | 0.3 | 20 |
| 5598 | Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 5603-5619. | 3.9 | 39 |
| 5599 | Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. <i>Journal of Clinical Investigation</i> , 2018, 128, 1355-1370. | 3.9 | 123 |
| 5600 | Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097560. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5601 | Metastatic Breast Cancer Epidemiology and Management With a Focus on Taxanes. <i>Clinical Journal of Oncology Nursing</i> , 2013, 17, 5-8. | 0.3 | 4 |
| 5602 | Genomic Alteration in Metastatic Breast Cancer and Its Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 30-43. | 1.8 | 107 |
| 5603 | ARTEMIS: Randomized trial with neoadjuvant chemotherapy for patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS1144-TPS1144. | 0.8 | 2 |
| 5604 | MammaPrint® Translating Research into a Diagnostic Test. , 2010, , 165-184. | | 3 |
| 5605 | - Computational Regulomics: Information Theoretic Approaches toward Regulatory Network Inference. , 2013, , 248-267. | | 1 |
| 5606 | Invasive Mucinous Carcinoma Arising in Ectopic Axillary Breast Tissue: A Case Report and Literature Review. <i>American Journal of Case Reports</i> , 2015, 16, 153-159. | 0.3 | 14 |
| 5607 | Sweetâ€™s Syndrome Induced by Aromatase Inhibitor in the Treatment of Early Breast Cancer. <i>European Journal of Case Reports in Internal Medicine</i> , 2019, 7, 001435. | 0.2 | 4 |
| 5608 | CYP2D6 testing to predict response to tamoxifen in women with breast cancerPharmacogenomic. <i>PLOS Currents</i> , 2010, 2, RRN1176. | 1.4 | 9 |
| 5609 | Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. <i>PLoS Genetics</i> , 2017, 13, e1006589. | 1.5 | 53 |
| 5610 | Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the â€œBasalâ€•Breast Cancer Subgroup. <i>PLoS ONE</i> , 2009, 4, e4710. | 1.1 | 88 |
| 5611 | Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and Validation. <i>PLoS ONE</i> , 2010, 5, e15649. | 1.1 | 4 |
| 5612 | Proteomic Analysis of Pathways Involved in Estrogen-Induced Growth and Apoptosis of Breast Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e20410. | 1.1 | 28 |
| 5613 | Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials. <i>PLoS ONE</i> , 2011, 6, e21030. | 1.1 | 149 |
| 5614 | Adjuvant Chemotherapy, with or without Taxanes, in Early or Operable Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698 Patients. <i>PLoS ONE</i> , 2011, 6, e26946. | 1.1 | 54 |
| 5615 | The Risk of Amenorrhea Is Related to Chemotherapy-Induced Leucopenia in Breast Cancer Patients Receiving Epirubicin and Taxane Based Chemotherapy. <i>PLoS ONE</i> , 2012, 7, e37249. | 1.1 | 17 |
| 5616 | How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists. <i>PLoS ONE</i> , 2012, 7, e37379. | 1.1 | 175 |
| 5617 | NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e38783. | 1.1 | 85 |
| 5618 | Engaging in Health Behaviors to Lower Risk for Breast Cancer Recurrence. <i>PLoS ONE</i> , 2013, 8, e53607. | 1.1 | 32 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5619 | The Prolyl Isomerase Pin1 Acts Synergistically with CDK2 to Regulate the Basal Activity of Estrogen Receptor $\hat{\pm}$ in Breast Cancer. PLoS ONE, 2013, 8, e55355. | 1.1 | 22 |
| 5620 | Biomarkers of Residual Disease, Disseminated Tumor Cells, and Metastases in the MMTV-PyMT Breast Cancer Model. PLoS ONE, 2013, 8, e58183. | 1.1 | 35 |
| 5621 | Reduced Androgen Receptor Expression Accelerates the Onset of ERBB2 Induced Breast Tumors in Female Mice. PLoS ONE, 2013, 8, e60455. | 1.1 | 11 |
| 5622 | What Can Be Learnt about Disease Progression in Breast Cancer Dormancy from Relapse Data?. PLoS ONE, 2013, 8, e62320. | 1.1 | 12 |
| 5623 | The Difference in Prognostic Factors between Early Recurrence and Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Nodal Stage Differently Impacts Early and Late Recurrence. PLoS ONE, 2013, 8, e63510. | 1.1 | 25 |
| 5624 | Tamoxifen and Ovarian Function. PLoS ONE, 2013, 8, e66616. | 1.1 | 26 |
| 5625 | Enhancement of Natural Killer Cell Cytotoxicity by Sodium/Iodide Symporter Gene-Mediated Radioiodine Pretreatment in Breast Cancer Cells. PLoS ONE, 2013, 8, e70194. | 1.1 | 16 |
| 5626 | Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG). PLoS ONE, 2013, 8, e70634. | 1.1 | 15 |
| 5627 | The Prognostic Significance of Wnt-5a Expression in Primary Breast Cancer Is Extended to Premenopausal Women. PLoS ONE, 2013, 8, e70890. | 1.1 | 7 |
| 5628 | Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen through Activation of Akt/mTOR Signaling. PLoS ONE, 2013, 8, e72053. | 1.1 | 36 |
| 5629 | Heterogeneity of Estrogen Receptor Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients. PLoS ONE, 2013, 8, e75038. | 1.1 | 114 |
| 5630 | Complementary or Alternative Medicine as Possible Determinant of Decreased Persistence to Aromatase Inhibitor Therapy among Older Women with Non-Metastatic Breast Cancer. PLoS ONE, 2013, 8, e81677. | 1.1 | 23 |
| 5631 | Post-Mastectomy Radiotherapy for Breast Cancer Patients with T1-T2 and 1-3 Positive Lymph Nodes: a Meta-Analysis. PLoS ONE, 2013, 8, e81765. | 1.1 | 33 |
| 5632 | The Impact of Androgen Receptor Expression on Breast Cancer Survival: A Retrospective Study and Meta-Analysis. PLoS ONE, 2013, 8, e82650. | 1.1 | 104 |
| 5633 | CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance. PLoS ONE, 2014, 9, e91771. | 1.1 | 109 |
| 5634 | Outcomes of Ethnic Minority Groups with Node-Positive, Non-Metastatic Breast Cancer in Two Tertiary Referral Centers in Sydney, Australia. PLoS ONE, 2014, 9, e95852. | 1.1 | 5 |
| 5635 | Integration of Molecular Profiling and Chemical Imaging to Elucidate Fibroblast-Microenvironment Impact on Cancer Cell Phenotype and Endocrine Resistance in Breast Cancer. PLoS ONE, 2014, 9, e96878. | 1.1 | 36 |
| 5636 | A Nation-Wide Multicenter 10-Year (1999-2008) Retrospective Clinical Study of Endocrine Therapy for Chinese Females with Breast Cancer. PLoS ONE, 2014, 9, e100159. | 1.1 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5637 | Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. PLoS ONE, 2014, 9, e107643. | 1.1 | 17 |
| 5638 | Survival after Locoregional Recurrence or Second Primary Breast Cancer: Impact of the Disease-Free Interval. PLoS ONE, 2015, 10, e0120832. | 1.1 | 39 |
| 5639 | Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population. PLoS ONE, 2015, 10, e0132853. | 1.1 | 44 |
| 5640 | Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials. PLoS ONE, 2015, 10, e0133569. | 1.1 | 95 |
| 5641 | Comparison of Clinicopathological Features and Treatments between Young (≤ 40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, Case Only Study. PLoS ONE, 2016, 11, e0152312. | 1.1 | 36 |
| 5642 | Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients. PLoS ONE, 2016, 11, e0154386. | 1.1 | 5 |
| 5643 | Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2016, 11, e0164663. | 1.1 | 11 |
| 5644 | Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study. PLoS ONE, 2016, 11, e0168730. | 1.1 | 16 |
| 5645 | Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. PLoS ONE, 2017, 12, e0170536. | 1.1 | 8 |
| 5646 | Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients. PLoS ONE, 2017, 12, e0171453. | 1.1 | 6 |
| 5647 | Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. PLoS ONE, 2017, 12, e0172351. | 1.1 | 10 |
| 5648 | Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer. PLoS ONE, 2017, 12, e0183452. | 1.1 | 11 |
| 5649 | Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay. PLoS ONE, 2017, 12, e0187679. | 1.1 | 3 |
| 5650 | Perspectives of pharmacogenetics approach to personalized tamoxifen therapy. World Journal of Personalized Medicine, 2017, 1, 27-35. | 0.3 | 5 |
| 5651 | Fertility Preservation in Breast Cancer. Southern Medical Journal, 2017, 110, 621-626. | 0.3 | 6 |
| 5652 | Why Hasn't Genomic Testing Changed the Landscape in Clinical Oncology?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e52-e55. | 1.8 | 9 |
| 5653 | Competing Risks in Low-Risk Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 32-39. | 1.8 | 3 |
| 5654 | Optimal Management of the Premenopausal Patient with Estrogen Receptor-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e12-e15. | 1.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5655 | Systemic Immune Activation and Peripheral Blood Lymphocytes during Primary Chemotherapy with the Combination of Doxorubicin and Paclitaxel in Patients with Breast Carcinoma. <i>Pteridines</i> , 2007, 18, 25-34. | 0.5 | 4 |
| 5656 | Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem. <i>Discoveries</i> , 2019, 7, e89. | 1.5 | 17 |
| 5657 | An Analytical Validation of the GenesWell™ BCT Multigene Prognostic Test in Patients with Early Breast Cancer. <i>Korean Journal of Clinical Laboratory Science</i> , 2017, 49, 79-87. | 0.1 | 2 |
| 5659 | Disseminated tumor cells of luminal breast cancer patients .. , 2018, 17, 53-57. | 0.3 | 12 |
| 5660 | Use of Guarana for Hot Flashes after Breast Cancer: Randomized, Double-Blind, Placebo-Controlled Phase II Trial. <i>Journal of Natural Remedies</i> , 2019, 19, 1-11. | 0.1 | 1 |
| 5661 | Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. <i>Aging</i> , 2020, 12, 20658-20683. | 1.4 | 26 |
| 5662 | Prolactin signaling through focal adhesion complexes is amplified by stiff extracellular matrices in breast cancer cells. <i>Oncotarget</i> , 2016, 7, 48093-48106. | 0.8 | 20 |
| 5663 | Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via downregulation of the epidermal growth factor receptor. <i>Oncotarget</i> , 2016, 7, 59809-59819. | 0.8 | 19 |
| 5664 | Influence of wound fluid on chemotherapy sensitivity in primary breast cancer cells. <i>Oncotarget</i> , 2016, 7, 65034-65041. | 0.8 | 5 |
| 5665 | Identification of breast cancer recurrence risk factors based on functional pathways in tumor and normal tissues. <i>Oncotarget</i> , 2017, 8, 20679-20694. | 0.8 | 12 |
| 5666 | Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. <i>Oncotarget</i> , 2016, 7, 79428-79441. | 0.8 | 11 |
| 5667 | Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. <i>Oncotarget</i> , 2016, 7, 79828-79841. | 0.8 | 53 |
| 5668 | Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells. <i>Oncotarget</i> , 2016, 7, 81123-81143. | 0.8 | 23 |
| 5669 | Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies. <i>Oncotarget</i> , 2017, 8, 5578-5591. | 0.8 | 39 |
| 5670 | The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients. <i>Oncotarget</i> , 2017, 8, 11372-11379. | 0.8 | 18 |
| 5671 | Polymorphisms of <i>ESR1</i> , <i>UGT1A1</i> , <i>HCN1</i> , <i>MAP3K1</i> and <i>CYP2B6</i> are associated with the prognosis of hormone receptor-positive early breast cancer. <i>Oncotarget</i> , 2017, 8, 20925-20938. | 0.8 | 39 |
| 5672 | A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients. <i>Oncotarget</i> , 2017, 8, 75864-75873. | 0.8 | 6 |
| 5673 | Impact of persistence on survival of patients with breast cancer treated with endocrine therapy in Northeast China: a prospective study. <i>Oncotarget</i> , 2017, 8, 102499-102510. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5674 | Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers. <i>Oncotarget</i> , 2017, 8, 63405-63416. | 0.8 | 8 |
| 5675 | Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. <i>Oncotarget</i> , 2014, 5, 9049-9064. | 0.8 | 20 |
| 5676 | Evaluating the benefits and adverse effects of an anthracycline-taxane-capecitabine combined regimen in patients with early breast cancer. <i>Oncotarget</i> , 2017, 8, 81636-81648. | 0.8 | 2 |
| 5677 | Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival. <i>Oncotarget</i> , 2017, 8, 99978-99989. | 0.8 | 38 |
| 5678 | Nitric oxide is cytoprotective to breast cancer spheroids vulnerable to estrogen-induced apoptosis. <i>Oncotarget</i> , 2017, 8, 108890-108911. | 0.8 | 9 |
| 5679 | Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. <i>Oncotarget</i> , 2017, 8, 100296-100311. | 0.8 | 25 |
| 5680 | Co-ordination of cell cycle, migration and stem cell-like activity in breast cancer. <i>Oncotarget</i> , 2014, 5, 7833-7842. | 0.8 | 15 |
| 5681 | ER β alters the chemosensitivity of luminal breast cancer cells by regulating p53 function. <i>Oncotarget</i> , 2018, 9, 22509-22522. | 0.8 | 19 |
| 5682 | Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. <i>Oncotarget</i> , 2018, 9, 33912-33930. | 0.8 | 39 |
| 5683 | Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. <i>Oncotarget</i> , 2019, 10, 1209-1216. | 0.8 | 9 |
| 5684 | FKBPL: a marker of good prognosis in breast cancer. <i>Oncotarget</i> , 2015, 6, 12209-12223. | 0.8 | 13 |
| 5685 | Nuclear estrogen receptor- β expression is an independent predictor of recurrence in male patients with pT1aNO lung adenocarcinomas, and correlates with regulatory T-cell infiltration. <i>Oncotarget</i> , 2015, 6, 27505-27518. | 0.8 | 21 |
| 5686 | A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. <i>Oncotarget</i> , 2015, 6, 31693-31701. | 0.8 | 6 |
| 5687 | Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound. <i>Oncotarget</i> , 2015, 6, 43779-43790. | 0.8 | 31 |
| 5688 | Aberrantly upregulated TRAP1 is required for tumorigenesis of breast cancer. <i>Oncotarget</i> , 2015, 6, 44495-44508. | 0.8 | 49 |
| 5689 | Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer. <i>Oncotarget</i> , 2015, 6, 44593-44608. | 0.8 | 39 |
| 5690 | Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer. <i>Oncotarget</i> , 2016, 7, 3098-3110. | 0.8 | 26 |
| 5691 | Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells. <i>Oncotarget</i> , 2016, 7, 1984-1999. | 0.8 | 18 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5692 | Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells. <i>Oncotarget</i> , 2016, 7, 23772-23784. | 0.8 | 17 |
| 5693 | Prostate derived Ets transcription factor and Carcinoembryonic antigen related cell adhesion molecule 6 constitute a highly active oncogenic axis in breast cancer. <i>Oncotarget</i> , 2013, 4, 610-621. | 0.8 | 13 |
| 5694 | Targeting BET bromodomain proteins in solid tumors. <i>Oncotarget</i> , 2016, 7, 53997-54009. | 0.8 | 86 |
| 5695 | High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome. <i>Acta Medica Okayama</i> , 2013, 67, 369-75. | 0.1 | 13 |
| 5696 | Impact of the 21-gene recurrence score assay on chemotherapy decision making and outcomes for breast cancer patients with four or more positive lymph nodes. <i>Annals of Translational Medicine</i> , 2019, 7, 446-446. | 0.7 | 5 |
| 5697 | The role of radiation therapy and systemic therapies in elderly with breast cancer. <i>Translational Cancer Research</i> , 2020, 9, S97-S109. | 0.4 | 2 |
| 5698 | Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 327-339. | 0.7 | 3 |
| 5699 | Evaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 468-476. | 0.7 | 6 |
| 5700 | FACE: the barefaced facts of AI potency. <i>Cancer Management and Research</i> , 2010, 2, 267. | 0.9 | 4 |
| 5701 | Gold Nanoparticles; Potential Nanotheranostic Agent in Breast Cancer: A Comprehensive Review with Systematic Search Strategy. <i>Current Drug Metabolism</i> , 2020, 21, 579-598. | 0.7 | 11 |
| 5702 | The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. <i>Current Signal Transduction Therapy</i> , 2009, 4, 88-102. | 0.3 | 24 |
| 5703 | Hair Loss Prevention by a Scalp Cooling Device in Early Breast Cancer Patients: The Poliambulanza Preliminary Experience. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 66-71. | 0.4 | 6 |
| 5704 | Phage Display Technology and its Applications in Cancer Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 229-235. | 0.9 | 11 |
| 5705 | The Effects of Petroselinum Crispum on Estrogen Receptor-positive Benign and Malignant Mammary Cells (MCF12A/MCF7). <i>Anticancer Research</i> , 2017, 37, 95-102. | 0.5 | 7 |
| 5706 | Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 4575-4586. | 0.5 | 3 |
| 5707 | Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update. , 2017, 37, 5329-5341. | | 18 |
| 5708 | Adjuvant Endocrine Therapy in Breast Cancer: A Novel e-Health Approach in Optimizing Treatment for Seniors (OPTIMUM): A Two-Group Controlled Comparison Pilot Study. <i>JMIR Research Protocols</i> , 2016, 5, e199. | 0.5 | 7 |
| 5709 | Natural and herbal compounds targeting breast cancer, a review based on cancer stem cells. <i>Iranian Journal of Basic Medical Sciences</i> , 2020, 23, 970-983. | 1.0 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5711 | Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer. <i>Radiology and Oncology</i> , 2019, 53, 285-292. | 0.6 | 7 |
| 5712 | 5-Year Survival Rates and Prognostic Factors in Patients with Synchronous and Metachronous Breast Cancer from 2010 to 2015. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 3489-3493. | 0.5 | 12 |
| 5713 | Physicians' influence on breast cancer patient compliance. <i>GMS German Medical Science</i> , 2014, 12, Doc03. | 2.7 | 7 |
| 5714 | The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy. <i>Deutsches A&#x0308;rztblatt International</i> , 2015, 112, 577-84. | 0.6 | 17 |
| 5715 | Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. <i>Health Technology Assessment</i> , 2019, 23, 1-328. | 1.3 | 35 |
| 5716 | Six versus 12 monthsâ€™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190. | 1.3 | 11 |
| 5718 | Risk of Second Primary Cancers Among Long-Term Survivors of Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1426. | 1.3 | 33 |
| 5719 | Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?. <i>Cancers</i> , 2015, 7, 1191-1214. | 1.7 | 13 |
| 5720 | Matters of the Heart: Cardiac Toxicity of Adjuvant Systemic Therapy for Early-Stage Breast Cancer. <i>Current Oncology</i> , 2008, 15, 16-29. | 0.9 | 19 |
| 5721 | The Role of Immunohistochemical Biomarkers as Prognostic Factors by the Use of a Tissue Microarray in Breast Cancer Patients Under 45-years-old. <i>The Journal of the Korean Society for Therapeutic Radiology and Oncology</i> , 2008, 26, 45. | 0.1 | 1 |
| 5722 | Tumor bed volumetric changes during breast irradiation for the patients with breast cancer. <i>Radiation Oncology Journal</i> , 2013, 31, 228. | 0.7 | 9 |
| 5723 | Regional nodal irradiation in pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation. <i>Radiation Oncology Journal</i> , 2020, 38, 44-51. | 0.7 | 5 |
| 5724 | Circulating non-coding RNAâ€™ biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?. <i>International Journal of Oncology</i> , 2020, 56, 47-68. | 1.4 | 20 |
| 5725 | Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer. <i>Molecular and Clinical Oncology</i> , 2019, 11, 517-522. | 0.4 | 5 |
| 5726 | Expression of KrÃ¼ppel-like factor 9 in breast cancer patients and its effect on prognosis. <i>Oncology Letters</i> , 2020, 20, 1311-1317. | 0.8 | 3 |
| 5727 | Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21â€™ gene recurrence score of 26â€™30. <i>Oncology Letters</i> , 2020, 20, 1545-1556. | 0.8 | 4 |
| 5728 | P2Y2 receptor promotes the migration and invasion of breast cancer cells via EMT-related genes Snail and E-cadherin. <i>Oncology Reports</i> , 2018, 39, 138-150. | 1.2 | 33 |
| 5729 | Hormonal therapies in young breast cancer patients: when, what and for how long?. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 1, S36-46. | 0.6 | 21 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5730 | Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2013, 2, 403-10. | 1.3 | 36 |
| 5731 | Stock identification of neon flying squid (ɪmp;#x2013;Ommastrephes bartramiiɪmp;#x2013;) in the North Pacific Ocean on the basis of beak and statolith morphology. <i>Scientia Marina</i> , 2014, 78, 239-248. | 0.3 | 12 |
| 5732 | Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer. <i>Advances in Chemical and Materials Engineering Book Series</i> , 2015, , 400-470. | 0.2 | 5 |
| 5734 | Survival Analysis of Korean Breast Cancer Patients Diagnosed between 1993 and 2002 in Korea - A Nationwide Study of the Cancer Registry. <i>Journal of Breast Cancer</i> , 2006, 9, 214. | 0.8 | 19 |
| 5735 | Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context. <i>Journal of Breast Cancer</i> , 2010, 13, 286. | 0.8 | 5 |
| 5736 | Hyperglycemia during Adjuvant Chemotherapy as a Prognostic Factor in Breast Cancer Patients without Diabetes. <i>Journal of Breast Cancer</i> , 2020, 23, 398. | 0.8 | 17 |
| 5737 | Adjuvant hormonal therapy in premenopausal women with breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 195-200. | 0.1 | 4 |
| 5738 | Accessory breast tissue in axilla masquerading as breast cancer recurrence. <i>Journal of Cancer Research and Therapeutics</i> , 2008, 4, 95. | 0.3 | 15 |
| 5739 | Mitochondrial and caspase pathways are involved in the induction of apoptosis by nardosinen in MCF-7 breast cancer cell line. <i>Research in Pharmaceutical Sciences</i> , 2018, 13, 12. | 0.6 | 25 |
| 5740 | Pain and Menopause Symptoms of Breast Cancer Patients with Adjuvant Hormonal Therapy in Korea: Secondary Analysis. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2018, 5, 262-269. | 0.7 | 12 |
| 5741 | Hormone receptors and human epidermal growth factor (HER2) expression in fine-needle aspirates from metastatic breast carcinoma – Role in patient management. <i>Journal of Cytology</i> , 2019, 36, 94. | 0.2 | 17 |
| 5742 | Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling. <i>South Asian Journal of Cancer</i> , 2018, 07, 096-101. | 0.2 | 7 |
| 5743 | Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer. <i>South Asian Journal of Cancer</i> , 2018, 07, 142-145. | 0.2 | 4 |
| 5744 | Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer. <i>Cancer Research and Treatment</i> , 2011, 43, 89-95. | 1.3 | 79 |
| 5745 | Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 1351-1362. | 1.3 | 6 |
| 5746 | Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23). <i>Cancer Research and Treatment</i> , 2017, 49, 739-747. | 1.3 | 27 |
| 5747 | Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418). <i>Cancer Research and Treatment</i> , 2017, 49, 927-936. | 1.3 | 11 |
| 5748 | Risk Factors for a False-Negative Result of Sentinel Node Biopsy in Patients with Clinically Node-Negative Breast Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 625-633. | 1.3 | 10 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5749 | Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418). <i>Cancer Research and Treatment</i> , 2019, 51, 1041-1051. | 1.3 | 13 |
| 5750 | Discrimination of the Effects of Doxorubicin on Two Different Breast Cancer Cell Lines on Account of Multidrug Resistance and Apoptosis. <i>Indian Journal of Pharmaceutical Sciences</i> , 2017, 79, . | 1.0 | 9 |
| 5751 | Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors?. <i>Advances in Breast Cancer Research</i> , 2015, 04, 87-99. | 0.1 | 2 |
| 5752 | Adjuvant Treatment for High-Risk Operable Prostate Cancer. <i>Journal of Cancer Therapy</i> , 2010, 01, 10-20. | 0.1 | 3 |
| 5753 | Comparing Oncotype DX Recurrence Score Categories with Immunohistochemically Defined Luminal Subtypes. <i>Journal of Cancer Therapy</i> , 2016, 07, 223-231. | 0.1 | 2 |
| 5754 | Expression of Mammaglobin and Carcinoembryonic Antigen in Peripheral Blood of Patients with Breast Cancer Using Real Time Polymerase Chain Reaction. <i>Open Journal of Clinical Diagnostics</i> , 2017, 07, 103-112. | 0.3 | 2 |
| 5755 | Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 248. | 0.9 | 48 |
| 5756 | MicroRNAs in cancer therapeutic response: Friend and foe. <i>World Journal of Clinical Oncology</i> , 2014, 5, 730. | 0.9 | 45 |
| 5757 | Past, present and future of primary systemic treatment in breast cancer. <i>World Journal of Obstetrics and Gynecology</i> , 2013, 2, 21. | 0.5 | 1 |
| 5758 | TAC Protocol in Early Breast Cancer Al Amal Hospital Experience. <i>Qatar Medical Journal</i> , 2011, 2011, . | 0.2 | 1 |
| 5759 | Up-regulation of <i>HOXB</i> cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells. <i>BMB Reports</i> , 2018, 51, 450-455. | 1.1 | 18 |
| 5760 | Endocrine Therapy Use Among Elderly Hormone Receptor-Positive Breast Cancer Patients Enrolled in Medicare Part D. <i>Medicare & Medicaid Research Review</i> , 2011, 1, E1-E26. | 1.3 | 53 |
| 5761 | Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines. <i>Cardiology Journal</i> , 2022, 29, 228-234. | 0.5 | 8 |
| 5762 | Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study. <i>Iranian Red Crescent Medical Journal</i> , 2014, 16, e16005. | 0.5 | 3 |
| 5763 | Variable Specimen Handling Affects Hormone Receptor Test Results in Women With Breast Cancer: A Large Multihospital Retrospective Study. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 606-612. | 1.2 | 31 |
| 5764 | Recommendations for Validating Estrogen and Progesterone Receptor Immunohistochemistry Assays. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 930-935. | 1.2 | 106 |
| 5765 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, e48-e72. | 1.2 | 855 |
| 5766 | Precautions for Patients Taking Tamoxifen. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, . | 0.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5767 | NCCN Task Force Report: Breast Cancer in the Older Woman. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, S-1-S-25. | 2.3 | 30 |
| 5768 | Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage III Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 676-686. | 2.3 | 5 |
| 5769 | ATM Expression Is Elevated in Established Radiation-Resistant Breast Cancer Cells and Improves DNA Repair Efficiency. International Journal of Biological Sciences, 2020, 16, 1096-1106. | 2.6 | 23 |
| 5770 | Molecular Mechanism of SAHA on Regulation of Autophagic Cell Death in Tamoxifen-Resistant MCF-7 Breast Cancer Cells. International Journal of Medical Sciences, 2012, 9, 881-893. | 1.1 | 105 |
| 5771 | Clinical Characteristics and Survival Analysis of Breast Cancer Molecular Subtypes with Hepatic Metastases. Asian Pacific Journal of Cancer Prevention, 2012, 13, 5081-5086. | 0.5 | 19 |
| 5772 | Health-Related Quality of Life of Breast Cancer Patients in Iran: Pooled Analysis using Generalized Estimating Equations. Asian Pacific Journal of Cancer Prevention, 2012, 13, 941-944. | 0.5 | 5 |
| 5773 | Trends of Breast Cancer and its Management in the Last Twenty Years in Aden and Adjacent Governorates, Yemen. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4347-4351. | 0.5 | 11 |
| 5774 | Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4549-4553. | 0.5 | 35 |
| 5775 | Risk of Treatment Related Death and Febrile Neutropaenia with Taxane-Based Adjuvant Chemotherapy for Breast Cancer in a Middle Income Country Outside a Clinical Trial Setting. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4623-4626. | 0.5 | 7 |
| 5776 | A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 4567-4570. | 0.5 | 3 |
| 5777 | Comparison between Early and Late Onset Breast Cancer in Pakistani Women Undergoing Breast Conservative Therapy: is There any Difference?. Asian Pacific Journal of Cancer Prevention, 2014, 15, 5331-5336. | 0.5 | 3 |
| 5778 | Alterations in Hormonal Receptor Expression and HER2 Status between Primary Breast Tumors and Paired Nodal Metastases: Discordance Rates and Prognosis. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9233-9239. | 0.5 | 13 |
| 5779 | Multivariate Analysis of Prognostic Factors in Male Breast Cancer in Serbia. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3233-3238. | 0.5 | 9 |
| 5780 | Prognostic Value of Chemotherapy-Induced Amenorrhea in Breast Cancer: a Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5939-5944. | 0.5 | 5 |
| 5781 | Aromatase Inhibition and Capecitabine Combination as 1 st or 2 nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6359-6364. | 0.5 | 11 |
| 5782 | Efficacy of Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel versus Conventional Dose Doxorubicin, Cyclophosphamide Followed by Paclitaxel or Docetaxel in Patients with Node-Positive Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1471-1477. | 0.5 | 3 |
| 5783 | Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia-Pacific Breast Initiatives I and II. Asian Pacific Journal of Cancer Prevention, 2016, 17, 697-702. | 0.5 | 2 |
| 5784 | Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?. Asian Pacific Journal of Cancer Prevention, 2016, 17, 2301-2305. | 0.5 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5785 | Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases. <i>PeerJ</i> , 2019, 7, e8298. | 0.9 | 14 |
| 5786 | The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model. <i>BioDiscovery</i> , 2012, , . | 0.1 | 5 |
| 5787 | Limitations of Personalized Medicine and Gene Assays for Breast Cancer. <i>Cureus</i> , 2017, 9, e1100. | 0.2 | 8 |
| 5788 | Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship. , 2020, 24, . | | 29 |
| 5789 | Locoregional and Locally Advanced Breast Cancer. <i>UNIPA Springer Series</i> , 2021, , 429-466. | 0.1 | 0 |
| 5790 | Metastatic Breast Cancer. <i>UNIPA Springer Series</i> , 2021, , 467-479. | 0.1 | 0 |
| 5791 | Surgical Advantage of Ultrasonically Activated Devices During Axillary Lymph Node Dissection for Breast Cancer. <i>International Surgery</i> , 2021, 105, 623-627. | 0.0 | 0 |
| 5792 | Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. <i>JCO Oncology Practice</i> , 2022, 18, 211-216. | 1.4 | 10 |
| 5793 | A careful reassessment of anthracycline use in curable breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 134. | 2.3 | 25 |
| 5794 | Aldehyde dehydrogenase 1 (ALDH1) immunostaining in axillary lymph node metastases is an independent prognostic factor in ALDH1-positive breast cancer. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110472. | 0.4 | 2 |
| 5795 | FAM49B promotes breast cancer proliferation, metastasis, and chemoresistance by stabilizing ELAVL1 protein and regulating downstream Rab10/TLR4 pathway. <i>Cancer Cell International</i> , 2021, 21, 534. | 1.8 | 9 |
| 5796 | DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. <i>Clinical Epigenetics</i> , 2021, 13, 184. | 1.8 | 2 |
| 5797 | Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. <i>Cancer</i> , 2021, , . | 2.0 | 3 |
| 5798 | FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer. <i>Cancers</i> , 2021, 13, 5205. | 1.7 | 23 |
| 5799 | Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. <i>Clinical Cancer Research</i> , 2021, 27, 6570-6579. | 3.2 | 1 |
| 5801 | Robotic-assisted nipple-sparing mastectomy followed by immediate microsurgical free flap reconstruction: Feasibility and aesthetic results – Case series. <i>International Journal of Surgery</i> , 2021, 95, 106143. | 1.1 | 12 |
| 5802 | <i>Gynäkologische Onkologie</i> . , 2001, , 594-676. | | 0 |
| 5803 | An Introduction to Molecular Pathology. , 2002, , 15-36. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5804 | The Impact of Taxotere on Adjuvant Breast Cancer. <i>European Oncology and Haematology</i> , 2005, , 1. | 0.0 | 0 |
| 5805 | Treatment of early stage breast cancer in the elderly. <i>Aging Health</i> , 2005, 1, 221-230. | 0.3 | 0 |
| 5806 | Success Predictors of Adjuvant Chemotherapy in Node-Negative Breast Cancer Patients Under 55 years¹. <i>Analytical Cellular Pathology</i> , 2006, 28, 295-303. | 0.7 | 13 |
| 5807 | Systemische Therapie des metastasierten Mammakarzinoms. , 2006, , 335-353. | | 0 |
| 5808 | Reducing the Risk of Late Relapse in Postmenopausal Women with Hormone-sensitive Breast Cancer â€” Extended Adjuvant Letrozole. <i>Oncology & Hematology Review</i> , 2006, 00, 28. | 0.2 | 0 |
| 5809 | Estrogen receptor as the predictive factor for response to chemotherapy in breast cancer. <i>Archive of Oncology</i> , 2006, 14, 156-160. | 0.2 | 0 |
| 5810 | Adjuvante systemische Therapie. , 2006, , 277-296. | | 0 |
| 5811 | GynÃkologische Tumoren. , 2006, , 419-483. | | 0 |
| 5812 | Mammakarzinom. , 2006, , 477-533. | | 0 |
| 5815 | NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, S-1-S-26. | 2.3 | 32 |
| 5818 | Recent Advances in Adjuvant Systemic Treatment for Breast Cancer: All Systems Go!. <i>Current Oncology</i> , 2006, 13, 147-159. | 0.9 | 0 |
| 5819 | Aging, Cancer, and Translational Research. <i>Translational Medicine Series</i> , 2007, , 57-68. | 0.0 | 0 |
| 5820 | Highlights of 10th St. Gallen Breast Cancer Conference: Systemic Adjuvant Treatment. <i>Journal of Breast Cancer</i> , 2007, 10, 1. | 0.8 | 1 |
| 5821 | Prognostic and predictive factors in human breast cancer. <i>Cancer Metastasis - Biology and Treatment</i> , 2007, , 279-305. | 0.1 | 0 |
| 5822 | Pharmacology and Pharmacogenetics of Chemotherapeutic Agents. <i>Translational Medicine Series</i> , 2007, , 45-56. | 0.0 | 0 |
| 5823 | Aromatase Inhibitors for Breast Cancer Treatment and Prevention. <i>Translational Medicine Series</i> , 2007, , 159-174. | 0.0 | 0 |
| 5824 | Chapter 2 Ovarian ablation. , 2007, , . | | 0 |
| 5825 | Mammaerkrankungen. , 2008, , 325-397. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5826 | A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?. , 2008, , 391-398. | | 0 |
| 5827 | The Role of Lymph Node Staging for Clinical Decision Making in Patients with Solid Cancers. , 2008, , 72-80. | | 0 |
| 5828 | Meta-Analyse randomisierter klinischer Studien, Publikationsbias und evidenzbasierte Medizin. , 2008, , 129-160. | | 10 |
| 5829 | A STUDY OF TOLERABILITY OF DOCETAXEL WITH CYCLOPHOSPHAMIDE (TC) THERAPY AS A POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR BREAST CANCER. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq1 1 0.784314ogBT /Over | | 0 |
| 5831 | Are Short-Term or Long-Term Recurrence Rates More Important in Breast Cancer Screening?. Annals of Internal Medicine, 2008, 149, 357. | 2.0 | 0 |
| 5832 | Estrogen Receptor Phenotypes Defined by Gene Expression Profiling. Cancer Treatment and Research, 2009, 147, 1-18. | 0.2 | 1 |
| 5833 | Biomarkers in Neoadjuvant Trials. Cancer Treatment and Research, 2009, 147, 1-36. | 0.2 | 0 |
| 5834 | Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings. Cancer Treatment and Research, 2009, 147, 1-29. | 0.2 | 1 |
| 5835 | Young Patients with Breast Cancer. Cancer Treatment and Research, 2009, 151, 291-298. | 0.2 | 0 |
| 5836 | Molecular Signatures of Drug Resistance. , 2009, , 271-294. | | 0 |
| 5837 | è...«ç~â†...ç\$âCE»â©ç««â~â•â,%o-â,âf“âf†âf³â,1â•â,âf¼âf€âf¼âf;â,âf%oâCE»ç™,-. Juntendoì,, Igaku, 2009, 55, 306-329. | | 0 |
| 5838 | Multidisciplinarity. , 2009, , 127-142. | | 0 |
| 5839 | Timing of Adjuvant Therapy. Cancer Treatment and Research, 2009, 151, 255-279. | 0.2 | 0 |
| 5840 | Targeted Approaches to Drug Development. , 2009, , 57-98. | | 3 |
| 5841 | Endocrine therapy with drug delivery system for breast cancer. Drug Delivery System, 2009, 24, 421-425. | 0.0 | 0 |
| 5842 | History of Adjuvant Therapy. Cancer Treatment and Research, 2009, 151, 3-12. | 0.2 | 0 |
| 5843 | Tumor tissue levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) and survival following adjuvant chemotherapy in pre-menopausal lymph node-positive breast cancer patients (N=525).. , 2009, , . | | 0 |
| 5845 | Immunohistochemistry of Biomarkers. Molecular Pathology Library, 2009, , 133-137. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5846 | Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. , 2009, , 971-1006. | | 0 |
| 5847 | Investigations After Adjuvant Therapy. Cancer Treatment and Research, 2009, 151, 331-352. | 0.2 | 0 |
| 5848 | Guidelines, Consensus Conferences and Overviews (Meta-analysis). Cancer Treatment and Research, 2009, 151, 63-76. | 0.2 | 0 |
| 5849 | Invasive breast cancer and ductal carcinoma in situ in young women. , 2009, , 331-339. | | 0 |
| 5850 | General Considerations for Follow-Up. , 2009, , 1405-1417. | | 0 |
| 5851 | Male breast cancer. , 2009, , 385-392. | | 1 |
| 5852 | Bilateral Breast Cancer. , 2009, , 1329-1337. | | 0 |
| 5853 | Adjuvant Chemotherapy for Early-Stage Breast Cancer. , 2009, , 1125-1143. | | 0 |
| 5854 | Endocrine Therapy for Breast Cancer. , 2009, , 1263-1285. | | 0 |
| 5856 | Locally Advanced Breast Cancer. , 2009, , 1189-1199. | | 0 |
| 5857 | Outcome of Primary Endocrine Therapy in Postmenopausal Patients with Endocrine-responsive Breast Cancer. Annals of Cancer Research and Therapy, 2009, 17, 32-35. | 0.1 | 0 |
| 5859 | Primary tumor and patient characteristics in breast cancer as predictors of adjuvant chemotherapy regimen: A regression model. Journal of Clinical Oncology, 2009, 27, e11632-e11632. | 0.8 | 0 |
| 5860 | Adjuvant Chemotherapy. , 2010, , 249-262. | | 0 |
| 5862 | Adjuvant Endocrine Therapy. , 2010, , 231-247. | | 1 |
| 5863 | Lung Cancer Prevention. , 2010, , 107-138. | | 0 |
| 5864 | Breast Cancer in the Elderly. , 2010, , 497-507. | | 0 |
| 5865 | Follow-Up Strategies After Breast Cancer Treatment. , 2010, , 937-943. | | 0 |
| 5866 | Breast Cancer in the Elderly. , 2010, , 777-785. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5867 | Revisi3n de la literatura para terapia sist3mica del c3ncer de mama en etapas tempranas. Medwave, 2010, 7, . | 0.2 | 0 |
| 5868 | Five-years of Breast Cancer Management in a New Hospital: Analysis Using Clinical Data Warehouse. Journal of Breast Cancer, 2010, 13, 96. | 0.8 | 2 |
| 5870 | Evidence-Based Medicine: What does it Mean and Where Are We Going?. , 2010, , 221-241. | | 0 |
| 5871 | Early and late tamoxifen resistance in breast cancer. Archives of Biological Sciences, 2010, 62, 249-256. | 0.2 | 0 |
| 5872 | Chemotherapeutic Agents. , 2010, , 353-372. | | 0 |
| 5875 | Pharmacogenetics in the Management of Breast Cancer. , 2010, , 45-59. | | 0 |
| 5876 | Adjuvant Therapy Choices in Breast Cancer. , 2010, , 600-603. | | 0 |
| 5877 | Hormone Receptor Positive Early Breast Cancer: What Role for Aromatase Inhibitors?. Clinical Medicine Reviews in Oncology, 0, 2, 89-98. | 0.0 | 0 |
| 5878 | Adjuvant Systemic Therapy for Breast Cancer: An Overview. , 2010, , 297-327. | | 0 |
| 5879 | Response to Paclitaxel in Node-positive Triple Negative Breast Cancer. [Chapchi] Journal Taehan Oekwa Hakhoe, 2010, 79, 173. | 1.1 | 0 |
| 5880 | Adjuvant Systemic Therapy. , 2010, , 741-753. | | 0 |
| 5881 | Breast Carcinoma: Stages I and II. , 2010, , 83-112. | | 0 |
| 5882 | Revisi3n de la literatura para la actualizaci3n en las normas de seguimiento de pacientes tratadas por un c3ncer de mama (etapas 0-III). Medwave, 2010, 7, . | 0.2 | 0 |
| 5883 | Design, Implementation, and Interpretation of Clinical Trials. , 2010, , 585-625. | | 0 |
| 5884 | Endocrine Therapy. , 2010, , 329-352. | | 0 |
| 5885 | Cancer of the Breast in the Elderly. , 2010, , 726-729. | | 0 |
| 5886 | Adjuvant Endocrine Therapy. , 2010, , 755-764. | | 0 |
| 5887 | The Estrogen and Progesterone Receptors. , 2010, , 21-42. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5888 | Pharmacodiagnosics and Personalized Medicine in Cancer. , 2010, , 325-344. | | 0 |
| 5890 | Hormonal Therapy in Cancer. , 2011, , 165-190. | | 0 |
| 5891 | Pharmacogenomics of Tamoxifen. , 2011, , 77-89. | | 0 |
| 5892 | Adjuvant Chemoendocrine Therapy. , 2011, , 75-78. | | 0 |
| 5895 | Contr le local et   distance des cancers. , 2011, , 99-110. | | 0 |
| 5896 | Le cancer du sein de la femme  g e. , 2011, , 85-89. | | 0 |
| 5897 | Hormonale aspecten van kanker, in het bijzonder mammacarcinoom. , 2011, , 197-210. | | 0 |
| 5898 | Traitements adjuvants du cancer du sein. , 2011, , 93-105. | | 0 |
| 5900 | Breast Cancer in Elderly Women. , 2011, , 479-492. | | 0 |
| 5901 | Significance of Ki-67 Expression and Risk Category (St. Gallen 2007) in Elderly Breast Cancer Patients, with Emphasis on the Need for Postoperative Adjuvant Therapy. The Showa University Journal of Medical Sciences, 2011, 23, 153-164. | 0.1 | 0 |
| 5903 | Maligne Tumoren der Mamma. , 2011, , 1-31. | | 2 |
| 5904 | Hormonoth rapie des cancers du sein. , 2011, , 47-53. | | 0 |
| 5905 | Brusttumoren. , 2011, , 475-486. | | 0 |
| 5906 | Le cancer du sein localis . , 2011, , 175-184. | | 0 |
| 5908 | Randomized Trial Comparing Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF) Regimen with Rotational CMFEV Regimen (E=Epirubicin, V=Vincristine) as Adjuvant Chemotherapy in Moderate Risk Operable Breast Carcinoma. Journal of Cancer Therapy, 2011, 02, 342-353. | 0.1 | 0 |
| 5909 | Two cases in which breast cancer recurred 25 or more years after mastectomy. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2011, 72, 863-868. | 0.0 | 1 |
| 5910 | Breast Cancer New Therapies: HER2, VEGF, and PARP as Targets. , 2011, , 526-528. | | 0 |
| 5911 | Long-term survival rates of older breast cancer patients: Population-based estimates over three decades.. Journal of Clinical Oncology, 2011, 29, 9051-9051. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5912 | The prognostic and predictive value of gene expression signatures in breast cancer. , 2011, , 4-12. | | 0 |
| 5913 | Interactions of STAP-2 with BRK and STAT3/5 in Breast Cancer Cells. , 0, , . | | 0 |
| 5914 | Principles of Medical Oncology and Chemotherapy. , 2012, , 3-13. | | 0 |
| 5915 | Tamoxifen Resistant Breast Cancer and Autophagy. , 0, , . | | 0 |
| 5916 | Cross Talk Between ER α and Src Signaling and Its Relevance to ER Status and Hormone Responsiveness. , 2012, , 61-78. | | 0 |
| 5917 | Breast and Ovarian Cancer Treatment: Facing Forward Women's Health Care. , 0, , . | | 0 |
| 5918 | Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer. Lecture Notes in Computer Science, 2012, , 286-286. | 1.0 | 590 |
| 5919 | Nonhematologic Complications of Systemic Treatment of Cancer in the Older-Aged Person. , 2012, , 127-132. | | 0 |
| 5921 | Literaturhinweise und Internetadressen. , 2012, , e1-e61. | | 0 |
| 5922 | Anti-HER-2 et hormonothérapies dans la prise en charge des cancers du sein: Indications. , 2012, , 553-564. | | 0 |
| 5923 | Pas d'œ hormonothérapie pour quels cancers RH (+)? , 2012, , 125-129. | | 0 |
| 5924 | œpidémiologie et diversité des cancers du sein Nœ étude sur une cohorte de plus de 5 000 patientes traitées au Centre Antoine Lacassagne (Nice, France). , 2012, , 441-456. | | 0 |
| 5925 | Breast cancer: rehabilitation. Acta Fisiológica, 2012, 19, 66-72. | 0.0 | 4 |
| 5926 | Quel œquilibre thérapeutique pour les cancers lobulaires infiltrants? Chimiothérapie. , 2012, , 152-156. | | 0 |
| 5927 | Les cancers du sein Nœ, HER2 négatifs, RH+: Quelles hormonothérapies? Quand faut-il faire une chimiothérapie?. , 2012, , 457-470. | | 0 |
| 5928 | Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer. , 2012, , 157-171. | | 0 |
| 5930 | Risk of treatment related death (TRD) with adjuvant chemotherapy for breast cancer: A study in University Malaya Medical Centre (UMMC). Journal of Cancer Therapeutics & Research, 2012, 1, 13. | 1.2 | 2 |
| 5932 | A Multidisciplinary Approach to Cancer. , 2012, , 13-16. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5933 | Estrogen-Induced Apoptosis in Breast Cancer Cells: Translation to Clinical Relevance. , 0, , . | | 0 |
| 5934 | Controversies in Adjuvant Endocrine Therapy for Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 20-26. | 1.8 | 1 |
| 5935 | Targeting Molecular Aberrations in Breast Cancer: Is It about Time?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 186-191. | 1.8 | 0 |
| 5936 | Prognostic Markers in Breast Cancer. , 2013, , 25-42. | | 0 |
| 5937 | Follow-Up in Inflammatory Breast Cancer. , 2013, , 129-139. | | 0 |
| 5938 | Breast Carcinoma Surveillance Counterpoint: USA. , 2013, , 277-280. | | 0 |
| 5939 | Breast Carcinoma Surveillance Counterpoint: Australia. , 2013, , 285-291. | | 0 |
| 5940 | Prognostic and Predictive Factors. , 2013, , 35-47. | | 0 |
| 5941 | Systemic Therapy for Breast Cancer: Success and Challenges. , 2013, , 909-921. | | 0 |
| 5944 | Rezepturazneimittel. , 2013, , 121-155. | | 0 |
| 5945 | Adjuvant Therapy: The Breakthrough. Milestones in Drug Therapy, 2013, , 69-84. | 0.1 | 1 |
| 5946 | Adjuvante Therapie des Mammakarzinoms. , 2013, , 355-366. | | 0 |
| 5947 | Sex Steroids and Breast Cancer: An Overview. Journal of Cancer Therapy, 2013, 04, 851-856. | 0.1 | 2 |
| 5949 | Mammakarzinom. , 2013, , 625-705. | | 0 |
| 5950 | Evaluating Trastuzumab and Lapatinib's Economic Impact in the Treatment of Metastatic Breast Cancer in Veneto Region Cohort. The Open Pharmacology Journal, 2013, 7, 17-25. | 0.4 | 0 |
| 5951 | ADJUVANT ANTIHORMONE THERAPY. , 2013, , 229-254. | | 0 |
| 5953 | Systemic Therapy. , 2014, , 381-420. | | 0 |
| 5956 | The Bioepidemiology of Multiple Primary Cancers. Medical Radiology, 2014, , 227-239. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 5957 | Mammacarcinoom. , 2014, , 89-97. | | 0 |
| 5958 | The role of adjuvant systemic therapy in patients with operable breast cancer. , 2014, , 199-218. | | 0 |
| 5960 | Adjuvant Chemoendocrine Therapy. , 2014, , 101-104. | | 0 |
| 5961 | Breast Cancer and Depression. , 2014, , 443-443. | | 39 |
| 5962 | Sentinel Node Biopsy and Axillary Dissection. Updates in Surgery Series, 2014, , 101-114. | 0.0 | 0 |
| 5963 | Breast Cancer in Women under 30 is Highly Aggressive with Extremely Low Frequency: a Case Report. SOJ Immunology, 2014, 2, . | 0.2 | 0 |
| 5965 | Progression of Hormone-Dependent Mammary Tumors After Dormancy: Role of Wnt Pathway. , 2014, , 59-75. | | 0 |
| 5966 | Molecular Testing in Breast Cancer. , 2014, , 169-188. | | 0 |
| 5967 | Modeling Breast Cancer Screening Outcomes. Lecture Notes in Computer Science, 2014, , 50-55. | 1.0 | 0 |
| 5968 | Pharmacogenomicsâ€“Pharmacoeugenomics of Breast Cancer Therapy: Clinical Implications. , 2014, , 499-518. | | 0 |
| 5969 | The role of adjuvant radiotherapy in the management of breast cancer. , 2014, , 242-257. | | 1 |
| 5970 | First Cycle Neutrophil Count and Subsequent Chemotherapy Dose Delivery in Breast Cancer Patients Receiving Adjuvant Chemotherapy. Journal of Cancer Therapy, 2014, 05, 172-178. | 0.1 | 1 |
| 5971 | Breast Cancer in the Elderly. Updates in Surgery Series, 2014, , 163-174. | 0.0 | 0 |
| 5973 | The Impact of Weight Change During and After Post-Operative Chemotherapy on Breast Cancer Control in Node-Positive Patients Treated With Trimodality Therapy. Cancer and Clinical Oncology, 2014, 3, . | 0.2 | 0 |
| 5974 | The Postoperative Breast. , 2015, , 315-392. | | 0 |
| 5975 | The Multidisciplinary Approach to Breast Cancer Management. , 2015, , 393-409. | | 0 |
| 5976 | Molecular Medicine and Personalized Therapy for Breast Cancer Patients. , 2015, , 321-334. | | 0 |
| 5977 | Early Breast Cancers. , 2015, , 61-112. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 5978 | Management of Metastatic Breast Cancer. , 2015, , 473-497. | | 0 |
| 5979 | Modeling Expression Plasticity of Genes that Differentiate Drug-sensitive from Drug-resistant Cells to Chemotherapeutic Treatment. Current Genomics, 2014, 15, 349-356. | 0.7 | 1 |
| 5980 | Hormonal Therapy in Nonmetastatic Breast Cancer. , 2015, , 339-344. | | 0 |
| 5981 | Fertility Preservation and Pregnancy After Breast Cancer: When and How?. ISGE Series, 2015, , 185-189. | 0.2 | 0 |
| 5983 | Understanding the New Biology of Estrogen-Induced Apoptosis and Its Application in Patient Care. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 101-114. | 0.1 | 0 |
| 5984 | Biomarkers for Early Detection of Familial Breast Cancer. , 2015, , 167-190. | | 0 |
| 5985 | Ethical Considerations in the Genomic Era. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 349-375. | 0.6 | 2 |
| 5986 | Onkologika. , 2015, , 833-876. | | 0 |
| 5987 | A Case of Glioblastoma Multiforme with Hematogenous Metastases to the Pleura. Japanese Journal of Neurosurgery, 2015, 24, 192-197. | 0.0 | 0 |
| 5990 | Targeting metastatic breast cancer: problems and potential. F1000Research, 2015, 4, 141. | 0.8 | 0 |
| 5993 | Rationalizing Optimal Timing for Adjuvant Hormone Therapy for Patients with Breast Cancer: Impact on Limited Resource Countries. International Journal of Clinical Medicine, 2016, 07, 419-432. | 0.1 | 0 |
| 5994 | Post-mastectomy Adjuvant Radiotherapy (PMRT). , 2016, , 205-217. | | 0 |
| 5995 | Breast Cancer in Young Women (Premenopausal Breast Cancer). , 2016, , 375-387. | | 0 |
| 5996 | Treatment of Metastatic Breast Cancer: Endocrine Therapy. , 2016, , 489-522. | | 0 |
| 5997 | Adjuvant Systemic Treatment for Breast Cancer: An Overview. , 2016, , 311-321. | | 0 |
| 5998 | Inflammatory and Locally Advanced Breast Cancer. , 2016, , 411-435. | | 0 |
| 5999 | Gene Arrays, Prognosis, and Therapeutic Interventions. , 2016, , 207-227. | | 0 |
| 6000 | Metastatic Breast Cancer. , 2016, , 451-474. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6001 | Onco-cardiology for Breast Cancer. , 2016, , 889-921. | | 0 |
| 6003 | The Risks and Benefits of Immediate Versus Delayed Autologous Breast Reconstruction. , 2016, , 1155-1162. | | 0 |
| 6004 | Systemic Therapy. , 2016, , 335-390. | | 0 |
| 6005 | Endocrine Therapy. , 2016, , 323-334. | | 0 |
| 6007 | Treatment of Elderly Breast Cancer Patients. Journal of the Nihon University Medical Association, 2016, 75, 132-135. | 0.0 | 0 |
| 6008 | Breast Cancer in Younger Women. , 2016, , 529-564. | | 0 |
| 6010 | Endocrine Therapy. , 2016, , 67-82. | | 0 |
| 6011 | Principe de surveillance et d'accompagnement des femmes aprÃs traitement d'un cancer du sein localisÃ©. , 2016, , 203-210. | | 0 |
| 6012 | Principes des chimiothÃ©rapies adjuvantes et nÃ©oadjuvantes desÂcancers du sein localisÃ©s. , 2016, , 79-87. | | 0 |
| 6013 | Breast Cancer in the Older Adult. , 2016, , 519-528. | | 0 |
| 6014 | Adjuvant Systemic Chemotherapy for HER2-Negative Disease. , 2016, , 131-187. | | 0 |
| 6015 | Novel Translational Research of Neo-adjuvant Endocrine Therapy. , 2016, , 189-216. | | 0 |
| 6016 | Design, Implementation, and Interpretation of Clinical Trials. , 2016, , 601-635. | | 0 |
| 6017 | Severe aortic stenosis in a patient with breast cancer. OnCOReview, 2016, 6, 49-56. | 0.1 | 0 |
| 6018 | Breast Cancer New Therapies: HER2, VEGF, and PARP as Targets. , 2017, , 677-680. | | 0 |
| 6019 | Ligand- and Structure-Based Drug Design of Non-Steroidal Aromatase Inhibitors (NSAIs) in Breast Cancer. , 2017, , 118-186. | | 0 |
| 6020 | Systemic Treatment for Specific Medical Situations. , 2017, , 599-607. | | 0 |
| 6021 | Mammaerkrankungen. , 2017, , 297-358. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6022 | Basisprincipes van "targeted therapy"™, inclusief hormonale therapie. , 2017, , 161-179. | | 0 |
| 6024 | Breast Cancer in Elderly Women. , 2017, , 1-25. | | 1 |
| 6025 | The Methodology of Meta-Analyses and Its Potential Contribution to Patient Care. , 2017, , 905-913. | | 0 |
| 6026 | Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-34. | 0.1 | 0 |
| 6028 | Fallopian tube metastasis in a patient with a history of breast cancer. Marmara Medical Journal, 2017, 30, 54-54. | 0.2 | 0 |
| 6031 | Radiation-Related Heart Disease: Up-to-Date Developments. , 0, , . | | 0 |
| 6032 | The Effect of Histone Hyperacetylation on Viability of Basal-Like Breast Cancer Cells MDA-MB-231. Razavi International Journal of Medicine, 2017, 5, . | 0.1 | 1 |
| 6033 | Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study. Anticancer Research, 2017, 37, 4539-4547. | 0.5 | 2 |
| 6034 | Tamoxifen: An Update. , 2018, , 291-299. | | 0 |
| 6036 | Surgery for Locally Recurrent Breast Cancer. , 2018, , 263-273. | | 0 |
| 6037 | CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER " PREVENTION OF NAUSEA AND VOMITING. Meditsinskiy Sovet, 2017, , 112-117. | 0.1 | 0 |
| 6038 | A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer. Anticancer Research, 2017, 37, 6863-6869. | 0.5 | 2 |
| 6039 | Meme Kanserli Kadınlarda Farklı Tedaviler ile Birlikte Verilen Kalistenik Egzersizlerin Fiziksel Aktivite Düzeyi ve Depresyona Etkisi. Fizyoterapi Rehabilitasyon, 0, , . | 0.0 | 2 |
| 6040 | Prediction of Postmenopausal Status in Premenopausal Early Stage Breast Cancer Patients after Adjuvant Chemotherapy. Hematology & Transfusion International Journal, 2017, 5, . | 0.1 | 0 |
| 6042 | Onkologika. , 2018, , 645-691. | | 1 |
| 6043 | The Role of Quality Metrics in Improving Oncologic Survival. , 2018, , 85-94. | | 1 |
| 6044 | Combination Therapies "in Advanced, Hormone "Receptor"Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2018, 9, . | 0.2 | 3 |
| 6045 | Is postmastectomy radiotherapy really needed in breast cancer patients with many positive axillary lymph nodes?. Radiology and Oncology, 2018, 52, 275-280. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6046 | Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant). South Asian Journal of Cancer, 2018, 07, 151-155. | 0.2 | 1 |
| 6047 | Practical consensus recommendations regarding the management of hormone receptor positive early breast cancer in elderly women. South Asian Journal of Cancer, 2018, 07, 123-126. | 0.2 | 1 |
| 6049 | The evaluation of gait problems and related factors in patients with Parkinson's disease. International Journal of Family & Community Medicine, 2018, 2, . | 0.1 | 0 |
| 6051 | Adverse effects of adjuvant endocrine therapy. Meditsinskiy Sovet, 2018, , 64-69. | 0.1 | 1 |
| 6052 | Importance of evaluation of ovarian function in women with breast cancer when using endocrinotherapy. Meditsinskiy Sovet, 2018, , 118-126. | 0.1 | 0 |
| 6053 | Características y supervivencia de pacientes con cáncer de seno metastásico HER2-positivo en la era post-trastuzumab. Revista Colombiana De Cancerología, 2018, 22, 112-118. | 0.0 | 2 |
| 6054 | COMPARISON OF CLINICO-PATHOLOGICAL FEATURES AND PROGNOSIS OF TRIPLE-NEGATIVE AND NON-TRIPLE-NEGATIVE FEMALE BREAST CANCER PATIENTS. Journal of Evolution of Medical and Dental Sciences, 2018, 7, 3412-3418. | 0.1 | 0 |
| 6055 | Prediction of breast cancer metastasis risk using circulating tumor markers: A follow-up study. Bosnian Journal of Basic Medical Sciences, 2019, 19, 172-179. | 0.6 | 1 |
| 6056 | Åstrojen-Progesteron Reseptör Pozitif ve Aksiller Lenf Nodu Negatif Meme Kanseri Tanımlanan Hastalarda Ki-67 Proliferasyon İndeksi. Konuralp Tıp Dergisi, 2018, 10, 387-394. | 0.1 | 1 |
| 6057 | Cancer in the Very Elderly and Management. , 2019, , 177-188. | | 0 |
| 6058 | Kardiotoxizität onkologischer Therapien (1): Myokardiale Dysfunktion und Herzinsuffizienz. Deutsches Ärzteblatt International, 0, , . | 0.6 | 2 |
| 6060 | Disease Presentation, Recognition and Prevention. , 2019, , 3-63. | | 0 |
| 6061 | The Role of Tumor Microenvironment and Impact of Cancer Stem Cells on Breast Cancer Progression and Growth. Serbian Journal of Experimental and Clinical Research, 2023, 24, 85-92. | 0.2 | 0 |
| 6062 | Breast Cancer Management in the TAILORx Era: Less is More. NAM Perspectives, 0, , . | 1.3 | 0 |
| 6063 | Post-Mastectomy Adjuvant Radiotherapy (PMRT). , 2019, , 187-198. | | 0 |
| 6064 | Small Breast Cancer (≤ 5 mm): Ultrasonographic Features and Clinical and Pathological Characteristics. Journal of the Korean Society of Radiology, 2019, 80, 728. | 0.1 | 0 |
| 6065 | Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing. , 2019, , 143-161. | | 0 |
| 6066 | Onkologika. , 2019, , 817-875. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6067 | Breast Cancer in Older Women. , 2019, , 325-335. | | 1 |
| 6068 | Onco-Cardiology for Breast Cancer. , 2019, , 757-779. | | 0 |
| 6069 | Treatment of Metastatic Breast Cancer: Endocrine Therapy. , 2019, , 419-447. | | 0 |
| 6071 | Adjuvant Systemic Chemotherapy for HER2-Negative Disease. , 2019, , 129-171. | | 0 |
| 6072 | EFFECTIVENESS OF CONVENTIONAL VS. HYPO FRACTIONATED RT SCHEDULES FOR CHEST WALL IRRADIATION IN BREAST CANCER TREATMENT AND OUTCOME. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 104-110. | 0.1 | 0 |
| 6073 | Gene Arrays, Prognosis, and Therapeutic Interventions. , 2019, , 173-189. | | 0 |
| 6074 | Increased Mortality Risk among Early Stage Hormone Receptor Positive Breast Cancer Patients Who Did Not Receive Adjuvant or Neoadjuvant Therapy. Journal of Cancer Therapy, 2019, 10, 1-20. | 0.1 | 0 |
| 6076 | Pancytopenia: A Rare and Unusual Initial Presentation of Breast Cancer. Cureus, 2019, 11, e4235. | 0.2 | 2 |
| 6078 | Prognostic Factors Affecting Local Recurrence and Systemic Metastasis in Early Stage Breast Cancer. Medical Science and Discovery, 0, , 119-122. | 0.1 | 0 |
| 6079 | Evaluaci3n Y Manejo De La Enfermedad Temprana Y Localmente Avanzada: 1er Consenso Nacional Del C3ncer De Mama de la Sociedad Paname3a de Oncolog3a (SPO). Revista Medica De Panama, 2019, 39, . | 0.0 | 0 |
| 6080 | Is Tamoxifen Use a Factor Affecting Continence in Breast Cancer Patients?. Cureus, 2019, 11, e5417. | 0.2 | 1 |
| 6081 | Biological rationale for a patient-specific approach in the treatment of breast cancer. Clinical value of novel biomarkers of breast cancer. Opuholi Zenskoj Reproktivnoy Sistemy, 2019, 15, 10-29. | 0.1 | 3 |
| 6082 | Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors. Opuholi Zenskoj Reproktivnoy Sistemy, 2019, 15, 30-41. | 0.1 | 0 |
| 6084 | Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China. Oncology Letters, 2019, 18, 6690-6696. | 0.8 | 5 |
| 6086 | MicroRNA Regulates Estrogen Receptor Alpha in Breast Cancer Metastasis. , 2019, 1, 1-5. | | 0 |
| 6087 | T3rkkiye3n do3usunda bir kentte kanser vakalar3n da3l3m3 ve ya3am analizi sonu3lar3: retrospektif bir 3sal3ma. Cukurova Medical Journal, 0, 44, 26-32. | 0.1 | 0 |
| 6088 | Large-scale randomized evidence: Trials and meta-analyses of trials. , 2020, , 51-66. | | 0 |
| 6089 | Onkologika. , 2020, , 671-732. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6090 | Histological Changes of Feline Mammary Carcinoma Treated by NPe6 HVJ-E PDT. Nippon Laser Igakkaishi, 2020, 40, 403-407. | 0.0 | 0 |
| 6094 | THE EVALUATION OF THE EFFECTS OF LYMPH NODE REVEALING SOLUTION ON AXILLARY DISSECTION MATERIAL. International Journal of Research -GRANTHAALAYAH, 2019, 7, 269-279. | 0.1 | 0 |
| 6096 | Features of ultrasound of endometrial pathological conditions in breast cancer patients receiving tamoxifen: a review of literature. Opuholi Zenskoj Reproktivnoj Sistemy, 2020, 16, 37-42. | 0.1 | 0 |
| 6098 | Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with boneâ€only and nonâ€boneâ€only metastasis. Oncology Letters, 2020, 20, 1-1. | 0.8 | 4 |
| 6100 | Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3355-3363. | 0.5 | 3 |
| 6101 | The role of tumor microenvironment and exosomes in dormancy and relapse. Seminars in Cancer Biology, 2022, 78, 35-44. | 4.3 | 24 |
| 6102 | Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer. Exploration of Targeted Anti-tumor Therapy, 0, , . | 0.5 | 2 |
| 6103 | Impact of Different Modules of 21-Gene Assay in Early Breast Cancer Patients. Frontiers in Endocrinology, 2021, 12, 759338. | 1.5 | 2 |
| 6105 | PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer. Oncotarget, 2020, 11, 4722-4734. | 0.8 | 1 |
| 6106 | Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 185-195. | 0.2 | 0 |
| 6107 | Modelo CBCRisk para determinar el riesgo de cÃncer de mama contralateral en el cÃncer de mama esporÃdico. CirugÃa EspaÃola, 2021, 99, 724-729. | 0.1 | 0 |
| 6108 | New opportunities of pharmacogenetics approach to personalized tamoxifen therapy (updated) Tj ETQq1 1 0.784314 rgBT /Qoverlock | 0.0 | 0 |
| 6110 | The expression of programmed death-ligand 1 in patients with invasive breast cancer. Gland Surgery, 2020, 9, 2106-2115. | 0.5 | 2 |
| 6111 | Determination of FABP4, RBP4 and the MMPâ€9/NGAL complex in the serum of women with breast cancer. Oncology Letters, 2020, 21, 85. | 0.8 | 9 |
| 6112 | SYNTHESIS OF TAMOXIFEN DERIVATIVES AND THEIR BIOLOGICAL ACTIVITIES. Plant Archives, 2020, 21, . | 0.1 | 0 |
| 6113 | Evaluation of early post-natal pig mammary gland development and human breast cancer gene expression. Developmental Biology, 2022, 481, 95-103. | 0.9 | 4 |
| 6114 | Effect of Adjuvant Hormonal Therapy on the Development of Pulmonary Fibrosis after Postoperative Radiotherapy for Breast Cancer. Journal of Breast Cancer, 2020, 23, 449. | 0.8 | 7 |
| 6116 | Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status. Journal of Breast Cancer, 2020, 23, 10. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6117 | INSILICO DOCKING APPROACH TO STUDY THE BINDING AFFINITY OF ISOFLAVONES ON THE CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA. Indian Drugs, 2017, 54, 7-15. | 0.1 | 0 |
| 6119 | Radiation therapy for the elderly" change of concepts in breast cancer?. Translational Cancer Research, 2020, 9, S131-S138. | 0.4 | 1 |
| 6120 | Basisprincipes van "targeted therapy"™, inclusief hormonale therapie. , 2020, , 173-190. | | 0 |
| 6122 | Endocrine Therapy-related Endocrinopathies" Biology, Prevalence, and Implications for the Management of Breast Cancer. Oncology & Hematology Review, 2020, 16, 17. | 0.2 | 3 |
| 6123 | Adjuvante Therapie des Mammakarzinoms. , 2020, , 403-419. | | 0 |
| 6124 | Prinzipien der primären Prävention von Krebserkrankungen. Springer Reference Medizin, 2020, , 1-14. | 0.0 | 0 |
| 6125 | Cardio-Oncology: Preventing Broken Hearts in Women with Breast Cancer. , 2020, , 217-236. | | 0 |
| 6126 | Breast Cancer in Elderly Women. , 2020, , 967-990. | | 0 |
| 6127 | T-Staging and Target Volume Definition by Imaging in Breast Tumours. Medical Radiology, 2020, , 183-202. | 0.0 | 0 |
| 6128 | Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer. World Journal of Oncology, 2020, 11, 106-111. | 0.6 | 3 |
| 6130 | Biological rationale for patient-specific treatment of breast cancer. Analysis of new data for breast cancer. Opuholi Zenskoj Reproktivnoy Sistemy, 2020, 15, 30-49. | 0.1 | 1 |
| 6133 | Radiation therapy with elective lymph node irradiation for breast cancer: dosimetric study and impact on cardiovascular risk and second neoplasms. Revista Da Associaçāo Māodica Brasileira, 2021, 67, 1118-1123. | 0.3 | 0 |
| 6134 | Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study. The Lancet Healthy Longevity, 2021, 2, e704-e711. | 2.0 | 14 |
| 6135 | CBCRisk model to determine the risk of contralateral breast cancer in sporadic breast cancer. Cirugāa Espaāola (English Edition), 2021, 99, 724-729. | 0.1 | 1 |
| 6137 | Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients. Breast, 2021, 60, 230-237. | 0.9 | 0 |
| 6138 | Synthesis, investigation of biological effects and <i>in silico</i> studies of new benzimidazole derivatives as aromatase inhibitors. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 2020, 75, 353-362. | 0.6 | 10 |
| 6139 | Sobrevida en pacientes con cāncer de mama segān su inmunohistoquāmica experiencia del Instituto Oncolōgico Nacional - Sociedad de Lucha Contra el Cāncer, Guayaquil Ecuador. Revista Medica Sinergia, 2020, 5, e542. | 0.0 | 1 |
| 6140 | Maligne Tumoren der Mamma. , 2014, , 1-30. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6141 | Axiller lenf nodu pozitif meme kanserinde non-sentinel lenf nodu pozitifliĖine etki eden faktörler ve nomogramların etkinliĖinin karĖılaĖtırılması. Dicle Medical Journal, 2018, 45, 397-406. | 0.2 | 0 |
| 6142 | Clinical studies with letrozole. , 2008, , 69-100. | | 0 |
| 6144 | Node-Negative Breast Cancer: Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells. , 2008, , 175-188. | | 0 |
| 6145 | Relevance of Dose-Intensity for Adjuvant Treatment of Breast Cancer. , 2008, , 351-360. | | 0 |
| 6146 | Concomitant Use of Tamoxifen with Radiotherapy Enhances Subcutaneous Breast Fibrosis in Hypersensitive Patients. , 2008, , 609-623. | | 0 |
| 6151 | Les cancers du sein de la femme Ėgée de plus de 70 ans Le point en France. , 2007, , 335-347. | | 1 |
| 6152 | Facteurs prédictifs de la chimiosensibilité en phase adjuvante. , 2007, , 357-367. | | 0 |
| 6153 | Peut-on se passer des anthracyclines?. , 2007, , 369-376. | | 0 |
| 6154 | Tailored Therapy for Breast Cancer in Very Young Women. , 2006, , 349-374. | | 0 |
| 6155 | Metastatic Breast Cancer: Tailored Endocrine Therapy for Premenopausal Women. , 2006, , 451-464. | | 0 |
| 6156 | Patients' Preferences: What Makes Treatments Worthwhile?. , 2006, , 925-944. | | 0 |
| 6158 | Progress in the Treatment of Early and Advanced Breast Cancer. , 2008, , 239-256. | | 0 |
| 6161 | Adjuvant Chemotherapy in Early Breast Cancer. , 2021, , 143-155. | | 0 |
| 6162 | Adjuvant Endocrine Therapy in Early Breast Cancer. , 2021, , 165-177. | | 0 |
| 6163 | Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer. Korean Journal of Internal Medicine, 2020, 35, 1489-1496. | 0.7 | 2 |
| 6164 | Improving Adherence to Adjuvant Hormonal Therapy Among Disadvantaged Women Diagnosed with Breast Cancer in South Carolina: Proposal for a Multimethod Study. JMIR Research Protocols, 2020, 9, e17742. | 0.5 | 5 |
| 6165 | Evaluating Estrogen Receptor Immunohistochemistry on Cell Blocks From Breast Cancer Patients in a Low-Resource Setting. Archives of Pathology and Laboratory Medicine, 2021, 145, 834-841. | 1.2 | 2 |
| 6167 | MiRNAs: A New Approach to Predict and Overcome Resistance to Anticancer Drugs. Clinical Cancer Drugs, 2020, 7, 65-77. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6168 | Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 397-404. | 0.7 | 5 |
| 6169 | Breast cancer clinical and translational research: analogies and implications for prostate cancer. Reviews in Urology, 2007, 9 Suppl 2, S28-39. | 0.9 | 1 |
| 6170 | A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. Therapeutics and Clinical Risk Management, 2007, 3, 665-73. | 0.9 | 16 |
| 6171 | Ambulatory care for cancer in the United States: results from two national surveys comparing visits to physicians' offices and hospital outpatient departments. Journal of the National Medical Association, 2007, 99, 1350-8. | 0.6 | 11 |
| 6172 | Adjuvant and preoperative therapy for localized gastric cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 139-45. | 0.8 | 2 |
| 6173 | A review of the use of exemestane in early breast cancer. Therapeutics and Clinical Risk Management, 2009, 5, 91-8. | 0.9 | 13 |
| 6175 | Does race affect outcomes in triple negative breast cancer?. Breast Cancer: Basic and Clinical Research, 2010, 4, 23-33. | 0.6 | 16 |
| 6176 | Arzoxifene: the evidence for its development in the management of breast cancer. Core Evidence, 2008, 2, 251-8. | 4.7 | 3 |
| 6177 | Predictive markers in primary breast cancer compared with lymph node and bloodspread metastases. International Journal of Physiology, Pathophysiology and Pharmacology, 2009, 1, 57-63. | 0.8 | 2 |
| 6178 | Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives. Oncology, 2010, 24, 322-7. | 0.4 | 2 |
| 6179 | Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 92-103. | 0.4 | 25 |
| 6181 | Pharmacoeconomic considerations in the treatment of breast cancer. ClinicoEconomics and Outcomes Research, 2010, 2, 47-61. | 0.7 | 7 |
| 6182 | Recent advances in adjuvant systemic treatment for breast cancer: all systems go!. Current Oncology, 2006, 13, 147-59. | 0.9 | 0 |
| 6183 | Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. International Journal of Molecular Epidemiology and Genetics, 2013, 4, 35-48. | 0.4 | 6 |
| 6184 | CYP2D6 testing in breast cancer: ready for prime time?. Oncology, 2009, 23, 1223-32. | 0.4 | 7 |
| 6185 | Treatment of breast cancer in young women: do we need more aggressive therapies?. Journal of Thoracic Disease, 2013, 5 Suppl 1, S47-54. | 0.6 | 3 |
| 6186 | How to improve breast cancer care measurement and reporting: suggestions from a complex urban hospital. Journal of Healthcare Management, 2013, 58, 205-23; discussion 223-4. | 0.4 | 6 |
| 6187 | New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009, 1, 1-18. | 1.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6188 | Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 331-9. | 0.5 | 7 |
| 6189 | Managing breast cancer in the older patient. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 341-7. | 0.3 | 12 |
| 6190 | Oral health-related complications of breast cancer treatment: assessing dental hygienists' knowledge and professional practice. <i>Journal of Dental Hygiene: JDH / American Dental Hygienists' Association</i> , 2014, 88, 100-13. | 0.1 | 1 |
| 6191 | How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?. <i>Gland Surgery</i> , 2012, 1, 156-8. | 0.5 | 0 |
| 6192 | Cox models survival analysis based on breast cancer treatments. <i>Iranian Journal of Cancer Prevention</i> , 2014, 7, 124-9. | 0.7 | 9 |
| 6193 | Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 5622-33. | 0.5 | 17 |
| 6194 | MicroRNA-26a inhibits proliferation by targeting high mobility group AT-hook 1 in breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 368-73. | 0.5 | 16 |
| 6195 | Longitudinal analysis of meta-analysis literatures in the database of ISI Web of Science. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 3559-65. | 1.3 | 3 |
| 6196 | Predictors for contralateral prophylactic mastectomy in breast cancer patients. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3748-64. | 0.5 | 19 |
| 6197 | S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5309-17. | 0.5 | 4 |
| 6198 | Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 9500-5. | 0.5 | 6 |
| 6199 | MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 2115-26. | 0.0 | 47 |
| 6200 | ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13279-83. | 0.5 | 10 |
| 6201 | Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 142-53. | 0.0 | 27 |
| 6202 | Epirubicin pretreatment enhances NK cell-mediated cytotoxicity against breast cancer cells in vitro. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 473-84. | 0.0 | 6 |
| 6203 | Clinical outcomes of modelling mammography screening strategies. <i>Health Reports</i> , 2015, 26, 9-15. | 0.6 | 3 |
| 6204 | Adjuvant endocrine therapy in premenopausal women with breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 663-72. | 0.3 | 14 |
| 6205 | Cardiotoxicity Following Cancer Treatment. <i>Ulster Medical Journal</i> , 2017, 86, 3-9. | 0.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6206 | Oral Health-Related Complications of Breast Cancer Treatment: Assessing Dental Hygienists' Knowledge and Professional Practice. <i>Journal of Dental Hygiene: JDH / American Dental Hygienists' Association</i> , 2015, 89 Suppl 2, 22-37. | 0.1 | 2 |
| 6207 | Endocrine Therapy for Early Breast Cancer: Updated Review. <i>Ochsner Journal</i> , 2017, 17, 405-411. | 0.5 | 44 |
| 6208 | Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 2825-2832. | 0.5 | 4 |
| 6209 | Editors' Choice Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group. <i>Nagoya Journal of Medical Science</i> , 2018, 80, 217-226. | 0.6 | 2 |
| 6210 | Genomic Testing in the Management of Early-Stage Breast Cancer. <i>Journal of Clinical Outcomes Management</i> , 2017, 24, 229-238. | 1.7 | 1 |
| 6211 | Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 43-54. | 0.2 | 5 |
| 6212 | Precautions for Patients Taking Tamoxifen. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 78-83. | 0.2 | 9 |
| 6213 | A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. <i>American Journal of Cancer Research</i> , 2018, 8, 2359-2376. | 1.4 | 24 |
| 6214 | Single nucleotide polymorphisms of let-7-related genes increase susceptibility to breast cancer. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 1748-1759. | 0.0 | 7 |
| 6215 | RILPL2 regulates breast cancer proliferation, metastasis, and chemoresistance via the TUBB3/PTEN pathway. <i>American Journal of Cancer Research</i> , 2019, 9, 1583-1606. | 1.4 | 5 |
| 6216 | Clinical characteristics and prognostic analysis of ipsilateral supraclavicular lymph node metastases in breast cancer patients: a retrospective study. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 3526-3534. | 0.5 | 4 |
| 6217 | Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 650-663. | 0.5 | 3 |
| 6218 | Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 286-294. | 0.5 | 3 |
| 6219 | Patient Messaging Content Associated with Initiating Hormonal Therapy after a Breast Cancer Diagnosis. <i>AMIA ... Annual Symposium proceedings</i> , 2019, 2019, 962-971. | 0.2 | 0 |
| 6221 | Breast Cancer Survivorship Tool: Facilitating breast cancer survivorship care for family physicians and patients. <i>Canadian Family Physician</i> , 2020, 66, 321-326. | 0.1 | 1 |
| 6222 | Multiresponsive carboxylated graphene oxide-grafted aptamer as a multifunctional nanocarrier for targeted delivery of chemotherapeutics and bioactive compounds in cancer therapy. <i>Nanotechnology Reviews</i> , 2021, 10, 1838-1852. | 2.6 | 11 |
| 6223 | Diagnostic Potential of miR-30a and miR-200c in Invasive Breast Ductal Carcinoma. , 2021, 1, . | | 0 |
| 6224 | Clinical and morphological factors associated with two groups of concordant breast cancer immunophenotypes. <i>International Journal for Innovation Education and Research</i> , 2021, 9, 197-213. | 0.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 6225 | Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 74 Cancer: Targets and Therapy, 2021, Volume 13, 625-640. | 1.0 | 0 |
| 6226 | Epsin β potentiates the NF κ B signaling pathway to regulate apoptosis in breast cancer. Molecular Medicine Reports, 2021, 25, . | 1.1 | 2 |
| 6227 | Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clinical Pharmacokinetics, 2022, 61, 527-537. | 1.6 | 17 |
| 6228 | Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics. Frontiers in Oncology, 2021, 11, 738222. | 1.3 | 0 |
| 6229 | Targeted Therapy in HR+ HER2 α Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options. Cancers, 2021, 13, 5994. | 1.7 | 11 |
| 6230 | Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 370. | 3.5 | 15 |
| 6231 | Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. Human Pathology Reports, 2021, 26, 300574. | 0.1 | 5 |
| 6232 | Revisiting Adjuvant Hormone Therapy in Premenopausal Women With Breast Cancer: Escalation and De-Escalation. JCO Oncology Practice, 2021, , OP2100730. | 1.4 | 0 |
| 6233 | The Future Perspectives of Drug Repurposing and Treatment for the Drug Resistant Breast Cancer: A Review. , 0, , . | | 0 |
| 6234 | Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy. Pharmaceuticals, 2021, 14, 1200. | 1.7 | 1 |
| 6235 | Surgical and radiotherapy patterns of care in the management of breast cancer in NSW and ACT Australia. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 442-454. | 0.9 | 6 |
| 6236 | Effect of Estrogen Receptor Expression Level and Hormonal Therapy on Prognosis of Early Breast Cancer. Cancer Research and Treatment, 2022, 54, 1081-1090. | 1.3 | 6 |
| 6237 | 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 2021, 385, 2336-2347. | 13.9 | 363 |
| 6238 | Electrochemical Biosensors for the Analysis of Breast Cancer Biomarkers: From Design to Application. Analytical Chemistry, 2022, 94, 269-296. | 3.2 | 51 |
| 6239 | Recent advances in targeted nanotherapeutic approaches for breast cancer management. Nanomedicine, 2021, 16, 2605-2631. | 1.7 | 11 |
| 6240 | Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. Annals of Oncology, 2021, , . | 0.6 | 9 |
| 6241 | Survival among Breast Cancer Patients: Comparison of the U.S. Military Health System with the Surveillance, Epidemiology and End Results Program. Clinical Breast Cancer, 2022, 22, e506-e516. | 1.1 | 6 |
| 6242 | FoxO3a Inhibits Tamoxifen-Resistant Breast Cancer Progression by Inducing Integrin β 5 Expression. Cancers, 2022, 14, 214. | 1.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6243 | Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e1. | 1.6 | 8 |
| 6244 | Evaluation of Optic Nerve Head Parameters and Electro-Physiology Among Breast Cancer Patients on Tamoxifen. <i>Cureus</i> , 2022, 14, e21042. | 0.2 | 0 |
| 6245 | Study design and protocol for tailored Acceptance and Commitment Therapy (ACT) to optimize quality of life in women living with metastatic breast cancer. <i>Contemporary Clinical Trials Communications</i> , 2022, 25, 100870. | 0.5 | 3 |
| 6246 | Mammakarzinom: Krebsregister deckt Metastasierungsprozess auf. , 0, , . | | 0 |
| 6247 | Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?â€”a meta-analysis of randomized controlled trials. <i>Translational Cancer Research</i> , 2020, 9, 7034-7043. | 0.4 | 5 |
| 6248 | Evaluation of the Effects of Nanomicellar Curcumin, Berberine, and Their Combination with 5-Fluorouracil on Breast Cancer Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1328, 21-35. | 0.8 | 5 |
| 6249 | Endocrine Treatment of Breast Cancer. , 2022, , 1783-1789. | | 0 |
| 6250 | Chemotherapy for ipsilateral breast tumor recurrence: a propensity score-matching study. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 143-152. | 1.1 | 1 |
| 6251 | Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis. <i>British Journal of Surgery</i> , 2022, 109, 411-417. | 0.1 | 4 |
| 6252 | Application of Nanoemulsions in Breast Cancer Treatment. <i>Advances in Chemical and Materials Engineering Book Series</i> , 2022, , 277-306. | 0.2 | 1 |
| 6253 | Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptorâ€”Positive/Human Epidermal Growth Factor Receptor 2â€”Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 449-458. | 0.8 | 25 |
| 6254 | Hormonal and Targeted Treatments in Breast Cancer. , 2022, , 443-463. | | 3 |
| 6255 | Detection of Breast Cancer Cell-MDA-MB-231 by Measuring Conductivity of Schottky Source/Drain GaN FinFET. <i>IEEE Sensors Journal</i> , 2022, 22, 6108-6115. | 2.4 | 4 |
| 6256 | Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial. <i>Clinical Drug Investigation</i> , 2022, 42, 163-175. | 1.1 | 3 |
| 6257 | FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 468. | 1.7 | 3 |
| 6258 | Temporality and Patterns of Metastatic Recurrence in Node-Positive Breast Cancer Following Trimodality Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 88-94. | 0.6 | 0 |
| 6259 | Can We Successfully De-Escalate Axillary Surgery in Women Aged â‰¥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy?. <i>Annals of Surgical Oncology</i> , 2022, 29, 2263-2272. | 0.7 | 3 |
| 6261 | Gene Expression Profiling in Early Breast Cancerâ€”Patient Stratification Based on Molecular and Tumor Microenvironment Features. <i>Biomedicines</i> , 2022, 10, 248. | 1.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6262 | Chitosan: A versatile bio-platform for breast cancer theranostics. <i>Journal of Controlled Release</i> , 2022, 341, 733-752. | 4.8 | 38 |
| 6263 | The Role of Community Pharmacists in Addressing Medication-related Issues for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy. <i>Anticancer Research</i> , 2022, 42, 661-666. | 0.5 | 1 |
| 6264 | How we treat HR-positive, HER2-negative early breast cancer. <i>Future Oncology</i> , 2022, 18, 1003-1022. | 1.1 | 11 |
| 6265 | Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. <i>Biomolecules</i> , 2022, 12, 132. | 1.8 | 7 |
| 6266 | PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 33-42. | 1.1 | 7 |
| 6267 | Closing the circle on Tamoxifen Tales. , 2022, , 171-186. | | 0 |
| 6268 | Hormone therapy for cancer treatment. , 2022, , 247-256. | | 0 |
| 6269 | Decoding Single Cell Morphology in Osteotropic Breast Cancer Cells for Dissecting Their Migratory, Molecular and Biophysical Heterogeneity. <i>Cancers</i> , 2022, 14, 603. | 1.7 | 5 |
| 6270 | Budget impact of the Oncotype DX [®] test compared to other gene expression tests in patients with early breast cancer in Germany. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100519. | 0.7 | 5 |
| 6272 | Individualizing Adjuvant Therapy in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Node-Positive Breast Cancer. <i>JCO Oncology Practice</i> , 2022, , OP2100780. | 1.4 | 1 |
| 6273 | Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters. <i>ESC Heart Failure</i> , 2022, , . | 1.4 | 12 |
| 6274 | STAT3/HIF1A and EMT specific transcription factors regulated genes: Novel predictors of breast cancer metastasis. <i>Gene</i> , 2022, 818, 146245. | 1.0 | 2 |
| 6275 | Assessing Estrogenic Activity of Classical -Binding Compounds. <i>Methods in Molecular Biology</i> , 2022, 2418, 187-201. | 0.4 | 1 |
| 6276 | RBMS2 Chemosensitizes Breast Cancer Cells to Doxorubicin by Regulating BMF Expression. <i>International Journal of Biological Sciences</i> , 2022, 18, 1724-1736. | 2.6 | 10 |
| 6277 | Perioperative Risk Factors for Prolonged Blood Loss and Drainage Fluid Secretion after Breast Reconstruction. <i>Journal of Clinical Medicine</i> , 2022, 11, 808. | 1.0 | 0 |
| 6278 | Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. <i>Lancet Oncology</i> , The, 2022, 23, 382-392. | 5.1 | 107 |
| 6279 | Concurrent chemo-endocrine treatment for early hormone-positive breast cancer: a no-go???. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 485. | 1.1 | 1 |
| 6280 | Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 667397. | 1.3 | 11 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6281 | A functionalized graphene oxide with improved cytocompatibility for stimuli-responsive co-delivery of curcumin and doxorubicin in cancer treatment. <i>Scientific Reports</i> , 2022, 12, 1959. | 1.6 | 29 |
| 6282 | Pharmacogenetics of Drugs Used in the Treatment of Cancers. <i>Genes</i> , 2022, 13, 311. | 1.0 | 10 |
| 6283 | RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes. <i>JCI Insight</i> , 2022, 7, . | 2.3 | 9 |
| 6284 | Special Considerations in Patients with Early-Stage Breast Cancer and Survivors. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, 49, 195-208. | 0.7 | 2 |
| 6285 | Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy. <i>Journal of Chemotherapy</i> , 2021, , 1-9. | 0.7 | 0 |
| 6287 | Mammaerkrankungen. , 2021, , 297-361. | | 0 |
| 6288 | The Margins™ Challenge: Risk Factors of Residual Disease After Breast Conserving Surgery in Early-stage Breast Cancer. <i>In Vivo</i> , 2022, 36, 814-820. | 0.6 | 4 |
| 6289 | Hematological Toxicity during Breast Cancer Chemotherapy in Pointe-Noire (Congo Brazzaville). <i>Journal of Cancer Therapy</i> , 2022, 13, 131-144. | 0.1 | 0 |
| 6290 | Leucopenia induced by tamoxifen in a breast cancer patient: a case report. <i>Annals of Cancer Research and Therapy</i> , 2022, 30, 8-10. | 0.1 | 1 |
| 6291 | Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand. <i>PharmacoEconomics - Open</i> , 2022, , 1. | 0.9 | 2 |
| 6292 | Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy. <i>Cancer</i> , 2022, , . | 2.0 | 1 |
| 6293 | Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy. <i>JAMA Network Open</i> , 2022, 5, e2145934. | 2.8 | 4 |
| 6294 | Validity of 1% Hormonal Receptor Positivity Cutoff by the ASCO/College of American Pathologists Guidelines at the Georgia Cancer Center. <i>JCO Precision Oncology</i> , 2022, 6, e2100201. | 1.5 | 2 |
| 6296 | Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients. <i>Biochemical Genetics</i> , 2022, 60, 1963-1985. | 0.8 | 3 |
| 6297 | Endothelial Cells Potentially Participate in the Metastasis of Triple-Negative Breast Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13. | 0.9 | 4 |
| 6298 | Evaluation of Monoexponential, Stretched-Exponential and Intravoxel Incoherent Motion <scp>MRI</scp> Diffusion Models in Early Response Monitoring to Neoadjuvant Chemotherapy in Patients With Breast Cancer—A Preliminary Study. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 1079-1088. | 1.9 | 8 |
| 6299 | Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. <i>Scientific Reports</i> , 2022, 12, 2742. | 1.6 | 13 |
| 6300 | Obesity and breast cancer: Preventive and therapeutic possibilities for bariatric surgery. <i>Obesity</i> , 2022, 30, 587-598. | 1.5 | 12 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6301 | Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 87-94. | 0.6 | 14 |
| 6302 | A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies. <i>Cancers</i> , 2022, 14, 1779. | 1.7 | 7 |
| 6303 | A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells. <i>Biomolecules</i> , 2022, 12, 531. | 1.8 | 3 |
| 6304 | Effect of hypertension on the optimal anthracycline cumulative dose for developing left ventricular dysfunction in patients with malignant lymphoma. <i>International Journal of Cardiovascular Imaging</i> , 0, 1. | 0.2 | 1 |
| 6305 | Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. <i>Npj Breast Cancer</i> , 2022, 8, 31. | 2.3 | 7 |
| 6306 | Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer. <i>Biomedicines</i> , 2022, 10, 748. | 1.4 | 0 |
| 6307 | Improvement of survival in Korean breast cancer patients over a 14-year period: A large-scale single-center study. <i>PLoS ONE</i> , 2022, 17, e0265533. | 1.1 | 2 |
| 6308 | Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. <i>Ultrasound in Medicine and Biology</i> , 2022, , . | 0.7 | 2 |
| 6309 | Treatment results and patient characteristics for breast cancer patients older than 70 Years. <i>Medical Science and Discovery</i> , 2022, 9, 143-148. | 0.1 | 0 |
| 6310 | Endocrine therapy initiation among women with stage III invasive, hormone receptor-positive breast cancer from 2001–2016. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 203-216. | 1.1 | 5 |
| 6311 | Selective pressure of endocrine therapy activates the integrated stress response through NF κ B signaling in a subpopulation of ER positive breast cancer cells. <i>Breast Cancer Research</i> , 2022, 24, 19. | 2.2 | 6 |
| 6312 | Risk of heart disease following treatment for breast cancer – results from a population-based cohort study. <i>ELife</i> , 2022, 11, . | 2.8 | 11 |
| 6313 | Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors. <i>Annals of Behavioral Medicine</i> , 2022, 56, 856-871. | 1.7 | 13 |
| 6314 | Right ventricular free wall strain for detection of anthracycline induced cardiac toxicity. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 1021-1028. | 0.2 | 0 |
| 6315 | Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications. <i>Seminars in Cancer Biology</i> , 2022, 86, 769-783. | 4.3 | 36 |
| 6316 | Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 161-173. | 1.1 | 7 |
| 6317 | Adjuvant Hormone Therapy–Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-7. | 2.3 | 1 |
| 6318 | Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials. <i>BMC Medical Research Methodology</i> , 2022, 22, 98. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6319 | Chemotherapy-Induced Amenorrhea and Its Prognostic Significance in Premenopausal Women With Breast Cancer: An Updated Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 859974. | 1.3 | 5 |
| 6320 | Knockdown of YAP/TAZ sensitizes tamoxifen-resistant MCF7 breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2022, 601, 73-78. | 1.0 | 11 |
| 6321 | RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation. <i>Oral Oncology</i> , 2022, 128, 105816. | 0.8 | 2 |
| 6322 | Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy. <i>Breast</i> , 2022, 63, 29-36. | 0.9 | 5 |
| 6324 | Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India. <i>South Asian Journal of Cancer</i> , 2021, 10, 213-219. | 0.2 | 5 |
| 6325 | CircCDK1 knockdown reduces CDK1 expression by targeting miR-489-3p to suppress the development of breast cancer and strengthen the sensitivity of Tamoxifen. <i>Anti-Cancer Drugs</i> , 2022, 33, 286-299. | 0.7 | 7 |
| 6326 | Prognostic Model Construction and Immune Microenvironment Analysis of Breast Cancer Based on Ferroptosis-Related lncRNAs. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9817-9831. | 0.8 | 7 |
| 6327 | Dexamethasone is Associated With a Lower Risk of the Progression of Thoracic Aortic Calcification in Breast Cancer Survivors. <i>Frontiers in Pharmacology</i> , 2021, 12, 740815. | 1.6 | 0 |
| 6329 | SBRT as Salvage Re-Irradiation for Isolated In-Field Regional Relapse After Bilateral Breast Cancer – a Case Report. <i>Journal of Medical & Radiation Oncology</i> , 2021, 1, 63-69. | 0.0 | 0 |
| 6330 | Survival and Time to Initiation of Adjuvant Chemotherapy Among Breast Cancer Patients in Uruguay. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 651-658. | 1.0 | 1 |
| 6331 | Breast Nurse Intervention to Improve Adherence to Endocrine Therapy Among Breast Cancer Patients in South Ethiopia. <i>Oncologist</i> , 2022, 27, e650-e660. | 1.9 | 7 |
| 6332 | Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 151-159. | 1.1 | 10 |
| 6333 | Anthracyclines in the treatment of patients with early breast cancer. <i>ESMO Open</i> , 2022, 7, 100461. | 2.0 | 4 |
| 6334 | –Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics–™. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 783494. | 1.6 | 6 |
| 6335 | Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2557-2567. | 0.8 | 49 |
| 6336 | Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. <i>Current Oncology</i> , 2022, 29, 2599-2616. | 0.9 | 5 |
| 6379 | Adjuvant Chemotherapy Following Surgery for Lung Cancer. , 0, , 221-232. | | 0 |
| 6380 | Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210903. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6381 | Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy. <i>Histology and Histopathology</i> , 2020, 35, 361-370. | 0.5 | 8 |
| 6382 | Expression of glucose-regulated protein 78 as prognostic biomarkers for triple-negative breast cancer. <i>Histology and Histopathology</i> , 2020, 35, 559-568. | 0.5 | 5 |
| 6385 | (Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 511. | 1.1 | 3 |
| 6388 | Endocrine therapies for breast and prostate cancers. <i>Canadian Family Physician</i> , 2022, 68, 271-276. | 0.1 | 2 |
| 6389 | Thérapies endocriniennes contre les cancers du sein et de la prostate. <i>Canadian Family Physician</i> , 2022, 68, e120-e126. | 0.1 | 0 |
| 6390 | Evaluation of cancer immunotherapy using mini-tumor chips. <i>Theranostics</i> , 2022, 12, 3628-3636. | 4.6 | 18 |
| 6391 | The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy. <i>BMC Women's Health</i> , 2022, 22, 135. | 0.8 | 4 |
| 6392 | Sociodemographic disparities in molecular testing for breast cancer. <i>Cancer Causes and Control</i> , 2022, 33, 843-859. | 0.8 | 2 |
| 6393 | No Association between ABCB1 G2677T/A or C3435T Polymorphisms and Survival of Breast Cancer Patients: A 10-Year Follow-Up Study in the Polish Population. <i>Genes</i> , 2022, 13, 729. | 1.0 | 1 |
| 6394 | Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). <i>Pharmaceuticals</i> , 2022, 15, 542. | 1.7 | 14 |
| 6395 | Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2022, , . | 1.1 | 0 |
| 6396 | Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020. <i>Radiotherapy and Oncology</i> , 2022, 172, 118-125. | 0.3 | 12 |
| 6397 | Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy. <i>Radiology</i> , 2022, 304, 310-319. | 3.6 | 15 |
| 6398 | Estimation of the risk of progression of breast cancer after the COVID-19 lockdown. <i>Deutsches Arzteblatt International</i> , 0, , . | 0.6 | 1 |
| 6399 | Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. <i>Lancet, The</i> , 2022, 399, 1941-1953. | 6.3 | 224 |
| 6400 | Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study. <i>Cureus</i> , 2022, , . | 0.2 | 2 |
| 6401 | Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies. <i>Clinical Breast Cancer</i> , 2022, 22, 611-618. | 1.1 | 6 |
| 6402 | Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 7858. | 1.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6404 | Cost-Effectiveness Analysis of Two Chemotherapy Regimens FAC vs. Taxane for Operable Breast Cancer Patients in Indonesia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 1147-1154. | 0.5 | 0 |
| 6405 | Gene expression signatures in early breast cancer: Better together with clinicopathological features. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103708. | 2.0 | 10 |
| 6407 | Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. <i>ELife</i> , 2022, 11, . | 2.8 | 11 |
| 6408 | Mir-4728 is a Valuable Biomarker for Diagnostic and Prognostic Assessment of HER2-Positive Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, . | 1.6 | 3 |
| 6409 | Cocreation with Dutch patients of decision-relevant information to support shared decision-making about adjuvant treatment in breast cancer care. <i>Health Expectations</i> , 2022, 25, 1664-1677. | 1.1 | 3 |
| 6410 | Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature. <i>Breast Cancer Research and Treatment</i> , 2022, , . | 1.1 | 2 |
| 6411 | The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems. <i>Cancer Causes and Control</i> , 2022, , . | 0.8 | 1 |
| 6413 | The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER ⁻ /PR ⁺) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute. <i>Breast Journal</i> , 2022, 2022, 1-9. | 0.4 | 4 |
| 6414 | The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103725. | 2.0 | 1 |
| 6415 | Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions. <i>Drug Safety</i> , 2022, 45, 601-621. | 1.4 | 10 |
| 6416 | Wnt Signaling in the Breast: From Development to Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, . | 1.8 | 10 |
| 6417 | A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. <i>Future Oncology</i> , 2022, 18, 2667-2682. | 1.1 | 13 |
| 6418 | Osteoporosis, Fracture and Survival: Application of Machine Learning in Breast Cancer Prediction Models. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 6419 | Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 60-72. | 1.8 | 15 |
| 6420 | The History of Early Breast Cancer Treatment. <i>Genes</i> , 2022, 13, 960. | 1.0 | 16 |
| 6421 | Effectiveness of internet-based support interventions on patients with breast cancer: a systematic review and narrative synthesis. <i>BMJ Open</i> , 2022, 12, e057664. | 0.8 | 12 |
| 6422 | Development and validation of a nomogram to predict survival for advanced male breast cancer. <i>Andrologia</i> , 2022, 54, . | 1.0 | 2 |
| 6423 | Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study. <i>British Journal of Cancer</i> , 2022, 127, 720-725. | 2.9 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6424 | Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. <i>British Journal of Cancer</i> , 2022, 127, 695-703. | 2.9 | 2 |
| 6425 | Adherence to oral hormonal anticancer agents in breast cancer. <i>Tumori</i> , 2023, 109, 262-268. | 0.6 | 1 |
| 6426 | Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. <i>BMJ Open</i> , 2022, 12, e056374. | 0.8 | 3 |
| 6427 | Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 1 |
| 6428 | Tamoxifen: The Past, Present, and Future of a Previous Orphan Drug. <i>European Journal of Medical and Health Sciences</i> , 2022, 4, 1-10. | 0.1 | 1 |
| 6432 | Low Fat-Free Mass Index Measured by Bioelectrical Impedance Analysis Correlates With Hematologic Adverse Events in Early-Stage Breast Cancer Patients Receiving Chemotherapy: A Prospective Observational Cohort Study. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211065. | 0.8 | 1 |
| 6433 | Timing of Postmastectomy Radiotherapy Following Adjuvant Chemotherapy for High-Risk Breast Cancer: A Post-Hoc Analysis of a Randomised Controlled Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 6434 | PCBP1-mediated regulation of WNT signaling is critical for breast tumorigenesis. <i>Cell Biology and Toxicology</i> , 0, , . | 2.4 | 0 |
| 6435 | Improving Adherence to Adjuvant Endocrine Therapy in Sub-Saharan Africa: Challenges and Innovative Nurse-Driven Solutions. <i>Oncologist</i> , 0, , . | 1.9 | 1 |
| 6436 | Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. <i>Oncologist</i> , 2022, 27, 722-731. | 1.9 | 6 |
| 6437 | AB186 Inhibits Migration of Triple-Negative Breast Cancer Cells and Interacts with β -Tubulin. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6859. | 1.8 | 3 |
| 6438 | Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment. <i>Journal of Translational Medicine</i> , 2022, 20, . | 1.8 | 4 |
| 6439 | Assessment of Predictive Biomarkers in Breast Cancer: Challenges and Updates. <i>Pathobiology</i> , 2022, 89, 263-277. | 1.9 | 7 |
| 6440 | Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 691-722. | 2.3 | 357 |
| 6441 | Breast Cancer with Low Recurrence Score on Oncotype DX®: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation. <i>Oncology and Therapy</i> , 0, , . | 1.0 | 0 |
| 6442 | Extended endocrine therapy in breast cancer: A basket of length-constraint feature selection metaheuristics to balance Type I against Type II errors. <i>Journal of Biomedical Informatics</i> , 2022, 131, 104112. | 2.5 | 0 |
| 6443 | Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, . | 0.9 | 12 |
| 6444 | To Give or Not to Give Adjuvant Chemotherapy in Breast Cancer? Can CanAssist Breast Assist?. <i>South Asian Journal of Cancer</i> , 2022, 11, 001-002. | 0.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6445 | Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, . | 1.8 | 12 |
| 6446 | Improving outcomes for women aged 70 years or above with early breast cancer: research programme including a cluster RCT. <i>Programme Grants for Applied Research</i> , 2022, 10, 1-114. | 0.4 | 1 |
| 6447 | Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from Vigibase. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211135. | 0.5 | 1 |
| 6448 | Leveraging values to promote adherence to endocrine therapy among breast cancer survivors: A mixed-methods investigation. <i>Journal of Contextual Behavioral Science</i> , 2022, 25, 122-129. | 1.3 | 1 |
| 6449 | Novel lncRNAs with diagnostic or prognostic value screened out from breast cancer via bioinformatics analyses. <i>PeerJ</i> , 0, 10, e13641. | 0.9 | 4 |
| 6450 | Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer. <i>Frontiers in Psychology</i> , 0, 13, . | 1.1 | 0 |
| 6451 | Comparisons of Metastatic Patterns, Survival Outcomes and Tumor Immune Microenvironment Between Young and Non-Young Breast Cancer Patients. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, . | 1.8 | 10 |
| 6453 | Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 65-74. | 1.1 | 6 |
| 6454 | The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103757. | 2.0 | 8 |
| 6455 | Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review. <i>European Journal of Cancer</i> , 2022, 172, 158-170. | 1.3 | 4 |
| 6457 | A Multidisciplinary Approach to Cancer: A Medical Oncologist's View. , 2023, , 14-18. | | 0 |
| 6458 | Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition. <i>JCI Insight</i> , 2022, 7, . | 2.3 | 4 |
| 6459 | Intervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-institutional Registry Study IMET, Protocol MF 14-02. <i>Annals of Surgical Oncology</i> , 2022, 29, 6327-6336. | 0.7 | 3 |
| 6460 | Clinical Outcomes of Adjuvant Hormone Therapy in a Cohort of Patients With Infiltrating Non-metastatic Breast Cancer in a Latin American Cancer Center. <i>Cureus</i> , 2022, , . | 0.2 | 0 |
| 6461 | Hsa_circ_0097922 promotes tamoxifen resistance and cell malignant behavior of breast cancer cells by regulating ACTN4 expression via miR-876a-3p. <i>Clinical and Experimental Pharmacology and Physiology</i> , 0, , . | 0.9 | 4 |
| 6462 | <i>Neurospora crassa</i> is a potential source of anti-cancer agents against breast cancer. <i>Breast Cancer</i> , 2022, 29, 1032-1041. | 1.3 | 2 |
| 6463 | Treatment outcomes according to the EndoPredict score in ER-positive, HER2-negative early breast cancer. <i>Breast Care</i> , 0, , . | 0.8 | 0 |
| 6465 | Personalized Approaches for the Prevention and Treatment of Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022, 12, 1201. | 1.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6467 | Local and systemic therapy may be safely de-escalated in elderly breast cancer patients in China: A retrospective cohort study. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 2 |
| 6470 | Osteoporosis, fracture and survival: Application of machine learning in breast cancer prediction models. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 6472 | Hot flushes and sweating, sleep problems, joint and muscular discomfort, and physical and mental exhaustion in breast cancer survivors during the first 24 months of tamoxifen therapy: a prospective observational study. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 6473 | Fungating and Ulcerating Breast Cancer: Wound Closure Algorithm, Complications, and Survival Trends. <i>Indian Journal of Surgical Oncology</i> , 0, , . | 0.3 | 0 |
| 6474 | Diagnostic diversity and heterogeneity of tumors: a real-world study of metastasis re-biopsy in advanced breast cancer. <i>Chinese Medical Journal</i> , 2022, 135, 2076-2082. | 0.9 | 1 |
| 6475 | The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience. <i>Clinical Breast Cancer</i> , 2022, 22, 823-827. | 1.1 | 2 |
| 6476 | Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis. <i>Menopause</i> , 2022, 29, 1093-1100. | 0.8 | 5 |
| 6477 | The emerging potentials of lncRNA DRAIC in human cancers. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 5 |
| 6478 | Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1343-1360. | 0.5 | 3 |
| 6479 | The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 178, 103781. | 2.0 | 3 |
| 6480 | Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial. <i>European Journal of Cancer</i> , 2022, 174, 153-164. | 1.3 | 3 |
| 6481 | An overview on Estrogen receptors signaling and its ligands in breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2022, 241, 114658. | 2.6 | 27 |
| 6482 | Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?. <i>Cancer Treatment Reviews</i> , 2022, 110, 102454. | 3.4 | 14 |
| 6484 | A machine learning ensemble approach for 5- and 10-year breast cancer invasive disease event classification. <i>PLoS ONE</i> , 2022, 17, e0274691. | 1.1 | 6 |
| 6486 | A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ER \pm -positive luminal breast cancer. <i>Biochemical Pharmacology</i> , 2022, 204, 115233. | 2.0 | 1 |
| 6487 | Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer. <i>European Journal of Cancer</i> , 2022, 175, 169-179. | 1.3 | 3 |
| 6488 | Relapse-free survival in Sudanese women with non-metastatic breast cancer. <i>Global Epidemiology</i> , 2022, 4, 100082. | 0.6 | 0 |
| 6489 | Feasibility of a Supervised Virtual Exercise Program for Women on Hormone Therapy for Breast Cancer. <i>Translational Journal of the American College of Sports Medicine</i> , 2022, 7, . | 0.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 6490 | The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer. Technology in Cancer Research and Treatment, 2022, 21, 153303382211174. | 0.8 | 0 |
| 6491 | Clinico-pathologic factors associated with the occurrence of early and late metastatic spread in a cohort of breast cancer patients. Breast Disease, 2022, 41, 365-372. | 0.4 | 0 |
| 6492 | Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial. BMJ Open, 2022, 12, e062034. | 0.8 | 5 |
| 6493 | Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated lncRNAs in tamoxifen resistance. Frontiers in Genetics, 0, 13, . | 1.1 | 3 |
| 6494 | A comparative analysis of recurrence risk predictions in ER+/HER2-early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast. Breast Cancer Research and Treatment, 2022, 196, 299-310. | 1.1 | 3 |
| 6495 | Five decades of progress in surgical oncology: Breast. Journal of Surgical Oncology, 2022, 126, 852-859. | 0.8 | 0 |
| 6496 | Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precision Oncology, 2022, , . | 1.5 | 20 |
| 6497 | Detection of relevant pharmacogenetic information through exome sequencing in oncology. Pharmacogenomics, 2022, 23, 759-770. | 0.6 | 0 |
| 6498 | Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer. Breast Cancer Research and Treatment, 2022, 196, 323-328. | 1.1 | 5 |
| 6499 | Knockdown circTRIM28 enhances tamoxifen sensitivity via the miR-409-3p/HMGA2 axis in breast cancer. Reproductive Biology and Endocrinology, 2022, 20, . | 1.4 | 5 |
| 6500 | Big data in basic and translational cancer research. Nature Reviews Cancer, 2022, 22, 625-639. | 12.8 | 67 |
| 6501 | Epigenetic factors in breast cancer therapy. Frontiers in Genetics, 0, 13, . | 1.1 | 1 |
| 6502 | Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer. ClinicoEconomics and Outcomes Research, 0, Volume 14, 619-633. | 0.7 | 1 |
| 6503 | The role of lncRNA H19 in tumorigenesis and drug resistance of human Cancers. Frontiers in Genetics, 0, 13, . | 1.1 | 9 |
| 6504 | The impact of mastectomy and reconstruction technique on patient perceived quality of Life. American Journal of Surgery, 2022, 224, 1450-1454. | 0.9 | 2 |
| 6505 | Influence of Tamoxifen on Different Biological Pathways in Tumorigenesis and Transformation in Adipose-Derived Stem Cells, Mammary Cells and Mammary Carcinoma Cell Lines—An In Vitro Study. Cells, 2022, 11, 2733. | 1.8 | 2 |
| 6506 | Breast cancer metastasis: mapping long term outcomes in Australia. Medical Journal of Australia, 0, , . | 0.8 | 1 |
| 6507 | Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer. Oncogene, 2022, 41, 4905-4915. | 2.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6508 | Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 591-602. | 1.1 | 1 |
| 6509 | Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study. <i>European Journal of Cancer</i> , 2022, 176, 58-69. | 1.3 | 2 |
| 6510 | NMR-Based Metabolomics to Evaluate Individual Response to Treatments. <i>Handbook of Experimental Pharmacology</i> , 2022, , 209-245. | 0.9 | 4 |
| 6512 | The Present and Future of Clinical Management in Metastatic Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 5891. | 1.0 | 7 |
| 6513 | Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach. <i>European Journal of Cancer Care</i> , 2022, 31, . | 0.7 | 5 |
| 6514 | Recurrence Score® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial. <i>Cancers</i> , 2022, 14, 5365. | 1.7 | 6 |
| 6518 | Asymptomatic uterine metastasis of breast cancer: Case report and literature review. <i>Medicine (United Tj ETQq0 0,0,rgBT /Oylock 10</i> | 0.4 | 2 |
| 6519 | Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 2022, 12, . | 1.3 | 4 |
| 6522 | Clinical Trials That Have Informed the Modern Management of Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022, , . | 0.6 | 0 |
| 6523 | Adenocarcinoma of the uterine corpus and sarcomas of the uterus. , 2023, , 125-174.e30. | | 0 |
| 6524 | High Expression of <i>CD58</i> and <i>ALDH1A3</i> Predicts a Poor Prognosis in Basal-like Breast Cancer. <i>Anticancer Research</i> , 2022, 42, 5223-5232. | 0.5 | 1 |
| 6525 | Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer. <i>Cancers</i> , 2022, 14, 5467. | 1.7 | 4 |
| 6526 | Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence Score® Test?. <i>Diagnostics</i> , 2022, 12, 2730. | 1.3 | 0 |
| 6527 | The Role of Phorbol Diesters in Mediating Human Placental Aromatase Cytochrome P450 Activity. , 2022, 1, 279-288. | | 0 |
| 6528 | Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13604. | 1.8 | 1 |
| 6529 | Return to Work and Mortality in Breast Cancer Survivors: A 11-Year Longitudinal Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14418. | 1.2 | 4 |
| 6530 | Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. <i>Pharmacogenetics and Genomics</i> , 0, Publish Ahead of Print, . | 0.7 | 0 |
| 6531 | Five-year survival rate and prognostic factors in women with breast cancer treated at a reference hospital in the Brazilian Amazon. <i>PLoS ONE</i> , 2022, 17, e0277194. | 1.1 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6532 | Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapyâ€”A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. <i>Cancers</i> , 2022, 14, 5635. | 1.7 | 3 |
| 6533 | Resemblance of the Recurrence Patterns in Primary Systemic, Primary Surgery and Secondary Oncoplastic Surgery. <i>Current Oncology</i> , 2022, 29, 8874-8885. | 0.9 | 1 |
| 6536 | Gene expression signatures in older patients with breast cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103884. | 2.0 | 2 |
| 6537 | Hormonal therapy for cancer. <i>Medicine</i> , 2023, 51, 28-31. | 0.2 | 3 |
| 6538 | Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2023, 247, 115013. | 2.6 | 3 |
| 6540 | Breast cancer radiation therapy: A bibliometric analysis of the scientific literature. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100556. | 0.9 | 8 |
| 6541 | A longitudinal study on the changes in the selfâ€œefficacy of breast cancer patients during adjuvant chemotherapy. <i>Nursing Open</i> , 0, , . | 1.1 | 2 |
| 6542 | Utility of a Clinically Guided Data-Driven Approach for Predicting Breast Cancer Complications: An Application Using a Population-Based Claims Data Set. <i>JCO Clinical Cancer Informatics</i> , 2022, , . | 1.0 | 1 |
| 6543 | Does the toxicity of endocrine therapy persist into long-term survivorship?: Patient-reported outcome results from a follow-up study beyond a 10-year-survival. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 475-485. | 1.1 | 1 |
| 6544 | LnNP@ZIF8 Smart System for In Situ NIR-II Ratiometric Imaging-Based Tumor Drug Resistance Evaluation. <i>Nanomaterials</i> , 2022, 12, 4478. | 1.9 | 3 |
| 6546 | Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 603-612. | 1.1 | 2 |
| 6547 | Local/Regional Recurrence Rates After Breast-Conserving Therapy in Patients Enrolled in Legacy Trials of the Alliance for Clinical Trials in Oncology (AFT-01). <i>Annals of Surgery</i> , 2023, 277, 841-845. | 2.1 | 0 |
| 6548 | Severe thrombocytopenia and anemia as an initial presentation of breast cancer: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, . | 0.2 | 0 |
| 6549 | Adjuvant aromatase inhibitor treatment worsens depressive symptoms and sleep quality in postmenopausal women with localized breast cancer: A one-year follow-up study. <i>Breast</i> , 2022, 66, 310-316. | 0.9 | 1 |
| 6550 | Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?. <i>Current Breast Cancer Reports</i> , 0, , . | 0.5 | 0 |
| 6551 | A propensity scoreâ€œweighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 23-29. | 1.1 | 2 |
| 6552 | Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer. <i>BMC Cancer</i> , 2022, 22, . | 1.1 | 2 |
| 6553 | Effect of adjuvant chemotherapy on the survival outcomes of elderly breast cancer: A retrospective cohort study based on SEER database. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 354-364. | 0.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6554 | Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. <i>Breast Cancer Research</i> , 2022, 24, . | 2.2 | 1 |
| 6555 | Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer. <i>Cancers</i> , 2023, 15, 148. | 1.7 | 3 |
| 6557 | The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 647-659. | 1.1 | 4 |
| 6558 | Exploring the Use of Cold Atmospheric Plasma to Overcome Drug Resistance in Cancer. <i>Biomedicines</i> , 2023, 11, 208. | 1.4 | 14 |
| 6559 | Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211417. | 1.4 | 0 |
| 6560 | Incidence of second primary malignancies in women with different stages of breast cancer. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 0 |
| 6561 | Assessing the role of tumour-associated macrophage subsets in breast cancer subtypes using digital image analysis. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 11-22. | 1.1 | 4 |
| 6563 | The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 0 |
| 6564 | Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2023, 30, 2130-2139. | 0.7 | 0 |
| 6565 | Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2 ⁺ metastatic breast cancer: an observational study of the SONABRE Registry. <i>Lancet Regional Health - Europe</i> , The, 2023, 26, 100573. | 3.0 | 5 |
| 6566 | 2D-CuPd nanozyme overcome tamoxifen resistance in breast cancer by regulating the PI3K/AKT/mTOR pathway. <i>Biomaterials</i> , 2023, 294, 121986. | 5.7 | 10 |
| 6567 | Functionalized liposomes for targeted breast cancer drug delivery. <i>Bioactive Materials</i> , 2023, 24, 401-437. | 8.6 | 33 |
| 6568 | Evaluating the Role of Circulating MicroRNAs in Predicting Long-Term Survival Outcomes in Breast Cancer: A Prospective, Multicenter Clinical Trial. <i>Journal of the American College of Surgeons</i> , 2023, 236, 317-327. | 0.2 | 8 |
| 6569 | Effects and Working Mechanisms of a Multilevel Implementation Program for Applying Shared Decision-Making while Discussing Systemic Treatment in Breast Cancer. <i>Current Oncology</i> , 2023, 30, 236-249. | 0.9 | 4 |
| 6570 | Survival in male breast cancer over the past 3 decades. <i>Journal of the National Cancer Institute</i> , 2023, 115, 421-428. | 3.0 | 2 |
| 6571 | Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy?. <i>Current Oncology</i> , 2023, 30, 392-400. | 0.9 | 6 |
| 6572 | Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial. <i>BMC Cancer</i> , 2022, 22, . | 1.1 | 1 |
| 6574 | Triple-Negative Breast Cancer Therapy: Recent Advances, Challenges, and Future Perspective. , 2023, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6575 | Incidence and risk factors of cardiovascular mortality in patients with gastrointestinal adenocarcinoma. <i>PLoS ONE</i> , 2023, 18, e0262013. | 1.1 | 1 |
| 6576 | Characterizing unique supportive care needs among women living with metastatic breast cancer: A qualitative study. <i>Journal of Psychosocial Oncology Research and Practice</i> , 2023, 5, . | 0.2 | 1 |
| 6577 | Co-drug development of gallic acid and metformin targeting the pro-inflammatory cytokines for the treatment of breast cancer. <i>Journal of Biochemical and Molecular Toxicology</i> , 2023, 37, . | 1.4 | 2 |
| 6578 | Adherence Disparities and Utilization Trends of Oncotype Dx Assay: A National Cancer Database Study. <i>Journal of Surgical Research</i> , 2023, 286, 65-73. | 0.8 | 0 |
| 6579 | CDK4/6 Inhibitors Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 1763. | 1.7 | 4 |
| 6580 | Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,000 women from 86 randomised trials. <i>Lancet, The</i> , 2023, 401, 1277-1292. | 6.3 | 23 |
| 6581 | A novel survival prediction signature outperforms PAM50 and artificial intelligence-based feature-selection methods. <i>Computational Biology and Chemistry</i> , 2023, 104, 107845. | 1.1 | 0 |
| 6582 | Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen. <i>Journal of Personalized Medicine</i> , 2023, 13, 272. | 1.1 | 6 |
| 6583 | Long-Term Adherence to Adjuvant Endocrine Therapy Following Various Radiotherapy Modalities in Early Stage Hormone Receptor Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2023, , . | 1.1 | 1 |
| 6584 | Personalized Injury Reduction Strategies in Sports Medicine: Lessons Learned from Advances in Breast Cancer Treatment: A Clinical Commentary. <i>International Journal of Sports Physical Therapy</i> , 2023, 18, . | 0.5 | 0 |
| 6585 | Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy. <i>Frontiers in Pharmacology</i> , 0, 14, . | 1.6 | 4 |
| 6586 | Association of Enolase-1 with Prognosis and Immune Infiltration in Breast Cancer by Clinical Stage. <i>Journal of Inflammation Research</i> , 0, Volume 16, 493-503. | 1.6 | 0 |
| 6587 | Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale. <i>Biomedicine and Pharmacotherapy</i> , 2023, 160, 114369. | 2.5 | 2 |
| 6588 | Donor Egg, Surrogacy, and Adoption for Breast Cancer Survivors. <i>Current Breast Cancer Reports</i> , 2023, 15, 24-29. | 0.5 | 0 |
| 6590 | Sonic Hedgehog stimulates migration of MCF-7 breast cancer cells through Rac1. <i>Journal of Biomedical Research</i> , 2019, 33, 297. | 0.7 | 2 |
| 6591 | Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients' Needs?. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 147-161. | 1.0 | 0 |
| 6592 | Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis. <i>Molecular Cancer</i> , 2023, 22, . | 7.9 | 19 |
| 6593 | Comparison of Rehabilitation Training at Different Timepoints to Restore Shoulder Function in Patients With Breast Cancer After Lymph Node Dissection: A Randomized Controlled Trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2023, 104, 728-737. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 6594 | Ninety-six-hour starved peripheral blood mononuclear cell supernatant inhibited LA7 breast cancer stem cells induced tumor via reduction in angiogenesis and alternations in Gch1 and Spr expressions. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 0 |
| 6595 | Cigarette smoke and tumor microenvironment copromote aggressiveness of human breast cancer cells. <i>Toxicological Sciences</i> , 2023, 192, 30-42. | 1.4 | 3 |
| 6596 | The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer. <i>Current Atherosclerosis Reports</i> , 2023, 25, 145-154. | 2.0 | 2 |
| 6597 | Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 499-508. | 1.1 | 1 |
| 6598 | Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers. , 2023, , 211-232. | | 0 |
| 6599 | Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group. <i>Frontiers in Oncology</i> , 0, 13, . | 1.3 | 3 |
| 6600 | Impact of de-escalating systemic therapy guided by 21-gene assay on locoregional recurrence after partial-breast irradiation. <i>Brachytherapy</i> , 2023, , . | 0.2 | 0 |
| 6601 | Bilateral Breast Cancer: Clinical Profile and Management. <i>Indian Journal of Surgical Oncology</i> , 0, , . | 0.3 | 0 |
| 6602 | Progress and Remaining Gaps in the Early Detection and Treatment of Breast Cancer. <i>Current Oncology</i> , 2023, 30, 3201-3205. | 0.9 | 0 |
| 6604 | Potential Role of Natural Antioxidant Products in Oncological Diseases. <i>Antioxidants</i> , 2023, 12, 704. | 2.2 | 18 |
| 6605 | Evaluation of Heterogeneity and Conformity Index Using IMRT and VMAT Techniques in Breast Cancer. <i>International Journal of Scientific Research in Science and Technology</i> , 2023, , 370-373. | 0.1 | 0 |
| 6606 | Prognostic Value of IMP3 and Its Role as an Epithelial-Mesenchymal Transition Promoter in Breast Carcinoma. <i>Indian Journal of Surgical Oncology</i> , 0, , . | 0.3 | 0 |
| 6607 | Imputation of single-cell transcriptome data enables the reconstruction of networks predictive of breast cancer metastasis. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2296-2304. | 1.9 | 0 |
| 6608 | Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer. <i>Journal of Nanobiotechnology</i> , 2023, 21, . | 4.2 | 4 |
| 6609 | Relationship between tumor microbiota transcriptional activity and gene expression in breast cancer. <i>BMC Cancer</i> , 2023, 23, . | 1.1 | 2 |
| 6610 | Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy. <i>Cardio-Oncology</i> , 2023, 9, . | 0.8 | 2 |
| 6611 | Evaluation of outcome of chemotherapy for breast cancer patients older than 70 years: A SEER-based study. <i>Frontiers in Oncology</i> , 0, 13, . | 1.3 | 1 |
| 6612 | The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy. <i>Breast Cancer Research</i> , 2023, 25, . | 2.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 6613 | MiR-640 and MiR-525-5p as Relapse-Associated MicroRNAs in Systematically Untreated Individuals with Low-Risk Primary Breast Cancer. <i>Tohoku Journal of Experimental Medicine</i> , 2023, 260, 171-179. | 0.5 | 1 |
| 6614 | Functional chromopeptide nanoarchitectonics: molecular design, self-assembly and biological applications. <i>Chemical Society Reviews</i> , 2023, 52, 2688-2712. | 18.7 | 39 |
| 6615 | Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials. <i>Breast Cancer Research and Treatment</i> , 0, , . | 1.1 | 0 |
| 6616 | Real-world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high-risk breast cancer subgroup patients. <i>Oncology Letters</i> , 2023, 25, . | 0.8 | 0 |
| 6617 | Prognosis after Local Recurrence in Patients with Early-Stage Breast Cancer Treated without Chemotherapy. <i>Current Oncology</i> , 2023, 30, 3829-3844. | 0.9 | 3 |
| 6618 | The Future of Breast Cancer Research in the Survivorship Field. <i>Oncology and Therapy</i> , 2023, 11, 199-229. | 1.0 | 4 |
| 6619 | BCR-Net: A deep learning framework to predict breast cancer recurrence from histopathology images. <i>PLoS ONE</i> , 2023, 18, e0283562. | 1.1 | 3 |
| 6621 | An emerging generation of endocrine therapies in breast cancer: a clinical perspective. <i>Npj Breast Cancer</i> , 2023, 9, . | 2.3 | 18 |
| 6622 | Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. <i>Nature Communications</i> , 2023, 14, . | 5.8 | 5 |
| 6623 | A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. <i>Frontiers in Oncology</i> , 0, 13, . | 1.3 | 0 |
| 6625 | Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047. <i>Cancer Discovery</i> , 2023, 13, 1084-1099. | 7.7 | 8 |
| 6626 | COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, . | 3.5 | 3 |
| 6627 | Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 3329-3338. | 0.8 | 7 |
| 6628 | Nanomedicine Technologies for Diagnosis and Treatment of Breast Cancer. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 671-682. | 2.5 | 7 |
| 6629 | Ductal Carcinoma in Situ: A Detailed Review of Current Practices. <i>Cureus</i> , 2023, , . | 0.2 | 1 |
| 6655 | Introduction and Overview of Cancer Therapeutics. <i>Cancer Treatment and Research</i> , 2023, , 1-13. | 0.2 | 0 |
| 6682 | Evaluation des Nutzens. , 2023, , 37-179. | | 0 |
| 6683 | Practical recommendations for using ctDNA in clinical decision making. <i>Nature</i> , 2023, 619, 259-268. | 13.7 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 6704 | Editorial: Hormone resistance in cancer. <i>Frontiers in Endocrinology</i> , 0, 14, . | 1.5 | 0 |
| 6705 | Wavelet transform and deep learning for breast cancer neoadjuvant chemotherapy efficacy prediction. , 2023, , . | | 0 |
| 6713 | Cancer treatment therapies: traditional to modern approaches to combat cancers. <i>Molecular Biology Reports</i> , 2023, 50, 9663-9676. | 1.0 | 2 |
| 6752 | Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2-breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , . | 1.1 | 0 |
| 6753 | Cancer Therapeutics: Mechanism of Action, Radiation Toxicity, and Drug Formulation. , 2023, , 185-200. | | 0 |
| 6766 | Breast Cancer in Young Women. , 2023, , 309-320. | | 0 |
| 6767 | Breast Cancer in the Older Woman. , 2023, , 329-336. | | 0 |
| 6768 | Evidence-Based Practice in Multidisciplinary Breast Cancer Management. , 2023, , 411-432. | | 0 |
| 6780 | The role of endocrine treatment on the risk of developing an ipsilateral invasive breast cancer in hormone receptor positive patients with ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 0, , . | 1.1 | 0 |
| 6787 | Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer. <i>Npj Breast Cancer</i> , 2023, 9, . | 2.3 | 1 |
| 6815 | Current status of optoacoustic breast imaging and future trends in clinical application: is it ready for prime time?. <i>European Radiology</i> , 0, , . | 2.3 | 0 |
| 6818 | Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA). <i>Breast Cancer Research and Treatment</i> , 0, , . | 1.1 | 0 |